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Abstract 
 
Clostridium difficile infection (CDI) is an infection of the gastrointestinal tract causing 
symptoms ranging from mild diarrhoea to life-threatening toxic megacolon. Between 
10-30% of patients suffer a recurrent episode (rCDI) after an initial episode. Some 
patients develop multiple recurrent episodes, leading to unpleasant cycles of disease 
and antimicrobial therapy. This thesis utilises a multidimensional approach to study 
rCDI.  
In Chapter 2, previously generated clinical data is used to assess the effect of 
treatment delay on two outcomes; diarrhoeal duration and risk of recurrence. It was 
hypothesised that delays initiating treatment result in increased symptom duration and 
recurrence risk. Logistic regression models highlighted treatment delay has no 
significant effect on diarrhoeal duration or recurrence risk. The only significant variable 
associated with risk of recurrence was previous CDI (P<0.001). These findings suggest 
clinicians should not be overly concerned by treatment delays in mild/moderate CDI. 
In Chapter 3, the germination and thermotolerance properties of five strains of C. 
difficile spores were investigated. In the nosocomial environment spores may be 
reingested by the patient, germinate and initiate fulminant disease. Additionally, spores 
can persist in the gastrointestinal tract and germinate in response to stimulatory cues. 
C. difficile spore recovery was optimised by using variety of media and supplements. 
The ribotype (RT) 078 strain germinated more efficiently in the absence of additional 
supplementation. RT 027/078 strains were more thermotolerant. Intrinsic differences in 
spore germination characteristics between clades could facilitate the increased ability 
of some strains to cause rCDI.  
In Chapter 4, an in vitro gut model was used to simulate rCDI. Previous research has 
characterised changes in the microbiota that occur in response to antibiotics. In this 
study a metaproteomic approach was utilised to study the overarching metabolic 
vi 
 
processes occurring during simulated rCDI. Although dysbiosis was evident, the 
metaproteome remained fairly constant throughout simulated infection.
vii 
 
 
Table of Contents 
Acknowledgements .................................................................................. iv 
Abstract ..................................................................................................... v 
Table of Contents .......................................................................................vii 
Table of Figures ..........................................................................................xi 
Table of Tables ...........................................................................................xv 
List of Abbreviations ................................................................................ xvi 
Chapter 1 - Introduction ..............................................................................1 
1.1 History & Presentation ......................................................................1 
1.2 Epidemiology ....................................................................................2 
1.3 Pathogenicity ....................................................................................4 
1.4 Recurrence .......................................................................................6 
1.5 Risk Factors ...................................................................................10 
1.5.1 Potential C. difficile reservoirs ...............................................13 
1.5.2 Treatment ..............................................................................14 
1.6 Study aims ......................................................................................30 
Chapter 2 – Treatment Delay and CDI ......................................................33 
2.1 Introduction .....................................................................................33 
2.2 Methods ..........................................................................................34 
2.2.1 Study overview ......................................................................34 
2.2.2 Participants and protocols .....................................................34 
2.2.3 Ethics ....................................................................................35 
2.2.4 Microbiological methods ........................................................35 
2.2.5 Statistical analysis .................................................................36 
2.3 Results ...........................................................................................39 
2.3.1 Patient cohort characteristics ................................................39 
2.3.2 Symptom duration analysis ...................................................42 
2.3.3 Recurrence analysis ..............................................................45 
2.3.4 Ribotype distribution ..............................................................46 
2.4 Discussion ......................................................................................48 
Chapter 3 A – Spore Germination and Recovery ....................................53 
 Background & Rationale .................................................................53 
3.1.1 Germination mechanism .......................................................54 
viii 
 
3.1.2 Bile acids ............................................................................... 56 
3.1.3 Amino acids .......................................................................... 58 
3.1.4 Non-germinant receptor germinants...................................... 60 
3.1.5 Optimising C. difficile recovery .............................................. 60 
 Methods ......................................................................................... 62 
3.2.1 Production of Spores............................................................. 62 
3.2.2 Phase Contrast Microscopy .................................................. 62 
3.2.3 Spore Recovery on Solid Media ............................................ 63 
3.2.4 Spore Germination in Broths ................................................. 63 
3.2.5 Agar-incorporated minimum inhibitory concentration (MIC) 
testing ................................................................................... 67 
3.2.6 Minimum Inhibitory Concentration (MIC) Testing in Microbroths
 67 
3.2.7 C. difficile spore desiccation .................................................. 67 
3.2.8 Statistical analysis ................................................................. 71 
 Results ........................................................................................... 71 
3.3.1 Spore Recovery on Solid Media ............................................ 71 
3.3.2 Spore Broth Pilot Study ......................................................... 74 
3.3.3 Spore Germination in Broths ................................................. 76 
3.3.4 C. difficile germination in the presence and absence of 
additional supplementation ................................................... 80 
3.3.5 Minimum Inhibitory Concentration (MIC) Testing .................. 83 
3.3.6 C. difficile spore desiccation .................................................. 86 
3.4 Discussion ...................................................................................... 89 
3.4.1 Recovery of C. difficile on solid agar ..................................... 89 
3.4.2 Germination of C. difficile in broths ....................................... 92 
3.4.3 The inhibitory nature of L-amino acids .................................. 95 
3.4.4 Desiccation of C. difficile spores ........................................... 97 
Chapter 3 B – Heat treatment of Clostridium difficile spores .............. 100 
3.5 Background & Rationale ............................................................... 100 
3.5.1 Superdormancy ................................................................... 103 
3.5.2 Biofilms ............................................................................... 104 
3.6 Methods ....................................................................................... 106 
3.6.1 Production of spores ........................................................... 106 
3.6.2 Transmission electron microscopy (TEM) ........................... 107 
3.6.3 Heat Treatment in PBS for 60 minutes................................ 107 
3.6.4 Heat Treatment Prior to Broth Inoculation ........................... 108 
ix 
 
3.6.5 Reversibility of Spore Heat Treatment ................................ 108 
3.6.6 Statistical Analysis .............................................................. 108 
3.7 Results ......................................................................................... 109 
3.7.1 Heat Treatment in PBS for 60 minutes ................................ 109 
3.7.2 Transmission Electron Microscopy ...................................... 115 
3.7.3 Heat Treatment Prior to Broth Inoculation ........................... 116 
3.7.4 Reversibility of Spore Heat Treatment ................................ 120 
3.8 Discussion .................................................................................... 122 
3.8.1 Heat Treatment in PBS ....................................................... 122 
3.8.2 Heat Treatment Prior to Broth Inoculation ........................... 127 
3.9 Conclusion .................................................................................... 128 
Chapter 4 A – Proteomics in an in vitro Clostridium difficile gut model
 .......................................................................................................... 130 
4.1 Background & Rationale ............................................................... 130 
4.1.1 Proteomics approaches....................................................... 132 
4.1.2 Peptide/Protein Identification ............................................... 137 
4.1.3 C. difficile in vitro gut model ................................................ 138 
4.2 In Vitro Gut Models ....................................................................... 140 
4.2.1 Methods .............................................................................. 140 
4.3 Quantification of Protein from the in vitro Gut Model Vessels ....... 145 
4.3.1 Methods .............................................................................. 145 
4.3.2 Results ................................................................................ 148 
4.4 Discussion .................................................................................... 154 
4.4.1 Quantification of Protein from the in vitro Gut Model Vessels
 154 
4.4.2 Isolation of Secreted Proteins from Gut Model Microorganisms
 155 
Chapter 4 B – rCDI Gut Models ............................................................... 157 
4.5 Methods ........................................................................................ 157 
4.5.1 Metaproteomic Analysis ...................................................... 163 
4.6 Results ......................................................................................... 167 
4.6.1 Model E – Multiple spore prep doses .................................. 167 
4.6.2 Model F – Single spore prep dose ...................................... 171 
4.6.3 Model G – FMT ................................................................... 176 
4.6.4 Overall Taxonomic analysis ................................................ 181 
4.6.5 Overall Functional analysis ................................................. 184 
4.7 Discussion .................................................................................... 186 
x 
 
Chapter 5 - Conclusions .......................................................................... 193 
References ............................................................................................... 200 
Appendix A - Research Study Protocol…………………………………... 233 
 A.1  Research Study Protocol - Substudy…………………………….. 233  
 A.2  Research Study Protocol - Original study……………………….. 245 
Appendix B - Media used for bacterial culture and enumeration……. 274 
 B.1  Solid agar……………………………………………………………. 274 
    B.1.1 Nutrient agar…………………………………………………….. 274 
    B.1.2 MacConkey agar…………………………………………………274 
    B.1.3 Kanamycin aesculin azide agar……………………………..... 274 
    B.1.4 Fastidious anaerobe agar……………………………………... 275 
    B.1.5 Bile aesculin agar………………………………………………. 276 
    B.1.6 LAMVAB agar…………………………………………………... 276 
    B.1.7 Beerens agar………………………………………………….... 277 
    B.1.8 CCEYL agar…………………………………………………….. 277 
    B.1.9 BHI agar…………………………………………………………. 278 
 B.2  Broth…………………………………………………………………. 278 
    B.2.1 Minimal media…………………………………………………... 279 
    B.2.2 Gut model media……………………………………………….. 279 
Appendix C - Table of Proteins…………………………………………..… 281 
 
 
xi 
 
Table of Figures 
 
Figure 1.1.1. Areas of study in this thesis and their relation to recurrent C. 
difficile infection (rCDI)………………………………………………………. 32 
Figure 2.2.1. The work flow used in statistical analysis for the clinical 
study…………………………………………………………………………… 38 
Figure 2.3.1. (a) & (b). Histograms showing the distribution of the study 
variable………………………………………………………………………... 41 
Figure 2.3.2. Duration of symptoms plotted against duration of symptom pre-
treatment on a scatter graph (n = 122)…………………………………….. 43 
Figure 2.3.3. The frequency of PCR ribotypes (RTs) isolated from stool of 
patients in the study population…………………………………………….. 47 
Figure 3.1.1. Ultrastructural representation of a Clostridium difficile 
spore…………………………………………………………………………... 55 
Figure 3.1.2. Glycine molecule, showing alkyl chain skeleton, amine group 
and hydroxyl groups. Diagram obtained from ChemDraw ®……………. 58 
Figure 3.2.1. An overview of the methodology used in solid agar 
experiments…………………………………………………………………... 65 
Figure 3.2.2. An overview of the methodology used in this study for broth 
experiments…………………………………………………………………... 66 
Figure 3.2.3. The desiccator used to age C. difficile spores………….... 68 
Figure 3.2.4. An overview of the methodology used to enumerated desiccated 
spores directly on to solid agar…………………………………………….. 69 
Figure 3.2.5. An overview of the methodology used to enumerate desiccated 
spores after 90 minutes broth incubation…………………………………. 70 
Figure 3.3.1. Mean (± SE) spore recovery of spores of five C. difficile strains 
inoculated on to a variety of solid agars…………………………………... 73 
Figure 3.3.2. Spore pilot study.……………………………………………. 75 
Figure 3.3.3. Mean (± SE) TVC and spore counts of five C. difficile strains of 
differing ribotypes (001, 015, 020, 027 & 078) germinated in two different 
broths (BHI & Schaedler) in the presence of different germinants (lysozyme 
(L), taurocholate (TC) & glycine (GLY))…………………………………... 78 
xii 
 
Figure 3.3.4. Phase contrast data for spores of five C. difficile strains of 
different ribotypes (001, 015, 020, 027 & 078) of C. difficile incubated for 90 
minutes in two broths (BHI & Schaedler) in the presence of a range of 
germinants (lysozyme (L), taurocholate (TC) & glycine (GLY))……………… 79 
Figure 3.3.5. Mean (± SE) TVC and spore counts of three C. difficile strains of 
differing ribotypes (001, 027 & 078) germinated in two broths (BHI & BHI(S)). 
BHI (S) is supplemented with 0.1 % taurocholate…………………………….. 81 
Figure 3.3.6. Phase contrast data for spores of three C. difficile strains of 
differing ribotypes (001, 027 & 078) incubated for 24 hours in two broths (BHI 
& BHI(S)). BHI (S) is supplemented with 0.1% taurocholate………………… 82 
Figure 3.3.7. MIC testing of spores of five C. difficile strains of differing 
ribotypes (001, 015, 020, 027 & 078) in BHI containing increasing 
concentrations of glycine (0, 1.5, 2.0 & 2.5%)……………………………….... 83 
Figure 3.3.8. Mean (± SE) growth of five C. difficile strains of differing 
ribotypes (001, 015, 020, 027 & 078) in BHI containing increasing 
concentrations (0, 1, 2, 3 & 4%) of one of three amino acids (glycine, L-
histidine, L-phenyalanine)………………………………………..……………… 85 
Figure 3.3.9. Mean (± SE) recovery of desiccated spores of four C. difficile 
strains of differing ribotypes (001, 015, 020 & 078) on three solid agars 
(BHI(S), CCEY &CCEYL)……………………………………………………….. 87 
Figure 3.3.10. Germination of desiccated spores of four C. difficile strains of 
differing ribotypes (001, 015, 020 & 078) in three liquid media (BHI, BHI(L) & 
BHI(S))…………………………………………………………………………….. 88 
Figure 3.7.1. Spore recovery of five C. difficile strains of differing ribotypes 
(001, 015, 020, 027 & 078) heated for 60 minutes at 70/80 ° C……………. 111 
Figure 3.7.2. Mean (± SE) spore recovery of five C. difficile strains of differing 
ribotypes (001, 015, 020, 027 & 078) heated for 60 minutes at 80 ° C……. 114 
Figure 3.7.3. Transmission electron microscopy (TEM) images (1000 X 
magnification) of biofilm produced spores (A) and planktonic produced C. 
difficile RT 027 spores (B)………………………………………………………. 115 
Figure 3.7.4. Mean (± SE) TVC and spore counts of five C. difficile strains of 
differing ribotypes (001, 015, 020, 027 & 078) incubated for 90 minutes in BHI 
supplemented with 0.1 % taurocholate/ 0.4 % glycine………………………. 118 
Figure 3.7.5. Percentage (± SE) of phase dark spores (PD), phase bright 
spores (PB) and vegetative cells (VC) of five C. difficile strains of differing 
xiii 
 
ribotypes (001, 015, 020, 027 & 078) incubated for 90 minutes in BHI 
supplemented with 0.1 % taurocholate/ 0.4 % glycine……………………… 119 
Figure 3.7.6. Mean (± SE) TVC and spore counts of five C. difficile strains of 
differing ribotypes (001, 015, 020, 027 & 078) incubated for 24 hours in BHI 
supplemented with 0.1 % taurocholate/ 0.4 % glycine……………………… 121 
Figure 4.1.1. An overview of the different proteomic approaches………… 135 
Figure 4.2.1. C. difficile in vitro gut model…………………………………… 144 
Figure 4.3.1. Mean (± SE) absorbance readings for protein standards of 10, 
20, 40, 60, 80 and 125 μg/ml of bovine serum albumin (BSA)…………….. 149 
Figure 4.3.2. Protein gel electrophoresis of proteins precipitated from Vessels 
1, 2, & 3 of the in vitro gut model…………………………………………….... 150 
Figure 4.3.3. Mean (± SE) recovery of obligate populations (total anaerobes, 
Bacteroides, Bifidobacterium) facultative populations (facultative anaerobes, 
Lactobacilli, Enterococci, Enterobacteriaceae) and spores (total spores) 
before, immediately following and 2h post-centrifugation of gut model 
fluid………………………………………………………………………………... 152 
Figure 4.3.4. Mean (± SE) absorbance reading for protein standards of 0.2, 
0.4 0.6, 0.8, 1.0 & 1.2 mg/ml of bovine serum albumin (BSA)……………… 153 
Figure 4.5.1. Overviews of the timeline for the E, F & G in vitro C. difficile gut 
models……………………………………………………………………………. 159 
Figure 4.5.2. An overview of the methodology used to produce, isolate and 
analyse in vitro gut model microbial proteins……………………………….... 162 
Figure 4.5.3. Methodology used for the taxonomic and functional analysis of 
MaxQuant output………………………………………………………………... 165 
Figure 4.6.1. Anaerobe counts for Model E over the duration of the model 
simulating CDI……………………………………………………………………. 169 
Figure 4.6.2. Facultative anaerobe counts for Model E over the duration of the 
model simulating CDI……………………………………………………………. 170 
Figure 4.6.3. Anaerobe counts for Model F over the duration of the model 
simulating CDI……………………………………………………………………. 173 
Figure 4.6.4. Facultative anaerobe counts for Model F over the duration of the 
model simulating CDI……………………………………………………………. 174 
Figure 4.6.5. Anaerobe counts for Model G over the duration of the model 
simulating CDI……………………………………………………………………. 179 
xiv 
 
Figure 4.6.6. Facultative anaerobe counts for Model G over the duration of the 
model simulating CDI……………………………………………………….… 180 
Figure 4.6.7. Tryptic peptides assignment using UniPept………………... 183 
Figure 4.6.8. Functional annotation of proteins using the ‘pathway’ function of 
UniProtKB/SwissProt………………………………………………………….. 185 
xv 
 
Table of Tables 
Table 2.3.1. Demographics of patients enrolled in the clinical study………………. 40 
Table 2.3.2. Coefficients entered in the multiple regression model for assessing the 
effect of duration of diarrhoea pre-treatment on symptom duration……………...… 44 
Table 2.3.3. Coefficients entered in the logistic regression model for assessing effect of 
duration of diarrhoea pre-treatment on recurrence…………………………………... 45 
Table 3.2.1. Solid agar plates utilised in C. difficile spore recovery experiments… 63 
Table 3.2.2. Range of broths utilised in C. difficile spore germination experiments 65 
Table 3.7.1. The model used to fit the data shown in Fig 3.7.1 (spore heat broth 
experiments in PBS) with the corresponding r2 correlation coefficient value…..…. 112 
Table 4.3.1. The different growth media utilised in bacterial identification and 
enumeration from gut model sampling……………………………………...………… 146 
Table 4.3.2. Mean (± SE) protein concentrations from Vessels 1, 2 & 3 of the gut 
model……………………………………………………………………………………....148 
Table 4.5.1. Samples taken from models E, F & G of the C. difficile gut models... 161 
Table 4.5.2. An example of MaxQuant Excel output……………………………..…. 166 
 
xvi 
 
List of Abbreviations 
CDI Clostridium difficile infection 
AAD Antibiotic associated diarrhoea 
ANOVA Analysis of variance 
BHI Brain heart infusion 
BSA Bovine serum albumin 
CBA Columbia blood agar 
CCEY Cycloserine-cefoxitine egg yolk 
CCEYL Cycloserine-cefoxitine egg yolk 
lysozyme  
CCFA Cycloserine-cefoxitin fructose agar 
CD Clostridium difficile 
CDRN Clostridium difficile ribotyping network 
CDT Clostridium difficile binary toxin 
CFU Colony forming units 
CTAB Cetyl trimethylammonium bromide 
DDSA Dodecenylsuccinic anhydride 
DMP-30 2,4,6-Tris(dimethylaminomethyl)phenol 
DNA Deoxyribonucleic acid 
DPA Dipicolinic acid 
ESI Electrospray ionisation 
FASP Filter-aided sample preparation 
FDR False discovery rate 
xvii 
 
FMT Faecal microbiota transplantation 
GPMDB Global proteome machine database 
HPLC High performance liquid 
chromatography 
HT Heat treated 
IBD Inflammatory bowel disease 
iST inStage-Tip method 
iST In-Stage tip method 
LC-MS/MS Liquid chromatography- tandem mass 
spectrometry 
LFQ Label free quantification 
LLOD Lower limit of detection 
MAb Monoclonal antibody 
MALDI-MS Matrix-assisted laser 
desorption/ionisation 
MIC Minimum inhibitory concentration 
MLVA Multiple locus variable tandem repeat 
analysis 
MOPS 3-(N-morpholino)propanesulfonic acid 
NAP1 North American pulsed-field gel 
electrophoresis type 1 
NCBI National centre for biotechnology 
information 
NHT Non-heat treated 
PB Phase bright 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
xviii 
 
PD Phase dark 
PDB Protein data bank 
PMC Pseudomembranous colitis 
PPI Proton pump inhibitor 
QDS Quater die sumendum; four times daily 
rCDI Recurrent Clostridium difficile infection 
REA Restriction endonuclease analysis 
RM-ANOVA Repeated measures analysis of variance 
RNA Ribonucleic acid 
RPM Revolutions per minute 
RT Ribotype 
RU Relative units 
SCFA Short chain fatty acid 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate -  
polyacrylamide gel electrophoresis 
SE Standard error  
ST3 Single-pot solid-phase-enhanced 
sample preparation 
STrap Suspension trapping method 
TOF Time-of-flight 
TSA Tryptone soy agar 
TVC Total viable count 
WBC White blood cells 
xix 
 
WGS Whole genome sequencing 
1 
 
Chapter 1 - Introduction 
1.1 History & Presentation 
Clostridium difficile is an anaerobic Gram-positive, spore forming bacillus first isolated 
from the stool of an infant in 1935, originally being known as “Bacillus difficilis” (1). A 
possible case of Clostridium difficile infection (CDI) was reported in 1892 in a patient 
who developed diarrhoea after gastric surgery. Interestingly, the patient received a 
local antiseptic (boric acid) prior to surgery (2). The increased association of 
pseudomembranous colitis (PMC) with antibiotic treatment led to further work trying to 
identify the aetiological agent (3). Work in the 1970s led to the conclusion that a 
clostridial species present in the stool samples of four patients with PMC was 
responsible for the cytotoxicity observed in tissue culture (4, 5). This was further 
validated in hamster models. C. difficile was finally identified in 1978 as the agent 
responsible for PMC;  a toxigenic strain was isolated from a patient previously treated 
with clindamycin (6). C. difficile toxin has subsequently found to be neutralised by the 
actions of a Clostridium sordellii antitoxin, which is commonly used as a control in cell 
cytotoxicity assays (7).  
In the 1980s, environmental contamination and transmission of C. difficile within the 
nosocomial environment was investigated due to the increasing incidence of CDI. 
McFarland et al showed that 21 % of 311 patients culture negative at admission to a 
single ward in an American hospital acquired C. difficile during hospitalisation (8). C. 
difficile was also found on 59 % of the staff caring for culture positive patients. Since 
then, many infection control measures have been implemented to decrease the 
incidence of CDI, including patient isolation, staff gowning/gloving, improved hand 
hygiene, environmental decontamination and antimicrobial stewardship (reducing use 
of high-risk CDI antibiotics)(9).  
CDI varies in presentation with mild diarrhoea being common, C. difficile has long been 
identified as the main aetiological agent of PMC, a rarer and far more serious 
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complication of the disease (3). PMC can develop into toxic megacolon, often 
considered a surgical emergency, with fatality rates quoted between 38-80% (10). CDI 
is defined by the occurrence of symptoms (typically diarrhoea) in addition to one of the 
following; detection of stool toxin, toxigenic C. difficile or colonoscopic evidence of PMC 
(9). CDI rates have been suggested to be over-reported when methods that detect the 
organism (e.g. nucleic acid amplification tests for toxin gene), as opposed to those that 
target free faecal toxin, are utilised for diagnostic stool testing (11). Toxin detection 
methods potentially differentiate between active CDI and asymptomatic colonisation of 
the organism, and this is now reflected in the recommendation for multi-step algorithms 
in diagnostic stool testing (9, 12).   
CDI is a major healthcare burden, causing significant morbidity and mortality. The 
latest figures from the Office of National Statistics indicate that C. difficile rates in 
England and Wales are declining since 2008, with fewer death certificates mentioning 
CDI (13). The case fatality rate (30 day all-cause mortality) has decreased from 26.3 % 
in 2007/8 to 15.2 % in 2017/18 in England (14). This is likely due to the changing 
distribution of C. difficile ribotypes and interventions emphasising antimicrobial 
stewardship. CDI is still a major problem; one Scottish study reported the average cost 
of caring for an inpatient with CDI was £7500 compared to £2800 for non-CDI case 
matched controls (15, 16). Treatment costs associated with CDI are related to ICU 
treatment, non-specialised hospital ward stays, diagnostic testing, CDI antibiotics and 
the implementation of infection control measures. This is not to mention the economic 
costs associated with decreased patient productivity (17). 
1.2 Epidemiology 
CDI was regarded as a primarily nosocomial pathogen in the 1990s, occurring rarely, 
particularly in the community. However, in the 2000s marked increases in CDIs were 
observed in some settings, driven often by outbreaks of the highly virulent restriction 
endonuclease type B1,  pulse field gel electrophoresis NAP1, PCR ribotype (RT) 027 
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strain (B1/NAP1/027), for example in North America and Europe (18). The UK 
experienced an 027 outbreak at the Stoke-Mandeville hospital in 2003/2004 with 174 
cases; CDI was a contributing factor to 19 deaths (19). CDI severity was also 
increasing, coinciding with the 027 strain outbreaks (20-22). Thereafter, cases of CDI  
in the UK have declined from 55,498 cases in 2007/2008 to 13,361 in 2013/2014 (23). 
C. difficile is still a burden on the healthcare system with 12,480 cases reported in the 
UK between April 2016 and March 2017(24). The proportion of cases assignable to the 
027 ribotype has fallen since 2008, with an increase in the proportion of CDI 
attributable to other ribotypes (25). One ribotype is usually responsible for outbreaks, 
with increased antibiotic resistance being vital to the success of the strain in causing 
disease (26).   
There have been a number of factors proposed to have contributed to the emergence 
of the RT 027 and RT 078 strains in recent years. The prescribing practices and 
emergence of resistance to antimicrobial agents have been suggested as contributors 
to the rise of epidemic strains. In the US, clindamycin resistance was found in a strain 
responsible for an outbreak in four hospitals (27). Antibiotic stewardship and the 
reduced use of fluoroquinolones in the UK coincided with a reduction in the proportion 
of infections ascribed to the 027 strain (28, 29). Two 027 lineages have been described 
(FQR1 and FQR2) both of which acquired a gyrA mutation encoding fluoroquinolone 
resistance (30). Comparable stewardship measures have not been implemented in the 
US, where numbers of CDIs continue to increase, with a substantial proportion still due 
to the B1/NAP1/027 strain (31, 32). RT 106 is now the most commonly isolated strain 
in CDI in the US (33). More recently, dietary trehalose has been postulated to play a 
role in the rise of the RT 027 and RT 078 strains (34). Eight RT 027 and three RT 078 
strains were found to exhibit improved growth in response to low concentrations of 
trehalose, an effect not observed in other ribotypes. In a CDI mouse model, mortality 
was greater in trehalose treated mice versus the control (34). The rise of the RT 027 
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and RT 078 strains is likely multifactorial, depending on factors including, but not 
limited to, fluoroquinolone use.  
Community-acquired CDI is now being reported with greater frequency; there is 
evidence suggesting community-acquired CDI is somewhat underreported (35). In one 
study in the Netherlands, 18 % of community cases were found to be patients under 20 
(36). This is likely due to a lack of clinical suspicion in the community setting; 
particularly in patients under the age of 65. In one American population study, 41% of 
CDI cases were found to be in the community (37). The median age of CDI patients in 
the community was younger (50 vs 72) and severe CDI was less likely (20 % vs. 31 %). 
One case control study found that in community cases, approximately a third of 
patients had not been hospitalised or taken an antibiotic course in the previous month 
(38). Having contact with a child younger than two was associated with CDI (P = 0.02) 
(38). More recently, Fawley et al have demonstrated the similarity in ribotype diversity 
between community and hospital associated CDI, although 027 was found to dominate 
in healthcare settings (P = 0.02)(39).  
1.3 Pathogenicity 
C. difficile produces up to three major toxins, which are responsible for the symptoms 
observed in CDI. The most studied toxins are the enterotoxin A and cytotoxin B, 
monoglucosyltransferases that activate pro-inflammatory signalling pathways leading to 
cell death of colonocytes (40). The genes responsible for toxin A/B production, tcdA 
and tcdB are located on the C. difficile pathogenicity locus, PaLoc. C. difficile strains 
are differentiated into ‘toxinotypes’ based on variation in the pathogenicity locus, 
PaLoc. Strains are compared to the reference strain VPI10463 (41). 
The role of each toxin has long been debated, with earlier papers suggesting virulence 
attributable to toxin A alone, with tcdB- tcdA+ mutants producing fulminant disease in 
hamster models (42). However, contrasting results have validated the  role of toxin B in 
disease, with work suggesting toxin B alone can cause disease; increasing numbers of 
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tcdA- tcdB+ clinical strains have been isolated from patients (40).The use of a novel 
gene knockout system (ClosTron) to produce isogenic mutants found both toxins could 
produce in vitro cytotoxicity, which translated to disease in an in vivo hamster model 
(43). Knockout of both genes created an avirulent strain. Both toxins are important and 
should be considered in the virulence of C. difficile. It should also be noted that 
differences in toxin A/B exist and have been utilised in the identification of different C. 
difficile strains. Faecal toxin A/B levels have been correlated with clinical severity in 
one study (44). Patients with severe disease were found to have significantly higher 
faecal toxin levels.  In Canada, an 027 strain (toxinotype III) responsible for outbreaks 
of severe disease was found to have in vitro production of toxins A/B 16 and 23 % 
higher than a collection of toxinotype 0 strains (22).  
The PaLoc pathogenicity locus also contains three regulators, tcdR (positive regulator), 
tcdC (negative regulator) and tcdE, as well as the toxin A/B genes. Initially the 
importance of these regulatory genes was overlooked, but recent work has suggested 
the presence of a truncated TcdC protein leads to increased toxin production and in 
vitro cell toxicity (45).The clinical importance of this finding is unclear. A strain with a 
partial tcdC deletion was isolated in 84.1 % of patients in an outbreak in Quebec (20). 
However, a cohort study studying 199 CDI patient isolates found no association 
between clinical severity of CDI and the presence of the tcdC deletion (46). This lack of 
association is supported by other clinical studies to date (47, 48).   
However, the picture is complicated by the presence of another more recently 
discovered toxin. Some C. difficile strains also produce a binary toxin (CDT), an actin 
specific ADP-ribosyltransferase, encoded by the cdtA and cdtB genes (18), outside the 
PaLoc locus. This toxin was first discovered in 1988 by Popoff et al (49). Binary toxins 
are a well-recognised group within the Clostridial family, with homologous toxins 
produced by a number of species including Clostridium perfringens and Clostridium 
botulinum (50, 51).  The toxin is made up of two independent subunits, the enzymatic 
portion (CDTa) and the component responsible for membrane binding (CDTb)(52). 
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Once bound, CDTa allows the cytosolic transit of CDTb, which disrupts the 
organisation of the cell cytoskeleton (52). The role of CDT toxin in disease is unclear, 
but the importance of this toxin is highlighted by a cohort of CDI patients infected with a 
ribotype 033 strain that produces CDT in the absence of toxin A/B (53). More recently a 
prospective multicentre study illustrated infection with binary toxin positive strains is 
associated with increased all-cause mortality (54). 
1.4 Recurrence 
Recurrent CDI (rCDI)  occurs in approximately 25 % of patients after successful 
treatment with metronidazole or vancomycin (55). Patients may experience multiple 
recurrences, requiring repeated cycles of antimicrobial therapy. This is a major patient 
burden and healthcare cost. The reasons for recurrence are largely uncertain, with 
some evidence indicating that long-term changes in indigenous populations secondary 
to antibiotic use are responsible (56). Faecal microbiota transplantation (FMT), 
otherwise known as faecal bacteriotherapy, has been recognised for several years as 
an alternative treatment for rCDI. Superior cure rates compared to vancomycin have 
been established (57). It is hypothesised restoration of a normal gut flora can prevent 
reestablishment of CDI in the gut.  
Other research has focused on the pathogen itself, with some C. difficile ribotypes 
being documented more commonly in rCDI (58).  It has been recognised that 
germination of C. difficile spores is dependent on a number of factors, most notably 
factors in the environment. The discovery and investigation of “superdormant spores” in 
Bacillus species (59, 60) generates new questions about possible superdormancy in C. 
difficile. Bacillus subtilis is well characterised and is used as a model organism to 
investigate spore biology (61). Superdormant spores could persist in the environment 
and increase the risk of future reinfection. The morphology and sporulation pathways of 
B. subtilis and C. difficile have been shown to be very different (62). C. difficile spores 
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have a germination-specific protease receptor, CspC (63), compared with B.subtilis 
that possesses three main germinant receptors, GerA, GerB and GerK (60).    
Recurrence of Clostridium difficile infection can occur within two contexts; the 
recrudescence of C. difficile spores persisting in the gut (relapse), or reinfection with 
spores obtained from the environment (reinfection). Differentiating between the two is 
challenging without further detailed analysis. Some evidence suggests a mixed picture, 
with 33 % of recurrence attributable to different strains in one study (64). This picture is 
further complicated by a proportion of patients harbouring mixed infection with distinct 
C. difficile genotypes. Varying rates for recurrence due to relapse have been reported 
in the literature, with relapse accounting for rates of ~52-88 % in recurrent CDI (65, 66).  
The greatest risk of recurrence due to relapse is during the first 14 days after 
successful treatment (67); greater time periods between initial and recurrent episodes 
are associated with reinfection (68, 69). One study found the median time to a 
recurrent episode of CDI was 26 vs 67.5 days (relapse vs reinfection) (69). 
Differentiation between relapse and reinfection can be challenging, however, the 
identification of reinfection within the nosocomial environment has important infection 
control implications. 
The use of PCR ribotyping has been hypothesised to lack the discriminatory power 
required to detect  reinfection with isolates genotypically similar to the original infecting 
strain; several smaller studies using more discriminatory techniques suggested 
reinfection accounting for ~50 % of cases of recurrence (65, 67). It had been previously 
hypothesised that relapse may have been overestimated due to the use of less 
discriminatory identification methods.   However, one group comparing whole genome 
sequencing (WGS) to PCR- based ribotyping in rCDI samples found consistency 
between the results obtained.  The majority of isolates causing relapse identified by 
PCR ribotyping were within two single nucleotide variations of one another when 
compared pairwise using WGS (70). Despite these findings, it was still concluded that 
WGS is superior in discrimination between relapse and reinfection in CDI.  
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The increased presence of certain ribotypes in recurrent disease is increasingly being 
documented. Several studies have shown restriction-endonuclease (REA) B1 strains to 
be a risk factor for recurrence (58, 71, 72). Analysing CDI cases from 82 patients using 
multi-locus variable number tandem repeat analysis (MLVA), initial infection with the 
hypervirulent  strain 027/B1/NAP1 was identified as a statistically significant risk factor 
for relapse (P = 0.008) (68). This highlights not only an association of RT 027 strains 
with recurrence, but recurrence due to relapsing disease. One suggestion for this 
association could be increased sporulation in RT 027 isolates; increasing the potential 
number of spores produced during infection within the host. Some work initially tried to 
support this notion, but was limited by the small number of isolates tested (73). More 
comprehensive work has since provided further evidence of hypervirulent RT 027 
strains sporulating earlier and more extensively (74), although all of the above 
experiments were in vitro, limiting the conclusions that can be drawn. 
 Increased frequency of other ribotypes has also been documented in the case of 
relapse. RT 001 strains were found in 36 % (9/26) of relapsing patients in one Swedish 
study (75). RT 001 strains are endemic and frequently encountered in Eastern Europe 
(76). Interestingly, by comparing hospitalised patient data the same study theorised an 
increased nosocomial transmission rate of RT 001. This reinforces the notion that 
strains implicated in relapsing disease (RT 001, 027) (68, 75) could have enhanced 
sporulation, thereby increasing spore levels in the host and the environment. However, 
in Korea, a country with low RT 027 incidence, RT 017 and RT 018 strains were 
associated with the highest rates of relapse in one study (69). Hypervirulence (as has 
been postulated for RT027 strains) does not account for the high relapse rates 
observed; RT 017 and RT 018 strains have not been implicated thus far in severe CDI. 
A comparative assessment of these strains in relation to clinical outcome needs to be 
carried out.  Although strains may be associated with increased relapse rates, it is 
imperative to consider the demographic of a population in which this is occurring, as 
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regional differences in prescribing and initial infection demographics may have a 
bearing on recurrent CDI.  
In the case of recrudescent disease, spores must remain in the host gut and proliferate 
in response to favourable conditions. It has been demonstrated that C. difficile 
vegetative cells can adhere to Caco-2 cells and extracellular proteins in vitro (77). 
Contemporary work has also described spore adherence to Caco-2 cells, and has also 
identified the two potential proteins responsible for this interaction (78). Additionally, in 
C. difficile spores bound to Caco-2, HeLa and HT-29 cells, no significant germination 
was observed (79).  This concurs with the current evidence on germination that spores 
germinate favourably in response to bile salts. The presence of human colonic 
epithelial cells alone is not necessarily sufficient.  Previous work has demonstrated the 
persistence of two different morphotypes of C. difficile spores produced from one 
culture (80). These two morphotypes were present in both biofilm and planktonic 
cultures. The spores from biofilm cultures were found on average to have a thinner 
exosporium compared to spores from planktonic cultures.  It is reasonable to speculate 
that spores produced in biofilms may have different properties from those produced 
from planktonic cells, thereby altering the ability of spores to attach to host cells. 
Although these experiments are in vitro, they suggest a potential mechanism of 
recurrence whereby spores could be capable of prolonged attachment in the gut.  
Although research has focused on the pathogen, host factors should not be ignored in 
the context of recurrence. It has been shown previously that a strong immunological 
response to toxin A in initial CDI reduces the chances a recurrent episode (81). 
Approximately 60 % of the populations have serum IgG and IgA active against toxin A, 
but only 2 % of the population are carriers (82). An antitoxin A vaccine trialled in 3 rCDI 
patients produced statistically significant serum IgG levels and prevented recurrence in 
all patients up to 22 months after (83). Low levels of serum antitoxin A and antitoxin B 
have been associated with increased risk of recurrent disease (84). These studies 
suggest that an inadequate response to initial CDI predispose to recurrent disease. If 
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high risk patients are identified at an early stage, steps may be taken (for instance, 
careful antibiotic selection) to reduce the risk of rCDI. It could be the case that 
susceptibility to CDI and subsequent rCDI may begin in childhood; a recent study found 
high levels of toxin A/B antibodies in the sera of colonised infants (85). 
One group characterised C-reactive protein (CRP) levels in response to initial and 
recurrent episodes of C. difficile; their findings suggest patients suffering a relapse 
produce statistically significantly lower levels of CRP in their first episode of CDI than 
those suffering reinfection with a different strain (86). It may be that in patients with a 
reduced immunological response against initial CDI, a failure in producing 
immunological memory predisposes to future infection with the same strain. 
Interestingly, it has been shown that commensal clostridia are able to modify and 
manipulate the host innate immune system; germ-free deficient mice have a reduced 
number of IgA-producing cells compared to those treated with commenal clostridia (87-
89). As well as the importance of the host immune response to C. difficile in predicting 
rCDI, other species may modulate the immune response, providing a potential 
explanation for the efficacy of faecal microbiota transplantation. Future work focusing 
on the immunological component of infection could serve to provide clinicians with 
diagnostic tools capable of predicting the risk of recurrent CDI.  
1.5 Risk Factors 
The greatest risk factor for initial episodes of CDI is the use of antibiotics. Hamster 
models conducted in various research groups revealed this role in 1978 (3, 5). Later 
investigation has proved supportive of this conclusion, with a broad range of antibiotic 
classes provoking CDI in hamsters carrying C. difficile (5, 90). Clindamycin, an 
antibiotic commonly used currently to simulate CDI in various in vivo and in vitro (91, 
92) experiments was found early on to have a prolonged tendency compared to other 
antibiotics to cause CDI. This has been replicated in more recent work investigating gut 
microbial population changes after antibiotic administration (93). A meta-analysis 
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performed in 1998 conclusively associated antibiotics with risk of CDI (94).  A 
mechanism for C. difficile proliferation after antibiotic instillation has been 
hypothesised; microflora disturbances secondary to antibiotic usage allow C. difficile 
spores to germinate. Due to disruption of the existing populations, colonisation 
resistance to C. difficile is lost and vegetative cells are able to proliferate.  
Fluoroquinolones have been identified as high-risk antibiotics in predisposing to CDI, 
with a range of other classes constituting an intermediate risk (95). As such, clinical 
guidelines now recommend clinicians consider restricting the use of fluoroquinolones, 
clindamycin, and cephalosporin use (9). Different classes of antibiotics have been 
found to differentially affect bacterial gut populations, with some antibiotics being low 
risk (e.g. gentamicin) because of little activity against anaerobes. In contrast, the 
fluoroquinolone enrofloxacin is associated with changes in 32 different bacteria groups 
(96, 97). Interestingly, one study found that antibiotic instillation in mice (kanamycin, 
clindamycin, cefoperazone, vancomycin) was associated with a decrease in 
Lachnospiraceae and Ruminococcaceae family organisms;  concurrent metabolomics 
revealed a decrease in the abundance of secondary bile acids, which are inhibitory to 
C. difficile (98). Buffie et al have demonstrated that Clostridium scindens is protective 
against CDI in mice due to its function; 7α-hydroxylation of primary to secondary bile 
acids (93). Antibiotics may predispose to CDI by their differential effects on the gut 
microbiota; different families are likely to be involved in dissimilar functional and 
metabolic functions.  
Another well recognised risk factor for CDI is advanced age. CDI rates were 13 times 
greater in patients over the age of 65 vs patients in the 18-44 age range in 2011 in the 
US (31, 99). Older patients are more likely to suffer from other diseases and the 
association between age and CDI incidence is still statistically significant when 
confounders are accounted for. It is unsurprising that advanced age is a risk factor for 
CDI, the microbiome changes throughout human life, with an overall reduction in the 
Shannon diversity, an index used to measure diversity within a bacterial community. 
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When compared with a younger population (30-60), older populations (70-100) have a 
stepwise increase decade by decade in the proportion of Proteobacteria phylum 
organisms, as well as an increased proportion of Bacteroidetes (100). However, large 
scale studies assessing the effect of ageing on the microbiome of populations from 
multiple demographics and locations have not been performed. As well as differences 
in the microbiome, older individuals generally have an impaired immune response and 
potentially lower levels of circulating antibodies against C. difficile (101) .  
Diet is factor that has recently been considered in the pathogenesis of CDI. Zackular et 
al used a mouse model to infer the detrimental effect of high concentrations of zinc 
(1,000 mg/kg) on the diversity of the gut microbiome (102). In addition, a high zinc diet 
caused an increase in colonic inflammation and increased toxin titres in CDI (102). 
Dietary zinc binds to the protein calprotectin, a protective protein that sequesters 
metals away from pathogens (103). Higher titres of calprotectin have been associated 
with an increased severity of CDI (104, 105). These findings are isolated and must be 
confirmed by more reliable study types. But it is unsurprising diet influences the 
microbiome; individuals can be identified as having a ‘Western’ lifestyle with high 
reliability on their gut microbiota alone (106). Diet is likely to be a factor influencing the 
structure of the human gut microbiome.  
In terms of risk factors for rCDI, a 2015 systematic review and meta-analysis combined 
the findings of 33 eligible multivariate studies to elucidate relative risks (RR); age ≥ 65 
years (RR 1.63), additional antibiotic during follow up (RR 1.76), PPI use (RR 1.58) and 
renal insufficiency (RR 1.59) (107). Risk factors were only included in this systematic 
analysis if they were present in 3 or more of the studies included in the analysis. Other 
risk factors could therefore play a tangible role in rCDI. The multifactorial nature of 
disease in individuals is further reflected in the inability of a model constructed from 
150 variables to correctly predict disease recurrence (108).  
Having had a previous episode of recurrent disease significantly increases your risk of 
having a further recurrence, with two or more recurrences doubling the risk (101). 
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Repeated cycles of antibiotics will lead to a prolonged dysbiosis and predispose 
individuals to rCDI through loss of colonisation resistance. As with initial CDI, rCDI risk 
factors are likely to be multifactorial; a small study in humans found rCDI patients have 
elevated primary bile acid levels in stool compared to initial CDI and controls (109). 
Although meta-analyses have been performed providing estimates of risk, high levels 
of bias and confounding still exist in in the evidence base used to generate measures 
of risk (99).   
1.5.1 Potential C. difficile reservoirs 
 
The source of the pathogen in community acquired CDI is unclear, but a number of 
potential reservoirs have been identified, including animals, the environment and food. 
C. difficile has been isolated from domesticated pets and their living spaces (110-112), 
horses, camels, donkeys, poultry and pigs (113). RT 078 strains have been isolated 
from pigs with high prevalence (80 %) (113, 114). Recently, Knetsch et al (2018) used 
whole genome phylogeny analysis to highlight high levels of geographical clustering 
between human and animal derived RT 078 strains, with evidence of bidirectional 
(animal to human and vice versa) and international transmission (115). This is an 
important study indicative of the transmission of the highly pathogenic RT 078 between 
humans and animals. Greater mortality rates have been reported in RT 078 when 
compared with the hypervirulent RT 027 (116). The prevalence of infection with a RT 
078 strain has increased, particularly in the Netherlands but also in the UK since the 
mid-2000s (114).  
Within the food industry C. difficile spores have been isolated from a variety of meat 
products, cooked and uncooked, including ground beef, chicken, chorizo, sausage and 
pork (117-119). Although many studies have not assessed overall spore burden within 
meats, 20-60 spores/g have been reported previously (120).  One study found a 
greater prevalence of C. difficile in ‘ready-to-eat’ meats (47.8 %)  when compared to 
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uncooked meats (40.0 %)(117). Sub lethal heat shock has also been found to ‘select’ 
for the RT 078 (121).  
 In addition to the isolation of C. difficile directly from food, one Western Australian 
study isolated C. difficile from 26.7 % of gardening products (fertilisers and soil 
conditioners) with 45.9 % of isolates demonstrating toxigenicity (122). The same group 
also found a high prevalence of C. difficile (~30 %) on root vegetables from farmers 
markets and retail stores in Western Australia, half of which were toxigenic strains 
(123). In a French study, salads were also found to be a source of C. difficile. C. difficile 
has also been isolated from swimming pools, lawns and soils (124, 125).  
The potential interplay between food and animals is highlighted by the finding of C. 
difficile in food consumed by pets (126-128). However, toxigenic C. difficile was only 
isolated from one sample (1/25) compared to a 20 % rate for C. perfringens (5/25) in 
one study (128). The use of fertilisers in the production of food produce also highlights 
the ‘crossover’ and interplay between two identified reservoirs. Although C. difficile has 
been isolated from animals and food products, both cooked and uncooked, further work 
is required to demonstrate the relevance of these reservoirs in clinical disease in 
humans. As well as the non-human reservoirs identified above, a substantial 
percentage (~0-15%) of the human population are asymptomatic carriers of C. difficile 
(129-132). Clearly interplay and crossover exists between the reservoirs identified 
previously and the asymptomatic carriage of C. difficile in the human population. 
To summarise, C. difficile is increasingly becoming a pathogen of concern in the 
community. In the case of reinfection, it is possible some or all of the reservoirs 
discussed could be implicated in rCDI. The isolation of C. difficile from cooked meats 
suggests further detailed investigation of the effects of heat on C. difficile spores is 
required.   
1.5.2 Treatment 
1.5.2.1 Antibiotics 
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Antibiotics are the standard treatment of choice for CDI, with vancomycin and 
metronidazole emerging as first line antibiotics in the 1980s (133). Comparable rates of 
disease resolution in first episodes of mild CDI are observed (98 % vancomycin vs 90 
% metronidazole)(134). However, recent studies have established the inferiority of 
metronidazole vs vancomycin in clinical success of treatment of CDI (P = 0.02, 72.7 % 
vs 81.1 %) (134, 135). Historically, metronidazole has been used as a first line agent in 
more moderate disease with vancomycin being reserved for more severe disease. The 
same therapeutic agent was prescribed in the case of a recurrent episode (136). Based 
on an evaluation of the evidence, clinical guidelines now recommend the use of 
vancomycin or fidaxomicin over metronidazole in a first case of CDI (9). In the case of 
recurrent episodes, vancomycin tapering/pulse therapy is recommended in the UK (9) 
(137). This consideration is informed by the superiority of tapered and pulsed doses of 
vancomycin in treating rCDI (101). However, it should be noted the evidence base is 
weaker than in the case of recommendations made for initial episodes. Using pulsed or 
tapered fidaxomicin dosing regimens has also proved to be successful; reducing C. 
difficile  and toxin levels in an in vitro gut model, perhaps reducing the potential for 
recurrence (91). All fidaxomicin regimes were sufficient to resolve CDI. In the EXTEND 
clinical study extended-pulsed fidaxomicin therapy was superior to vancomycin for 
reducing recurrence (138).  
Fidaxomicin, a macrocyclic narrow spectrum antibiotic previously known as OPT-80, 
has emerged more recently as a new drug for CDI. Preliminary activity against 207 C. 
difficile  strains in vitro was observed in 2004 (139), and in recent times fidaxomicin has 
demonstrated non-inferiority to vancomycin in clinical trials in the USA and also in 
Europe (140). The main advantage of fidaxomicin treatment has been the reduced 
incidence of recurrent disease. Microbiota disturbances produced by fidaxomicin are of 
a reduced magnitude than those produced by vancomycin; particularly reductions in 
Bacteroides and Prevotella genera organisms (141). Vancomycin has a greater effect 
on the diversity of the microbiome resulting in a less diverse microbiota compared to 
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the use of fidaxomicin. The importance of the spared species and their significance in 
recurrent CDI is the focus of ongoing research. It is hypothesised the reduced 
microbiota disturbance promoted by fidaxomicin administration is responsible for the 
decreased rates of recurrence observed. Although fidaxomicin decreases recurrence 
rates, it is more expensive than the alternatives; however, a study in Canada estimated 
each recurrence avoided cost $13,202 (142). 
Other antibacterial agents that have been and continue to be studied for the treatment 
of CDI include ramoplanin, teicoplanin, rifaximin, ridinilazole, nitrazoxanide, fusidic acid 
and rifampin (143). Antibacterial agents that reduce the incidence of recurrent episodes 
are of particular interest.  Ramoplanin is a glycolipodepsipeptide antibiotic that binds 
lipid II, thus preventing the formation of the cell wall. In 2004, a phase II trial found 
rates of disease resolution to be comparable between vancomycin and ramoplanin 
treated patients (84 % vs 86 %), with similar rates of recurrence. Due to the study 
being open-label and harbouring a small n size, superiority of ramoplanin to 
vancomycin could not be established.  This data suggest that ramoplanin may not be 
suitable in preventing recurrences. In vivo and in vitro observations support the efficacy 
of ramoplanin, which has been found to be comparable to vancomycin in CDI 
resolution in both hamster models and an in vitro gut model (144). Importantly 
ramoplanin appeared to reduce spore shedding and decreased the recovery of spores 
from stool when compared to vancomycin treatment. This phenomenon was recreated 
in 2015; C. difficile spores exposed to 300 μg/ml ramoplanin showed no outgrowth 
when plated on solid agar (145). Reduced spore load and recovery provide a feasible 
mechanism for recurrence reduction, as is the case in fidaxomicin. Ramoplanin is yet to 
be evaluated in phase III trials. Furthermore, ramoplanin derivatives have been isolated 
from other  members of the Actinomycetales order of bacteria; ramoplanin is produced 
by Actinoplanes sp. ATCC 33076 (146). The closely related teicoplanin has been found 
to be helpful in severe refractory CDI (147) and has previously been found to be 
associated with reduced recurrence rates when compared with metronidazole, fusidic 
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acid and vancomycin (148). These compounds could be more efficacious than 
ramoplanin in treating CDI; reducing the incidence of recurrence.  
Several drugs in the rifamycin class have been investigated for their potential benefits 
in rCDI, including rifaximin, rifampin and rifalazil. Rifamycins bind to prokaryotic DNA-
dependent RNA polymerase with high affinity, preventing RNA synthesis. Due to the 
nature of this inhibitory mechanism, levels of resistance are high and as such 
rifamycins are often used in combination with other antibiotics. Spontaneous mutations 
in the rpoB gene (ribosomal polymerase gene) occur readily, mediating resistance. In a 
retrospective analysis 53 % (17/35) of rCDI patients had no recurrence 12 weeks after 
rifaximin therapy after routine metronidazole/vancomycin treatment (149). In an earlier 
study, 7 out of 8 women who had previously suffered 4-8 rCDI episodes suffered no 
further relapses after a two week course of rifaximin immediately following vancomycin 
(150). Perhaps the most concerning discovery of this small study is the high rifaximin 
MIC encountered in the patient who required a second round of rifaximin therapy.  
Rifaximin has also been used as a first line agent in a prospective small open label 
study; of the 8 patients who completed the study all were clinically cured and 7 were 
free of recurrence up to 162 days post-CDI (151). The largest study to date compared 
rifaximin vs placebo as a chaser therapy in a randomised, blinded pilot study enrolling 
68 patients (152). Patients given rifaximin experienced a decreased recurrence rate (15 
%) vs the placebo (31 %). Although promising, due to the lack of larger clinical trials 
and the possibility of resistance, rifamycins such as rifaximin cannot currently be 
recommended as a first line or chaser therapy for rCDI.  
Oxazolidinones are another class of antibiotics that have shown promise in treating 
CDI and preventing recurrence. This class of antibiotics exert their antimicrobial effects 
by binding to the 50S subunit of the bacterial ribosome and preventing protein 
synthesis. The oxazolidinone antibiotic cadazolid has been demonstrated to be highly 
active against 100 C. difficile isolates including 30 epidemic strains; cadazolid also 
proved to be effective in treating simulated CDI in an in vitro gut model, with no signs of 
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recurrence (153). A phase II randomised, double-blind study including 84 first 
recurrence patients also illustrated the clinical non-inferiority of cadazolid to 
vancomycin in the treatment of CDI/rCDI (154). In addition, cadazolid treated patients 
harboured lower recurrence rates vs vancomycin (18.2 to 25.0 % versus 50 %). 
However, a statement by Actelion indicated cadazolid reached the primary endpoint 
(resolution of disease) in IMPACT 1 but not in IMPACT 2 (155). Both IMPACT 1 and 
IMPACT 2 were phase III clinical trials. Due to cadazolid not reaching its primary 
endpoint, its continued development is unlikely (156). 
One of the most promising agents in development is ridinilazole. Ridinilazole 
(SMT19969) is a small molecule antibiotic with a very narrow spectrum of activity (157, 
158). The mechanism of action is not fully understood, but one study found cell division 
ceased on exposure to ridinilazole (159). The same study also found ridinilazole 
significantly reduced levels of both toxin A and toxin B at sub-MIC concentrations.  In a 
phase II trial (CoDIFy) recruiting 100 patients, recurrence rates were 14% for patients 
treated with ridinilazole compared to 35 % in the vancomycin group (160). Ridinilazole 
was also superior to vancomycin for sustained clinical cure. The antibiotic has also 
been found to be well tolerated with adverse events reported to be mild in severity 
(161). The high tolerability, narrow spectrum of action, efficacy in reducing recurrence 
and low systemic absorption make this a promising potential treatment. Phase III 
studies are planned to commence in 2019. 
 
1.5.2.2 Faecal microbiota transplantation 
FMT has been documented as a treatment since the 1950s for pseudomembranous 
colitis (162), and is increasingly being evaluated as a CDI treatment, particularly for 
patients exhibiting persistent rCDI. FMT alongside antimicrobial therapy is now 
recommended by European guidelines for the treatment of non-responsive rCDI (163). 
A wide variety of administration protocols have been utilised; FMT infuses donor faeces 
either by nasogastric tube, colonoscopy or enema into the patient’s gastrointestinal 
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tract with the aim of reconstituting the patient’s microflora. Antibiotics have wide 
ranging detrimental effects on the gut microflora, which is believed to interrupt the 
‘colonisation resistance’ of the host to pathogens such as C. difficile. It is believed FMT 
reconstitutes the patient’s gut with a ‘healthy’ microflora from a donor. When 4 patients 
with rCDI treated with FMT were followed up for 84 days, 16s-rRNA sequencing 
highlighted the similarity of patient and donor microbiome immediately after FMT (164). 
Pre-FMT samples were found to have high levels of Proteobacteria and low levels of 
Firmicutes and Bacteroidetes phyla organisms. Interestingly both donor and recipient 
microbiome profiles diverged significantly over the long term. These results are limited 
by the low number of patients in the study and the lack of diversity in donors; all 
patients received FMT samples from the same donor. 
Although FMT had been identified as a promising treatment for rCDI, up until 2011, 
systematic reviews found there were no randomised controlled studies available 
comparing FMT to other treatments (165, 166). Before 2012, ~13 different studies had 
studied FMT as a treatment for rCDI (64), with cure rates ranging from 81-100 %. Since 
2012, two randomised control trials have been carried out to assess FMT for treatment 
of rCDI. The FECAL study was carried out in 2013, and involved randomly assigning 
patients to three treatment arms; vancomycin treatment followed by bowel lavage and 
duodenal infusion of donor faeces, vancomycin with bowel lavage, and vancomycin 
alone (57). Eighty-one percent of patients had disease resolution in the duodenal 
infusion group vs. 31 % and 23 % in the other groups, respectively. Although 
promising, this study was open label, had a fairly low number of participants and also 
excluded a number of groups from the study. The results of the second randomised 
trial were published in 2016; a double-blind, randomised control trial comparing 
autologous stool FMT (n = 24) to donor stool FMT (n=22) in for treatment of rCDI (167). 
Overall, resolution of rCDI occurred in 91% of patients treated with donor faeces and 
63% with their own. There were big differences in resolution rates of rCDI between 
sites for autologous FMT, with one site reporting 90 %. It is unclear why recycling a 
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patient’s own stool via FMT could be curative for rCDI. Nevertheless, both of these 
randomised control studies support the use of FMT for treatment of rCDI.  
A systematic review found that differences did exist between the different methods of 
transplant instillation; lower GI instillation had a resolution rate of 89-96 % vs 76 % in 
upper GI infusion (168). There were also differences in resolution observed between 
transplants prepared with different diluents (saline, water, milk) and in different 
volumes. A statistically significant difference in efficacy has been demonstrated 
between colonoscopy and nasogastric tube administration in an open label randomised 
trial (169). However, it should be noted that this trial only involved 10 patients in each 
arm and larger clinical trials are necessary. 
The changes associated with antibiotics may be associated with a loss of metabolic 
function in the microbiota. One study found that when comparing pre-FMT stool 
samples to post-FMT and donor stool samples not only was there a statistically 
significant decrease in the Shannon diversity index, but a significant shift in the bile 
acid profile (170). The same group later confirmed this associated with in vitro studies; 
10 C. difficile clinical isolates failed to germinate and outgrow in the same bile acid 
profile environment as the post-FMT stool samples (171). Distinct differences in the bile 
acid profiles of patients presenting with an initial case of CDI and rCDI have also been 
investigated; a study involving 60 patients (20 CDI, 19 rCDI, 21 controls) managed to 
distinguish CDI from rCDI patients correctly 84.2 % of the time (109) based on 
deoxycholate: glycursodeoxycholate stool ratios alone.  
These studies illustrate a potential metabolic mechanism for the efficacy of FMT, 7α-
hydroxylation of primary bile acids into inhibitory secondary bile acids. However, this 
model is too simplistic as some primary bile acids are inhibitory to spore germination 
(e.g. chenodeoxycholate) and some secondary bile acids are stimulatory to spore 
germination (e.g. deoxycholate). In normal healthy patients chenodeoxycholate is 
metabolised to another inhibitory bile acid, lithocholate. In antibiotic treated patients 7α-
hydroxylating species such as C. scindens may be absent, and chenodeoxycholate is 
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more rapidly taken up by colonocytes than cholate, ensuring a higher ratio of 
cholate:chenodeoxycholate favouring germination (172). More recently taurocholate 
mediated germination (0.1 %) been shown to be significantly different in a number of 
clinical strains in the presence secondary bile acids; there are almost certainly 
differences between the response of different strains (173). These results should be 
considered carefully, as they are from in vitro work.   
The creation of a donor bank of frozen faeces could be a viable option in the future 
(Openbiome)(174). This would make FMT available for clinicians in their practice; 
currently, outside of the US/Canada, FMT is not widely available. One study assessing 
the viability of faeces frozen with 10 % glycerol for 6 months found no statistically 
significant decrease of six bacterial groups (Bifidobacteria, E. coli, total coliforms, 
Lactobacilli, total anaerobic bacteria, total aerobes), and stools frozen for >2 months 
were used to clinically cure 16 patients (175). The same study also underlined that 
faeces frozen in minimally nutritious conditions (saline alone) suffers microbial 
degradation over time. Only 16 patients were included in this study and there was no 
comparator. Other open label studies supported these findings; with an overall cure 
rate of ~90 % achieved (169, 176).  Interestingly, clinical cure was also observed in 3 
children; the majority of studies only include adults. The aforementioned studies were 
small pilot studies; the conclusions were quite limited due to low n size, no comparators 
and no blinding. More recently, a double-blinded, randomised clinical trial compared 
fresh and frozen faeces by enema for treating rCDI (177). Non-inferiority of frozen 
faeces for clinical cure was observed (83.5 % for the frozen FMT group and 85.1 % 
fresh faeces) indicating the feasibility of frozen faeces for FMT.  
However, FMT should be used only with considerable deliberation. Clearly, 
colonoscopy can only be carried out by a trained physician, and there is a small risk of 
perforation and bowel injury. In addition, although donor faeces are screened for 
infectious diseases, there is still a small transmission risk. The role of the microbiota in 
gastrointestinal diseases and autoimmune disease is increasingly being appreciated 
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(178) and donors should not suffer from these ailments (179). Transplantation of a 
‘normal’ individual’s microbiota into a patient could still represent a risk. A fundamental 
and thorough understanding of the interactions in the gut is absent and needs further 
investigation. In the future it may be possible for targeted therapy rather than the 
‘shotgun’ approach of FMT. For example, same species strains from donor and 
recipient have been found to coexist, but new species do not readily establish 
themselves in the recipient gut microbiome (180). Detailed strain specific knowledge of 
donor and recipient could allow targeted therapy for establishment of desirable 
populations. 
FMT is clearly an exciting and promising therapy for rCDI, but it is not appropriate for 
the vast majority of patients. Microbiota-host interactions are still not fully understood, 
and a risk of prospective problems such as metabolic syndrome, cancer and 
cardiovascular risk in recipients is recognised. These considerations manifest in clinical 
guidelines, where FMT is indicated only in cases where appropriate antibiotic regimens 
have failed in 3 or more cases (9). 
1.5.2.3 Probiotics 
The term probiotic was introduced in 1965 by Lilly & Stillwell to describe protozoan 
stimulatory molecules (181). The first instance of its contemporary usage was by 
Parker in 1974 to describe growth enhancement in animals by microbial 
supplementation (182). A historical definition of probiotic was devised in 1991 by Fuller; 
“A live microbial feed supplement which beneficially affects the host animal by 
improving its microbial balance”(183). This definition has some weaknesses, notably 
what an improvement in ‘microbial balance’ actually entails. In contemporary 
microbiology the term ‘probiotic’ has become somewhat controversial, particularly 
regarding ethical implications in the food industry. There are widespread 
misconceptions by the public due to the manufacturing of supplements that have 
exploited the term probiotic. This has led to extensive discussion and deliberation by an 
international expert panel on what is admissible as being labelled a ‘probiotic’ and what 
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is not (184). In addition, a 2016 systematic review of seven randomised control trials 
found no significant differences in diversity of microbiota of healthy adults 
supplemented with probiotics compared to placebo (185). Although no conclusive 
evidence exists which demonstrates a beneficial effect of probiotics on healthy 
patients, this does not discount probiotics being effective in the context of CDI. 
A number of species have been investigated in the prevention of antibiotic associated 
diarrhoea (AAD) including Lactobacillus, Bifidobacterium, Enterococcus, Bacillus and 
Saccharomyces species. A systematic review and meta-analysis of 63 randomised 
control trials found a relative risk ratio for AAD of 0.52 in patients treated with a 
probiotic during concurrent antibiotic therapy (186). Although this indicates a beneficial 
effect of probiotics on diarrhoea prevention, many of the studies included in the 
analysis used different strains of the same species; varying formulations and patients 
were often on different antibiotics and had diverse comorbidities. Differences in the 
reconstitution of an antibiotic disrupted gut have been illustrated in a mouse model; 
different Lactobacillus strains were more effective at rebuilding a diverse microbiome 
(187). More research is required to individually elucidate the efficacy of each strain 
used.   
The inhibition of in vitro C. difficile growth by other microorganisms was reported in the 
1980s (188). When the term probiotic is applied to C. difficile, it is generally considered 
to describe populations that could; a) decrease the risk of developing CDI in antibiotic 
induced dysbiosis, b) treat the underlying C. difficile infection or c) decrease the risk of 
a recurrent episode. In the case of a) and c), the probiotic strains may counteract the 
deleterious effects of antibiotics on the gut microflora and restore colonisation 
resistance. In the case of b) any probiotic strains would be assumed to have an 
inhibitory effect on some aspect of the C. difficile life cycle. In 2005, a meta-analysis 
investigating the use of probiotics in the treatment or prevention of CDI found no 
substantial evidence for probiotic use, possibly due a low number of eligible studies 
and a high level of methodological heterogeneity (189). However, a more recent larger 
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meta-analysis (26 randomised control trials included) found that adjuvant probiotic 
therapy significantly decreased the risks of both AAD and CDI by 45.8 and 60.5 % 
respectively (190). This is in accordance with a previous meta-analysis in 2013 which 
found a 64 % CDI reduction in adults and children (191). The timing of administration 
has also been investigated with metaregression analysis of 19 studies finding a 
decreasing efficacy of probiotics the longer probiotic administration is delayed from 
antibiotic treatment onset (192).  However, all of the cited studies suffer from the same 
methodological flaw; primarily that they analyse studies using a wide range of different 
species and strains. Further work is required to elucidate important species and at what 
dose and duration they are efficacious in the prevention of CDI.  
The mechanism of action of probiotics is unclear, particularly as different species and 
strains have been used. Different mechanisms could exist for the different species 
used.  The strain used in a probiotic is important, different subspecies of Lactobacillus 
have shown varying efficacy in the prevention of AAD. The PLACIDE study, a 
randomised, double-blind placebo controlled trial found no effect of a mixture of 
Lactobacillus and Bifidobacterium strains (two strains of Lactobacillus acidophilus, 
Bifidobacterium bifidum and Bifidobacterium lactis) on prevention of AAD or CDI (193). 
On the other hand, this study only investigated a few species and strains, and cannot 
be extrapolated to discount other species/strains. One group illustrated in a mouse 
model that some Lactobacillus strains offered protection through their high 
fructooligosaccharide metabolism and cell adhesion properties (187).  Efficacious 
probiotics increase the diversity of the microbiota and consequently increase the 
production of antimicrobial short chain fatty acids (SCFAs) which potentiates protection 
against pathogenic species and fosters a diverse microbiota.   
Pre-inoculation twice daily for two days with 107 vegetative cells of a non-toxigenic 
strain of C. difficile (CD37) successfully prevented CDI in mice with a hypervirulent 027 
(UK6) (194). This study had a low n (10) and was carried out in mice so it is unclear 
how relatable this is to human patients. Bifidobacterium longum ATCC15707 inhibited 
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C. difficile growth in vitro  and in vivo; mice receiving live cells of B. longum had a 70 % 
survival rate vs 40 % in the case of CDI (195).  Bifidobacterium longum produces a 
range of acids including lactate, acetate and formate and in in vitro experiments pH 
was deemed responsible for the inhibition of C. difficile growth. The non-pathogenic 
yeast Saccharomyces boulardii has also been investigated a probiotic for CDI; in 1999  
the proteolytic cleavage of toxin A/B by an S. boulardii protease was discovered (196). 
Other mechanisms include colonic receptor destruction. In a double-blind randomised 
control trial, S. boulardii administration alongside vancomycin produced a recurrence 
rate of 16.7 % (3/18) vs 50 % (7/14) for vancomycin alone (P = 0.05)(197) . 
As well as the administration of live vegetative organisms, there is increasing interest in 
the administration of spore preparations. Spore preparations avoid the negative stigma 
of FMT and also circumvent the unpleasant side effects of FMT such as ‘faecal 
belching’. Spores also have an increased ability to survive the low pH inherent in the 
stomach, in contrast to vegetative cells (198, 199). Stomach acid acts as a barrier to 
bacterial entry and colonisation of the gastrointestinal tract (200). It is hypothesised 
ingested spores germinate and reconstitute the gastrointestinal tract in vegetative form, 
as in FMT. Recently, a novel spore preparation called SER-109 containing Firmicutes 
organisms was produced from 7 healthy donors (201). A group of 30 rCDI patients 
(mean previous rCDI episodes = 3) were treated with either a dose of ~1.9x109 on two 
days or 1.1x108 spores on one day after successful antibiotic treatment of CDI. After 8 
weeks follow-up, 86.7 % of patients experienced no recurrence. Unfortunately, this 
work had major limitations; a lack of a suitable placebo arm and the open label design 
of the study limit its impact. SER-109 failed to show efficacy in the phase II 
ECOSPORTM study (202), probably because of issues concerning use of a suboptimal 
CDI diagnosis method and a single rather than repeat dose of SER-109, but is now 
undergoing phase III testing after modification. The initial study does provide further 
evidence that spore preparations could be a feasible alternative to FMT in the future for 
rCDI.  
26 
 
The literature discussed suggests a role for probiotics in the prevention of initial CDI. 
Probiotics could not be recommended for all patients on antibiotics until further work is 
carried out elucidating effective species and dosage. In addition, there is a scarcity of 
literature regarding the use of probiotics in rCDI. The use of prophylactic antibiotics is 
not recommended under current clinical guidelines due to the low quality and scarcity 
of literature (9). 
1.5.2.4 Alternatives 
The efficacy of treatments including antimicrobials, probiotics and FMT are primarily 
due to their effects on the microbial composition of the gut. This is achieved by 
rectifying dysbiosis by reconstituting the microbiota with FMT or probiotics.  However, 
CDI and rCDI are mediated through the injurious actions of toxins on the large colon. 
As such, a number of alternative therapies targeting the toxins themselves have been 
investigated and some have shown limited success.  
Direct neutralisation of the toxins has become an avenue of exploration. The 
manufacture of monoclonal antibodies (MAbs) directed against the C. difficile toxins 
has become of increasing interest; by blocking the actions of toxins disease cannot 
recur. Three-thousand non-CDI human sera samples were tested for activity against 
toxins A/B; 8 samples showed activity. B cells were isolated and the variable region of 
the produced IgG was cloned and used to produce recombinant MAbs (203). Three 
different antibodies were manufactured (2 anti-toxin B, 1 anti-toxin A) and administered 
alone and in combination, protecting against mortality 100% in a hamster model when 
used in combination. However, the MAbs offered no protection alone or in combination 
when used against a more hypervirulent strain. Clearly, rodent models of CDI are 
limited in scope; hamsters are exquisitely sensitive to toxigenic strains of C. difficile and 
disease does not mirror that in humans. As well as targeting the toxin, some work has 
shown a median decrease in recurrence of 2 days in hamsters treated with an anti-
spore immunoglobulin Y (chicken derived) (204), highlighting the potential for 
antibodies targeting other components necessary to rCDI. 
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The effects of two MAbs (anti-toxin A - MK3415) (anti-toxin B – MK6072) on the 
immune response in human colonocytes and peripheral blood monocytes has been 
investigated. Both MAbs reduced the production of the proinflammatory cytokines TNF-
α and IL-1β in monocytes (205), providing evidence that MAbs can reduce the innate 
immune response and conceivably reduce disease severity and mortality. Although this 
therapy shows promise, some strains of hypervirulent C. difficile produce an 
antigenically variable form of toxin (206).  Further studies are required to elucidate toxin 
variability, and the widespread feasibility of clinical use of MAbs, considering this. It is 
unclear how long circulating antibodies could protect against disease, which is of 
particular importance in rCDI. Over time levels of artificially administered antibodies 
may drop, reducing their effectiveness in the case of recurrent disease. One toxin A 
neutralising antibody (CDA1) failed to significantly reduce recurrence rates in a phase II 
study (207). On the other hand, MK6072 (now renamed bezlotoxumab) has shown 
suitability for further investigation (67).   
The monoclonal antibody bezlotoxumab has shown particular promise for rCDI in 
humans, with two phase III trials (MODIFY I & II) showing the superiority of 
bezlotoxumab alongside antimicrobial therapy over a placebo in preventing recurrence 
(16 % [61 of 383] vs. 28 % [109 of 395] in MODIFY I & 15 % [58 of 390] vs. 26 % [97 of 
378] in MODIFY II) with 2655 patients enrolled (208). A subsequent post-hoc analysis 
found a significant decrease in CDI-related readmissions (-53.4 % relative difference) 
in the bezlotoxumab treated group (209). The dose-dependent neutralisation of toxins 
A/B by a combination of bezlotoxumab-actoxumab was previously described in mouse 
models of CDI (210); however, the MODIFY studies showed actoxumab to have no 
significant effect on recurrence. Bezlotoxumab is now indicated as an adjuvant to 
antibiotic therapy in patients at high risk of recurrence (9, 208). 
In animal models, the vaccination of hosts against toxins A/B has been shown to 
protect against CDI. The patient immune response to toxins A/B has long been 
presented as protecting against recurrence and severe disease; one study found 
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higher serum IgG and faecal IgA levels in patients with a single episode of CDI versus 
rCDI patients (211). Indeed, more recently studies on human sera have elucidated that 
higher sera IgA/IgG levels directed against TcdA/TcdB are associated with a lower risk 
of recurrent disease (84). Vaccinating against C. difficile toxins thereby developing 
higher sera antibody titres against tcdA/B could be a useful strategy in decreasing 
disease severity. Immunisation of hamsters against TcdA/TcdB was carried out in 
1995, with intranasal, intraperitoneal and subcutaneous immunisation of inactivated 
toxin A/B toxoid offering 100 % protection against death and 40% protection against 
diarrhoea (212). Interestingly, the route of immunisation caused significantly different 
outcomes; hamsters vaccinated rectally or intragastrically experienced no protection 
against death, even after accounting for inactivation of the vaccine by acid/protease 
degradation.  High antibody responses correlated to protection against severe disease, 
as noted in previous human studies. Vaccination against other antigenic components of 
C. difficile is also feasible, facilitating an immune response against the pathogen itself. 
Bacterial spores are one potential vehicle of foreign antigen carriage. Spore-based 
vaccines have been shown to elicit systemic and local immune responses (213), 
Potecki et al have managed to express the C. difficile flagella protein FliD alongside the 
adjuvant, human IL-2 (214).  
Non-antibody therapies targeting toxins A/B have also shown limited success. Five 
toxin-binding agents have been identified and their mechanisms described; 
cholestyramine, colestipol, tolevamer, and calcium aluminosilicate (215, 216).  Oral 
cholestyramine has been used in the past and is described in a limited number of case 
studies (217, 218) for long term control of rCDI, but the evidence is inadequate to 
recommend its use. Cholestyramine is not recommended in the UK (137) or Europe 
(163) for the treatment of CDI or recurrent episodes. Like cholestyramine, colestipol 
binds the C. difficile toxins and has theoretical use in managing rCDI. Unfortunately, 
the one clinical study to date showed no difference in the toxin levels in patients’ faeces 
when treated with colestipol (219). No further studies have investigated this agent. 
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Tolevamer is a toxin binding anionic polymer (216). In initial work using hamsters, 
tolevamer was found to be 80-fold more effective than cholestyramine in blocking the 
permeability inducing actions of toxin A in the ileum (220), by binding covalently to the 
toxin. A phase II study of 289 patients found tolevamer to be non-inferior to vancomycin 
in reaching diarrhoea resolution (221). In phase III trials, tolevamer proved to be inferior 
to vancomycin and metronidazole in achieving clinical cure (44.2 % vs 77.2 % vs 81.1 
%)(135). Of note, the human gut model (which will be used in my experimental studies) 
correctly predicted that tolevamer would not be efficacious in humans (222). The 
complex calcium aluminosilicate uniform particle size nonswelling M-1 (CAS UPSN M-
1) was described in 2015 and has shown binding affinity to toxin A/B at concentrations 
matching those found in the stools of CDI patients. Currently the evidence for non-
antibiotic toxin binding resins such as those described is not sufficient to recommend 
their use in the treatment of rCDI. Clinical studies are required for agents such as 
calcium aluminosilicate to elucidate their safety profile and efficacy. It is realistic to 
expect that the discovery of such agents will continue into the future.  
In addition to toxin binding agents, some other therapies have been investigated for 
preventing rCDI. Non-toxigenic C. difficile spores have been studied as a method of 
preventing infection. It is believed non-toxigenic strains of C. difficile can fill the same 
niche in the gastrointestinal tract as toxigenic strains; outcompeting them but without 
producing disease-causing toxin. In a phase II clinical trial, C. difficile M3 non-toxigenic 
spores were administered in two doses for 7 days (104 (n = 43) & 107/ day (n = 44)) in 
initial or recurrent CDI patients alongside regular treatment (223). Recurrence occurred 
in 5% (2/43) of patients treated with the higher 107/ day dose of spores vs 30 % (13/43) 
in placebo treated patients. Although these results are promising, colonisation by the 
M3 spores did not occur in all patients (69 %) and a higher level of recurrence (31 %) 
was reported in patients who were not successfully colonised.  Furthermore, horizontal 
gene transfer between a toxigenic strain and 3 non-toxigenic strains of C. difficile has 
been observed to take place in vitro (224). It is likely that this could occur in in patients, 
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providing a further limitation for the use of non-toxigenic C. difficile spores as an rCDI 
treatment.  
In addition to producing narrow spectrum antibiotics, research has focused on 
producing compounds that ameliorate the microbiota disturbances produced by 
antibiotic treatment.  The β-lactams are commonly prescribed broad-spectrum 
antibiotics; ceftriaxone is a well-known example associated with CDI risk (95) . 
Intravenously administered antibiotics have previously been found to be excreted in 
bile into the gastrointestinal tract (225). SYN-004 (ribaxamase) is a β -lactamase 
designed to degrade systemically administered β-lactams entering the gut, hydrolysing 
the amide bond of the β-lactam ring (226, 227). In phase 1 trials SYN-004 was shown 
to have low systematic absorption and adverse event severity comparable to the 
placebo group (228). A phase IIa study illustrated the degradation of biliary excreted 
ceftriaxone by SYN-004 and validated the previously reported safety profile (229). 
DAV132 is a product devised to ameliorate the deleterious effects on the gut microbiota 
of commonly prescribed oral antibiotics including fluoroquinolones and cephalosporins. 
DAV132 differentially releases an adsorbent (activated charcoal) on reaching the distal 
colon that selectively adsorbs any free antibiotic (230). A clinical study including 44 
healthy human volunteers found that when DAV132 was administered alongside 
moxifloxacin, exposure of the microbiota in the large intestine to the antibiotic was 
reduced by 99% (231). Trials of DAV132 involving patients at risk of C. difficile are still 
to be undertaken. The results of these studies are promising; DAV132 is suitable for 
co-administration with oral antibiotics absorbed in the small intestine. Protecting the gut 
microbiota against disruption will reduce the risk of initial CDI and ultimately also rCDI  
1.6 Study aims 
This study sought to use a number of approaches to investigate rCDI. Several different 
approaches were exploited to evaluate contributory factors in the development of rCDI.  
Firstly, a pilot study using data generated from a previously ethically approved clinical 
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study evaluated the effect of treatment delay on symptom duration and recurrence 
rates in CDI. The results from this pilot study could inform future clinical practice in 
treatment of CDI. 
Secondly, the behaviour of C. difficile spores in response to a number of conditions 
was evaluated. The effect of changing germinant conditions, heat and environmental 
ageing on C. difficile spore recovery and outgrowth was assessed. The findings of this 
work could illuminate the role of environmental spores in causing recurrent disease in a 
variety of environments. In the nosocomial environment, inadequate disinfection could 
allow spores to persist in the environment, potentially altering their germination 
efficiency. In the food industry, insufficient heat treatment of products could allow the 
acquisition of C. difficile spores and cause disease in the community. 
Finally, using a previously successful in vitro gut model to simulate rCDI, this study 
sought to optimise a proteomic methodology for use alongside traditional culture-based 
methods. Metaproteomics within the gut model provides extra information about the 
metabolic ecological niche associated with antibiotic instillation and FMT.  
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Figure 1.1.1.  Areas of study in the thesis and their relation to recurrent C. 
difficile infection (rCDI).
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Chapter 2 – Treatment Delay and CDI 
2.1 Introduction 
The clinical symptoms of Clostridium difficile infection (CDI) are mediated through the 
action of secreted bacterial toxins (43). Toxins act on the mucosal epithelium of the 
gastrointestinal tract causing oedema, inflammation and diarrhoea, and in severe 
cases, colonic perforation and death (42). Severe dehydration can also lead to 
hypokalaemia, hypotension and metabolic acidosis. The aims of antibiotic treatment of 
CDI are to infection, theoretically reducing the risk of recurrence. It is hypothesised that 
earlier treatment will reduce bacterial and toxin load. Reducing toxin production at an 
earlier stage could reduce the duration of symptoms, decrease mortality and the risk of 
recurrence. 
Several studies have attempted to outline the reasons for delay in treating patients with 
CDI, but none has looked at the impact this delay might have on patient outcomes 
(137, 232, 233). Delays in providing stool sampling kits to patients were found to 
increase time to treatment (232); incorrect labelling of samples had the same effect. 
Delays in diagnosis may lead to inappropriate empirical therapy in mild/moderate CDI 
(233). This is not an issue for severe disease where clinical suspicion facilitates 
immediate management in the absence of laboratory results.    The introduction of in-
house toxin testing significantly decreased the time to diagnosis and subsequent 
treatment in one study (233). In-house stool culture was utilised before the introduction 
of toxin testing. Although delayed treatment has not been associated with an increased 
risk of complications in CDI (234), no study has directly assessed the effect of 
treatment delay on symptom duration or recurrence risk. 
The primary aim of this study was to investigate the effect of treatment delay on CDI 
symptom duration and recurrence. It was hypothesised that patients who experienced 
a delay in treatment initiation for CDI would suffer greater symptom duration (days of 
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diarrhoea) and an increased risk of recurrence. It is hypothesised that earlier treatment 
will reduce the amount of toxin and spores produced. Reducing toxin levels will reduce 
colonic inflammation and reported symptoms. Reducing spore levels could lead to a 
reduced risk of recurrence due to decreased adherence of spores in the gut (in the 
case of recrudescent disease) and a smaller number of environmental spores (in the 
case of relapsing disease).  To test these hypotheses, patient data generated from a 
previous clinical trial were statistically analysed. 
2.2 Methods 
2.2.1 Study overview 
This was a retrospective, non-interventional, survival analysis of the impact of treatment 
delay on outcomes in inpatients diagnosed with CDI between January 2015 and 
December 2016. Patient data for this study were generated from a previously ethically 
approved study (REC reference number 14/NW/1398, Clinicaltrials.gov identifier 
NCT02461901). Patients were recruited from four sites across the UK; Leeds Teaching 
Hospitals NHS Trust (n = 202), St George’s Healthcare NHS Trust (n = 18), Bradford 
Royal Infirmary (n = 27) and Guy's and St Thomas' NHS Foundation Trust (n = 7). A 
complete study protocol for the original study can be found in Appendix A; information 
most relevant to my current study is documented below. 
2.2.2 Participants and protocols 
The database consisted of information collected from patients (n = 254) who consented 
to take part in the original study.  Patients with CDI were identified by the detection of 
toxin (cell cytotoxin assay) in stool samples submitted for laboratory testing. Patients 
within a positive toxin result were considered eligible for the study. Adult patients (18-
100 y/o) suffering a first or recurrent episode of CDI treated with metronidazole, 
vancomycin or fidaxomicin were recruited. CDI was defined as the presence of diarrhoea 
(>3 unformed stools in 24 hours over the previous 7 days) with a positive cytotoxin assay 
result. Patients treated with fidaxomicin in the three months prior to admission were 
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ineligible for recruitment; a detailed account of inclusion and exclusion criteria can be 
found in Appendix A, A.1. 
Patients were asked how many days of diarrhoea were experienced prior to diagnosis 
and treatment. Whilst patients were admitted the number of daily episodes of diarrhoea 
were documented. Markers of CDI severity were recorded (max total WBCs, serum 
creatinine levels, radiological/clinical evidence of colitis and temperature >38.5 ° C). 
Severe CDI was defined by the presence of one or both of the following at admission; 
WBC count >15x109 /l or creatinine rise >50 % of baseline. These criteria were chosen 
based on evidence highlighting the association between elevated WBC, serum 
creatinine and mortality (8). The primary endpoint of the study was the duration of 
symptoms (diarrhoea), measured in days following treatment initiation. Symptom 
resolution was defined as <3 episodes of diarrhoea per day for 48 hours after treatment 
initiation. The secondary endpoint was recurrence of infection (up to 28 days after 
treatment completion).  
2.2.3 Ethics 
The current study received ethical approval prior to commencement (North East - 
Newcastle & North Tyneside 1 Research Ethics Committee, REC Reference 
18/NE/0054). 
2.2.4 Microbiological methods 
All sample processing for the original study was carried out at LTHT in a category 2 
laboratory. Cell cytotoxin assay was performed to test for toxin in stool samples. Vero 
cells were prepared as previously described by Crowther (235). Twenty-mililitres of 
Dulbecoo’s Modified Eagles Medium (DMEM) (Sigma) supplemented with newborn calf 
serum (50 ml) (Gibco, Paisley, UK), antibiotic/antimycotic solution (5 ml)(Sigma) and L-
glutamine (5 ml)(Sigma) was used to culture vero cells (African Green Monkey Kidney 
Cells, ECACC 84113001) in a flat bottom tissue culture flask. Flasks were incubated at 
37° C in 5 % CO2. 
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When Vero cells formed confluent monolayers (confirmed by microscopy; Olympus UK 
Ltd, Middlesex, UK) the monolayer was harvested by removal of DMEM and rinsing 
with 1 ml of Hanks Balanced Salt Solution (HBSS) (Sigma) containing trypsin-EDTA 
(0.25 g/ L) (Sigma). Subsequently, 6 ml of HBSS-EDTA was added to the flask and 
incubated for 10 minutes at 37° C at 5 % CO2. After the cells no longer adhered to the 
flask, further passage was achieved by diluting the HBSS-EDTA cell mixture (1:20) in 
DMEM in a 96F microtiter tray (Nunc). Vero cells were harvested (160 μl) and 
inoculated into wells to which antitoxin would later be added. To other wells trypsinised 
Vero cells (180 μl) were added. Trays were incubated for 2 days in 5 % CO2 at 37° C. 
Sample supernatant and positive controls were serially diluted 10-fold in PBS to 10-5. 
The positive control was produced from a 48 hour culture of C. difficile grown in BHI 
broth. Serial dilutions were transferred to trays containing Vero cell monolayers. 
Clostridium sordellii antitoxin (Prolab Diagnostics, Neston, UK) neutralised the cytotoxic 
effects and ensured specificity of cell rounding to C. difficile. A positive test was 
indicated by rounding of ~80 % of the Vero cells. 
Polymerase chain reaction (PCR) ribotyping of isolates was carried out by the 
Clostridium difficile ribotyping network (CDRN) using a previously described protocol 
(236, 237). PCR product analysis was carried out using the ABI-PRISM 313xl 
automated sequencer and fragment analysis system, a 16 capillary 36cm array with 
POP-7 separation matrix (Life Technologies, Paisley, UK) and a GeneScan 600 LIZ as 
an internal marker. Fluorescent signals were imported into BioNumerics v.7.1 (Applied 
Maths, Sint-Martens-Latem, Belgium) and fragments sized using GeneMapper v.4.0 
(Applied Biosystems, Life Technologies, Grand Island, NY). PCR ribotype band cluster 
analysis was performed using the DICE similarity coefficient. UPMGA dendrograms 
were used to represent relationships within BioNumerics v.7.1. Band profiles were 
identified by comparison with the CDRN reference library. 
2.2.5 Statistical analysis  
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Statistical analysis was carried out in Rstudio by Professor Robert West, University of 
Leeds. Variables included in statistical analysis included patient age, sex, duration of 
symptoms prior to treatment initiation, CDI severity, presence of prescribed concomitant 
antibiotics and treatment group (vancomycin, metronidazole or fidaxomicin). 
Interrogation of the dataset was not permissible prior to gaining ethical approval; initially 
a survival analysis was planned to measure the effect of duration of diarrhoea pre-
treatment (days) on duration of symptoms. As censoring was not prevalent within the 
dataset, a multiple linear regression model was used for symptom duration analysis. 
Univariate (Pearson’s chi squared tests) and multivariate linear regression analyses 
were used to identify factors associated with symptom duration and recurrence. Where 
log transformations were employed, the raw value had 1 added prior to transformation 
to avoid taking the logarithm of 0. The following potentially confounding variables were 
included in the models; age, sex, gender, CDI severity, presence of prescribed 
concomitant antibiotics, previous CDI episodes and treatment arm (vancomycin, 
metronidazole or fidaxomicin).  
Where data for confounding variables were missing (concomitant antibiotics, previous 
CDI), patients were either removed from the analysis, or if a large quantity of data was 
missing (severity) a separate ‘missing’ variable category was created alongside severe 
and non-severe. 
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Patient records 
n = 254 
Excluded due to missing study 
variable (days of diarrhoea 
pre-treatment) and/or both 
outcome variables 
n = 81 
n = 173 
Symptom duration analysis 
n = 119 
Recurrence analysis 
n = 160 
Excluded due to missing 
outcome variable 
(symptom duration) 
n = 51 
Excluded due to 
missing outcome 
variable 
(recurrence) 
n = 10 
Figure 2.2.1. The work flow used in statistical analysis for the clinical study. 
Patients were removed from analysis if study variable or outcome 
variable data were missing. Three patients were also removed from 
analysis due to missing data on confounding variables (previous CDI, 
presence of concomitant antibiotics). Data from a subpopulation of 160 
patients were used for analysis relating to recurrence and 119 patients for 
symptom duration analysis. 
Excluded due to missing 
confounding variables 
Previous CDI (n = 1) 
Concomitant antibiotics (n = 2) 
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2.3 Results 
2.3.1 Patient cohort characteristics  
Patient demographics were comparable between the cohorts included in statistical 
analysis for both arms (Table 2.3.1). The median (range) age of the study population 
was 77(21-96), 50 % of patients were male. CDI was classed as severe in 49 % of the 
patients.  Eleven (6.4 %) patients died during the study. Vancomycin was the most 
commonly prescribed antibiotic, used in 44 % of cases. This is probably reflecting the 
changing attitude of clinicians to metronidazole, given its decreased efficacy compared 
with vancomycin, at least in severe disease (135, 238, 239). Most patients (66 %) in 
the study population were receiving concomitant antibiotics at the time of CDI 
diagnosis. The median duration of diarrhoea pre-treatment was 3 days (Table 2.3.1. & 
Fig 2.3.2 (a)). Approximately half (51 %) of the patients reported having pre-treatment 
duration of diarrhoea of 3 days or less.  
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Table 2.3.1. Demographics of patients enrolled in the study. Overall 
demographics of the subpopulations used in statistical analysis are shown. 
Durations (in days) are reported the nearest whole number.  
 
 
 Study 
population 
(n = 170) 
Symptom 
duration 
subpopulation   
(n = 119) 
Recurrence 
subpopulation 
(n = 160) 
Variables     
 
Age (years) 
 
Median 
(range) 
 
77 (21-96) 
 
79 (23-96) 
 
77 (21-96) 
Sex Male (n, %) 
Female (n, %) 
85, 50 
85, 50 
58, 48 
61, 52 
81, 50 
79, 50 
CDI severity Severe (n, %) 
Non-severe 
(n, %) 
65, 49 
69, 51 
45, 50 
44, 50 
60, 50 
60, 50 
Concomitant 
antibiotics 
Yes (n, %) 
No (n, %) 
112, 66 
58, 34 
81, 69 
38, 32 
104, 65 
56, 35 
Treatment arm Vancomycin 
(n, %) 
Metronidazole 
(n, %) 
Fidaxomicin 
(n, %) 
74, 44 
 
51, 30 
 
48, 26 
53, 43 
 
36, 31 
 
31, 26 
69, 43 
 
46, 29 
 
45, 28 
Duration of 
diarrhoea pre-
treatment 
(days) 
Median 
(range) 
3 (0-60)  3 (0-60) 3 (0-60) 
Outcomes     
Symptom 
duration (days) 
Median 
(range) 
 1 (0-9)  
Recurrence Yes (n, %) 
 
No (n, %) 
  12, 7 
 
148, 93  
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Figure 2.3.1 (a) & (b). Histograms showing the distribution of the study variable 
(a; duration of diarrhoea pre-treatment) and one of the outcome variables 
(b; symptom duration). In (a) each bar represents the frequency for 5 days 
(0-5, 5-10, etc). In (b) each bar represents the frequency for 1 day (0-1, 1-2, 
etc). Both distributions show positive skew.  
Duration of diarrhoea pre-treatment/ days 
Symptom duration/ days 
a 
b 
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2.3.2 Symptom duration analysis 
The median symptom duration reported for the 119-patient cohort after starting 
antibiotic therapy was 1 day, 49 % of patients reported having 0 days of symptom 
duration (Table 2.3.1 & Fig 2.3.2). When a least squares regression line was fitted to a 
scatter graph of symptom duration plotted against days of diarrhoea pre-treatment, 
there was limited evidence of a small positive correlation. However, this fit might be 
misleading due to the presence of high leverage outliers; to avoid this issue, data for 
both study and outcome variables were log-transformed (Fig 2.3.2). The least squares 
regression line for the transformed data demonstrated a negligible relationship between 
duration of diarrhoea pre-treatment and symptom duration.  
For completeness, a multiple regression model incorporated confounding variables as 
well as the study and outcome variable used in initial analysis.  This model indicated no 
significant association between any of the potential risk factors (treatment group, 
duration of pre-treatment diarrhoea, CDI severity, age. concomitant antibiotic, previous 
CDI) and symptom duration (Table 2.3.2).  
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Figure 2.3.2. Duration of symptoms plotted against duration of symptoms pre-
treatment on a scatter graph (n = 122). One was added to the In both graphs a 
least squares regression line of best fit has been fitted to the data. Data was 
transformed due to the presence of high-leverage outliers. The least squares 
regression line illustrates little evidence of association between duration of 
diarrhoea pre-treatment and symptom duration. The dark grey area indicates 
the confidence intervals. 
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Table 2.3.2. Coefficients entered in the multiple regression model for 
assessing effect of duration of diarrhoea pre-treatment on symptom duration; 
there is no statistical evidence of association between ln(duration of 
diarrhoea + 1) and any of the potential risk factors (treatment group, severity, 
concomitant antibiotics, age, gender, previous CDI).    
Coefficients Estimate Std. error t value P value 
ln (duration of diarrhoea+1) 0.06 0.09 0.71 0.48 
Treatment group 
(vancomycin) 
-0.11 0.18 -0.60 0.55 
Treatment group 
(metronidazole) 
-0.13 0.16 -0.77 0.44 
Severe (no) 0.14 0.17 0.78 0.43 
Severe (yes) 0.25 0.17 1.45 0.15 
Concomitant antibiotics (yes) -0.1 0.14 -0.67 0.50 
Age 0.00 0.00 -0.81 0.42 
Gender (male) -0.04 0.13 -0.3 0.77 
Previous CDI (yes) 0.16 0.20 0.81 0.42 
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2.3.3 Recurrence analysis 
 
Recurrence occurred in 11/160 (7 %) patients included in the analysis. There was no 
significant association between duration of diarrhoea pre-treatment and recurrence (X2 
= 0.62, df = 1, P = 0.43). A logistic regression model found that having a previous 
episode of CDI was the only predictive risk factor for recurrent CDI from those included 
(duration of diarrhoea pre-treatment, severity, concomitant antibiotics, age, gender, 
previous CDI) (Table 2.3.3). This association was highly significant (P < 0.001). 
Coefficients Estimate Std. error z value P value 
Duration of diarrhoea pre-treatment -0.02 -0.02 0.06 0.76 
Severe (no) 0.30 1.06 0.27 0.79 
Severe (yes) 1.00 1.05 0.96 0.34 
Concomitant antibiotics (yes) -0.42 0.84 -0.50 0.62 
Age 0.01 0.03 0.36 0.72 
Gender (male) 1.09 0.85 1.28 0.20 
Previous CDI (yes) 3.50 0.80 4.35 <0.001*** 
Table 2.3.3. Coefficients entered in the logistic regression model for 
assessing effect of duration of diarrhoea pre-treatment on recurrence; 
previous CDI is the only variable predictive of future recurrence; P< 0.001 ***. 
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2.3.4 Ribotype distribution 
RT was not included as a variable in either of the models due to the heterogeneity and 
low number of each RT (Fig 2.3.3). C. difficile strains of 34 different PCR RTs were 
isolated from stool of the study population. A high degree of heterogeneity was 
observed; RT 002 accounted for more than 10 % of isolates (14.3 %). RT 014, RT 015 
and RT 078 strains accounted for 9.6 % of isolates each. Only one RT 027 strain was 
isolated. Strains of more than one RT were isolated from 6 (3.5 %) patients in the study 
population. 
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2.4 Discussion 
This study corroborates the previously reported observation that patients experiencing 
their second (or more) episode of CDI are more likely to suffer relapse than those 
suffering a first episode. Interestingly, treatment delay had no significant effect on 
either of the outcome measures; symptom duration and recurrence (Tables 2.3.2 & 
2.3.3). Delayed treatment having no significant association with symptom duration is 
surprising. It was hypothesised that prompt treatment would reduce bacterial load and 
reduce toxin levels; toxin A and B are pro-inflammatory and responsible for colonocyte 
death, with both toxins being recognised as important to CDI pathology (43).  
Faecal toxin levels have been associated with increased disease and symptom 
severity, including increased diarrhoeal frequency (11, 44, 240). Some studies have 
suggested treatment with vancomycin/metronidazole has no effect on toxin A/B 
production and actually instigates increased spore production (241, 242). In the current 
study, treatment arm (fidaxomicin, metronidazole or vancomycin) was not significantly 
associated with symptom duration. Fidaxomicin has been found to repress toxin A and 
B levels both clinically and in vitro, in contrast to vancomycin that repressed both toxins 
at the midpoint, but lost this effect thereafter (243). The clinical study was relatively 
small (n =34) and open label, limiting statistical power. Due to the toxin-repressing 
effects of fidaxomicin, it was theorised that fidaxomicin treatment would have led to a 
reduced duration of symptoms in the current study. A recent study suggests increased 
binary toxin (CDT) levels are associated with CDI severity, but this was a cross-
sectional study with a small n size (244). Fidaxomicin has not been found to repress 
levels of the CDT toxin. Disease severity was also not associated with symptom 
duration. 
Detailed comorbidity data were not collected as part of the original study; the clinical 
markers used for CDI severity could have been influenced by concurrent disease and 
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infection. The majority of patients in the study were receiving concomitant antibiotic 
therapy (Table 2.3.1). Forty-nine percent of the 119 cases used in symptom duration 
analysis were reported to have symptom duration of 0 days after treatment initiation. 
The criteria used to dictate symptom resolution may have been inappropriate; in some 
patients, increased diarrhoeal frequency recurred after an initial period of symptom 
resolution. More likely, the low threshold for stool sampling combined with the high 
sensitivity of the cell cytotoxin assay allowed the detection of a large number of mild 
cases of CDI (245). The data for duration of diarrhoea pre-treatment were collected 
from medical notes, stool charts and patient discussions. A substantial proportion of 
patients in the study reported long durations of diarrhoea preceding treatment (up to 60 
days pre-treatment) (Fig 2.3.2). These diarrhoeal episodes are unlikely to be related to 
CDI and could be more indicative of chronic disease (e.g. irritable bowel syndrome). 
However, the majority of patients in this study reported 0 days of diarrhoea prior to 
antibiotic therapy (Fig 2.3.2). This is counterintuitive given one of the inclusion criteria 
for the original study (>3 unformed stools in 24 hours over the previous 7 days). One 
explanation for this is that diarrhoea in mild CDI cases largely resolved before 
treatment initiation. This indicates that treatment may not be required in some mild 
cases of CDI.  
There was no statistically significant evidence of an association between treatment 
delay and risk of future recurrence (Table 2.3.3). Interestingly, this study validates 
previous findings that having one or more recurrence of CDI is a strong predictor of 
further future recurrence. Fidaxomicin has been extensively associated with a reduced 
incidence of recurrence, as demonstrated recently by two randomised control trials 
(246).  Fidaxomicin also completely inhibited sporulation in vitro in stationary phase 
vegetative cells of two strains of C. difficile at 1/4x MIC, an effect not observed with 
vancomycin, metronidazole or control (247). In addition, spores treated with 200 mg/L 
fidaxomicin for one hour prior to incubation in broth failed to outgrow into vegetative 
50 
 
cells after 48 hours (248) potentially reducing the risk of recrudescent (recurrent) 
disease.  
As discussed previously, the possible effects of fidaxomicin on toxin A/B levels in 
relation to recurrence should not be ignored. Tolevamer is a non-antibiotic drug that 
initially showed promise in treating CDI. The mechanism of action is not bactericidal; it 
is a toxin binding anionic polymer (216). Although it was found to be inferior to 
vancomycin and metronidazole in phase III clinical trials (135), it did show a decrease 
in recurrence rates in patients who observed clinical cure on the drug. This suggests 
that removal of toxin A/B may not be sufficient for clinical cure, but could reduce the 
risk of recurrent CDI. Based on the evidence above, fidaxomicin is suggested to have 
several mechanisms whereby recurrence risk is reduced. On the contrary, the current 
study finds no association between treatment arm and risk of recurrence. This could be 
a limitation of the small sample size. In any event, the finding that recurrence is 
strongly associated with previous CDI is important. In future clinical policy may wish to 
concentrate on prevention of initial infection as a strategy to reduce recurrence.   
The recurrence rate for patients in the recurrence analysis was low at 7 % (Table 
2.3.1). One possible explanation for this is the successful antimicrobial stewardship 
programmes employed in the UK; the epidemiology of C. difficile infection has changed 
considerably, with RT 027 strains no longer being the dominant ribotype (25, 28) (Fig 
2.3.4). A number of studies, including randomised control trials have previously found 
infection with RT 027 strains to be significantly associated with recurrence (58, 68, 71, 
72, 249).It has been suggested RT 027 strains may have accelerated sporulation; 
increasing number of spores produced during infection. A number of in vitro studies 
have supported this notion (73, 74). Only one case of infection with RT 027 was 
identified in the current study and no PCR ribotype dominated infection. RT 001, 017 
and 018 have previously been associated with recurrent disease in Sweden and Korea 
respectively (69, 75). These associations are not as strong as those described for RT 
027 strains and the wide distribution of infection amongst different PCR ribotypes is 
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likely to minimise any potential effect in the current study.Perhaps more likely, the low 
levels of recurrence in this study may highlight the fact that many of the patients 
deemed to have CDI were in fact suffering from transient diarrhoea of an unrelated 
cause. If this is the case, some of the patients reporting diarrhoea could not have a 
recurrence, as they were not suffering from an initial episode.  
A number of studies have investigated the reasons for delay in treatment for CDI. In 
one cohort late and improper specimen collection were identified as a major source of 
delay in treatment initiation (232). Importantly, all 22 physicians interviewed in this 
study admitted the decision to start empirical treatment was influenced by whether or 
not they expected results to be available within 6 hours. Clinical guidelines recommend 
diagnostic confirmation of C. difficile before treatment initiation, but due to recognised 
delays in testing diarrhoea, clinical suspicion is also considered suitable to start 
treatment (137). These issues were highlighted previously and measures put into place 
to reduce these delays (233). Research has looked at trying to decrease these delays 
in diagnosis and treatment by use of different strategies such as algorithms and policy 
changes, likely to accelerate the placement of appropriate infection control measures 
and reduce nosocomial transmission. The results of the current study suggest further 
strategies should focus on prevention of CDI, with rapid diagnosis and treatment 
providing little tangible benefit in relation to symptom duration and future risk of 
recurrence.  
This study had a number of limitations. The original study was not powered for this sub 
analysis. In future work, a bespoke trial designed for the specific hypotheses 
formulated in this study would have more power. It would also allow the collection of 
more relevant patient information. In particular, a more robust inclusion criteria whereby 
patients with evidence of CDI can be identified would be beneficial. In this study, it is 
likely a large number of the patients reporting transient diarrhoea did not have CDI, but 
diarrhoea of an unrelated aetiology. More detailed information on patient comorbidities 
would allow differentiation between transient diarrhoea and true CDI.  
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Patient data from the original cohort of 254 had to be filtered due to missing values for 
both study (duration of diarrhoea prior to treatment) and outcome variables (relapse, 
symptom duration) further reducing the power of the study and potentially introducing 
systematic bias. Patients were only followed up for 28 days after finishing treatment, 
the majority of relapses occur within 8 weeks after initial infection (83 %) (66).  
Although the majority of relapses occur in the first 14 days after successful treatment 
(67), patients may have suffered recurrent disease, due to reinfection or relapse, after 
this 28 day window. More detailed information on patient comorbidities would have 
allowed the calculation of a Charlson score, allowing inclusion of comorbidity data in 
the statistical analysis. This would also increase confidence in the designation of 
severity; the clinical markers used could be altered in response to disease unrelated to 
CDI.  
In summary, this study found no association between any of the risk factors and 
symptom duration in CDI. This suggests clinicians should not be too concerned about 
delays in diagnosis unless severe disease is suspected. When recurrence risk was 
assessed the only factor predictive of CDI recurrence was previous CDI. Larger studies 
will need to be carried out with a greater number of patients and improved data 
collection; the current study was limited by the low study population size and 
insufficient data collection. It is a possibility that the liberal inclusion criteria used in the 
study identified patients who were not suffering from diarrhoea due to CDI, but were 
experiencing transient diarrhoea from an unrelated cause. 
 
Finance 
This study was funded by the University of Leeds. The original study (Clinicaltrials.gov 
identifier NCT02461901) was funded by Astellas Pharmaceuticals. 
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Chapter 3 A – Spore Germination and Recovery 
 Background & Rationale 
C. difficile spores play a vital role in the transmission of CDI. Recurrent CDI is an 
umbrella term encompassing two different mechanisms; recurrent disease due to 
recrudescence of C. difficile spores persisting in the gut (relapse), or reinfection with 
the same or different strain. Varying rates of relapse and reinfection have been 
documented, with relapse accounting for ~52-88 % of recurrence (65, 66, 250). In both 
the case of relapse and reinfection, spores play an important role. Reinfection occurs 
due to the ingestion of C. difficile spores from the patient’s environmental surroundings, 
which can occur with the same or a different strain.  In the contrasting scenario of 
relapsing disease, recrudescent C. difficile spores retained within the gut lumen 
germinate and outgrow successfully in response to cues in the gut. Spores are 
metabolically dormant, environmentally robust and are the main mode of transmission 
of C. difficile.  
The response of C. difficile spores to being left in the environment for extended periods 
of time (environmental ageing) is of interest from both scientific and clinical 
perspectives. Spores persist in the environment for extended periods of time and are 
resistant to traditional cleaning agents, which is problematic in a hospital environment. 
Spores left in the environment for extended periods of time could have a greater 
likelihood of becoming superdormant. “Superdormant” spores are those described as 
failing to germinate in response to the typical germinants, but still remaining in a viable 
state (59). Comparison of hospital and laboratory cleaning agents suggests only 
chlorine-releasing agents are effective at decontamination of spore contaminated 
surfaces (251). It was appreciated early on in the 1980s that carriage of C. difficile 
spores on hospital workers may be contributing to the high levels of new infection 
(252). Reducing spore loads in the environment in hospitals is an important strategy for 
combatting the incidence of rCDI. The discovery of potential ‘superdormant’ spores 
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creates yet more difficulty.  In the laboratory spore activation by heat treatment can be 
utilised to induce germination of spores (253), but this is not possible on the wards. 
Novel strategies have been trialled to induce germination, for instance germination 
solution sprays (254). The use of such sprays could reduce the need for more 
corrosive detergents such as chlorine-based agents and peracetic acid, but are not 
feasible in a hospital setting. 
Spores are vital in the context of CDI, and the recent discovery of superdormant spores 
raises issues particularly relevant to rCDI. Spores retained in the gut could be 
responsible for recrudescent disease (relapse). Reinfection can occur by ingestion of 
superdormant spores from the external environment. 
3.1.1 Germination mechanism 
Spore germination is a complex process, ultimately resulting in a proliferative 
vegetative population. The ultrastructure of the C. difficile spore is multifaceted and 
consists of numerous peptidoglycan and proteinaceous layers including the germ cell 
wall, coat and exosporium surrounding a central Ca2+-dipicolinate (DPA) core (255). 
High levels of Ca2+-DPA contribute to sustaining dormancy.  
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The germination of spores can be measured by detecting a reduction in the optical 
density of a spore suspension that occurs simultaneously with the release of Ca2+-DPA 
from the core (250). In contrast to B. subtilis, the spore coat must be hydrolysed prior to 
Ca2+-DPA release in C. difficile spores (256).  Germination begins when a molecule, 
termed a germinant, interacts with the homologs of the GerA, GerB and GerK 
germinant receptors commonly recognised in Bacillus and other Clostridia (257). 
Spores of C. difficile are receptive to a different spectrum of germinants to both Bacilli 
and other Clostridia. The receptor involved has been identified as CspC, a bile acid 
binding protein (63). Upon binding of the germinant to CspC a sequence of proteolytic 
reactions is initiated, resulting in the cleavage of pro-SleC to SleC, a cortex hydrolase 
(255), which consequently hydrolyses the cortex. Initially it was believed that binding of 
germinants to CspC was stimulatory; increasing binding would lead to increased SleC 
formation and cortex hydrolysis. Recent research has shown an inverse correlation 
between CspC levels and germination rates (r2=0.81) (258). It is postulated CspC 
Figure 3.1.1. Ultrastructural representation of a Clostridium difficile 
spore; i (core), ii (inner membrane), iii (germ cell wall), iv 
(cortex), v (outer membrane), vi (cortex) & vii (exosporium). 
Figure adapted from Paredes-Sabja et al (2011). 
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activates CspB, but CspB is unable to cleave pro-SleC unless GerS is present. The 
concluding stage of germination is the release of a vegetative cell from the ruptured 
spore coat/exosporium. Further work is required to elucidate these interactions and 
refine the model currently proposed for C. difficile spore germination. 
Recently it has been discovered that the pseudoprotease domain CspA and its fusion 
to CspB is highly significant in regulation of the germination cascade, with a nonsense 
mutation in cspBA reducing the efficiency of C. difficile spores to germinate (255). 
CspBA is cleaved by YabG to form CspA and CspB, CspB is responsible for the 
cleavage of pro-SleC to the active SleC.  Additionally, CD0311, a protein named GerG 
has found to be important in the germination process. GerG mutants are found to 
require 10-times the levels of germinant to initiate germination, and it has been shown 
that lower levels of CspC receptors are present in these mutants (259). It is believed 
GerG has an important role in the incorporation of CspA, CspB and CspC into the 
spore. GerG has been suggested to be a novel target for therapeutics, potentially 
decreasing spore germination and the risk of recurrence. This is highly speculative and 
requires more research.  
Germination is a tightly regulated and complex process. The homology of this system 
to other members of the Peptostreptococcaceae rather than Clostridiceceae family is in 
accordance with the genomic data regarding reclassification of C. difficile to the 
Peptostreptococcaceae family (260).  
3.1.2 Bile acids 
The germination of C. difficile spores is strongly dependent on environmental cues and 
has been found to be altered in response to bile acids. In general, primary bile acids 
are stimulatory to germination and secondary bile acids are inhibitory. However, there 
are some exceptions. Ratios of primary: secondary bile acids along the gastrointestinal 
tract could alter in response to environmental insult, facilitating C. difficile spore 
germination. The primary bile acids are cholate, chenodeoxycholate, taurocholate and 
glycocholate. Derivative secondary bile acids include deoxycholate. Previously, 0.1 % 
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taurocholate saturated BHIS (supplemented brain heart infusion) plates showed a 105 
increase in recovery compared to controls (261). Early on, it was documented the 
concentration and purity of the taurocholate preparations tested in vitro was important; 
higher concentrations of sodium taurocholate inhibited vegetative cell division (262). 
Initially, the mechanism of taurocholate-induced germination was unclear, but kinetic 
data alluded to a sequential receptor based process involving glycine (263). 
Taurocholate is now routinely used to germinate C. difficile spores.  
The primary bile acid chenodeoxycholate is inhibitory to spore germination; incubation 
of spores with 0.1 % chenodeoxycholate produced a 0.006 % recovery rate, compared 
to 0.024 % with an equal 0.1 % mixture of cholate: chenodeoxycholate (264). Further 
work indicated chenodeoxycholate derivatives are produced by 7α-hydroxylation, a 
process carried out by Clostridium scindens, considered in recent times to be a 
protective species in the microbiome (93, 264). Other work found chenodeoxycholate 
to be stimulatory at 1-10 mmol/l to C. difficile germination, but also noted higher levels 
of sodium taurocholate (>100 mmol/l) to be inhibitory (265).  
Human bile acid perfusion studies have indicated a ~9-fold increase in the absorption 
in the large intestine of chenodeoxycholate compared with cholate (266). This creates 
a favourable environment for spore germination. Only single formulations were 
perfused, ignoring any in vivo interactions between different bile acids. Experiments 
using a mouse model also suggest a role for bile acids in germination of C. difficile 
spores. Caecal extracts from antibiotic-treated mice produced colony formation levels 
in C. difficile spores 50-65 times higher than from untreated mouse tissue (267). This 
effect was lost when bile-acid binding cholestyramine was added to extracts. The study 
concluded that increased ratio of primary: secondary bile acids in antibiotic treated 
samples are responsible for the increase in CFU observed. However, there is no 
discussion of the relative concentrations of individual primary bile acids. More recent 
mice metabolomics data had a similar finding; a relative increase of primary bile acids 
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in antibiotic treated ‘CDI susceptible’ mice (268). The two studies used different 
antibiotics to simulate CDI conditions (clindamycin vs. cefoperazone). 
3.1.3 Amino acids 
The amino acid glycine has been found to be a vital co-germinant; its inclusion with 
taurocholate is a standard approach for maximising germination of C. difficile spores. 
Glycine was utilised early on (1966) to increase germination of Clostridium botulinum 
along with cysteine (269). Subsequently, the germination of C. difficile spores has been 
improved using glycine with taurocholate (261, 265). The binding and functional groups 
involved in the substrate-receptor interaction have been mapped by adding 30 glycine 
derivatives to taurocholate treated spores and documenting germination rates (270). 
The chemical manipulations targeted singular modifications in the carboxy/amine 
groups or the alkyl chain of the glycine molecule (Fig 3.1.2). 
 
 
 
By creating a derivative library, the authors were able to deduce that both the intact 
carboxylate and amine groups are necessary for recognition by the germinant receptor, 
as modifications of these groups produces a substantial decrease in germination rates. 
The size of the methylene bridge between the functional groups does not appear to 
Figure 3.1.2. Glycine molecule, showing alkyl chain 
skeleton, amine group and hydroxyl groups. 
Diagram obtained from ChemDraw®  
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affect germination levels.  Although glycine is the most explored and widely understood 
amino acid used for C. difficile germination optimisation, this study provides evidence 
of other amino acids for instance β-alanine being equally as effective at initiating 
germination in C. difficile. One study identified an 80 % increase in germination rates 
on addition of histidine (0.4 %) to taurocholate (0.1 %) with glycine (0.4 %)(271). L-
phenylalanine has been found to be as effective as glycine, which is surprising given 
the initial hypothesis that the germinant receptor would not be able to accommodate 
aromatic groups due to size (270). Multiple binding sites have been suggested, but 
there is currently no evidence to support this. Unlike L-phenylalanine, histidine (0.4 %) 
added to taurocholate (0.1 %) without glycine did not produce an increase in 
germination; both L-phenylalanine and histidine are aromatic amino acids.  
Recent developments (2018) have elucidated the hierarchical nature of amino acid 
recognition in C. difficile spores. Shrestha & Sorg investigated the efficacy of various 
amino acids (including D- alanine, D-serine & D-lysine) as co-germinants to taurocholate 
(272). Glycine was found to be the most effective germinant, but importantly all amino 
acids were stimulatory to spore germination to some extent at 37° C. Interestingly, the 
author proposed that glycine being the smallest amino acid could contribute to its 
effectiveness; small molecules can more easily reach the spore cortex. These findings 
are congruent with those of Howerton et al (270), with aromatic residues being less 
effective. Nevertheless, the mechanism of co-germinant binding is still unknown; it is 
unclear whether signalling is mediated through a single receptor responsive to all 
amino acids or numerous receptors for each individual amino acid.  
Additionally, the role of calcium in spore germination has been investigated. Calcium 
has been found to have a critical role in the activation of SleC, the cortex hydrolase. 
When spores were incubated with taurocholate, glycine and EGTA (a calcium chelator) 
germination was completely inhibited at all concentrations vs. taurocholate/ glycine 
alone (273). It is hypothesised that individuals deficient in calcium absorption are at an 
increased risk of CDI due to the stimulatory effects of superfluous intestinal calcium on 
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germination. This provides a potential mechanism for the association of protein pump 
inhibitors (PPIs) with CDI. This risk may be amplified by the observation that the cell 
membrane interactions of toxin A in binding to colonic cells is mediated by free calcium 
ions (274).  
3.1.4 Non-germinant receptor germinants 
In addition to germinant receptor-derived germination, other factors have been 
identified as facilitating increased recovery of C. difficile spores. In 2000 it was found 
that incorporation of 5 mg/l of lysozyme into CCEY (without egg yolk) agar significantly 
increased the recovery of C. difficile from environmental swabs compared to CCEY (24 
% vs 11 %, P = 0.004) (275). This observation has been made previously with 
increased recovery rates (10-47 %) observed in four strains recovered by sodium 
thioglycollate-lysozyme treatment after heat treatment of bacterial suspensions at 90ºC 
for 10 minutes (276). Pre-treatment with thioglycollate was not associated with 
increased recovery rates. Lysozyme could be the mediator of germination in these 
instances and not thioglycollate pre-treatment. One hypothesis is that lysozyme 
mediates germination directly by enzymatically degrading the spore cortex. The above 
study (276) also found 0.1 % taurocholate addition did not permit recovery of spores 
subjected to the same heat treatment. This is not surprising considering the more 
recent work indicating the importance of glycine as a co-germinant. 
3.1.5 Optimising C. difficile recovery 
Different solid media are used according to individual requirements for C. difficile 
recovery. The appropriateness of a culture medium for C. difficile will depend on a 
number of factors. Firstly, a medium must allow the germination and proliferation of C. 
difficile spores. In order for substantial germination to take place, stimulatory 
germinants must be present. The growth of other species must be suppressed by the 
medium. CCEYL (cycloserine-cefoxitine, egg yolk and lysozyme) is a selective medium 
most suitable for recovering C. difficile from faecal samples, and has recently been 
shown to be the most sensitive and cost-efficient medium for isolating C. difficile from 
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stool samples when compared to cycloserine-cefoxitin fructose agar (CCFA), tryptone 
soy agar (TSA) and ChromeID agar (277). Five-percent lysozyme was incorporated 
due to evidence suggesting the increased recovery of environmental spores treated 
with lysozyme (275). CDRN (C. difficile ribotyping network) use CCEYL (without egg 
yolk) to isolate C. difficile from faeces due to the bacteriostatic action of cycloserine-
cefoxitin (39).   
BHI agar (brain heart infusion) is used by the majority of research labs working with C. 
difficile. Often taurocholate is incorporated (a primary bile acid) alongside glycine.  
CCEYL also contains an unknown quantity of the primary bile acid cholate in its 
ingredients. BHI is suited to pure culture of C. difficile, due to its non-selectivity (278). It 
is unclear which conditions are optimal for spore recovery. Although primary bile acids 
and amino acids are known to be important for inducing spore germination in C. 
difficile, a direct comparison of CCEYL and supplemented BHI has not been 
performed.  
Although the importance of germinants and amino acids has been discussed in the 
context of germination, one study found germination will occur spontaneously in the 
absence of germinants in a subpopulation of spores (279) . This could be important in 
experiments utilising spores that have been aged or left for extended periods of time in 
the environment. Over time, a small population of spores are likely to spontaneously 
germinate, decreasing spore numbers.  
There were a number of aims for this study. Firstly, conditions optimal to C. difficile 
spore recovery and outgrowth in liquid and on solid media were explored. C. difficile 
germination and growth was assessed in two solid media and two liquid media with the 
incorporation of different combinations and concentrations of germinants. Additionally, 
this study highlighted the inhibitory nature of high concentrations of L-amino acids on C. 
difficile vegetative growth. Five strains of different ribotypes were grown in broths with 
increasing concentrations of 3 amino acids (glycine, L-phenylalanine and L-histidine). 
Finally, the phenomenon of superdormancy was explored; spores were left in a 
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homemade desiccator for an extended period (6 months) to simulate environmental 
ageing. It was hypothesised that environmental ageing would affect the ability of spores 
to germinate in the presence of germinants. 
 Methods 
3.2.1 Production of Spores 
Spores of five PCR ribotypes (RT 001,015,020, 027 & 078) of C. difficile were prepared 
as previously described (248). Briefly, 100 µl of a spore preparation was spread on to 
Brazier’s CCEYL agar (Oxoid, UK) and grown anaerobically for 5 days in a Don Whitley 
A95 anaerobic workstation. Growth was harvested and streaked on to 10 Columbia 
Blood Agar (CBA) plates. CBA agar plate growth was removed through swabbing after 
10 days of anaerobic incubation and suspended in 4 ml of 50 % ethanol to kill 
vegetative cells. Spore stocks were serially diluted in phosphate-buffered saline 
(PBS)(BioVision, USA) and enumerated on CCEYL agar.  
All experiments were carried out in triplicate and all spores were fresh (<30 days old) 
unless otherwise stated. In all experiments agar plates were incubated anaerobically at 
37° C and counts of colony forming units (CFU) were carried out 48 hours post-
inoculation.  
3.2.2 Phase Contrast Microscopy 
Slides were prepared by spreading 50 µl of spore suspension uniformly over a 
microscope slide and drying aerobically for 30 minutes at 50° C. Slides were overlaid 
with 50 µl of Wilkins-Chalgren agar and dried for a further hour. Phase bright spores, 
phase dark spores and vegetative cells were visualised in ten fields of view and 
counted on a phase contrast microscope at 1000 X magnification. All entities were 
counted in each field of view. In broth experiments one slide was prepared per 
biological replicate (broth). Phase dark spores indicate those that have germinated, 
phase bright spores have not germinated, and vegetative cells are the product of spore 
germination and outgrowth. 
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3.2.3 Spore Recovery on Solid Media 
Spore suspensions were serially diluted (10-fold) in PBS to 10-9. Twenty-microlitres of 
each dilution was spread on to a range of solid agar plates (Table 3.2.1). Media (BHI 
(Oxoid, UK) and CCEY (LabM)) was prepared in house according to manufacturer’s 
instructions (see Appendix B, B.1.8 & B.1.9). In the case of additive preparation, 
taurocholate and glycine (Oxoid, UK) were added prior to autoclaving, lysozyme was 
added subsequently. Spores of five C. difficile ribotypes were utilised. An overview of 
the methodology can be seen in Fig 3.2.1. 
Table 3.2.1. Solid agar plates utilised in C. difficile spore recovery experiments. 
Media types and additives are shown 
   
 
3.2.4  Spore Germination in Broths 
Broths of 4.95 ml were prepared in glass Wassermans, autoclaved and pre-reduced 
overnight in an anaerobic chamber. Media (BHI and Schaedler (Oxoid, UK)) was 
prepared in house according to manufacturer’s instructions (see Appendix B, B.2). All 
broths were carried out in biological duplicate unless otherwise stated. Broths utilised 
can be seen below (Table 3.2.2). At time point 0 phase contrast microscopy was 
Media  Additional Additives 
 
 
BHI 
 
Nil 
5% lysozyme 
0.1% taurocholate, 0.4% glycine 
1% taurocholate, 0.8% glycine 
1% taurocholate, 4% glycine 
 
 
CCEY 
 
 
Nil 
5% lysozyme 
0.1% taurocholate, 0.4% glycine 
1% taurocholate, 0.8% glycine 
1% taurocholate. 4% glycine 
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carried out on spore suspensions. Subsequently, 50 µl of spore suspension was 
aliquoted and incubated anaerobically in broth for 90 minutes. At 90 minutes, 20 µl of 
broth was removed and serially diluted in PBS to 10-7 in technical triplicate. For spore 
enumeration, broth (100 µl) was aliquoted into 100 µl of 100 % ethanol and after an 
hour serially diluted in PBS to 10-4. Twenty-microlitres of each dilution were aliquoted 
on to CCEYL agar. In addition, 500 µl of broth was removed and centrifuged at 9500 g 
for 1 minute. The supernatant was removed and spores were resuspended in 50 µl of 
PBS, which was spread on to a slide for phase contrast microscopy. An overview of the 
methodology can be seen in Fig 3.2.3.
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Table 3.2.2 Range of broths utilised in C. difficile spore germination experiments. 1 
Broth types and additives are shown. 2 
3 Broth Additional Additives 
 
 
BHI 
 
Nil 
5 % lysozyme 
0.1 % taurocholate, 0.4 % glycine 
0.1 % taurocholate, 0.4 % histidine  
0.1 % taurocholate, 0.4 % glycine, 0.4 % histidine 
1% taurocholate, 4% glycine 
 
Schaedler 
 
Nil 
5 % lysozyme 
0.1 % taurocholate, 0.4 % glycine 
1 % taurocholate, 4 % glycine 
 
Figure 3.2.1. An overview of the methodology used in solid agar experiments. 
 
20 μl  20 μl  
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3.2.5 Agar-incorporated minimum inhibitory concentration (MIC) 
testing  
The minimum inhibitory concentration (MIC) for glycine and taurocholate was tested 
both alone an in combination (4:1 ratio) against C. difficile strains of five ribotypes (001, 
015, 020, 027, 078). An agar-incorporation MIC methodology was utilised that has 
been used previously by Baines et al (280). Test compounds were weighed out in 
doubling concentrations and added to individual aliquots of Wilkins-Chalgren anaerobe 
agar or CCEY agar. CCEY agar was supplemented with 2 % lysed, defibrinated horse 
blood. C. difficile vegetative populations were grown up overnight in Schaedler’s broth 
in an anaerobic cabinet.  Both spore and vegetative (1ː10 dilution of 24-hour 
Schaedler’s broth culture) populations of the five C. difficile strains were inoculated 
(~104 cells) on to glycine/taurocholate incorporated agar. Inhibition of growth was 
assessed after anaerobic incubation at 37° C for 48 hours, where the lowest 
concentration at which visible C. difficile growth was inhibited was recorded as the MIC.  
3.2.6 Minimum Inhibitory Concentration (MIC) Testing in 
Microbroths 
BHI broths with increasing concentrations (1, 2, 3, 4 %) of three amino acids (glycine, 
L-histidine, L-phenylalanine) were prepared and 180 μl was aliquoted into a 96-well 
plate. Twenty-microlitres of spore solution (~5x105 /ml) were aliquoted into each well at 
time point 0; five strains of different ribotypes were utilised (001, 015, 020, 027, 078). 
At 0, 24- and 48-hours absorbance readings were determined at 595 nm in a Tecan 
Infinite 200 Pro reader at 20° C and under 1 atm of pressure. Negative controls were 
prepared for each concentration, and the absorbance for the blanks was subtracted 
from the absorbance of the inoculated wells to determine an accurate absorbance 
reading based on growth alone. All wells were prepared in triplicate.  
3.2.7 C. difficile spore desiccation 
One day old (1 ml) spores of four ribotypes (001, 015, 020 & 078) were aliquoted into 
Eppendorfs in biological triplicate and left in a homemade desiccator (Fig 3.2.3). At the 
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0, 3- and 6-month time points spores were resuspended in the appropriate volume of 
PBS and enumerated by serial dilution (10-5) on a range of solid media (CCEY, CCEYL 
and BHI (0.1 % taurocholate, 0.4 % glycine)). At the stated time points, 20 µl of spores 
were transferred to 180 µl of three different broths (BHI, BHI (5 % lysozyme) & BHI 
(0.1% taurocholate, 0.4 % glycine)) in biological triplicate. After 3 hours incubation, 
spores and TVCs were enumerated by serial dilution (10-5) on CCEYL agar as 
previously documented. CCEYL plates were incubated anaerobically for 48 hours. An 
overview of the methodology for the desiccation experiments can be found in Fig 3.2.4 
& Fig 3.2.5. 
 
Figure 3.2.3. The desiccator used to age C. difficile spores. The desiccator 
consisted of an air tight container filled with silica crystals to remove 
moisture from the air. Silica crystals in dehydrated form are blue but 
become red after hydration. 
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1 
Figure 3.2.4. An overview of the methodology used to enumerate 
desiccated spores directly on to solid agar. Spores were 
enumerated on three agars; CCEY, CCEYL & BHI. BHI was 
supplemented with 0.1 % taurocholate and 0.4 % glycine (BHI(S)). 
This diagram represents sampling for one ribotype. Four strains of 
differing ribotypes were utilised in total (001, 015,020 & 078). 
Spores were enumerated at 0, 3, & 6 months.  
20 μl 20 μl 
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2 
Figure 3.2.5. An overview of the methodology used to enumerate 
desiccated spores after 90 minutes broth incubation. Spores 
were incubated in three different broths; BHI, BHI(L) & BHI(S). 
BHI was supplemented with 5 % lysozyme (BHI(L)) or 0.1 % 
taurocholate 0.4 % glycine (BHI(S)). After incubation spore and 
TVC counts were enumerated on CCEYL agar. This diagram 
represents sampling for one ribotype. Four strains of differing 
ribotypes were utilised in total (001, 015 020, & 078). Spores 
were incubated in broths at 0, 3 & 6 months. 
Spore 
suspension 
(PBS) 
Broth 
incubation 
(90 
minutes) 
Serial 
Dilution 
Spore 
enumeration 
(CCEYL) 
20µl 
20µl 20µl 
20 μl 
20 μl 20 μl 
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3.2.8 Statistical analysis  
Statistical analysis was carried out in on IBM SPSS Statistics 22. Prior to statistical 
analyses data was assessed for normality and homogeneity of variance between 
groups. Data normality was assessed using histograms and Kolmogorov-Smirnov 
tests. Homogeneity of variance was assessed using Levene’s test; in the case of 
significant differences in variance between groups Welch’s ANOVA was utilised. All 
means are reported with standard error of the mean (SE). A statistical significance level 
of <0.05 was adopted, <0.01 highly significant and <0.001 very highly significant. x̅ 
represents the mean of several specified ribotypes. Individual details of statistical 
analysis are found with each experiment.  
 
 Results 
3.3.1 Spore Recovery on Solid Media 
Spore recovery varied considerably between different media types (Fig 3.3.1). In the 
absence of supplementation, recovery was ~1 log10CFU/ml greater on CCEY vs BHI 
media (range = 0.1 – 2.4 log10CFU/ml). The increased recovery of spores on CCEY vs 
BHI was observed in all but the RT 078 strain (P > 0.05). Greatest spore recovery was 
achieved in CCEY (x̅ = 8.20 ± 0.03 log10CFU/ml), CCEYL (x̅ = 8.26 ± 0.05 
log10CFU/ml) and BHI supplemented with taurocholate (x̅ = 8.25 ± 0.06 log10CFU/ml). 
The incorporation of 5% lysozyme had no substantial effect on the recovery of spores 
in either media (CCEY x̅ = 8.20 ± 0.03 vs 8.26 ± 0.04 log10CFU/ml, BHI x̅ = 7.28 ± 0.20 
log10CFU/ml vs 7.10 ± 0.18 log10CFU/ml) (P > 0.05). In BHI, supplementation with 
taurocholate (0.1 % or 1 %) significantly increased the recovery of spores by on 
average ~1 log10CFU/ml (range = 0 – 2.7 log10CFU/mL).  Differences were observed 
between strains; the RT 001 strain showed a very highly significant increase (5.80 ± 
0.13 log10CFU/ml vs 8.45 ± 0.08 log10CFU/ml) (P<0.001), in contrast to the negligible 
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difference observed for the RT 078 strain (7.95 ± 0.05 log10CFU/ml vs 8.03 ± 0.04 
log10CFU/ml) (P>0.05). On the contrary, taurocholate supplementation alone had no 
substantial effect on the recovery of spores on CCEY media (x̅ = 8.20 ± 0.03 
log10CFU/ml vs 8.29 ± 0.05 log10CFU/ml). 
Incorporation of 4 % glycine alongside taurocholate caused a marked reduction in 
spore recovery to below the lower limit of detection (1.22 log10CFU/ml) in both CCEY 
and BHI. Lower concentrations of glycine (0.4 % & 0.8 %) had no substantial effect on 
recovery in BHI, but in CCEY this decreased ~3 log10CFU/ml and ~6 log10CFU/ml, 
respectively.
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3.3.2 Spore Broth Pilot Study 
RT 027 spore numbers showed a time dependent decrease (Fig 3.3.2), decreasing 
~1log from 30 to 90 minutes (6.25 ± 0.02 log10CFU/ml vs 5.10 ± 0.03 log10CFU/ml; P< 
0.001), indicating spore germination. Total viable counts (TVCs) remained relatively 
stable between the 30- and 90-minute mark (7.02 ± 0.03 log10CFU/ml vs 7.06 ± 0.01 
log10CFU/ml; P < 0.05). Spore numbers continued to decrease after 90 minutes at a 
reduced rate; spore numbers decreased from 5.10 ± 0.03 log10CFU/ml to 4.87 ± 0.04 
log10CFU/ml after 120 minutes.
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3.3.3 Spore Germination in Broths 
Spore germination was induced by the inclusion of taurocholate and glycine at either 
concentration utilised (0.1 % taurocholate/ 0.4 % glycine, 1 % taurocholate/ 4 % 
glycine) (Fig 3.3.3). In BHI, spore levels were significantly lower (~2 log10CFU/ml) in 
taurocholate supplemented broths (x̅ = 4.32 ± 0.05 log10CFU/ml and 4.20 ± 0.07 
log10CFU/ml) vs 5 % lysozyme (x̅ = 6.38 ± 0.06 log10CFU/ml) and non-supplemented (x̅ 
= 6.43 ± 0.06 log10CFU/ml; P<0.001) BHI broths. Incorporation of lysozyme did not 
appear to have a substantial effect on the germination of spores. Total viable counts 
were comparable between all of the BHI broths at 90 minutes (range; x̅ = 6.69 ± 0.09 
log10CFU/ml – 6.75 ± 0.09 log10CFU/ml). In addition, germination of spores in 
Schaedler broth was comparable to BHI, with similar levels of spore decrease in 
taurocholate supplemented (x̅ = 4.22 ± 0.05 log10CFU/ml vs 4.26 ± 0.05 log10CFU/ml) 
lysozyme supplemented (x̅ = 6.27 ± 0.06 log10CFU/ml vs 6.39 ± 0.06 log10CFU/ml; 
P>0.05) and non-supplemented broths (x̅ = 6.28 ± 0.06 log10CFU/ml vs 6.43 ± 0.06 
log10CFU/ml; P> 0.05). There was no significant difference between total viable counts 
in any of the Schaedler broths at 90 minutes (range; x̅ = 6.67 ± 0.10 log10CFU/ml – 
6.70 ± 0.06 log10CFU/ml; P = 0.97).  
Phase contrast microscopy showed that in broths supplemented with taurocholate and 
glycine, phase dark spores predominated after 90 minutes were (Fig 3.3.4). At the 
zero-time point, the RT 078 strain contained a majority of phase dark spores compared 
with phase bright spores in both BHI and Schaedlers (x̅ = 76.40 ± 2.00 % vs 7.45 ± 
1.00 %; P< 0.001).  In non-supplemented BHI broths, after 90 minutes incubation, 
phase bright spores were more prevalent than phase dark spores or vegetative cells in 
four of the strains (001, 015, 020 & 027) (x̅ = 70.7 ± 11.2 % vs 18.0 ± 8.3 % vs 11.4 ± 
10.1 %). In contrast, in both sets of supplemented BHI broths, phase dark spores were 
the predominant entity in all five strains with minimal levels of phase bright spores (<3 
%). Vegetative populations made up a minority of the identified entities in all broths 
77 
(range = 9.2% - 30.1%). The trends observed in BHI were also seen in Schaedler 
broths.  
78 
Figure 3.3.3. Mean (± SE) TVC and spore counts of five C. difficile strains of 
different ribotypes (001, 015, 020, 027 & 078) germinated in two different 
broths (BHI & SCH) in the presence of different germinants lysozyme (L), 
taurocholate (TC) & glycine (GLY). (L) indicates broths supplemented with 
lysozyme. 0.1 %/1 % indicates the taurocholate concentration, glycine 
concentrations were four times that of taurocholate (0.4 %/4 %). Broths 
were incubated for 90 minutes, after which aliquots were serially diluted in 
PBS to obtain total viable counts. One set of aliquots was ethanol shocked 
to obtain spore levels. TVC and spore counts for each broth at the 90-
minute time point are presented in adjacent columns (e.g. BHI TVC, BHI 
Spores). Broths were carried out in biological duplicate and processed in 
technical triplicate. One-way ANOVA with Tukey’s multiple comparisons 
was used for statistical analysis. Very highly significant findings (P< 0.001) 
are highlighted with ***. 
Media 
 
79 
Figure 3.3.4. Phase contrast data for spores of five C. difficile strains of 
differing ribotypes (001, 015, 020, 027 & 078) incubated for 90 minutes in two 
broths (BHI & SCH) in the presence of a range of germinants (lysozyme (L), 
taurocholate (TC) & glycine (GLY). (L) indicates broths supplemented with 
lysozyme. 0.1 %/1 % indicates the taurocholate concentration, glycine 
concentrations were four times that of taurocholate (0.4 %/4 %).. Data 
represents the mean (± SE) of entities read from duplicate slides in 10 fields of 
view.  One-way ANOVA was used for statistical analysis. Very highly 
significant differences (P<0.001) are highlighted with ***. 
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3.3.4 C. difficile germination in the presence and absence of 
additional supplementation 
After 24 hours of incubation, spore counts were lower in the BHI(S) broths compared to 
BHI alone (x̄ = 3.79 ± 0.12 log10CFU/ml vs 5.08 ± 0.21 log10CFU/ml; P< 0.001) (Fig 
3.3.5). Over the first 6 hours of incubation, a gradual increase in TVC to reach peak 
numbers was observed in the supplemented BHI broth (x̄ = 6.46 ± 0.02 log10CFU/ml, 
6.92 ± 0.09 log10CFU/ml, 7.57 ± 0.16 log10CFU/ml; P< 0.01). In contrast, the non-
supplemented BHI broth took the whole 24-hour period to reach peak recorded TVC 
levels (x̄ = 6.43 ± 0.03 log10CFU/ml vs 7.95 ± 0.08 log10CFU/ml; P< 0.001).  
Spore numbers decreased significantly in both supplemented and non-supplemented 
broths after 3 hours but to different extents (x̄ = 5.97 ± 0.10 log10CFU/ml vs 4.04 ± 0.07 
log10CFU/ml & 6.04 ± 0.08 log10CFU/ml vs 5.33 ± 0.29 log10CFU/ml; P < 0.05). RT 078 
showed considerable germination of spores after 3 hours in the non-supplemented 
broth compared with RT 001 and RT 027 (3.72 ± 0.06 log10CFU/ml vs 6.13 ± 0.13 
log10CFU/ml; P< 0.001). At the equivalent time point all three strains (001, 027 & 078) 
showed similar levels of germination in the supplemented broth (x̄ = 4.04 ± 0.07 
log10CFU/ml). Although very significant, spore numbers at 0 vs 24 hours were only 
slightly lower in RT 001 and RT 027 when incubated in the non-supplemented BHI 
broth (x̄ = 6.15 ± 0.11 log10CFU/ml vs 5.70 ± 0.05 log10CFU/ml; P< 0.001). This 
contrasts with RT 078, which showed a ~2 log10CFU/ml drop after 24 hours (5.84 ± 
0.06 log10CFU/ml vs 3.85 ± 0.04 log10CFU/ml; P< 0.001). 
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3.3.5 Minimum Inhibitory Concentration (MIC) Testing 
3.3.5.1 Agar-incorporated minimum inhibitory concentration testing 
 
The MIC value for glycine was the same for all the strains utilised; 2% (20 g/L) (Fig 
3.3.7). MIC values were equivalent in vegetative compared to spore populations (data 
not shown). The inhibition was observed independently in glycine alone and in 
combination with taurocholate.   
001         015         020           027          078 
C. difficile PCR ribotype 
0 
1.5 
2.0 
2.5 G
ly
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%
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Figure 3.3.7. MIC testing of spores of five C. difficile strains of differing PCR 
ribotypes (001, 015, 020, 027 & 078) against increasing concentrations of 
glycine (0, 1.5, 2.0 & 2.5 %). Growth was substantially inhibited in all strains 
at a glycine concentration of 2.0 %.  
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3.3.5.2 Minimum inhibitory concentrations testing in microbroths 
At the highest concentration of amino acid (3%), growth of C. difficile was completely 
inhibited by all three amino acids (glycine, L-histidine & L-phenylalanine) (Fig 3.3.8). L-
phenylalanine exerted the most potent effect against microbial growth, with growth 
being very significantly inhibited at a concentration of 1 % (P< 0.001). Glycine inhibited 
growth at 2 % (P< 0.001) and L-histidine was the least potent of the three amino acids, 
with concentrations of 3 % required (P< 0.001). 
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Figure 3.3.8. Mean (± SE) growth of five C. difficile strains of differing ribotypes (001, 
015, 020, 027 & 078) in BHI containing increasing concentrations (0, 1, 2, 3, & 4 
%) of one of three amino acids (glycine, L-histidine, L-phenylalanine). 
Absorbance readings (595 nm) shown are at 0- and 24-hours post-spore 
inoculation. At higher concentrations of amino acids, growth is inhibited. One-
way ANOVA with Tukey’s multiple comparisons was used for statistical analysis. 
Very highly significant findings (P<0.001) are highlighted with ***.  
*** *** *** 
*** *** 
*** *** *** 
*** 
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9
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3.3.6 C. difficile spore desiccation  
A statistically significant decrease in spore recovery was observed on solid agar when 
the mean recovery of all five ribotypes was compared between the 0 and 6 month time 
points (P< 0.01) (Fig 3.3.9). Spore recovery dropped in BHI(S) (8.78 ± 0.12log10CFU/ml 
vs 8.61 ± 0.13log10CFU/ml), CCEY (8.75 ± 0.13 log10CFU/ml vs 8.58 ± 
0.16log10CFU/ml) and CCEYL (8.75 ± 0.13 log10CFU/ml vs 8.63 ± 0.12 log10CFU/ml) 
over the sixth month desiccation period. There was no difference in recovery between 
the three different solid media at any of the time points.   
Decreased TVCs were observed in desiccated spores incubated in BHI and BHI(L) 
broths comparing the 0- and 6-month time period (Fig 3.3.10). At 6 months, BHI TVC 
counts had decreased from 7.73 ± 0.02 log10CFU/ml to 7.37 ± 0.02 log10CFU/ml (P< 
0.001) and 7.71 ± 0.03 log10CFU/ml to 7.41 ± 0.01 log10CFU/ml (P< 0.001) in BHI(L). A 
similar time-dependent decrease in spores was observed in these broths. The same 
decrease in TVC was not observed in BHI(S) broths, but a significant decrease in 
spore numbers was seen at the 6-month time period (5.44 ± 0.05 log10CFU/ml vs 4.64 
± 0.03 log10CFU/ml) (P< 0.001).  
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3.4 Discussion 
3.4.1 Recovery of C. difficile on solid agar 
A variety of supplementation regimens were implemented in two solid media in order to 
optimise recovery in C. difficile spores of five C. difficile strains, with extensive variation 
in recovery observed (Fig 3.3.1). CCEY and BHI were chosen due to their popularity as 
media in culturing C. difficile. CCEY (cefoxitin-cycloserine egg yolk) agar has been 
used by clinical laboratories to isolate C. difficile from stool samples; this has been 
validated as a low-cost and highly sensitive medium for isolation of C. difficile (277) . 
Cycloserine (an antibiotic active against Gram-negative species) and cefoxitin 
(selective for enterococci and C. difficile) help to eliminate the background gut flora 
(278). Supplemented BHI (brain-heart infusion) is regularly used for sub culturing C. 
difficile.  BHI is not selective and is often supplemented with taurocholate and glycine 
to increase germination of C. difficile spores. It has been established that the primary 
bile acids, including cholate, glycocholate and taurocholate contribute to increasing the 
germination efficiency of C. difficile spores (62, 270); up to 105 greater in some studies 
(261). The experimental evidence formed the basis for including this combination 
(taurocholate & glycine) in the current work.  
Taurocholate supplementation increased spore recovery on BHI but not 
on CCEY 
Taurocholate supplementation increased recovery in BHI by ~1 log (Fig 3.3.1). The 
additional inclusion of glycine did not increase spore recovery further. Inclusion of 
taurocholate at either concentration had no significant effect on the recovery of spores 
on CCEY. The inherent presence of cholate, a primary bile acid stimulatory to C. 
difficile germination in CCEY may explain the lack of effect of taurocholate inclusion. It 
should be noted that the lowest concentration of taurocholate used in this study was 
0.1 %, but lower concentrations (0.05 %) have been found to be equally effective in 
some studies (281). The addition of glycine did not increase recovery further in BHI 
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supplemented with taurocholate (8.3 vs 8.2 log10CFU/ml). It is hypothesised that BHI 
inherently contains a source of glycine sufficient to support the action of taurocholate in 
stimulating germination. Additional supplementation of glycine could be considered 
superfluous to requirements. Optimal concentrations for germination ranged between 
~0.07-0.7 % for five identified amino acid co-germinants in one study (282). Although 
higher glycine concentrations increase the rate of germination, overall levels of 
germination are unlikely to be affected after sufficient time has passed to allow 
germination (263). 
Inter-strain variation in response to the addition of germinants was seen. RT 027 and 
RT 078 recovery increased to a lesser extent compared to other strains when 0.1 % 
taurocholate was added to non-supplemented media. Germination in the absence of 
taurocholate of a RT 078 strain (M120) has been found previously in studies 
investigating spore germination (173). On the contrary, in this study 078 recovery was 
~0.5 log10CFU/ml higher in BHI plates supplemented with 1 % taurocholate and 0.8 % 
glycine; suggesting that germination may be more tightly regulated in RT 078 and 
require more glycine participation.  
Remarkably, one study found that strains associated with more severe disease had 
impaired germination in the presence of taurocholate alone (271). This suggests some 
strains may have a highly regulated germination mechanism whereby spores only 
germinate in the most favourable of conditions. Previously it has been found that some 
strains will germinate in BHI alone in the absence of taurocholate. This phenomenon 
did not appear to be RT dependent, suggesting germination responses are not global 
within RTs (283). However, the ability of spores to germinate in the absence of 
taurocholate has been questioned in recent work by Bhattacharjee et al (258). Different 
strains were found to have dissimilar affinities for taurocholate. Bile acids are present in 
blood and could be present in animal products such as media. Germination of spores 
may be mediated by a high affinity for taurocholate at low concentrations. This provides 
a potential explanation for why RT 078 germinated in the apparent absence of 
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taurocholate. The question still remains as to why RT 078 required greater 
concentrations of glycine to optimise germination.  
Higher concentrations of glycine were inhibitory to C. difficile 
In the case of higher concentrations of germinants (1 % taurocholate, 4 % glycine) 
spore recovery was inhibited to below the lower level of detection (Fig 3.3.1). A level of 
inhibition was also visible in CCEY plates supplemented with lower concentrations, but 
not in BHI. Initially taurocholate supplementation alone was not included in the 
experiment; leading to the hypothesis that inhibition could be due to the increased 
levels of primary bile acids in the media. As taurocholate and other primary bile acids 
have been found to be inhibitory to a range of other species (284), it was hypothesised 
higher concentrations could be toxic to C. difficile. The disparity between CCEY and 
BHI could be explained by the presence of cholate in CCEY, producing a higher 
concentration of inhibitory primary bile acid.  
To investigate this hypothesis, taurocholate was included alone in the absence of 
glycine. The hypothesis was rejected due to spore recovery returning to normal levels. 
This led to a new hypothesis; glycine was the inhibitory agent in the media. Decreased 
levels of glycine were chosen (0.8%) in addition to the previously utilised combination 
(0.1 % taurocholate/ 0.4 % glycine & 1 % taurocholate, 4 % glycine) and in CCEY 
recovery increased slightly to above the LLOD (1.22 log10CFU/ml) supporting the 
inhibitory role of glycine. Glycine was explored further in order to determine its 
inhibitory nature. Spore recovered was not inhibited in BHI media supplemented with 
0.8 % glycine. This is likely due to the differing composition of the two media; CCEY 
may inherently contain larger concentrations of glycine, negating the requirement of 
supplementation to observe inhibition.  
In summary, this work indicates the comparability of two solid media commonly used in 
C. difficile research for spore recovery; supplemented BHI and CCEY/CCEYL. 
Although CCEY and CCEYL recovery was comparable, CCEYL was used preferentially 
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in subsequent experiments for spore recovery due to being readily available. 
Additionally, the inhibitory nature of glycine has been identified. The nature of inhibition 
was unknown, and further work is required to elucidate the mechanism.  
3.4.2 Germination of C. difficile in broths 
The germination of C. difficile was investigated in liquid media, with the same 
germinants and similar concentrations to those used in solid agar recovery experiments 
(Fig 3.3.3). It was hypothesised recovery would be greatest in broths supplemented 
with taurocholate and glycine. An initial spore pilot study using one strain (027) in 0.1 % 
taurocholate/ 0.4 % glycine supplemented broths was carried out to evaluate 
appropriate time-scales for sampling (Fig 3.3.2). At 90 minutes substantial germination 
was evident; spore numbers decreased by ~1 log10CFU/ml from the 60-minute mark 
and the ratio between TVC and spores increased. Sampling at 90 minutes was chosen 
for future experiments, as levels of germination were substantial and this allowed time 
for processing the broths without further significant germination.  
Taurocholate and glycine are necessary for optimal germination of C. 
difficile 
Germination was greatest in the presence of taurocholate and glycine; increasing 
concentrations above 0.1 % taurocholate/ 0.4 % glycine had no additional effect (Fig 
3.3.3). Schaedler and BHI were comparable for germinating spores in liquid media. 
Spores incubated in 5 % lysozyme did not show any additional germination compared 
to non-supplemented media, as observed in the agar experiment. The spores used in 
this experiment were pure and in large numbers, providing a potential explanation. The 
lack of activity compared to traditional germinants (taurocholate & glycine) does 
question the legitimacy of lysozyme as a germinant. Based on the contradictory 
relationship between the literature and this dataset (275, 276, 285), the activity of 
lysozyme as a germinant could be limited to situations where small numbers of spores 
are present, particularly in the case of recovery from environmental specimens. 
Lysozyme was used alone without cogerminants, which is another consideration.  
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Contrary to what was observed on solid agar, the higher concentration of glycine (4 %) 
appeared to have no substantial effect on spore recovery in broths. This supports the 
conclusions made previously that glycine acts on vegetative C. difficile cells. Ninety-
minutes in the broths is sufficient to elicit germination in the spores, but a large 
proliferative population will take longer to develop. This notion is supported by the 
phase contrast microscopy data; the majority (~75 %) of entities being identified in 
supplemented broths were phase dark spores and a minority vegetative cells (~20 %) 
at 90 minutes (Fig 3.3.4). Spores transition from phase bright spores to phase dark 
spores upon germination (286). Following broth incubation spores were removed and 
streaked on to CCEYL, a medium free from high concentrations of glycine. This 
medium will allow vegetative cells to proliferative.  
RT 078 presented with different germination characteristics 
RT 078 showed some unanticipated characteristics. At the zero-hour time point the 
phase contrast data were different to that of the other strains (Fig 3.3.4). Most of the 
entities identified were phase-dark spores. There are several explanations; firstly, RT 
078 spores may germinate more readily than other spores when left on the bench in 50 
% ethanol. Work has shown that C. difficile spores will germinate in both anaerobic and 
aerobic environments. One would expect substantial biological decay over time, which 
has not been observed in the literature. RT 078 spores could have a divergent spore 
coat with different optical properties than those of other strains. In theory, this would 
allow identification of phase dark spores in the absence of germination. This seems 
highly unlikely given that phase bright spores were observed, albeit in small numbers. 
The mostly likely explanation is based on how the slides were processed. RT 078 
spores may have germinated during the 50° C slide drying stage. This is the most likely 
explanation given the incongruity between the phase contrast data and the broth 
enumeration, where germination appeared comparable with the other strains.  
C. difficile spores will germinate in the absence of additional 
supplementation 
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When C. difficile spores of three RTs (001, 027 & 078) were incubated for 24 hours in 
BHI and BHI(S), germination occurred more rapidly in the supplemented broths (Fig 
3.3.5). The spores still germinated in BHI alone, but at a slower rate. At the end of 
incubation spore levels were ~1 log10CFU/ml higher in non-supplemented BHI than in 
BHI(S). A vegetative population was present in both sets of broths, suggesting a 
minority of spores were germinating in the absence of supplementation. At the 0-time 
point, it would be expected spore and TVC numbers would be similar due to lack of 
germination. Spore germination began immediately in RT 001 in supplemented broths, 
with a substantial drop in spore numbers. The same trend was seen in RT 078; RT 027 
took 3 hours to begin germination. Most strikingly, RT 078 germinated immediately in 
the absence of supplementation.  
Previously a RT 027 strain was found to have increased germination in 0.1% 
taurocholate compared to a RT 106 and a RT 078 strain (287). Strains associated with 
severe CDI and recurrence were also found to have increased germination efficiencies. 
It might be the case that hypervirulent RT 027 strains associated with recurrence have 
a highly regulated germination cascade allowing the greatest chance of outgrowth. The 
lack of requirement for high concentrations of taurocholate in RT 078 may illustrate 
divergent epidemiology; with non-human animals being identified as a potential major 
reservoir (288).  
Previous studies have identified strains that appear to germinate in the absence of 
stimulatory germinants and in the presence of inhibitory bile acids such as 
chenodeoxycholate (283). Bhattacharjee et al suggested that media derived from 
animal products contain a small amount of stimulatory bile acids (258). In the cited 
study, strains appeared to be germinating in the absence of germinants; the CspC 
germinant receptors had a higher affinity for stimulatory versus inhibitory bile acids. 
These strains can germinate in lower concentrations of stimulatory bile acids, without 
additional supplementation. In addition, RT 078 showed a decreased response to 
additional supplementation with taurocholate. This could be due to being responsive to 
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lower levels of primary bile acids, which could be important in the case of recrudescent 
disease.   
Lysozyme did not increase spore recovery in either media 
Lysozyme has been considered a C. difficile spore germinant for several decades 
(285), with other studies elucidating its value in recovering environmentally aged and 
heat treated spores (275, 276). While lysozyme is generally bactericidal, vegetative C. 
difficile is highly resistant (289) possibly due to variants in the peptidoglycan wall (290). 
However, in this study no beneficial effects of recovery on spores were observed in the 
presence of lysozyme. Conversely, in one strain (078) the addition of lysozyme in BHI 
appeared to inhibit recovery to some degree. However, this phenomenon was not seen 
when the same strain was grown on CCEYL. This could indicate an unidentified 
mechanism but is likely an artefact; there is no logical reason lysozyme would inhibit 
the growth of RT 078 on BHI(L) agar, but not CCEYL. 
Spores incubated in 5% lysozyme did not show any substantial germination additional 
to that observed in non-supplemented media (Fig 3.3.3). This is in accordance to the 
results seen on solid agar (Fig 3.3.1). The equivalent explanation can be given for this 
being contrary to what is observed in the literature. The spores used in this experiment 
were pure and in large numbers. However, the lack of any activity compared to the 
traditional germinants (taurocholate & glycine) does question the legitimacy of 
lysozyme as a germinant. Based on the contradictory relationship between the 
literature (275, 276, 285) and this dataset, the use of lysozyme could be limited to 
situations where small numbers of spores are present, particularly in the case of 
recovery from environmental specimens. It may also be considered that lysozyme was 
used alone in the current study; it could act as a co-germinant.  
3.4.3 The inhibitory nature of L-amino acids 
Further investigation of the inhibitory nature of glycine was required. Previously, high 
concentrations of glycine (4 %) had been shown to be inhibitory to C. difficile recovered 
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on solid agar. It was necessary to use a gold-standard methodology of agar-
incorporated minimum inhibitory concentration testing to elucidate this interaction 
further. Two scenarios were possible, glycine could be inhibitory to spore germination 
or to vegetative cell proliferation. It was unclear whether this inhibition was unique to 
glycine.   
Glycine was inhibitory to C. difficile proliferation 
Both spore and vegetative populations were inoculated on plates with increasing 
concentrations of glycine and taurocholate. Agar-incorporated MIC testing with glycine 
illustrated the inhibitory nature of glycine at 2.5 % in all five strains tested (Fig 3.3.7). 
This inhibition was seen in both vegetative and spore populations, supporting the 
conclusions made previously that glycine acts on vegetative C. difficile cell proliferation.  
Glycine has been historically reported as being inhibitory to other bacterial species, 
including E.coli (291), and the role of glycine has more recently been evaluated due to 
its penicillin synergism in H. pylori eradication (292). It has even been investigated in 
dentistry as a replacement for sodium bicarbonate in airbrushing dental appliances 
(293). The mechanism of glycine inhibition is thought to involve the replacement of D-
alanine residues in tetrapeptides responsible for cell wall linkage in the bacterial cell 
wall (294). These tetrapeptides hold together the glycan strands, and changes to the 
terminal amino acid D-alanine result in defective linkage. It has also been observed that 
the D-alanine substitution proposed can be induced by amino acids other than glycine, 
for instance D-threonine, D-valine, D-leucine and D-methionine (295, 296). It is unclear if 
this mechanism could account for the inhibition seen in C. difficile.   
The picture is further complicated by the microbroth MIC results (Fig 3.3.8). In addition 
to glycine two other amino acids, L-phenylalanine and L-histidine, exhibit inhibitory 
properties against C. difficile growth. Previously, amino acids have been found to be 
suppressive on the production of toxins A and B in one C. difficile strain (297). L-amino 
acids are ubiquitous in nature, and their inhibitory nature has not been reported 
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previously. One explanation rests on the observation that the peptidoglycan cell wall is 
different in C. difficile; extensive levels of 3-3 cross linkage catalysed by L, D-
transpeptidation are present in contrast to the 4-3 cross links produced by D,D-
transpeptidation in other bacteria (298). It seems feasible amino acid substitutions at 
higher concentrations could be possible. Another potential solution rests with recent 
work documenting the presence of a C. difficile alanine racemase on spores (299). 
Alanine racemases are embedded on the spore coat of many spore forming bacteria, 
and it is believed they facilitate the conversion of L-alanine to its enantiomer D-alanine. 
Interestingly, the same work found the racemase would also accommodate L-serine 
and its subsequent conversion (299). It is theoretically possible other such racemases 
exist, or the currently identified racemases can accommodate additional L-amino acids. 
This seems plausible and would form the basis for a possible mechanism for explaining 
the inhibition seen in this work. Racemase activity could lead to L-D isomer conversion, 
and as stated previously a potential mechanism of D-amino acid inhibition exists that 
could explain the inhibition seen in this study. At present, the mechanism remains 
unidentified and warrants further investigation. 
3.4.4 Desiccation of C. difficile spores 
Spores exhibited a significant time-dependent decrease in recovery 
 
When spores of four ribotypes (001, 015, 020 & 078) were pelleted and left in a 
homemade desiccator for 6 months, a decrease in spore recovery was observed on 
both solid agar (BHI, CCEY, CCEYL) (Fig 3.3.9) and when spores were incubated in 
broths (BHI, BHI(L), BHI(S)) (Fig 3.3.10). However, in the case of spore recovery on 
solid agar there was no significant difference in spore recovery on the agars used. It 
has been suggested that environmentally aged or distressed spores may require 
additional germinants such as lysozyme to optimise C. difficile spore recovery (275), 
with ageing suggested to induce spore “superdormacy”. Although spore recovery was 
found to decrease over the 6-month time period, the use of 5 % lysozyme did not 
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mitigate this drop suggesting no role for superdormancy. The previous study 
highlighting a role for lysozyme was recovering small numbers of C. difficile spores 
from environmental samples (275). At 3 and 6 months, a small but visible amount of 
spore pellet was not amenable to resuspension in PBS despite vigorous vortexing and 
manual homogenisation; perhaps accounting for the observed drop in spore recovery.  
Spore germination efficiency appeared to increase after 6 months of 
desiccation  
There was a ~1 log decrease in spore numbers at 6 months compared to the 0-month 
time point (Fig 3.3.10). No corresponding decrease in TVC was observed. One 
hypothesis is that this represents an increased germination efficiency of the spores at 
the 6 month time point. Previous work studying three strains observed that R20291 
exhibited increased germination efficiency after incubation at room temperature in PBS 
for 4 months (300), however, the opposite effect was observed in two other strains 
(M120 (PCR ribotype 078) and DK1 (unidentified PCR ribotype). The author suggested 
R20291 spores could be exhibiting decreased superdormancy in response to age, the 
reverse occurring in M120 and DK1 spores. Thus, increased spore germination 
efficiency with age has been observed previously. It is hard to reconcile these findings; 
the current study did not include a RT 027 strain and increased spore germination 
efficiency is reported in all four strains used. Desiccation was also used in contrast to 
storage in PBS, and it is conceivable that dry storage could have a considerable effect 
on the spore exosporium and consequently the spore germinant response.  
Superdormancy is of importance in rCDI for several reasons. Recurrence can occur 
within two contexts; relapse and reinfection. In a patient who has not suffered a 
previous episode of CDI, ingestion of spores may facilitate disease. Superdormant 
spores with an increased germination efficiency will outgrow more rapidly, producing 
more spores. The additional spores produced are likely to adhere to the colonic 
epithelium and increase the risk of relapsing disease in the future. The same scenario 
of increased germination of superdormant C. difficile spores could occur in patients 
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who reingest spores from the environment, facilitating initial infection or reinfection. The 
findings presented in this thesis at least support the hypothesis that spores of some 
strains may exhibit increased germination efficiency when ‘environmentally aged’.  
Conclusion 
C. difficile spores can be recovered optimally on solid agar using non-supplemented 
CCEY or BHI supplemented with 0.1 % taurocholate. Additional amino acid 
supplementation does not appear to be necessary. Germination of C. difficile is 
optimised in broths by using the same combination; taurocholate appears to be the 
important prerequisite for optimal recovery.  Lysozyme is not an effective germinant 
when used on large numbers of laboratory prepared pure spores. Glycine and two 
other amino acids, L-phenylalanine and L-histidine were inhibitory to C. difficile growth. 
The mechanism remains unidentified, but several hypotheses have been suggested. 
Although interesting, it is unlikely that this phenomenon could be translated into a 
clinical context due to difficulty in reaching therapeutic amino acid levels in the host. 
Desiccation for 6 months (mimicking environmental ageing) revealed an increase in the 
germination efficiency of spores. This could be of importance in the case of rCDI, 
where ingestion of environmental spores leads to recurrence due to reinfection. One of 
the most remarkable findings of this study highlights the divergent germination 
characteristics of a RT 078 strain. This effect was observed when the strain was 
recovered on solid agar and cultured in liquid media. Although experiments utilising 
more RT 078 strains would strengthen these conclusions, it is feasible that the ability of 
RT 078 to germinate in less selective conditions could explain its epidemiological 
prevalence. 
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Chapter 3 B – Heat treatment of Clostridium 
difficile spores 
3.5 Background & Rationale 
Bacterial spores have a high resistance to the damaging effects of heat.  The effect of 
heat on bacterial spores is of concern for two reasons. Spores of several spore-formers 
(B. subtilis, C. perfringens) have been reported to be ‘activated’ in response to sub 
lethal heat treatment (301-303) . The administration of heat at sub-lethal levels is 
usually administered between 60-75° C for ~30 minutes. In one study C. difficile 
germination was found to be increased by ~30 % in environmentally aged spores in 
response to sub lethal heat treatment (253). The same effect was not observed in 
freshly produced spores. Other studies have also failed to ‘heat activate’ freshly 
produced C. difficile spores (304, 305).  A number of different temperatures and 
durations have been utilised in trying to optimise C. difficile germination, but no 
consensus exists (254, 261).  
The survival of clostridia spores at high temperatures is a concern in food processing. 
Species of clinical concern include C. difficile, C. botulinum and C. perfringens. The 
importance of heat resistance has been documented in the case of C. perfringens food 
poisoning; spores of foodborne chromosomal CPE (chromosomal enterotoxin gene) 
carrying isolates display increased heat resistance versus non-foodborne plasmid CPE 
carrying isolates, allowing these spores to survive and cause human disease (306). C. 
perfringens spores are particularly resistant to heat treatment; spores are able to 
survive temperatures exceeding 100° C for short periods of time (307). The detrimental 
effect of heat on microorganisms has been evaluated by the calculation of D and Z 
values (308-310). The time taken for a 90 % (1 log) reduction in numbers is defined as 
the D-value; the Z-value denotes the temperature increase required to decrease the D-
value by a magnitude of ten (i.e. a 10-fold decrease in the time taken for a reduction of 
90 % reduction in numbers). The D value at 100 ° C for C. perfringens has been 
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reported at between 16-21 minutes and a D-value of 55 minutes at 85° C (311, 312). C. 
perfringens spores were also found to exhibit higher thermal tolerance in response to 
prior sublethal heat treatment (311). 
Since the 1980s the effects of heat on C. difficile  have been studied (276). The heat 
resistance of C. difficile spores has been investigated, with some strains being shown 
to resist high temperatures (90° C) for more than 10 minutes (313). One study 
illustrated that C. difficile spores can survive extended heating at 71° C, a 
recommended minimum cooking temperatures (253). Viable spores of 20 clinical 
strains were isolated after heating at 71° C for two hours (314). The current guidelines 
for reheating food in the UK recommend a temperature of 82 ºC, below that required 
for the complete inactivation of C. perfringens spores (315). This is of lesser 
importance in C. difficile, due to the discovery of lower D values vs other Clostridia (C. 
botulinum, C. perfringens) (314). Although not fully appreciated, foodborne 
transmission of C. difficile is possible and has been evaluated using thermal death 
models (316). 
 The survival of C. difficile spores has been investigated in media other than 
phosphate-buffered saline. One study compared the recovery of spores (four C. difficile 
strains) after heat treatment at several temperatures for 10 minutes in peptone water or 
fresh pork. Higher D-values were observed in the pork heated spores, suggesting the 
environmental conditions and surrounding matrix could be buffering the heat and 
subsequently protecting the spores (316). This phenomenon  has been replicated in 
other work (253). In addition, research using B. cereus indicates that matrix could have 
altered the ability of the spore to recover subsequent to heat treatment (317). Many of 
the reported D-values for C. difficile spores use only one medium, leading to a potential 
underestimation of heat resistance. This is of importance in the food industry, where 
higher temperatures than those reported in the literature are required in the case of 
sterilisation of meat products.  
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Community acquired CDI accounted for ~32 % of cases in the United States in 2013 
and whole genome sequencing has been used to recognise a lack of a clear 
transmission pathway in a substantial number of CDI cases in the UK (318, 319). Food 
could serve as one of a number of environmental reservoirs for C. difficile, including 
soil,  nosocomial surfaces, swimming pools and the household (124). C. difficile has 
been isolated from a number of cooked meats and food products as well as raw meat 
products (118, 119). In addition to being present in uncooked meat products such as 
poultry, C. difficile spores have been isolated from raw ‘ready to eat’ vegetables in 
France (320).  However, only 2.9 % of samples (3/104) contained toxigenic C. difficile. 
Conversely, the contamination of 26.8 % (22/82) of fertilisers with C. difficile illustrates 
a possible mechanism of foodborne contamination in Western Australia (122). Further 
work by the same group found a ~15 % contamination rate with toxigenic C. difficile in 
root vegetables commonly sold in retail stores and farmers markets (123). 
The thermal tolerance of C. difficile spores could potentially account for the 
transmission of spores to patients through food. However, whilst food could serve as a 
C. difficile reservoir and facilitate asymptomatic carriage in the community, a 2016 
prospective study found C. difficile in only 0.2 % of hospital food (910 samples, 149 
patients), with neither patient receiving the food becoming colonised (321). It is unlikely 
that foodborne C. difficile plays a large role in nosocomial acquisition, but it should be 
noted different practices and food preparation techniques are likely to be present in the 
UK.  
In summary, food is a possible reservoir of C. difficile. In the nosocomial environment, 
food is unlikely to be a major source of CDI and subsequent potential recurrences. 
Although no transmission has been demonstrated and no outbreaks are attributable to 
foodborne CDI (288) , food may present a possible route of transmission, particularly in 
the community setting. As the majority of recurrence due to relapse occurs within 14 
days of the initial episode (67), any recurrent episodes attributable to food are likely to 
be due to reinfection, potentially in the community. In the case of reinfection, patients 
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must be ingesting C. difficile spores from a source and food is one of many potential 
reservoirs. 
3.5.1 Superdormancy 
Heat treatment of C. difficile spores has also become of interest due to the observed 
effects of heat on spore germination and outgrowth. The phenomenon of 
‘superdormancy’ was first recognised in Bacillus subtilis (59), and the mechanisms 
have since been discovered to be similar in other Bacillus species including Bacillus 
cereus and Bacillus megaterium (322). Superdormancy is a phenomenon in which a 
small percentage of spores will fail to germinate in contrast to the vast majority. 
Germination of these spores can take weeks or months and often requires non-
germinant-receptor based germinants, or a heterogenous mixture suggesting 
superdormant spores require additional ‘signals’ to initiate germination. In 2009 a 
nutrient exhaustion method was used by Ghosh et al. to produce and purify 
superdormant spores of B. subtilis and B. megaterium (59), and a negative association 
between germinant receptor numbers per spore and production of superdormant 
spores was identified. Genetic differences did not account for superdormancy.  
In one study C. difficile spores aged for > 20 weeks showed an increase in germination 
efficiency compared to freshly produced spores when they were heated to 65° C or 71° 
C for 30 minutes (253). Heat activation has been described for spores of several 
species including Bacillus megaterium (323), Bacillus anthracis (324), Bacillus subtilis 
(325), Clostridium perfringens (326) and Clostridium botulinum (327) . Conversely, 
Wang et al. found heating spores of two strains of C. difficile at 65° C for 30 minutes 
did not stimulate germination in C. difficile (304). Only two C. difficile strains were used, 
and the isolates were from RTs of limited clinical significance (RT 060 & RT 031). Deng 
et al (2017) found spore recovery to drop ~1 log after 3 months of storage in PBS 
(328). However, one of the three strains demonstrated increased recovery after this 
storage period, demonstrating a loss of superdormancy. Taken together, these findings 
suggest superdormancy may be not only be strain dependent, but condition dependent. 
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Nevertheless, these findings are congruent with those of Rodriguez-Palacios et al. 
(253), suggesting sub-lethal heat activation has no beneficial effect on the germination 
efficiency of freshly produced C. difficile spores. However, the finding that aged spores 
germinated more efficiently when heated at sub-lethal temperatures suggests the 
possibility of ‘superdormant’ spores of C. difficile that are reactivated by the effects of 
sub-lethal heat.  
Should superdormancy exist in C. difficile spores, it may play a role in recurrent 
disease. After successful treatment of a first episode of CDI, C. difficile spores could 
persist in the patient’s gastrointestinal tract, posing no immediate risk. As the healthy 
microflora reconstitutes, the gut becomes more nutrient rich including the production of 
germinants. This could provide a niche for the germination and outgrowth of 
superdormant spores, which require a greater array of germinants. More controlled 
germination would also give superdormant spores an advantage over non-
superdormant spores in causing later disease. More highly regulated germination 
would allow outgrowing into an environment only in peak optimal conditions. It would 
also render the ‘activate to eradicate’ germination solutions for C. difficile spore 
eradication in the nosocomial environmental  implausible (254).  
To conclude, superdormant spores may be important in the context of rCDI for several 
reasons. Superdormant spores are more likely to persist in the gut of patients who 
have had a first episode of CDI; which could later result in recrudescent disease. In 
addition, sub-lethal heating could also ‘reactivate’ superdormant spores, which is of 
importance in the case of potential foodborne transmission.  
3.5.2 Biofilms 
C. difficile forms biofilms in the gastrointestinal tract, serving as a potential reservoir of 
spores. Many of the proteins associated with maximal biofilm formation such as the 
flagella, Cwp84, and LuxS have been identified as virulence factors (329).  
The existence of two morphotypes of C. difficile spores has been investigated in 
previous work (80). Both spores produced within biofilms and by sporulating planktonic 
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cultures have been found to exhibit two morphotypes of spores; a ‘thin-exosporium’ or 
‘thick-exosporium’ appearance. However, when spores from biofilm and sporulating 
cultures were compared, biofilm-produced ‘thin-exosporium’’spores were found to have 
a thinner exosporium. In addition, the two morphotypes appeared in a different ratio to 
that in spores produced by planktonic culture. It is unclear what role if any the 
differences in biofilm produced spores could have on recurrence. Further work will 
need to be carried out investigating the attachment and persistence of these spores in 
the gastrointestinal tract, using a wider variety of strains. Data on the germination 
efficiencies and response to heat treatment would also serve to understand their role 
more completely.  
Curiously, one study found an inverse association between possessing an appendix 
and rCDI risk (330). Eleven variables were retrospectively analysed in the case of 254 
patients with CDI. The study was limited by its retrospective nature and data was only 
obtained from one centre. Nevertheless, the appendix is an important site of biofilm 
activity and is rich in lymphoid tissue, a prerequisite for immune function.  A separate 
study of 509 patients with CDI found a statistically significant increase in colectomy 
amongst CDI patients who had previously had an appendicectomy (330). It is 
hypothesised that the absence of an appendix allows more pervasive biofilm formation 
by C. difficile, leading to a greater chance of recurrence due to persistence. In a recent 
study, the importance of biofilms in CDI has been highlighted by the finding that 
fidaxomicin has a greater ability to penetrate biofilms, coating spores (248) and killing 
vegetative cells (331). Given the decreased recurrence rates observed with fidaxomicin 
treatment, spores produced within biofilms may be an important target in preventing 
rCDI. 
In this work it is hypothesised that spores of different RTs have intrinsic differences in 
their resistance to heat. In addition, it is theorised that environmentally aged spores 
germinate in response to heat, thereby ‘reactivating’. Finally, it is hypothesised that 
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spores produced on solid agar are more heat resistant than those produced in liquid 
media, complementing the findings of the existing literature.  
3.6 Methods 
All strains used were clinical isolates obtained from the Clostridium difficile ribotyping 
network (CDRN). All experiments were carried out in biological duplicate (different 
spore preparations) and technical triplicate (each biological replicate processed in 
triplicate) unless otherwise stated. Spore viability was assessed by recovery on CCEYL 
agar. CCEYL agar is comparable to BHI supplemented with taurocholate for recovery 
of C. difficile spores (38). CCEYL inherently contains cholate, a stimulatory bile acid 
comparable to taurocholate. Lysozyme was incorporated into CCEY due to previous 
efficacy in recovering heat-treated spores and clinical isolates (21, 40). 
3.6.1 Production of spores 
3.6.1.1 Spores produced on solid media 
Spores were produced as outlined in the germination experiments of Chapter 3A. 
3.6.1.2 Spores produced in liquid media 
Spores of five PCR RTs (001, 015, 020, 027 & 078) were produced as follows; ~5x108 
spores were aliquoted into 500 ml of BHI (supplemented with 0.1 % taurocholate) and 
incubated anaerobically for 10 days. For all ribotypes, both biofilm-derived and 
planktonically-derived spore populations were produced. For production of spores in 
planktonic culture flasks were continuously shaken at 0.5 g for the duration of 
incubation. 
After 10 days, the contents were centrifuged at 3750 g. The spores were purified using 
a modified protocol utilising HistoDenzTM (Sigma-Aldrich) as previously described (261). 
Briefly, the pellet was resuspended in 400 μl of 20 % HistoDenzTM and layered on to 
500 μl of 50 % HistoDenzTM. The solution was centrifuged at 15000 g for 15 minutes, 
after which the supernatant containing vegetative cells and cell debris was carefully 
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removed. The pellet was washed three times in PBS and resuspended in 1 ml of PBS. 
Spores were checked for purity by phase contrast microscopy.  
3.6.2 Transmission electron microscopy (TEM) 
Sample processing and image acquisition for TEM was carried out by Mr Martin Fuller 
of the Astbury Biostructure Laboratory, University of Leeds. 
Planktonic and biofilm produced spores of RT 027 were visualised by TEM. Spores 
were fixed with 2.5 % glutaraldehyde in 0.1 M phosphate buffer for 150 minutes. Two 
subsequent washes in 0.1 M phosphate buffer were performed. Osmium tetroxide (1 
%) was used to stain samples overnight. Sample dehydration was performed by 
incubation with an ascending alcohol series (20, 40, 60, 80, 100 %). Each step lasted 
60 minutes. These steps were performed in Eppendorf tubes, with samples centrifuged 
and resuspended after each stage.  
Spores were embedded in an epoxy resin (AGAR Araldite CY212, Essex, UK) using an 
accelerator (DMP30, Sigma Aldrich, Dorset, UK) and hardener (DDSA, Sigma  Aldrich,  
Dorset, UK) and left overnight to polymerise at 60° C (332). Samples were cut into thin 
sections (~80-100 nm) using an ultramicrotome (Reichert Jung Ultracut E) which were 
picked up on 3.05 mm copper grids. Grids were stained with saturated uranyl acetate 
(120 minutes) and Reynolds lead citrate (30 minutes). Samples were visualised at a 
maximum of 10000X direct magnification in the bright field setting on a JEOL JEM1400 
TEM (Jeol, London, UK) at 120 kV. Images were taken on an AMT 1k CCD (AMT, 
Suffolk, UK) using AMTv602 software 
3.6.3 Heat Treatment in PBS for 60 minutes  
Fifty-microlitres of spore suspension were aliquoted into 450 µl of PBS in an 
Eppendorf. The final concentration of spores for heating was ~ 2x107 spores/ ml. 
Eppendorfs were transferred to a heat plate and heated for 1 hour aerobically under 1 
atm of pressure.  Heating at 50, 60, 70 and 80° C was performed. At time points 0, 15, 
30, 45 and 60 minutes. Twenty-microlitre aliquots were removed and serially diluted in 
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PBS in a 96-well plate.  Twenty-microlitres of the appropriate dilution were streaked on 
to CCEYL agar. 
3.6.4 Heat Treatment Prior to Broth Inoculation 
Fifty-microlitres of spore suspension were aliquoted into 950 µl of PBS and heated at 
50, 60, 70 or 80 ° C for 10 minutes aerobically on a heat plate. The final concentration 
of spores for heating was ~107 spores/ ml. This concentration was in accordance with 
previous work (333, 334). Subsequently the contents were transferred into a 4 ml BHI 
broth to produce a final volume of 5 ml (0.1 % taurocholate, 0.4 % glycine). Broths 
were incubated anaerobically for 90 minutes under 1 atm of pressure. At 90 minutes, 
20 µl of broth was removed and serially diluted in PBS to 10-7 in technical triplicate.   
One hundred microlitres of broth was aliquoted into 100 µl of 100 % ethanol and after 
an hour serially diluted in PBS to 10-4. Twenty-microlitres of each dilution were 
aliquoted on to CCEYL agar. In addition, 500 µl of broth was removed and centrifuged 
at 9500 g for 1 minute. The supernatant was removed and spores were resuspended in 
50 µl of PBS, which was spread on to a slide for phase contrast microscopy. A zero 
time point aliquot was included for phase contrast microscopy. 
3.6.5 Reversibility of Spore Heat Treatment 
Fifty-microlitres of spore suspension were aliquoted into 950 µl of PBS and heated at 
50, 60, 70 or 80° C for 10 minutes on a heat plate. The final concentration of spores for 
heating was ~107 spores/ ml. Subsequently the contents were transferred into a 4 ml 
BHI broth to produce a final volume of 5 ml (0.1 % taurocholate, 0.4 % glycine). At 24 
and 48 hours, 20 µl of broth was removed and serially diluted in PBS to 10-7 in technical 
triplicate. One hundred microlitres of broth was aliquoted into 100 µl of 100 % ethanol 
and after an hour serially diluted in PBS to 10-4. Twenty-microlitres of each dilution 
were aliquoted on to CCEYL agar. 
3.6.6 Statistical Analysis 
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Statistical analysis was carried out by IBM SPSS version 22. Data normality was 
assessed visually by histograms and statistically with Kolmogorov-Smirnov tests. 
Homogeneity of variance between groups was assessed using Levene’s test. If the 
assumption of homogeneity was violated, Welch’s ANOVA was utilised. x̄ represents 
the mean of two or more specified ribotypes. All means are reported with the standard 
error of the mean (SEM). P values <0.05 were considered significant, <0.01 highly 
significant and <0.001 very highly significant. 
For PBS heat treatment experiments, curves were added to the data using the GInaFiT 
software (335). Due to the non-log-linear nature of spore inactivation observed, 
calculation of D and Z-values was not performed.  
3.7 Results 
3.7.1 Heat Treatment in PBS for 60 minutes 
3.7.1.1 Spores produced on solid agar 
Heat treatment at 80° C was inhibitory to recovery in all five of the strains used (Fig 
3.7.1). Spore recovery dropped significantly after 15 minutes for all of the strains 
(P<0.001) and continued to decrease substantially for the next 15 minutes in all but the 
001 and 078 strain. The minimum level of spore recovery was reached after 15 minutes 
in 001, no further substantial decrease was observed. In the 078 strain, spore recovery 
dropped only marginally after a further 15 minutes of heating (4.88 ± 0.06 log10CFU/ml 
vs 4.70 ± 0.07 log10CFU/ml; P<0.001). After the 30-minute time point spore viability 
recovery stabilised in all strains except the 078. In the 078-strain spore recovery 
increased at 45 minutes vs the 30-minute time point (4.40 ± 0.07 log10CFU/ml vs 5.17 ± 
0.04 log10CFU/ml; P<0.001). Two of the strains (015 & 020) exhibited a greater overall 
decrease in spore recovery (x̄ = 7.46 ± 0.03 log10CFU/ml vs 4.18 ± 0.04 log10CFU/ml; 
P<0.001) over the 60-minute time period. The other three strains (001, 027 & 078) 
exhibited a smaller decrease in spore recovery (x̄= 7.58 ± 0.05 log10CFU/ml vs 5.09 ± 
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0.04 log10CFU/ml; P< 0.001). All of the strains exhibited log-linear with tailing 
inactivation kinetics when heated at 80° C (336). 
At 70° C, four of the strains (RTs 001, 015, 020 & 027) showed a ~2 log10CFU/ml 
decrease in spore recovery after 60 minutes of heating (x̄ = 7.47 ± 0.04 log10CFU/ml vs 
5.32 ± 0.06 log10CFU/ml; P< 0.001). RT 078 showed a very highly statistically 
significant decrease after 60 minutes, but of a smaller magnitude than the other four 
strains (7.59 ± 0.04 log10CFU/ml vs 7.31 ± 0.01 log10CFU/ml; P< 0.001) (data not 
shown). Decreases in spore recovery were strain-dependent in regard to time; after 15 
minutes of heat treatment four strains showed no substantial decrease in spore 
recovery (RTs 001, 020, 027 & 078). In contrast, spore recovery decreased 
significantly in RT 015 after only 15 minutes of heating at 70° C (7.55 ± 0.03 
log10CFU/ml vs 5.65 ± 0.03 log10CFU/ml; P< 0.001). In contrast, RT 027 took 45 
minutes for a significant decrease in spore recovery to occur (7.69 ± 0.03 log10CFU/ml 
vs 6.59 ± 0.03 log10CFU/ml).In contrast to 80° C, spore heat inactivation at 70° C 
corresponded to a number of different models dependent on strain (Table 3.7.1); 
sigmoidal (336), biphasic (337) and linear with shoulder (336).   
At 50 and 60° C, all of the strains except the 078 showed no significant decreases in 
spore recovery across the 60-minute time period (x̄ = 7.49 ± 0.03 log10CFU/ml vs 7.48 
± 0.03 log10CFU/ml; P = 0.96). RT 078 showed a similar decrease to that observed at 
70° C when heated for 60 minutes at 60° C, with spore recovery decreasing 
significantly (7.57 ± 0.03 log10CFU/ml vs 7.30 ± 0.06 log10CFU/ml ;P<0.01). When 
heated for the same time period at 50° C, an even greater decrease in recovery was 
observed (7.59 ± 0.07 log10CFU/ml vs 6.13 ± 0.05 log10CFU/ml; P<0.001).  
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Figure 3.7.1. Spore recovery of five C. difficile strains of differing ribotypes 
(001, 015, 020, 027 & 078) of C. difficile heated for 60 minutes at 70 or 80° C. 
Spores were enumerated at 0, 15, 30, 45 & 60 minutes. Experiments were 
carried out in biological duplicate and processed in technical triplicate. 
Spore recovery was compared between time points using RM-ANOVA with 
Tukey’s multiple comparisons. Statistically significant results (P< 0.05) are 
highlighted by *, highly significant (P < 0.01) by ** and very highly significant 
(P< 0.001) by ***. Curves of best fit were fitted using the GInaFiT Excel add-in. 
The models fitted included linear with shoulder, sigmoidal and biphasic 
(Table 3.7.1). The lower limit of detection for this experiment was 1.52 
log10CFU/ml. 
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Table 3.7.1. The model used to fit the data shown in Figure 3.7.1 (spore heat 
broth experiments in PBS) with the corresponding r2 correlation coefficient 
value (2 decimal places). Data for the 078 strain at 70° C was not modelled 
using GInaFiT software due to the small difference in recovery over 60 
minutes observed (7.59 ± 0.04 log10CFU/ml vs 7.31 ± 0.01 log10CFU/ml). 
Model derivations are referenced in brackets. 
     
 
 
 
 
 
 
 Temperature/ ° C 
70 80 
Ribotype Model r2 Model r2 
001 Sigmoidal 
(336) 
0.98 Linear with 
tailing (336) 
0.99 
015 Biphasic (337) 0.97 Linear with 
tailing 
0.98 
020 Sigmoidal 0.98 Linear with 
tailing 
0.99 
027 Linear with 
shoulder 
0.98 Linear with 
tailing 
0.96 
078 N/A N/A Linear with 
tailing 
0.94 
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3.7.1.2 Spores produced in liquid media 
 
Significant decreases in spore recovery were observed in all spores tested after 60 
minutes of 80° C heat treatment (Fig 3.7.2). Biofilm spores exhibited greater viability at 
the 60-minute time point versus planktonic produced spores (x̄ = 5.62 ± 0.07 vs 4.49 ± 
0.05log10CFU/ml; P< 0.001). The greatest decrease in spore viability in both biofilm and 
planktonic spores was present after 15 minutes (x̄ = 7.47 ± 0.02 vs 5.79 ± 
0.07log10CFU/ml & 7.42 ± 0.08 vs 4.96 ± 0.10log10CFU/ml; P< 0.001). A gradual 
decline in spore recovery was observed in planktonic spores of RT 020 and RT 027 
between 15 and 60 minutes (4.69 ± 0.02 vs 4.47 ± 0.03log10CFU/ml & 4.45 ± 0.04 vs 4. 
13 ± 0.02log10CFU/ml). In contrast, biofilm spores of three strains (020, 027 & 078) 
showed no significant difference in spore recovery at 15 vs 60 minutes (x̄ = 5.72 ± 0.09 
vs 5.68 ± 0.08log10CFU/ml; P = 0.73).  The most heat resistant spores of any type were 
RT 078 biofilm spores (6.18 ± 0.03 vs x̄ = 4.90 ± 0.08log10CFU/ml; P< 0.001). 
Planktonic RT 078 spores were also more heat resistant than planktonic spores of 
other strains (4.84 ± 0.06 vs x̄ = 4.38 ± 0.20log10CFU/ml; P<0.001). No difference in 
recovery was observed at any time point in spores at temperatures lower than 80° C 
(50, 60, 70° C) (data not shown). 
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3.7.2 Transmission Electron Microscopy 
 
Endospores were observed in both biofilm and planktonic culture produced samples 
(Fig 3.7.3). Two morphotypes of spore with differing exosporium sizes were observed 
in both sets of spores. In addition, detached exosporium was visible in in both samples. 
A B C 
D 
Figure 3.7.3. Transmission electron microscopy (TEM) images (1000X 
magnification) of biofilm produced spores (A) and planktonic culture 
produced C. difficile RT 027 spores (B). Both sets were produced from 
the 027 strain used previously in this study. Two spore morphotypes are 
visible in both; thick-exosporium spores are designated by red arrows, 
thin-exosporium morphotype spores by blue arrows. Detached 
exosporium was visible in micrographs of both samples (white arrows). 
Higher magnification (10000X) example images of thick (C) and thin-
exosporium (D) spores are presented. 
 B
 
C 
D 
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3.7.3 Heat Treatment Prior to Broth Inoculation 
After aerobic heat treatment, spores were aliquoted into BHI containing taurocholate to 
induce germination. The sensitivity of vegetative cells to ethanol allowed the 
differentiation between non-germinating spores and germinating/vegetative cells. The 
difference between total viable counts and spores indicates the number of spores that 
have germinated.  Spore recovery was inhibited to differing extents after heating for 10 
minutes at 70 and 80° C (Fig 3.7.4). In contrast, comparable TVC and spore counts to 
the control were observed at the 90-minute time point after spores were heated at 50 
and 60 ° C ((TVC; x̄ = 6.63 ± 0.08 log10CFU/ml vs 6.63 ± 0.06 log10CFU/ml vs 6.68 ± 
0.06 log10CFU/ml; P>0.05). On average spore counts were ~3 log10CFU/ml lower than 
TVC in 50 and 60° C heat treated and control broths. TVC and spore counts were 
similar to heat treatment at 50 and 60° C in three strains heated at 70° C (001, 015, 
020). In contrast, when RT 027 and RT 078 were heated at 70 ° C, spore counts were 
higher compared to the other strains (5.48 ± 0.04 log10CFU/ml & 4.78 ± 0.05 
log10CFU/ml vs x̄ = 3.76 ± 0.05 log10CFU/ml).   
When spores were heated at 80° C, RT 027 and RT 078 exhibited lower TVC (x̄ =4.05 
± 0.05 log10CFU/ml vs 4.80 ± 0.12 log10CFU/ml; P< 0.001) and spore counts (3.56 ± 
0.13 log10CFU/ml vs 4.69 ± 0.14 log10CFU/ml; P<0.001) compared with the other 
strains. At 80° C TVC and spore counts were comparable (x̄ = 4.50 ± 0.10 vs 4.24 ± 
0.14 log10CFU/ml; P = 0.14), indicating spores accounted for the majority of 
enumerated entities. 
Phase contrast microscopy revealed a very highly significant increase in visualised 
phase bright spores in 80° C heat treated spores vs the control (x̄ =82.7 ± 1.1 % vs 0.8 
± 0.3 %; P< 0.001) (Fig 3.7.5). Results were comparable between control and 50 and 
60 ° C treated spores in all strains; most entities identified were phase dark 
(germinated) spores (x̄ = 81.8 ± 1.3 %, 83.2 ± 1.3 %, and 84.9 ± 1.1 %). At 70 ° C 
interstrain variation was observed; RT 027 and RT 078 showed similar levels of phase 
bright and phase dark spores (x̄ = 50.6 ± 2.1 % vs 39.9 ± 1.8 %), the other strains (001, 
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015 & 020) showed results consistent with the control (x̄ = 0.3 ± 0.2 % vs 85.4 ± 1.1 
%).
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3.7.4 Reversibility of Spore Heat Treatment 
When newly produced (<14 days old) spores were heat treated prior to broth 
inoculation, an increased vegetative population was observed at 24 hours vs the non-
heat-treated control (Fig 3.7.6). This difference was very highly significant in three of 
the strains (001, 027, 078) (x̄ =7.40 ± 0.03 log10CFU/ml vs 6.45 ± 0.04 log10CFU/ml; P< 
0.001). This observation was also significant in RT 015 and RT 020, but to a lesser 
extent (x̄ = 7.62 ± 0.03 log10CFU/ml vs 7.45 ± 0.04 log10CFU/ml; P< 0.05). 
An increased vegetative population at 24 hours was also present when old (<12 weeks 
old) spores were heated prior to broth incubation (Fig 3.7.6). A very highly significant 
increase in TVCs was observed in heat-treated broths of all strains when compared to 
non-heat-treated spores (7.81 ± 0.06 log10CFU/ml vs 6.76 ± 0.08 log10CFU/ml; P< 
0.001). 
The trend exists in both new and old spores, but differences between time points in 
individual ribotypes existed. Vegetative populations only increased marginally in RT 
015 and RT 020 in response to heat in new spores (x̄ = 7.61 ± 0.03 log10CFU/ml vs 
7.45 ± 0.05 log10CFU/ml). However, a greater increase occurred in old heat-treated 
spores (x̄ =7.60 ± 0.03 log10CFU/ml vs 6.33 ± 0.04 log10CFU/ml). The old non-heat-
treated spores of RT 015 and RT 020 produced a smaller vegetative population in 
contrast to new spores. Spores of the other three strains (RTs 001, 027 & 078) 
exhibited similar behaviour independent of age.
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Figure 3.7.6. Mean (± SE) TVC and spore counts of five C. difficile strains of 
differing ribotypes (001, 015, 020, 027 & 078) 24 hours post-broth 
inoculation. Both new spores (< 14 days old) and old spores (> 12 weeks 
old) were utilised. Heat treated spores (HT) were heated for 10 minutes at 
80° C, non-heat treated (NHT) received no treatment. A trend towards 
increased TVCs in heat treated samples was present. Broths were carried 
out in biological duplicate and technical triplicate. TVC means were 
compared using two-tailed paired T tests. Highly significant (P < 0.01) 
findings are highlighted by ** and very highly significant (P< 0.001) by ***. 
The lower limit of detection for this experiment was 1.52 log10CFU/ml. 
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3.8 Discussion 
3.8.1 Heat Treatment in PBS  
C. difficile spore heat inactivation is not adequately modelled by log-linear 
kinetics 
When spores were heated in PBS for 60 minutes, substantial variation was observed 
(Fig 3.7.1). The differences observed were mainly strain-dependent; the observed 
trends were consistent between different temperatures. Fifty and 60° C heat treatment 
had no significant effect on four of the utilised strains (001, 015, 020 & 027). However, 
at higher temperatures heat began to have a substantial effect on spore recovery. 
Three of the strains (RTs 015, 020, and 027) took 0, 15 and 30 minutes respectively for 
spore recovery to decrease at 70° C. If the time delay was due to a ‘lag phase’ such as 
the Eppendorfs getting up to temperature, the same delay would be expected in all 
strains. The heat took an additional 30 minutes to influence RT 027 compared to RT 
015 strain at 70° C.  
Traditionally, thermal inactivation of microorganisms has been illustrated using log-
linear kinetic models, based on the assumption of a homogeneous population, sharing 
the same intrinsic heat resistance (338). Implicit in this model is the recognition of a 
single-system that is responsible for heat resistance. This approach is particularly 
prevalent in food microbiology and food safety, where it is possible to easily calculate 
D-values and Z-values. The D-value is defined as the time taken for a 90% (or 1log) 
reduction in numbers from the starting population, the Z-value is the temperature 
increase required to decrease the D-value by a magnitude of ten. In fact, this method is 
still being used to evaluate thermal resistance in C. difficile spores (253, 316). 
Deviations from this model have been recognised even since the 1970s, although this 
recognition has not translated into studies concerning C. difficile. In this study, 70° C 
and 80° C heat curves were not adequately modelled using log-linear kinetics. In order 
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to accurately assess and model the thermal inactivation of C. difficile spores, a number 
of different survival curves were used to describe the data (335). 
GInaFit is a software that incorporates 9 different survival curves; linear, linear with 
tailing, sigmoidal, linear with shoulder, biphasic, concave, biphasic with shoulder and 
convex curves (335).The mathematic models derived by Geeraerd et al. are beyond 
the scope of the current study, but are based on empirical datasets. In this study, the 
largest interstrain difference in recovery occurred at 70° C. The survival curve at 70° C 
for two of the strains (001 & 020) was best illustrated by the fitting of a sigmoidal curve, 
for RT 027 a linear with shoulder curve, and for RT 078 a linear model (Fig 3.7.1 & 
Table 3.7.1). Previously, differing heat inactivation kinetics and thermal resistance 
values have been discovered when comparing 39 different strains of B. cereus (339). 
Differing heat resistances have also been documented when comparing two strains of 
C. botulinum (340).   
It has been hypothesised that during the ‘shoulder’ phase in these curves, a protective 
surrounding ensures the survival of the spores by buffering the deleterious effects of 
heat (335). Once this protective matrix is destroyed/inactivated by sufficient heating, 
log-linear heat inactivation of spores resumes. The spores used in this experiment 
were not purified; it is plausible that proteinaceous cellular debris (in the form of dead 
vegetative cells) acted as a protective matrix. However, it is still unclear why some of 
the strains have a prolonged period of buffering, for example the 027 strain. Other 
reasons for the presence of a shoulder in thermal inactivation curves have been 
proposed; clumping, the inability of bacteria to continually synthesise protective 
proteins over time and the cumulative damaging effect of heating over a sustained 
period (336, 341). C. difficile spores are metabolically dormant; the synthesis of heat 
shock proteins is irrelevant. Cetyl trimethylammonium bromide (CTAB) and sonication 
have previously been used in this study to try and prevent spore clumping, with minimal 
success (data not shown). The diverse aggregative properties of spores of different C. 
difficile strains could be responsible for the differing resistances earlier in heating.  
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In addition, ‘tailing’ was observed in some strains at 70° C (Fig 3.7.1). Tailing has been 
discussed since the 1970s (337), and its presence is not surprising in C. difficile spores 
given it has been demonstrated to occur in spores of other species (342, 343). 
Intrastrain variability is a possible mechanism by which tailing occurs; a subpopulation 
of spores are maintained due to their higher intrinsic heat resistance. Spore clumping 
was found to increase in Bacillus licheniformis spores after 20 minutes of heat 
treatment, suggesting spore clumping could be involved in the tailing discussed. In 
addition, spore surfaces became more hydrophobic after heat treatment (343). It 
should be noted that the subpopulation of spores persisting in the ‘tail’ of the curve 
account for less than 0.1 % of the starting inoculum.  
At 80° C the thermal death curve for all strains was more typical and spore recovery 
began to decrease as soon as heat treatment began. The greater thermal resistances 
of RT 027 and RT 078 at 80° C found in our study are concordant with the findings of 
recent work (121, 334). After initial screening, Rodriguez-Palacios et al (121) used a 
multinomial logistic regression model to suggest the increased thermal resistance of a 
RT 078 compared to two other strains when spores were heated in meat. Although 
interesting, a larger sample size of ribotypes will be required to test this association.   
Interstrain variability in C. difficile is something that has been observed previously in 
the literature as early as 1985 (313). However, the reason for these differences is 
largely unknown. Dipicolinic acid (DPA) is responsible for maintaining a dehydrated 
core and is important in wet-heat resistance in B. subtilis (344). SpoVA is an ion 
transporter responsible for the transport of DPA into the core in Clostridium 
perfringens; spoVA mutants have a loss of wet-heat resistance as well as impaired 
germination (345). Foodborne B. subtilis strains harbouring the spoVA2mob operon were 
found to have increased heat activation requirements compared to non-foodborne 
strains (346); high heat resistance is attributed to this operon (347). More recently, the 
importance of DPA has been highlighted in C. difficile spoVAC and dpaAB mutants. 
DpaAB is the gene from which an enzyme responsible for DPA synthesis is 
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synthesised. Both sets of mutants showed statistically significant decreases in wet-heat 
resistance at temperatures above 50° C versus the wild-type (348). It is likely that 
natural heterogeneity exists in different C. difficile strains of the levels of proteins 
responsible for DPA synthesis and transport. On the contrary, Rose et al showed that 
in B. subtilis wet-heat resistance is probably dependent on factors other than just spore 
DPA content (349). This is likely true for C. difficile.  
The cortex has also been suggested to play a role in heat resistance. The cortex 
serves in an osmoregulatory capacity, expanding to accommodate superfluous water, 
reducing spore water content (350). Rao et al discovered that decoated B. cereus, B 
megaterium and B. subtilis spores had comparable heat resistances to wild-type 
spores, suggesting reduced heat resistance was not due to the loss of the cortex, but 
rather the loss of vital germination proteins (351). These studies have not been 
replicated in C. difficile, but one study found that conditions of high osmolarity permitted 
cortex degradation, but not DPA release in germinating C. difficile spores (352). 
RT 078 exhibits different behaviour to all the other strains at 50° C. A number of 
potential mechanisms have been proposed to explain differences in spore heat 
resistance, including core DPA content, enzymes responsible for DPA transport, and 
enzymatic degradation at high temperatures (344, 348). None of these factors seem to 
address this RT 078-specific phenomenon. Previously, RT 078  has been found to be 
phylogenetically dissimilar and highly divergent from other C. difficile strains based on 
lineage (30). Based on the data it is plausible that in addition to the previously 
discussed mechanisms, RT 078 possesses another mechanism of heat resistance that 
50° C heat treatment inhibits.   
The differences between our work and that of others in evaluating thermal resistance 
can be attributed to a number of causes. Notably, the method of C. difficile spore 
production differs considerably (253, 276, 313, 316, 348), with a variety of solid and 
liquid media being utilised to produce the C. difficile spores. Spores produced in liquid 
media in both Alicyclobacillus acidoterrestris (353) and Bacillus subtilis (349) have 
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been found to have a lower thermal resistance than their counterparts produced on 
solid agar.  
Biofilm produced C. difficile spores are more heat-resistant 
After 60 minutes, the viability of biofilm produced spores was ~1 log10CFU/ml higher 
than spores produced in planktonic culture (Fig 3.7.2). In addition, all of the spores 
produced in liquid media were more heat resistant than those produced on solid agar, 
which does not conform to the findings of the aforementioned studies (349, 353). 
Transmission electron microscopy showed the presence of thin and thick-exosporium 
spores in both samples (Fig 3.7.3). These observations were made previously in the 
R20291 strain (80). Despite purification of spores by HistoDenz™, detached 
exosporium was present in both samples. It is possible that an increased presence of 
exosporium/extracellular matrix in the biofilm produced spores could result in a more 
heat-resistant population. One study also found that C. difficile spores produced in 
biofilms spores began to accumulate a surrounding ‘shroud’ that attached to the spore 
after 7-14 days of incubation (354). This ‘layer’ was found to consist of dead cellular 
debris, and it is hypothesised C. difficile spores accumulate this layer after mother cell 
lysis (354). In addition, spores were found to be less responsive to germinants and 
exhibited decreased germination. If the increased heat resistance of biofilm produced 
spores is due to an extracellular matrix/ shroud or an intrinsic spore property, biofilm 
spores in non-laboratory conditions are likely to retain this resistance. Biofilm produced 
spores are still likely to exhibit increased heat resistance in non-laboratory scenarios. 
On the other hand, in the first 15 minutes of 80° C heat treatment biofilm spores 
exhibited log-linear inactivation kinetics. Previously, it has been suggested the 
‘shoulder’ seen in some heat inactivation models is due to an extracellular matrix 
buffering the effects of heat (341).  
Unfortunately, the processing of other strains used in this study was not practicable 
due to insufficient resources. In addition, no quantitative measure of exosporium size or 
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spore morphotype number was possible. Further work providing quantitative 
measurements and exploring a range of ribotypes is needed to strengthen conclusions. 
Despite these limitations, this study supports the existence of two distinct C. difficile 
spore morphotypes. Building on previous work, it is suggested biofilm produced C. 
difficile spores are more environmentally robust and could exhibit increased levels of 
superdormancy in addition to increased heat resistance (354).  
3.8.2 Heat Treatment Prior to Broth Inoculation 
80° C heat treatment inhibited initial outgrowth but promoted later 
outgrowth 
Both freshly produced (<7 days old) and environmentally aged (>3 months old) were 
heat treated prior to broth inoculation (Fig 3.7.4). Initially this experiment was 
performed to assess the immediate effect of heat on spore recovery and outgrowth (90-
minute incubation times), but the longer term effects of heat on spore recovery were 
also documented (24 and 48 hour incubation times). In both new and old spores, the 
same trends were observed. When spores were heat treated and left for 90 minutes, 
spore outgrowth was inhibited compared to heat treatment at lower temperatures and 
the control. Both TVCs and spore counts decreased, indicating a global decrease in 
spore recovery. On the other hand, when spores were left for a longer time period, at 
24 hours the heat-treated samples contained higher levels of vegetative cells and 
comparable levels of spores to non-heat treated samples (Fig 3.7.6).  
Initially these results appear inconsistent, if heat is inhibiting spore germination at an 
early stage, it is unclear why a more rapidly growing vegetative population is present at 
a later point. One study also observed that heat treatment at 85° C decreased 
recovery, but this was due to an impairment of vegetative growth and not germination 
(253). This is in accordance in the current study, where spores were able to revert to 
vegetative growth. It could be hypothesised the heat treatment causes a greater 
number of spores to germinate, but there is an initial lag in outgrowth due to the heat 
treatment. Contrarily, the phase contrast data illustrates a shift from the predominance 
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of phase dark spores at 70° C to phase bright spores at 80° C, indicating an inhibition 
of the transition from phase bright to phase dark i.e. germination (Fig 3.7.5).   
Heat activation has commonly been used as a strategy to increase spore germination 
in B. subtilis (301) and more recently C. difficile in older spores. The previously cited  
study also found that aged spores (>20 weeks old) exhibited increased recovery (30 % 
increase) in response to heat treatment at 63° C vs freshly produced spores (253). In 
the current study, both newly produced and environmentally aged spores demonstrated 
increased outgrowth in response to heat treatment, albeit in producing a proliferative 
vegetative population. Heat is suggested to mediate its stimulatory effects by inducing 
germinant receptor conformational changes. An absence of inner membrane bound 
germinant receptors in C. difficile spores is proposed to explain the lack of effect of 
heat (62, 355). This hypothesis is consistent with work demonstrating heat has no 
activation effect on germinant-receptor independent germination in B. subtilis (356, 
357). Although the results of the current study suggest heat has an effect on the 
outgrowth and subsequent proliferation of new and old C. difficile spore populations, 
this effect is not necessarily mediated through spore germination directly. The results 
are therefore not contradictory to those cited above.  
3.9 Conclusion 
To summarise, 80° C heat treatment appears to have an initial inhibitory effect on 
spore recovery and outgrowth, which then reverts, with a more rapidly proliferating 
vegetative population being produced. This effect is seen independently of spore age, 
at least up to 3 months. The log-linear inactivation kinetics typically described in 
microbial heat decay experiments was not observed in this study. A range of kinetic 
inactivation models were fitted to the data dependent on strain and temperature (70/80 
° C), consistent with other work (339, 340).  
Spore heat resistance differed between spores produced on solid agar (CCEYL) and 
those produced in liquid media (supplemented BHI). Contrary to the findings of 
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previous studies (349, 353), spores produced in liquid media were more heat resistant.  
Biofilm spores appear to have a greater capacity for withstanding heat than spores 
produced in planktonic culture, but this effect needs further exploration. The findings of 
this work illustrate that heat ‘activates’ spores in a way not previously observed. 
Although spores are initially inhibited by the injurious effects of heat treatment, 
vegetative population proliferation is promoted at a later time point, independent of 
spore age.  
At recommended cooking temperatures, spores can persist in food and even 
reactivate, providing a potential C. difficile reservoir for community acquired CDI.This is 
particularly important in the case of biofilm-produced spores, which exhibit increased 
thermal resistance. Although the majority of spores were inactivated temporarily by 80° 
C heat treatment, a subpopulation persisted.  Spores present in food prior to cooking 
may survive the cooking process and potentially cause initial or recurrent CDI. 
Combined with the findings of chapter 3A, superdormant spores may be able to survive 
minimum recommended cooking temperatures and exhibit increased germination 
efficiency when ingested into the bile-rich gastrointestinal tract. Conversely, it seems 
unlikely that spores could be present in food after cooking unless they persisted the 
cooking process. 
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Chapter 4 A – Proteomics in an in vitro Clostridium difficile gut 
model 
4.1 Background & Rationale 
Research fields such as proteomics, metabolomics and transcriptomics are becoming 
increasingly important in the investigation of the human microbiome. Comprehensive 
sequencing studies investigating the composition of the human microbiome have been 
very successful, mapping a total of 3.3 million bacterial genes (358). Metagenomic 
studies have identified the potential major biosynthetic functions of the gut, with genes 
responsible for methane production, carbohydrate metabolism and vitamin biosynthesis 
recognised (359). These studies are useful in identifying constituent differences 
between microbiomes, but do not quantify the expression of genes within the 
ecosystem and overall functionality. The human microbiota provides important 
functions in the host including nutrient processing (360), priming of the immune system 
(361), and defence against pathogens (362). Consequently, potential relationships 
between microbial metabolism and human disease are increasingly being recognised.  
Metabolomics and proteomics are increasingly being investigated and represent an 
important step in characterising the human gastrointestinal tract in health and disease. 
One well documented use of metabolomics is the analysis of short chain fatty acids 
(SCFAs) such as propionate and butyrate. SCFAs are produced by the fermentation of 
fibre in the human gastrointestinal tract by several bacterial species (363). Defects in 
this process have been associated with a number of diseases, for instance IBD (363), 
and SCFAs are suggested to influence diabetic control in type 2 diabetes (364). 
Currently, literature is available linking varying diseases with the metabolic products of 
the microbiota. However, reported studies are largely inferential, as causality is difficult 
to establish without time consuming and potentially unethical longitudinal studies. 
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Proteomics is used to quantify total gene translation products (365). By integrating this 
data with metagenomics and metatranscriptomics data, additional information about 
the functions carried out by the microbiota is obtained. Metaproteomics has 
advantages over metagenomics alone; the gene products obtained can be from dead, 
dormant or living cells and measurement of gene expression is lacking. The 
‘metaproteome’ refers to the complex set of proteins expressed and produced by a 
microbial ecosystem. Historically, proteomics has involved the extraction and 
separation of proteins using gel electrophoresis. This method is limited in its ability to 
discriminate and separate proteins in highly heterogenous mixtures such as those 
produced by the human gut microbiota. In 2009 high throughput sequencing (liquid 
chromatography followed by tandem mass spectrometry) was used for the first time on 
two faecal samples from monozygotic twins in investigating the metaproteome (366), 
which was found to consist of proteins predominantly obtained from Bacteroidetes and 
Firmicutes organisms. Analogous approaches are now routinely used in defining 
complex ecosystems. As expected, the spectra obtained mapped predominantly to 
Bacteroides and Firmicutes organism proteins. 
Proteomics-based approaches have been used for a number of purposes in 
investigating C. difficile. One study used SDS-PAGE and mass spectrometry  to 
separate and  identify 42 C. difficile cell wall proteins that were immunoreactive, giving 
a deeper understanding of the pathogenesis and subsequent immune response to CDI   
(367). The changes exhibited in the proteome of Caco-2 cells in response to toxin A 
have also been investigated. Using LC-MS/MS and SILAC, incubation of cells with 
toxin A for 24 hours caused a significant difference in the expression of cytoskeletal 
proteins, underlining the rearrangement of cell microarchitecture and the loss of tight 
cell-cell junctions (368). LC-MS/MS has also proved useful in quantifying the changes 
in protein expression in strain CD630 heated at 41° C vs 37° C (369). However, it 
should be noted that the above work used single strains, which means there is a 
reasonable possibility that inter-strain differences have been missed.  
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 The hypervirulence of some strains has also been investigated in the context of 
proteomics, protein expression quantified in response to osmotic shock and nutrient 
shift revealed increased response coordination of gene networks in two hypervirulent 
strains vs two historically prevalent, non-hypervirulent strains (370). This study 
elucidates a potential mechanism for the hypervirulence of some strains, in comparison 
to the descriptive information gained in metagenomics studies. Furthermore, this study 
highlighted the heterogeneity in protein expression in isolates grown in different media, 
an observation that has been validated in other work (371), thus providing a possible 
explanation for differences seen in heat resistance, germination and outgrowth of 
spores grown on different media (327, 349, 353, 371).  The unique nature of the C. 
difficile spore coat has likewise been highlighted by the finding of 29 unique spore 
proteins (333). Proteomics is beginning to be used successfully as a tool for probing an 
explaining some of the behavioural differences observed between C. difficile strains.  
4.1.1 Proteomics approaches 
Two approaches are employed in proteomics; top-down proteomics or bottom-up 
proteomics. In top-down proteomics, complete proteins are analysed in contrast to 
bottom-up proteomics whereby proteolytic digestion is employed and the resulting 
peptide fragments are analysed.  Both approaches have advantages and weaknesses 
which will be discussed. 
Historically in top-down proteomics 2D electrophoresis has been utilised. After 
electrophoresis, bands are excised, proteolysed and subsequently analysed by mass 
spectrometry. This approach has had limited success, being able to interrogate 
hundreds of mouse brain proteins (in this case by MALDI-MS), representing a low 
percentage of the total proteome (372). Unfortunately this method favours the detection 
of highly abundant soluble proteins, and is not adequate to detect membrane bound 
proteins (373). It should also be noted some of the literature has taken issue with this 
methodology as being described as ‘top-down’ due to the proteolysis step prior to mass 
spectrometry (374). Rather than using gel electrophoresis, proteins can be ionised 
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directly in the mass spectrometer, advantageous due to the possible detection of post-
translational modifications, which is not possible in bottom-up proteomics. However, 
the use of top-down approaches has commonly been limited to simple mixtures of 
proteins, and for peptides larger than 50 kDa, fragmentation sequencing becomes 
difficult (375). Due to the large size of protein ions, the ionisation, fragmentation and 
separation stages can be difficult to achieve in top-down proteomics (376) 
Bottom-up proteomics is the most widely used approach in MS workflows in 
contemporary proteomics research. In general, proteins are cleaved into peptide 
fragments by enzymatic digestion prior to MS analysis, usually by trypsin. Gel 
electrophoresis can be used prior to MS analysis, or the total protein mixture can be 
proteolysed known as ‘shotgun proteomics’ (376). As stated previously, one of the 
difficulties in bottom-up proteomics is solubilising all proteins regardless of their 
hydrophobicity. Traditionally, SDS-PAGE has been used to separate proteins followed 
by proteolysis and mass spectrometry. In-solution digestion has also been utilised, but 
detergents are required and can interfere with later proteolytic cleavage and must be 
removed prior to analysis (377). A quick, inexpensive and efficient method of sample 
preparation that is free from the solubilisation issues of gel electrophoresis is required. 
A number of gel-free protein preparation methods have been described in the literature, 
including filter-aided sample preparation (FASP), in-StageTip method (iST), single-pot 
solid-phase-enhanced sample preparation (ST3) and the suspension trapping method 
(STrap). One study found all of these methods to be comparable in terms of 
performance when starting with 20 μg of protein extract, but the precision of FASP fell 
drastically when the amount of starting material was decreased to 10 μg (378). 
FASP is a method described in 2009 by Wisniewski et al (379). In summary, samples 
are solubilised in SDS, concentrated, retained and subsequently processed in the 
molecular weight cut off filter or ‘reactor’. This method allows the removal of detergents 
and is inexpensive. Several studies have modified the FASP protocol, increasing 
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peptide retention and decreasing throughput times (380, 381). Notably, in 2014 
Zougman et al developed the ‘STrap method’, capable of quicker processing times and 
avoids the temperamental nature of the membrane filters used in the FASP method 
(377). In this method, the acidified-protein mixture is added to a methanolic solution in 
an S-tip. A fine particulate protein suspension is created, which is amenable to 
trypsinisation. The suspension is trapped in the quartz filtration material of the tip. The 
contaminating solution is removed; the protein is trypsinised and subsequently eluted 
and concentrated in the C18 filter ready for MS. The iST method also uses an S-tip as 
its basis, but does not require solvents or SDS; strong cation exchange resins are used 
for peptide separation (382) . 
In addition to top-down and bottom-up proteomics, some research has tried to use a 
hybrid approach of ‘middle-down’ proteomics. In these workflows proteases such as 
Asp-N and Glu-C are utilised to produce medium sized peptide fragments. The 
advantage of this approach is the increased proteome coverage in medium sized 
proteins (3.0 kDa < MW < 10 kDa)(383). An overview of the three approaches can be 
viewed below (Fig 4.1.1).
135 
 
 
 
 
 
F
ig
u
re
 4
.1
.1
. 
A
n
 o
v
e
rv
ie
w
 o
f 
th
e
 d
if
fe
re
n
t 
p
ro
te
o
m
ic
 a
p
p
ro
a
c
h
e
s
. 
B
o
tt
o
m
-u
p
 a
n
d
 m
id
d
le
-d
o
w
n
 a
p
p
ro
a
c
h
e
s
 u
ti
li
s
e
 p
ro
te
o
ly
s
is
 p
ri
o
r 
to
 
fr
a
g
m
e
n
t 
s
e
p
a
ra
ti
o
n
 a
n
d
 M
S
 a
n
a
ly
s
is
. 
T
o
p
-d
o
w
n
 a
p
p
ro
a
c
h
e
s
 d
o
 n
o
t 
u
s
e
 p
ro
te
o
ly
s
is
 p
ri
o
r 
to
 M
S
 a
n
a
ly
s
is
. 
A
t 
th
e
 s
e
p
a
ra
ti
o
n
 a
n
d
 M
S
 
s
ta
g
e
s
 d
if
fe
re
n
t 
in
s
tr
u
m
e
n
ts
 c
a
n
 b
e
 u
s
e
d
, 
b
u
t 
th
e
 p
ri
n
c
ip
le
s
 r
e
m
a
in
 t
h
e
 s
a
m
e
. 
136 
 
 
 
Mass spectrometry-based methods are now used routinely in the identification of 
complex protein mixtures. There are a wide variety of methodologies utilised, 
depending on the sample being investigated. Any mass spectrometer consists of three 
vital components, an ion source (ionises the analytes), a mass analyser (measures the 
mass: charge ratio of incoming ions) and a detector (identifies the number of ions of a 
particular m/z ratio)(384). 
There are two main approaches to ionisation; electrospray ionisation (ESI)(385) and 
matrix assisted laser desorption/ionisation (MALDI)(386). ESI is routinely coupled to 
liquid chromatography separation techniques such as HPLC and is only possible in the 
case of a liquid matrix. ESI is the preferred method for the analysis of complex 
mixtures; it is most often coupled with other mass spectrometry tools in the case of 
large-scale bacterial proteomics studies. On the other hand, MALDI uses laser pulses 
to produce ions from a crystalline matrix and is preferred for simple protein mixtures. 
MALDI is routinely coupled to time-of-flight (TOF) analysers for the identification of 
microorganisms in microbiology (387). The ionisation source must be coupled to an 
analyser of which several types. In its simplest form, an ion trap is anything that uses 
magnetic or electric fields to trap charged particles. Historically, three different ion traps 
have been described into which all instruments fall; Paul trap, Penning trap and the 
Kingdon trap. 
 A number of different configurations exist including linear ion traps, quadrupole and 
Fourier transform ion cyclotrons (FT-MS)(384). In most contemporary instruments 
these analysers can be combined to overcome individual limitations. The orbitrap is an 
example of a FT-MS instrument and is a Kingdon trap. Orbitraps  are a relatively newly 
developed tool and have the advantage of being able to discern ions of close m/z ratios 
(388). It consists of an outer and inner electrode; ions are injected into the trap from a 
C-trap. The ions move around the inner electrode both axially and horizontally; part of 
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the outer electrode can detect the movement of the ions and use the Fourier 
transformation to convert this to a mass spectrum.  
4.1.2 Peptide/Protein Identification 
Undoubtedly the most important step in metaproteomics is database selection. In 
general, there are three options; public reference, matched or ‘pseudo’-metagenomic 
databases (389). A matched database utilises synchronised metagenomics, identifying 
the species present within a sample and thereby eliminating superfluous sequences 
from the metaproteomic analysis. In contrast, reference databases may contain 
sequences not present in the sample. Unfortunately, there is no way to discern which 
species are present within a sample. As metagenomics is expensive 16s-rRNA 
sequencing can be utilised alongside metaproteomics to produce a ‘pseudo’-
metagenome that contains only reference database sequences of relevant species 
(365, 366, 390). 
 A variety of public reference databases exist. Some of the most commonly used 
databases include UniProt, ENSEMBL (392), NCBI RefSeq (393) and UniRef(394) 
(395).UniProt has two sections; UniProtKB/SwissProt and UniProtKB/trEMBL (391). 
UniProtKB/SwissProt is manually curated and of a high quality, sequences are non-
redundant. In contrast, UniProtKB/trEMBL is automatically annotated, containing 
possible redundant sequences and potentially hypothetical proteins. The UniRef 
database is different from the above in that it clusters all fragments with more than 11 
residues into one entry. In practice, this means that peptides that match to more than 
one organism will be combined in the same entry (396). UniRef is a useful database for 
family classification and inference of functional groups. However, clustering related 
sequences is not necessarily desirable when conducting large scale gut microbiota 
studies.  
In addition to the selection of a database, a search algorithm is needed to implement 
the matching of spectrum with theoretical peptides. For tandem MS data, database 
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sequences are in silico digested during analysis; the resulting theoretical spectra are 
compared to the experimentally derived spectra. A number of different search 
algorithms are available  for matching spectra to peptides, the most common being 
Mascot and SEQUEST (397). Another prominent example is X! Tandem (398).  More 
recently, the Andromeda search engine has gained popularity, probably due to being 
open source and user friendly for non-specialists (399). Andromeda is a search engine 
implemented in the MaxQuant software suite. Like Mascot, Andromeda uses a 
probability-based approach to match theoretical sequences to mass spectra (400).   
After peptide identification, the next step is protein inference. Protein inference 
presents another challenge due to the existence of ‘degenerate’ peptides. Degenerate 
peptides are shared between proteins in differing species (401, 402). Many of these 
identifications can be erroneous, particularly if a non-specific public database is being 
used. Many proteomics packages will report proteins in groups according to shared 
peptides, with journals requiring that only the first protein identification (with the most 
peptide matches) be reported in publications in line with the rule of parsimony (403).  
4.1.3 C. difficile in vitro gut model 
The in vitro gut model presents a unique opportunity to simulate CDI and subsequent 
recurrence. It has been utilised extensively (91, 92, 153, 404). In general terms, the in 
vitro gut model has been used to evaluate the efficacy of antibiotic agents in the 
initiation or treatment of CDI, assessing the effects on both C. difficile and the normal 
flora. Traditionally, a series of selective solid agars have been utilised to monitor 
bacterial populations over time. Microbial culture offers an easy and relatively 
inexpensive method of elucidation of a wide range of bacterial populations over a 
prolonged period. However, in recent years molecular techniques have superseded 
traditional culture-based methods in extending our knowledge of the diverse microbial 
community along the gastrointestinal tract. Although sequencing based approaches are 
powerful, metagenomics has been found to overlook minor populations thus 
systematically decreasing the observed population diversity (405). In order to maximise 
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knowledge about phylogenetic and functional aspects of a microbial community, both 
culture and sequence-based technologies should be combined to mitigate the 
weaknesses of one another (406). This approach has been highlighted previously, 
where ~90 ‘unculturable’ species were isolated with a culture based approach (407).  
A novel approach to the in vitro gut model would be the combination of traditional 
culture-based approaches with metaproteomics. Combining the two might give useful 
insight into microbiological factors that predispose to rCDI. Metaproteomics can be 
seen as a bridge between culture based and metagenomic approaches to the gut 
microbiota. In the context of rCDI and the in vitro gut model, culture based and 
metagenomics approaches can be combined for a greater appreciation of microbiota 
dynamic throughout disease. However, metaproteomics has the added ability of 
potentially identifying the overarching metabolic niche created during infection by 
antibiotics. Metabolic processes performed by particular groups of bacteria could 
create an environment suitable for C. difficile proliferation. Although host factors are 
absent in the in vitro gut model, studies have shown that some species of bacteria may 
modulate host immune function. Of particular interest Bifidobacterium longum DJ010A 
and Bacteroides fragilis YCH46 were found to produce peptides (FR-17 & LR-17) that 
modulate IL-22 induction, a cytokine important in promoting the integrity of the gut 
epithelium and protecting against pathogens such as C. difficile (408).  A database 
containing over 300 milllion peptide entries (Mechanism of Action of the Human 
Microbiome (MAHMI)) now exists to try and identify the immunoregulatory functions of 
proteins secreted by the gut microbiota (409). 
Adopting a proteomics approach within the in vitro gut model presents a number of 
technical challenges. The proteinaceous nature of the media feeding the model means 
samples cannot be taken directly for LC-MS/MS analysis; media peptides are 
contaminants. In addition, the bacterially produced proteins could be at such low 
concentrations that instruments used for LC-MS/MS are not sufficiently sensitive for 
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peptide identification.  As well as the experimental difficulties encountered, microbial 
metaproteomics is still a field in its infancy. A variety of approaches exist for accurately 
aligning peptide sequences for protein identification. A diverse range of databases are 
utilised and this has been found to have a substantial influence on the results of 
metaproteomic studies (390). 
Chapter 4A investigated a methodology for isolating secreted bacterial proteins from in 
vitro gut model populations. The baseline protein levels in Vessels 1, 2 and 3 were 
determined by acetone precipitation and Bradford assay. Vessels 1, 2 and 3 of the gut 
model simulated the changing conditions encountered down the gastrointestinal tract. 
Subsequently a minimal media method was devised to isolate and concentrate 
bacterial proteins. Bacterial viability using this method was validated. Chapter 4B 
utilised this novel methodology to isolate bacterial proteins from different stages of 
simulated C. difficile infection in three recurrence gut models. Bacterial proteins were 
analysed by mass spectrometry using a bottom-up proteomics approach. The 
taxonomic and functional alterations in the metaproteome at each stage of infection 
were presented.  
4.2 In Vitro Gut Models  
4.2.1 Methods 
The in vitro gut model used in these experiments is a triple-stage chemostat model (Fig 
4.2.1). The maintenance and setting up of the in vitro gut model has been extensively 
described previously (235). It consists of  three glass Vessels (Soham Scientific, Ely, 
UK) connected in a Weir cascade based on that of MacFarlane et al (410) . The 
volumes of Vessels 1, 2 and 3 are 280 ml, 300 ml and 300 ml respectively. A circulated 
heated water bath (Grant Instruments, Cambridgeshire, UK) connected to a jacketed 
system allowed Vessels to be kept at 37° C. The system was kept anaerobic by a 
continuous source of oxygen free nitrogen in all Vessels. The Vessels were kept at pH 
levels reflective of the increasing alkalinity of the gastrointestinal tract; 5.5 (± 0.2), 6.2 
141 
 
 
(± 0.2), 6.8 (± 0.2) and pH was monitored by probes (P200 chemotrode, Hamilton, 
USA) and maintained by the addition of sodium hydroxide/ hydrochloric acid, 
administered by a controller unit (Biosolo, Brighton Systems, UK). A peristaltic pump 
was used to top feed a complex growth medium through the Weir cascade; a flow rate 
of 13.2 ml/h was achieved.  
Populations of various microorganisms were monitored daily by the use of a range of 
selective media (Table 4.2.1).  
4.2.1.1 Gut Model Preparation 
Pooled faecal emulsion (150 ml) was added to each of the gut model Vessels. Growth 
media was added to fill Vessel 1 to ~280 ml, after which pumping of media through the 
Weir cascade was initiated. Faeces were obtained from three healthy donors. 
Antimicrobial therapy in the previous 2 months was an exclusion criterion for donation. 
Samples were transported in an anaerobic zip lock bag (Benton Dickinson, Sparks, 
MD, USA) within 12 hours for storage in an anaerobic cabinet.  Donor faeces were 
screened for C. difficile prior to use by anaerobic incubation for 48 hours in duplicate on 
CCEYL. Samples positive for C. difficile were not utilised in models. Emulsions were 
prepared by the suspension of 10 % w/v faeces in pre-reduced PBS. A smooth slurry 
was created by emulsification of the suspension in a stomacher (Stomacher Lab-
Blender 400, Borolabs, Aldermaston, UK). The slurry was passed through a muslin 
cloth (Bigger Trading Limited, Watford, UK). Pooled faecal emulsions were flash frozen 
in liquid nitrogen and stored at -80° C as previously described (175). The use of the 
same donor faeces increased homogeneity between the three models used in the 
study.  
4.2.1.2 Gut Model Media Preparation 
Gut model media was prepared in 2 L Büchner flasks. The complex media (for 
ingredients see Appendix B, B.2.2) was sterilised by autoclaving (Priorclave, London, 
UK) at 123° C for 15 minutes. After sterilisation, 5 mg/L resazurin (Sigma Aldrich) and 
142 
 
 
0.4 g/L glucose were added to the media through a 0.22 µm filter syringe (Merck 
Millipore, Feltham, UK).  
 
4.2.1.3 Bacterial Population Enumeration 
A range of organisms were enumerated on selective and non-selective agars (Table 
4.2.1). A full list of ingredients and agars can be found in Appendix B, B.1. From each 
vessel of the gut model 1 ml of fluid was removed from the outlet port. Gut model fluid 
was serially diluted in pre-reduced peptone water (Oxoid, Basingstoke, UK) to 10-7. 
Four appropriate dilutions were spread on to quarter plates in technical triplicate. Both 
facultative and strict anaerobic populations were enumerated. Strict anaerobes were 
incubated in an anaerobic chamber; facultative anaerobes (aerobes) were incubated 
aerobically at 37° C. for 48 hours. C. difficile spore counts were obtained by diluting gut 
model fluid in a 1:1 ratio in 100 % ethanol. After 1-hour spores were serially diluted and 
incubated on agar as described above.  
After 48 hours of incubation, bacterial colonies were identified and counts were 
transformed to log10CFU/ml by multiplying by 50 and 10X, where X is the logarithmic 
dilution factor. In the case of uncertainty regarding bacterial colony identification, 
MALDI-TOF was utilised as a second means of identification. 
4.2.1.4 Cytotoxicity assay 
Vero cells were prepared as previously described by Crowther (235). Twenty-mililitres 
of Dulbecoo’s Modified Eagles Medium (DMEM) (Sigma) supplemented with newborn 
calf serum (50 ml) (Gibco, Paisley, UK), antibiotic/antimycotic solution (5 ml)(Sigma) 
and L-glutamine (5 ml)(Sigma) was used to culture vero cells (African Green Monkey 
Kidney Cells, ECACC 84113001) in a flat bottom tissue culture flask. Flasks were 
incubated at 37° C in 5 % CO2. 
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When Vero cells formed confluent monolayers (confirmed by microscopy; Olympus UK 
Ltd, Middlesex, UK) the monolayer was harvested by removal of DMEM and rinsing 
with 1 ml of Hanks Balanced Salt Solution (HBSS) (Sigma) containing trypsin-EDTA 
(0.25 g/ L) (Sigma). Subsequently, 6 ml of HBSS-EDTA was added to the flask and 
incubated for 10 minutes at 37° C at 5 % CO2. After the cells no longer adhered to the 
flask, further passage was achieved by diluting the HBSS-EDTA cell mixture (1:20) in 
DMEM in a 96F microtiter tray (Nunc). Vero cells were harvested (160 μl) and 
inoculated into wells to which antitoxin would later be added. To other wells trypsinised 
Vero cells (180 μl) were added. Trays were incubated for 2 days in 5 % CO2 at 37° C. 
Sample supernatant and positive controls were serially diluted 10-fold in PBS to 10-5. 
The positive control was produced from a 48 hour culture of C. difficile grown in BHI 
broth. Serial dilutions were transferred to trays containing Vero cell monolayers. 
Clostridium sordellii antitoxin (Prolab Diagnostics, Neston, UK) neutralised the cytotoxic 
effects and ensured specificity of cell rounding to C. difficile. A positive test was 
indicated by rounding of ~80 % of the Vero cells. Cytotoxin quantity (in relative units; 
RU) was assigned based on the greatest dilution a positive test was observed (i.e. 10 -5 
+ve = 5 RU, 10-1 +ve = 1 RU). 
4.2.1.5 C. difficile spore production 
Spores of Clostridium difficile strain 210 (PCR ribotype 027) were prepared as 
previously described (333). C. difficile spores were incubated in BHI broth 
anaerobically at 37° C for 6 days preceding overnight benchtop aerobic incubation. 
Growth was harvested by incubation with PBS supplemented with 10 mg/ml lysozyme 
at 37° C overnight and subsequent centrifugation. Samples were resuspended in PBS 
supplemented with 20 ng/ml protease K and 200 nM EDTA to digest cellular debris. 
Sucrose gradient centrifugation was used to separate vegetative cells/cellular debris 
from spores. Spores were washed twice before resuspension in 30 ml PBS. After 
enumeration spore concentrations were adjusted to ~107 spores/ml.
144 
 
 
Figure 4.2.1. C. difficile in vitro gut model. Vessels 1 (V1), 2 (V2) & 3 (V3) are 
highlighted. They simulate the changing conditions encountered along 
the gastrointestinal tract. Image taken by the Healthcare Associated 
Infection Research Group. 
V1 
V2 
V3 
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4.3 Quantification of Protein from the in vitro Gut Model 
Vessels 
4.3.1 Methods 
4.3.1.1 Acetone Protein Precipitation 
One-millilitre aliquots were taken from Vessel 1, 2 and 3 of the gut model. Samples 
were centrifuged at 9500 g for 10 minutes and the supernatant filter sterilised through a 
0.22 µm filter and transferred to a sterile tube. Four volumes of chilled (-20° C) 80 % 
acetone were added to the supernatant and the sample was left overnight at -20° C. 
Subsequently the samples were centrifuged at 9500 g for 10 minutes to produce a 
protein pellet. The pellet was stored at -80° C until required.  
4.3.1.2 Bradford Assay 
The Bradford assay was performed using the protocol from Bio Basic Inc. Protein 
standards of 10, 20, 40, 60, 80, 100 and 125 µg/ml were prepared using Bovine Serum 
Albumin (BSA) (Sigma Aldrich, UK). Briefly, 1 ml of Bradford Reagent (BioBasic, UK) 
(linear range 10-150 µg/ml) was added to 100 µl of protein standard, vortexed and 
incubated at room temperature for 10 minutes. One-millilitre was transferred to a 
microcuvette and read at 595 nm in a Thermoscientific Genesys 20™ 
spectrophotometer. Absorbance values were plotted against protein standards to 
produce a standard curve.  
4.3.1.3 Isolation of Secreted Proteins from Gut Model Microorganisms 
4.3.1.4 Minimal Media Resuspension Method 
On two consecutive days three 1 ml aliquots were taken from Vessel 3 of the gut 
model. Enumeration of gut flora on selective media (Table 4.3.1; full list of media 
ingredients in Appendix B, B.2.2) was carried out immediately on the first 1 ml aliquot. 
The remaining aliquots were centrifuged at 9500 g for 1 minute and the resulting 
supernatant was discarded. Bacterial pellets were washed three times and 
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resuspended by using a loop and vigorous vortexing in 1 ml of minimal media. One 
aliquot was sampled immediately after washing and the remaining aliquot was sampled 
after anaerobic incubation for 1 hour. All agar plates for bacterial enumeration were 
incubated anaerobically in triplicate for 48 hours post-inoculation. 
Table 4.3.1 The different growth media utilised in bacterial identification and 
enumeration from gut model sampling.  
Media  Media Selectivity 
Nutrient agar (NA) Facultative anaerobes/ 
aerobes 
MacConkey agar (MAC) Enterobacteriaceae 
Kanamycin aesculin azide 
agar (KAA);  
Enterococcus sp. 
Fastidious anaerobe agar 
(FAA); 5 % horse blood 
Anaerobes 
Fastidious anaerobe agar 
(FAA) 
Spore Counts 
Bacteroides bile aesculin 
agar (BBE);  
Bacteroides sp.  
LAMVAB agar  Lactobacillus sp.  
Beerens agar (BEER) Bifidobacterium sp.  
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4.3.1.5 Protein Quantification and Concentration 
Samples of 15ml were taken from Vessel 3 of the in vitro gut model. Samples were 
divided into 15 Eppendorf tubes and centrifuged for 1 minute at 9500 g. The minimal 
media resuspension method was utilised as previously described. After 2 hours 
anaerobic incubation the Eppendorfs were removed and centrifuged at 9500 g for 1 
minute. Subsequently the supernatant was filter sterilised through a 0.22 µm filter and 
stored at 4° C until required.  
Supernatants were concentrated using Amicon Ultra-15 spin concentrators (MWCO 3 
kDA). Samples were centrifuged at 11400 g for 60 minutes in a Beckman Coulter X12 
centrifuge. The filtrate was discarded and the retentate stored in a sterile Eppendorf at 
4° C. Further validation of protein concentration was carried out by Bradford Assay. 
Alfa Aesar Bradford Reagent was utilised (linear range 100-1500 µg/ml). Protein 
standards of 200, 400, 600, 800, 1000 and 1200 µg were prepared using BSA (Sigma 
Aldrich, UK). Briefly, 3 ml of Bradford Reagent was added to 100 µl of concentrated 
sample in a microcuvette and incubated at room temperature for 10 minutes. 
Microcuvettes were read at 595 nm in a Thermoscientific Genesys 20™ 
spectrophotometer. Absorbance values were plotted against protein standards to 
produce a standard curve.  
To further characterise and validate the presence of bacterially secreted proteins; SDS-
PAGE was carried out in NuPAGE™ Novex™ 4-12 % Bis-Tris Protein Gels. Sixteen-
microlitres of NuPAGE® LDS Sample Buffer was added to 4 μl of sample and 
subsequently heated at 100° C for 20 minutes. Twenty-microlitres of each sample was 
loaded into each well, with SeeBlue® Plus2 being used as a protein standard. Gels 
were run at 200V for 50 minutes, using NuPAGE® MOPS SDS Running Buffer. After 
50 minutes, the gel was removed and washed three times for 10 minutes in sterile 
deionised water. Gels were stained for 1 hour with SimplyBlue™ SafeStain, after which 
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stain was removed and one further wash in sterile deionised water was carried out to 
minimise background staining. 
4.3.2 Results 
4.3.2.1 Bradford Assay 
 A statistically significant increase in protein concentrations occurred from Vessel 1 to 
Vessel 3 of the gut model (19.8 ± 1.6 vs 69.0 ± 0.6 μg/ml) (P < 0.05) (Table 4.3.2). 
Protein concentrations were calculated using the equation of the standard curve (y = 
0.0014x) plotted for BSA standards (Fig 4.3.1).  
Table 4.3.2. Mean (± SE) protein concentrations from Vessels 1, 2 & 3 of the gut 
model. Values represent the results of triplicate experiments. Groups were 
compared using the Kruskal-Wallis H test with post-hoc multiple comparisons. 
Statistically significant differences (P< 0.05) are highlighted using *. Statistically 
significant differences in protein concentrations between vessels 1 and 3 were 
observed.  
 
 
 
 
 
 
 
 
 
Vessel Mean (± SE) Protein 
Concentration (μg/ml)  
1 19.8 ± 1.6 
2 53.8 ± 1.7 
3 69.0 ± 0.6 
 
* 
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4.3.2.2 SDS-PAGE 
The presence of a variety of protein bands could be identified in samples originating 
from Vessels 2 and 3 of the gut model, but not in Vessel 1 (Fig 4.3.2). No protein bands 
were observed for Vessel 1 samples. Decreased visual band intensity was observed in 
samples from Vessels 2 and 3 compared to the protein ladder.
Ladder V1 V2 V3 
Figure 4.3.2. Protein gel electrophoresis of proteins 
precipitated from gut fluid from Vessels 1, 2 & 3 of the in 
vitro gut model. V1 = Vessel 1, V2 = Vessel 2, V3 = Vessel 3. 
Low levels of banding can be seen in Vessels 2 & 3 lanes, 
but not in Vessel 1.  
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4.3.2.3 Isolation of Secreted Proteins from Gut Model Microorganisms 
4.3.2.4 Minimal Media Resuspension Method 
Centrifugation and resuspension in minimal media had no significant effect on the 
majority of groups recovered on selective media between any of the utilised time points 
(Fig 4.3.3). Total anaerobe numbers remained constant pre-centrifugation and 2h post-
centrifugation (8.68 ± 0.11 log10CFU/ml vs 8.71 ± 0.02 log10CFU/ml). Significant 
differences occurred due to centrifugation and/or incubation in the Enterococci and 
total spore groups. Enterococci recovery increased from pre-centrifugation to 2h post-
centrifugation (6.03 ± 0.14 log10CFU/ml vs 6.67 ± 0.04 log10CFu/ml) (P < 0.001). In 
contrast, a significant decrease in total spore counts was detected across the three 
treatment groups (before, immediately following and 2 hours post-centrifugation), (3.97 
± 0.19 log10CFU/ml vs 2.89 ± 0.05 log10CFU/ml) (P < 0.05). All other organisms showed 
stable counts across all three treatments with no substantial variation.  
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4.4 Discussion 
4.4.1 Quantification of Protein from the in vitro Gut Model Vessels 
The Bradford assay and gel electrophoresis highlighted the presence of substantial 
levels of protein in all three Vessels of the gut model. Although counterintuitive, the 
Bradford assay indicated an increase in protein levels from Vessel 1 to Vessel 3. 
Initially it was hypothesised protein levels would decrease from Vessel 1 to Vessel 3, 
due to the uptake of media proteins by the bacterial populations. There are possible 
explanations as to why this occurred. It is likely that bacteria are using up the peptides 
in the media to produce more complex proteins. These proteins bind with greater 
affinity to the Coomassie blue dye; Coomassie blue interacts primarily with arginine 
and to a lesser extent aromatic residues (411). In addition, the increasing alkalinity 
across the gut model from Vessel 1 to Vessel 3 could have affected the binding of the 
acidic dye.  
Although the presence of protein was highlighted in the gut model Vessels, these 
absolute values are unlikely to be accurate. The optimal method for producing a 
standard curve is against standards of the isolated protein you are quantifying. This 
was not feasible due to the heterogeneous nature of the gut model protein. BSA was 
used, and its use as a standard has been questioned by the proteomic field with protein 
underestimations long reported (412). Additionally, although acetone precipitation is 
effective, 100 % precipitation is not achievable; concentrations are likely to be 
underestimated. All these factors could have impacted on the reported measurements 
and are acknowledged. 
In summary, these experiments demonstrate the viability of isolating proteins from the 
gut model Vessels. However, to isolate bacterially produced peptides and avoid media 
contaminants, another methodology is required.  
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4.4.2 Isolation of Secreted Proteins from Gut Model 
Microorganisms 
Isolation of bacterial populations from the gut model fluid by repeated washing steps 
and resuspension removed the media contaminants. The minimal media utilised (M9 
salts solution) for bacterial resuspension contained no peptides but allows the survival 
of bacteria due to glucose availability. By isolating bacteria and removing the 
contaminating gut model media, the bacteria can respire whilst still producing proteins. 
If the process by which bacteria are isolated is not bactericidal, it could be an effective 
strategy for isolating bacterial proteins at various points during simulated rCDI infection. 
When the effect of centrifugation and subsequent resuspension and incubation in 
minimal media was assessed, most cultured groups were not significantly affected. 
However, spore populations were found to decrease significantly in response. Spore 
germination during the incubation period is the most plausible explanation for this 
decrease; the greatest decrease in spore recovery was observed in the samples 
incubated for 2 hours anaerobically. The statistically significant increase observed in 
Enterococci is more difficult to account for. Unavoidably, samples were processed 
aerobically during the centrifugation and resuspension steps during this optimisation 
process. It is possible that the death of strict anaerobes created a niche that the 
facultative anaerobic Enterococci could utilise to their advantage, thereby dividing and 
becoming a more prominent population. However, these data highlight the feasibility of 
using the minimal media resuspension for bacterial protein isolation; the methodology 
is not detrimental to bacterial cell viability.  
In addition to assessing the effect of the minimal media resuspension method on cell 
viability, concentration and quantification of protein levels were necessary prior to LC-
MS/MS. In this instance, a 3 kDa membrane spin concentrator was utilised. The 3 kDa 
cut-off was chosen due to the heterogeneous nature of the proteins produced; a more 
selective filter would have systematically removed any smaller peptides. If this method 
identified important groups of similar proteins associated with rCDI a more selective 
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filter with a higher molecular weight cut off (MWCO) could be utilised. Concentration of 
~15 ml of supernatant produced ~500 μl of supernatant with a concentration of ~500 
μg/ml of protein. Approximately 250 μg of protein is ample for downstream LC-MS/MS.  
In this study a minimal media resuspension method has been optimised for isolation of 
bacterial proteins from the in vitro gut model. It successfully removes the peptide 
impurities associated with media and permits bacterial cell viability. Additionally, 
concentration of protein by spin centrifugation produces a total protein weight of 
approximately 250 μg. As such, this methodology can be carried forward for produce 
subsequent samples for LC-MS/MS analysis.  
 
.   
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Chapter 4 B – rCDI Gut Models 
4.5 Methods 
Samples for analysis were taken from three gut models (E, F & G), the running of 
which was funded by Seres Therapeutics. The current study was not directly financially 
supported by Seres Therapeutics. The models were seeded initially with the same 
donor faeces.  
Sixteen-millilitres of gut model fluid was taken from Vessel 3 of models E, F and G. 
This was divided into eight 2 ml aliquots in Eppendorfs. All processing was undertaken 
anaerobically at 37° C. Eppendorfs were centrifuged for 1 minute at 9500 g. The 
supernatant was discarded and the pellet resuspended in 2 ml of PBS by loop 
homogenisation and vortexing. The washing step was repeated three times. After the 
final resuspension step the Eppendorfs were incubated for two hours. After incubation 
the supernatant was filter sterilised through a 0.22 μm filter syringe. After sterilisation 
the supernatant (~16 ml per model) was concentrated in an Amicon Ultra-15 3 kDa 
spin filter by centrifugation at 11400 g for 60 minutes in a Beckman Coulter X12 
centrifuge. The filtrate was discarded and the retentate stored at 4° C. 
Samples were taken to Dr Alexandre Zougman at the University of Leeds for processing 
and subsequent LC-MS/MS by the STRap method (377). The S-tip was comprised of a 
combination of QM-A (Whatman), MK360 and Empore C18  (3M) plugs in a pipette tip. 
Membranes were placed in the pipette tip using 1/16’ PEEK tubing (1535, Upchurch 
Scientific). The O-tube consisted of a 1.5 ml microcentrifuge tube (Sarstedt) with an 
artificially punctured lid. The S-tip was inserted in to the O-tube and 120 μl of 90 % 
methanol, 100 mM Tris/HCl was added to the S-tip. After 1 minute 2 μl of 12.15 % 
phosphoric acid solution (in H2O) was added to 18 μl of the sample. The sample was 
added to the S-tip and centrifuged for 2 minutes at 2800 g. The filtrate was discarded 
and 70 μl 90% methanol, 100 mM Tris/HCl was added before a further centrifugation 
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step for 45 seconds at 2800 g. Thirty-microlitres of 50 mM ammonium bicarbonate 
solution (in H2O) was added and the contents centrifuged for 30 seconds at 2800 g. 
Twenty-two microliters of 0.033 μg/μl trypsin (V5111, Promega) and incubated for 60 
minutes at 47° C in a heat block (PHMT, Grant). After incubation, the S-tip was removed 
from the spin-unit and 50 μl of 50 mM ammonium bicarbonate solution (in H2O) was 
added. The spin-unit was centrifuged for 60 seconds at 2300 g. One-hundred microliters 
of 0.5% trifluoroacetic acid (in H2O) was added to the S-tip and centrifuged for 90 
seconds at 2500 g. The S-tip was then placed in a fresh O-tube and 80 μl of 70 % 
acetonitrile, 0.5 % formic acid (in H2O) was added and centrifuged for 5 seconds at 
2500g. After 30 seconds a further centrifugation of 1 minute at 2500 g was undertaken. 
The eluate was concentrated in a SpeedVac to a final volume of 5 – 12 μl. If required, 
the concentrated peptides were diluated to the required volume with 0.2 % formic acid 
(in H2O). 
A schematic outlining the time scales and treatments involved in each of the three gut 
models (E, F & G) is outlined in Figure 4.5.1.  A table of samples taken is shown (Table 
4.5.1)An overview of the optimised methodology utilised for these set of experiments can 
be also seen below in Figure 4.5.2.
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Figure 4.5.1. Overviews of the timeline for the E, F & G in vitro C. difficile 
recurrence gut models. The graphs show the daily average total viable 
counts of C. difficile (spores & vegetative cells) and toxin levels in the three 
models. All the models underwent an adjustment ‘steady state’ period (i) 
prior to the establishment of a C. difficile reservoir (ii). Two doses of RT 027 
C. difficile spores (1.7 x 107 spores/ml) were added 7 days apart to establish 
a reservoir.  C. difficile infection was induced by a 7-day course of 
clindamycin (iii) (33.9 mg/L Q.D.S). Simulated CDI (iv) was treated with 
vancomycin (v) (125 mg/L Q.D.S) for 7 days. After treatment each model 
received an additional treatment (vi); three 10 ml spore prep (SER-109) doses 
(model E), a single 10 ml spore prep (SER-109) preparation (model F) or 
simulated faecal microbiota transplantation (model G). In the proceeding 
period (vii) model F was the only model for recurrence to take place. 
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Table 1.5.1. Samples taken from models E, F, & G of the C. difficile gut models. 
Stage of infection is presented with the model day. Roman numerals correspond 
to Figure 3.2.1. Intotal, 15 samples were taken for MS analysis; 3 from steady 
state (E, F, G), 3 from the dysbiotic niche created by clindamycin (E, F, G), 3 from 
during CDI (E, F, G), 2 from after vancomycin treatment (F, G), 1 from after 
multiple (3) spore prep infusions (E) 1 from after FMT (G) & 1 rCDI sample (F). 
Recurrence of CDI occurred in one model (F). Where samples are absent (E – 
CDI, F – post-spore prep) this is due to inadequate protein concentrations 
Model(s) Stage of Infection Model day 
E,F,G Steady state (ii) - first dose 
C. difficile spores 30 
E,F,G Last day of Clindamycin 
instillation (iii) 42 
F,G CDI (iv) 57 
E,F CDI (iv) (E), last day of 
vancomycin dosing (v) (F) 65 
G +3 days from last day of 
vancomycin dosing (v) (G),  70 
G +4 days from FMT (vi) (G) 74 
E Last day of vancomycin 
dosing (vi) (E) 77 
E Post-spore prep (vi) 87 
F rCDI (vii) 95 
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4.5.1 Metaproteomic Analysis 
Peptide identification and protein assignment were obtained by searching mass spectra 
against the manually curated UniProtKB/SwissProt complete bacterial database in 
MaxQuant version 1.6.1.0. The algorithm incorporated into MaxQuant was used for 
these purposes (Andromeda). The following parameters were employed in MaxQuant; 
a MS scan mass tolerance of 7 ppm, a fragment mass tolerance for MS/MS of 0.5 Da, 
protein N-terminal acetylation, oxidation of methionine and carbamidomethylation of 
cysteine were set as variable modifications. The maximum false discovery rate (FDR) 
for proteins/peptides was set at 0.1.  
An overview of metaproteomic analysis can be seen below (Fig 4.5.3). For taxonomic 
analysis, the tryptic peptides were analysed by the MetaProteomics analysis module in 
Unipept 3.3.5. Unipept taxonomically assigns peptides based on a lowest common 
ancestor approach. Isoleucine and leucine were equated, duplicate peptides were 
removed and the advanced missed cleavage handling function was applied. For 
functional analysis of proteins, in line with the rule of parsimony, only the first protein 
from each assigned protein group was taken for functional analysis. It is possible for 
unique peptides to match to more than one protein, particularly in different organisms. 
As such, protein groups (proteins sharing the same peptides) can contain more than 
one protein ID (Table 4.5.2).  As a rule of parsimony, only the first protein ID with the 
highest indication is reported. This is in accordance with Molecular & Cellular 
Proteomics guidelines (403). However, a full table of reported protein groups can be 
found in Appendix C. Protein function was allocated using the UniProtKB/SwissProt 
database.  
This workflow is based on the work of Tanca et al (413).  
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4.5.1.1 Culture on selective media 
As detailed previously, selected bacterial populations were enumerated throughout the 
duration of the gut models. On days microbial culture data was absent, data from the 
proceeding nearest day were utilised. In this instance the day of the model is indicated 
for transparency. For detailed gut model methodologies refer to 4.2.1.  
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Figure 4.5.3. Methodology used for the taxonomic and functional analysis of 
MaxQuant output. The Andromeda search engine was used to match mass 
spectra to the UniProtKB/SwissProt bacterial database. The tryptic peptide 
list was used to assign peptide taxonomy based on a lowest common 
ancestor (LCA) approach in UniPept 3.3.5. The first inferred protein from each 
MaxQuant output group was used for functional annotation of proteins in 
UniProtKB/SwissProt.  
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4.6 Results 
4.6.1 Model E – Multiple spore prep doses 
579 bacterial tryptic peptides were identified in steady state. Peptides were assigned to 
Firmicutes (13.0 %), Bacteroidetes (0.9 %), Actinobacteria (41.1 %) and Proteobacteria 
(2.5 %). The majority of peptides could not be assigned below the Bacteria LCA level 
(60.0 %). The steady state sample corresponds to day 30 of the gut model. At day 30 
of the model, high levels of anaerobes were reported (Fig 4.6.1); total anaerobes (8.74 
± 0.14 log10CFU/ml) ,Clostridia (7.45 ± 0.05 log10CFU/ml), Bifidobacteria (7.26 ± 0.04 
log10CFU/ml). Substantially lower levels of B. fragilis were reported (5.50 log10CFU/ml). 
In facultative anaerobes, low levels of Enterococci (5.13 ± 0.08 log10CFU/ml) and high 
levels of and Lactobacilli (7.26 ± 0.04 log10CFU/ml) were reported (Fig 4.6.2). Lactose-
fermenting Enterobacteriaceae (LFAs) were enumerated at 6.61 ± 0.02 log10CFU/ml. 
At the end of clindamycin exposure, 773 tryptic peptides were identified. An increase in 
the proportion of proteins assigned to the Proteobacteria (28.2 %) and Firmicutes phyla 
(24.3 %) steady state was observed. A large decrease in the proportion of 
Actinobacteria assignments was observed (0.1 vs 41.1 %). 47.0 % of peptides could 
not be distinguished further below the Bacteria superkingdom. This proteomics sample 
was taken on day 42 of the gut model. On day 42 reductions in strict anaerobes, 
Clostridia (7.45 ± 0.05 vs 3.57 ± 0.04 log10CFU/ml) and Bifidobacteria (7.26 ± 0.04 vs 
below the LLOD) were observed vs day 30 (steady state). B. fragilis populations were 
not altered substantially by clindamycin exposure (5.50 vs 5.49 ± 0.03 log10CFU/ml).  
Populations of the facultative anaerobic Lactobacilli and Enterococci were comparable 
to steady state. In contrast, a substantial increase in lactose-fermenting 
Enterobacteriaceae (6.61 ± 0.02 vs 8.38 ± 0.10 log10CFU/ml) was evident.  
The sample corresponding to day 65 was taken towards the end of CDI. Peak C. 
difficile TVC counts (4.75 ± 0.05 log10CFU/ml) occurred on day 64 with peak toxin 
levels (3 relative units) following on day 66 (Fig 4.5.1). A total of 646 bacterial tryptic 
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peptides were assigned. The proportion of protein identifications decreased from 
Firmicutes (19.5 vs 24.3 %) and Proteobacteria (13.6 vs 28.2 %) phyla organisms vs 
post-clindamycin. The proportion of Bacteroidetes identifications increased to 12.7 %. 
53.4 % of peptides could not be distinguished below the Bacteria superkingdom level. 
Compared to post-clindamycin the number of strict anaerobes identified by culture 
increased substantially (8.54 ± 0.03 vs 9.17 ± 0.01 log10CFU/ml), with increases in 
B.fragilis (5.47 ± 0.03 vs 8.18 ± 0.07 log10CFU/ml) and Clostridial (3.57 ± 0.04 vs 6.50 ± 
0.06 log10CFU/ml) populations. Interestingly, although Bifidobacteria populations 
increased in to the earlier stages of CDI (days 46-64) to a maximum (5.00 ± 0.01 
log10CFU/ml), by day 65 Bifidobacteria populations were undetectable.  In contrast, 
facultative anaerobic levels decreased (8.56 ± 0.07 vs 7.78 ± 0.06 log10CFU/ml), with a 
corresponding decrease in lactose-fermenting Enterobacteriaceae (8.38 ± 0.04 vs 7.40 
± 0.02 log10CFU/ml). E. faecalis numbers increased ~10-fold (5.21 ± 0.10 vs 6.18 ± 
0.08 log10CFU/ml) whilst Lactobacilli numbers remained comparable to post-
clindamycin levels (7.32 ± 0.04 vs 7.60 ± 0.25 log10CFu/ml).  
Although a post-vancomycin sample was produced for model E, protein concentrations 
were too low for LC-MS/MS even after concentration (<30 µg/ml). 
In the sample produced after multiple doses of an undefined spore prep, 470 tryptic 
peptides were processed and assigned as follows; Firmicutes (19.4 %), Bacteroidetes 
(20.9 %), Actinobacteria (0.4 %) and Proteobacteria (12.3 %). 47.0 % of peptides could 
not be distinguished further below the Bacteria superkingdom level. This sample 
corresponds to day 87 of the model. 
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4.6.2 Model F – Single spore prep dose 
476 peptides were assigned from the LC-MS/MS sample from steady state. The 
identified peptides were from Firmicutes (25.9 %) Actinobacteria (10.5 %), 
Bacteroidetes (7.8 %) and Proteobacteria (17.4 %) phyla. Thirty-eight percent of 
peptides could not be assigned below the Bacteria superkingdom level. This sample 
corresponds to day 30 of the model. At day 30 culture revealed total strict anaerobe 
levels of 8.88 ± 0.08 log10CFU/ml with levels of B.fragilis (6.60 log10CFU/ml), 
Bifidobacteria (8.83 ± 0.06 log10CFU/ml) and Clostridia (7.88 ± 0.08 log10CFU/ml), 
respectively (Fig 4.6.3. On day 29, total levels of facultative anaerobes were 
enumerated at 7.52 ± 0.02 log10CFU/ml) with populations of lactose-fermenting 
Enterobacteriacae (7.77 ± 0.01 log10CFU/ml), Enterococci (5.82 ± 0.01 log10CFU/ml) 
and Lactobacilli (8.12 ± 0.01 log10CFU/ ml) (Fig 4.6.4). 
At the end of clindamycin exposure, 771 peptides were identified. A decrease in the 
proportion of proteins assigned to the Proteobacteria phylum vs steady state was 
observed (13.7 vs 17.4 %) as well as in Firmicutes (13.7 vs 25.9 %))and Actinobacteria 
(10.5 vs 0.3 %) assignments. Interestingly, Bacteroidetes assignments increased (18.3 
vs 7.8 %). 53.8 % of peptides could not be distinguished below the Bacteria 
superkingdom level. This sample corresponds to day 42 of the model. Microbial culture 
revealed a total strict anaerobe population of 8.98 ± 0.03 log10CFU/ml, with comparable 
levels of B.fragilis (6.60 vs 6.72 ± 0.03 log10CFU/ml)  but decreased levels of 
Bifidobacteria (8.83 ± 0.06 log10CFU/ml vs below LLOD) and Clostridia (7.88 ± 0.08 vs 
3.41 ± 0.03 log10CFU/ml) compared to steady state.   Total facultative anaerobes 
increased vs steady (7.52 ± 0.02 vs 8.19 ± 0.02 log10CFU/ml), with similar levels of 
lactose-fermenting Enterobacteriaceae (7.77 ± 0.01 vs 8.05 ± 0.04 log10CFU/ml), 
increased levels of Enterococci (5.82 ± 0.02 vs 6.92 ± 0.01 log10CFU/ml) and a 
considerable reduction in Lactobacilli (8.12 ± 0.10 vs 5.85 ± 0.05 log10CFU/ml). 
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A total of 367 peptides were identified during CDI. The proportion of peptide 
assignments increased from Firmicutes (42.0 vs 13.7 %). Bacteroidetes (7.4 vs 18.3 %) 
and Proteobacteria (5.7 vs 13.7 %) proportions dropped vs post-clindamycin. 43.9 % of 
peptides could not be distinguished below the Bacteria superkingdom level. This 
sample corresponds to day 57 of the model. Toxin detection began at day 47, with 
peak toxin detected at days 51 and 56 (Fig 4.5.1) and the highest C. difficile TVC 
counts at day 50 (Fig 4.5.1). When compared to the post-clindamycin sample, microbial 
culture revealed an increase in total strict anaerobes (8.93 ± 0.07 vs 9.33 ± 0.07 
log10CFU/ml) with similar levels of Bacteroidetes (6.92 ± 0.08 vs 7.22 ± 0.01 
log10CFU/ml) and Clostridia (6.12 ± 0.10 vs 6.00 ± 0.14 log10CFU/ml), but a substantial 
increase in Bifidobacterium from below the LLOD ( <LLOD vs 5.37 ± 0.30 
log10CFU/ml). 
In the post-vancomycin sample, 594 peptides were identified; Firmicutes (8.9 %), 
Bacteroidetes (1.9 %), Actinobacteria (0.0 %) and Proteobacteria (42.1 %). The 
proportion of all phyla decreaed compared to Proteobacteria. 46.0 % of peptides could 
not be distinguished below the Bacteria superkingdom level. The sample was taken on 
day 65 of the model. A decrease in total strict anaerobes (9.33 ± 0.07 vs 8.53 ± 0.03 
log10CFU/ml) was observed compared to the sample taken during CDI, with >2.5 log 
decreases in Bifidobacteria (5.37 ± 0.30 log10CFU/ml vs <LLOD), Bacteroidetes (7.22 ± 
0.01 log10CFU/ml vs <LLOD) and Clostridia (6.00 ± 0.14 vs 3.37 ± 0.30 log10CFU/ml).  
Despite combination of several samples, protein levels in Vessel 3 of model F were too 
low even after spin concentration. Therefore, no results are available for this time point.  
In the sample taken after recurrence, 363 peptides were identified; Firmicutes (56.2 %), 
Bacteroidetes (1.1 %), Actinobacteria (3.3 %) and Proteobacteria (4.7 %). 34.7 % of 
peptides could not be distinguished below the Bacteria superkingdom level. This 
sample was taken on the last day of the model (day 95). The recurrence of CDI is 
illustrated by the high levels of C. difficile vegetative cells on day 80 and the 
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corresponding peak toxin levels on day 84. The increased level of C. difficile vegetative 
cells compared to spores is indicative of germination.
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4.6.3 Model G – FMT 
453 peptides were identified from the LC-MS/MS sample from steady state. The 
identified peptides were assigned to Firmicutes (33.8 %) Actinobacteria (8.6%), 
Bacteroidetes (7.3 %) and Proteobacteria (13.2 %) phyla organisms. 37.1% of peptides 
could not be distinguished below the Bacteria superkingdom level. The steady state 
sample was taken on day 30 of the model. Microbial culture revealed high levels of 
total strict anaerobes (9.16 ± 0.05 log10CFU/ml), with substantial populations of 
Bacteroidetes (7.67 log10CFU/ml), Bifidobacteria (6.90 ± 0.04 log10CFU/ml) and 
Clostridia (8.18 ± 0.21 log10CFU/ml) (Fig 4.6.5). Total facultative anaerobes were 
enumerated at 8.11 ± 0.05 log10CFU/ml, with considerable levels of lactose-fermenting 
Enterobacteriaceae (7.77 ± 0.03 log10CFU/ml), Enterococci (5.73 ± 0.15 log10CFU/ml) 
and Lactobacilli (7.15 ± 0.07 log10CFU/ml) (Fig 4.6.6) 
At the end of clindamycin exposure, 443 peptides groups were identified. An increase 
in the proportion of proteins assigned to the Proteobacteria phylum (21.7 vs 13.2 %) vs 
steady state was observed. The proportion of assignments to other groups decreased 
when compared to steady state; Firmicutes (19.6 vs 33.8 %), Actinobacteria (0.0 vs 8.6 
%) and Bacteroidetes (2.3 vs 7.3 %). 55.8 % of peptides could not be distinguished 
below the Bacteria superkingdom level. The post-clindamycin sample was taken on 
day 45 of the model. On day 44, compared to day 30 (steady state) total strict 
anaerobe levels decreased (9.16 ± 0.05 vs 8.62 ± 0.10 log10CFU/ml) with reductions in 
Bifidobacteria (6.90 ± 0.04 log10CFU/ml vs <LLOD) and Clostridia (8.18 ± 0.21 vs 5.82 
± 0.10 log10CFU/ml) observed. In contrast, total facultative anaerobes were comparable 
(8.11 ± 0.05 vs 8.23 ± 0.06 log10CFU/ml), with similar levels of lactose-fermenting 
Enterobacteriaceae (7.77 ± 0.03 vs 7.73 ± 0.10 log10CFU/ml), Enterococci (5.73 ± 0.15 
vs 5.62 ± 0.09 log10CFU/ml) and Lactobacilli (7.15 ± 0.07 vs 7.43 ± 0.09 log10CFU/ml) 
vs steady state.  
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A total of 594 peptides were assigned from the sample taken from during CDI.  The 
proportion of peptide assignments increased from Firmicutes (31.7 vs 19.6 %) 
Bacteroidetes (9.1 vs 2.3 %) and Actinobacteria (0.0 vs 0.7 %) phyla organisms vs the 
post-clindamycin sample. The proportion of Proteobacteria phylum peptide 
assignments decreased (15.5 vs 21.7 %). 41.0 % of peptides could not be 
distinguished below the Bacteria superkingdom level. The sample for CDI was taken on 
day 57. Compared to day 44 (post-clindamycin), total strict anaerobe populations were 
higher (8.62 ± 0.10 vs 9.14 ± 0.14 log10CFU/ml) with increased levels of Bacteroidetes 
(7.59 ± 0.02 vs 7.87 ± 0.10 log10CFU/ml) and Bifidobacteria (<LLOD vs 5.83 ± 0.05 
log10CFU/ml), and comparable levels of Clostridia (5.82 ± 0.10 vs 5.52 log10CFU/ml) on 
day 56. In contrast, over the same time period total facultative anaerobes decreased 
(8.23 ± 0.06 vs 7.32 ± 0.02log10 CFU/ml), with reductions in lactose-fermenting 
Enterobacteriaceae (7.73 ± 0.10 vs 6.63 ± 0.02 log10CFU/ml) and increases in 
Enterococci (5.62 ± 0.09 vs 6.53 ± 0.04 log10CFU/ml). Lactobacilli populations 
remained comparable to post-clindamycin (7.43 ± 0.09 vs 7.49 ± 0.02 log10CFU/ml).  
In the post-vancomycin sample, 594 peptides were identified and assigned. Decreases 
in assignment of peptides occurred in all but the Proteobacteria phyla (42.1 vs 15.5 %); 
Firmicutes (8.9 vs 31.7 %), Bacteroidetes (1.9 vs 9.1 %) and Actinobacteria (0.0 vs 0.7 
%). 46.0 % of peptides could not be assigned to a lower level than the Bacteria 
superkingdom.  This sample was taken on day 70 of the model. Compared to CDI, a 
small decrease in total strict anaerobes was observed (9.14 ± 0.14 vs 8.62 ± 0.01 
log10CFU/ml) when cells were cultured on selective media. Bacteroidetes (7.87 ± 0.10 
log10CFU/ml vs <LLOD) and Bifidobacteria (5.83 ± 0.05 log10CFU/ml vs <LLOD) 
numbers both dropped below the LLOD, Clostridia numbers decreased marginally 
(5.52 vs 5.22 log10CFU/ml). In contrast, total facultative anaerobes increased ~2.5 
log10CFU/ml, with substantial increases in lactose-fermenting Enterobacteriaceae (6.38 
± 0.02 vs 8.91 ± 0.03 log10CFU/ml)) and Lactobacilli (7.49 ± 0.02 vs 9.15 ± 0.05 
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log10CFU/ml). Enterococci populations decreased (6.53 ± 0.04 vs 3.92 ± 0.10 
log10CFU/ml). 
In the post-FMT sample, 179 peptides were identified and assigned; Firmicutes (56.2 
%), Bacteroidetes(1.1 %), Actinobacteria (3.3 %) and Proteobacteria (4.7 %). 34.7 % of 
peptides could not be assigned to a lower level than the Bacteria superkingdom.  This 
sample was taken on day 74 of the model. 
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4.6.4 Overall Taxonomic analysis 
The taxonomic assignment of tryptic peptides from all stages of infection in all three 
models are visualised below (Fig 4.6.7). 1289 tryptic bacterial peptides were assigned 
from all 3 model samples in steady state. Peptides were assigned to Firmicutes (24.2 ± 
6.1 %), Bacteroidetes (5.3 ± 2.2 %), Actinobacteria (20.1 ± 10.5 %) and Proteobacteria 
(11.0 ± 4.5 %). A large percentage of peptides could not be assigned below the 
Bacteria LCA level (39.1 ± 1.6 %).  
At the end of clindamycin exposure, 1369 bacterial tryptic peptides were analysed. An 
increase in the proportion of proteins assigned to the Proteobacteria (21.2 ± 4.2 %) 
was observed and a substantial decrease in the proportion of Actinobacteria peptides 
(0.1 ± 0.1 %). Levels of Firmicutes (19.2 ± 3.1 %) and Bacteroidetes (6.9 ± 5.7 %) 
assignments were comparable to steady state. 52.2 ± 2.7 % of peptides could not be 
assigned below the Bacteria superkingdom.  
CDI is demonstrated by the presence of high toxin in all three models after the end of 
clindamycin exposure (Fig 4.5.1). In samples taking during CDI, a total of 990 bacterial 
tryptic peptides were analysed. Compared to post-clindamycin, more peptides were 
assigned to Firmicutes (31.1 ± 6.5 %) and less to Proteobacteria (11.6 ± 3.0 %) phyla 
organisms. Actinobacteria (0.5 ± 0.2 %) and Bacteroidetes (9.7 ± 1.6 %) assignments 
were comparable. 46.1 ± 3.7 % of peptides could not be assigned below the Bacteria 
superkingdom.  
At the end of vancomycin treatment, 876 bacterial peptides were analysed. Only the 
results from two samples are presented (models F & G) as the sample from model E 
failed LC-MS/MS due to low protein concentration. Compared to CDI samples, a 
decrease in Firmicutes (15.7 ± 6.8 %) and Bacteroides (1.2 ± 0.8 %) assignments were 
observed. Proteobacteria assignments increased substantially (39.3 ± 2.9 %). 43.0 ± 
3.0 % of peptides could not be assigned below the Bacteria superkingdom.  
182 
 
 
Compared with the post-vancomycin samples, the sample proceeding multiple spore 
doses (model E) had substantially increased levels of Bacteroidetes (20.9 %) assigned 
peptides. Proteobacteria assignments were substantially decreased (12.3 %) whilst 
Firmicutes (19.4 %) and Actinobacteria (0.4 %) assignments were comparable with 
post-vancomycin. 47.0 % of peptides could not be assigned below the Bacteria 
superkingdom. In comparison, the post-FMT sample had increased levels of Firmicutes 
(59.0 %), with low levels of Bacteroidetes (1.7 %), Actinobacteria (0.6 %) and 
Proteobacteria (5.6 %) assignments. Interestingly, the sample taken late in recurrence 
(model F) had a similar profile; Firmicutes (56.2 %), Bacteroidetes (1.1 %), 
Actinobacteria (3.3 %) and Proteobacteria (4.7 %). However, at the class level a 
greater proportion of peptides were assigned to clostridia (77.4 %) in the post-FMT 
sample compared to the rCDI sample (45.1 %). Bacilli assignment accounted for the 
remaining peptides. Levels of peptides unassigned below the Bacteria level were also 
similar between the post-FMT and rCDI samples (33.0, 34.7 %).  
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4.6.5 Overall Functional analysis 
The functional assignment of proteins to metabolic pathways can be seen below (Fig 
4.6.8). The dominant metabolic processes in all models throughout all stages of 
simulated infection were carbohydrate degradation, carbohydrate biosynthesis and 
amino acid biosynthesis. The overall metabolic profile of the models is not changing 
substantially over time with an obvious trend. However, in model G clindamycin 
exposure caused proteins involved in carbohydrate degradation/biosynthesis to 
decrease from 73.5 % of the total to 56.5 %. At the end of recurrence, 62.5 % of 
isolated proteins were involved in carbohydrate degradation/biosynthesis compared to 
51.2 % following vancomycin treatment. Interestingly, proteins involved in antibiotic 
biosynthesis were only present in post-vancomycin samples.
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4.7 Discussion 
The metaproteome varied considerably between different models and time points (Fig 
4.6.7). Despite using the same frozen faecal material to seed the models, the 
metaproteome differed considerably between models in steady state. Using frozen 
faeces for FMT proved non-inferior to fresh faeces in resolving rCDI in a double-blind 
randomised control trial (177). In model E there was a high abundance of 
Actinobacteria and lower levels of Firmicutes and Bacteroidetes peptides compared to 
models F. This is in accordance with culture data documenting high levels of 
Bifidobacteria (7.26 ± 0.04 log10CFU/ml) and low levels of B.fragilis group organisms 
(5.50 log10CFU/ml) (Fig 4.6.1). Models G and F appear to be more consistent with 
previous data illustrating human faeces to be dominated by Firmicutes and 
Bacteroidetes phyla organisms, with low levels of Proteobacteria (414) (Fig 4.6.7). In 
experiments using Drosophila melanogaster (415, 416) and Caenorhabditis elegans 
(416, 417) to study gut colonisation it was highlighted that initial gut bacterial 
colonisation is stochastic like a ‘lottery’; different outcomes can arise from the same 
starting inoculum. Some bacterial species may have a greater chance of colonisation 
due to their ability to persist in the gut and resist displacement from ingested microbes 
(415-417). Although the in vitro gut model has no immune component or external 
bacterial displacement, the stochastic nature of colonisation may account for 
differences between models in steady state.  The high levels of Proteobacteria 
identifications in steady state are consistent with previous gut model data where 
substantial numbers of lactose-fermenting Enterobacteriaceae were isolated (91, 92, 
286, 404). The initial faecal processing required for seeding of the models exposes 
faecal bacterial populations to a brief aerobic period. In addition, sampling leads to 
transient oxygenation of the gut model Vessels, potentially accounting for the increased 
Proteobacteria presence.  
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After clindamycin treatment, the number of Actinobacteria assignments decreased 
substantially in all the models, most notably in model E (Fig 4.6.7). These findings are 
consistent with culture data where Bifidobacteria levels dropped substantially (≤ 5 
log10CFU/ml) to below the lower limit of detection in all three models (Figs 4.6.2, 4.6.4, 
4.6.6). Bifidobacteria species are particularly susceptible to clindamycin as illustrated 
by MIC testing in a wide range of species (418). A trend of increased Proteobacteria 
assignments was observed. This is expected due to the sensitivity of a range of 
anaerobes to clindamycin including streptococci, pneumococci, staphylococci and 
B.fragilis. In contrast clindamycin has practically no activity against the facultatively 
anaerobic organisms. As well as various classes of Proteobacteria, clindamycin also 
has no activity against some Firmicutes such as enterococci (419). In mice models, a 
single dose of clindamycin was found to induce Enterobacteriaceae predominance in 
conjunction with an overall decreased biodiversity as demonstrated by 16s-rRNA 
sequencing (420). Interestingly, Bacteroidetes assignments increased proportionally in 
model F. This coincided with decreased levels of Firmicutes peptides; coinciding with 
substantial drops in both clostridia (7.88 ± 0.08 vs 3.41 ± 0.03 log10CFU/ml) and 
Lactobacilli (8.12 ± 0.10 vs 5.85 ± 0.05 log10CFU/ml) on culture media (Fig 4.6.3). The 
increased proportion of Bacteroidetes peptide assignments can be accounted for by 
the overall reduction in Firmicutes organisms, as demonstrated by the culture data. It is 
unclear why B. fragilis numbers remained relatively unaffected by clindamycin, but 
reduced susceptibility to clindamycin has been documented in 21.2 % of faecal isolates 
previously (421). In model E, the relative increase in Firmicutes peptide assignments 
can be accounted for by the drastic reductions in Bifidobacteria. The differences 
between the models after clindamycin exposure are likely due in part to variable initial 
steady state populations.  
After the cessation of clindamycin, high C. difficile toxin levels in all three models were 
indicative of CDI (Fig 4.5.1). The end of antibiotic pressure allowed the recovery of 
Bacteroidetes, Firmicutes and Actinobacteria organisms as exemplified by increased 
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peptide assignments. The recovery of Firmicutes and Bacteroidetes organisms during 
CDI and the subsequent dominance of Proteobacteria (entirely Gammaproteobacteria) 
after vancomycin treatment raises questions; vancomycin treatment could be 
precipitating rCDI by its deleterious effects.  
Recurrent CDI only occurred in model F, as illustrated by high C. difficile TVCs and 
toxin on day 78 (Fig 4.5.1). It should be noted C. difficile TVC counts increased to ~2 
log10CFU/ml above spore levels prior to the end of model E. Despite the absence of 
toxin, recurrence might have occurred if the model had been left for a longer time 
period. In contrast, model G showed no signs of resurgence in C. difficile vegetative 
populations. Interestingly the metaproteomic composition of the post-FMT (model G) 
and post-multiple spore dose (E) samples were substantially different; model E was 
dominated by Bacteroidetes peptides compared to the high levels of Firmicutes peptide 
assignments observed in model G (Fig 4.6.7).  
One would not expect the spore preparation to directly increase levels of Bacteroidetes 
phyla organisms as they are non-spore formers. Specific Firmicutes assignments in 
model E were a mixture of bacilli and clostridia contrasting with the dominance of 
clostridia in model G. Culture data shows higher levels of B. fragilis group organisms in 
model G and clostridia levels ~3 log10CFU/ml higher than in model E. These results are 
concordant with previous studies documenting an increase in Clostridium species as a 
result of FMT (164). One study by Wang et al found that prior to recurrence, patients 
had a paucity of Lachnospiraceae and Ruminococcaceae family organisms in their gut 
compared to patients who did not suffer a further recurrence (422). Interestingly, the 
metaproteomes of the post-FMT sample and the sample taken from late in rCDI from 
model F are comparable. Despite this, culture data for the rCDI sample demonstrate 
lower levels of clostridia and B. fragilis group organisms compared with post-FMT.  
The success of both FMT and the unknown spore preparation illustrates the underlying 
complexity of achieving colonisation resistance against C. difficile. A number of 
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mechanisms have been suggested; out competition by other bacterial species, 
community regulation by bacteriophage competition, production of specific 
antimicrobial compounds and production of unfavourable metabolic substrates (for 
example, short-chain fatty acids)(423, 424). The primary mechanism of efficacy for 
FMT remains unclear and is likely to be multifactorial (424). Previous work has 
demonstrated the efficacy of C. scindens in preventing C. difficile infection in mice due 
to an ability to convert primary to secondary bile acids (93, 172). Short-chain fatty acids 
(butyrate, acetate, and propionate) have very recently been shown to be upregulated 
after FMT for rCDI in humans (425). Interestingly, one publication illustrates a 
paradoxical increase in levels of SCFAs in rCDI compared to after FMT transplant in 10 
patients (426). Some bacteria are known to produce bacteriocins that are inhibitory to 
C. difficile growth. An example of this is thuricin CD, a post-translationally modified 
bacteriocin produced by Bacillus thuringiensis (427). A combination of mechanisms is 
assumed to underlie colonisation resistance; a notion supported by the data in this 
study. 
Functional analysis illustrated a large percentage of proteins were involved in 
carbohydrate metabolism (Fig 4.6.8). This was true for all stages of each gut model. 
Previous human metaproteome work has shown that proteins involved in carbohydrate 
metabolism are isolated in greater abundance than would be expected from 
corresponding metagenomics data (366). In addition, another study presented 
concordant data highlighting a stable set of ~1000 peptides in faecal samples collected 
from three human individuals over a 12 month period (428). A stable ‘core’ accounting 
for ~10 % of peptides was associated with carbohydrate metabolism/degradation was 
present, supportive of the functional data presented in the current study. On the other 
hand, it is plausible that bacterial resuspension in a minimal media containing only 
glucose as an energy source created an artificial environment that altered bacterial 
metabolism. In contrast to metagenomics work suggesting an increased abundance of 
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genes involved in particular metabolic pathways, the current study suggests the overall 
functional processes of the microbiome remain undisturbed by antibiotics (429).  
There are limitations in this study that could be addressed in future work. Initially, this 
study sought to characterise the secreted proteins from gut model bacterial 
populations. Cell disruption due to repeated centrifugation and resuspension in 
processing is a limitation, but centrifugation cannot be avoided. A methodology that 
removes proteinaceous media, allows continued bacterial metabolism whilst also 
facilitating supernatant isolation and concentration is impracticable. Bead-beating, 
freeze-thawing and cell lysis are routinely used to characterise the metaproteome in 
bacteria, including spores (430-432). Bead-beading facilitates the mechanical 
disruption and fragmentation of the bacterial cell wall, allowing the release of the 
cytosolic contents. If bead-beating had been utilised in the current study, a larger 
number of proteins could have been identified. However, it is probable that the 
increased kinetic energy inherent in bead-beating protocols could lead to extensive cell 
wall fragmentation. Cell wall proteins do not reflect the metabolic activity of a cell and 
could distort results without extensive filtering in analysis.  
The UniProtKB/SwissProt database was used to generate the tryptic peptide list 
necessary for taxonomic analysis. In the original methodology of Tanca et al, the much 
larger UniProtKB/trEMBL database was utilised (413). UniProtKB/trEMBL has ~200X 
the number of sequences present in UniProtKB/SwissProt (433). This difference is 
accounted for by the fact UniProtKB/SwissProt is manually annotated, focuses on 
protein annotation from ‘model organisms’ and is non-redundant. Non-redundancy in 
this sense is defined by one record accounting for all protein sequences produced from 
one gene in one species (434). This is in contrast to UniProtKB/trEMBL where different 
protein isoforms are stored in different entries despite being produced by the same 
gene in the same species (433). The higher quality of UniProtKB/SwissProt makes it 
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suitable for functional analysis. Despite being of lower quality, UniProtKB/trEMBL 
would have generated a much larger and more representative tryptic peptide list. 
The use of such a large database in MaxQuant (~10 gb) was impracticable in the 
current study due to vast running times and lack of computational power. Multiple 
processing nodes (a computer cluster) would be necessary and large databases still 
pose problems with controlling the FDR (390, 435). Additionally, although the LCA 
approach devised in UniPept is robust, peptides can be largely conserved between 
different species. This creates many peptides that cannot be discriminated below the 
bacteria superkingdom as illustrated in Fig 4.6.8. Metaproteomes may appear to be 
similar (for instance in model E; CDI and post- multiple spore prep samples), but this 
could be purely due to a lack of taxonomic discrimination below the phylum level.  
Despite these limitations, the taxonomic analysis presented in this study is likely to be 
representative in proportion to the true populations. Variations in taxonomic assignment 
between samples correlated well with the culture data. The problems outlined are 
inherent in gut metaproteomic studies.  
In summary, this chapter presents the optimisation and deployment of a novel 
methodology for evaluating the metaproteome of the gut microbiota communities within 
an in vitro model of C. difficile infection. Studying the active metabolic components of 
bacterial populations circumvents some of the limitations inherent in culture-based and 
metagenomics-based approaches. Although additional biological replicates would have 
been beneficial, this work highlights the complex nature of colonisation resistance and 
suggests a holistic approach to preventing rCDI should be considered rather than 
focussing on the relevance of any single species. Antibiotic instillation did not 
substantially alter the overall metabolic profile of the microbiome. Vancomycin 
treatment substantially increased the metaproteomic representation of Proteobacteria, 
underlying the paradoxical notion of treating CDI with antibiotics. As well as highlighting 
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relevant findings, this methodology provides a springboard that can be built upon in 
future experiments. 
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Chapter 5 - Conclusions 
rCDI is still a major problem for health systems, with up to 35 % of patients suffering at 
least one recurrence after an initial episode (65, 208, 436). Patients suffering from rCDI 
are at increased risk of developing further recurrences, potentially leading to a cycle of 
intractable recurrent disease. This thesis employs a multidimensional approach to 
studying the factors important in rCDI. Firstly, statistical methods are employed to 
assess the effect of treatment delay on risk of recurrence in a clinical data set produced 
from a previous study. This could inform future clinical practice in CDI. Secondly, the 
optimal germination conditions for C. difficile are investigated to elucidate the 
conditions necessary in the host. The effects of heat on C. difficile spores were also 
studied, as food is a potential reservoir of C. difficile spores necessary for rCDI. Finally, 
a novel metaproteomic approach was utilised in a previously validated in vitro gut 
model to study the overarching metabolic processes inherent during simulated CDI.  
In Chapter 2, a statistical analysis was carried out to assess the effect of treatment 
delay on C. difficile recurrence and symptom duration. Previously it has been shown 
that delays in treatment initiation exist due to obtaining and processing faecal samples 
(233). Symptom duration had no correlation with any of the variables inputted into the 
analysis, including time to treatment. Unsurprisingly, recurrence was significantly 
associated with previous CDI. To the author’s knowledge this is the first-time treatment 
delay has been assessed in relation to rCDI. These data suggest that in mild CDI, 
clinicians need not be overly concerned if delays in initiating treatment occur; there was 
no significant correlation between treatment delay and either of the two outcome 
variables (recurrence and symptom duration). 
In a large proportion of cases diarrhoea was found to have resolved by the time that 
treatment was initiated. It could be the case that the inclusion criteria in this study were 
too liberal, identifying transient episodes of diarrhoea before a positive diagnostic 
sample for CDI was obtained. These transient episodes are unlikely to be CDI, but 
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rather due to comorbidities commonly experienced by patients in the older population.  
In contrast to the findings of other studies, no difference in recurrence rates were 
observed between different treatment arms. In line with earlier data, ribotype 
distribution was varied with no ribotype accounting for a majority of infections (25). The 
original study was not powered for the analysis carried out in this thesis which weakens 
the reliability of any conclusions. More detailed data collection on concomitant 
antibiotics and Charlson scores would be beneficial and increase the reliability of the 
results. Larger studies need to be carried out with greater patient numbers and 
comprehensive data collection to confirm these findings. These results highlight the 
complex aetiology of disease with patient, environmental and microbial factors 
contributing. Reducing delays in treatment initiation is unlikely to significantly decrease 
recurrence rates, but the limitations of this study should be considered; if patients with 
‘transient’ diarrhoea were not included in any future it could affect the risk of 
recurrence.  
In Chapter 3A, the conditions necessary for spore germination were investigated. rCDI 
can be due to germination of persistent spores in the gastrointestinal tract (relapse) or 
by ingestion of spores from the environment (reinfection). This chapter sought to 
investigate the conditions necessary for optimal germination of C. difficile spores in 
vitro, gaining an insight into those necessary in the host and also informing future 
practice in C. difficile experimentation. C. difficile spores were also left for an extended 
period of time in a desiccator to simulate environmental ageing. Superdormant spores 
obtained from the hospital environment may exhibit altered germination characteristics, 
potentially increasing or decreasing the risk of rCDI. Ingested superdormant spores 
may increase the risk of both recrudescent and relapsing disease. In recrudescent 
disease, superdormant spores exhibit an increased rate of germination, producing a 
rapidly proliferative population. Theoretically spore numbers increase, and spores are 
able to adhere to the colonic epithelium (78), increasing the risk of subsequent 
outgrowth and recurrent disease. In the case of relapsing disease, the increased levels 
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of spore numbers will lead to increased environmental decontamination and an 
increased risk of reingestion. 
This study highlights the comparability of CCEY to supplemented BHI in the recovery of 
C. difficile spores. Although a number of media have been previously compared (277, 
281), supplemented BHI is routinely used in C. difficile germination experiments (62, 
261, 272, 282). CCEY has the added advantage of inhibiting other bacterial species. In 
addition, for the first time the inhibitory nature of high concentrations of three amino 
acids on C. difficile spore germination is shown. The high concentrations used in this 
study are unlikely to be achievable in the human gastrointestinal tract. However, the 
paradoxical inhibition of spore germination at high concentrations of glycine, a 
stimulatory ‘co-germinant’ at lower concentrations is of scientific interest. Further 
investigation beyond the current thesis may yield novel insights into the germination 
machinery in C. difficile spores. Further work should assess the nature of the inhibition 
described in this study, using a wider variety of amino acids. Molecular characterisation 
of the inhibition will allow the development of targeted therapeutics  that can arrest the 
growth of planktonic C. difficile.  
After incubation in a homemade desiccator for 6 months, increased germination 
efficiency in broths was observed in all four RTs used. C. difficile spores present in a 
hospital environment due for a prolonged period of time due to poor decontamination 
methods may exhibit a similar alteration in germination characteristics. As suggested 
previously, an increased germination propensity could result in an increased ability to 
proliferate in the gastrointestinal tract if ingested. Further work utilising a wider array of 
strains, time points and conditions would be beneficial in testing this hypothesis. 
Environmentally ageing spores and subsequent observation of behaviour in the 
presence of germinants and colonic human cell lines could be an avenue of exploration 
in the future. Although altered germination characteristics after ambient storage have 
been observed previously, the current study attempted to accelerate this process. A 
wider range of recovery media (solid and liquid) were utilised, thereby eliminating the 
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need for lysozyme.  Lysozyme has only shown efficacy in inducing cell outgrowth when 
small numbers of environmental spores were encountered (275).  
In Chapter 3B, the effects of wet heat on C. difficile spore recovery and germination are 
documented. The direct effect of continuous heat (up to 60 minutes) on spore recovery 
was examined. ‘Heat activation’ has been discussed in the literature, with some 
research failing to find such an effect in C. difficile spores (121, 253, 316, 325). The 
current study documents the transient and persisting effects of heat on the germination 
of C. difficile spores. C. difficile spores have been found in a range of foods, sub-lethal 
heat treatment may lead to their persistence in food (123, 126, 320, 321). Spores 
exhibiting increased germination efficiency in response to heat may germinate more 
efficiently in the gastrointestinal tract, leading to an increased risk of clinical disease, 
contributing to rCDI. In recrudescent disease, the increased spore load produced by a 
more rapidly proliferative population will increase the adherence of spores to the 
colonic epithelium, increasing the risk of recurrent disease. 
RT 027 and RT 078 demonstrated increased resistance to heat at higher temperatures 
(70/80° C). If foodborne C. difficile spores are heated at high temperatures, RT 027 and 
RT 078 spores may be more likely to survive. If food is indeed a significant reservoir for 
C. difficile spores, differences in thermal resistance between clades could allow some 
RTs to survive and proliferate, hence allowing a greater propensity to cause rCDI. In 
particular, RT 078 was able to germinate more efficiently at lower concentrations of 
germinants. In an otherwise healthy individual, RT 078 C. difficile spores could be 
ingested in food. After ingestion, the lower germinant requirements allow the rapid 
germination and outgrowth of RT 078 spores. The high spore number facilitates 
adherence to the colonic epithelium. After successful antimicrobial treatment, spores 
are able to persist in the gastrointestinal tract and increase the risk of recurrent 
infection. 
Heating for 10 minutes before broth incubation allowed the effect of heat on 
germination at various time points to be assessed. Previously heat has been 
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hypothesised to ‘activate’ spores and increase germination (253, 301, 324, 325). In the 
current study heat did not significantly increase the initial rate of germination but did 
produce a larger proliferative vegetative population at 24 hours. C. difficile spores may 
resist the deleterious effects of initial heat treatment and subsequently produce a larger 
bacterial population. Germination rates were also found to be increased in some of the 
strains in ‘old’ spores compared to newly produced spores. The mechanisms behind 
this phenomenon are not clear and require elaboration. These findings reinforce the 
idea that C. difficile spores aged in the environment may exhibit altered germination 
characteristics when reingested. Increased proliferation in the gastrointestinal tract may 
produce increased levels of spores, increasing epithelial adherence in the gut and 
enabling subsequent recurrent infection. Further work should utilise a wider range of 
strains. The clinical effects of differences in germination between spores of different 
ages could be observed in the simulated gut model utilised in this thesis.  
In Chapter 4A, a methodology was devised to separate and concentrate secreted 
proteins from bacterial populations in an in vitro gut model. Proteins were successfully 
concentrated and validated; the majority of proteins were cytosolic, indicating spillage 
of cystolic bacterial cell contents into the solution during processing. The author still 
believes this to be a useful methodology as bead-beating would have led to a higher 
number of cell wall protein identifications in addition to those identified in this study. 
These cell wall proteins would not be reflective of the cytoplasmic proteins important in 
cell metabolism. This is the first time a metaproteomic approach has been adopted in 
the in vitro gut model described (91, 92, 153). In future work, the effect on peptide 
identification of protocols involving bead-beating and/or cell lysis should be compared 
to the methodology presented here. This was not achievable within the current thesis 
due to the high costs associated with mass spectrometry, decreased costs may allow 
this in future. The methodology described was taken forward to investigate the 
overarching metabolic processes and taxonomic shifts in different stages of simulated 
rCDI. 
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In Chapter 4B, the devised methodology was used to assess the effect of antibiotic 
therapy, FMT and unknown spore prep on the taxonomy and functionality of the 
microbiome in simulated infection. Interestingly, even at the zero-time point variations 
in phyla abundance were noted. However, some common trends were observed. The 
relative abundance of Proteobacteria phyla organisms increased in response to both 
clindamycin and vancomycin. The metabolic processes occurring remained relatively 
constant across all time points. During CDI, levels of Firmicutes and Bacteroidetes 
phyla organisms increased. As suggested in Chapter 2, it could be possible that 
vancomycin treatment is actually precipitating recurrence by producing a more severe 
and prolonged dysbiosis. This is strengthened by the fact that both FMT and the 
unknown spore prep prevented recurrence. Although different in composition, both 
FMT and the multiple spore prep increased the levels of Firmicutes and/or 
Bacteroidetes phyla organisms.  
The culture data were largely complementary to the metaproteomics data. In particular, 
antibiotic treatment was associated with reductions in the numbers of Clostridia and 
Bacilli. An increase in the number of lactose-fermenting Enterobacteriaceae was 
observed. In contrast, the FMT treatment was found to increase levels of B. fragilis, 
which has previously been found to prevent CDI in a mice model (437). The unknown 
spore preparation produced increased levels of both Clostridia and Bacteroides 
organisms. C. scindens has been extensively associated with a reduced risk of 
infection (170, 438). The divergent nature of the alterations produced by the FMT and 
spore preparation highlight the multifactorial nature of colonisation resistance. Further 
work should consider the microbiome of the gastrointestinal tract as a functional unit, 
rather than a taxonomic unit. This study provides the first step in utilising such an 
approach in a previously validated in vitro gut model. 
In summary, this thesis approaches the problem of rCDI with a multidimensional 
approach. In all three approaches the complex interplay between different factors in the 
onset of recurrent disease is highlighted. In Chapter 2, host factors and approaches to 
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treatment are investigated. The findings of this chapter should encourage larger 
analyses to assess the effect of treatment delay on recurrence risk.  In Chapter 3, C. 
difficile spores and factors involved in their germination are examined. Food as a 
potential reservoir for C. difficile should be taken seriously; the stimulatory effects of 
heat in aged spores should try to be recreated in other media including food. In 
Chapter 4, the functionality of the microbiome in different stages of simulated infection 
is investigated. The metaproteomic approach utilised in this thesis can be used in 
future gut models. 
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Appendix A 
A.1  Research Study Protocol - Substudy 
 
 
Short Title: Does treatment delay affect symptom duration in CDI? 
 
Full Title: Does delay in treatment initiation have an effect on duration of 
diarrhoea or future recurrence risk in Clostridium difficile infection (CDI)? 
 
Version 1.2. 2/1/2018 
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Study summary: 
 
Introduction: Clostridium difficile infection (CDI) is treated with three antibiotics; 
metronidazole, vancomycin or fidaxomicin. The most commonly reported symptom in 
CDI is diarrhoea (≥3 unformed stools/ day). Delays in treatment initiation can occur for 
a number of reasons. In mild cases of CDI, delays in diagnostic testing can lead to a 
delay in the patient receiving treatment. Although a small number of studies have been 
carried out assessing the reasons for treatment delay, no studies to date have 
assessed the impact of treatment delay on the duration of symptoms in patients, or the 
risk of future recurrence. This study aims to investigate the effect of treatment delay on 
two outcomes; symptom duration and disease recurrence.  
 
Methods: This is a retrospective, non-interventional study performing analyses on data 
already collected as part of a previously ethically approved study (REC reference 
number 14/NW/1398, Clinicaltrials.gov identifier NCT02461901). The primary endpoint 
is the duration of symptoms, measured in days previous to treatment. The secondary 
endpoints are mortality (up to 30 days following treatment initiation) and recurrence of 
infection (up to 28 days after treatment completion). Using the database, Kaplan-Meier 
log-rank tests will be performed and a Cox regression model using the following 
variables will be analysed; patient age; sex, duration of symptoms prior to treatment 
initiation, disease severity score, modified comorbidity score and antimicrobial agents 
used for therapy. The database will be anonymised to the principal investigator by 
removal of patient identifiable information.  
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Introduction: 
Clostridium difficile is a pathogen that causes potentially life-threatening diarrhoea. CDI 
can result in pseudomembranous colitis and subsequent toxic megacolon, a surgical 
emergency that carries a high risk of mortality (10). Varying morality rates have been 
reported for toxic megacolon (38-80%)(10). C. difficile is still a major burden on the 
healthcare system, there were 12,480 cases reported in the UK between April 2016 
and March 2017(24). In addition, a significant proportion of patients (~25%)(55) who 
are successfully treated for an initial episode of CDI will have at least one recurrent 
episode. A small number of patients will suffer from multiple recurrences, leading to 
increased hospitalisation and antibiotic administration.  
 
 The clinical symptoms of CDI  are mediated through the action of secreted bacterial 
toxins (43). Toxins act on the mucosal epithelium of the gastrointestinal tract causing 
oedema, inflammation and diarrhoea, and in severe cases, colonic perforation and 
death (42). Severe dehydration can also lead to hypokalaemia, hypotension and 
metabolic acidosis. We hypothesise that treating CDI at an earlier stage of infection 
could reduce the duration of symptoms, decrease mortality and the risk of recurrence.  
 
Several studies have attempted to outline the reasons for delay in treating patients with 
CDI, but none have looked at the impact this delay might have on patient outcomes 
(137, 232, 233).  
The primary aim of this study is to investigate the effect of treatment delay on duration 
of diarrhoea. The secondary aims are to investigate its impact on recurrence of disease 
and mortality. 
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Hypotheses: 
 
 Delayed treatment initiation results in an increased time to resolution of 
diarrhoea in CDI. 
 Delayed treatment initiation in CDI results in an increased risk of future 
recurrent disease.  
 
 
Study aim and objectives: 
 
Aims: 
 To determine the effect of treatment delay on symptom duration and recurrence 
rates in CDI. 
 
Objectives: 
 To evaluate how time to treatment (in days) impacts on the duration of 
diarrhoea in patients with CDI.  
 To evaluate how time to treatment (in days) impacts on the future risk of 
recurrence in patients with CDI. 
 
Study end points: 
 
Primary endpoint: 
 The duration of symptoms, measured as the time from initiation of therapy to 
resolution of diarrhoea. Resolution of diarrhea was defined as <3 stools per day 
(Bristol stool chart T5-T7). 
 
Secondary endpoints: 
 Mortality (all cause, within the period from initiation of therapy to 30 days 
following therapy). 
 Recurrence of CDI, up to day 28 after completion of treatment (defined as 
recurrence of diarrhoea with further toxin positive stool sample). 
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Study design: 
A retrospective, observational, non-interventional study. 
 
Study locations: 
. Data from the original study (REC reference number 14/NW/1398, Clinicaltrials.gov 
identifier NCT02461901) was generated from the following centres;  
 
Three UK teaching hospital centres:  
 Leeds Teaching Hospitals NHS Trust (LTHT) 
 Bradford Royal Infirmary 
 St George’s Healthcare NHS Trust (SGHT) 
 
The analysis of this data for the current study will be carried out at the University of 
Leeds. 
 
Ethics: 
 
This study will use patient data already generated from a previous study;REC 
reference number 14/NW/1398, Clinicaltrials.gov identifier NCT02461901. The original 
database is pseudonymised, using patient study identifiers, and is under the custody of 
the project coordinator (Mrs Kerrie Davies). All patient identifiable information will be 
removed from the dataset, by Kerrie Davies, before supply for this current study. 
Therefore the dataset for this study will be fully anonymised to the principal 
investigator. Due to the retrospective nature of this study, no additional patient 
recruitment is necessary and no additional patient data will be collected. 
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Patient identification, inclusion and exclusion criteria: 
 
Identification of participants: 
The nature of this study means that no new patient recruitment is necessary; the study 
data have already been generated from the previous study (n = 254).  
 
(The recruitment process of the original study NCT02461901 was; 
Research nurses at each centre used the microbiology laboratory information system 
to identify positive C. difficile toxin results (tested by cell cytotoxin assay) in routine 
stool samples from in-patients at their hospital(s) who were aged ≥ 18 years old.) 
 
Inclusion criteria: 
All participants with a full set of relevant study data from the original study will be 
included (NCT02461901). 
(The inclusion criteria for the original study (NCT02461901) are outlined below; 
 The presence of diarrhoea, defined as three or more episodes of unformed 
stools (Bristol stool type 5-7) in 24 hours at any point in the last 7 days 
 Prescribed CDI-specific treatment (fidaxomicin, oral vancomycin or 
metronidazole)) 
 
Exclusion criteria:  
Nil – there are no exclusion criteria for this study.  
 
(Exclusion criteria for the original study (NCT02461901) were as follows;  
 The patient’s clinical care team believes it would be inappropriate to include him or 
her, e.g. to avoid disturbing a terminally ill patient 
 In a patient on vancomycin or metronidazole, treatment with fidaxomicin within the 
previous 3 months (given evidence that fidaxomicin may persist in the gut after 
treatment (248) 
 In a patient on fidaxomicin, treatment with greater than 24 hours of metronidazole 
or vancomycin immediately prior to starting fidaxomicin 
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 In the skin swab and faecal sample sub-study, patients unable/unwilling to give 
informed consent and with no opportunity to obtain consultee approval 
In the skin swab and faecal sample sub-study, patients who are non-English 
speakers (unless a member of hospital staff is available to act as a translator) 
 
Patient recruitment and consent: 
Details of the patient recruitment in the original study can be found in the adjoined 
protocol for the original study NCT0246190 (Appendix A). 
No additional recruitment or consent is planned for the present study, which is justified 
in the following section. At the time of recruitment, patients did not consent for their 
data to be used within the remits of the current study. As it would not be practicable for 
retrospective consent to be taken for the purposes of the current study, and the 
Declaration of Helsinki (statement 32) states that ethical approval may be considered in 
"exceptional situations where consent would be impossible or impracticable to obtain 
for such research", we hope to be able to undertake this additional analysis without 
additional consent. Additionally, this study does not require the generation of any new 
data and poses no significant risk of harm to patients who were part of the original 
study.  
 
Patient withdrawal from the study:  
All patient data generated from the original study will be included in answering the 
central research questions in this study. Patients will therefore be unable to withdraw. 
In the original study (NCT02461901) for patients who withdrew for any reason, data 
collected up to the point of withdrawal was included in the final analysis.If an enrolled 
patient was switched from either metronidazole or vancomycinto fidaxomicin, after 
receiving more than 24 hours of either metronidazole or vancomycin he/she was 
withdrawn from the study, but data collected to that point was be included in the 
analysis. Enrolled patients who received any fidaxomicin before being switched to 
metronidazole or vancomycin, were excluded. Patients who were switched between 
metronidazole and vancomycin, or simultaneous prescribed both agents, remained in 
the study.  
 
Sample size calculation:  
The sample size is opportunistic, based on the number of patients recruited to the 
original study NCT0246190. A post-hoc analysis will be undertaken to determine the 
242 
 
 
statistical power of the estimates. It is not possible to interrogate the data before ethical 
approval is obtained, but a guide to the power for statistical analysis is guided by the 
following consideration.  The patients might be split by delay into two groups: those 
treated within 3 days and those with a delay of more than 3 days.  We anticipate 
around 76 patient (30%) in the first group and 178 in the second. The duration of 
symptoms will have a skewed distribution which might be transformed to normality 
(perhaps a log transformation).  In that case the sample size of 76 + 178 provides 80% 
power to detect a standardised difference of 0.386 and 90% power a difference of 
0.446.  The power will be reduced a little by adjustment for confounders but increase 
by the use of survival analysis which can take the treatment delay to be a continuous 
variable.  Overall therefore we anticipate that this study should have sufficient power to 
provide robust clinical findings for appropriate effect sizes.  
 
Study duration: 
The study will be carried out over the remaining duration of the principal investigator’s 
Doctor of Philosophy degree (1/12/2017 - 01/10/2019).  
 
Data collection: 
No additional data collection will be carried out in this study. Statistical analysis will be 
carried out on an already existing database from a previous ethically approved study 
NCT02461901. The original database is pseudonymised, using patient study 
identifiers, and is under the custody of the project coordinator (Mrs Kerrie Davies). All 
patient identifiable information has been removed from the dataset, by Kerrie Davies, 
before supply for this current study. The principal investigator does not have access to 
the link-back information tying a patient to their study identifier. The data will therefore 
be anonymised to the principal investigator.  
 
Data storage and transfer: 
 
Patient confidentiality will be preserved throughout the study; the database from the 
original study will be anonymised to the principal investigator. There will be no way for 
the principal investigator to access any patient information in the original database. The 
anonymised database will be kept on a secure password protected server at the 
University of Leeds. Data will be transferred to the statistician for analysis on an 
encrypted USB memory stick. 
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Data generated for the present study will be stored for the remaining duration of the 
principal investigator’s Doctor of Philosophy degree (1/10/2019). After this date data 
will no longer be available to the principal investigator.  
 
 
Statistical analysis: 
 
A survival analysis will be used to measure the effect of duration of symptoms prior to 
initiation of therapy (days) on duration of symptoms, mortality and relapse. Analyses to 
be included are Kaplan-Meier with log-rank tests and either a Cox regression model 
(should a proportional hazards assumption be valid) or an accelerated time model.  The 
following potentially confounding variables will be included in the model;   age, sex, CDI 
severity score, comorbidity score, treatment arm (vancomycin/metronidazole or 
fidaxomicin) and site. 
 
Project Management:  
Mr Daniel Pickering will be the Principal investigator for the study. Throughout this study 
he will be under the supervision of Professor Mark Wilcox, Mrs Kerrie Davies and Dr 
Jonathan Sandoe, all of whom have previously been involved in managing numerous, 
large national and international research studies. 
 
Reporting/Publication: 
 
The study results will be submitted for publication as oral or poster presentations at 
international conferences of microbiology/infectious diseases and then in peer 
reviewed scientific journals.  
 
 
Finance: 
 
The project is being funded by the University of Leeds as part of a PhD degree.  
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The original study was funded by Astellas Pharma Europe Ltd; permission has been 
granted for the data to be used for the purposes of the current study. 
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A.2 Research Study Protocol – Original Study 
 
 
Short Title: Does fidaxomicin therapy reduce spread of Clostridium difficile? 
 
Full Title: Does using fidaxomicinto treat Clostridium difficile infection (CDI) 
reduce the recovery of C. difficile from patients’ faeces, skin and their immediate 
environment, compared to treatment with vancomycin or metronidazole? 
 
Version 10.4, 26/09/2017 
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Study Personnel: 
 
Chief Investigator (and Principle Investigator at Leeds Teaching Hospitals NHS 
Trust) 
 
Professor Mark Wilcox 
Consultant/Clinical Lead for Microbiology (Leeds Teaching Hospitals NHS Trust) 
Professor of Medical Microbiology (University of Leeds) 
Lead on C. difficile infection (Public Health England) 
Department of Microbiology 
Old Medical School 
Thoresby Place 
Leeds, LS1 3EX 
Tel: 0113 3926818 
E-mail: mark.wilcox@nhs.net 
 
Principle Investigator (St George’s Healthcare NHS Trust): 
 
Dr Timothy Planche 
Senior Lecturer and Honorary Consultant/Clinical Lead for Medical Microbiology 
Department of Microbiology 
St George’s Healthcare NHS Trust 
Blackshaw Road 
Tooting 
London, SW17 0QT 
Tel: 020 8725 2683 
E-mail: tplanche@sgul.ac.uk 
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Principle Investigator (Bradford Teaching Hospitals NHS Foundation Trust): 
 
Dr Phil Stanley 
Consultant in Infectious Diseases, Director of Infection Prevention and Control 
Bradford Royal Infirmary, 
Duckworth Lane, 
Bradford, BD9 6RJ 
Tel: 01274 364049 
E-mail: philip.stanley@bthft.nhs.uk 
 
Principle Investigator (Guy’s and St Thomas’ NHS Foundation Trust): 
 
Dr Simon Goldenberg 
Consultant Medical Microbiologist  
Honorary Senior Lecturer (King’s College London) 
St Thomas’ Hospital 
Westminster Bridge Road 
London, SE1 7EH 
Tel: 020 7188 3152 
Email: simon.goldenberg@gstt.nhs.uk 
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Co-investigator (Leeds Teaching Hospitals NHS Trust): 
 
Dr Jonathan Sandoe 
Consultant Medical Microbiologist 
Associate Professor of Medical Microbiology (University of Leeds) 
Department of Microbiology 
Old Medical School 
Thoresby Place 
Leeds, LS1 3EX  
Tel: 0113 3922893 
E-mail: jonathan.sandoe@nhs.net 
 
Study Co-ordinator (until 31/08/2016): 
Dr Damian Mawer 
Research Fellow 
Department of Microbiology 
Old Medical School 
Thoresby Place 
Leeds, LS1 3EX 
Tel: 0113 3926818 
E-mail: damian.mawer@nhs.net 
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Study Co-ordinator (from 01/09/2016): 
 
Mrs Kerrie Davies 
Clinical Scientist 
Visiting Research Fellow (University of Leeds) 
Department of Microbiology 
Old Medical School 
Thoresby Place 
Leeds, LS1 3EX 
Tel: 0113 3928663 
E-mail: kerrie.davies@nhs.net 
 
Statisticians: 
 
Dr Sarah Walker 
Oxford Biomedical Research Centre 
Microbiology, Level 6 
John Radcliffe Hospital 
Headley Way 
Oxford, OX3 9DU 
Tel: 01865 851180 
Email: sarah.walker@ndm.ox.ac.uk 
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Study summary: 
 
Introduction: Current infection control measures for Clostridium difficile infection (CDI) 
focus on the isolation of symptomatic patients, along with environmental 
decontamination, to prevent secondary cases through the ingestion of spores by 
vulnerable individuals. Despite these efforts, onward transmission is still seen. Clinical 
and in vitro studies have shown that fidaxomicin produces a greater and more 
prolonged reduction in C. difficile spore counts, in the faeces of patients with CDI, than 
vancomycin. This study aims to investigate whether there is also a difference in 
contamination of the surrounding environment and on the skin of CDI patients treated 
with fidaxomicin compared to vancomycin or metronidazole, as this could influence the 
risk of onward transmission. 
 
Methods: This is a prospective, observational study to be carried out in two teaching 
hospital NHS trusts. The co-primary endpoints are the presence of environmental and 
skin contamination with C. difficile spores during and following treatment for CDI. 
Secondary endpoints are C. difficile spore counts in patient faeces and absolute spore 
counts from skin swabs. As no consent is required for environmental screening, all 
hospital patients with CDI (aged ≥16) during the study period will have swabs of their 
environment taken following diagnosis, every 2-3 days during treatment, at the end of 
treatment and on days 7, 14 and 28 post treatment. To achieve appropriate statistical 
power, informed consent (or consultee approval in those lacking capacity) needs to be 
obtained from 100 hospital patients with CDI (comprising 40 receiving fidaxomicin and 
60 receiving vancomycin or metronidazole) for skin swab and faecal sampling across 
the two study centres. Skin swabbing will take place at the same time as environmental 
sampling; stool samples will be collected as close as possible to these dates. All 
sampling will cease early if the patient is discharged. Data on relevant demographic 
factors, comorbidities and clinical markers of severe CDI will be collected from medical 
records.  
 
The flow-diagram in Appendix 1 further outlines the study method.
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Introduction: 
 
Clostridium difficile is a spore forming Gram positive bacillus. Its spores are resistant to 
many disinfectants and can survive for prolonged periods in the environment 1. It is 
estimated that patients with C. difficile infection (CDI) excrete between 1x104 and 1x107 
of C. difficile per gram of faeces 2. Numerous studies have shown that the environment 
around CDI cases is frequently contaminated with spores 3-5, in part due to 
aerosolisation of the organism during each episode of diarrhoea 6. This contamination 
may be sustained by the fact that patients often continue to shed spores for a 
considerable time, even after their symptoms have resolved 7. It is contact with these 
spores in the environment that is the likely source for secondary cases of CDI in 
hospital settings 8. For these reasons, prompt isolation of symptomatic cases and 
adequate environmental decontamination are two central recommendations for 
preventing onward transmission of C. difficile 9,10. 
 
In 2011/12, the American and European regulatory authorities approved the use of a 
novel macrocyclic antibiotic, fidaxomicin, for the treatment of CDI 11,12. This followed the 
publication of two large, phase 3 clinical trials, which showed that fidaxomicin was non-
inferior to vancomycin in the initial clinical cure of CDI 13,14. Of note, there were 
significantly fewer recurrences among patients receiving fidaxomicin (26% for 
vancomycin vs 14% for fidaxomicin). This is an important finding as treatment with 
metronidazole or vancomycin is associated with a recurrence rate of approximately 
20% 15. 
 
The mechanism by which fidaxomicin prevents recurrences of CDI is unclear, but could 
be related to one or more of the following. In vitro, fidaxomicin has been shown to 
inhibit the outgrowth of C. difficile spores, possibly due to its ability to adhere to the 
spore coat 16. In an artificial gut model of CDI, fidaxomicin achieved an intraluminal 
concentration that was well above the minimum inhibitory concentration for C. difficile 
and these levels were sustained for at least three weeks after it is instilled, perhaps due 
to sequestration within biofilms 12. In a Phase II clinical study, fidaxomicin treated 
patients had a significantly lower mean spore count at day 11-18 post treatment, 
compared to those who had received vancomycin  (3.1 log10 CFU/g of faeces versus 
5.4 log10 CFU/g, respectively) 17. This study also showed that the drug is relatively 
sparing of other gut microflora 17. 
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Given that fidaxomicin reduces spore counts in the faeces of treated patients and 
inhibits spore outgrowth, it can be postulated that there may be less contamination with 
C. difficile on the skin of patients and in the surrounding environment, both during 
treatment and in the period immediately afterwards, when patients often continue to 
shed spores. If it is the case, treatment with fidaxomicin may help reduce onward 
transmission of C. difficile to other patients.  
 
Hypotheses: 
 
1. Treatment of CDI with fidaxomicin results in lower rates of recovery of C. 
difficile from patient’s faeces, skin and the immediate environment, compared to 
treatment with either vancomycin or metronidazole. 
 
 
Study aim and objectives: 
 
Aims: 
 To determine if there is a difference in C. difficile shedding and contamination of 
the skin and immediate environment, between CDI patients treated with 
fidaxomicin and those treated with either vancomycin or metronidazole.  
 
Objectives: 
 To measure rates of contamination with C .difficile spores in the immediate 
environment around CDI patients, both during and after treatment with 
fidaxomicin, vancomycin or metronidazole. 
 To measure rates and absolute levels of contamination with C. difficile spores 
on the skin of CDI patients both during and after treatment with fidaxomicin, 
vancomycin or metronidazole. 
 To measure the concentration of C. difficile spores in the faeces of CDI patients 
both  during and after treatment with fidaxomicin, vancomycin or metronidazole 
 To measure the concentration of fidaxomicin, vancomycin and metronidazole in 
faecal samples during and after treatment 
 For all of these parameters, to investigate how they change with time during 
and after CDI treatment 
253 
 
 
 
Study end points: 
 
Co-Primary endpoints: 
 The presence of environmental contamination with C. difficile spores during and 
following treatment with fidaxomicin, vancomycin or metronidazole.  
 The presence of skin contamination with C. difficile spores during and following 
treatment with fidaxomicin, vancomycin or metronidazole. 
 
Secondary endpoints: 
 C.difficile spore counts in the faeces of CDI patients before, during and after 
treatment with fidaxomicin, vancomycin or metronidazole. 
 Total C. difficile spore counts from skin swab samples during and following 
treatment with fidaxomicin, vancomycin or metronidazole. 
 
Study design: 
 
A prospective, observational study. 
 
Study locations: 
 
Two UK teaching hospital centres:  
 Leeds Teaching Hospitals NHS Trust (LTHT) 
 St George’s Healthcare NHS Trust (SGHT) 
 
Study blinding: 
 
Laboratory staff will be blinded to the CDI-specific drug treatment that each patient is 
on. 
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Patient identification, inclusion and exclusion criteria: 
 
Identification of potential subjects: 
Research nurses at each centre will use the microbiology laboratory information 
system to identify positive C. difficile toxin results (tested by cell cytotoxin assay) in 
routine stool samples from in-patients at their hospital(s) who are aged ≥ 18 years old. 
 
Inclusion criteria: 
Study staff will then confirm (using medical records) if the patient meets the criteria for 
inclusion in the study. These are:  
 The presence of diarrhoea, defined as three or more episodes of unformed 
stools (Bristol stool type 5-7) in 24 hours at any point in the last 7 days 
 Prescribed CDI-specific treatment (fidaxomicin, oral vancomycin or 
metronidazole) 
Exclusion criteria:  
 The patient’s clinical care team believes it would be inappropriate to include him or 
her, e.g. to avoid disturbing a terminally ill patient 
 In a patient on vancomycin or metronidazole, treatment with fidaxomicin within the 
previous 3 months (given evidence that fidaxomicin may persist in the gut after 
treatment 16) 
 In a patient on fidaxomicin, treatment with greater than 24 hours of metronidazole 
or vancomycin immediately prior to starting fidaxomicin 
 In the skin swab and faecal sample sub-study, patients unable/unwilling to give 
informed consent and with no opportunity to obtain consultee approval 
 In the skin swab and faecal sample sub-study, patients who are non-English 
speakers (unless a member of hospital staff is available to act as a translator) 
 
Patient recruitment and consent: 
 
In keeping with other environmental studies informed consent will not be obtained for 
sampling of the hospital environment around treated-CDI cases and the collection of a 
limited amount of associated patient information 18. All patients who meet the inclusion 
criteria will therefore be included in this aspect of the study. Patient-identifiable records 
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will only be accessed by a member of the patient’s care team (a research nurse or 
doctor working for the Microbiology department, which provide diagnostic services). In 
addition data will be anonymised before analysis and the study will have no influence 
on patient care.  
 
Skin swabbing and additional stool sampling represent interventions not usually 
performed on CDI cases. Informed consent will therefore be sought from all CDI 
patients for these interventions and the collection of related patient-identifiable data. 
Each patient who meets the inclusion criteria will be approached by a research nurse 
or doctor within 24 hours of the diagnosis (extending up to 72 hours if the diagnosis is 
made at the weekend). During the initial visit, the research nurse or doctor will explain 
of all aspects of the study, including the consent process, and provide a patient 
information leaflet (PIL). The PIL will also describe the study, what the patient is being 
asked to provide consent for, and how he/she can communicate again with the study 
team.  The information provided about the study will include its aims, methods, funding, 
anticipated benefits, withdrawing from the study and the potential negative 
consequences of involvement (e.g. inconvenience of having stool and skin swab 
sampling). It will be made clear that the study will not influence care and that 
environmental swabbing will not require consent. Non-English speaking patients will be 
included only if a member of staff is available to act as a translator.  
 
The first set of environmental swabs will also be taken during the initial visit. 
Patients will not be asked to give consent at the first visit. Unless they have declined to 
be involved the research nurse or doctor will return, at the earliest the following day, to 
answer any questions that the patient has and to obtain their consent, if given. Patients 
will still be included if they consent to either skin swabbing or faecal sample collection, 
but not both. 
 
The research nurses and doctor will be trained in Good Clinical Practice and the 
assessment of mental capacity In line with the Mental Capacity Act (2005) all patients 
will be assumed to have capacity to consent for the study, unless there is evidence that 
they do not. Assessment of capacity will be done primarily by direct discussion with the 
patient. If needed, the research doctor or nurse will also discuss the issue with the 
clinical team and review the medical notes for relevant factors. 
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Inclusion of Incapacitated Adults: 
Advanced age is a well-recognised risk factor for CDI, which therefore 
disproportionately affects the elderly, particularly those in hospital 19. In this group, 
delirium causing mental incapacity (due to acute illness or underlying chronic disease), 
occurs in 14-56% 20. To exclude those patients who lack capacity to provide informed 
consent, from a study aiming to improve the management of CDI, would threaten the 
validity of the results and their applicability to patient care more generally. Furthermore, 
this study involves neither invasive tests nor risk to the patient. The planned 
interventions (skin swabbing and stool sample collection) should cause minimal 
inconvenience. Therefore patients who lack mental capacity (as defined by the Mental 
Capacity Act 2005) should be included if consultee approval can be obtained.  
 
Having identified that a patient lacks capacity, the research nurse or doctor will 
approach any relative or friend who is visiting at that time. If there is no one present, 
they will make three attempts to contact, by telephone, the relatives/close friends 
whose details are on the hospital next of kin form. If the relative/close friend, when 
contacted, declines to act as a personal consultee he/she will be asked to suggest 
another individual who might be willing to take on the responsibility. 
 
If a relative/close friend agrees to act as a personal consultee, the research team 
member will arrange a time to meet in person, preferably the same day. At that meeting 
they will explain the role and responsibility of a personal consultee, discuss the study 
and go through the written information, including the form that personal consultees 
need to sign. If the relative or friend does not attend, the research team member will 
attempt to meet him/her on up to two further occasions. 
 
If no personal consultee is available, or it has not been possible to meet with a potential 
consultee, by the start of day 3 of a patient’s CDI treatment a nominated consultee will 
be approached. This is to ensure that a skin swab set can be taken within the first 3 
days of treatment, as per the schedule outlined below (pages17-18), For this study the 
consultant in charge of the patient’s care will be approached to act as a nominated 
consultee, as he/she will have no connection with the project. He/she will be sent a 
copy of the protocol and PIL by email, and will then meet with a member of the 
research team to go through consultee form if he/she is satisfied that it is appropriate 
for the patient to participate in the study.  
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Whenever possible conversations regarding consultee approval will take place in the 
presence of the patient, to ensure he/she is involved in the process and does not 
actively decline to participate in the study. 
 
As capacity can fluctuate it will be reassessed by the research nurse or doctor at each 
study visit. If a subject who initially lacked mental capacity regains it during the study, 
he/she will be informed of the study and their involvement though consultee approval. 
He/she will be asked to give informed consent if he/she wants to remain in the trial. If 
he/she wishes to withdraw from the trial, no further trial related procedures will be 
performed, but data to that point will be used in analysis. Data from any patient who 
dies before regaining capacity (but for whom there was consultee approval for 
involvement) will be included in analysis.  
 
If a patient looses capacity during the study consultee approval will be sought for their 
continued involvement, following the process outlined above. 
 
Original consent and consultee approval forms will be held by the research team. 
Copies will be given to the patient/consultee and also filed in the patient’s notes, along 
with a PIL so that the clinical team can contact the research team if needed. 
  
Patient withdrawal from the study:  
 
Any patient (or consultee for those who lack capacity) will be free to refuse participation 
in all or any part of the trial, at any time and for any reason, without affecting their 
treatment. However, if a patient decides to withdraw from the study, data collected up 
to the point of withdrawal from the study will be included in the final analysis. This will 
be made clear during the initial visit by the research nurse and in the PIL. 
 
All sampling and data collection will cease if the patient is discharged from hospital or 
dies before the end of their planned involvement in the study. Data collected up to the 
point of discharge will be included in the analysis. 
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If an enrolled patient is switched from either metronidazole or vancomycinto 
fidaxomicin, after receiving more than 24 hours of either metronidazole or vancomycin 
he/she will be withdrawn from the study, but data collected to that point will be included 
in the analysis. Enrolled patients who have received any fidaxomicin before being 
switched to metronidazole or vancomycin, will be excluded. Patients who are switched 
between metronidazole and vancomycin, or simultaneous prescribed both agents, will 
remain in the study.  
 
Sample size calculation: 
 
Primary endpoints: 
The co-primary endpoints of the study are skin and environmental contamination. 
These two outcomes have been chosen as they are considered of equal importance in 
this study. Whilst it could be argued that there might be a relationship between patient 
skin contamination and subsequent environmental contamination, each of the two 
outcomes is likely to be sufficiently influenced by different variables to allow them to be 
considered independent from one another. For example, only environmental 
contamination will be affected by different surface materials, cleaning products and 
procedures, and by C. difficile spore contamination by different patients (who may have 
contaminated the ward before the study period, given the ability of spores to persist 
long term). As these outcomes are being considered independent from each other, no 
adjustment to the alpha value has been made when performing power calculations. 
 
For skin contamination, assuming patients contribute 4 samples at approximate 2-3 
day intervals through to the end of treatment, and that with metronidazole/vancomycin, 
the proportions with recoverable C. difficile are approximately 90%, 75%, 60% and 
45% following Sethi et al 7, then including a total of 60 patients treated with 
vancomycin/metronidazole and 40 patients treated with fidaxomicin (approximate 
anticipated ratio) would provide >80% power to detect a 50% faster decline in 
colonisation (OR(fidaxomicin vs vancomycin/metronidazole)=0.5; two-sided 
alpha=0.05), assuming 5% and 10% drop-out at the third and fourth time points 
respectively. Recruitment would continue until at least 40 fidaxomicin patients have 
been included, or until a total of 100 patients have been included, whichever occurs 
first, in order to ensure that a reasonable number with fidaxomicin are included whilst 
retaining sufficient power. 
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Summary data as of June 2016 indicate that the proportion of enrolled patients 
receiving fidaxomicin is 32% rather than 40% as anticipated, and further that missing 
samples are more common (percentage with the first four samples is approximately 
35%, 70%, 70% and 60%, vs predicted 100%, 100%, 95%, 90%; a much larger 
proportion than expected are missing their baseline sample in particular). To retain the 
same power to detect the same difference in decline in colonisation above, using these 
revised proportions receiving fidaxomicin and providing samples, requires the sample 
size to be increased to 120 patients, of whom at least 38 would be expected to be 
receiving fidaxomicin.  
 
The environment of all CDI cases during the study period will be sampled. It is 
anticipated that 50% of patients will consent to skin and stool sampling. Therefore, if 
the study aims to recruit at least 100 patients to this latter group, environmental 
samples will be obtained from a total of at least 200 CDI cases overall. This number will 
provide >80% power to detect a 33% faster decline in environmental contamination 
(OR (fidaxomicin vs vancomycin/metronidazole) =0.67; two-sided alpha=0.05).  
 
Secondary endpoints: 
Skin contamination is a binary outcome variable, and therefore power to detect 
differences between fidaxomicin and vancomycin/metronidazole would be expected to 
be higher for the continuous secondary outcomes of skin and faecal spore counts.  
 
Study duration: 
 
From April to September 2014 there were approximately 140 cases of CDI in patients 
aged ≥ 18 years old across the two hospital trusts involved in the study. We estimate 
that 10% of these patients meet the exclusion criteria,10% do not receive treatment, 
and that CDI rates may be falling by up to 20% annually. Making these allowances we 
anticipate approximately 170 patients will be recruited into the environmental sampling 
arm of the study in 12 months. If 50% of these patients consent to skin swabbing and 
faecal sample collection we estimate that it will take approximately 15 months to recruit 
the 100 patients required in this arm of the study.  
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At the beginning of March 2016 a decision was made to extend study recruitment until 
the end of December 2016 on the basis of both slower than anticipated recruitment to 
the environmental sampling arm and only approximately 1/3 of these patients 
consenting to skin swabbing and faecal sample collection. A timeline for the study can 
be found in Appendix 2. 
 
Data collection: 
 
The following patient data will be collected by a research nurse or doctor using 
standardised case report forms (CRF), one for patient identifiable information and one 
for clinical data. It will be obtained from medical and nursing records, the microbiology 
laboratory information system, discussion with the patient and his or her 
nursing/medical team. The clinical data CRF will be updated at each patient visit. 
 
1. Patient demographics: 
a. Name 
b. Date of birth (as a second identifier; only age, which is not considered 
identifiable, will be used in the analysis) 
c. Sex 
d. Dates of admission and discharge 
e. Specialty (at time of diagnosis and any subsequent changes) 
f. Ward (at time of diagnosis and any subsequent moves) 
2. Patient medical history: 
a. Number and dates of previous episodes of CDI 
b. History of any gastrointestinal disease 
c. History of immunosuppression (defined as the presence of one or more 
of the following: acquired immune deficiency syndrome (AIDS), solid 
organ or haematopoietic stem cell transplant, neutropenia, 
immunosuppressive drug or systemic corticosteroid for >1 month, 
corticosteroid >10mg or cytotoxic chemotherapy in the last 2 months) 
d. Presence of faecal incontinence (during CDI episode) 
3. Patient medication (during CDI episode): 
a. Antimicrobials 
b. Chemotherapy  
c. Peristaltic agents 
d. Enteral feeding 
261 
 
 
e. Laxatives 
f. Proton pump inhibitors 
4. CDI episode: 
a. Duration of diarrhoea (days) 
b. Daily frequency of diarrhoea 
c. Antimicrobial treatment (drug, dose and duration) 
d. CDI severity markers at onset of episode (as defined by Department of 
Health criteria 21) : 
i. temperature above 38.5 (within 48 hours before/after diagnosis)  
ii. clinical or radiological evidence of colitis or toxic megacolon 
(clinical = abdominal pain/tenderness/distension or absent bowel 
sounds; radiological = imaging report by consultant radiologist 
documenting colitis/toxic megacolon) 
iii. total white cell count (x109/L; within 48 hours before/after 
diagnosis, if available) 
iv. serum creatinine (µmol/L; within 48 hours before/after diagnosis, 
if available) 
Note no additional diagnostic tests will be done as a part of this protocol. 
The results of tests done for clinical purposes will be recorded.  
e. Recurrence of CDI (up to day 28 after completion of treatment; defined 
as recurrence of diarrhoea with further toxin positive stool sample) 
5. Diagnostic stool sampling: 
a. Date of collection of C. difficile toxin positive stool collection 
b. Date of C. difficile toxin positive stool result 
c. Results of any other investigations performed on the stool sample 
6. In environmental study: 
a. Ward hygiene (decontamination practice for CDI cases (cleaning 
frequency, disinfectant used), time between cleaning and sample 
collection) 
b. Presence of CDI outbreak on the ward 
c. Environmental sampling (sites sampled and day (of CDI episode) 
sampling performed) 
7. In skin swab and stool sample study: 
a. Stool sampling (collection date(s) of further stool samples and Bristol 
stool type) 
b. Patient skin sampling (sites sampled and day (of CDI episode) sampling 
performed)  
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c. Patient bathing (time between bathing and skin sampling in hours) 
d. Patient hand washing (time between hand washing and hand swabbing 
in hours) 
 
Data storage and transfer: 
 
Patient confidentiality will be preserved throughout the study. Each patient will be 
assigned a unique study number at enrolment to allow data to be anonymised. The 
only staff members who will have access to the data before it is anonymised are the 
research nurses and doctors, who are NHS employees and part of the direct care 
team.  
 
One CRF will be used to collect patient-identifiable data. This will also link participants 
to their unique study number. The number will be the only identifier used on a separate 
CRF for collecting clinical data, on the electronic database, on study samples and in 
the analysis of results.  
 
Consent and consultee approval forms will be kept with CRFs in a locked cabinet in 
secure offices of the Microbiology Department at each study site. Electronic data held 
at each study site will be kept on a password-protected database that will be hosted on 
encrypted servers within the NHS firewall. It will be backed up daily. 
 
Patient identifiable data will be kept for 6-12 months after the study ends. All other 
study data will be kept for 10 years. The end of the study is defined as the date of 
collection of the last sample set from the final patient recruited. 
 
Data transfer between study sites will be required for analysis. Only anonymised data 
will be transferred via password protected, secure email accounts. These will be 
accessed from computers that are within the NHS firewall, thus ensuring that the data 
remains encrypted during transfer.  
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Environmental sampling (all patients): 
 
Environmental sampling will be performed before treatment (if feasible, or a soon as 
possible after it has started)  then every 2-3 days during treatment. Samples will also 
be collected on the day treatment ends, and at days 7± 3 days, 14± 3 days and 28± 5 
days thereafter. Sampling will not continue if a patient dies or leaves hospital before 
their study participation is due to end.  
 
Samples will be obtained by a research nurse or doctor using a flocked swab (Copan, 
Brescia, Italy) moistened with sterile water. The researcher will wear sterile gloves 
whilst doing the sampling. Used swabs will be labelled with the patient’s study number, 
sample site and date, and then transported to the laboratory. 
 
Environmental surfaces to be tested are as follows: 
 
 Bed rail 
 Bedside table 
 Call bell 
 Commode/toilet seat 
 Floor area (parallel to right hand bed edge at level of the bottom wheel) 
 
A  5 x 20cm2 area of flat surfaces will be measured out and swabbed, whilst the entire 
surface of the call bell will be included. A 13.3cm length of the bed rail will be measured 
and the entire surface area swabbed. All study team members who collect 
environmental swabs will receive training to ensure sampling is standardised. 
In the laboratory, samples will be culture to detect the presence of C. difficile spores. 
Isolates will then undergo ribotyping (see laboratory manual v3.0, 28/1/15).  
 
Skin sampling (consented patients):  
 
Patient’s skin surfaces will be sampled on the same days as their environment (see 
above). Sampling will be done by a research nurse or doctor wearing gloves (which will 
be changed between sampling each site). The areas to be included are 7:  
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 Groin (right hand side) 
 Lower abdomen (defined as the area directly below the umbilicus) 
 Dominant hand 
 
Sites will be sampled using a flocked swab (pre-moistened with 1ml sterile water).  A 5 
x 20cm2 area of the groin and abdomen will be sampled (marked out using a template), 
whilst the whole of the patient’s dominant hand will be swabbed. Used swabs will be 
transported to the lab in a sterile container labelled with the patient’s study number. All 
study team members who collect skin samples will receive training to ensure sampling 
is standardised. In the laboratory samples will be culture for C. difficile spores (both 
their presence and absolute number) and isolates will be ribotyped. Detailed 
information can be found in the laboratory manual v3.0, 28/1/15. 
 
Faecal sampling (consented patients): 
 
The initial stool sample with a positive test for C. difficile toxin will be cultured to provide 
pre-treatment spore levels. Further stool samples will then be collected every 2-3 days 
during treatment, at the end of treatment, and at 7 ± 3 days, 14 ± 3 days and 28 ± 5 
days after treatment has been completed. To preserve their dignity, patients who can 
toilet independently will be asked if they wish to collect the sample themselves. Those 
who decline to collect their own samples or who require assistance with toileting will 
have them collected by ward nursing staff. All samples will be submitted to the 
microbiology laboratory using a study-specific collection pot and proforma. Research 
nurses will ensure there is a supply of these on the ward, pre-labelled with the patient’s 
study number, and will remind patients/nursing staff on days when samples are to be 
collected.  
 
In the laboratory faecal samples will be processed to measure the concentration of C. 
difficile spores they contain. In consenting patients who are not taking other 
antimicrobials they will also be processed for the concentration of fidaxomicin, 
vancomycin or metronidazole. Detailed information can be found in the laboratory 
manual v3.0, 28/1/15. 
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The initial stool sample with a positive test for C. difficile toxin will also be required from 
patients in the environmental arm of the study. A portion of this sample will be cultured 
for C. difficile which will then undergo ribotyping and, if necessary, multiple locus 
variable number tandem repeat (MLVA) analysis, to allow comparison with any C. 
difficile isolates obtained from the patient’s environment. Consent will not be requested 
for using the samples as these typing methods form part of standard Infection Control 
practice in hospitals for controlling CDI. Members of the research team will use limited 
personal data in order to identify the stool samples in the microbiology laboratory. 
Those accessing this data and the samples will be employees of the microbiology 
department and therefore members of the clinical care team providing diagnostic 
services to the patinet. 
 
Sample storage: 
 
Anonymised environmental and skin swab samples will be stored at 5oC until testing. A 
portion of the faecal sample will be frozen at -20oC within 2 hours of receipt for 
antibiotic concentration testing. The remainder will be stored at 5oC. Refrigerators and 
freezers will be located within the Departments of Microbiology at Leeds General 
Infirmary and St George’s Hospital. In accordance with the Human Tissue Act 2004 
these samples will be destroyed at the end of the study. C. difficile isolates will be 
stored at -20oC in nutrient broth with 10% glycerol. 
 
Statistical analysis: 
 
For comparisons between treatment with fidaxomicin or vancomycin/metronidazole, 
any patient who does not receive one of the antibiotics for at least 48 hours will be 
excluded from the final analysis. 
In patients receiving fidaxomicin/vancomycin/metronidazole for >=48 h, the following 
outcomes will be compared between fidaxomicin and vancomycin/metronidazole 
treatment groups over time: 
 
 Percentage of skin samples that are positive for C. difficile spores 
 Percentage of environmental samples that are positive for C. difficile spores 
 C. difficile total spore counts in skin samples 
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 C. difficile spore counts in faecal samples 
 
All total spore counts will be log10 transformed for normality. For each outcome, means 
(+/- standard error of the mean) or percentages (+/- 95% confidence intervals) as 
relevant will be calculated in each group at each time point (based on observed values) 
and plotted to describe the impact of time. The treatment groups will be compared 
using methods which adjust for the repeated measures nature of the data. The primary 
analysis will use generalised estimating equations (binomial response, logit link, 
independent correlation structure) and will include a categorical factor to test for 
differences at each time point through to the end of treatment, based on a global test of 
difference. This test does not make any assumptions about the relationship between 
time and each outcome in each treatment group, and, for example, can accommodate 
a small difference which widens and then narrows again, or a simple difference in rate 
of change over time. If the global test for difference reaches statistical significance 
(p<0.05), then pairwise tests comparing treatment groups will be conducted at each 
time point to quantify the duration of differences in contamination rates between 
groups. If the descriptive analysis suggests that a linear time effect is plausible, models 
also fitting a constant slope (linear function of time) in each treatment group will also be 
fitted as this analysis will provide more power if the underlying model is not mis-
specified. In this situation, secondary analyses will also consider different models for 
the data, specifically mixed or random effects models. 
 
Primary analyses will restrict to the period over which treatment is given, because this 
will typically be 10 days in all patients (regardless of treatment group) and sampling 
should be fairly complete during this period as patients will likely remain in hospital. 
Secondary analyses will include all observed time points; of note, if fidaxomicin 
reduces recurrence, fewer post-treatment observations might be expected in this group 
as patients may be more likely to be discharged. Time to last sample will be compared 
between randomised groups to explore the potential for this type of selection bias using 
Kaplan-Meier and log-rank tests. 
 
Baseline characteristics will be compared between fidaxomicin and 
vancomycin/metronidazole groups. Because the study is non-randomised, there is the 
potential for confounding to influence the comparisons of primary and secondary 
outcomes described above. It is acknowledged, for example, that differences in 
environmental cleaning protocols between study centres may introduce inter-site 
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variations. Therefore analyses will also be conducted adjusting for effects of any 
baseline characteristics that may differ between the treatment groups (using a less 
strict criteria of p<0.1 to ensure that moderate confounding is not influencing results), 
allowing effects of baseline factors both on the initial t=0 measurement, and the 
measurements at subsequent timepoints.  
 
 
Project management: 
 
Professor Mark Wilcox will be the Chief Investigator and the Principle Investigator at 
LTHT. Dr Tim Planche will be the Principle Investigator at SGHT. Both of these 
individuals have previously been involved in managing numerous, large national and 
international research studies.  A research registrar based at LTHT will co-ordinate the 
day to day running of the study. Microbiology research nurses at each centre will recruit 
patients, collect environmental and skin samples, co-ordinate the collection of stool 
samples, complete CRFs and input the data from them on to the electronic database. 
Processing of samples will be performed at LTHT by research laboratory staff.  
 
The study will comply with the principles of Good Clinical Practice, the Mental Capacity 
Act (2005), the Data Protection Act (1998) and NHS research governance. 
 
 
 
Reporting: 
 
This is an observational study. Results will be reported to the sponsor but not to 
clinicians. A summary sheet of the study outcomes will be available for study 
participants if requested. 
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Publication: 
 
The study results will be submitted for publication as oral or poster presentations at 
international conferences of microbiology/infectious diseases and then in peer 
reviewed scientific journals. All patient data in any publications will be fully anonymised.  
 
Finance: 
 
The project is being funded by Astellas Pharma Europe Ltd.  
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Appendix 2: Study timeline 
 
Study phase 
 
Set up Start of 
recruitment 
Complete 
recruitment 
Analysis and 
write up 
Timescale 
(completion date) 
 
Dec 2014 Jan 2015 December 
2016 
March 2017 
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Appendix B Media used for bacterial culture and 
incubation 
B.1 Solid agar  
All media were prepared according to manufacturer’s instructions unless otherwise 
instructed, before being autoclaved at 121° C for 15 minutes. The reagents and media 
prepared have been reported previously (235). 
B.1.1 Nutrient agar (CM0003, Oxoid)  
Ingredients g/ litre 
`Lab-Lemco’ powder 1.0  
Agar 15.0 
Peptone 5.0 
Sodium chloride 5.0 
Yeast extract 2.0 
 
B.1.2 MacConkey agar (CM0115, Oxoid)  
Ingredients g/ litre 
Agar 15.0 
Bile salts no.3 1.5 
Crystal violet 0.01 
Lactose 10.0 
Neutral red 0.03 
Peptone 20.0 
Sodium chloride 5.0 
 
B.1.3 Kanamycin aesculin azide agar (CM0591, Oxoid)   
The following were added in addition to the agar base; 10 mg/L nalidixic acid, 10 mg/L 
aztreonam, 20 mg/L kanamycin and 1 mg/L lincomycin. 
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Ingredients g/ litre 
Aesculin 1.0 
Agar 10.0 
Ferric ammonium citrate 0.5 
Mix for streptococci 0.6 
Sodium azide 0.15 
Sodium chloride 5.0 
Sodium citrate 1.0 
Starch 0.6 
Tryptone  18.0 
Yeast extract 5.0 
 
B.1.4 Fastidious anaerobe agar (LAB090, LabM) 
The following were added in addition to the agar base; 5 % horse blood. 
Ingredients g/ litre 
Agar 12.0 
Arginine 1.0 
Ferric pyrophosphate 0.3 
Glucose 1.0 
Haemin 0.005 
L-cysteine HCl 0.4 
Peptone mix 23.0 
Sodium bicarbonate 0.4 
Sodium chloride 5.0 
Sodium pyruvate 1.0 
Sodium succinate 0.5 
Starch 1.0 
Vitamin K 0.004 
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B.1.5 Bile aesculin agar (CM888, Oxoid) 
The following were added in addition to the agar base; 2 % haemin and 0.002 % 
vitamin K1. 
Ingredients g/ litre 
Peptone  14.0 
Bile salts 15.0 
Ferric citrate 0.5 
Aesculin 1.0 
Agar 14.0 
 
B.1.6 LAMVAB Agar  
LAMVAB agar was prepared by mixing two solutions (X + Y). Solution X (500 ml) was 
prepared with 104.4 g/L MRS Broth (CM359, Oxoid), supplemented with 0.5 g/L 
cysteine hydrochloride (C1276, Sigma).  
MRS Broth 
Ingredients g/ litre 
Dipotassium hydrogen phosphate 2.0 
Glucose 20.0 
Lab-Lemco powder 8.0 
Magnesium sulphate 4H20 0.05 
Magnesium sulphate 7H20 0.2 
Peptone 10.0 
Sodium acetate 5.0 
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Sorbitan mono-oleate 1 ml 
Triammonium citrate 2.0 
Yeast extract 4.0 
 
Solution X (500 ml) was 40 g/L Agar technical 3 (LP0013, Sigma).  
After autoclaving, solution X + Y were mixed and 1ml vancomycin (V2002, Sigma) was 
added. The pH of the solution was adjusted to 5.0 +/- 0.1 using 4 M HCl (Sigma). 
B.1.7 Beerens Agar 
The following were added in addition to the Columbia agar base; 5 g/L glucose (G7528, 
Sigma), 0.5 g/L cysteine HCl (C1276, Sigma). After heating the mixture to 100° C it 
was cooled to 55° C, subsequent to which 5 ml/L propionic acid (P1386, Sigma) 
was added to adjust the mixture to pH 5.  
Columbia agar base 
Ingredients g/ litre 
Agar 10.0 
Sodium chloride 5.0 
Special peptone 23.0 
Starch 1.0 
 
B.1.8 CCEYL Agar (LAB 160, LabM) 
The following were added in addition to the agar base; 8 mg/L cefoxitin & 250 mg/L 
cycloserine (X093, LabM), 2 % lysed horse blood (BHB400, E & O) and 5 mg/L 
lysozyme (L6876, Sigma).  
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Ingredients g/ litre 
Agar 10.0 
Gelatin peptone 10.0 
Glucose 1.0 
Haemin 0.005 
L-arginine 1.0 
Menadione 0.0005 
Sodium chloride 5.0 
Sodium pyruvate 1.0 
Tryptone 10.0 
Yeast extract 5.0 
B.1.9 BHI Agar (Oxoid) 
Ingredients g/ litre 
Agar 10.0 
Beef heart infusion solids 5.0 
Brain infusion solids 12.5 
Disodium phosphate 2.5 
Glucose 2.0 
Proteose peptone 10.0 
Sodium chloride 5.0 
 
B.2 Broth 
BHI and CCEYL broth have the same ingredients as their agar counterparts, minus the 
addition of agar. 
B.2.1 Minimal Media 
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Minimal media was used for incubating gut model bacterial populations. All ingredients 
were added prior to autoclaving except glucose, calcium chloride and magnesium 
sulphate which were dissolved in dH20 and sterilised through a 0.22μm syringe filter.  
After autoclaving, 200ml of 5X minimal salts solution was transferred to 800ml of sterile 
distilled H2O, producing a solution with the following concentration of ingredients; 
Ingredients g/ litre 
Ammonium chloride 1.3 
Calcium chloride 0.01 
Glucose 0.7 
Magnesium sulphate 0.2 
Potassium dihydrogenphosphate 3.8 
Sodium chloride 0.6 
Sodium phosphate 5H20 16.0 
 
B.2.2 Gut Model Vessel Media 
Ingredients Manufacturer g/ litre 
Arabinogalactan Sigma 1.0 
Bile salts no.3 Sigma 0.5 
Calcium chloride  Sigma 0.01 
Cysteine HCl  Sigma 0.5 
Di-potassium 
monohydrogen phosphate 
AnalR 0.04 
Glucose Sigma 0.4 
Haemin Sigma 0.005 
Magnesium sulphate Sigma 0.01 
Pectin Oxoid 2.0 
Peptone water Oxoid 2.0 
Potassium dihydrogen 
phosphate 
Sigma 0.04 
280 
 
 
Sodium chloride Sigma 0.1 
Sodium hydrogen 
carbonate 
Sigma 2.0 
Starch Fisher 3.0 
Tween 80 Sigma 2.0 mL/ L 
Vitamin K Sigma 10 ul/L 
Yeast extract Oxoid 2.0 
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Appendix C Table of Proteins 
Protein IDs Fasta headers 
Mol. 
weight 
[kDa] 
P24295 
>sp|P24295|DHE2_CLOSY 
NAD-specific glutamate 
dehydrogenase OS=Clostridium 
symbiosum GN=gdh PE=1 
SV=4 
49.295 
Q042T5 
>sp|Q042T5|EFTU_LACGA 
Elongation factor Tu 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=tuf PE=3 SV=2 
43.677 
P22983;Q92HI8;Q4ULI7;Q1RH78;
Q9ZD55;Q68WP2;Q59754 
>sp|P22983|PPDK_CLOSY 
Pyruvate, phosphate dikinase 
OS=Clostridium symbiosum 
GN=ppdK PE=1 SV=5 
96.653 
Q74JU6 
>sp|Q74JU6|EFTU_LACJO 
Elongation factor Tu 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=tuf PE=3 SV=1 
43.664 
Q042F2 
>sp|Q042F2|PGK_LACGA 
Phosphoglycerate kinase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=pgk PE=3 SV=1 
43.043 
Q042F4;C0QI43;B4U9X7;O32513;
C4XLR9 
>sp|Q042F4|ENO2_LACGA 
Enolase 2 OS=Lactobacillus 
gasseri (strain ATCC 33323 / 
DSM 20243 / JCM 1131 / 
NCIMB 11718 / AM63) 
GN=eno2 PE=1 SV=1 
46.91 
Q046C7;Q74L90;Q1GBM0;Q1WVA
0;Q9ZEU4;Q6YQV9;Q2NJ19;B3QZ
H4;Q9Z9L7;Q5WLR5;Q250N5;B8G
1W3;Q8CQ82;Q6GJC1;Q6GBU0;Q
5HRK5;Q5HIC8;Q4L3K8;Q2YSB4;
Q2G0N1;Q2FJ93;P68791;P68790;
P68789;P68788;A7WYX4;A6TZ24;
A6QEJ9;A5IQA1;Q839G9;Q49V57;
>sp|Q046C7|EFG_LACGA 
Elongation factor G 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=fusA PE=3 
SV=1;>sp|Q74L90|EFG_LACJO 
Elongation factor G 
OS=Lactobacillus johnsonii 
76.947 
282 
 
 
Q88XY8;Q03PV4;Q11QB0;B3EUF
3 
(strain CNCM I-12250 / La1 / 
NCC 533) GN 
Q042F3 
>sp|Q042F3|TPIS_LACGA 
Triosephosphate isomerase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=tpiA PE=3 SV=1 
27.294 
P62413 
>sp|P62413|PGK_LACJO 
Phosphoglycerate kinase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=pgk PE=3 SV=1 
43.018 
P62052 
>sp|P62052|LDH1_LACJO L-
lactate dehydrogenase 1 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ldh1 PE=3 SV=1 
35.079 
C4Z2R9;Q1GP97 
>sp|C4Z2R9|EFTU_EUBE2 
Elongation factor Tu 
OS=Eubacterium eligens (strain 
ATCC 27750 / VPI C15-48) 
GN=tuf PE=3 SV=1 
43.997 
Q74K79 
>sp|Q74K79|TPIS_LACJO 
Triosephosphate isomerase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=tpiA PE=3 SV=1 
27.338 
Q043Z5 
>sp|Q043Z5|ENO1_LACGA 
Enolase 1 OS=Lactobacillus 
gasseri (strain ATCC 33323 / 
DSM 20243 / JCM 1131 / 
NCIMB 11718 / AM63) 
GN=eno1 PE=3 SV=1 
46.652 
P19413 
>sp|P19413|BAIF_CLOSV Bile 
acid-CoA transferase 
OS=Clostridium scindens (strain 
JCM 10418 / VPI 12708) 
GN=baiF PE=1 SV=3 
47.469 
Q74K78 
>sp|Q74K78|ENO1_LACJO 
Enolase 1 OS=Lactobacillus 
johnsonii (strain CNCM I-12250 / 
La1 / NCC 533) GN=eno1 PE=3 
SV=1 
47.071 
Q74IV0 
>sp|Q74IV0|ENO3_LACJO 
Enolase 3 OS=Lactobacillus 
johnsonii (strain CNCM I-12250 / 
La1 / NCC 533) GN=eno3 PE=3 
SV=1 
46.633 
A8YXK3 
>sp|A8YXK3|EFG_LACH4 
Elongation factor G 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=fusA 
PE=3 SV=1 
76.821 
A9KRZ4 
>sp|A9KRZ4|EFTU_LACP7 
Elongation factor Tu 
OS=Lachnoclostridium 
43.856 
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phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=tuf PE=3 SV=1 
Q5FMJ3 
>sp|Q5FMJ3|GPMA_LACAC 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=gpmA PE=3 SV=1 
26.525 
Q5FM92 
>sp|Q5FM92|EFG_LACAC 
Elongation factor G 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=fusA PE=3 
SV=1 
76.853 
P32370 
>sp|P32370|BAIH_CLOSV 
NADH-dependent flavin 
oxidoreductase OS=Clostridium 
scindens (strain JCM 10418 / 
VPI 12708) GN=baiH PE=3 
SV=1 
72.029 
P19337 
>sp|P19337|BAIA2_CLOSV 
3alpha-hydroxy bile acid-CoA-
ester 3-dehydrogenase 2 
OS=Clostridium scindens (strain 
JCM 10418 / VPI 12708) 
GN=baiA2 PE=1 SV=1 
26.538 
Q74LL9 
>sp|Q74LL9|GPMA1_LACJO 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase 1 OS=Lactobacillus 
johnsonii (strain CNCM I-12250 / 
La1 / NCC 533) GN=gpmA1 
PE=3 SV=1 
26.608 
P30901 
>sp|P30901|LDHD_LACHE D-
lactate dehydrogenase 
OS=Lactobacillus helveticus 
PE=1 SV=2 
37.779 
P07914 
>sp|P07914|BAIA1_CLOSV 
3alpha-hydroxy bile acid-CoA-
ester 3-dehydrogenase 1/3 
OS=Clostridium scindens (strain 
JCM 10418 / VPI 12708) 
GN=baiA1 PE=1 SV=3 
26.657 
Q02T82;P09591;A6UZH4;Q0ABH7
;A5EX84;Q0AIJ7;Q0AF46;A1WVD
6;A1WVC4;Q83ES6;A9NAK7;A9K
D33;Q981F7;A1B002;Q92GW4;Q8
KTA6;Q8KTA3;Q8KTA1;Q8KT99;Q
8KT97;Q8KT95;P48865;P0A3B0;P
0A3A9;C4K2I2;C3PPA9;B0BUR2;A
8GT71;A8F2E9;Q9P9Q9;Q877P8;
Q81ZS3;Q6FF97;Q31IY4;Q4FQG6
;Q1Q8P2;Q7UMZ0 
>sp|Q02T82|EFTU_PSEAB 
Elongation factor Tu 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=tuf1 
PE=1 
SV=1;>sp|P09591|EFTU_PSEA
E Elongation factor Tu 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
1 
43.369 
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Q5FL50 
>sp|Q5FL50|PGK_LACAC 
Phosphoglycerate kinase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=pgk PE=3 
SV=1 
42.818 
Q5FL49 
>sp|Q5FL49|TPIS_LACAC 
Triosephosphate isomerase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=tpiA PE=3 
SV=1 
27.502 
Q5FKM6;A8YUV4 
>sp|Q5FKM6|ENO_LACAC 
Enolase OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=eno PE=3 
SV=1;>sp|A8YUV4|ENO_LACH
4 Enolase OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=eno PE=3 SV=1 
46.625 
Q02H55;P30718;B7UZG3;A6VB57;
Q8GBB4;Q1I5E2;Q88N55;B1J3K5;
A5W8M6;B0KFQ2;A4XYM0;A4VP8
2;Q4K764;Q87X14;Q4ZP20;Q48EI
5;P48216;O33500;Q2SDG0;Q8RIT
7;Q8PPZ1;Q8PD23;Q5GUT1;Q4U
ZA7;Q3BY61;Q2NY29;B2SJG4;B0
RN52;C5BP08;B3DZP5 
>sp|Q02H55|CH60_PSEAB 60 
kDa chaperonin 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=groL 
PE=3 
SV=1;>sp|P30718|CH60_PSEA
E 60 kDa chaperonin 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / P 
57.085 
A6LPP6;P18906 
>sp|A6LPP6|EFTU_CLOB8 
Elongation factor Tu 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=tuf1 PE=3 SV=1 
43.623 
Q189R2 
>sp|Q189R2|FTHS_PEPD6 
Formate--tetrahydrofolate ligase 
OS=Peptoclostridium difficile 
(strain 630) GN=fhs PE=3 SV=1 
59.985 
Q5FKR8 
>sp|Q5FKR8|EFTU_LACAC 
Elongation factor Tu 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=tuf PE=3 SV=1 
43.579 
Q1GB26;Q04BH1;O32756;Q8GIZ5
;Q03UX8 
>sp|Q1GB26|PGK_LACDA 
Phosphoglycerate kinase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=pgk PE=3 
SV=1;>sp|Q04BH1|PGK_LACD
B Phosphoglycerate kinase 
42.711 
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OS=Lactobacillus delbrueckii 
sub 
C4Z3R4;A8ZNW7;Q05972;A6QBP
8;Q46J70;Q0I7U3;B0CEZ1;A7I0W
5;A2C4I2;Q8YQZ8;Q7TUS4;Q7TU
44;Q7TTX1;Q3M704;Q3AZK3;Q3A
HM4;Q2JUN7;Q2JL43;Q10WQ4;P
22879;P12834;A7ZCV2;A7GZ43;A
5GNA9;A2C6Z6;A2BYG1;Q8DMD4
;Q7TV93;Q5HTP2;Q318V6;O6928
9;O50323;A8G6T6;A8FMS6;A7H2
F8;A3PES4;A2BT10;A1W0K4;A0R
NU3;Q93GW2;A6Q2B4;A5GV53;Q
7V2M3;A8G3G6;A3PBH4;A2BPT4;
Q31C83;A2BVB2 
>sp|C4Z3R4|CH60_EUBE2 60 
kDa chaperonin 
OS=Eubacterium eligens (strain 
ATCC 27750 / VPI C15-48) 
GN=groL PE=3 SV=1 
57.395 
Q043V2;Q74JM8 
>sp|Q043V2|PFKA_LACGA 
ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=pfkA PE=3 
SV=1;>sp|Q74JM8|PFKA_LACJ
O ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus johnsonii 
(strai 
34.296 
P27346 
>sp|P27346|DHE2_CLODI 
NAD-specific glutamate 
dehydrogenase 
OS=Clostridioides difficile 
GN=gluD PE=3 SV=1 
46.015 
A8YUE4;Q88YH4 
>sp|A8YUE4|TPIS_LACH4 
Triosephosphate isomerase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=tpiA 
PE=3 SV=1 
27.611 
A8YUE3;B2GAL8;B2UKW8;B1MW
69 
>sp|A8YUE3|PGK_LACH4 
Phosphoglycerate kinase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=pgk 
PE=3 SV=1 
42.834 
Q8XFP8;Q0TMN0;Q0SQC8;Q877L
9;A5N4N1 
>sp|Q8XFP8|EFTU_CLOPE 
Elongation factor Tu 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=tufA 
PE=3 
SV=1;>sp|Q0TMN0|EFTU_CLO
P1 Elongation factor Tu 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 / 
NCTC 8237 / Type A) GN 
43.557 
Q9I3D1;P14218;P18925;P31052 
>sp|Q9I3D1|DLDH2_PSEAE 
Dihydrolipoyl dehydrogenase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
50.164 
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22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=lpdG PE=1 
SV=1;>sp|P14218|DLDH_PSEF
L Dihydrolipoyl dehydrogenase 
OS=Pseudomonas fluor 
Q9XD38;Q72NF9;Q055E6;Q04PT6 
>sp|Q9XD38|EFTU_LEPIN 
Elongation factor Tu 
OS=Leptospira interrogans 
serogroup Icterohaemorrhagiae 
serovar Lai (strain 56601) 
GN=tuf PE=3 
SV=1;>sp|Q72NF9|EFTU_LEPI
C Elongation factor Tu 
OS=Leptospira interrogans 
serogroup Icterohaemorrhagiae 
serovar copenh 
43.574 
Q93GB7;Q7VC41;B0S1G9;Q898R
2 
>sp|Q93GB7|TPIS_LACDL 
Triosephosphate isomerase 
OS=Lactobacillus delbrueckii 
subsp. lactis GN=tpiA PE=1 
SV=1 
27.481 
Q74K31 
>sp|Q74K31|G6PI_LACJO 
Glucose-6-phosphate isomerase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=pgi PE=3 SV=1 
49.91 
Q18AR0;P45362 
>sp|Q18AR0|THLA_PEPD6 
Acetyl-CoA acetyltransferase 
OS=Peptoclostridium difficile 
(strain 630) GN=thlA PE=1 
SV=1 
40.86 
Q042K0 
>sp|Q042K0|G6PI_LACGA 
Glucose-6-phosphate isomerase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=pgi PE=3 SV=1 
49.856 
B7GU46 
>sp|B7GU46|EFTU_BIFLS 
Elongation factor Tu 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12) GN=tuf 
PE=3 SV=1 
43.879 
Q8A414;Q9PP01;Q5HUM7;B9KD7
9;A8FLY1;A7H3B9;A1VZR5;A4IRZ
2;Q7MQ03 
>sp|Q8A414|PCKA_BACTN 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pckA PE=3 SV=1 
59.163 
B2G6R2;A5VJ92 
>sp|B2G6R2|EFTU_LACRJ 
Elongation factor Tu 
OS=Lactobacillus reuteri (strain 
JCM 1112) GN=tuf PE=3 
43.432 
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SV=1;>sp|A5VJ92|EFTU_LACR
D Elongation factor Tu 
OS=Lactobacillus reuteri (strain 
DSM 20016) GN=tuf PE=3 
SV=1 
B2UYA3;B2TIG8 
>sp|B2UYA3|RPOB_CLOBA 
DNA-directed RNA polymerase 
subunit beta OS=Clostridium 
botulinum (strain Alaska E43 / 
Type E3) GN=rpoB PE=3 
SV=1;>sp|B2TIG8|RPOB_CLOB
B DNA-directed RNA 
polymerase subunit beta 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN= 
139.57 
A6LPQ4;Q0TMN8;Q0SQD6;P0C2E
7;Q890N4;Q250P0;B8G1V8;Q3A9
Q7;Q2RFN9;A4J103;B0TC48;A5D
5I2;C1FMV9;B1IGG2;A7FZ77;A5I7
L4;B9DYA1;A7GJ82;A5N4N9;B1K
SN3;Q97EG9;C3KVQ9;A0PXT8;A6
TWJ0;Q67JT3;A3DIZ4;Q8R7U6;B0
KCJ2;B0K5G8;Q18CF1;Q2JX64;Q
2JJ19;Q9RQZ7;Q46J22;A2C4N2;Q
7VA29;A9BCH6;Q7V5P1;Q7V006;
Q7U8K4;Q3AZA4;Q3AHX5;Q318Q
7;Q0I7L7;A8G6Y6;A5GVF3;A5GN
H3;A3PEX4;A2C6S8;A2BYL1;A2B
T61;Q110H1;P77965;P59643;Q73J
J7;Q8F0S2;Q72UA8;Q054E2;Q04
QI9;Q9KK59;B0SSI4;B0SAG1 
>sp|A6LPQ4|RPOB_CLOB8 
DNA-directed RNA polymerase 
subunit beta OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=rpoB PE=3 
SV=1;>sp|Q0TMN8|RPOB_CLO
P1 DNA-directed RNA 
polymerase subunit beta 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 
138.83 
O32755;P58072 
>sp|O32755|G3P_LACDE 
Glyceraldehyde-3-phosphate 
dehydrogenase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus GN=gap 
PE=3 SV=1 
36.564 
B9MQG5;A4XI30 
>sp|B9MQG5|RPOB_CALBD 
DNA-directed RNA polymerase 
subunit beta 
OS=Caldicellulosiruptor bescii 
(strain ATCC BAA-1888 / DSM 
6725 / Z-1320) GN=rpoB PE=3 
SV=1;>sp|A4XI30|RPOB_CALS
8 DNA-directed RNA 
polymerase subunit beta 
OS=Caldicellulosiruptor 
saccharolyticu 
138.42 
B2GBC2 
>sp|B2GBC2|EFTU_LACF3 
Elongation factor Tu 
OS=Lactobacillus fermentum 
(strain NBRC 3956 / LMG 
18251) GN=tuf PE=3 SV=1 
43.474 
A8MLD2 
>sp|A8MLD2|RPOB_ALKOO 
DNA-directed RNA polymerase 
subunit beta OS=Alkaliphilus 
139.08 
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oremlandii (strain OhILAs) 
GN=rpoB PE=3 SV=1 
Q1GAQ0;Q04B37 
>sp|Q1GAQ0|EFTU_LACDA 
Elongation factor Tu 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=tuf PE=3 
SV=1;>sp|Q04B37|EFTU_LACD
B Elongation factor Tu 
OS=Lactobacillus delbrueckii 
subsp.  
43.28 
Q18CF4 
>sp|Q18CF4|EFG_PEPD6 
Elongation factor G 
OS=Peptoclostridium difficile 
(strain 630) GN=fusA PE=3 
SV=1 
75.896 
P42480;A0M3Z6;Q11Q98 
>sp|P42480|EFTU_PAROE 
Elongation factor Tu 
OS=Parahymenobacter 
ocellatus GN=tuf PE=3 SV=1 
43.038 
B8I5N7;Q8DVV4;Q67JU0;Q927I5;
Q8Y421;Q71WB8;C1KZK7;B8DAY
6;A0ALY9;Q6MU82;Q2SSW9;Q8E
TY5;Q8E3E7;Q8DXS7;Q5XDW4;Q
48VB6;Q3JZB5;Q2RFP4;Q1JNH7;
Q1JIM6;Q1J8I4;P69948;P69946;P
0DA85;P0DA84;C0MF25;C0M937;
B9DVS2;B5XJR1;B4U0V9;A5D5I7;
A2RCI2;Q5M2M6;Q5LY21;Q04MH
7;Q03IS1;P64023;P64022;C1CPE5
;C1CIF3;C1CC62;C1CB46;B8ZKU
0;B5E6U5;B2ISJ9;B1I8Z9;A8AUR6
;A4VYX6;A4VSN3;A3CQM2;A8M5
32;A4XBP9;A9B746;A7NR66;A5U
SJ2;B9LJC8;B8G6S9;A9WH62;Q8
KAG9;Q3B6G4;B4S5N0;B3QR64;B
3EP64;A4SCQ6;Q1AU26 
>sp|B8I5N7|EFG_CLOCE 
Elongation factor G 
OS=Clostridium cellulolyticum 
(strain ATCC 35319 / DSM 5812 
/ JCM 6584 / H10) GN=fusA 
PE=3 
SV=1;>sp|Q8DVV4|EFG_STRM
U Elongation factor G 
OS=Streptococcus mutans 
serotype c (strain ATCC 700610 
/ UA159) GN=fusA PE=3 S 
76.44 
A9KRZ3;A4T1R3;Q1BDD4;B1MGH
8;A3PV95;A1UBL0 
>sp|A9KRZ3|EFG_LACP7 
Elongation factor G 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=fusA PE=3 SV=1 
78.188 
Q47JA5 
>sp|Q47JA5|EFTU_DECAR 
Elongation factor Tu 
OS=Dechloromonas aromatica 
(strain RCB) GN=tuf1 PE=3 
SV=1 
43.161 
Q2GFN6;Q5FCW3;Q5HAS0;Q5FF
E6;Q3YRK7;Q5PBH1 
>sp|Q2GFN6|EFTU_EHRCR 
Elongation factor Tu 
OS=Ehrlichia chaffeensis (strain 
ATCC CRL-10679 / Arkansas) 
GN=tuf1 PE=3 
SV=1;>sp|Q5FCW3|EFTUL_EH
RRW Putative elongation factor 
43.386 
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Tu-like protein OS=Ehrlichia 
ruminantium (strain 
Welgevonden) 
GN=ERWE_CDS_01630 PE=5  
Q21SF0;Q21RV6 
>sp|Q21SF0|EFTU1_RHOFT 
Elongation factor Tu 1 
OS=Rhodoferax ferrireducens 
(strain ATCC BAA-621 / DSM 
15236 / T118) GN=tuf1 PE=3 
SV=1;>sp|Q21RV6|EFTU2_RH
OFT Elongation factor Tu 2 
OS=Rhodoferax ferrireducens 
(strain ATCC BAA-621 / DSM 
15236 / T118) GN=tuf2  
42.991 
Q18CE4 
>sp|Q18CE4|EFTU_PEPD6 
Elongation factor Tu 
OS=Peptoclostridium difficile 
(strain 630) GN=tuf1 PE=3 
SV=1 
44.026 
A9KSJ1 
>sp|A9KSJ1|CH60_LACP7 60 
kDa chaperonin 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=groL PE=3 SV=1 
57.062 
Q8G756 
>sp|Q8G756|RS6_BIFLO 30S 
ribosomal protein S6 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=rpsF 
PE=3 SV=1 
11.174 
Q8G5B7;B3DT29 
>sp|Q8G5B7|EFTU_BIFLO 
Elongation factor Tu 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=tuf PE=3 
SV=1;>sp|B3DT29|EFTU_BIFL
D Elongation factor Tu 
OS=Bifidobacterium longum 
(strain DJO10A) GN=tuf PE=3 
SV=1 
43.936 
Q1G9S9;Q049Y3 
>sp|Q1G9S9|ENO_LACDA 
Enolase OS=Lactobacillus 
delbrueckii subsp. bulgaricus 
(strain ATCC 11842 / DSM 
20081 / JCM 1002 / NBRC 
13953 / NCIMB 11778) GN=eno 
PE=3 
SV=1;>sp|Q049Y3|ENO_LACD
B Enolase OS=Lactobacillus 
delbrueckii subsp. bulgaricus 
(strain ATCC BAA- 
46.34 
P34038 
>sp|P34038|KPYK_LACDE 
Pyruvate kinase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus GN=pyk PE=1 
SV=3 
62.919 
P26297 
>sp|P26297|LDHD_LACDA D-
lactate dehydrogenase 
37.049 
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OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=ldhA PE=1 SV=3 
C4Z5P8 
>sp|C4Z5P8|UXAC_EUBE2 
Uronate isomerase 
OS=Eubacterium eligens (strain 
ATCC 27750 / VPI C15-48) 
GN=uxaC PE=3 SV=1 
53.929 
Q64MV4;Q5L7N5 
>sp|Q64MV4|PCKA_BACFR 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Bacteroides fragilis (strain 
YCH46) GN=pckA PE=3 
SV=1;>sp|Q5L7N5|PCKA_BAC
FN Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 93 
59.027 
A6LFQ4 
>sp|A6LFQ4|PCKA_PARD8 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=pckA PE=3 
SV=1 
58.959 
Q03AK4;B3WCW7;Q3A578;Q8GR
70;Q8DTS9;Q9XDS7;Q97QS2;Q8
DPS0;Q5M561;Q5M0M5;Q04KG2;
Q03LI0;C1CRM6;C1CKJ0;C1CEB3
;C1C7C0;B8ZPW9;B5E4P1;B2IPX
8;B1IBR3;A8AY46;A3CMA7;Q5XD
01;Q48UF7;Q3K2B2;Q1JML5;Q1J
HQ6;Q1JCN8;Q1J7I5;P69951;P69
949;P64081;P64080;P0DA95;P0D
A94;C0MH89;C0M6K5;B9DRR9;B5
XKM7;B4U2B8;A4W2T1;A2RFE3;
Q8RP81 
>sp|Q03AK4|ENO_LACP3 
Enolase OS=Lactobacillus 
paracasei (strain ATCC 334 / 
BCRC 17002 / CIP 107868 / 
KCTC 3260 / NRRL B-441) 
GN=eno PE=3 
SV=1;>sp|B3WCW7|ENO_LAC
CB Enolase OS=Lactobacillus 
casei (strain BL23) GN=eno 
PE=3 SV=1 
47.086 
Q8A0W0;Q25QU7;A5FHP3 
>sp|Q8A0W0|MDH_BACTN 
Malate dehydrogenase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=mdh PE=3 SV=1 
32.763 
Q03AK6;B3WCW5 
>sp|Q03AK6|PGK_LACP3 
Phosphoglycerate kinase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=pgk PE=3 
SV=1;>sp|B3WCW5|PGK_LAC
CB Phosphoglycerate kinase 
42.237 
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OS=Lactobacillus casei (strain 
BL23) GN=pgk PE=3 SV=1 
Q035Y9;O32847;B3W9W7;Q1WS
W0;Q88YM5;Q38YR7;Q9AME7;Q8
CX22;Q8CX00;Q3JYQ0;C0MES3;
C0M7S3;B4U081;B9DW28;Q2JKV
7;Q5M670;Q5M1M9;Q03MK3;Q2J
XD4;Q8NZ56;Q5X9L8;P69883;P0D
A23;P0DA22;A2RGR1;Q48R03;Q1
JJL5;Q1JEL5;Q1J9G4;Q1J4D1;Q3
AUZ9 
>sp|Q035Y9|CH60_LACP3 60 
kDa chaperonin 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=groL PE=3 
SV=1;>sp|O32847|CH60_LACZ
E 60 kDa chaperonin 
OS=Lactobacillus zeae 
GN=groL PE=3 
SV=1;>sp|B3W9W7|CH60_LAC
CB  
57.427 
Q9KJV3;P0A439;P0A438 
>sp|Q9KJV3|PTHP_LACCA 
Phosphocarrier protein HPr 
OS=Lactobacillus casei 
GN=ptsH PE=1 SV=1 
9.2534 
Q9KJ23;Q045Q8 
>sp|Q9KJ23|CH60_LACJO 60 
kDa chaperonin 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=groL PE=3 
SV=2;>sp|Q045Q8|CH60_LAC
GA 60 kDa chaperonin 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=g 
57.517 
Q5L890;P33165 
>sp|Q5L890|EFTU_BACFN 
Elongation factor Tu 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=tuf 
PE=3 
SV=1;>sp|P33165|EFTU_BACF
R Elongation factor Tu 
OS=Bacteroides fragilis (strain 
YCH46) GN=tuf PE=3 SV=1 
43.58 
A6KYK9;B2RL52 
>sp|A6KYK9|EFTU_BACV8 
Elongation factor Tu 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=tuf PE=3 
SV=1;>sp|B2RL52|EFTU_POR
G3 Elongation factor Tu 
OS=Porphyromonas gingivalis 
(strain ATCC 33277 / DSM 
20709 / C 
43.563 
Q8RQP4;P31026 
>sp|Q8RQP4|DHE4_COREF 
NADP-specific glutamate 
dehydrogenase 
OS=Corynebacterium efficiens 
(strain DSM 44549 / YS-314 / AJ 
12310 / JCM 11189 / NBRC 
100395) GN=gdh PE=3 
48.962 
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SV=2;>sp|P31026|DHE4_COR
GL NADP-specific glutamate 
dehydrogenase 
OS=Corynebacterium glutam 
A6LE88;Q8A463;P42474 
>sp|A6LE88|EFTU_PARD8 
Elongation factor Tu 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=tuf PE=3 
SV=1 
43.61 
A0PXT1 
>sp|A0PXT1|EFTU_CLONN 
Elongation factor Tu 
OS=Clostridium novyi (strain 
NT) GN=tuf1 PE=3 SV=1 
43.095 
Q9Z9L6 
>sp|Q9Z9L6|EFTU_BACHD 
Elongation factor Tu 
OS=Bacillus halodurans (strain 
ATCC BAA-125 / DSM 18197 / 
FERM 7344 / JCM 9153 / C-
125) GN=tuf PE=3 SV=1 
43.383 
P11221 
>sp|P11221|OPRI_PSEAE 
Major outer membrane 
lipoprotein OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=oprI 
PE=3 SV=1 
8.8348 
P07515;Q9ZAD9;O07125 
>sp|P07515|PTHP_ENTFA 
Phosphocarrier protein HPr 
OS=Enterococcus faecalis 
(strain ATCC 700802 / V583) 
GN=ptsH PE=1 
SV=2;>sp|Q9ZAD9|PTHP_LAC
LC Phosphocarrier protein HPr 
OS=Lactococcus lactis subsp. 
cremoris GN=ptsH PE=3 SV=1 
9.3205 
A1USL2;A1USC1 
>sp|A1USL2|EFTU2_BARBK 
Elongation factor Tu 2 
OS=Bartonella bacilliformis 
(strain ATCC 35685 / KC583) 
GN=tuf2 PE=3 
SV=1;>sp|A1USC1|EFTU1_BA
RBK Elongation factor Tu 1 
OS=Bartonella bacilliformis 
(strain ATCC 35685 / KC583) 
GN=tuf1 PE=3 SV=1 
42.786 
Q1QN33;B6JET0;Q89J81;Q6N4T4;
Q3SSW9;Q2IXR3;Q211E5;Q134S6
;Q07KL5;B3QBY3;A5ELN0;B8IS82
;B8ELG6;B7L0Q8;B2IK59;B1ZLK1;
B1LWS3;B0UHX2;A9W4P8;A8IAT
3;A7IFX8;Q9A3K4;B8H414;B4R8L
3;B0SUQ6;Q2IJ93;Q5LMR4;Q160
Y3;A8LM45;Q28UW8;Q1GK42;Q8
EX19;P75544;P47335;Q8KQB3;Q6
>sp|Q1QN33|EFG_NITHX 
Elongation factor G 
OS=Nitrobacter hamburgensis 
(strain DSM 10229 / NCIMB 
13809 / X14) GN=fusA PE=3 
SV=1;>sp|B6JET0|EFG_OLICO 
Elongation factor G 
OS=Oligotropha 
carboxidovorans (strain ATCC 
75.693 
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FZB9;B0CH35;A9IW31;Q11HP9;Q
92QH2;Q8UE15;Q1MIE4;P70782;
C3MAX7;B9JVN4;B9JDS6;B5ZYT2
;A6U856;Q3J5S5;B9KL88;A1B023 
49405 / DSM 1227 / KCTC 
32145 / OM5) GN=fusA  
Q1MPT8 
>sp|Q1MPT8|EFTU_LAWIP 
Elongation factor Tu 
OS=Lawsonia intracellularis 
(strain PHE/MN1-00) GN=tuf 
PE=3 SV=1 
43.589 
Q02TT1;B7V467;A6UYU5;Q9I636;
C0ZZZ0;Q1B860;O32913;B8ZSN3;
B2HSY2;A3Q0E7;A1UGU7;A0PSI5
;Q73ZQ2;A1T9P9;A0QGM8;B1MB
69;A4TAC4;P9WK17;P9WK16;P0A
5J5;C1APB4;A5U3K4;A1KJP9;Q98
DK4;B9JG75;Q937W7;Q92TA4;Q2
KE51;Q1MNB0;B5ZVA2;B3PWJ0;
Q9AE55;C3MBD2;A6UEL4;Q88QX
8;Q88AB2;Q4K4S5;Q3K5N4;O051
37;Q5YWU1;B9JXY6;Q9KB03;Q8Y
IR3;Q8FZ50;Q57BM8;Q2YRK5;C0
RES0;B2S793;A9WWC9;A9M752;
A6WYD2;A5VS09;Q8UJ85 
>sp|Q02TT1|MASZ_PSEAB 
Malate synthase G 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=glcB 
PE=3 
SV=1;>sp|B7V467|MASZ_PSEA
8 Malate synthase G 
OS=Pseudomonas aeruginosa 
(strain LESB58) GN=glcB PE=3 
SV=1;>sp|A6UYU5|MASZ_PSE
A7 Malate synthase G 
OS=Pseudomon 
78.631 
P42475 
>sp|P42475|EFTU_FIBSS 
Elongation factor Tu 
OS=Fibrobacter succinogenes 
(strain ATCC 19169 / S85) 
GN=tuf1 PE=3 SV=2 
43.286 
O66131;Q9WX53;Q81GZ2;Q6HMD
5;Q63EX2;Q5L091;C5DA06;C3LC
Y4;C1EKE4;B9IT52;B7JCV9;B7IKB
1;B7HYU3;B7HG04;A9VI58;A0RA
P3;Q8R8J4;B0K754;B0K643;Q9KD
W8;Q893Q3;Q3AB25;A6TKR6;Q8
ENK7;Q1WVJ0;A8MG11;P18157 
>sp|O66131|GLPK_THETH 
Glycerol kinase OS=Thermus 
thermophilus GN=glpK PE=1 
SV=1;>sp|Q9WX53|GLPK_THE
AQ Glycerol kinase 
OS=Thermus aquaticus 
GN=glpK PE=1 
SV=1;>sp|Q81GZ2|GLPK_BAC
CR Glycerol kinase OS=Bacillus 
cereus (strain ATCC 14579 / 
DSM 31 / JCM 2152 / N 
54.836 
A9KJL3 
>sp|A9KJL3|RPOC_LACP7 
DNA-directed RNA polymerase 
subunit beta 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=rpoC PE=3 SV=1 
140.84 
A8YUS2 
>sp|A8YUS2|EFTU_LACH4 
Elongation factor Tu 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=tuf PE=3 
SV=1 
43.566 
A7HBL7 
>sp|A7HBL7|EFTU_ANADF 
Elongation factor Tu 
OS=Anaeromyxobacter sp. 
(strain Fw109-5) GN=tuf1 PE=3 
SV=1 
43.397 
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Q9I0K4 
>sp|Q9I0K4|ACEA_PSEAE 
Isocitrate lyase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=PA2634 PE=1 
SV=1 
58.886 
Q8G3Z7;A1A091 
>sp|Q8G3Z7|IF1_BIFLO 
Translation initiation factor IF-1 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=infA 
PE=3 
SV=1;>sp|A1A091|IF1_BIFAA 
Translation initiation factor IF-1 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194 
8.3777 
Q74LB6;Q046F1;Q5WB51;Q9K6E
9;Q8EM58;Q71WN0;P0A486;P0A4
85;C1KYW5;B8DBG1;Q1GBQ0;Q0
4C49;Q034T0;B3WAR8;Q38V50;A
0ALN3 
>sp|Q74LB6|RL31B_LACJO 
50S ribosomal protein L31 type 
B OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rpmE2 PE=3 
SV=1;>sp|Q046F1|RL31B_LAC
GA 50S ribosomal protein L31 
type B OS=Lactobacillus gasseri 
(strain ATCC 33323 / DSM 
20243 / JC 
9.3815 
Q74L76;Q046B2 
>sp|Q74L76|RS8_LACJO 30S 
ribosomal protein S8 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rpsH PE=3 
SV=1;>sp|Q046B2|RS8_LACGA 
30S ribosomal protein S8 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718  
14.655 
Q74K59;Q042H3 
>sp|Q74K59|GLMM_LACJO 
Phosphoglucosamine mutase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=glmM PE=3 
SV=2;>sp|Q042H3|GLMM_LAC
GA Phosphoglucosamine 
mutase OS=Lactobacillus 
gasseri (strain ATCC 33323 / 
DSM 20243 / JCM 1131 / 
NCIMB 11 
49.164 
Q74JY1 
>sp|Q74JY1|FTSZ_LACJO Cell 
division protein FtsZ 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ftsZ PE=3 SV=1 
48.861 
Q74JD5;Q5FK05;Q043J4;A8YVH1 
>sp|Q74JD5|PPAC_LACJO 
Probable manganese-
34.232 
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dependent inorganic 
pyrophosphatase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ppaC PE=3 
SV=1;>sp|Q5FK05|PPAC_LAC
AC Probable manganese-
dependent inorganic 
pyrophosphatase 
OS=Lactobacillus ac 
Q06700 
>sp|Q06700|GCDA_ACIFV 
Glutaconyl-CoA decarboxylase 
subunit alpha 
OS=Acidaminococcus 
fermentans (strain ATCC 25085 
/ DSM 20731 / VR4) GN=gcdA 
PE=1 SV=1 
64.346 
Q046B1;Q74L75;Q63Q26;Q62GM0
;Q3SLN4;Q3JMS8;Q39KF2;Q2SU4
2;Q1BRW3;Q13TI5;Q0BJ31;B4E5
D5;B2T736;B2JI50;B1YRP4;B1JU3
7;B0TLZ7;A9ADK8;A4JAQ5;A3Q99
7;A3P098;A3NEG4;A3MRW9;A2S7
J1;A1V888;A0K3P0;Q8XV27;Q5P3
17;Q2L270;B3PK52;A9IHT3;A6T3I
9 
>sp|Q046B1|RL6_LACGA 50S 
ribosomal protein L6 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=rplF PE=3 
SV=1;>sp|Q74L75|RL6_LACJO 
50S ribosomal protein L6 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / N 
19.366 
Q046A5;Q74L69 
>sp|Q046A5|KAD_LACGA 
Adenylate kinase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=adk PE=3 
SV=1;>sp|Q74L69|KAD_LACJO 
Adenylate kinase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=adk PE 
24.228 
Q045X9 
>sp|Q045X9|SYE_LACGA 
Glutamate--tRNA ligase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=gltX PE=3 SV=1 
57.11 
Q044A9;Q74IT6 
>sp|Q044A9|DNAK_LACGA 
Chaperone protein DnaK 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=dnaK PE=3 
SV=1;>sp|Q74IT6|DNAK_LACJ
O Chaperone protein DnaK 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 
66.911 
P62415 
>sp|P62415|PGK_MYCMS 
Phosphoglycerate kinase 
44.414 
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OS=Mycoplasma mycoides 
subsp. mycoides SC (strain 
PG1) GN=pgk PE=3 SV=1 
P19412 
>sp|P19412|BAIE_CLOSV Bile 
acid 7-alpha dehydratase 
OS=Clostridium scindens (strain 
JCM 10418 / VPI 12708) 
GN=baiE PE=1 SV=1 
19.533 
O32765;Q8CMZ0;Q5HL31;Q8NUM
9;Q6GDK1;Q6G674;Q5HCV0;Q2Y
WF6;Q2G1Y5;Q2FDQ7;P99119;P6
5258;P0C7U6;A7X6Y1;A6U4Y2;A6
QK89;A5IW27;Q03DZ7;Q59645 
>sp|O32765|LDH_LACHE L-
lactate dehydrogenase 
OS=Lactobacillus helveticus 
GN=ldh PE=1 SV=1 
35.111 
B7GTK2 
>sp|B7GTK2|ENO_BIFLS 
Enolase OS=Bifidobacterium 
longum subsp. infantis (strain 
ATCC 15697 / DSM 20088 / 
JCM 1222 / NCTC 11817 / S12) 
GN=eno PE=3 SV=1 
46.623 
B0KC73;B9MQ10;A8AWW6;A4XH
T8;A3CNY4;Q8DT23;A3DHM4;Q38
YF8;C0MCM1;C0M9M7;B4U228;Q
7NHG0;B9DSM6;Q97RN9;Q8DQH
0;Q0AXL1;Q04LE0;C1CQM2;C1CJ
L0;C1CDB0;C1C6A5;B8ZNB7;B5E
364;B2INE5;B1IAT8;A4W351;A4V
WU8;Q5M434;Q5LZI0;Q99Z77;Q8
P0G6;Q8E5Y0;Q8E0A3;Q5XBJ6;Q
48SU7;Q3K1M7;Q1JL80;Q1JGA1;
Q1JB36;Q1J626;P0DF55;P0DF54;
B5XM14;A2RE06;Q9CEE0;Q02WN
8;A2RN40;Q8DK88;B1XPB0;B7KF
F5;Q3MF32;B8HWM0 
>sp|B0KC73|METK_THEP3 S-
adenosylmethionine synthase 
OS=Thermoanaerobacter 
pseudethanolicus (strain ATCC 
33223 / 39E) GN=metK PE=3 
SV=1;>sp|B9MQ10|METK_CAL
BD S-adenosylmethionine 
synthase 
OS=Caldicellulosiruptor bescii 
(strain ATCC BAA-1888 / DSM 
6725 / Z-1 
43.302 
A8YW74 
>sp|A8YW74|RTPR_LACH4 
Adenosylcobalamin-dependent 
ribonucleoside-triphosphate 
reductase OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=rtpR PE=3 SV=1 
83.182 
A8YVR9;Q5FJM3 
>sp|A8YVR9|RS2_LACH4 30S 
ribosomal protein S2 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rpsB 
PE=3 
SV=1;>sp|Q5FJM3|RS2_LACA
C 30S ribosomal protein S2 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsB PE=3 
SV=1 
28.754 
A8YV22;Q5FKG6;Q836R3 
>sp|A8YV22|PFKA_LACH4 
ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=pfkA 
PE=3 
SV=1;>sp|Q5FKG6|PFKA_LAC
34.334 
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AC ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=pfk 
A3DHP0;Q184E7 
>sp|A3DHP0|VATA_CLOTH V-
type ATP synthase alpha chain 
OS=Clostridium thermocellum 
(strain ATCC 27405 / DSM 1237 
/ NBRC 103400 / NCIMB 10682 
/ NRRL B-4536 / VPI 7372) 
GN=atpA PE=3 
SV=1;>sp|Q184E7|VATA_PEPD
6 V-type ATP synthase alpha 
chain OS=Peptoclostridiu 
65.363 
A1A143;B8DTI9 
>sp|A1A143|ENO_BIFAA 
Enolase OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=eno PE=3 
SV=1 
46.48 
A1A0T1;B8DTV7;P09953;C5CC66;
C5C0J3;B8HD11;A9WSW5;A1R8U
9;A0JZ88;B1ZPC5;B0RB36;A5CU
B6 
>sp|A1A0T1|EFTU_BIFAA 
Elongation factor Tu 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=tuf PE=3 
SV=1 
44.105 
P94598;P95544 
>sp|P94598|DHE3_BACTN 
Glutamate dehydrogenase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=gdhA PE=3 SV=2 
49.016 
O66214;Q7MAZ7;A1SXK4;A1ST72
;A6VWY0;B0VSP5;Q6F8P6;B7I618
;B7GY36;B0VDR6;A3M836;B2HXB
6 
>sp|O66214|CH60_RAOOR 60 
kDa chaperonin (Fragment) 
OS=Raoultella ornithinolytica 
GN=groL PE=3 SV=1 
56.361 
B5Y368;A6TH53;O66026 
>sp|B5Y368|CH60_KLEP3 60 
kDa chaperonin OS=Klebsiella 
pneumoniae (strain 342) 
GN=groL PE=3 
SV=1;>sp|A6TH53|CH60_KLEP
7 60 kDa chaperonin 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=groL PE=3 
SV=1;>sp|O66026|CH60_KLEP
N 60 k 
57.125 
Q039K9;B3WE38 
>sp|Q039K9|EFTU_LACP3 
Elongation factor Tu 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=tuf PE=3 
43.573 
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SV=1;>sp|B3WE38|EFTU_LAC
CB Elongation factor Tu 
OS=Lactobacillus casei (strain 
BL23) GN=tuf PE=3 SV=1 
O66218 
>sp|O66218|CH60_PANAN 60 
kDa chaperonin (Fragment) 
OS=Pantoea ananas GN=groL 
PE=3 SV=1 
56.816 
O66212;A8AMQ6;A8G8S7;Q1C0Y
0;Q8ZIY3;Q66FD5;Q1CED4;B2K1
Y4;B1JMR1;A9QYQ1;A7FN01;A4T
RR0;P48219;A1JIP3 
>sp|O66212|CH60_RAOPL 60 
kDa chaperonin (Fragment) 
OS=Raoultella planticola 
GN=groL PE=3 
SV=1;>sp|A8AMQ6|CH60_CITK
8 60 kDa chaperonin 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=groL PE=3 
SV=1;>sp|A8G8S7|CH60_SER
P5 60 kDa chaper 
56.654 
Q88YH3;Q7UIR2 
>sp|Q88YH3|ENO1_LACPL 
Enolase 1 OS=Lactobacillus 
plantarum (strain ATCC BAA-
793 / NCIMB 8826 / WCFS1) 
GN=eno1 PE=3 SV=1 
48.029 
A7MKI5;Q83JC4;Q5PIW4;Q57H76;
Q3YWT3;Q3YV04;Q32B27;Q31VV
0;Q0SY20;P0A1H6;P0A1H5;A9MT
05;A9MHG0;Q1R5Y2;Q1R5U4;Q0
TCC0;Q0TA85;P0CE48;P0CE47;P
0A6N3;P0A6N2;B1IVA7;B1IPW0;A
8A779;A8A5E6;A7ZSL4;A1AIF3;A1
AGM6;Q0SZX8;A7ZUJ2;A1JS52;A
4SHU2;B0TM14;A8GYW2 
>sp|A7MKI5|EFTU_CROS8 
Elongation factor Tu 
OS=Cronobacter sakazakii 
(strain ATCC BAA-894) GN=tuf1 
PE=3 
SV=1;>sp|Q83JC4|EFTU_SHIF
L Elongation factor Tu 
OS=Shigella flexneri GN=tufA 
PE=3 
SV=3;>sp|Q5PIW4|EFTU_SALP
A Elongation factor Tu 
OS=Salmonella paratyphi 
43.204 
Q64P62;Q5L8Z8 
>sp|Q64P62|MDH_BACFR 
Malate dehydrogenase 
OS=Bacteroides fragilis (strain 
YCH46) GN=mdh PE=3 
SV=1;>sp|Q5L8Z8|MDH_BACF
N Malate dehydrogenase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=mdh 
PE=3 SV=1 
32.676 
Q64NJ8;Q5L898;A6GYT9;B1ZPB7;
B3E164;Q2S1Q6;B3QQS1;B3QYL
5;B8G4U8;A7NJM0;B9LL90;A9WH
11;A5USR6;A9B6J1;O33431;A8Z5
T2 
>sp|Q64NJ8|RPOC_BACFR 
DNA-directed RNA polymerase 
subunit beta OS=Bacteroides 
fragilis (strain YCH46) GN=rpoC 
PE=3 
SV=1;>sp|Q5L898|RPOC_BAC
FN DNA-directed RNA 
polymerase subunit beta 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCT 
158.6 
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B2GAI0;Q03H05;Q04E64;B2G5X7;
A5VIE9;Q9WYX6;Q9EZV1;B1L8Y8
;A7HNA3;A5IJR6;Q2RL13;B7IFA6;
A8F401;A6LJ30;Q1AXU6;Q5SLM2;
P61490 
>sp|B2GAI0|CH60_LACF3 60 
kDa chaperonin 
OS=Lactobacillus fermentum 
(strain NBRC 3956 / LMG 
18251) GN=groL PE=3 
SV=1;>sp|Q03H05|CH60_PEDP
A 60 kDa chaperonin 
OS=Pediococcus pentosaceus 
(strain ATCC 25745 / CCUG 
21536 / LMG 10740 / 183-1w) 
GN=groL PE=3 SV=1;> 
56.856 
Q9KKF0;Q18CT5;Q47LP1;A0LR17
;A8LYN0;A4X1K4;O33659;A1SNU
4;P0CY97;P0CY96;Q2JFC5;B8E1
A9;B5YDR9;A9WN14;Q2J4P8;Q0R
B64;A0LRS7;Q0RQ25;Q0RBS5 
>sp|Q9KKF0|CH60_CLODI 60 
kDa chaperonin 
OS=Clostridioides difficile 
GN=groL PE=3 
SV=1;>sp|Q18CT5|CH60_PEP
D6 60 kDa chaperonin 
OS=Peptoclostridium difficile 
(strain 630) GN=groL PE=3 
SV=1 
57.676 
Q8R7U7 
>sp|Q8R7U7|RPOC_CALS4 
DNA-directed RNA polymerase 
subunit beta 
OS=Caldanaerobacter 
subterraneus subsp. 
tengcongensis (strain DSM 
15242 / JCM 11007 / NBRC 
100824 / MB4) GN=rpoC PE=3 
SV=1 
133.28 
B1YEP6 
>sp|B1YEP6|CH60_EXIS2 60 
kDa chaperonin 
OS=Exiguobacterium sibiricum 
(strain DSM 17290 / JCM 13490 
/ 255-15) GN=groL PE=3 SV=1 
57.875 
A8EZL8 
>sp|A8EZL8|EFTU_RICCK 
Elongation factor Tu 
OS=Rickettsia canadensis 
(strain McKiel) GN=tuf PE=3 
SV=1 
42.864 
Q9PPW7;B5ZC32;B1AJG4;Q7NAV
3 
>sp|Q9PPW7|EFG_UREPA 
Elongation factor G 
OS=Ureaplasma parvum 
serovar 3 (strain ATCC 700970) 
GN=fusA PE=3 
SV=1;>sp|B5ZC32|EFG_UREU
1 Elongation factor G 
OS=Ureaplasma urealyticum 
serovar 10 (strain ATCC 33699 / 
Western) GN=fusA PE=3 
SV=1;>sp|B1AJG4|EFG_UREP 
76.429 
Q932F8;Q8CQ84;Q6GJC6;Q6GBU
5;Q5HRL0;Q5HID3;Q4L3K3;Q49V
52;Q2YSB9;Q2FJ98;P60279;P602
78;P47768;A8YZP0;A7WYW7;A6T
Z19;A6QEJ4;A5IQ96;B9DKV0 
>sp|Q932F8|RPOB_STAAM 
DNA-directed RNA polymerase 
subunit beta 
OS=Staphylococcus aureus 
(strain Mu50 / ATCC 700699) 
GN=rpoB PE=3 
SV=1;>sp|Q8CQ84|RPOB_STA
133.24 
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ES DNA-directed RNA 
polymerase subunit beta 
OS=Staphylococcus epidermidis 
(strain ATCC 12228) GN=rpoB 
P 
Q8VT58;Q8KJ20;Q8KJ18;Q8KJ16;
Q04IQ3;P0A336;P0A335;C1CTD6;
C1CML7;C1CGD7;C1C9H6;B8ZNK
9;B5E223;B2ILZ5;B1I8B2;A8AZE1;
A3CKI1;Q93EU6;Q8CWW6 
>sp|Q8VT58|CH60_STRGN 60 
kDa chaperonin 
OS=Streptococcus gordonii 
GN=groL PE=3 
SV=1;>sp|Q8KJ20|CH60_STRA
P 60 kDa chaperonin 
OS=Streptococcus anginosus 
GN=groL PE=3 
SV=1;>sp|Q8KJ18|CH60_STRC
V 60 kDa chaperonin 
OS=Streptococcus constellatus 
GN=groL PE=3 SV=1 
56.769 
Q88YH5;Q1WTB5 
>sp|Q88YH5|PGK_LACPL 
Phosphoglycerate kinase 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=pgk PE=3 
SV=1 
42.796 
Q6GIL8;Q6GB58;Q5HHP5;P99136
;P0A038;P0A037;P0A036 
>sp|Q6GIL8|G3P1_STAAR 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 
OS=Staphylococcus aureus 
(strain MRSA252) GN=gapA1 
PE=1 
SV=1;>sp|Q6GB58|G3P1_STA
AS Glyceraldehyde-3-phosphate 
dehydrogenase 1 
OS=Staphylococcus aureus 
(strain MSSA476) GN=gapA1 
PE=3 SV=1;>sp| 
36.28 
Q67KB8 
>sp|Q67KB8|CH60_SYMTH 60 
kDa chaperonin 
OS=Symbiobacterium 
thermophilum (strain T / IAM 
14863) GN=groL PE=3 SV=1 
57.897 
Q60024;B0KBR3;B0K3P6 
>sp|Q60024|CH60_THEBR 60 
kDa chaperonin 
OS=Thermoanaerobacter 
brockii GN=groL PE=1 
SV=2;>sp|B0KBR3|CH60_THE
P3 60 kDa chaperonin 
OS=Thermoanaerobacter 
pseudethanolicus (strain ATCC 
33223 / 39E) GN=groL PE=3 
SV=1;>sp|B0K3P6|CH60_THEP
X 60 kDa chaperonin OS=Th 
58.059 
Q03A55;B3WDC0;Q03QV7;Q03Z9
4;B1MX40 
>sp|Q03A55|G6PI_LACP3 
Glucose-6-phosphate isomerase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=pgi PE=3 
49.322 
301 
 
 
SV=1;>sp|B3WDC0|G6PI_LAC
CB Glucose-6-phosphate 
isomerase OS=Lactobacillus 
casei (strain BL23) GN 
C4K4F8 
>sp|C4K4F8|EFTU_HAMD5 
Elongation factor Tu 
OS=Hamiltonella defensa 
subsp. Acyrthosiphon pisum 
(strain 5AT) GN=tuf PE=3 SV=1 
43.486 
B9MQH0;A4XI36 
>sp|B9MQH0|EFG_CALBD 
Elongation factor G 
OS=Caldicellulosiruptor bescii 
(strain ATCC BAA-1888 / DSM 
6725 / Z-1320) GN=fusA PE=3 
SV=1;>sp|A4XI36|EFG_CALS8 
Elongation factor G 
OS=Caldicellulosiruptor 
saccharolyticus (strain ATCC 
43494 / DSM 8903 / Tp8T 6331) 
77.22 
A8MLD3;B0S2E5 
>sp|A8MLD3|RPOC_ALKOO 
DNA-directed RNA polymerase 
subunit beta OS=Alkaliphilus 
oremlandii (strain OhILAs) 
GN=rpoC PE=3 
SV=1;>sp|B0S2E5|RPOC_FINM
2 DNA-directed RNA 
polymerase subunit beta 
OS=Finegoldia magna (strain 
ATCC 29328) GN=rpoC PE=3 
SV=2 
132.05 
A6LEJ3 
>sp|A6LEJ3|EFG_PARD8 
Elongation factor G 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=fusA PE=3 
SV=1 
78.377 
A6L903 
>sp|A6L903|MDH_PARD8 
Malate dehydrogenase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=mdh PE=3 
SV=1 
32.848 
Q9HWC9;Q02T86;A6UZI2;A4VHM
4;A4XZ96;Q889X7;Q4ZMN8;Q4K5
27;Q48D30;Q3K5Y2;C3K2Y2 
>sp|Q9HWC9|RPOC_PSEAE 
DNA-directed RNA polymerase 
subunit beta OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=rpoC 
PE=3 
SV=1;>sp|Q02T86|RPOC_PSE
AB DNA-directed RNA 
polymerase subunit 
154.38 
Q9HVC4;Q02G03;B7V0L7;A6VC67 
>sp|Q9HVC4|RL25_PSEAE 50S 
ribosomal protein L25 
21.962 
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OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=rplY PE=3 
SV=1;>sp|Q02G03|RL25_PSEA
B 50S ribosomal protein L25 
OS=Pseudomonas aeruginosa 
Q9HVA2;Q02FX9;B7V1A6;A6VCE
7;A4VPI6;C1DFH7;Q7WCP6;Q7W
566;Q7VZU4;Q2KWH7;A9IGJ3 
>sp|Q9HVA2|ILVC_PSEAE 
Ketol-acid reductoisomerase 
(NADP(+)) OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=ilvC 
PE=1 
SV=1;>sp|Q02FX9|ILVC_PSEA
B Ketol-acid reductoisomerase 
(NADP(+)) O 
36.424 
Q9HI36 
>sp|Q9HI36|MAJE_PSEAE 
Major exported protein 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=hcpA PE=1 
SV=1 
19.091 
Q93G07 
>sp|Q93G07|CH60_LACAC 60 
kDa chaperonin 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=groL PE=3 
SV=2 
57.82 
Q8G3N6 
>sp|Q8G3N6|IMDH_BIFLO 
Inosine-5-monophosphate 
dehydrogenase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=guaB 
PE=3 SV=1 
58.262 
Q88UI4;Q38WF1;Q1WUR2;Q83X
M3;B2G649;A5VIL5 
>sp|Q88UI4|G6PI_LACPL 
Glucose-6-phosphate isomerase 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=pgi PE=3 
SV=1;>sp|Q38WF1|G6PI_LACS
S Glucose-6-phosphate 
isomerase OS=Lactobacillus 
sakei subsp. sakei (strain 23K) 
GN=pgi PE=3 SV=1 
49.846 
Q877T5;Q8DD27;Q8DCQ7;Q7MG
R1;A7MXE4 
>sp|Q877T5|EFTU_VIBPA 
Elongation factor Tu OS=Vibrio 
parahaemolyticus serotype 
O3:K6 (strain RIMD 2210633) 
GN=tufA PE=3 
SV=1;>sp|Q8DD27|EFTU1_VIB
VU Elongation factor Tu 1 
OS=Vibrio vulnificus (strain 
43.152 
303 
 
 
CMCP6) GN=tuf1 PE=3 
SV=2;>sp|Q8DCQ7|EFTU2_VIB
VU Elongati 
Q81VT2;Q814C4;Q73F98;Q6HPR0
;Q63H92;C3P9Q3;C3LJ80;C1ET37
;B9IZJ2;B7JKB7;B7IT17;B7HQU2;
B7HJ46;A0R8H8;A9VP75 
>sp|Q81VT2|EFTU_BACAN 
Elongation factor Tu 
OS=Bacillus anthracis GN=tuf 
PE=3 
SV=1;>sp|Q814C4|EFTU_BAC
CR Elongation factor Tu 
OS=Bacillus cereus (strain 
ATCC 14579 / DSM 31 / JCM 
2152 / NBRC 15305 / NCIMB 
9373 / NRRL B-3711) GN=tuf 
PE=3 SV=1;>sp|Q73F98|EFTU 
42.938 
Q6D7E3;C6DCF6;A8GBA2;A4W89
7;Q3Z455;Q32IH0;Q324G4;Q0T6Y
5;P62710;B7LK04;B2TUY6;Q0TJU
6;P62709;P62708;P62707;C4ZXS6
;B7ULM8;B7NNH7;B7N9Z7;B7MP
N9;B7MGL2;B7M6B8;B7LAF6;B6I7
Q9;B5YRF2;B1X786;B1LM46;B1IX
Y1;A7ZY11;A7ZJD0;A1A8Z8;B2S1
01;A1R083;B5RQ00;B5RMK4;B4E
ST0;Q929G8;Q8Y571;Q71XG0;C1
KXG0;B8DFA5;A0AKV8;Q7VR80;
Q492W5;A6LUA1;C6E639;B5EC38
;Q732Z5;Q97FJ6;Q81DD2;Q737X5
;Q6KSL4;Q6HIL9;Q63B92;C3PAW
8;C3LIE5;C1EUQ5;B9J102;B7JPK
2;B7IX37;B7HS46;B7H7P4;A7GPN
5;A1WDX2;A0RE96;Q8KFC8;Q74
CR0;Q3B5J2;Q3AU60;Q39V40;Q2
1YW0;C5CWV9;B9MEZ2;B3QPN8;
B3EFK8;B1Y3R5;A4SDM0;A1WBJ
3;A1TTW5;A1BE55;Q6NJL2;Q6MJ
P3;Q660L2;Q0SMJ5;Q01YD0;O51
602;C4LLD4;C0QV47;B7J2L3;B5Y
7Q7;B3DZZ7;Q8R7C8;Q82TU0;Q6
AAU8;C4K389;B4SEI0;B3QVL0;B1
GZZ1;A1K9B9;Q8FSH0;C5BEL3;Q
2Y9Z7;B0KBW9;B0K4E2;Q4JSW4 
>sp|Q6D7E3|GPMA_PECAS 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=gpmA 
PE=3 
SV=1;>sp|C6DCF6|GPMA_PEC
CP 2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Pectobacte 
28.423 
Q6ACZ0 
>sp|Q6ACZ0|EFTU_LEIXX 
Elongation factor Tu 
OS=Leifsonia xyli subsp. xyli 
(strain CTCB07) GN=tuf PE=3 
SV=1 
43.394 
Q67Q63;A0Q880;Q662C3;Q0SNS
0;Q5NIE5;Q2A1W9;Q14JU8;Q0BK
K9;B2SF32;A7NE12;A4IW85 
>sp|Q67Q63|GLPK_SYMTH 
Glycerol kinase 
OS=Symbiobacterium 
thermophilum (strain T / IAM 
14863) GN=glpK PE=3 
SV=1;>sp|A0Q880|GLPK_FRAT
N Glycerol kinase 
OS=Francisella tularensis 
subsp. novicida (strain U112) 
GN=glpK PE=3 
54.499 
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SV=1;>sp|Q662C3|GLPK_BOR
BP Glycerol ki 
Q59309;O52631 
>sp|Q59309|G3P_CLOPA 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Clostridium 
pasteurianum GN=gap PE=1 
SV=1;>sp|O52631|G3P_CLOAB 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Clostridium 
acetobutylicum (strain ATCC 
824 / DSM 792 / JCM 1419 / 
LMG 5710 / VKM B- 
36.078 
Q3A6R2;Q3A6P9;P50065 
>sp|Q3A6R2|EFTU1_PELCD 
Elongation factor Tu 1 
OS=Pelobacter carbinolicus 
(strain DSM 2380 / NBRC 
103641 / GraBd1) GN=tuf1 
PE=3 
SV=1;>sp|Q3A6P9|EFTU2_PEL
CD Elongation factor Tu 2 
OS=Pelobacter carbinolicus 
(strain DSM 2380 / NBRC 
103641 / GraBd1) GN=tuf2 PE 
43.586 
Q30X04;Q1MPW9 
>sp|Q30X04|RPOC_DESAG 
DNA-directed RNA polymerase 
subunit beta OS=Desulfovibrio 
alaskensis (strain G20) 
GN=rpoC PE=3 
SV=1;>sp|Q1MPW9|RPOC_LA
WIP DNA-directed RNA 
polymerase subunit beta 
OS=Lawsonia intracellularis 
(strain PHE/MN1-00) GN=rpoC 
PE=3 SV=1 
154.09 
Q2YAZ9 
>sp|Q2YAZ9|EFTU_NITMU 
Elongation factor Tu 
OS=Nitrosospira multiformis 
(strain ATCC 25196 / NCIMB 
11849 / C 71) GN=tuf1 PE=3 
SV=1 
42.925 
Q2NWR5 
>sp|Q2NWR5|RPOC_SODGM 
DNA-directed RNA polymerase 
subunit beta OS=Sodalis 
glossinidius (strain morsitans) 
GN=rpoC PE=3 SV=1 
155.49 
Q2LQ86;Q1Q8Q0;Q4FQH4;A5WH
34 
>sp|Q2LQ86|RPOC_SYNAS 
DNA-directed RNA polymerase 
subunit beta OS=Syntrophus 
aciditrophicus (strain SB) 
GN=rpoC PE=3 
SV=1;>sp|Q1Q8Q0|RPOC_PSY
CK DNA-directed RNA 
polymerase subunit beta 
OS=Psychrobacter 
cryohalolentis (strain K5) 
GN=rpoC PE=3 SV=1;>sp|Q4F 
153.99 
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Q1WSY0 
>sp|Q1WSY0|ENO_LACS1 
Enolase OS=Lactobacillus 
salivarius (strain UCC118) 
GN=eno PE=3 SV=1 
48.052 
Q0WD32 
>sp|Q0WD32|IMDH_YERPE 
Inosine-5-monophosphate 
dehydrogenase OS=Yersinia 
pestis GN=guaB PE=3 SV=1 
51.824 
Q046D1;Q74L94;B2G8Y5;A5VLL3;
B2GDX6 
>sp|Q046D1|RPOC_LACGA 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
gasseri (strain ATCC 33323 / 
DSM 20243 / JCM 1131 / 
NCIMB 11718 / AM63) 
GN=rpoC PE=3 
SV=1;>sp|Q74L94|RPOC_LACJ
O DNA-directed RNA 
polymerase subunit beta 
OS=Lactobacillus john 
136.37 
Q03AK5;B3WCW6 
>sp|Q03AK5|TPIS_LACP3 
Triosephosphate isomerase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=tpiA PE=3 
SV=1;>sp|B3WCW6|TPIS_LAC
CB Triosephosphate isomerase 
OS=Lactobacillus casei (strain 
BL23) GN=tpiA P 
26.979 
P94316 
>sp|P94316|DHE2_BACFR 
NAD-specific glutamate 
dehydrogenase OS=Bacteroides 
fragilis (strain YCH46) GN=gdhB 
PE=2 SV=2 
48.39 
P0ADG9;P0ADG8;P0ADG7;Q9L6B
7;P44334;P49058;Q9ZL14;P56088;
Q9KGN8;Q8NY70;Q8CMQ7;Q6GJ
Q7;Q6GC82;Q5HRX2;Q5HIQ7;Q4
L385;Q49UU8;Q2YVL6;Q2G0Y7;Q
2FJM6;P99106;P65169;P31002;Q5
X9A3;P68839;P0DB89;P0DB88;P0
C0H7;P0C0H6;Q8KCW4;O50316;
Q9KH33;Q7UJL3;P21879 
>sp|P0ADG9|IMDH_SHIFL 
Inosine-5-monophosphate 
dehydrogenase OS=Shigella 
flexneri GN=guaB PE=3 
SV=1;>sp|P0ADG8|IMDH_ECO
57 Inosine-5-monophosphate 
dehydrogenase OS=Escherichia 
coli O157:H7 GN=guaB PE=3 
SV=1;>sp|P0ADG7|IMDH_ECO
LI Inosine-5-monophosphate de 
52.022 
O68324;A8YTH8 
>sp|O68324|CH60_LACHE 60 
kDa chaperonin 
OS=Lactobacillus helveticus 
GN=groL PE=3 
SV=1;>sp|A8YTH8|CH60_LACH
4 60 kDa chaperonin 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=groL 
PE=3 SV=1 
57.638 
C4Z0Q6 
>sp|C4Z0Q6|PCKA_EUBE2 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Eubacterium eligens (strain 
58.996 
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ATCC 27750 / VPI C15-48) 
GN=pckA PE=3 SV=1 
B7K834 
>sp|B7K834|EFTU_CYAP7 
Elongation factor Tu 
OS=Cyanothece sp. (strain PCC 
7424) GN=tuf PE=3 SV=1 
44.856 
B2GAM0;Q03GW5 
>sp|B2GAM0|ENO_LACF3 
Enolase OS=Lactobacillus 
fermentum (strain NBRC 3956 / 
LMG 18251) GN=eno PE=3 
SV=1;>sp|Q03GW5|ENO_PED
PA Enolase OS=Pediococcus 
pentosaceus (strain ATCC 
25745 / CCUG 21536 / LMG 
10740 / 183-1w) GN=eno PE=3 
SV=1 
47.79 
B1HMZ1 
>sp|B1HMZ1|EFG_LYSSC 
Elongation factor G 
OS=Lysinibacillus sphaericus 
(strain C3-41) GN=fusA PE=3 
SV=1 
76.432 
B0RB35;A5CUB7 
>sp|B0RB35|EFG_CLAMS 
Elongation factor G 
OS=Clavibacter michiganensis 
subsp. sepedonicus (strain 
ATCC 33113 / DSM 20744 / 
JCM 9667 / LMG 2889 / C-1) 
GN=fusA PE=3 
SV=1;>sp|A5CUB7|EFG_CLAM
3 Elongation factor G 
OS=Clavibacter michiganensis 
subsp. michiganensi 
77.46 
B0CCD0 
>sp|B0CCD0|EFTU_ACAM1 
Elongation factor Tu 
OS=Acaryochloris marina (strain 
MBIC 11017) GN=tuf PE=3 
SV=1 
44.773 
A8YXJ9;Q1GBM4;Q04C21 
>sp|A8YXJ9|RPOC_LACH4 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=rpoC PE=3 SV=1 
135.72 
A6KYK3;A6LE81;Q7MX27;B2RL45
;Q9F3X8;A6GYU0;A5FIJ3;A0M3Y9 
>sp|A6KYK3|RPOB_BACV8 
DNA-directed RNA polymerase 
subunit beta OS=Bacteroides 
vulgatus (strain ATCC 8482 / 
DSM 1447 / JCM 5826 / NBRC 
14291 / NCTC 11154) GN=rpoB 
PE=3 
SV=1;>sp|A6LE81|RPOB_PAR
D8 DNA-directed RNA 
polymerase subunit beta 
OS=Parabacteroides di 
142.48 
A1A316;Q8G515;B3DTE1;Q7NDF8
;P14563;B8HTV9;B0C2D1;Q5MZ2
2;P42079;Q3M5C9;P22704;B7KK7
8;B7JWQ8;B2J199;P74177;B0JSN
>sp|A1A316|RPOC_BIFAA 
DNA-directed RNA polymerase 
subunit beta 
OS=Bifidobacterium 
148.15 
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9;Q2JQT5;Q2JJ18;B1WP07;A9BC
H5;Q7V5P2;Q7V007;Q7U8K3;Q55
346;Q3AZA3;Q3AHX6;Q318Q8;Q0
I7L8;P42076;A8G6Y5;A5GVF1;A3
PEX3;A2C6S9;A2BYL0;A2BT60;Q
46J23;A2C4N1;Q55085;Q110H2;Q
3ZX00;Q3Z8V3;A5FRK6;Q4FLL3;B
2UQY1;B0TX11;Q5NID1;Q2A1M8;
Q14JT4;Q0BKC6;B2SFD7;A4IWA0
;A0Q866;B4U738;Q9X6Y2;B1GZ76 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=rpoC PE=3 
SV=1 
Q9PMC8;Q5HSP5;A8FNK1;A7H5
Q5;A1W1E0 
>sp|Q9PMC8|Y1541_CAMJE 
UPF0271 protein Cj1541 
OS=Campylobacter jejuni 
subsp. jejuni serotype O:2 
(strain ATCC 700819 / NCTC 
11168) GN=Cj1541 PE=3 
SV=1;>sp|Q5HSP5|Y1712_CA
MJR UPF0271 protein CJE1712 
OS=Campylobacter jejuni (strain 
RM1221) GN=CJE1712 PE=3 
SV 
28.084 
Q9I4Z4 
>sp|Q9I4Z4|PAL_PSEAE 
Peptidoglycan-associated 
lipoprotein OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=pal PE=3 
SV=1 
17.925 
Q9HYR9 
>sp|Q9HYR9|CLPP2_PSEAE 
ATP-dependent Clp protease 
proteolytic subunit 2 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=clpP2 PE=3 
SV=1 
22.142 
Q8RHF4;A6LJS5;A7HLZ4;Q8R7L3
;B0KC36;B0K5A5;Q2RM91;P2116
4 
>sp|Q8RHF4|FTHS_FUSNN 
Formate--tetrahydrofolate ligase 
OS=Fusobacterium nucleatum 
subsp. nucleatum (strain ATCC 
25586 / CIP 101130 / JCM 8532 
/ LMG 13131) GN=fhs PE=3 
SV=1;>sp|A6LJS5|FTHS_THEM
4 Formate--tetrahydrofolate 
ligase OS=Thermosipho 
melanesiensis  
58.32 
Q8RCE4;Q03VI4;B1N092;Q03AU4
;B3WCC9 
>sp|Q8RCE4|METK_CALS4 S-
adenosylmethionine synthase 
OS=Caldanaerobacter 
subterraneus subsp. 
tengcongensis (strain DSM 
15242 / JCM 11007 / NBRC 
100824 / MB4) GN=metK PE=3 
SV=1;>sp|Q03VI4|METK_LEUM
M S-adenosylmethionine 
43.46 
308 
 
 
synthase OS=Leuconostoc 
mesenteroides  
Q8G759;B7GTS5;B3DU42 
>sp|Q8G759|RL9_BIFLO 50S 
ribosomal protein L9 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=rplI 
PE=3 
SV=1;>sp|B7GTS5|RL9_BIFLS 
50S ribosomal protein L9 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12 
15.445 
Q8G510;B7GUH2;B3DTE6;A1A32
1 
>sp|Q8G510|Y1209_BIFLO 
UPF0210 protein BL1209 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=BL1209 
PE=3 
SV=1;>sp|B7GUH2|Y2054_BIFL
S UPF0210 protein 
Blon_2054/BLIJ_2131 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ N 
47.605 
Q89S69 
>sp|Q89S69|SYGB_BRADU 
Glycine--tRNA ligase beta 
subunit OS=Bradyrhizobium 
diazoefficiens (strain JCM 10833 
/ IAM 13628 / NBRC 14792 / 
USDA 110) GN=glyS PE=3 
SV=1 
76.433 
Q84BU4 
>sp|Q84BU4|DNAK_LACAC 
Chaperone protein DnaK 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=dnaK PE=3 
SV=1 
66.323 
Q833I9;Q8R965;B3QLX7 
>sp|Q833I9|PGK_ENTFA 
Phosphoglycerate kinase 
OS=Enterococcus faecalis 
(strain ATCC 700802 / V583) 
GN=pgk PE=3 
SV=1;>sp|Q8R965|PGK_CALS4 
Phosphoglycerate kinase 
OS=Caldanaerobacter 
subterraneus subsp. 
tengcongensis (strain DSM 
15242 / JCM 11007 / NBRC 
10082 
42.397 
Q74M28;Q047E8 
>sp|Q74M28|RS6_LACJO 30S 
ribosomal protein S6 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rpsF PE=3 
SV=1;>sp|Q047E8|RS6_LACGA 
30S ribosomal protein S6 
11.57 
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OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718  
Q74L27 
>sp|Q74L27|SYE_LACJO 
Glutamate--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=gltX PE=3 SV=1 
57.094 
Q74KS1;Q045L5;Q5FIP3;A8YWU4 
>sp|Q74KS1|SYL_LACJO 
Leucine--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=leuS PE=3 
SV=1;>sp|Q045L5|SYL_LACGA 
Leucine--tRNA ligase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63)  
92.334 
Q74IC0;Q041U6 
>sp|Q74IC0|SYT_LACJO 
Threonine--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=thrS PE=3 
SV=1;>sp|Q041U6|SYT_LACG
A Threonine--tRNA ligase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / AM 
73.41 
Q74I52;Q041K5;Q1GBF4;Q04BV7 
>sp|Q74I52|GATA_LACJO 
Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=gatA PE=3 
SV=1;>sp|Q041K5|GATA_LAC
GA Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Lactobacillus gasseri (strain 
ATCC 
52.277 
Q6MMS8 
>sp|Q6MMS8|RIMP_BDEBA 
Ribosome maturation factor 
RimP OS=Bdellovibrio 
bacteriovorus (strain ATCC 
15356 / DSM 50701 / NCIB 
9529 / HD100) GN=rimP PE=3 
SV=1 
19.552 
Q6AP86 
>sp|Q6AP86|EFTU1_DESPS 
Elongation factor Tu 1 
OS=Desulfotalea psychrophila 
(strain LSv54 / DSM 12343) 
GN=tuf1 PE=3 SV=1 
43.425 
Q6A6N4 
>sp|Q6A6N4|RL29_PROAC 
50S ribosomal protein L29 
OS=Propionibacterium acnes 
(strain KPA171202 / DSM 
16379) GN=rpmC PE=3 SV=1 
8.885 
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Q5XDW3;P68777;P0DB19;P0DB1
8;P0C0G7;P0C0G6 
>sp|Q5XDW3|G3P_STRP6 
Glyceraldehyde-3-phosphate 
dehydrogenase 
OS=Streptococcus pyogenes 
serotype M6 (strain ATCC BAA-
946 / MGAS10394) GN=gap 
PE=1 
SV=3;>sp|P68777|G3P_STRP8 
Glyceraldehyde-3-phosphate 
dehydrogenase 
OS=Streptococcus pyogenes 
serotype M18 (str 
35.942 
Q5N0G7;Q31LF9;Q6N976;B3Q8J5
;Q2ITA9;Q20ZU5;Q13B10;A5W384 
>sp|Q5N0G7|PHK_SYNP6 
Probable phosphoketolase 
OS=Synechococcus sp. (strain 
ATCC 27144 / PCC 6301 / 
SAUG 1402/1) GN=syc2013_c 
PE=3 
SV=1;>sp|Q31LF9|PHK_SYNE7 
Probable phosphoketolase 
OS=Synechococcus elongatus 
(strain PCC 7942) 
GN=Synpcc7942_2080 PE=3 
SV=1;> 
89.025 
Q5FMX8;Q03PB4 
>sp|Q5FMX8|RTPR_LACAC 
Adenosylcobalamin-dependent 
ribonucleoside-triphosphate 
reductase OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=rtpR PE=3 SV=1 
83.52 
Q5FM77;A8YXL9;Q1GBK4;Q04C0
1;Q38US5 
>sp|Q5FM77|RS8_LACAC 30S 
ribosomal protein S8 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsH PE=3 
SV=1;>sp|A8YXL9|RS8_LACH4 
30S ribosomal protein S8 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rpsH 
PE=3 SV=1 
14.532 
Q5FM12;Q74L08;Q045V5;A8YTF2;
Q03ST6 
>sp|Q5FM12|RL7_LACAC 50S 
ribosomal protein L7/L12 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplL PE=3 
SV=1;>sp|Q74L08|RL7_LACJO 
50S ribosomal protein L7/L12 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN= 
12.493 
Q5FJM5 
>sp|Q5FJM5|PYRH_LACAC 
Uridylate kinase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=pyrH PE=3 
SV=1 
25.832 
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Q5FJG2;Q74IL7 
>sp|Q5FJG2|EFP2_LACAC 
Elongation factor P 2 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=efp2 PE=3 
SV=1 
20.862 
Q59636;Q02RW1;B7UWI4;A6V0V6
;C1DE61;A4XY36;A4VNX5 
>sp|Q59636|NDK_PSEAE 
Nucleoside diphosphate kinase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=ndk PE=3 
SV=2;>sp|Q02RW1|NDK_PSEA
B Nucleoside diphosphate 
kinase OS=Pseudomonas aerug 
15.592 
Q59199;P52694 
>sp|Q59199|G3P_BACFR 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Bacteroides 
fragilis (strain YCH46) GN=gap 
PE=3 
SV=2;>sp|P52694|G3P_RALSO 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Ralstonia 
solanacearum (strain GMI1000) 
GN=gapA PE=3 SV=2 
35.662 
Q59112 
>sp|Q59112|GCTB_ACIFV 
Glutaconate CoA-transferase 
subunit B OS=Acidaminococcus 
fermentans (strain ATCC 25085 
/ DSM 20731 / VR4) GN=gctB 
PE=1 SV=3 
29.166 
Q4JT41;C4LL63;Q8FS84;Q6NJD5;
P42439;A4QBH0;B1VET1 
>sp|Q4JT41|EFTU_CORJK 
Elongation factor Tu 
OS=Corynebacterium jeikeium 
(strain K411) GN=tuf PE=3 
SV=1;>sp|C4LL63|EFTU_CORK
4 Elongation factor Tu 
OS=Corynebacterium 
kroppenstedtii (strain DSM 
44385 / JCM 11950 / CIP 
105744 / CCUG 35717) GN=tuf 
PE=3 SV=1;>sp 
43.914 
Q38US0;Q034Z1;Q74L81;Q5FM82
;Q1GBL0;Q04C07;A8YXL3;A4WVK
0;A8LM65 
>sp|Q38US0|RL29_LACSS 50S 
ribosomal protein L29 
OS=Lactobacillus sakei subsp. 
sakei (strain 23K) GN=rpmC 
PE=3 
SV=1;>sp|Q034Z1|RL29_LACP
3 50S ribosomal protein L29 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-44 
7.6568 
Q1GAP9;Q04B36 
>sp|Q1GAP9|TIG_LACDA 
Trigger factor OS=Lactobacillus 
delbrueckii subsp. bulgaricus 
48.63 
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(strain ATCC 11842 / DSM 
20081 / JCM 1002 / NBRC 
13953 / NCIMB 11778) GN=tig 
PE=3 
SV=1;>sp|Q04B36|TIG_LACDB 
Trigger factor OS=Lactobacillus 
delbrueckii subsp. bulgaricus (st 
Q18BQ3 
>sp|Q18BQ3|Y1384_PEPD6 
UPF0271 protein CD630_13840 
OS=Peptoclostridium difficile 
(strain 630) GN=CD630_13840 
PE=3 SV=1 
29.129 
Q0AUH8;Q0AUG3 
>sp|Q0AUH8|EFTU1_SYNWW 
Elongation factor Tu 1 
OS=Syntrophomonas wolfei 
subsp. wolfei (strain DSM 2245B 
/ Goettingen) GN=tuf1 PE=3 
SV=1;>sp|Q0AUG3|EFTU2_SY
NWW Elongation factor Tu 2 
OS=Syntrophomonas wolfei 
subsp. wolfei (strain DSM 2245B 
/ Goettingen) GN=t 
44.179 
Q044C7 
>sp|Q044C7|RRF_LACGA 
Ribosome-recycling factor 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=frr PE=3 SV=1 
20.358 
Q042I3;P62037 
>sp|Q042I3|Y1276_LACGA 
Probable transcriptional 
regulatory protein LGAS_1276 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=LGAS_1276 PE=3 
SV=1;>sp|P62037|Y904_LACJO 
Probable transcriptional 
regulatory protein L 
26.562 
Q00752;P94360;O32151 
>sp|Q00752|MSMK_STRMU 
Multiple sugar-binding transport 
ATP-binding protein MsmK 
OS=Streptococcus mutans 
serotype c (strain ATCC 700610 
/ UA159) GN=msmK PE=3 
SV=1;>sp|P94360|MSMX_BAC
SU Maltodextrin import ATP-
binding protein MsmX 
OS=Bacillus subtilis (strai 
41.963 
P62053;P59390 
>sp|P62053|LDH2_LACJO L-
lactate dehydrogenase 2 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ldh2 PE=3 
SV=1;>sp|P59390|LDH2_LACP
L L-lactate dehydrogenase 2 
OS=Lactobacillus plantarum 
33.283 
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(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=ldh2 
P59159;B7GUR7;B3DQI6;Q5YP50 
>sp|P59159|GPMA_BIFLO 2,3-
bisphosphoglycerate-dependent 
phosphoglycerate mutase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=gpmA 
PE=3 
SV=1;>sp|B7GUR7|GPMA_BIF
LS 2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Bifidobacterium 
longum subsp. i 
27.605 
P53641;Q88PD5;P09223 
>sp|P53641|SODF_PSEAE 
Superoxide dismutase [Fe] 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=sodB PE=3 
SV=3;>sp|Q88PD5|SODF_PSE
PK Superoxide dismutase [Fe] 
OS=Pseudomonas putida (st 
21.351 
P52042 
>sp|P52042|ACDS_CLOAB 
Acyl-CoA dehydrogenase, short-
chain specific OS=Clostridium 
acetobutylicum (strain ATCC 
824 / DSM 792 / JCM 1419 / 
LMG 5710 / VKM B-1787) 
GN=bcd PE=1 SV=1 
41.386 
P45364 
>sp|P45364|HBD_CLODI 3-
hydroxybutyryl-CoA 
dehydrogenase 
OS=Clostridioides difficile 
GN=hbd PE=3 SV=1 
30.667 
P41791;P0ABF5;P0ABF4 
>sp|P41791|EUTM_SALTY 
Ethanolamine utilization protein 
EutM OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=eutM PE=3 
SV=1;>sp|P0ABF5|EUTM_ECO
L6 Ethanolamine utilization 
protein EutM OS=Escherichia 
coli O6:H1 (strain CFT073 / 
ATCC 700928 
9.8424 
P19410 
>sp|P19410|BAICD_CLOSV 
Probable oxidoreductase BaiCD 
OS=Clostridium scindens (strain 
JCM 10418 / VPI 12708) 
GN=baiCD PE=3 SV=2 
70.273 
P11569 
>sp|P11569|HGDA_ACIFV (R)-
2-hydroxyglutaryl-CoA 
dehydratase subunit alpha 
OS=Acidaminococcus 
fermentans (strain ATCC 25085 
53.896 
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/ DSM 20731 / VR4) GN=hgdA 
PE=1 SV=3 
C4Z987 
>sp|C4Z987|Y1565_AGARV 
UPF0210 protein 
EUBREC_1565 
OS=Agathobacter rectalis (strain 
ATCC 33656 / DSM 3377 / JCM 
17463 / KCTC 5835 / VPI 0990) 
GN=EUBREC_1565 PE=3 
SV=1 
47.419 
C4Z2T8;A9KJI6 
>sp|C4Z2T8|RL29_EUBE2 50S 
ribosomal protein L29 
OS=Eubacterium eligens (strain 
ATCC 27750 / VPI C15-48) 
GN=rpmC PE=3 
SV=1;>sp|A9KJI6|RL29_LACP7 
50S ribosomal protein L29 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=rpmC P 
7.5736 
B9L7K0 
>sp|B9L7K0|EFG_NAUPA 
Elongation factor G OS=Nautilia 
profundicola (strain ATCC BAA-
1463 / DSM 18972 / AmH) 
GN=fusA PE=3 SV=1 
77.727 
B8CM45;A8H995 
>sp|B8CM45|GLPK_SHEPW 
Glycerol kinase OS=Shewanella 
piezotolerans (strain WP3 / JCM 
13877) GN=glpK PE=3 
SV=1;>sp|A8H995|GLPK_SHEP
A Glycerol kinase 
OS=Shewanella pealeana 
(strain ATCC 700345 / ANG-
SQ1) GN=glpK PE=3 SV=1 
53.932 
B7GQU7;Q8G6D6;B3DRV9 
>sp|B7GQU7|PGK_BIFLS 
Phosphoglycerate kinase 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12) GN=pgk 
PE=3 
SV=1;>sp|Q8G6D6|PGK_BIFLO 
Phosphoglycerate kinase 
OS=Bifidobacterium longum 
(strain NCC 2705) G 
41.895 
B7GNG8 
>sp|B7GNG8|RL7_BIFLS 50S 
ribosomal protein L7/L12 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12) GN=rplL 
PE=3 SV=1 
13.22 
B3PME9 
>sp|B3PME9|EFG_MYCA5 
Elongation factor G 
OS=Mycoplasma arthritidis 
77.77 
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(strain 158L3-1) GN=fusA PE=3 
SV=1 
B3EP63;Q3B6G3;B4S5M9 
>sp|B3EP63|EFTU_CHLPB 
Elongation factor Tu 
OS=Chlorobium 
phaeobacteroides (strain BS1) 
GN=tuf PE=3 
SV=1;>sp|Q3B6G3|EFTU_CHL
L7 Elongation factor Tu 
OS=Chlorobium luteolum (strain 
DSM 273 / 2530) GN=tuf PE=3 
SV=1;>sp|B4S5M9|EFTU_PRO
A2 Elongation factor Tu OS 
43.11 
B2G8Y0;A5VLK8 
>sp|B2G8Y0|EFG_LACRJ 
Elongation factor G 
OS=Lactobacillus reuteri (strain 
JCM 1112) GN=fusA PE=3 
SV=1;>sp|A5VLK8|EFG_LACR
D Elongation factor G 
OS=Lactobacillus reuteri (strain 
DSM 20016) GN=fusA PE=3 
SV=1 
76.77 
B1KTJ6;B1IDB7;A7G9Y1;A7FQN8 
>sp|B1KTJ6|TPIS_CLOBM 
Triosephosphate isomerase 
OS=Clostridium botulinum 
(strain Loch Maree / Type A3) 
GN=tpiA PE=3 
SV=1;>sp|B1IDB7|TPIS_CLOB
K Triosephosphate isomerase 
OS=Clostridium botulinum 
(strain Okra / Type B1) GN=tpiA 
PE=3 
SV=1;>sp|A7G9Y1|TPIS_CLOB 
27.337 
A9KQ65;Q9PHN5;Q5HVD9;A8FL5
3;A1VYZ2 
>sp|A9KQ65|ILVC_LACP7 
Ketol-acid reductoisomerase 
(NADP(+)) 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=ilvC PE=3 
SV=1;>sp|Q9PHN5|ILVC_CAMJ
E Ketol-acid reductoisomerase 
(NADP(+)) OS=Campylobacter 
jejuni subsp. jejuni ser 
36.771 
A8YVR7;Q74IR8;Q1G9N8;Q049U4
;Q044C8 
>sp|A8YVR7|PYRH_LACH4 
Uridylate kinase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=pyrH 
PE=3 SV=1 
25.857 
A8YVQ3;Q1G9R2;Q049W6;Q1WU
E8 
>sp|A8YVQ3|DNAK_LACH4 
Chaperone protein DnaK 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=dnaK 
PE=3 SV=1 
65.7 
A8YTD2;A9NEI5;B1YGS7;A8F960;
A7Z0L4;Q839V7;Q81VV3;Q81J61;
Q73FB9;Q6HPT0;Q65PD0;Q63HB
>sp|A8YTD2|SYE_LACH4 
Glutamate--tRNA ligase 
OS=Lactobacillus helveticus 
57.621 
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2;A9VNA0;A7GJZ9;A0R8F9;Q38Y
Y5;Q1WSS4;Q03E40;Q88YY0;Q03
5R5;B3WA39;B2GAB3;Q1G8Y5;Q
048S3;O86083;P22250;Q1AU10;Q
4UME8;A8GPB2;A8EY39;A5FZX8;
Q68WB4;Q9ZCT8;Q0BTZ0;B3CST
4;A5CD02;Q9CDZ7;Q02W76;A2R
NK5;A4W496;Q0C1A6;Q8EU02;P2
2249;A4IJG6;Q5L431;Q92F38;Q8Y
AB3;Q724H5;A0AF36;Q03SU7;Q0
4GX5;Q03ZR1;B1MWU1;Q73R87;
Q92H06;B0BUL7;A8GT27;A8F2B0 
(strain DPC 4571) GN=gltX 
PE=3 SV=1 
A6LR06 
>sp|A6LR06|TPIS_CLOB8 
Triosephosphate isomerase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=tpiA PE=3 SV=1 
26.894 
A5V9S7 
>sp|A5V9S7|SECA_SPHWW 
Protein translocase subunit 
SecA OS=Sphingomonas 
wittichii (strain RW1 / DSM 6014 
/ JCM 10273) GN=secA PE=3 
SV=1 
102.11 
A5EED4 
>sp|A5EED4|SYGB_BRASB 
Glycine--tRNA ligase beta 
subunit OS=Bradyrhizobium sp. 
(strain BTAi1 / ATCC BAA-1182) 
GN=glyS PE=3 SV=1 
76.575 
A1A3P5;Q8G6W1;B3DNP9;B7GT4
7;B8DT62;A6WFV7;Q6AC76;Q6F1
49;P05646;Q8RH05;B1YKS9;Q81L
S2;Q818E9;Q730M1;Q6HDK7;Q63
4M7;C3P8M0;C3L5R7;C1ESK8;B9
IY81;B7JN39;B7IYG7;B7HPL3;B7H
CU0;A9VHU1;A7GT08;A0RIT3;P0
CY99;P0CY98;B1VMF3;Q54215;Q
05558;A1SPX5;Q82EX9;A0K1L3;B
2GGP0;B8H6Q1;C5C3P2;Q30Q10;
B6YRF7;Q2VYT1 
>sp|A1A3P5|DNAK_BIFAA 
Chaperone protein DnaK 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=dnaK PE=3 
SV=1;>sp|Q8G6W1|DNAK_BIF
LO Chaperone protein DnaK 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=dnaK 
PE=3 SV=1;> 
66.839 
A1A317;Q8G514;B7GUG7;B3DTE
2;A6W5T0;A0JZ93;A1R8V4;Q0RR
T0;A8LC64;Q47LI5;Q6A6K6;Q9L0
L0;Q82DQ5;Q5YQP4;Q5YPE0;Q4J
T32;A4FPP3;Q8NT26;A4QBG2;A1
SEK1;A1T4J2;Q0SFB3;C4LL71;C1
AYV9;C0ZVQ6;Q50388;P60281;Q8
FS97;Q1BDF0;A3PV78;A1UBJ3;A
4T1P4;Q73SE4;P60280;A9WSY0;
A0QL49;B2HSJ3;A0PM24;A5U052;
P9WGY9;P9WGY8;P30760;P0A68
1;B8ZSC7;A1KGE7;Q2JFI5;Q93GF
2;P59642;B0RB25;A5CUC7;Q6AC
X5;Q9L637;A0LRL3;B1VES1 
>sp|A1A317|RPOB_BIFAA 
DNA-directed RNA polymerase 
subunit beta 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=rpoB PE=3 
SV=2;>sp|Q8G514|RPOB_BIFL
O DNA-directed RNA 
polymerase subunit beta 
OS=Bifidobacterium longum ( 
131.48 
A1A1I2 
>sp|A1A1I2|RRF_BIFAA 
Ribosome-recycling factor 
OS=Bifidobacterium 
adolescentis (strain ATCC 
20.154 
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15703 / DSM 20083 / NCTC 
11814 / E194a) GN=frr PE=3 
SV=1 
A1A033;Q8G443;B8DVY5;B3DPX4 
>sp|A1A033|RL7_BIFAA 50S 
ribosomal protein L7/L12 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=rplL PE=3 
SV=1;>sp|Q8G443|RL7_BIFLO 
50S ribosomal protein L7/L12 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=rplL P 
13.249 
Q8A753;Q7MU77 
>sp|Q8A753|PGK_BACTN 
Phosphoglycerate kinase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pgk PE=3 SV=1 
45.026 
Q8A6P8 
>sp|Q8A6P8|CH60_BACTN 60 
kDa chaperonin 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=groL PE=3 SV=1 
58.202 
G8JZS4 
>sp|G8JZS4|SUSB_BACTN 
Glucan 1,4-alpha-glucosidase 
SusB OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susB PE=1 SV=1 
84.377 
Q8A8L4 
>sp|Q8A8L4|SERC_BACTN 
Phosphoserine 
aminotransferase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=serC PE=3 SV=1 
39.434 
Q8A474;Q64NK6;Q5L8A7;A6KYJ7 
>sp|Q8A474|EFG_BACTN 
Elongation factor G 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=fusA PE=3 
SV=1;>sp|Q64NK6|EFG_BACF
R Elongation factor G 
OS=Bacteroides fragilis (strain 
YCH46) GN=fusA PE=3 
SV=1;>sp|Q5 
77.587 
Q8A5W2;A6L7P7;Q97FP8;Q8XI54;
Q0TN51;Q0SQS9 
>sp|Q8A5W2|G6PI_BACTN 
Glucose-6-phosphate isomerase 
OS=Bacteroides 
48.89 
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thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) GN=pgi 
PE=1 SV=1 
P31242;A6TGU6;Q56850;A1JRU8;
A8GKC3;Q8ZAS9;Q664X6;Q1CNR
7;Q1CC20;A7FDH5;A4TH46;Q7N9
87;A7MPN7;Q8Z1T9;Q5PKZ7;B5B
JV4;B4TQP9;B4TDL4;B4T1S6 
>sp|P31242|LAMB_KLEPN 
Maltoporin OS=Klebsiella 
pneumoniae GN=lamB PE=3 
SV=1;>sp|A6TGU6|LAMB2_KL
EP7 Maltoporin 2 OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) 
GN=lamB2 PE=3 SV=1 
47.804 
Q88VE0 
>sp|Q88VE0|EFTU_LACPL 
Elongation factor Tu 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=tuf PE=3 
SV=1 
43.377 
P18815 
>sp|P18815|MALE_KLEAE 
Maltose-binding periplasmic 
protein OS=Klebsiella 
aerogenes GN=malE PE=3 
SV=1 
43.136 
P0AEY0;P0AEX9 
>sp|P0AEY0|MALE_ECO57 
Maltose-binding periplasmic 
protein OS=Escherichia coli 
O157:H7 GN=malE PE=1 
SV=1;>sp|P0AEX9|MALE_ECO
LI Maltose-binding periplasmic 
protein OS=Escherichia coli 
(strain K12) GN=malE PE=1 
SV=1 
43.387 
B2VL84 
>sp|B2VL84|CH60_ERWT9 60 
kDa chaperonin OS=Erwinia 
tasmaniensis (strain DSM 17950 
/ CIP 109463 / Et1/99) GN=groL 
PE=3 SV=1 
57.374 
A6LQ87 
>sp|A6LQ87|CH60_CLOB8 60 
kDa chaperonin OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=groL PE=3 
SV=1 
57.553 
A6L5A6 
>sp|A6L5A6|SERC_BACV8 
Phosphoserine 
aminotransferase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=serC PE=3 SV=1 
39.555 
P24017 
>sp|P24017|OMPA_KLEPN 
Outer membrane protein A 
OS=Klebsiella pneumoniae 
GN=ompA PE=1 SV=2 
37.061 
P19576 
>sp|P19576|MALE_SALTY 
Maltose-binding periplasmic 
protein OS=Salmonella 
43.18 
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typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=malE PE=1 SV=2 
P07206 
>sp|P07206|PULA_KLEPN 
Pullulanase OS=Klebsiella 
pneumoniae GN=pulA PE=1 
SV=2 
118.1 
B2UZ02;B2TIX0 
>sp|B2UZ02|CH60_CLOBA 60 
kDa chaperonin OS=Clostridium 
botulinum (strain Alaska E43 / 
Type E3) GN=groL PE=3 
SV=1;>sp|B2TIX0|CH60_CLOB
B 60 kDa chaperonin 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=groL PE=3 SV=1 
57.82 
A6L2X7 
>sp|A6L2X7|DNAK_BACV8 
Chaperone protein DnaK 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=dnaK PE=3 SV=1 
68.354 
A0Q2T1;P48212;B9MLY9;A4XJ09;
Q7MAE3 
>sp|A0Q2T1|CH60_CLONN 60 
kDa chaperonin OS=Clostridium 
novyi (strain NT) GN=groL PE=3 
SV=1 
58.151 
Q64UR4;Q5LDN9 
>sp|Q64UR4|SERC_BACFR 
Phosphoserine 
aminotransferase 
OS=Bacteroides fragilis (strain 
YCH46) GN=serC PE=3 
SV=1;>sp|Q5LDN9|SERC_BAC
FN Phosphoserine 
aminotransferase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=serC 
PE=3 S 
39.196 
Q64PM7;Q5L9E3 
>sp|Q64PM7|G6PI_BACFR 
Glucose-6-phosphate isomerase 
OS=Bacteroides fragilis (strain 
YCH46) GN=pgi PE=3 
SV=1;>sp|Q5L9E3|G6PI_BACF
N Glucose-6-phosphate 
isomerase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=pgi PE=3 SV=1 
48.749 
P0ABK6;P0ABK5 
>sp|P0ABK6|CYSK_ECO57 
Cysteine synthase A 
OS=Escherichia coli O157:H7 
GN=cysK PE=3 
SV=2;>sp|P0ABK5|CYSK_ECO
LI Cysteine synthase A 
OS=Escherichia coli (strain K12) 
GN=cysK PE=1 SV=2 
34.489 
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P0A1E4;P0A1E3;P57171;Q8KA48 
>sp|P0A1E4|CYSK_SALTI 
Cysteine synthase A 
OS=Salmonella typhi GN=cysK 
PE=3 
SV=2;>sp|P0A1E3|CYSK_SALT
Y Cysteine synthase A 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=cysK PE=1 SV=2 
34.535 
A6LPQ8 
>sp|A6LPQ8|EFG_CLOB8 
Elongation factor G 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=fusA PE=3 SV=1 
75.866 
Q8AAP2;A6L7J7 
>sp|Q8AAP2|SYT_BACTN 
Threonine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=thrS PE=3 SV=1 
74.552 
Q8A4N6;Q64N73;Q5L7Z7;Q7MW7
9;B2RIW6;B6YRB0;Q3APY4;B4SD
X4;Q3B2E2;B3QM09;A1BDY1;Q8K
BY3;B4S5G5;B3EH06 
>sp|Q8A4N6|PNP_BACTN 
Polyribonucleotide 
nucleotidyltransferase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pnp PE=3 
SV=1;>sp|Q64N73|PNP_BACF
R Polyribonucleotide 
nucleotidyltransferase 
OS=Bacteroides fragi 
78.367 
Q8A0Z3 
>sp|Q8A0Z3|EFTS_BACTN 
Elongation factor Ts 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) GN=tsf 
PE=3 SV=1 
35.897 
Q8A004;Q64XV7;Q5LH03 
>sp|Q8A004|PUR7_BACTN 
Phosphoribosylaminoimidazole-
succinocarboxamide synthase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=purC PE=3 
SV=1;>sp|Q64XV7|PUR7_BAC
FR 
Phosphoribosylaminoimidazole-
succinocarboxam 
35.765 
Q891G4;Q24QE3;B8FNT7 
>sp|Q891G4|CH60_CLOTE 60 
kDa chaperonin OS=Clostridium 
tetani (strain Massachusetts / 
E88) GN=groL PE=3 SV=1 
58.466 
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P24748 
>sp|P24748|G3P_CITFR 
Glyceraldehyde-3-phosphate 
dehydrogenase (Fragment) 
OS=Citrobacter freundii GN=gap 
PE=3 SV=1 
31.477 
Q8A0U2 
>sp|Q8A0U2|TPIS_BACTN 
Triosephosphate isomerase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=tpiA PE=3 SV=1 
26.801 
Q89Z05 
>sp|Q89Z05|ENO_BACTN 
Enolase OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=eno PE=3 SV=1 
46.158 
Q64VP2;Q5LEQ6;Q7MVQ5;B2RJD
6;Q11UK3;A6GY22;A5FP01 
>sp|Q64VP2|SYT_BACFR 
Threonine--tRNA ligase 
OS=Bacteroides fragilis (strain 
YCH46) GN=thrS PE=3 
SV=1;>sp|Q5LEQ6|SYT_BACF
N Threonine--tRNA ligase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=thrS 
PE=3 SV=1 
74.405 
P24164 
>sp|P24164|G3P_KLEPN 
Glyceraldehyde-3-phosphate 
dehydrogenase (Fragment) 
OS=Klebsiella pneumoniae 
GN=gap PE=3 SV=2 
32.305 
P0AE11;P0AE10;P0AE09;P0AE08 
>sp|P0AE11|AHPC_SHIFL Alkyl 
hydroperoxide reductase C 
OS=Shigella flexneri GN=ahpC 
PE=3 
SV=2;>sp|P0AE10|AHPC_ECO
57 Alkyl hydroperoxide 
reductase C OS=Escherichia 
coli O157:H7 GN=ahpC PE=3 
SV=2;>sp|P0AE09|AHPC_ECO
L6 Alkyl hydroperoxide 
reductase C OS=Escher 
20.761 
P0A252;P0A251 
>sp|P0A252|AHPC_SALTI Alkyl 
hydroperoxide reductase C 
OS=Salmonella typhi GN=ahpC 
PE=3 
SV=2;>sp|P0A251|AHPC_SALT
Y Alkyl hydroperoxide reductase 
C OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ahpC PE=1 SV=2 
20.747 
P09373;P42632 
>sp|P09373|PFLB_ECOLI 
Formate acetyltransferase 1 
OS=Escherichia coli (strain K12) 
GN=pflB PE=1 SV=2 
85.356 
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P07811 
>sp|P07811|PULA_KLEAE 
Pullulanase OS=Klebsiella 
aerogenes GN=pulA PE=1 
SV=1 
119.33 
O83023;Q0I554;B0UWS7;A6VKV4 
>sp|O83023|PCKA_SELRU 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Selenomonas ruminantium 
GN=pckA PE=3 SV=1 
59.705 
B4EXE2 
>sp|B4EXE2|CH60_PROMH 60 
kDa chaperonin OS=Proteus 
mirabilis (strain HI4320) 
GN=groL PE=3 SV=1 
57.651 
B0TVL3;A8H8W3;A8FQY1;B8CID3
;B1KIR6;Q8KIX0;Q07WX7 
>sp|B0TVL3|CH60_SHEHH 60 
kDa chaperonin OS=Shewanella 
halifaxensis (strain HAW-EB4) 
GN=groL PE=3 
SV=1;>sp|A8H8W3|CH60_SHE
PA 60 kDa chaperonin 
OS=Shewanella pealeana 
(strain ATCC 700345 / ANG-
SQ1) GN=groL PE=3 
SV=1;>sp|A8FQY1|CH60_SHE
SH 60 kDa chaperonin OS 
57.302 
A8AQM8;B2VK36;C4K4F9;Q8ZJB3
;Q664R6;Q1CCT8;Q1C2U0;B2K5N
5;B1JIV5;A9R462;A7FNN9;A4TGY
6;C4LBU4;Q7NQF0;Q7N9B2;Q7V
NA2;Q057A1;Q492B1;C1DAR4;A5
CXN7;Q8D3H2;P59451;Q72CI3;A1
VEB9;Q5P335;Q8DCQ8;Q87L45;Q
7MH42;C5CP58;A4SUV8;A1AVJ7;
Q8XRM7;Q7WRC7;Q7W2F8;Q7VT
D5;Q63Q08;Q62GK2;Q3JMR0;Q39
KH0;Q2SU24;Q2L2H1;Q1BRU5;Q
13TG7;Q12GX4;A2SLG0;A2S7H3;
A1WHC2;A1TJ04;Q8K948;P57593;
B8D9V0;B8D852;B9MB70;A1W2Q
4;Q46WE0;O50565;Q8XV10;Q1LI2
9;Q4FQG5;Q1Q8P1;Q7VRN9;B7I7
S1;B7GYM8;B2HUQ4;B0VTG3;B0
V8Y3;A3M306;Q1MPS9;B8DN94;Q
4FLL6;Q30Z38;Q3SLQ2;Q47JA6;Q
1H4P0;A1KB30;Q9KUZ7;Q8EK71;
Q605A9;Q5E8B9;Q12SW2;Q0I0A8
;Q0HNU0;Q089Q7;Q21RV5;B1Y7
G9;B1XSP8;Q13UU8;Q15YA7;A4G
9U1;Q7W455;Q2KV83;Q7WFL2 
>sp|A8AQM8|EFG_CITK8 
Elongation factor G 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=fusA PE=3 
SV=1 
77.459 
A6KXA0 
>sp|A6KXA0|CH60_BACV8 60 
kDa chaperonin 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=groL PE=3 SV=1 
58.143 
Q9HWD2;Q4K530;A4XZ93;Q88QN
8;Q4ZMP1;Q48D33;C3K2X9;A8Z6I
6;A7GZJ4;Q5NHX0;Q2A5H2;Q14J
>sp|Q9HWD2|EFG1_PSEAE 
Elongation factor G 1 
OS=Pseudomonas aeruginosa 
77.784 
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C2;Q0BNS9;B2SDY7;A7N9S4;A4I
ZT6;A0Q4I1;B0U0Z1 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fusA PE=1 
SV=1;>sp|Q4K530|EFG_PSEF5 
Elongation factor G 
OS=Pseudomonas fluorescens 
(strain A 
Q8XJW5;Q0TPW7;Q0SSI2;A7GGL
4;A7FWQ7;A5I557;Q97QA8;C1CE
S2;B8ZK31;B5E552;B1ICC9;A0PZ
C6;B2UWY4;B2TP91;B1KXT6;B1IJ
M8;Q08636;A8AUJ7;A3CK48;Q72J
72;Q56403;B8CZG8;B0K8E8;B0K5
J0;Q9A1Q3;Q8P2U6;Q5XE50;Q48
VL3;Q1JNS8;Q1JIX5;Q1JDX0;Q1J
8S5;P0DA07;P0DA06;B5XJH3;A2
RC97;Q896K4;Q891P1;Q834X9 
>sp|Q8XJW5|VATA_CLOPE V-
type ATP synthase alpha chain 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=atpA 
PE=3 
SV=1;>sp|Q0TPW7|VATA_CLO
P1 V-type ATP synthase alpha 
chain OS=Clostridium 
perfringens (strain ATCC 13124 
/ DSM 756 / JCM 1290 / NCIMB 
6125 /  
64.872 
Q8KNX9;Q5LG64;A6L3M9;B8I4U1 
>sp|Q8KNX9|ENO_BACFR 
Enolase OS=Bacteroides fragilis 
(strain YCH46) GN=eno PE=3 
SV=1;>sp|Q5LG64|ENO_BACF
N Enolase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=eno PE=3 
SV=1;>sp|A6L3M9|ENO_BACV
8 Enolase OS=Bacteroides vu 
46.403 
Q8ABB0 
>sp|Q8ABB0|HIS1_BACTN ATP 
phosphoribosyltransferase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=hisG PE=3 SV=1 
31.333 
Q8AB53 
>sp|Q8AB53|Y258_BACTN 
Putative glucosamine-6-
phosphate deaminase-like 
protein BT_0258 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=BT_0258 PE=3 SV=1 
75.265 
Q8A9K9;Q64U07;Q5LCU8 
>sp|Q8A9K9|SYI_BACTN 
Isoleucine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=ileS PE=3 SV=1 
132.49 
Q8A9J0;A6L4U5 
>sp|Q8A9J0|UXAB_BACTN 
Altronate oxidoreductase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
53.962 
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10582 / E50 / VPI-5482) 
GN=uxaB PE=3 SV=1 
Q8A9B8;Q5LCH4;P0CJ84;E1WNR
6 
>sp|Q8A9B8|HTPG_BACTN 
Chaperone protein HtpG 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=htpG PE=3 
SV=1;>sp|Q5LCH4|HTPG_BAC
FN Chaperone protein HtpG 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / 
78.436 
Q8A4A2;Q64NN5;Q5L8D6;A6KYH
0 
>sp|Q8A4A2|RPOA_BACTN 
DNA-directed RNA polymerase 
subunit alpha OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=rpoA PE=3 
SV=1;>sp|Q64NN5|RPOA_BAC
FR DNA-directed RNA 
polymerase subunit alpha 
OS=Bacteroides fr 
37.448 
Q8A468;Q64NJ6;Q5L896;A6KYK4;
Q11QA4;Q15YB2;A6LE82 
>sp|Q8A468|RL7_BACTN 50S 
ribosomal protein L7/L12 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=rplL PE=3 
SV=1;>sp|Q64NJ6|RL7_BACFR 
50S ribosomal protein L7/L12 
OS=Bacteroides fragilis (strain 
YCH46) GN=rpl 
12.679 
Q8A1D5;Q64Z17;Q5LI12;A6KYP1 
>sp|Q8A1D5|PYRE_BACTN 
Orotate 
phosphoribosyltransferase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pyrE PE=3 
SV=1;>sp|Q64Z17|PYRE_BACF
R Orotate 
phosphoribosyltransferase 
OS=Bacteroides fragilis (strain Y 
23.453 
Q8A155 
>sp|Q8A155|PUR9_BACTN 
Bifunctional purine biosynthesis 
protein PurH OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=purH PE=3 SV=1 
55.879 
Q88YE7 
>sp|Q88YE7|GLMS_LACPL 
Glutamine--fructose-6-
phosphate aminotransferase 
65.466 
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[isomerizing] OS=Lactobacillus 
plantarum (strain ATCC BAA-
793 / NCIMB 8826 / WCFS1) 
GN=glmS PE=3 SV=2 
Q64U78;Q5LD58;Q8A9S7;A6L5K3;
Q7MXW0;B2RGR2 
>sp|Q64U78|GLYA_BACFR 
Serine 
hydroxymethyltransferase 
OS=Bacteroides fragilis (strain 
YCH46) GN=glyA PE=3 
SV=1;>sp|Q5LD58|GLYA_BAC
FN Serine 
hydroxymethyltransferase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=glyA 
PE=3 
46.857 
Q64P83;Q5L923;A6KXL2 
>sp|Q64P83|TPIS_BACFR 
Triosephosphate isomerase 
OS=Bacteroides fragilis (strain 
YCH46) GN=tpiA PE=3 
SV=1;>sp|Q5L923|TPIS_BACF
N Triosephosphate isomerase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=tpiA 
PE=3 SV=1 
26.593 
Q64P30;Q5L8W8;A6LHM8 
>sp|Q64P30|EFTS_BACFR 
Elongation factor Ts 
OS=Bacteroides fragilis (strain 
YCH46) GN=tsf PE=3 
SV=1;>sp|Q5L8W8|EFTS_BAC
FN Elongation factor Ts 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=tsf 
PE=3 SV=1 
36.014 
Q5L9Q6 
>sp|Q5L9Q6|DAPDH_BACFN 
Meso-diaminopimelate D-
dehydrogenase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=ddh PE=1 SV=1 
32.327 
Q1WU83 
>sp|Q1WU83|EFTU_LACS1 
Elongation factor Tu 
OS=Lactobacillus salivarius 
(strain UCC118) GN=tuf PE=3 
SV=1 
43.273 
Q03SL5 
>sp|Q03SL5|ENO_LACBA 
Enolase OS=Lactobacillus 
brevis (strain ATCC 367 / JCM 
1170) GN=eno PE=3 SV=1 
47.675 
P24016 
>sp|P24016|OMPA_CITFR 
Outer membrane protein A 
(Fragment) OS=Citrobacter 
freundii GN=ompA PE=3 SV=1 
25.663 
P12267 
>sp|P12267|FM3_KLEPN 
Fimbrial subunit type 3 
20.695 
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OS=Klebsiella pneumoniae 
GN=mrkA PE=3 SV=1 
P02938;Q8XFI1;Q7CQN4;Q5PH64
;P69780;P69778;P69777;P69776;
Q6D622;Q8Z6K1;Q5PH62;Q8ZDZ
6;Q66A25;P02939;Q5PH63;Q8ZPP
9 
>sp|P02938|LPP_SERMA Major 
outer membrane lipoprotein 
OS=Serratia marcescens 
GN=lpp PE=3 
SV=1;>sp|Q8XFI1|LPP1_SALTI 
Major outer membrane 
lipoprotein 1 OS=Salmonella 
typhi GN=lpp1 PE=3 
SV=1;>sp|Q7CQN4|LPP1_SAL
TY Major outer membrane 
lipoprotein 1 OS=Salmone 
8.2391 
C3L3G7;C1FVU0;B1KZN7;B1ILM3;
A7GHH6;A7FXL5;A5I640;B9E041;
A5N6M2;Q0TNS7;Q0SRE3;P2682
3;Q892R0 
>sp|C3L3G7|DNAK_CLOB6 
Chaperone protein DnaK 
OS=Clostridium botulinum 
(strain 657 / Type Ba4) 
GN=dnaK PE=3 
SV=1;>sp|C1FVU0|DNAK_CLO
BJ Chaperone protein DnaK 
OS=Clostridium botulinum 
(strain Kyoto / Type A2) 
GN=dnaK PE=3 
SV=1;>sp|B1KZN7|DNAK_CLO
BM Chaperone 
66.841 
A6LTP1;B2V351;B2TN05 
>sp|A6LTP1|SYD_CLOB8 
Aspartate--tRNA ligase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=aspS PE=3 
SV=1;>sp|B2V351|SYD_CLOBA 
Aspartate--tRNA ligase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=aspS PE=3 
SV=1;>sp|B2TN05|SYD_C 
68.01 
A6L9S2 
>sp|A6L9S2|SYT_PARD8 
Threonine--tRNA ligase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=thrS PE=3 
SV=1 
74.917 
Q9I5Z0;Q02TL9;B7V4D3;A6UZ09;
C1DKE3 
>sp|Q9I5Z0|METK_PSEAE S-
adenosylmethionine synthase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=metK PE=3 
SV=1;>sp|Q02TL9|METK_PSE
AB S-adenosylmethionine 
synthase OS=Pseudomonas ae 
42.709 
Q9HVN5;Q889C2;Q88Q71;Q9JYQ
8;Q9JTP9;Q7NWN7;Q7V2A3;Q82
SD8;Q9CB26;Q73T66;P9WPD1;P9
WPD0;P63287;Q73IE4;Q9RA63;Q
>sp|Q9HVN5|CLPB_PSEAE 
Chaperone protein ClpB 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
95.004 
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72IK9;Q8DEV2;Q7MNK1;Q8EBE6;
Q9A9T4;Q9PGC1;Q8PHQ4;Q8P6A
0;Q87AX8;Q8XZR0;Q7U637;Q7VB
L0;Q7WHB6;Q7W9E6;Q7VYV6;Q7
V8B1;Q929G7;Q8Y570;Q81GM5;Q
71XF9;G2K265;Q9CFF3;Q88VX7;
O68185;Q98G96;Q92MK7;Q831Y7
;Q99VB5;Q8NXE7;Q8CPT5;Q7A6
G6;Q6GIB2;Q6GAV1;Q5HQI5;Q5H
HB0;Q7CU92;Q8KA87;Q8EW28;P
47597;P75247;Q7NAZ3;Q9S5Z2;Q
9CI09;P35594;Q8EU05;Q8CQ88;Q
5HRM8;Q99W78;Q8NXY8;Q7A797
;Q6GJE4;Q6GBW3;Q2YSD6;Q2G0
P5;Q2FJB5;P0C281;Q49V34;Q4L3
I4;P9WPC9;P9WPC8;P24428;P0A
523;A0R574;Q6NF05;Q9RVI3;Q8F
M94;P53532;Q7X2S8;Q6MIV0;Q9Z
6E4;Q92JK8;Q4UN57;Q1RGR1;Q7
3K92;Q8F509;Q72QU2;Q97KG0;Q
82EU9;Q8DJ40;Q7NFE9;P74361;
O87444;Q8YJ91;Q7CEG6;P53533;
O83110;Q89UL2;Q6N1H2;Q8YUL9
;Q7UM33;Q8G4X4;P74459;O3167
3;P37571 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=clpB PE=3 
SV=1 
Q8ZKP7;Q8Z2Y2;Q5PJE0;Q57HD
6;B5RF90;B5QX14;B5FPS9;B5F0
R2;B5BJJ8;B4TPU2;B4TCL7;B4T0
S7;A9MZG8;Q7X222;Q3YV59;Q32
A84;Q31U71;Q0SZA9;P0A861;B7L
VC6;B2TVR1;Q1R3Z9;Q0TAE5;P0
A860;P0A859;P0A858;B7NU88;B7
NFL6;B7MI51;B7M6X0;B6I4R2;B5
YZ57;B1XB85;B1LNM2;B1IVG0;A8
A724;A7ZUD3;A1AI95;Q8ZJK9;Q6
6GA1;Q1CD40;Q1C2A4;B2JZB1;B
1JQ90;A9R6B0;A8GLA8;A7FCW8;
A4TSA1;A1JHZ7;Q6CZ81;Q2NQX
4;B2VF53;B4F161 
>sp|Q8ZKP7|TPIS_SALTY 
Triosephosphate isomerase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=tpiA PE=3 
SV=1;>sp|Q8Z2Y2|TPIS_SALTI 
Triosephosphate isomerase 
OS=Salmonella typhi GN=tpiA 
PE=3 
SV=1;>sp|Q5PJE0|TPIS_SALP
A Triosephosphate is 
26.916 
Q8XJ28;Q0TP28;Q0SRP8 
>sp|Q8XJ28|SYD_CLOPE 
Aspartate--tRNA ligase 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=aspS 
PE=3 
SV=1;>sp|Q0TP28|SYD_CLOP
1 Aspartate--tRNA ligase 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 / 
NCTC 8237 / Type A)  
68.025 
Q8AA75 
>sp|Q8AA75|PYRG_BACTN 
CTP synthase OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pyrG PE=3 SV=1 
59.864 
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Q8A9E3;A6LBU6;A6L585;Q64TQ1;
Q5LCK2;Q7MXM0;B2RHE0 
>sp|Q8A9E3|SYD_BACTN 
Aspartate--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=aspS PE=3 
SV=1;>sp|A6LBU6|SYD_PARD
8 Aspartate--tRNA ligase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 207 
66.563 
Q8A469;Q64NJ7;Q5L897;Q11QA5 
>sp|Q8A469|RPOB_BACTN 
DNA-directed RNA polymerase 
subunit beta OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=rpoB PE=3 
SV=1;>sp|Q64NJ7|RPOB_BAC
FR DNA-directed RNA 
polymerase subunit beta 
OS=Bacteroides frag 
142.49 
Q8A1E9 
>sp|Q8A1E9|AOTC_BACTN N-
acetylornithine 
carbamoyltransferase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=argF PE=1 SV=1 
36.382 
Q8A0B5 
>sp|Q8A0B5|KDUI2_BACTN 4-
deoxy-L-threo-5-hexosulose-
uronate ketol-isomerase 2 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=kduI2 PE=3 SV=2 
33.05 
Q81VE1;Q73ER9;Q6HPC7;Q63GV
7;C3PAV1;C3L507;C1EUB1;B9J1H
2;B7JM60;B7HS05;A0R8W4;Q814
B0;B7H4Q7;Q4MPR6;B7IUT0;A9V
QG8;A7GKG0;Q5L3E6;Q07201;C5
D4F4;A4IJV3;P26209;Q8VV84;Q9
AGE6;Q929V0;Q71XU6;C1KX21;B
8DH59;A0AKH5;Q65MZ8;A8FAG3;
A7Z207;P28598;Q0C0T0 
>sp|Q81VE1|CH60_BACAN 60 
kDa chaperonin OS=Bacillus 
anthracis GN=groL PE=3 
SV=1;>sp|Q73ER9|CH60_BAC
C1 60 kDa chaperonin 
OS=Bacillus cereus (strain 
ATCC 10987 / NRS 248) 
GN=groL PE=3 
SV=2;>sp|Q6HPC7|CH60_BAC
HK 60 kDa chaperonin 
OS=Bacillus thuringiensis sub 
57.431 
Q81K75;Q816G0;Q72YI4;Q6HC08;
Q632G4;B7JDF6;B7IMR7;B7HTY6;
B7HBD4;A6TN07;A0RK94;P13376;
A6L8C4;Q5KVS7;P13375;A4ISB8;
Q180C9;A9VMW5;A7GUA6;Q8R92
4;Q5WDX0 
>sp|Q81K75|G6PI_BACAN 
Glucose-6-phosphate isomerase 
OS=Bacillus anthracis GN=pgi 
PE=1 
SV=1;>sp|Q816G0|G6PI_BACC
R Glucose-6-phosphate 
isomerase OS=Bacillus cereus 
(strain ATCC 14579 / DSM 31 / 
50.344 
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JCM 2152 / NBRC 15305 / 
NCIMB 9373 / NRRL B-3711) 
GN=pgi PE=3 SV 
Q7CQ01;Q7AMH5 
>sp|Q7CQ01|CLPB_SALTY 
Chaperone protein ClpB 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=clpB PE=3 
SV=1;>sp|Q7AMH5|CLPB_SAL
TI Chaperone protein ClpB 
OS=Salmonella typhi GN=clpB 
PE=3 SV=1 
95.436 
Q74X11;Q9CKC0;P44403;Q6LMY0
;Q7VNH1;Q83F55;Q9KU18;Q87S6
3 
>sp|Q74X11|CLPB_YERPE 
Chaperone protein ClpB 
OS=Yersinia pestis GN=clpB 
PE=3 
SV=2;>sp|Q9CKC0|CLPB_PAS
MU Chaperone protein ClpB 
OS=Pasteurella multocida 
(strain Pm70) GN=clpB PE=3 
SV=1;>sp|P44403|CLPB_HAEI
N Chaperone protein ClpB 
OS=Haemophilus influenzae ( 
95.643 
Q71WX1;P64075;P64074;C1KY94;
B8DDA1;A0ALD9 
>sp|Q71WX1|ENO_LISMF 
Enolase OS=Listeria 
monocytogenes serotype 4b 
(strain F2365) GN=eno PE=3 
SV=1;>sp|P64075|ENO_LISIN 
Enolase OS=Listeria innocua 
serovar 6a (strain ATCC BAA-
680 / CLIP 11262) GN=eno 
PE=3 
SV=1;>sp|P64074|ENO_LISMO 
Enolase OS=Listeria mono 
46.486 
Q65W89 
>sp|Q65W89|EFG_MANSM 
Elongation factor G 
OS=Mannheimia 
succiniciproducens (strain 
MBEL55E) GN=fusA PE=3 
SV=1 
77.226 
Q64XP2;Q5LGU0;Q8A094;A6L7Q8
;A6LHV2 
>sp|Q64XP2|NAGB_BACFR 
Glucosamine-6-phosphate 
deaminase OS=Bacteroides 
fragilis (strain YCH46) GN=nagB 
PE=3 
SV=1;>sp|Q5LGU0|NAGB_BAC
FN Glucosamine-6-phosphate 
deaminase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=nagB  
29.895 
Q64U74;Q5LD54;A6L5J9;Q8A9S3;
Q7MX58 
>sp|Q64U74|PYRB_BACFR 
Aspartate carbamoyltransferase 
OS=Bacteroides fragilis (strain 
YCH46) GN=pyrB PE=3 
SV=1;>sp|Q5LD54|PYRB_BAC
FN Aspartate 
35.577 
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carbamoyltransferase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=pyrB 
PE=3 S 
Q5F541;P57006;P48215;P42385;P
29842;B4RRA1;A9M0Q6;A1KW52;
Q2KXZ3;A9I685;C5CPP8 
>sp|Q5F541|CH60_NEIG1 60 
kDa chaperonin OS=Neisseria 
gonorrhoeae (strain ATCC 
700825 / FA 1090) GN=groL 
PE=3 
SV=1;>sp|P57006|CH60_NEIM
A 60 kDa chaperonin 
OS=Neisseria meningitidis 
serogroup A / serotype 4A 
(strain Z2491) GN=groL PE=3 
SV=1;>sp|P48215|CH60_N 
57.35 
Q03YI2;B1MY04 
>sp|Q03YI2|EFTU_LEUMM 
Elongation factor Tu 
OS=Leuconostoc 
mesenteroides subsp. 
mesenteroides (strain ATCC 
8293 / NCDO 523) GN=tuf PE=3 
SV=1;>sp|B1MY04|EFTU_LEU
CK Elongation factor Tu 
OS=Leuconostoc citreum (strain 
KM20) GN=tuf PE=3 SV=1 
43.371 
P94166;B3H1P4;B0BPV1;A3N120;
P31294 
>sp|P94166|CH60_ACTPL 60 
kDa chaperonin 
OS=Actinobacillus 
pleuropneumoniae GN=groL 
PE=3 
SV=3;>sp|B3H1P4|CH60_ACTP
7 60 kDa chaperonin 
OS=Actinobacillus 
pleuropneumoniae serotype 7 
(strain AP76) GN=groL PE=3 
SV=1;>sp|B0BPV1|CH60_ACTP
J 60 kDa chaperonin OS=Ac 
57.644 
P63286;P63285;P63284;Q7UBW5;
Q7N788 
>sp|P63286|CLPB_ECOL6 
Chaperone protein ClpB 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=clpB PE=3 
SV=1;>sp|P63285|CLPB_ECO5
7 Chaperone protein ClpB 
OS=Escherichia coli O157:H7 
GN=clpB PE=3 
SV=1;>sp|P63284|CLPB_ECOL
I Chaperone protein 
95.584 
P56512;P56511 
>sp|P56512|LDH1_LACPL L-
lactate dehydrogenase 1 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=ldh1 PE=3 
SV=2;>sp|P56511|LDH_LACPE 
L-lactate dehydrogenase 
34.205 
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OS=Lactobacillus pentosus 
GN=ldh PE=1 SV=1 
P0CJ83;E1WS50 
>sp|P0CJ83|FTN_BACFR 
Bacterial non-heme ferritin 
OS=Bacteroides fragilis (strain 
YCH46) GN=ftnA PE=1 
SV=1;>sp|E1WS50|FTN_BACF
6 Bacterial non-heme ferritin 
OS=Bacteroides fragilis (strain 
638R) GN=ftnA PE=2 SV=1 
18.064 
P0A9Q8;P0A9Q7 
>sp|P0A9Q8|ADHE_ECO57 
Aldehyde-alcohol 
dehydrogenase OS=Escherichia 
coli O157:H7 GN=adhE PE=3 
SV=2;>sp|P0A9Q7|ADHE_ECO
LI Aldehyde-alcohol 
dehydrogenase OS=Escherichia 
coli (strain K12) GN=adhE PE=1 
SV=2 
96.126 
P09146 
>sp|P09146|OMPA_KLEAE 
Outer membrane protein A 
OS=Klebsiella aerogenes 
GN=ompA PE=3 SV=1 
37.575 
P03833 
>sp|P03833|NIFJ_KLEPN 
Pyruvate-flavodoxin 
oxidoreductase OS=Klebsiella 
pneumoniae GN=nifJ PE=3 
SV=2 
128.04 
P00343;Q01462;P04034 
>sp|P00343|LDH_LACCA L-
lactate dehydrogenase 
OS=Lactobacillus casei GN=ldh 
PE=1 SV=3 
35.53 
O86428 
>sp|O86428|ILVE_PSEAE 
Branched-chain-amino-acid 
aminotransferase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=ilvE PE=1 
SV=2 
34.084 
O09460 
>sp|O09460|PCKA_ANASU 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Anaerobiospirillum 
succiniciproducens GN=pckA 
PE=1 SV=1 
58.642 
C4ZBL1 
>sp|C4ZBL1|PCKA_AGARV 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Agathobacter rectalis (strain 
ATCC 33656 / DSM 3377 / JCM 
17463 / KCTC 5835 / VPI 0990) 
GN=pckA PE=3 SV=1 
59.052 
C3L0B0;C1FS53;B1KWK1;B1II43;
A7FVY7;A5I4I7 
>sp|C3L0B0|PNP_CLOB6 
Polyribonucleotide 
nucleotidyltransferase 
77.412 
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OS=Clostridium botulinum 
(strain 657 / Type Ba4) GN=pnp 
PE=3 
SV=1;>sp|C1FS53|PNP_CLOBJ 
Polyribonucleotide 
nucleotidyltransferase 
OS=Clostridium botulinum 
(strain Kyoto / Type A2) 
GN=pnp PE=3 SV 
B7NS00;B1LPK1;Q83IP5;Q3YUU9;
Q0SXQ2;Q8CVI4;Q1R3Q0;Q0TA2
5;P02943;C5A130;B7UPJ7;B7NFY
0;B7N2P4;B7MJ27;B7M7U8;B7LA
Y3;B6I5Q0;B1XC35;B1IUL5;A8A7
D6;A7ZUQ8;A1AIL4;Q8X5W7;B5Z
177;B7LL09 
>sp|B7NS00|LAMB_ECO7I 
Maltoporin OS=Escherichia coli 
O7:K1 (strain IAI39 / ExPEC) 
GN=lamB PE=3 
SV=1;>sp|B1LPK1|LAMB_ECO
SM Maltoporin OS=Escherichia 
coli (strain SMS-3-5 / SECEC) 
GN=lamB PE=3 
SV=1;>sp|Q83IP5|LAMB_SHIFL 
Maltoporin OS=Shigella flexneri 
GN=lam 
49.928 
B7NDU8;Q83JC3;Q3YWT2;Q32B2
6;Q31VU9;Q0SZX7;B7LS46;B2U2
U7;Q1R5U3;Q0TCB9;P0A6N0;P0A
6M9;P0A6M8;C4ZUJ5;B7UK50;B7
NLP5;B7N0X6;B7MCV5;B7M1P1;B
7L4L1;B6I240;B5YTP7;B1X6J0;B1
LHE0;B1IPV9;A8A5E7;A7ZSL5;A1
AGM7 
>sp|B7NDU8|EFG_ECOLU 
Elongation factor G 
OS=Escherichia coli 
O17:K52:H18 (strain UMN026 / 
ExPEC) GN=fusA PE=3 
SV=1;>sp|Q83JC3|EFG_SHIFL 
Elongation factor G OS=Shigella 
flexneri GN=fusA PE=3 
SV=3;>sp|Q3YWT2|EFG_SHIS
S Elongation factor G 
OS=Shigella sonnei ( 
77.638 
B5Y242;A6T4F4;Q8Z9R1;Q5PDJ5;
Q57TP3;Q56073;C0Q4F3;B5RF08;
B5R5I2;B5FHA6;B5F6Y8;B5BLH8;
B4TVZ5;B4TIB4;B4T6D6;A9MXI2;
A9MR77;A7MIK5;Q2NVZ1;Q1LST3
;C4K3I6 
>sp|B5Y242|DNAK_KLEP3 
Chaperone protein DnaK 
OS=Klebsiella pneumoniae 
(strain 342) GN=dnaK PE=3 
SV=1;>sp|A6T4F4|DNAK_KLEP
7 Chaperone protein DnaK 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=dnaK PE=3 
SV=1;>sp|Q8Z9R1|DNAK_ 
69.149 
B5Y1K1;A6T4X2 
>sp|B5Y1K1|EFTS_KLEP3 
Elongation factor Ts 
OS=Klebsiella pneumoniae 
(strain 342) GN=tsf PE=3 
SV=1;>sp|A6T4X2|EFTS_KLEP
7 Elongation factor Ts 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=tsf PE=3 SV=1 
30.45 
B3H1D9;B0BP80;A3N0G0;B8F4W
1;Q7VLT3 
>sp|B3H1D9|PCKA_ACTP7 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Actinobacillus 
pleuropneumoniae serotype 7 
59.426 
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(strain AP76) GN=pckA PE=3 
SV=1;>sp|B0BP80|PCKA_ACT
PJ Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Actinobacillus 
pleuropneumoniae serotype 3 
(strain  
B2UYA2;B2TIG7 
>sp|B2UYA2|RL7_CLOBA 50S 
ribosomal protein L7/L12 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=rplL PE=3 
SV=1;>sp|B2TIG7|RL7_CLOBB 
50S ribosomal protein L7/L12 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=rplL PE=3 SV=1 
12.537 
B2UY23;B2TPX4 
>sp|B2UY23|PGK_CLOBA 
Phosphoglycerate kinase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=pgk PE=3 
SV=1;>sp|B2TPX4|PGK_CLOB
B Phosphoglycerate kinase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=pgk PE=3 SV=1 
42.471 
B2UWY3;B2TP90 
>sp|B2UWY3|VATB_CLOBA V-
type ATP synthase beta chain 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=atpB PE=3 
SV=1;>sp|B2TP90|VATB_CLOB
B V-type ATP synthase beta 
chain OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=atpB PE=3 SV=1 
51.081 
A7MKJ6 
>sp|A7MKJ6|EFG_CROS8 
Elongation factor G 
OS=Cronobacter sakazakii 
(strain ATCC BAA-894) 
GN=fusA PE=3 SV=1 
77.679 
A6LFK9 
>sp|A6LFK9|PNP_PARD8 
Polyribonucleotide 
nucleotidyltransferase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=pnp PE=3 
SV=1 
82.018 
A4W6D5 
>sp|A4W6D5|DNAK_ENT38 
Chaperone protein DnaK 
OS=Enterobacter sp. (strain 
638) GN=dnaK PE=3 SV=1 
69.432 
A1AST1 
>sp|A1AST1|CH60_PELPD 60 
kDa chaperonin OS=Pelobacter 
propionicus (strain DSM 2379 / 
58.844 
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NBRC 103807 / OttBd1) 
GN=groL PE=3 SV=1 
Q9ZML6 
>sp|Q9ZML6|DXR_HELPJ 1-
deoxy-D-xylulose 5-phosphate 
reductoisomerase 
OS=Helicobacter pylori (strain 
J99 / ATCC 700824) GN=dxr 
PE=3 SV=1 
40.154 
Q9Z6B9;A4WG77 
>sp|Q9Z6B9|TPIS_ENTCL 
Triosephosphate isomerase 
OS=Enterobacter cloacae 
GN=tpiA PE=3 
SV=1;>sp|A4WG77|TPIS_ENT3
8 Triosephosphate isomerase 
OS=Enterobacter sp. (strain 
638) GN=tpiA PE=3 SV=1 
26.913 
Q9XCB1 
>sp|Q9XCB1|DNAK_RHOMR 
Chaperone protein DnaK 
OS=Rhodothermus marinus 
GN=dnaK PE=3 SV=1 
70.2 
Q9I589;Q02I11 
>sp|Q9I589|CBPD_PSEAE 
Chitin-binding protein CbpD 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=cbpD PE=1 
SV=1;>sp|Q02I11|CBPD_PSEA
B Chitin-binding protein CbpD 
OS=Pseudomonas aerugi 
41.916 
Q9I3F5;Q8ZP52;P37032;P25516 
>sp|Q9I3F5|ACNA_PSEAE 
Aconitate hydratase A 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=acnA PE=3 
SV=1 
99.147 
Q9I3D2;Q92J43;Q68XI8;P20708;Q
9ZDY4;Q4UKI7;P52993 
>sp|Q9I3D2|ODO2_PSEAE 
Dihydrolipoyllysine-residue 
succinyltransferase component 
of 2-oxoglutarate 
dehydrogenase complex 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=sucB PE=3 
SV=1 
42.887 
Q9HZQ8;Q02PA2 
>sp|Q9HZQ8|LAP_PSEAE 
Aminopeptidase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=lap PE=1 
SV=1;>sp|Q02PA2|LAP_PSEAB 
57.511 
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Aminopeptidase 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=l 
Q9HZJ2;Q02PH8;B7UYR6;A6V382
;B1J5A5;A4XSM8;Q9AHY3;Q93Q1
2;Q88L02;Q4KFC4;Q3K9D8;Q1I7D
4;P28793;C3K613;B0KH74;A5W6H
0;Q87ZB2;Q4ZRA0;Q48GW3 
>sp|Q9HZJ2|FADB_PSEAE 
Fatty acid oxidation complex 
subunit alpha 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fadB PE=3 
SV=1;>sp|Q02PH8|FADB_PSE
AB Fatty acid oxidation complex 
subun 
76.953 
Q9F166 
>sp|Q9F166|PTHP_BACTI 
Phosphocarrier protein HPr 
OS=Bacillus thuringiensis 
subsp. israelensis GN=ptsH 
PE=1 SV=1 
9.2384 
Q9CKR4 
>sp|Q9CKR4|PCKA_PASMU 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Pasteurella multocida 
(strain Pm70) GN=pckA PE=3 
SV=1 
58.879 
Q9AE24 
>sp|Q9AE24|RPRY_BACFR 
Transcriptional regulatory 
protein RprY OS=Bacteroides 
fragilis (strain YCH46) GN=rprY 
PE=3 SV=2 
27.177 
Q98QY7 
>sp|Q98QY7|DNAK_MYCPU 
Chaperone protein DnaK 
OS=Mycoplasma pulmonis 
(strain UAB CTIP) GN=dnaK 
PE=3 SV=1 
65.52 
Q97D83;Q97D82 
>sp|Q97D83|RRBR2_CLOAB 
Reverse rubrerythrin-2 
OS=Clostridium acetobutylicum 
(strain ATCC 824 / DSM 792 / 
JCM 1419 / LMG 5710 / VKM B-
1787) GN=rbr3B PE=1 
SV=1;>sp|Q97D82|RRBR1_CL
OAB Reverse rubrerythrin-1 
OS=Clostridium acetobutylicum 
(strain ATCC 824 / DSM 
20.107 
Q927A3;Q8Y3T8;Q71W21;Q9K6E
4;A8FIE1;A7Z9T0;Q8CX76;Q5KUG
6;Q24ML5;C5D9P4;B8FZ81;A4ITL
5;Q899F3;Q81V33;Q81HW6;Q73D
H4;Q6HNE4;Q63FX6;B1YEL0;A7G
LA6;Q5WB47;C3KTY4;C1FL18;B1
L010;B1IJR0;A9KPQ3;A7GCY3;A7
FTH1;A5I1C9;Q81MY9;Q81B21;P1
9669 
>sp|Q927A3|TAL1_LISIN 
Probable transaldolase 1 
OS=Listeria innocua serovar 6a 
(strain ATCC BAA-680 / CLIP 
11262) GN=tal1 PE=3 
SV=1;>sp|Q8Y3T8|TAL1_LISM
O Probable transaldolase 1 
OS=Listeria monocytogenes 
serovar 1/2a (strain ATCC BAA-
679 / EGD-e) GN=tal1 P 
23.154 
Q8ZJ87;Q7MYH5;Q664U6;Q5PK1
0;Q57J56;Q3YWW4;Q32B56;Q31V
>sp|Q8ZJ87|RPOA_YERPE 
DNA-directed RNA polymerase 
36.508 
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Y1;Q1CCW8;Q1C2X1;Q0T007;P0
A7Z9;P0A7Z8;P0A7Z7;A8GKH3;A8
AQJ0;A7MPF8;A7FNL0;A6TEU8;A
4WFA3;A4TH15;A1JS01;Q1R637;
Q0TCG6;P0A7Z6;P0A7Z5;P0A7Z4
;A8A5A0;A7ZSI4;A1AGI6;Q6CZZ5;
Q2NQP7;Q9S0Q8;Q8EK47;Q12ST
4;Q0I080;Q0HNR2;Q089M9;C4L7V
5;A6WHV3;A4YBV8;A4SSY1;A3Q9
A7;A3DA47;A1S243;A1RED9;A0K
RP9;A0KF45;Q4QM97;P43737;A5
UHV5;A5UDS2;Q5E889;B6EPU9;B
5FGE1;Q9KP08;Q8DE63;Q87SZ0;
Q7MPG4;C3LRN3;B7VLD2;A7N0H
8;A5F572;Q1LTB3;A1T0B7;P7496
3;Q6LV91;P57566;Q7VKF8;Q65Q
Y0;P57941;A6VLL3;O69232;P5945
5 
subunit alpha OS=Yersinia 
pestis GN=rpoA PE=3 
SV=1;>sp|Q7MYH5|RPOA_PH
OLL DNA-directed RNA 
polymerase subunit alpha 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=rpoA 
Q8ZIL4;P63738;Q8Z9L7;P14846;Q
8FLB0;P63737;P00968;Q88DU6;Q
87WP4;Q8RSS3;Q9JXW8;Q9JW0
2;Q59599;Q87EB8 
>sp|Q8ZIL4|CARB_YERPE 
Carbamoyl-phosphate synthase 
large chain OS=Yersinia pestis 
GN=carB PE=3 
SV=3;>sp|P63738|CARB_SHIF
L Carbamoyl-phosphate 
synthase large chain 
OS=Shigella flexneri GN=carB 
PE=3 
SV=2;>sp|Q8Z9L7|CARB_SALT
I Carbamoyl-phosphate 
synthase lar 
118.24 
Q8Z7N9;B5R6H0;B5R056;B5FR47
;B5F202;B4TSN0;B4TEP2;B4T2V2
;A9N6R4;A9MH45;Q5PG91;B5BB
G6;Q8ZQ40;C0Q886 
>sp|Q8Z7N9|NQOR_SALTI 
NAD(P)H dehydrogenase 
(quinone) OS=Salmonella typhi 
GN=STY1155 PE=3 
SV=3;>sp|B5R6H0|NQOR_SAL
G2 NAD(P)H dehydrogenase 
(quinone) OS=Salmonella 
gallinarum (strain 287/91 / 
NCTC 13346) GN=SG1008 
PE=3 
SV=1;>sp|B5R056|NQOR_SAL
EP NAD(P)H deh 
20.837 
Q8XZJ0 
>sp|Q8XZJ0|EFTS_RALSO 
Elongation factor Ts 
OS=Ralstonia solanacearum 
(strain GMI1000) GN=tsf PE=3 
SV=2 
31.134 
Q8XL57 
>sp|Q8XL57|PFKA2_CLOPE 
ATP-dependent 6-
phosphofructokinase 2 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=pfkA2 
PE=3 SV=1 
39.514 
Q8XJ32;Q0TP32;Q0SRQ2;Q8EM7
3;Q5FMC0;B2V398;B2TN52;Q8CR
N3;Q88UT5;Q831F9;Q6GEW2;Q6
G7J7;Q6F211;Q5HMB0;Q5HE87;Q
>sp|Q8XJ32|GLYA_CLOPE 
Serine 
hydroxymethyltransferase 
OS=Clostridium perfringens 
45.188 
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49Z60;Q2YUJ1;Q2FWE5;Q2FF15;
P99091;P66804;P66803;A8YY80;A
7X4V7;A6U3J8;A6QIV7;A5IUQ8;Q
6MS85;Q2ST43;Q9CHW7;Q031D7
;A2RIS0;Q5M4W1;Q5M0B4;Q03L7
7;Q1WTR3;Q99ZP1;Q8P122;Q8E5
C6;Q8DZM7;Q5XC65;Q3K122;P0D
F71;P0DF70;B5XLJ2;A2REH5;C0
MF11;C0M6L7;B9DS48;B4U313;Q
48TK6;Q1JLP8;Q1JGU8;Q1JBR5;
Q1J6L7 
(strain 13 / Type A) GN=glyA 
PE=3 
SV=1;>sp|Q0TP32|GLYA_CLO
P1 Serine 
hydroxymethyltransferase 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 /  
Q8XHJ2;Q0TMG2;Q0SQ60;Q8R75
1;B2UXS5;B2TI06;B0KBF4;B0K46
0;Q97E91;C3KWA2;C1FNF2;B1KT
E8;B1IH03;A7GJE0;A7FPK3;A5I7S
1;A5N4I4;A0PXK7 
>sp|Q8XHJ2|SP5G_CLOPE 
Putative septation protein 
SpoVG OS=Clostridium 
perfringens (strain 13 / Type A) 
GN=spoVG PE=3 
SV=1;>sp|Q0TMG2|SP5G_CLO
P1 Putative septation protein 
SpoVG OS=Clostridium 
perfringens (strain ATCC 13124 
/ DSM 756 / JCM 1290 / NCIMB 
6125 
10.299 
Q8XH44 
>sp|Q8XH44|SSB_CLOPE 
Single-stranded DNA-binding 
protein OS=Clostridium 
perfringens (strain 13 / Type A) 
GN=ssb PE=3 SV=1 
16.023 
Q8R967;B5RRF1;B5RLS2;Q0SNH
5;O51312;B7J1R2;B2S044;Q661T
0 
>sp|Q8R967|ENO_CALS4 
Enolase OS=Caldanaerobacter 
subterraneus subsp. 
tengcongensis (strain DSM 
15242 / JCM 11007 / NBRC 
100824 / MB4) GN=eno PE=3 
SV=1;>sp|B5RRF1|ENO_BORR
A Enolase OS=Borrelia 
recurrentis (strain A1) GN=eno 
PE=3 
SV=1;>sp|B5RLS2|ENO_BORD
L En 
46.296 
Q8KCH7 
>sp|Q8KCH7|TPIS_CHLTE 
Triosephosphate isomerase 
OS=Chlorobium tepidum (strain 
ATCC 49652 / DSM 12025 / 
NBRC 103806 / TLS) GN=tpiA 
PE=3 SV=1 
25.956 
Q8CVW1 
>sp|Q8CVW1|OMPC_ECOL6 
Outer membrane protein C 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=ompC PE=1 SV=1 
41.225 
Q8AAW1;A6L2R5 
>sp|Q8AAW1|ARAA_BACTN L-
arabinose isomerase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=araA PE=3 
57.174 
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SV=1;>sp|A6L2R5|ARAA_BAC
V8 L-arabinose isomerase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JC 
Q8A9X8 
>sp|Q8A9X8|HCP_BACTN 
Hydroxylamine reductase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=hcp PE=3 SV=1 
59.839 
Q8A9J2;A6L4U4;B3PBK5;B1ZP77 
>sp|Q8A9J2|UXAC_BACTN 
Uronate isomerase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=uxaC PE=3 
SV=2;>sp|A6L4U4|UXAC_BAC
V8 Uronate isomerase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / 
54.316 
Q8A6P7;Q64QU1;Q5LAF5;A6KXA
1;Q052X8;Q04S02;P61437;P61436
;B0SKU1;B0SCB9 
>sp|Q8A6P7|CH10_BACTN 10 
kDa chaperonin 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=groS PE=3 
SV=1;>sp|Q64QU1|CH10_BAC
FR 10 kDa chaperonin 
OS=Bacteroides fragilis (strain 
YCH46) GN=groS PE=3 
SV=1;>sp|Q5LA 
9.6602 
Q8A624 
>sp|Q8A624|PFKA2_BACTN 
ATP-dependent 6-
phosphofructokinase 2 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pfkA2 PE=3 SV=1 
35.257 
Q8A608;B6YQV1 
>sp|Q8A608|ILVD_BACTN 
Dihydroxy-acid dehydratase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=ilvD PE=3 SV=1 
64.045 
Q8A525;Q0AW22;B1ZNB4 
>sp|Q8A525|GUAA2_BACTN 
Putative GMP synthase 
[glutamine-hydrolyzing] 2 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
48.285 
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10582 / E50 / VPI-5482) 
GN=guaA2 PE=5 SV=1 
Q8A407;Q64MT2;Q83A77;B6J6H1;
B6J3R0;A9KD88;Q9ZNA5;P28183;
O50562;Q5NR48;Q2G6T1;B8IPU4;
B7KSJ4;B1ZLX0;B0UM37;A9VYP7
;Q6N2N5;B3QJT3;Q8KEG8;Q3B53
2;Q3AQC2;Q2IZR1;Q13AQ5;B4SD
43;B3QMF5;B3EDY3;A4SF77;A1B
EZ2;Q1GWT5;C6C1F4;Q89HP6;A
5ENA7;A0A087WNH6;Q01VU1;Q7
2EH1;Q30WL8;B8DR41;A1VFZ7;Q
9PEJ1;Q8PP84;Q8PCH5;Q87EI8;
Q4UQZ8;Q3BXC6;Q2NZE3;B2SP
N6;B2I7N4;B0U232 
>sp|Q8A407|SAHH_BACTN 
Adenosylhomocysteinase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=ahcY PE=3 
SV=1;>sp|Q64MT2|SAHH_BAC
FR Adenosylhomocysteinase 
OS=Bacteroides fragilis (strain 
YCH46) GN=ahcY PE=3 SV= 
52.739 
Q8A2F4 
>sp|Q8A2F4|SYC_BACTN 
Cysteine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=cysS PE=3 SV=1 
55.996 
Q8A2E6 
>sp|Q8A2E6|ACP_BACTN Acyl 
carrier protein OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=acpP PE=3 SV=1 
8.4763 
Q8A287 
>sp|Q8A287|GPMI_BACTN 2,3-
bisphosphoglycerate-
independent phosphoglycerate 
mutase OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=gpmI PE=3 SV=1 
55.645 
Q8A1G8 
>sp|Q8A1G8|ACKA_BACTN 
Acetate kinase OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=ackA PE=3 SV=1 
43.34 
Q8A1G1 
>sp|Q8A1G1|SUSC_BACTN 
TonB-dependent receptor SusC 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susC PE=1 SV=1 
111.14 
Q8A1G0 
>sp|Q8A1G0|SUSA_BACTN 
Neopullulanase SusA 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susA PE=3 SV=1 
71.183 
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Q8A015 
>sp|Q8A015|LPXZ_BACTN 
Bifunctional enzyme LpxC/FabZ 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=lpxC/fabZ PE=3 SV=1 
51.6 
Q84FI0;B5XYT2;A6T6Q6 
>sp|Q84FI0|DPS_KLEPN DNA 
protection during starvation 
protein OS=Klebsiella 
pneumoniae GN=dps PE=3 
SV=1;>sp|B5XYT2|DPS_KLEP3 
DNA protection during starvation 
protein OS=Klebsiella 
pneumoniae (strain 342) 
GN=dps PE=3 
SV=1;>sp|A6T6Q6|DPS_KLEP7 
DNA protection 
18.752 
Q83N78;Q83FI1;Q8RHQ8;Q7VQF
3;Q826F2 
>sp|Q83N78|CLPB_TROW8 
Chaperone protein ClpB 
OS=Tropheryma whipplei (strain 
TW08/27) GN=clpB PE=3 
SV=1;>sp|Q83FI1|CLPB_TROW
T Chaperone protein ClpB 
OS=Tropheryma whipplei (strain 
Twist) GN=clpB PE=3 SV=1 
77.781 
Q82K46;B1VYP2 
>sp|Q82K46|SYP1_STRAW 
Proline--tRNA ligase 1 
OS=Streptomyces avermitilis 
(strain ATCC 31267 / DSM 
46492 / JCM 5070 / NBRC 
14893 / NCIMB 12804 / NRRL 
8165 / MA-4680) GN=proS1 
PE=3 
SV=1;>sp|B1VYP2|SYP_STRG
G Proline--tRNA ligase 
OS=Streptomyces griseus 
subsp. 
61.193 
Q82JK7 
>sp|Q82JK7|DNLJ_STRAW 
DNA ligase OS=Streptomyces 
avermitilis (strain ATCC 31267 / 
DSM 46492 / JCM 5070 / NBRC 
14893 / NCIMB 12804 / NRRL 
8165 / MA-4680) GN=ligA PE=3 
SV=1 
80.422 
Q7MYB3 
>sp|Q7MYB3|TPIS_PHOLL 
Triosephosphate isomerase 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=tpiA PE=3 SV=1 
26.808 
Q6Y1R6;Q6XZR0;Q3Z3X3;Q32I91;
Q323Y1;P0ABT4;B7LMB6;B2TVB6
;Q1REB2;Q0TJN6;P0ABT3;P0ABT
2;C4ZXY4;B7UM08;B7NNP4;B7NA
B2;B7MQR6;B7MGS0;B7M787;B7
LC95;B6I7W9;B5YSA4;B1X7E2;B1
>sp|Q6Y1R6|DPS_PROHU 
DNA protection during starvation 
protein OS=Proteus hauseri 
GN=dps PE=3 
SV=1;>sp|Q6XZR0|DPS_KLUC
R DNA protection during 
18.722 
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LMA4;B1IXF6;A7ZY70;A7ZJM7;Q8
FJM0;Q8XF78;Q84FI1;Q7CQV9;Q
5PG12;Q57RC9;C0PX17;B5R797;
B5QXT6;B5FP96;B5F0B0;B5BBZ6;
B4TQX5;B4TC86;B4T089;A9MST4
;A9MIS0;A8GBU5;Q84AP1;Q84AP
0;Q6D3H7;C6DEE2;A1JU34 
starvation protein OS=Kluyvera 
cryocrescens GN=dps PE=3 
SV=1;>sp|Q3Z3X3|DPS_SHISS 
DNA protection during starvation  
Q6NCX8;B3Q978 
>sp|Q6NCX8|DAPB_RHOPA 4-
hydroxy-tetrahydrodipicolinate 
reductase 
OS=Rhodopseudomonas 
palustris (strain ATCC BAA-98 / 
CGA009) GN=dapB PE=3 
SV=1;>sp|B3Q978|DAPB_RHO
PT 4-hydroxy-
tetrahydrodipicolinate reductase 
OS=Rhodopseudomonas 
palustris (strain TIE-1) GN= 
27.783 
Q64PS6;Q5L9I8;A6L3E7 
>sp|Q64PS6|ILVD_BACFR 
Dihydroxy-acid dehydratase 
OS=Bacteroides fragilis (strain 
YCH46) GN=ilvD PE=3 
SV=1;>sp|Q5L9I8|ILVD_BACFN 
Dihydroxy-acid dehydratase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=ilvD 
PE=3 SV=1;>sp| 
64.37 
Q64MX8;Q5L7Q8 
>sp|Q64MX8|SYR_BACFR 
Arginine--tRNA ligase 
OS=Bacteroides fragilis (strain 
YCH46) GN=argS PE=3 
SV=1;>sp|Q5L7Q8|SYR_BACF
N Arginine--tRNA ligase 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=argS 
PE=3 SV=1 
66.759 
Q5PGJ4;Q57R48;Q3Z3N6;Q32E03
;Q323L9;Q0T8P2;P69227;P69226;
P69225;A9N7Y7;A9MI00;A8AIJ9;A
7MEQ6;A6T6Y1;Q1RE30;Q0TJG6;
P69224;P69223;P69222;A7ZYI7;A
7ZJV1;Q8D2W3;Q7VR35;Q6LT12;
Q6D3U1;Q66CK8;Q492S0;Q480P2
;Q2NTZ7;Q1CGE2;Q1CA94;Q0A8
P2;P65115;P65114;A8GCD9;A7FJ
Z1;A4W8Q8;A4TN38;A1JMD0 
>sp|Q5PGJ4|IF1_SALPA 
Translation initiation factor IF-1 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=infA PE=3 
SV=1;>sp|Q57R48|IF1_SALCH 
Translation initiation factor IF-1 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=infA PE=3 
SV=1;>sp|Q3Z3N6| 
8.2816 
Q5PD74;Q57T28;Q3Z5H8;Q32JS9
;Q325W0;P0A6Q9;P0A1I0;P0A1H9
;C0Q6K3;B7LW77;B5Y1J1;B5RHG
5;B5R419;B5FJ27;B5F8U1;B5BAN
7;B4TYE0;B4TK55;B4SV09;B2U32
3;A9N0T0;A9MPI1;A6T4Y2;A4W6S
5;Q0TLF3;P0A6Q8;P0A6Q7;P0A6
Q6;C4ZRS2;B7UJ81;B7NIE2;B7N8
47;B7MP40;B7MBG1;B7M1Y3;B7L
>sp|Q5PD74|FABZ_SALPA 3-
hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=fabZ PE=3 
SV=1;>sp|Q57T28|FABZ_SALC
H 3-hydroxyacyl-[acyl-carrier-
protein] dehydratase FabZ 
16.999 
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GP2;B6HZF4;B5Z0F9;B1XD49;B1L
GY2;B1IQG1;A7ZWC6;A7ZHS0;B2
VHX7;A7MI19 
OS=Salmonella choleraesuis 
(stra 
Q5PD62;Q57T38;P64053;P64052;
B5RHF5;B5R3I3;B5FJ17;B5F8T1;
B5BAM7;B4TXS2;B4TK45;B4SUZ9
;A8ALC0 
>sp|Q5PD62|EFTS_SALPA 
Elongation factor Ts 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=tsf PE=3 
SV=1;>sp|Q57T38|EFTS_SALC
H Elongation factor Ts 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=tsf PE=3 
SV=2;>sp|P64053|EFTS_SALTI 
Elongation factor 
30.386 
Q5L8L6;Q8A129;Q64NW2 
>sp|Q5L8L6|CLPP_BACFN 
ATP-dependent Clp protease 
proteolytic subunit 
OS=Bacteroides fragilis (strain 
ATCC 25285 / DSM 2151 / JCM 
11019 / NCTC 9343) GN=clpP 
PE=3 
SV=1;>sp|Q8A129|CLPP_BACT
N ATP-dependent Clp protease 
proteolytic subunit 
OS=Bacteroides thetai 
22.858 
Q5FM65;A8YXN0 
>sp|Q5FM65|RPOA_LACAC 
DNA-directed RNA polymerase 
subunit alpha OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=rpoA PE=3 
SV=1;>sp|A8YXN0|RPOA_LAC
H4 DNA-directed RNA 
polymerase subunit alpha 
OS=Lactobacillus helveticus 
(strain DPC  
34.956 
Q51567;Q9AKE1;Q92I22;O08371;
P45102 
>sp|Q51567|SUCD_PSEAE 
Succinate--CoA ligase [ADP-
forming] subunit alpha 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=sucD PE=1 
SV=2 
30.266 
Q493I4 
>sp|Q493I4|RPOA_BLOPB 
DNA-directed RNA polymerase 
subunit alpha OS=Blochmannia 
pennsylvanicus (strain BPEN) 
GN=rpoA PE=3 SV=1 
37.072 
Q48473;P0A264;P0A263;P21420 
>sp|Q48473|OMPC_KLEPN 
Outer membrane protein C 
OS=Klebsiella pneumoniae 
GN=ompC PE=1 SV=1 
39.663 
Q47VD0 
>sp|Q47VD0|PCKA_COLP3 
Phosphoenolpyruvate 
carboxykinase (ATP) 
59.306 
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OS=Colwellia psychrerythraea 
(strain 34H / ATCC BAA-681) 
GN=pckA PE=3 SV=1 
Q3Z5I8;Q32JT9;Q325X0;Q0T839;
P0A6P4;B7LWA9;B2U313;Q1RG1
9;Q0TLG3;P0A6P3;P0A6P2;P0A6
P1;C4ZRR2;B7UIL5;B7NID1;B7N8
37;B7MP30;B7MBF1;B7M1B0;B7L
GN1;B6HZE4;B5Z0E9;B1XD39;B1
LGX2;B1IQH1;A7ZWB6;A7ZHR0;A
8GIE5;Q6D8E2;C6DAI4;B2VE09;B
7IH86;A7HJI3;B0SM65;B0SDN6;A
8ZTM1;Q8RA22;B8DSA5;Q2LTQ6;
Q2RJP2;B9MKQ0;B0K9R5;B0K1P
8;A4XM01;Q0AYK3;A6TRM2;A8M
HH0;Q7VCB5;Q3AB78;Q24UF8;B8
FRG4;A4J5Z2;Q7TV13;Q7TUA9;Q
31BC3;Q0IAN8;P74070;B1XQQ0;A
9BAS8;A8G4D2;A3PCG2;A2CA99;
A2BW76;A2BQP0;Q7U794;Q3AXJ
0;Q2IMM0;Q116Q3;B8J9V0;B4UM
B7;A7H715;A5GLD9;Q3AKA4;Q5N
1Q1;Q31K58;B0S185;B0C074;B0J
TL3;Q2JLB2;B8HXK3;Q2JQK3;B8
CQ84;B1KNU2;A8FY41;A3QGA2;
Q8EGH4;Q12NY6;Q0HT63;Q0HG
V6;Q085E1;P61330;B8E7R5;B0TP
82;A9KUK6;A6WLA7;A4Y544;A3D
2K6;A1S4P1;A1RLM6;A0KZ22;Q8
ZH65;Q667J0;Q1CFE7;Q1CAN4;C
5BHB7;B2JZ33;B1JQG1;A9R395;A
7FFH0;A4TL91;A1JP81;B7K735;Q
8CPG8;Q5QXS1;Q5HPT4;Q4L5V9
;Q49X42;Q9KA64;Q8NWZ6;Q6GH
H8;Q6G9V6;Q65JJ8;Q5HGH4;Q2Y
XL1;Q2FZ23;Q2FHI1;P99171;P640
54;B9EBD7;A8Z3T8;A8FDB4;A7Z4
S1;A7X1N5;A6U176;A6QGF7;A5IS
E1;Q92B02;Q8Y6M7;Q8EQV2;Q71
Z12;Q5WFS9;Q5L0K1;Q1MRE2;C
5D9B6;C1KVV3;B8DFR4;A4IMC4;
A0AJB0;Q81WK9;Q812X3;Q732P3
;Q6HEY9;Q636K0;C3P5M8;C3L7A
1;C1EP50;C0ZF65;B9IVB5;B7JJA4
;B7IUI5;B7HLF9;B7HDU9;B1HQZ1
;A9VT64;A7GRF6;A0RHJ9;Q8DIA3
;A5FZ68;Q8XJQ7;Q3A396;Q0TPQ
4;Q0SSC1;B2V4F5;B2TJ41;Q67PB
6;A6Q584;B9E1I9;B7KZG1;B1ZLB
6;A9W4G4;A5N829;A0Q0R9;Q9X5
E8;Q92Q54;C3MBQ3;C3L0D2;C1F
SK4;B9L8B2;B8IQY5;B6ISV0;B1K
WM4;B1II65;B0UCS1;A8I464;A7IN
R5;A7GG22;A7FPZ7;A6U8K3;A5I4
L2;Q2K8Y6;Q2G8K9;Q1MH53;Q1
GRQ1;B5ZN84;B3PYP3;B1LTQ7;Q
9ZE60;Q92JF4;Q7PAL9;Q68XV6;
Q4UND7;Q1RH00;C4K1A1;C3PM
>sp|Q3Z5I8|EFTS_SHISS 
Elongation factor Ts 
OS=Shigella sonnei (strain 
Ss046) GN=tsf PE=3 
SV=1;>sp|Q32JT9|EFTS_SHID
S Elongation factor Ts 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=tsf PE=3 
SV=1;>sp|Q325X0|EFTS_SHIB
S Elongation factor Ts 
OS=Shigel 
30.423 
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C3;B0BW39;A8GUK0;A8GQP8;A8
GM33;A8F0J0;A8EXF1;B8EKA0;Q
2W4C4;Q8YMY3;Q3MBF4;B2J6U8
;P80700 
Q3AC47 
>sp|Q3AC47|ACKA_CARHZ 
Acetate kinase 
OS=Carboxydothermus 
hydrogenoformans (strain ATCC 
BAA-161 / DSM 6008 / Z-2901) 
GN=ackA PE=3 SV=1 
43.868 
Q31WI5;Q0T0X4;P0A7A1;Q8XD03
;Q0TDT0;P0A7A0;P0A799;B1IT77;
A7ZR34;A1AFB0;Q3YXU6;Q32BY
6;A8A466;Q4QN23;P43726;A5UH3
0;A5U9X0;P57973;Q65W08;A6VL
R3;B3H222;B0BQI3;A3N1Q1;B4E
UH8;A8GIV0;Q8DCA0;Q87LL1;Q7
MHL1;Q8GF87;Q7N7Z5;C4LE53;A
4SRF1;A0KGD3;B8GP44;C1DKE9;
Q9I5Y4;Q02TL3;B7V4D9;A6UZ15;
P0C6Q3;A5F9G2;Q9PF55;Q8PHB
2;Q8P5Z4;Q87AH8;Q5GXA2;Q4U
Y23;Q3BPW7;Q2P0F7;B4STV2;B2
SI21;B2FSF3;B0RPF1;Q12QA3;Q3
SMD2;Q1GZ23;A1U543;A7MTQ1;
A4XPG4;Q3K5F2;Q88D64;Q88AK
3;Q48CH7;Q1I3Y0;B1J302;B0KLY
7;A5W9Z6;Q5E7Q9;B6EMW2;B5F
9T5;Q0VL87;Q2SLS9;Q8K9B3;Q3I
LL7;P62418;Q6FB08;B7I501;B7H3
N8;B2HZB6;B0VMX3;B0VD03;A3M
4X6;Q7VRG3 
>sp|Q31WI5|PGK_SHIBS 
Phosphoglycerate kinase 
OS=Shigella boydii serotype 4 
(strain Sb227) GN=pgk PE=3 
SV=1;>sp|Q0T0X4|PGK_SHIF8 
Phosphoglycerate kinase 
OS=Shigella flexneri serotype 
5b (strain 8401) GN=pgk PE=3 
SV=1;>sp|P0A7A1|PGK_SHIFL 
Phosphoglycerate ki 
41.118 
Q317B9 
>sp|Q317B9|PURA_DESAG 
Adenylosuccinate synthetase 
OS=Desulfovibrio alaskensis 
(strain G20) GN=purA PE=3 
SV=1 
46.375 
Q2NQI3 
>sp|Q2NQI3|PCKA_SODGM 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Sodalis glossinidius (strain 
morsitans) GN=pckA PE=3 
SV=1 
59.266 
Q2JFH9;Q0RRS4;A8LC59;A8EXK
1;Q9PJV6;Q824G0;Q5L6S5;Q3KL
R3;Q253F1;O84444;B0BC74;B0B8
09;Q8KTB7;Q8KTB0;A8GV17;A8F
0P0;Q1RHC3;Q92J93;Q8KTC1;Q8
KTB9;Q8KTB8;Q8KTB6;Q8KTB4;Q
8KTB2;Q8KTA8;P41084;C4K1P6;C
3PMH0;B0BWA2;A8GQV7 
>sp|Q2JFH9|EFG_FRACC 
Elongation factor G OS=Frankia 
casuarinae (strain DSM 45818 / 
CECT 9043 / CcI3) GN=fusA 
PE=3 
SV=1;>sp|Q0RRS4|EFG_FRAA
A Elongation factor G 
OS=Frankia alni (strain 
ACN14a) GN=fusA PE=3 
SV=1;>sp|A8LC59|EFG_FRAS
N Elongation factor G OS=Fr 
76.734 
Q0TMS5;Q0SQH3;P0C2E6 
>sp|Q0TMS5|RPOA_CLOP1 
DNA-directed RNA polymerase 
subunit alpha OS=Clostridium 
35.176 
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perfringens (strain ATCC 13124 
/ DSM 756 / JCM 1290 / NCIMB 
6125 / NCTC 8237 / Type A) 
GN=rpoA PE=3 
SV=1;>sp|Q0SQH3|RPOA_CLO
PS DNA-directed RNA 
polymerase subunit alpha 
OS=Clost 
Q07064;Q1WTW0;B2IC30;Q97EB3
;Q8XHL4;Q5XZD9;Q59925;Q0TMI
3;Q0SQ82;P13419;B8I3S9;B2UXU
5;B2TI29;A6LPL1;A3DI22;Q1GE26
;Q160C2;Q92AD2;Q8Y624;Q71YD
9;C1KWH6;B8DDM6;A0AJY2;A5W
I04 
>sp|Q07064|FTHS_CLOCY 
Formate--tetrahydrofolate ligase 
OS=Clostridium cylindrosporum 
GN=fhs PE=3 
SV=1;>sp|Q1WTW0|FTHS_LAC
S1 Formate--tetrahydrofolate 
ligase OS=Lactobacillus 
salivarius (strain UCC118) 
GN=fhs PE=3 
SV=1;>sp|B2IC30|FTHS_BEII9 
Formate--tetrahy 
59.096 
Q04FQ4 
>sp|Q04FQ4|EFTU_OENOB 
Elongation factor Tu 
OS=Oenococcus oeni (strain 
ATCC BAA-331 / PSU-1) 
GN=tuf PE=3 SV=1 
43.624 
Q035Y8;O32846;B3W9W8 
>sp|Q035Y8|CH10_LACP3 10 
kDa chaperonin 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=groS PE=3 
SV=1;>sp|O32846|CH10_LACZ
E 10 kDa chaperonin 
OS=Lactobacillus zeae 
GN=groS PE=3 
SV=1;>sp|B3W9W8|CH10_LAC
CB  
10.039 
Q035A9;B3WAJ2;Q839D9;Q38UT7
;Q88XW0;Q1WSB6;Q04ML1;P667
09;P66708;Q9CDY3;Q8DS36;Q5M
2D9;Q5LXT7;Q03IH7;Q02W51;A8
AZJ9;A2RNM7;Q8CRI4;Q71WH2;
Q6GEK9;Q6G797;Q65P79;Q5WLN
5;Q5L3R2;Q5HM25;Q5HDY4;Q4L8
88;Q49ZE2;Q2YYM2;Q2FW32;Q2
FER5;Q04G60;Q03ZM0;Q03EE2;P
66707;P66706;P66705;P66700;P6
6699;O50634;C1KZF5;C0ZIK7;B9E
9L7;B8DB34;B2G8V2;A8F9B2;A7Z
0R5;A7X5C4;A6QJ66;A5VLH9;A4I
JL4;A0ALU2;B2A4Q0;A6TWF3;Q0
AUK9;Q03PY3;A8MLG9;P20429 
>sp|Q035A9|RPOA_LACP3 
DNA-directed RNA polymerase 
subunit alpha OS=Lactobacillus 
paracasei (strain ATCC 334 / 
BCRC 17002 / CIP 107868 / 
KCTC 3260 / NRRL B-441) 
GN=rpoA PE=3 
SV=1;>sp|B3WAJ2|RPOA_LAC
CB DNA-directed RNA 
polymerase subunit alpha 
OS=Lactobacill 
34.758 
Q034X8;B3WAM2;Q04ED6;Q73IX
7;Q3AW54;Q1D777;C0R543;Q748
Y8;Q2RQV7;Q31PV4;P18667;Q2S
909;Q03ZQ2;B1MW21;Q5QWB4 
>sp|Q034X8|EFG_LACP3 
Elongation factor G 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=fusA PE=3 
76.819 
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SV=1;>sp|B3WAM2|EFG_LACC
B Elongation factor G 
OS=Lactobacillus casei (strain 
BL23) GN=fusA PE=3 
SV=1;>sp|Q 
Q02UU0 
>sp|Q02UU0|AHPC_PSEAB 
Alkyl hydroperoxide reductase C 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=ahpC 
PE=1 SV=1 
20.541 
Q02T55;O52760;A6UZL3;Q8L2F8;
A4VHQ5;B3PK62;Q88QL1;Q889U
6;Q4ZMR8;Q4K557;Q48D61;Q3K6
12;Q1IFU1;A5VXS2;A4XZ65;Q5P3
07;A1KB01;B1Y7M9;Q3IJI6;Q21M
33;Q488Y8;Q15X48;Q057C9;A3N3
82;Q5ZYL8;Q5X834;Q5WZI7;A5IH
P1;Q7VQC3;Q1R0F0;B8GV33;Q2
S937;A1TYM2;Q47J77;Q63Q37;Q
62GN1;Q3JMT9;Q39KE1;Q2SU53;
Q1BRX4;Q13TJ6;Q0BJ20;B4E5E6;
B2T725;B2JI39;B1YRQ5;B1JU48;A
9ADL9;A6T3H8;A4JAR6;A4G9R3;
A3P087;A3NEF3;A3MRY0;A2S7K2
;A1V877;A0K3Q1;A1AVM5;Q8XV3
8;Q46WG9;Q1LI63;Q0K645;B3R7
E3;B2UEJ3;B1XSS7;A4SUY6;Q83
EQ2;B6J5F7;B6J238;A9NAZ5;A9K
D06;Q7NQH7;C1DAU3;Q8D1Y8;Q
605D7;Q5F5V2;P66704;P66703;A1
SXW8;A1KRJ9;Q2L238;Q1H4L2;P
0A4E7;P0A4E6;P0A4E5;A9IHR6;Q
31IV8;Q0I137;Q21QP9;Q12G77;C
5CQ75;Q5QXV8;B9MBW2;A1WK9
2;A1W333;A1VJ40;A1TJU2;Q0ABF
0;Q3J8T8;A1WV97;A9BRX5;A2SL
D1;Q2YAX2;Q6F7T7;Q4FUD1;Q1
QDG1;B7IA14;B7GW27;B2HZ83;B
0VQU3;B0V6U7;A5WCL4;A3M959 
>sp|Q02T55|RPOA_PSEAB 
DNA-directed RNA polymerase 
subunit alpha 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=rpoA 
PE=3 
SV=1;>sp|O52760|RPOA_PSE
AE DNA-directed RNA 
polymerase subunit alpha 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 1 
36.649 
Q02QC9;P35483 
>sp|Q02QC9|PPBH_PSEAB 
Alkaline phosphatase H 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=phoA 
PE=1 
SV=1;>sp|P35483|PPBH_PSEA
E Alkaline phosphatase H 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / P 
50.392 
Q02DZ3;P0DMR4;G3XDA8 
>sp|Q02DZ3|PSTS_PSEAB 
Phosphate-binding protein PstS 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=pstS 
PE=1 
SV=1;>sp|P0DMR4|PSTS_PSE
AI Phosphate-binding protein 
34.473 
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PstS OS=Pseudomonas 
aeruginosa GN=pstS PE=1 
SV=1;>sp|G3XDA8|PSTS_PSE
AE Phosphate-binding pr 
P77983;Q8Z6K2;P0AD62;P0AD61;
O30853 
>sp|P77983|KPYK1_SALTY 
Pyruvate kinase I 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=pykF PE=3 
SV=2;>sp|Q8Z6K2|KPYK1_SAL
TI Pyruvate kinase I 
OS=Salmonella typhi GN=pykF 
PE=3 
SV=1;>sp|P0AD62|KPYK1_EC
O57 Pyruvate kinase I 
OS=Escherichi 
50.657 
P76015 
>sp|P76015|DHAK_ECOLI 
PEP-dependent 
dihydroxyacetone kinase, 
dihydroxyacetone-binding 
subunit DhaK OS=Escherichia 
coli (strain K12) GN=dhaK PE=1 
SV=2 
38.215 
P75089 
>sp|P75089|ALF_MYCPN 
Fructose-bisphosphate aldolase 
OS=Mycoplasma pneumoniae 
(strain ATCC 29342 / M129) 
GN=fba PE=3 SV=1 
31.068 
P53638 
>sp|P53638|SODF_BACFR 
Superoxide dismutase [Fe] 
OS=Bacteroides fragilis (strain 
YCH46) GN=sodB PE=3 SV=2 
21.771 
P52041 
>sp|P52041|HBD_CLOAB 3-
hydroxybutyryl-CoA 
dehydrogenase OS=Clostridium 
acetobutylicum (strain ATCC 
824 / DSM 792 / JCM 1419 / 
LMG 5710 / VKM B-1787) 
GN=hbd PE=1 SV=2 
30.582 
P45359;Q8CQN7;Q5HS07;P45855
;P76461 
>sp|P45359|THLA_CLOAB 
Acetyl-CoA acetyltransferase 
OS=Clostridium acetobutylicum 
(strain ATCC 824 / DSM 792 / 
JCM 1419 / LMG 5710 / VKM B-
1787) GN=thlA PE=1 
SV=1;>sp|Q8CQN7|THLA_STA
ES Probable acetyl-CoA 
acyltransferase 
OS=Staphylococcus epidermidis 
(strai 
41.24 
P38100;O67869;Q9RWK0;Q5SKN
1;P96495;Q1IWM0;C1CXR4;Q9KP
H9;Q8K9Z7;Q8DEM2;Q87SF3;Q7
MNU0;P57244;Q1D6Y8;Q9PIL7;C1
F1S6;Q9WZ27;Q9A4D6;B9KB91;B
1L8T8;A5IJL8;O50236;Q8YIC2;Q8
UDE9;Q8FZJ3;Q92PZ4;Q98I87 
>sp|P38100|CARB_PSEAE 
Carbamoyl-phosphate synthase 
large chain OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
117.33 
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PRS 101 / PAO1) GN=carB 
PE=3 SV=3 
P33109 
>sp|P33109|ASPA_SERMA 
Aspartate ammonia-lyase 
OS=Serratia marcescens 
GN=aspA PE=3 SV=1 
52.543 
P27302;Q87LK8;Q7MDD4;Q5DZP
0;Q5E7R1;Q9KLW7;Q9KUP2 
>sp|P27302|TKT1_ECOLI 
Transketolase 1 
OS=Escherichia coli (strain K12) 
GN=tktA PE=1 SV=5 
72.211 
P23847 
>sp|P23847|DPPA_ECOLI 
Periplasmic dipeptide transport 
protein OS=Escherichia coli 
(strain K12) GN=dppA PE=1 
SV=1 
60.293 
P21179 
>sp|P21179|CATE_ECOLI 
Catalase HPII OS=Escherichia 
coli (strain K12) GN=katE PE=1 
SV=1 
84.162 
P19543 
>sp|P19543|NIFJ_ENTAG 
Pyruvate-flavodoxin 
oxidoreductase 
OS=Enterobacter agglomerans 
GN=nifJ PE=3 SV=3 
128.24 
P17584 
>sp|P17584|DHD2_LACPA D-2-
hydroxyisocaproate 
dehydrogenase 
OS=Lactobacillus paracasei 
PE=1 SV=2 
36.893 
P17215;P25399;P0AD98;P0AD97;
P0AD96 
>sp|P17215|LIVJ_SALTY 
Leu/Ile/Val/Thr-binding protein 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=livJ PE=1 
SV=1;>sp|P25399|LIVJ_CITFR 
Leu/Ile/Val-binding protein 
OS=Citrobacter freundii GN=livJ 
PE=3 
SV=1;>sp|P0AD98|LIVJ_ECO57 
Leu/Il 
38.787 
P16481;P0AA09;P0AA08;P0AA07;
P0AA06;P0AA05;P0AA04 
>sp|P16481|PTHP_KLEPN 
Phosphocarrier protein HPr 
OS=Klebsiella pneumoniae 
GN=ptsH PE=3 SV=1 
9.1193 
P14407 
>sp|P14407|FUMB_ECOLI 
Fumarate hydratase class I, 
anaerobic OS=Escherichia coli 
(strain K12) GN=fumB PE=1 
SV=2 
60.105 
P13794 
>sp|P13794|PORF_PSEAE 
Outer membrane porin F 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=oprF PE=1 
SV=1 
37.639 
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P0DJO6;I2BAK7;P04845 
>sp|P0DJO6|OMPA_SHIBL 
Outer membrane protein A 
(Fragment) OS=Shimwellia 
blattae GN=ompA PE=3 
SV=1;>sp|I2BAK7|OMPA_SHIB
C Outer membrane protein A 
OS=Shimwellia blattae (strain 
ATCC 29907 / DSM 4481 / JCM 
1650 / NBRC 105725 / CDC 
9005-74) GN=ompA PE=3 
SV=1;> 
25.917 
P0ADB3;P0ADB2;P0ADB1 
>sp|P0ADB3|OSME_SHIFL 
Osmotically-inducible putative 
lipoprotein OsmE OS=Shigella 
flexneri GN=osmE PE=3 
SV=1;>sp|P0ADB2|OSME_ECO
57 Osmotically-inducible 
putative lipoprotein OsmE 
OS=Escherichia coli O157:H7 
GN=osmE PE=3 
SV=1;>sp|P0ADB1|OSME_ECO
LI Osmotical 
12.021 
P0AC40;Q8XDS0;P0AC39;P0AC3
8;P44324;P07346 
>sp|P0AC40|ASPA_SHIFL 
Aspartate ammonia-lyase 
OS=Shigella flexneri GN=aspA 
PE=3 
SV=1;>sp|Q8XDS0|ASPA_ECO
57 Aspartate ammonia-lyase 
OS=Escherichia coli O157:H7 
GN=aspA PE=3 
SV=2;>sp|P0AC39|ASPA_ECO
L6 Aspartate ammonia-lyase 
OS=Escherichia coli O6:H1 
(strain 
52.356 
P0AA30;P0AA29;P0AA28;P0AA27;
P0AA26;P0AA25;P52233 
>sp|P0AA30|THIO_SHIFL 
Thioredoxin 1 OS=Shigella 
flexneri GN=trxA PE=3 
SV=2;>sp|P0AA29|THIO_SALTI 
Thioredoxin 1 OS=Salmonella 
typhi GN=trxA PE=1 
SV=2;>sp|P0AA28|THIO_SALT
Y Thioredoxin 1 OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=trxA 
11.806 
P0A914;P0A913;P0A912 
>sp|P0A914|PAL_SHIFL 
Peptidoglycan-associated 
lipoprotein OS=Shigella flexneri 
GN=pal PE=3 
SV=1;>sp|P0A913|PAL_ECO57 
Peptidoglycan-associated 
lipoprotein OS=Escherichia coli 
O157:H7 GN=pal PE=3 
SV=1;>sp|P0A912|PAL_ECOLI 
Peptidoglycan-associated 
lipoprotein 
18.824 
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P0A338;P0A337 
>sp|P0A338|CH602_THEVL 60 
kDa chaperonin 2 
OS=Thermosynechococcus 
vulcanus GN=groL2 PE=3 
SV=1;>sp|P0A337|CH602_THE
EB 60 kDa chaperonin 2 
OS=Thermosynechococcus 
elongatus (strain BP-1) 
GN=groL2 PE=3 SV=1 
57.102 
P0A2F5;P0A2F4;P0AGD6;P0AGD
5;P0AGD4;P0AGD3 
>sp|P0A2F5|SODF_SALTI 
Superoxide dismutase [Fe] 
OS=Salmonella typhi GN=sodB 
PE=3 
SV=2;>sp|P0A2F4|SODF_SALT
Y Superoxide dismutase [Fe] 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=sodB PE=3 
SV=2;>sp|P0AGD6|SODF_SHIF
L Superoxide dismuta 
21.308 
P0A2C6;P0A2C5 
>sp|P0A2C6|RBSB_SALTI 
Ribose import binding protein 
RbsB OS=Salmonella typhi 
GN=rbsB PE=3 
SV=1;>sp|P0A2C5|RBSB_SALT
Y Ribose import binding protein 
RbsB OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=rbsB PE=1 SV=1 
30.962 
P0A1V7;P0A1V6;P0A719;P0A718;
P0A717;Q8ZEY2;Q7N590;Q1LTH2
;P57266;Q7VR76;Q8DFF5;Q87RN
8;Q7MMZ1;Q8K9X2;P59512;Q9CP
22;Q8EAQ9;Q7VL55 
>sp|P0A1V7|KPRS_SALTI 
Ribose-phosphate 
pyrophosphokinase 
OS=Salmonella typhi GN=prs 
PE=3 
SV=2;>sp|P0A1V6|KPRS_SALT
Y Ribose-phosphate 
pyrophosphokinase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=prs PE=1 
SV=2;>sp|P0A719|KPRS_ECO5
7 Ri 
34.216 
P06996;Q8XE41 
>sp|P06996|OMPC_ECOLI 
Outer membrane protein C 
OS=Escherichia coli (strain K12) 
GN=ompC PE=1 
SV=1;>sp|Q8XE41|OMPC_ECO
57 Outer membrane protein C 
OS=Escherichia coli O157:H7 
GN=ompC PE=3 SV=1 
40.368 
P06959 
>sp|P06959|ODP2_ECOLI 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase 
complex OS=Escherichia coli 
66.095 
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(strain K12) GN=aceF PE=1 
SV=3 
P02925;P44737 
>sp|P02925|RBSB_ECOLI 
Ribose import binding protein 
RbsB OS=Escherichia coli 
(strain K12) GN=rbsB PE=1 
SV=1 
30.95 
P02924 
>sp|P02924|ARAF_ECOLI L-
arabinose-binding periplasmic 
protein OS=Escherichia coli 
(strain K12) GN=araF PE=1 
SV=2 
35.54 
P00363;P20922 
>sp|P00363|FRDA_ECOLI 
Fumarate reductase flavoprotein 
subunit OS=Escherichia coli 
(strain K12) GN=frdA PE=1 
SV=3;>sp|P20922|FRDA_PROV
U Fumarate reductase 
flavoprotein subunit OS=Proteus 
vulgaris GN=frdA PE=3 SV=1 
65.971 
O83553 
>sp|O83553|PFP_TREPA 
Pyrophosphate--fructose 6-
phosphate 1-
phosphotransferase 
OS=Treponema pallidum (strain 
Nichols) GN=pfp PE=1 SV=1 
62.426 
O08439;O08458;P45482 
>sp|O08439|FTSZ_ENTFA Cell 
division protein FtsZ 
OS=Enterococcus faecalis 
(strain ATCC 700802 / V583) 
GN=ftsZ PE=3 
SV=2;>sp|O08458|FTSZ_ENTH
R Cell division protein FtsZ 
OS=Enterococcus hirae 
GN=ftsZ PE=3 
SV=2;>sp|P45482|FTSZ_NOSS
1 Cell division protein Fts 
44.147 
B8J4A8 
>sp|B8J4A8|SAT_DESDA 
Sulfate adenylyltransferase 
OS=Desulfovibrio desulfuricans 
(strain ATCC 27774 / DSM 
6949) GN=sat PE=3 SV=1 
46.912 
B7NMG6;B7NE08;B7N136;B7MDM
9;B1LHK1;A1AGS9;Q83J96;Q3YW
M2;Q31VN1;B2U3L1;Q8FCU4;Q0T
C64;P22259;C4ZUQ8;B7UKA7;B7
M1V7;B7L4T1;B6I2W3;B1X750;B1I
P62;A8A5L1;A7ZST1;Q0SZR5;Q8
X733;B5YTV3;Q32AL7;B7LSA4;Q6
LLS2;Q87TE1;Q5E1X3;B5FCE7;Q
9KNK0;C3LSG5;A5F4Q4;B7VHF2;
B6EGP7;Q8DDS6 
>sp|B7NMG6|PCKA_ECO7I 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Escherichia coli O7:K1 
(strain IAI39 / ExPEC) GN=pckA 
PE=3 
SV=1;>sp|B7NE08|PCKA_ECO
LU Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Escherichia coli 
O17:K52:H18 (strain UMN026 / 
ExPEC) GN=pckA P 
59.615 
B7LUY6;Q8FF10;Q0TEQ9;B7UH1
8;B7NRN5;B7N6H0;B7MIR4;B1LP
92;A1AEA9;Q32CU0;Q8XFE0;Q7C
>sp|B7LUY6|GRCA_ESCF3 
Autonomous glycyl radical 
cofactor OS=Escherichia 
14.268 
352 
 
 
Q05;Q5PLH7;Q57L55;Q3YYT6;Q3
1XQ5;C0PVZ1;B5RD61;B5QTW0;
B5FRD8;B5F227;B5BAR8;B4TS28;
B4TE27;B4T289;B2TYK2;A9N0W4
;A9MGW0;A8AD08;A4WDE8;P680
67;P68066;C4ZYK2;B7MYL2;B7M8
J4;B7LDH2;B6I5F4;B5Z153;B1XB
Q6;B1IVP8;A8A391;A7ZQ24;Q9CP
H6;Q83K21;Q6D209;Q65VN1;Q4Q
PM7;Q0T1S7;Q0I272;P44455;P18
953;C6DC10;C5BAK4;B8F6C4;B0
UWA8;A8GI38;A7MH19;A6VLV5;A
5UFJ0;A5UBC1;A1JKI9;Q7VMC2;
B3H0M3;B0BTB3;A3MZ79;Q8DEP
5;Q87SC7;Q7MNR2;A7MS83;Q8Z
D84;Q667T8;Q1CKF7;Q1C569;B4
F057;B2VED1;B2KA62;B1JRB2;A9
R3Y7;A7FFS5;A4TKZ1 
fergusonii (strain ATCC 35469 / 
DSM 13698 / CDC 0568-73) 
GN=grcA PE=3 
SV=1;>sp|Q8FF10|GRCA_ECO
L6 Autonomous glycyl radical 
cofactor OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
7009 
B5XY03;A4W5E0;Q8ZAS2;Q664W
9;Q1CNS4;Q1CC27;B2K4Y6;B1JJ
M7;A9R536;A7FDG8;A4TH39;A1J
RV9;B3GY24;B0BQ77;A3N1E1;Q6
D022;Q2NR04;C6DFP4;B2VKB1;Q
7MZB4;A8GKD1;Q9CNL2;C5B6Z1;
Q4QL07;P44312;A5UED2;A5UCG
6;A1SRS5;Q7VNR9;B8F632;Q2RQ
51;B4EYR8;Q65TC2;Q0I3C7;B0U
UD4;Q6LM51;Q5E847;B7VI73;B6E
LK8;B5FGI2;A7MSY9;Q1LU73 
>sp|B5XY03|G6PI_KLEP3 
Glucose-6-phosphate isomerase 
OS=Klebsiella pneumoniae 
(strain 342) GN=pgi PE=3 SV=1 
61.297 
B5XXP0 
>sp|B5XXP0|NQOR_KLEP3 
NAD(P)H dehydrogenase 
(quinone) OS=Klebsiella 
pneumoniae (strain 342) 
GN=KPK_3530 PE=3 SV=1 
20.895 
B5XUB8 
>sp|B5XUB8|PGK_KLEP3 
Phosphoglycerate kinase 
OS=Klebsiella pneumoniae 
(strain 342) GN=pgk PE=3 
SV=1 
41.091 
B5XNF9;A6TCJ1 
>sp|B5XNF9|GRCA_KLEP3 
Autonomous glycyl radical 
cofactor OS=Klebsiella 
pneumoniae (strain 342) 
GN=grcA PE=3 
SV=1;>sp|A6TCJ1|GRCA_KLE
P7 Autonomous glycyl radical 
cofactor OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) GN=grcA 
PE 
14.243 
B2V2I5;B2TLZ7 
>sp|B2V2I5|DNAK_CLOBA 
Chaperone protein DnaK 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=dnaK PE=3 
SV=1;>sp|B2TLZ7|DNAK_CLO
65.82 
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BB Chaperone protein DnaK 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=dnaK PE=3 SV=1 
B2UZ05;B2TIX3;Q97FM9;C4ZCQ4
;C4Z3X1;A7FYP0;A5I720;A0Q2S8 
>sp|B2UZ05|GUAA_CLOBA 
GMP synthase [glutamine-
hydrolyzing] OS=Clostridium 
botulinum (strain Alaska E43 / 
Type E3) GN=guaA PE=3 
SV=1;>sp|B2TIX3|GUAA_CLOB
B GMP synthase [glutamine-
hydrolyzing] OS=Clostridium 
botulinum (strain Eklund 17B / 
Type B) GN=guaA PE= 
56.882 
B2KAX0 
>sp|B2KAX0|DNAK_ELUMP 
Chaperone protein DnaK 
OS=Elusimicrobium minutum 
(strain Pei191) GN=dnaK PE=3 
SV=1 
66.365 
B2G669;A5VIN9 
>sp|B2G669|ARCA_LACRJ 
Arginine deiminase 
OS=Lactobacillus reuteri (strain 
JCM 1112) GN=arcA PE=3 
SV=1;>sp|A5VIN9|ARCA_LACR
D Arginine deiminase 
OS=Lactobacillus reuteri (strain 
DSM 20016) GN=arcA PE=3 
SV=1 
46.242 
B2G653;A5VIM0 
>sp|B2G653|OTC_LACRJ 
Ornithine carbamoyltransferase 
OS=Lactobacillus reuteri (strain 
JCM 1112) GN=arcB PE=3 
SV=1;>sp|A5VIM0|OTC_LACR
D Ornithine 
carbamoyltransferase 
OS=Lactobacillus reuteri (strain 
DSM 20016) GN=arcB PE=3 
SV=1 
37.559 
B0UQS5 
>sp|B0UQS5|GLSA_METS4 
Glutaminase 
OS=Methylobacterium sp. 
(strain 4-46) GN=glsA PE=3 
SV=1 
33.331 
A9HK37 
>sp|A9HK37|CH601_GLUDA 60 
kDa chaperonin 1 
OS=Gluconacetobacter 
diazotrophicus (strain ATCC 
49037 / DSM 5601 / PAl5) 
GN=groL1 PE=3 SV=1 
57.917 
A8AIW9;A4W8F0;A7MEY6 
>sp|A8AIW9|DPS_CITK8 DNA 
protection during starvation 
protein OS=Citrobacter koseri 
(strain ATCC BAA-895 / CDC 
4225-83 / SGSC4696) GN=dps 
PE=3 
SV=1;>sp|A4W8F0|DPS_ENT3
8 DNA protection during 
18.706 
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starvation protein 
OS=Enterobacter sp. (strain 
638) GN=dps PE=3 S 
A7NIK8;A5V0S2;A9B6A4 
>sp|A7NIK8|CH601_ROSCS 60 
kDa chaperonin 1 
OS=Roseiflexus castenholzii 
(strain DSM 13941 / HLO8) 
GN=groL1 PE=3 
SV=1;>sp|A5V0S2|CH602_ROS
S1 60 kDa chaperonin 2 
OS=Roseiflexus sp. (strain RS-
1) GN=groL2 PE=3 
SV=1;>sp|A9B6A4|CH60_HERA
2 60 kDa chaperonin OS=He 
58.586 
A7MJQ4 
>sp|A7MJQ4|PGK_CROS8 
Phosphoglycerate kinase 
OS=Cronobacter sakazakii 
(strain ATCC BAA-894) GN=pgk 
PE=3 SV=1 
41.277 
A7GG00 
>sp|A7GG00|PNP_CLOBL 
Polyribonucleotide 
nucleotidyltransferase 
OS=Clostridium botulinum 
(strain Langeland / NCTC 10281 
/ Type F) GN=pnp PE=3 SV=1 
77.555 
A6TCA1;A9MHQ2;Q8ZN71;Q8Z4R
8;Q5PLS1;B5BB16;B4TR62;B7LK
G3;A7MP70;Q3YZ74;Q32D87;Q31
Y13;Q0T239;P0A6L3;B2TXQ4;P63
944;P63943;P0A6L2;B7NQL6;B7M
YB7;B7M7I1;B7LCL6;B6I548;B5Z0
15;B1LNC8;B1IWI1;A8A2X1;A7ZP
S4;B2VE56 
>sp|A6TCA1|DAPA_KLEP7 4-
hydroxy-tetrahydrodipicolinate 
synthase OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) 
GN=dapA PE=3 
SV=1;>sp|A9MHQ2|DAPA_SAL
AR 4-hydroxy-
tetrahydrodipicolinate synthase 
OS=Salmonella arizonae (strain 
ATC 
31.162 
A6M1Y8;B2V358;B2TN12 
>sp|A6M1Y8|GLPK_CLOB8 
Glycerol kinase OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=glpK PE=3 
SV=1 
55.547 
A6LUK9;A9KSH6;Q8F6A0;Q72PY2
;Q04ZF5;Q04R46;A4W0W9;A4VU
M9 
>sp|A6LUK9|GLYA_CLOB8 
Serine 
hydroxymethyltransferase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=glyA PE=3 
SV=1;>sp|A9KSH6|GLYA_LAC
P7 Serine 
hydroxymethyltransferase 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823  
44.986 
A6LSR0;B2V4H5;B2TJ61;Q5WFU8 
>sp|A6LSR0|PNP_CLOB8 
Polyribonucleotide 
nucleotidyltransferase 
76.981 
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OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=pnp PE=3 
SV=1;>sp|B2V4H5|PNP_CLOB
A Polyribonucleotide 
nucleotidyltransferase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E 
A6LR05;A0PYP1;C1FQW3;B1IDB6
;A7G9Y0;A7FQN7;A5HYC0;A5CY
N8;Q3B116;A4SH15;C3KYR4;B9E
6B4;A5N2N8;Q181T8 
>sp|A6LR05|PGK_CLOB8 
Phosphoglycerate kinase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=pgk PE=3 SV=1 
41.877 
A6LA97 
>sp|A6LA97|PYRB_PARD8 
Aspartate carbamoyltransferase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=pyrB PE=3 
SV=1 
35.1 
A6L1V8;Q8A6L7 
>sp|A6L1V8|LEUC_BACV8 3-
isopropylmalate dehydratase 
large subunit OS=Bacteroides 
vulgatus (strain ATCC 8482 / 
DSM 1447 / JCM 5826 / NBRC 
14291 / NCTC 11154) GN=leuC 
PE=3 
SV=1;>sp|Q8A6L7|LEUC_BACT
N 3-isopropylmalate 
dehydratase large subunit 
OS=Bacteroides  
50.046 
A6L1L8;Q8A0M6;Q64YB4;Q5LHE6
;B0S104;A4XKP4;A5UY81 
>sp|A6L1L8|SYA_BACV8 
Alanine--tRNA ligase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=alaS PE=3 
SV=1;>sp|Q8A0M6|SYA_BACT
N Alanine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / 
97.261 
A6GYJ4 
>sp|A6GYJ4|PUR7_FLAPJ 
Phosphoribosylaminoimidazole-
succinocarboxamide synthase 
OS=Flavobacterium 
psychrophilum (strain JIP02/86 / 
ATCC 49511) GN=purC PE=3 
SV=1 
36.21 
A1TTM6 
>sp|A1TTM6|SYS_ACIAC 
Serine--tRNA ligase 
OS=Acidovorax citrulli (strain 
AAC00-1) GN=serS PE=3 SV=1 
48.487 
A0QWW2 
>sp|A0QWW2|G3P_MYCS2 
Glyceraldehyde-3-phosphate 
dehydrogenase 
OS=Mycobacterium smegmatis 
35.947 
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(strain ATCC 700084 / 
mc(2)155) GN=gapA PE=1 
SV=1 
A0L8B0 
>sp|A0L8B0|HTPG_MAGMM 
Chaperone protein HtpG 
OS=Magnetococcus marinus 
(strain ATCC BAA-1437 / JCM 
17883 / MC-1) GN=htpG PE=3 
SV=1 
72.967 
V3TQ67 
>sp|V3TQ67|FRDA_SERS3 
Fumarate reductase flavoprotein 
subunit OS=Serratia sp. (strain 
ATCC 39006) GN=frdA PE=1 
SV=1 
66.096 
T2G6Z9 
>sp|T2G6Z9|APRA_DESGI 
Adenylylsulfate reductase 
subunit alpha OS=Desulfovibrio 
gigas GN=aprA PE=1 SV=1 
74.879 
Q9ZKQ6;O25598 
>sp|Q9ZKQ6|Y944_HELPJ 
RutC family protein jhp_0879 
OS=Helicobacter pylori (strain 
J99 / ATCC 700824) 
GN=jhp_0879 PE=3 
SV=1;>sp|O25598|Y944_HELP
Y RutC family protein HP_0944 
OS=Helicobacter pylori (strain 
ATCC 700392 / 26695) 
GN=HP_0944 PE=3 SV=1 
13.4 
Q9ZKD8;P55990 
>sp|Q9ZKD8|DHE4_HELPJ 
NADP-specific glutamate 
dehydrogenase 
OS=Helicobacter pylori (strain 
J99 / ATCC 700824) GN=gdhA 
PE=3 
SV=1;>sp|P55990|DHE4_HELP
Y NADP-specific glutamate 
dehydrogenase 
OS=Helicobacter pylori (strain 
ATCC 700392 / 26695) 
GN=gdhA PE=3 SV= 
49.49 
Q9ZFV8 
>sp|Q9ZFV8|MAO2_SALTY 
NADP-dependent malic enzyme 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=maeB PE=3 SV=2 
82.321 
Q9ZF60 
>sp|Q9ZF60|GLTI_SALTY 
Glutamate/aspartate import 
solute-binding protein 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=gltI PE=3 SV=3 
33.402 
Q9ZF44;Q6ACE6;Q92AP4;Q8Y6C
6;Q71YQ4;Q9KF52;P12039 
>sp|Q9ZF44|PUR2_LACLA 
Phosphoribosylamine--glycine 
ligase OS=Lactococcus lactis 
subsp. lactis (strain IL1403) 
GN=purD PE=3 
SV=2;>sp|Q6ACE6|PUR2_LEIX
44.288 
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X Phosphoribosylamine--glycine 
ligase OS=Leifsonia xyli subsp. 
xyli (strain CTCB07) GN=purD 
PE=3 SV=1;>sp|Q9 
Q9ZF28;Q9ZF25;A4WEY3;Q3YX7
3;Q32BG5;B7LR37;B2U207;Q9ZF3
1;Q8Z3H7;Q5PLB0;Q57JH9;C0PZ
54;B5REN6;B5QZV8;B5FI13;B5F6
T8;B5BGJ5;B4TWD8;B4TJ06;B4T6
Z8;A9N732;A9MP36;A8AQ58;B5X
SX4;A6TEI7;Q1R6H0;Q0TCU1;P5
9587;P0A706;P0A705;C4ZSQ9;B7
UJ63;B7NKN7;B7NDF4;B7N0V3;B
7MB89;B7M076;B7LHN3;B6I1P3;B
5YS58;B1XGY0;B1LFS0;B1IQV3;A
8A4Y4;A7ZS65;A1AG73 
>sp|Q9ZF28|IF2_KLEOX 
Translation initiation factor IF-2 
OS=Klebsiella oxytoca GN=infB 
PE=3 
SV=1;>sp|Q9ZF25|IF2_ENTCL 
Translation initiation factor IF-2 
OS=Enterobacter cloacae 
GN=infB PE=3 
SV=1;>sp|A4WEY3|IF2_ENT38 
Translation initiation factor IF-2 
OS=Ent 
98.094 
Q9Z4H7 
>sp|Q9Z4H7|HTRA_LACHE 
Serine protease Do-like HtrA 
OS=Lactobacillus helveticus 
GN=htrA PE=3 SV=2 
42.646 
Q9XCA1;B5XTI2;A6TFL4;A4W527;
Q83PP2;Q5PC05;Q3YVY3;Q329N
6;Q31V04;Q0SYE8;P67913;P6791
2;B7LVH8;B5RGG8;B5R5E3;B5FLI
8;B5EXC5;B5BHZ3;B4TZW1;B4T9
A3;B4SXC1;B2U5D7;A9MVL2;A9M
KQ6;A7MQ91;Q8FCA0;Q1R4X2;Q
0TBI8;P67911;P67910;C4ZXL1;B7
ULH4;B7NPC7;B7NES6;B7N1S3;B
7MFI2;B7M4A5;B7L745;B6I3J9;B5
YWC0;B1X953;B1IZH2;A8A683;A7
ZTH2;A1AHF5;A8GLC8;Q57IC3;C
0Q1V2;A8ARK8;B4F132;B1LK58 
>sp|Q9XCA1|HLDD_KLEPN 
ADP-L-glycero-D-manno-
heptose-6-epimerase 
OS=Klebsiella pneumoniae 
GN=hldD PE=3 
SV=2;>sp|B5XTI2|HLDD_KLEP
3 ADP-L-glycero-D-manno-
heptose-6-epimerase 
OS=Klebsiella pneumoniae 
(strain 342) GN=hldD PE=3 
SV=1;>sp|A6TFL4|HLDD_KLEP
7 ADP-L-g 
34.965 
Q9X6N0;P0A2I0;P0A2H9 
>sp|Q9X6N0|DSBA_SALTI 
Thiol:disulfide interchange 
protein DsbA OS=Salmonella 
typhi GN=dsbA PE=3 
SV=1;>sp|P0A2I0|DSBA_SALE
N Thiol:disulfide interchange 
protein DsbA OS=Salmonella 
enteritidis GN=dsbA PE=3 
SV=1;>sp|P0A2H9|DSBA_SALT
Y Thiol:disulfide interchang 
22.91 
Q9WY52;B9K6R9;B9E7A4;B1L9U3
;A8MLY0;A5IKL2;Q8DTX6;Q9L9E3
;Q03KB7 
>sp|Q9WY52|PFKA_THEMA 
ATP-dependent 6-
phosphofructokinase 
OS=Thermotoga maritima 
(strain ATCC 43589 / MSB8 / 
DSM 3109 / JCM 10099) 
GN=pfkA PE=1 
SV=1;>sp|B9K6R9|PFKA_THE
NN ATP-dependent 6-
phosphofructokinase 
OS=Thermotoga neapolitana 
(strain ATCC 49049 / DS 
34.487 
Q9S508;Q02L47;O69753;Q51788 
>sp|Q9S508|PHZB2_PSEAE 
Phenazine biosynthesis protein 
19.027 
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PhzB 2 OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=phzB2 
PE=1 
SV=1;>sp|Q02L47|PHZB2_PSE
AB Phenazine biosynthesis 
protein PhzB  
Q9RWN1 
>sp|Q9RWN1|PFKA_DEIRA 
ATP-dependent 6-
phosphofructokinase 
OS=Deinococcus radiodurans 
(strain ATCC 13939 / DSM 
20539 / JCM 16871 / LMG 4051 
/ NBRC 15346 / NCIMB 9279 / 
R1 / VKM B-1422) GN=pfkA 
PE=3 SV=2 
34.62 
Q9REU4;Q93M78;B8DTZ2;Q9EY7
6;Q8G879;B7GPR8;B3DPK4;Q9KI
57;Q9KI71 
>sp|Q9REU4|CH60_BIFAA 60 
kDa chaperonin 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=groL PE=3 
SV=3 
56.247 
Q9PPU9;B5ZC49;B1AJI2 
>sp|Q9PPU9|RL11_UREPA 
50S ribosomal protein L11 
OS=Ureaplasma parvum 
serovar 3 (strain ATCC 700970) 
GN=rplK PE=3 
SV=1;>sp|B5ZC49|RL11_UREU
1 50S ribosomal protein L11 
OS=Ureaplasma urealyticum 
serovar 10 (strain ATCC 33699 / 
Western) GN=rplK PE=3 
SV=1;>sp|B 
16.336 
Q9PL86;Q822B2 
>sp|Q9PL86|IF3_CHLMU 
Translation initiation factor IF-3 
OS=Chlamydia muridarum 
(strain MoPn / Nigg) GN=infC 
PE=3 
SV=1;>sp|Q822B2|IF3_CHLCV 
Translation initiation factor IF-3 
OS=Chlamydophila caviae 
(strain GPIC) GN=infC PE=3 
SV=1 
21.068 
Q9L9I7;Q8Z326;Q83PB8;Q5PKA6;
Q57H61;Q3YUZ0;Q32AG7;Q31U0
3;Q0SY06;C0Q2S6;B7LUK8;B5XY
E4;B5FQK9;B5F1H7;B5BJR3;B4T
QK4;B4TCT3;B4T0Z6;B2TWI1;A9
N0K6;A9MHD6;A6TGQ1;Q8X6X9;
Q8FB77;Q0TA71;P30136;C5A0T5;
B7UPE9;B7NRS7;B7NFT5;B7MRC
0;B7MIY0;B7M7Q3;B7LA88;B6I5K
5;B5Z090;B1XBZ7;B1LNU6;B1IUQ
3;A8A794;A7ZUK9;A1AIG5 
>sp|Q9L9I7|THIC_SALTY 
Phosphomethylpyrimidine 
synthase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=thiC PE=1 
SV=1;>sp|Q8Z326|THIC_SALTI 
Phosphomethylpyrimidine 
synthase OS=Salmonella typhi 
GN=thiC PE=3 
70.844 
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SV=1;>sp|Q83PB8|THIC_SHIFL 
Phos 
Q9L6T3;Q7CPD8;Q5PJY9;Q57HV
1;P0ADN5;P0ADN4;P0ADN3;P0A
DN2 
>sp|Q9L6T3|YIFE_SALTI 
UPF0438 protein YifE 
OS=Salmonella typhi GN=yifE 
PE=3 
SV=1;>sp|Q7CPD8|YIFE_SALT
Y UPF0438 protein YifE 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=yifE PE=3 
SV=1;>sp|Q5PJY9|YIFE_SALP
A UPF0438 protein YifE 
OS=Salm 
13.077 
Q9L6L4;Q7CPD4;Q5PKQ1;Q57HM
5;C0Q3F4;B5XYG9;B5RFL5;B5Q
W86;B5FNX9;B5EZW1;B5BIZ1;B4
TNZ2;B4TBS6;B4SZ86;A9MYB1;A
8ACZ6;A6TGM5;Q83PG0;Q3YVC0
;Q32A22;Q31UE2;B7LTY8;B2TVJ6
;Q8X8I1;Q8FBI1;Q1R465;Q0TAK9;
P21165;C5A021;B7UNH5;B7NV19;
B7NFE8;B7N2F3;B7MHD2;B7M65
0;B7L9A5;B6I4I7;B5YY94;B1XAK9;
B1LM33;B1IW60;A8A6V2;A7ZU52;
A1AI34 
>sp|Q9L6L4|PEPQ_SALTI Xaa-
Pro dipeptidase OS=Salmonella 
typhi GN=pepQ PE=3 
SV=1;>sp|Q7CPD4|PEPQ_SAL
TY Xaa-Pro dipeptidase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=pepQ PE=3 
SV=1;>sp|Q5PKQ1|PEPQ_SAL
PA Xaa-Pro dipeptidase 
OS=Salmone 
50.17 
Q9KUF0;Q8ZB62;Q8DEJ0;Q87SI4;
Q83Q07;Q7N079;Q7MNX0;Q6DAE
6;Q665L0;Q5PJS6;Q5E2N0;Q57JC
4;Q3YX18;Q32BA9;Q31W98;Q2N
WI3;Q1CE09;Q1C1G9;Q0T058;P6
6644;P66643;C6DIQ2;C5B748;C3L
S61;C0PZN9;B7VIY4;B7LRJ8;B6E
LJ4;B5XSS2;B5R0L7;B5FIS2;B5F
B54;B5F7K4;B5BGP9;B4TWJ4;B4
TJR8;B4T754;B2U1V5;B2K3Z6;B1
JL67;A9R1R9;A9N839;A9MNY1;A8
GK02;A8AQC0;A7MWN0;A7FDX5;
A6TEN8;A5F998;A4WF42;A4THJ2;
A4SHZ5;A1JR92;A0KPZ2;Q1R6B0
;Q0TCN6;P0A7X5;P0A7X4;P0A7X
3;C4ZSW8;B7UJW2;B7NKU2;B7N
DK8;B7N102;B7MBZ1;B7M0U2;B7
LHT8;B6I1U8;B5YSV6;B1XHK3;B1
LGJ6;B1IQP9;A8A539;A7ZSC4;A1
AGC3 
>sp|Q9KUF0|RS9_VIBCH 30S 
ribosomal protein S9 OS=Vibrio 
cholerae serotype O1 (strain 
ATCC 39315 / El Tor Inaba 
N16961) GN=rpsI PE=3 
SV=1;>sp|Q8ZB62|RS9_YERP
E 30S ribosomal protein S9 
OS=Yersinia pestis GN=rpsI 
PE=3 
SV=1;>sp|Q8DEJ0|RS9_VIBVU 
30S ribosomal p 
14.686 
Q9KTW2;Q8DF07;Q87S07;Q7MN
E1;Q5E763;C3LT21;B7VJU8;B6EG
Z6;B5FAY1;A7MU26;A5F3F1;Q82
XZ6;Q0ADW4;Q8PK88;Q8P8Q6;Q
5NYE5;Q5H0S2;Q4UVC5;Q3BSP7
;Q2P3Q9;B4SSX7;B2SLG1;B2FNS
1;B0RSB6;A1K5U3;Q9PAR6;Q87B
K6;Q2Y9R9;B2I6W2;B0U3R8;Q4Q
NW4;Q0I2D2;P44335;B0USI5;A5U
G27;A5UAR3;Q8ZN60;Q8ZCU4;Q
8Z4Q3;Q8EC52;Q83QL1;Q668A8;
>sp|Q9KTW2|GUAA_VIBCH 
GMP synthase [glutamine-
hydrolyzing] OS=Vibrio cholerae 
serotype O1 (strain ATCC 
39315 / El Tor Inaba N16961) 
GN=guaA PE=3 
SV=1;>sp|Q8DF07|GUAA_VIBV
U GMP synthase [glutamine-
hydrolyzing] OS=Vibrio 
vulnificus (strain CMCP6) 
GN=guaA PE= 
57.763 
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Q5PI52;Q57LJ8;Q47WD1;Q3YZ45;
Q3IHJ1;Q32D55;Q31XY3;Q2NS52;
Q1CK82;Q1C5J6;Q15R63;Q12PS0
;Q0T212;Q0HX50;Q0HKV2;Q085S
4;C5BER5;C4L8C4;C4K7H1;C0PY
P4;B8E9T4;B8CKS4;B7LKD4;B5X
NM4;B5RCX9;B5R569;B5FR52;B5
F185;B5BAZ5;B4TR83;B4TD82;B4
T0N7;B4RV80;B4EY59;B2TXT2;B2
K9P0;B1KLC1;B1JSB0;B0TLJ4;A9
R7Z2;A9N218;A9MHM5;A9KWW6;
A8H254;A8GHV1;A8FY04;A8AD80
;A7MGU1;A7FFZ9;A6WQP0;A6TC
C2;A4Y8T3;A4WD82;A4TMS8;A3Q
CH0;A3D6V2;A1S856;A1RHR0;A1
JKT2;A0KUK2;Q1H280;Q6LU31;Q
13XE2;B2T5G8;B2JIA0;B1XTW6;A
4SYS2;Q39F73;Q1BHF2;Q0BE45;
B4EC68;B1YS44;B1JUC0;A6SZM5
;A4JF45;A4G4U7;A0K8B3;Q1R8M
9;Q0TEY1;P64295;P64294;P04079
;C4ZX82;B7UGU5;B7NQV3;B7N69
1;B7MYD5;B7MHY8;B7M7L1;B7LC
P7;B6I579;B5Z0X6;B1XAY2;B1LN
F9;B1IWF4;A8A313;A7ZPV1;A1AE
43;Q1LSJ1 
Q9KPW3;C3LQ21;A5F629 
>sp|Q9KPW3|FABZ_VIBCH 3-
hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ OS=Vibrio 
cholerae serotype O1 (strain 
ATCC 39315 / El Tor Inaba 
N16961) GN=fabZ PE=3 
SV=1;>sp|C3LQ21|FABZ_VIBC
M 3-hydroxyacyl-[acyl-carrier-
protein] dehydratase FabZ 
OS=Vibrio cho 
17.278 
Q9KPE9 
>sp|Q9KPE9|XERD_VIBCH 
Tyrosine recombinase XerD 
OS=Vibrio cholerae serotype O1 
(strain ATCC 39315 / El Tor 
Inaba N16961) GN=xerD PE=3 
SV=1 
34.564 
Q9KNS1;Q7MZX9;Q5PL77;Q3YUJ
2;Q3IFP5;Q328H8;Q31T82;Q2NW
91;Q0SXD0;Q0I4U4;P64037;P640
36;P57811;P0A6N7;C3LS89;C0Q6
A6;B7LLS9;B5Y354;B5R995;B5R0
09;B5FRK6;B5F2L4;B5BKF8;B4TS
D0;B4TF84;B4T2P5;B4EXC9;B2VL
81;B2TY23;B0UWM5;A9MFR5;A8
AMQ1;A7MMC3;A6TH65;A5F4X8;
Q5QVT8;Q1R3B2;Q0T9P4;P0A6N
6;P0A6N5;P0A6N4;C5A1D9;B7UP
W7;B7NTK6;B7NG85;B7MSG8;B7
MKV2;B7M8R0;B7LC03;B6I254;B5
Z2F6;B1XDQ0;B1LQG8;B1ITQ1;A
8A7P4;A7ZV18;A1AJ55 
>sp|Q9KNS1|EFP_VIBCH 
Elongation factor P OS=Vibrio 
cholerae serotype O1 (strain 
ATCC 39315 / El Tor Inaba 
N16961) GN=efp PE=3 
SV=1;>sp|Q7MZX9|EFP_PHOL
L Elongation factor P 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01)  
20.576 
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Q9KFI7 
>sp|Q9KFI7|UXAB_BACHD 
Altronate oxidoreductase 
OS=Bacillus halodurans (strain 
ATCC BAA-125 / DSM 18197 / 
FERM 7344 / JCM 9153 / C-
125) GN=uxaB PE=3 SV=1 
58.449 
Q9K8D2;Q9EYQ9;Q6GI02;Q6GAD
1;Q5HH02;P99143;P23534;P0A0E
3;P0A0E2;P0A0E1 
>sp|Q9K8D2|PTHP_BACHD 
Phosphocarrier protein HPr 
OS=Bacillus halodurans (strain 
ATCC BAA-125 / DSM 18197 / 
FERM 7344 / JCM 9153 / C-
125) GN=ptsH PE=3 
SV=1;>sp|Q9EYQ9|PTHP_STA
XY Phosphocarrier protein HPr 
OS=Staphylococcus xylosus 
GN=ptsH PE=1 SV=1;>sp|Q6GI 
9.1243 
Q9K7L8 
>sp|Q9K7L8|G6PI_BACHD 
Glucose-6-phosphate isomerase 
OS=Bacillus halodurans (strain 
ATCC BAA-125 / DSM 18197 / 
FERM 7344 / JCM 9153 / C-
125) GN=pgi PE=3 SV=1 
50.428 
Q9I7C4 
>sp|Q9I7C4|DPO3B_PSEAE 
Beta sliding clamp 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=dnaN PE=1 
SV=1 
40.694 
Q9I747 
>sp|Q9I747|HCP1_PSEAE 
Protein hcp1 OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=hcp1 
PE=1 SV=1 
17.414 
Q9I6M5 
>sp|Q9I6M5|DAVD_PSEAE 
Glutarate-semialdehyde 
dehydrogenase DavD 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=davD PE=1 
SV=1 
51.622 
Q9I6M4;Q88RB9 
>sp|Q9I6M4|DAVT_PSEAE 5-
aminovalerate aminotransferase 
DavT OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=davT 
PE=1 SV=1 
45.22 
Q9I5Y1;O87796 
>sp|Q9I5Y1|ALF_PSEAE 
Fructose-bisphosphate aldolase 
OS=Pseudomonas aeruginosa 
38.573 
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(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fba PE=3 
SV=1;>sp|O87796|ALF_PSEST 
Fructose-bisphosphate aldolase 
OS=Pseudomonas stu 
Q9I2V5 
>sp|Q9I2V5|ACNB_PSEAE 
Aconitate hydratase B 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=acnB PE=3 
SV=1 
93.627 
Q9I2U2;Q02KU3;B7VB77;A6V720;
Q87YR5;Q4ZVM8;Q4K9J5;Q48KZ
1;Q3K9W8;C3JYK1;A4XTZ4;C1DH
E8;Q88KJ1;Q1ICA9;B1J691;B0KJ
G5;A5W636 
>sp|Q9I2U2|TIG_PSEAE 
Trigger factor 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=tig PE=3 
SV=1;>sp|Q02KU3|TIG_PSEAB 
Trigger factor 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=t 
48.581 
Q9HZP7 
>sp|Q9HZP7|ETFA_PSEAE 
Electron transfer flavoprotein 
subunit alpha 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=etfA PE=3 
SV=1 
31.422 
Q9HZP6 
>sp|Q9HZP6|ETFB_PSEAE 
Electron transfer flavoprotein 
subunit beta OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=etfB 
PE=3 SV=1 
26.376 
Q9HZJ3;Q4ZRA1;Q4KFC3;Q02PH
7;A6V383 
>sp|Q9HZJ3|FADA_PSEAE 3-
ketoacyl-CoA thiolase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fadA PE=3 
SV=1;>sp|Q4ZRA1|FADA_PSE
U2 3-ketoacyl-CoA thiolase 
OS=Pseudomonas syringae pv. 
s 
41.643 
Q9HZA7;Q02PS5;B1H0E3;Q8KC7
1;Q3ATW0;B4SEP9;B4S459;B3QL
38;B3EFW3;A1BI17;Q3B5Y0;B4R
>sp|Q9HZA7|ACCD_PSEAE 
Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit 
31.843 
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UR0;A4SD85;Q3A6L1;Q15VG1;B5
EAK5;Q31HH2;A1AN64;Q47XK5;A
9G853;Q8D2P4;Q7VRV0;A4SNT7;
A0KLN6;Q47HQ3;Q1BM67;B4EFK
3;B3R112;B2JQF1;A9AMA4;A6V2
W2;Q3IF41;Q5QUD9;Q492H4;A6V
P44;A4XVV4;Q65TC9;Q1LTA5;Q4
QJY5;P43778;A5UF50;A5UBS0;Q8
8LD9;Q1ICS2;B3H159;B1J539;B0
KF95;B0BNR1;A5W6X9;A4VKF5;A
3MZZ7;Q0I3I5;B0UU81;A4WCV0;B
2VJ00;A8GH40;A1JL77;Q9CN12;Q
8XFJ5;Q83KA2;Q7CQ41;Q668X1;
Q5PCV4;Q57LY8;Q3YZP5;Q32DM
0;Q31YE2;Q1CHM2;Q1C680;Q0W
DC3;Q0T2G9;B5RCJ1;B5R347;B5
FPL0;B5EZQ0;B5BCI0;B4TQA2;B4
TBN5;B4SZN8;B2TW98;B2K8H3;B
1JGI4;A9R7U5;A9N478;A9MJ59;A
8ADR3;A7FGM3;A4TM62;Q6D2N9
;Q87YI2;Q4ZVW0;Q48L24;Q3KF15
;Q2NSI3;A7MH52;A6TC02;Q7UHX
0;Q7N2B5;B4EZF5;C4Z8P1;Q8FF
H5;Q1R996;Q0TFD0;P0A9Q6;P0A
9Q5;B1X927;B1LLS1;B1IXM6;A8A
2I5;A7ZPD1;A1ADG5 
beta OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=accD 
PE=1 
SV=1;>sp|Q02PS5|ACCD_PSE
AB Acetyl-coenzy 
Q9HZ71;Q9JZ44 
>sp|Q9HZ71|RS1_PSEAE 30S 
ribosomal protein S1 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=rpsA PE=3 
SV=1 
61.869 
Q9HXY7;Q02RB7;B7V7U3;A6V1E
3;Q4KHG5;Q3KHA1 
>sp|Q9HXY7|FABZ_PSEAE 3-
hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fabZ PE=1 
SV=1;>sp|Q02RB7|FABZ_PSE
AB 3-hydroxyacyl-[acyl-car 
16.773 
Q9HWX5;Q02SM0;B7V7Q5;A6V04
9;Q88QH6;Q889Q6;Q1IFM0;B0KL
70;A5VXW0;A4VHT4;A4XZ35 
>sp|Q9HWX5|RISB_PSEAE 
6,7-dimethyl-8-ribityllumazine 
synthase OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=ribH 
PE=3 
SV=1;>sp|Q02SM0|RISB_PSEA
B 6,7-dimethyl-8-ribityllumazine 
syntha 
16.413 
Q9HV59;Q02FT2;B7V1F2;A6VCJ6;
Q88DW0;Q1IF39;O87792;B1J2B3;
>sp|Q9HV59|PNP_PSEAE 
Polyribonucleotide 
75.452 
364 
 
 
B0KHX3;A5W983;Q87WQ8;Q4ZN
R6;Q48E81;Q3KI80;C3K255;A4VP
N6;C1DFK5;A4XYD6;Q4KIF2;B1X
UJ5;A4SXQ7 
nucleotidyltransferase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=pnp PE=3 
SV=1;>sp|Q02FT2|PNP_PSEA
B Polyribonucleotide 
nucleotidyltransfer 
Q9HV43;Q02FR1;B7V1H3;A6VCL8
;A4VPQ5;Q4KIH1;B0KIS5;A5W9A3
;Q8DF66;Q7MN85;B7VJW9;Q3KIA
0;C3K275;A7MWW0;O87384;Q88
DU2;Q1IF59;Q6LS31;A1U614 
>sp|Q9HV43|DNAK_PSEAE 
Chaperone protein DnaK 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=dnaK PE=3 
SV=1;>sp|Q02FR1|DNAK_PSE
AB Chaperone protein DnaK 
OS=Pseudomonas aeruginosa 
(stra 
68.402 
Q9HUN2;Q02F86;B7V1Z5;A6VD45 
>sp|Q9HUN2|RL9_PSEAE 50S 
ribosomal protein L9 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=rplI PE=3 
SV=1;>sp|Q02F86|RL9_PSEAB 
50S ribosomal protein L9 
OS=Pseudomonas aeruginosa 
(st 
15.532 
Q9HUC8;Q02EW6;B7V3E4;A6VD
H2;Q4KJK0;Q3KJB3;A4XPN9 
>sp|Q9HUC8|SYR_PSEAE 
Arginine--tRNA ligase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=argS PE=3 
SV=1;>sp|Q02EW6|SYR_PSEA
B Arginine--tRNA ligase 
OS=Pseudomonas aeruginosa 
(strain U 
65.199 
Q9HT20;Q02DF4;B7V791;A6VF32;
Q4K3A9;Q1I2I7;B1JFU1;Q3K441;C
3K1E6;A4Y187;Q88BX4;B0KRA8;
A5WBA3;A4VS62;C1D5G2;Q87TT
4;Q4ZL24;Q48BG5;Q0AJB0;Q2YC
A3;Q7P095;Q477Z1;Q12GQ0;A9B
PU7;A2SC70;A1WF58;A1VIV2;A1T
J41;A2S6J8;P42468;Q63PI0;Q62F
R5;Q3JXV8;Q39KX6;Q2STE9;Q1B
RB0;Q13SQ2;Q0BJL5;B4EEY9;B1
YQL4;B1JSV7;A9AJG4;A4JA35;A3
P0Z0;A3NF40;A3MQJ9;A1V8T1;A0
K2Y3;A6T470;A4GAG9;Q223D6 
>sp|Q9HT20|ATPB_PSEAE 
ATP synthase subunit beta 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=atpD PE=3 
SV=1;>sp|Q02DF4|ATPB_PSE
AB ATP synthase subunit beta 
OS=Pseudomonas aeruginosa 
49.499 
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Q9HT18;Q02DF2;B7V793;A6VF34;
A4Y189;A5WBV9;A4VS64;Q12GQ
2 
>sp|Q9HT18|ATPA_PSEAE 
ATP synthase subunit alpha 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=atpA PE=3 
SV=1;>sp|Q02DF2|ATPA_PSE
AB ATP synthase subunit alpha 
OS=Pseudomonas aerugino 
55.393 
Q9CL47;Q7VKF0;Q6CZY7;Q65QX
2;Q4QMA4;Q2NQN9;Q0I145;P443
74;B0UX31;A7MPG7;A6VLK5;A5U
HU8;A5UDT0;A4WFB1;A3N374;Q8
ZJ95;Q664T8;Q5PK01;Q57J49;Q3
YWV6;Q32B48;Q31VX3;Q1CCW1;
Q1C2W4;Q0SZZ9;P0A7W6;P0A7
W5;P0A7W4;A9MSY1;A9MN66;A8
GKI0;A8AQJ8;A7FNL7;A6TEV5;A4
TH09;A1JS11;Q1R627;Q0TCF8;P0
A7W3;P0A7W2;P0A7W1;B1IPZ6;A
8A5A8;A7ZSJ2;A1AGJ2;Q6LV99;Q
1R0F8;A1TYL4;Q5QXW2;Q5E897;
B7VLE0;B6EPU2;B5FG26;Q2S929
;Q1LTC1;A1T0C5;Q488Z6;A5EXA
1 
>sp|Q9CL47|RS5_PASMU 30S 
ribosomal protein S5 
OS=Pasteurella multocida 
(strain Pm70) GN=rpsE PE=3 
SV=1;>sp|Q7VKF0|RS5_HAED
U 30S ribosomal protein S5 
OS=Haemophilus ducreyi (strain 
35000HP / ATCC 700724) 
GN=rpsE PE=3 
SV=1;>sp|Q6CZY7|RS5_PECA
S 30S ribosomal  
17.442 
Q9CHU6;P96789;Q931R3;Q8CP47
;Q6GGI7;Q6G954;Q5HP42;Q5HFR
2;P63335;P63334;P21577;Q9Z8I3;
P52208;Q7VMX4;P70718;P43774;
O83351;P12013;P80859 
>sp|Q9CHU6|6PGD_LACLA 6-
phosphogluconate 
dehydrogenase, decarboxylating 
OS=Lactococcus lactis subsp. 
lactis (strain IL1403) GN=gnd 
PE=3 
SV=1;>sp|P96789|6PGD_LACL
M 6-phosphogluconate 
dehydrogenase, decarboxylating 
OS=Lactococcus lactis subsp. 
cremoris (stra 
52.424 
Q9CDS1;P59200;P59199;O32801 
>sp|Q9CDS1|DPO1_LACLA 
DNA polymerase I 
OS=Lactococcus lactis subsp. 
lactis (strain IL1403) GN=polA 
PE=3 
SV=1;>sp|P59200|DPO1_STRR
6 DNA polymerase I 
OS=Streptococcus pneumoniae 
(strain ATCC BAA-255 / R6) 
GN=polA PE=3 
SV=1;>sp|P59199|DPO1_STRP
N DNA polymeras 
98.732 
Q9AGA6;P31450 
>sp|Q9AGA6|AGLB_KLEPN 6-
phospho-alpha-glucosidase 
OS=Klebsiella pneumoniae 
GN=aglB PE=1 SV=1 
49.255 
Q98QN2 
>sp|Q98QN2|RL27_MYCPU 
50S ribosomal protein L27 
OS=Mycoplasma pulmonis 
9.5037 
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(strain UAB CTIP) GN=rpmA 
PE=3 SV=1 
Q98FG0 
>sp|Q98FG0|ISPG_RHILO 4-
hydroxy-3-methylbut-2-en-1-yl 
diphosphate synthase 
(flavodoxin) OS=Rhizobium loti 
(strain MAFF303099) GN=ispG 
PE=3 SV=1 
44.705 
Q97L67;O34354 
>sp|Q97L67|UXAB_CLOAB 
Altronate oxidoreductase 
OS=Clostridium acetobutylicum 
(strain ATCC 824 / DSM 792 / 
JCM 1419 / LMG 5710 / VKM B-
1787) GN=uxaB PE=3 
SV=1;>sp|O34354|UXAB_BACS
U Altronate oxidoreductase 
OS=Bacillus subtilis (strain 168) 
GN=uxaB PE=2 SV=1 
55.25 
Q97HT8;Q97CX3;Q899R2 
>sp|Q97HT8|SSB2_CLOAB 
Single-stranded DNA-binding 
protein 2 OS=Clostridium 
acetobutylicum (strain ATCC 
824 / DSM 792 / JCM 1419 / 
LMG 5710 / VKM B-1787) 
GN=ssb2 PE=3 
SV=1;>sp|Q97CX3|SSB3_CLO
AB Single-stranded DNA-
binding protein 3 
OS=Clostridium acetobutyl 
14.98 
Q93GI5 
>sp|Q93GI5|BGAL_BIFLI Beta-
galactosidase III 
OS=Bifidobacterium longum 
subsp. infantis GN=beta-galIII 
PE=1 SV=1 
77.452 
Q92SI7;A6U5H0 
>sp|Q92SI7|MIAB_RHIME 
tRNA-2-methylthio-N(6)-
dimethylallyladenosine synthase 
OS=Rhizobium meliloti (strain 
1021) GN=miaB PE=3 
SV=1;>sp|A6U5H0|MIAB_SINM
W tRNA-2-methylthio-N(6)-
dimethylallyladenosine synthase 
OS=Sinorhizobium medicae 
(strain WSM419) GN=miaB 
52.261 
Q92QL0 
>sp|Q92QL0|YQGF_RHIME 
Putative pre-16S rRNA nuclease 
OS=Rhizobium meliloti (strain 
1021) GN=R01309 PE=3 SV=1 
17.977 
Q92N73;Q8YIG1;Q8UDA9;Q8FZF0
;Q89DJ1 
>sp|Q92N73|KPRS_RHIME 
Ribose-phosphate 
pyrophosphokinase 
OS=Rhizobium meliloti (strain 
1021) GN=prs PE=3 
SV=1;>sp|Q8YIG1|KPRS_BRU
ME Ribose-phosphate 
pyrophosphokinase 
OS=Brucella melitensis biotype 
33.521 
367 
 
 
1 (strain 16M / ATCC 23456 / 
NCTC 10094) GN=prs PE=3 
SV=2; 
Q92CU3;Q8Y825;Q720Y0;Q2NRT
4;C1L207;B8DCC1;A0AHK4;A7MN
W9;A4W9K3;A8AHD1 
>sp|Q92CU3|NADE_LISIN 
NH(3)-dependent NAD(+) 
synthetase OS=Listeria innocua 
serovar 6a (strain ATCC BAA-
680 / CLIP 11262) GN=nadE 
PE=3 
SV=1;>sp|Q8Y825|NADE_LISM
O NH(3)-dependent NAD(+) 
synthetase OS=Listeria 
monocytogenes serovar 1/2a 
(strain ATCC BAA-679  
30.485 
Q92A41;Q8Y5T8;P37535 
>sp|Q92A41|Y2081_LISIN 
Uncharacterized protein Lin2081 
OS=Listeria innocua serovar 6a 
(strain ATCC BAA-680 / CLIP 
11262) GN=lin2081 PE=3 
SV=1;>sp|Q8Y5T8|Y1967_LISM
O Uncharacterized protein 
Lmo1967 OS=Listeria 
monocytogenes serovar 1/2a 
(strain ATCC BAA-679 
45.476 
Q928K4;Q8Y4K4 
>sp|Q928K4|DCEC_LISIN 
Probable glutamate 
decarboxylase gamma 
OS=Listeria innocua serovar 6a 
(strain ATCC BAA-680 / CLIP 
11262) GN=lin2528 PE=3 
SV=1;>sp|Q8Y4K4|DCEC_LISM
O Probable glutamate 
decarboxylase gamma 
OS=Listeria monocytogenes 
serovar 1/2a (strain  
53.689 
Q8ZRS8 
>sp|Q8ZRS8|ACNB_SALTY 
Aconitate hydratase B 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=acnB PE=1 SV=1 
93.528 
Q8ZRC9;Q5PFQ2;Q57SC9;B5Y0
W4;B5FKU0;B5EXH5;B4TMB5;B4
T9D0;B4SWS7;A9MWZ5;A8AK28;
A6T5G0;Q8Z8W2;A4W797 
>sp|Q8ZRC9|YAJQ_SALTY 
UPF0234 protein YajQ 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=yajQ PE=3 
SV=2;>sp|Q5PFQ2|YAJQ_SAL
PA UPF0234 protein YajQ 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=yajQ PE=3 
SV=2;>sp|Q57SC9|YAJQ_ 
18.319 
Q8ZQX7;Q8Z8G0;Q5PCH6;Q57R
Q0;C0PWA5;B5R824;B5QWC8;B5
FNB9;B5EZC1;B5BCC5;B4TPZ8;B
4TB82;B4SYN7;A9MUG8;A8AJE0;
A4W844;A8GB41 
>sp|Q8ZQX7|NAGB_SALTY 
Glucosamine-6-phosphate 
deaminase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=nagB PE=3 
29.632 
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SV=1;>sp|Q8Z8G0|NAGB_SAL
TI Glucosamine-6-phosphate 
deaminase OS=Salmonella 
typhi GN=nagB PE=3 
SV=1;>sp|Q5PCH6|NAGB_SAL
PA Gl 
Q8ZQU3;P0AC43;P0AC42;P0AC4
1;G4V4G6 
>sp|Q8ZQU3|SDHA_SALTY 
Succinate dehydrogenase 
flavoprotein subunit 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=sdhA PE=3 
SV=1;>sp|P0AC43|SDHA_ECO
57 Succinate dehydrogenase 
flavoprotein subunit 
OS=Escherichia coli O157:H7 
GN=sdhA PE=3 
64.461 
Q8ZQU2;P07014 
>sp|Q8ZQU2|SDHB_SALTY 
Succinate dehydrogenase iron-
sulfur subunit OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=sdhB PE=3 
SV=2;>sp|P07014|SDHB_ECOL
I Succinate dehydrogenase iron-
sulfur subunit OS=Escherichia 
coli (strain K12) GN=sdhB P 
26.733 
Q8ZQT5;Q8Z8C0;Q83MM7;Q5PC
N2;Q3Z464;Q324H2;Q0T6X7;B5R
699;B5QX24;B5BC62;B2TUC6;Q1
REI5;Q0TJV4;P0A857;P0A856;P0
A855;C4ZWL5;B7ULM0;B7NMV9;
B7N9Y9;B7MPN1;B7MFZ3;B7M6B
0;B7LAE7;B5YRE4;B1X6S1;B1IXY
9;A7ZJC2;Q32II1;Q57RK3;A4W88
9;Q934G6;Q7N6T6;Q6D7F2;Q2NU
L4;C6DCE7;C5BEL8;A8GB93;Q8Z
GZ1;Q66D90;Q1CFM9;Q1CAF2;B
2VBQ7;B2K8G1;B1JG47;A9R2G2;
A7FKQ3;A4TNS8;A1JRK8 
>sp|Q8ZQT5|TOLB_SALTY 
ProteintolB OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=tolB PE=3 
SV=1;>sp|Q8Z8C0|TOLB_SALT
I ProteintolB OS=Salmonella 
typhi GN=tolB PE=3 
SV=1;>sp|Q83MM7|TOLB_SHIF
L ProteintolB OS=Shigella 
flexneri GN=tolB PE 
46.148 
Q8ZPV9 
>sp|Q8ZPV9|YEAD_SALTY 
Putative glucose-6-phosphate 1-
epimerase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=yeaD PE=1 SV=1 
32.56 
Q8ZNW0;P21599;Q8K9M3 
>sp|Q8ZNW0|KPYK2_SALTY 
Pyruvate kinase II 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=pykA PE=3 
SV=3;>sp|P21599|KPYK2_ECO
LI Pyruvate kinase II 
OS=Escherichia coli (strain K12) 
GN=pykA PE=1 SV=3 
51.387 
Q8ZNN4;Q8Z5C3;Q83KH0;Q5PJ4
3;Q57MI5;Q3Z096;Q32EI8;Q323B4
>sp|Q8ZNN4|SYM_SALTY 
Methionine--tRNA ligase 
76.273 
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;Q0T324;C0Q0Y1;B7LV75;B5XP89
;B5RBZ5;B5R0E7;B5FMX1;B5EXZ
5;B5BE81;B4TNL2;B4T9X0;B4SXY
7;B2TVX7;A9N7I2;A9MKV0;A8AEB
2;A7MHL3;A6TBK7;Q8X7E7;Q8FF
X8;Q1R9V8;Q0TFX8;P00959;C4Z
SJ8;B7UFD1;B7NPL8;B7NCE4;B7
MX36;B7MEG9;B7M4V9;B7L9Y6;B
6HYV5;B5YV64;B1X7K4;B1LN54;B
1IYW7;A8A1X8;A7ZNT3;A1ACX8;
Q1LT75;Q8ZG01;Q7N6J6;Q66C72
;Q1CGU4;Q1C9T8;B4ESY6;B2JZK
3;B1JPY8;A9R2M7;A8GC37;A7FJJ
6;A4TKM9;A1JTX6;Q6D7B6;C6DC
I4;B2VIF6;A4WCF6;Q2NUD0;Q0V
P51 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=metG PE=3 
SV=3;>sp|Q8Z5C3|SYM_SALTI 
Methionine--tRNA ligase 
OS=Salmonella typhi GN=metG 
PE=3 
SV=3;>sp|Q83KH0|SYM_SHIFL 
Methionine--tRNA ligase O 
Q8ZND6 
>sp|Q8ZND6|PTA_SALTY 
Phosphate acetyltransferase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=pta PE=1 SV=1 
77.277 
Q8ZN40;Q8Z4N0;Q5PNG1;Q57LG
9;C6DBJ1;B5XNJ7;B5RD12;B5R5
A2;B5FR85;B5F1C0;B5BAW6;B4T
RX5;B4TDB6;B4T0S2;A9N1X5;B2
VI32;Q6D259;A9MHJ4;A6TCF1;A4
WDB1;Q0T1Y9;P0A6C0;C0PYK7;
B7LKA9;B2TXV5;Q0TEV5;P0A6B9
;P0A6B8;P0A6B7;C4ZXA5;B7UGX
6;B7NRH9;B7N6B7;B7MYG3;B7MI
M0;B7M7N3;B7LDC2;B6I5A2;B5Z1
04;B1XB05;B1LNI6;B1IWD1;A8A3
36;A7ZPX4;Q7N224;Q57337;Q0I1
L2;P57803;C5BEU5;B0UVL5;A7M
GX8;A6VMN7;A5UGI1;A5UAA8;A8
GHY3;Q7VMA9;B8F356 
>sp|Q8ZN40|ISCS_SALTY 
Cysteine desulfurase IscS 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=iscS PE=3 
SV=1;>sp|Q8Z4N0|ISCS_SALTI 
Cysteine desulfurase IscS 
OS=Salmonella typhi GN=iscS 
PE=3 
SV=1;>sp|Q5PNG1|ISCS_SALP
A Cysteine desulfura 
45.092 
Q8ZM06;P58744 
>sp|Q8ZM06|DKGA_SALTY 
2,5-diketo-D-gluconic acid 
reductase A OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=dkgA PE=3 
SV=1;>sp|P58744|DKGA_SALT
I Putative 2,5-diketo-D-gluconic 
acid reductase A 
OS=Salmonella typhi GN=dkgA 
PE=5 SV=2 
30.995 
Q8ZLM7;Q8Z1W9;Q83PZ1;Q5PIT8
;Q57J64;Q3YWX3;Q32B63;Q31VZ
0;Q0T016;B7LRQ3;B5RH49;B5R1
E3;B5FJI2;B5F7R3;B5BGV3;B4TX
B0;B4TJX7;B4SUQ8;B2VK93;A9N
8B1;A9MN80;A8GKG5;A8AQI1;Q8
ZJ79;Q7MYI2;Q664V4;Q1CCX6;Q
1C2X9;B2K504;B1JJH8;A9R927;A
7FNK2;A4TH23;A1JRZ1;Q1R646;
Q0TCH5;P0A6K5;P0A6K4;P0A6K3
>sp|Q8ZLM7|DEF_SALTY 
Peptide deformylase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=def PE=3 
SV=1;>sp|Q8Z1W9|DEF_SALTI 
Peptide deformylase 
OS=Salmonella typhi GN=def 
PE=3 
SV=1;>sp|Q83PZ1|DEF_SHIFL 
19.282 
370 
 
 
;C4ZUE1;B7UK10;B7NLK6;B7NDQ
8;B7N171;B7MCQ2;B7M0Z2;B7LH
Y3;B6I200;B5YT06;B1X6D9;B1LG
P3;B1IQ13;A8A591;A1AGH8 
Peptide deformylase 
OS=Shigella fle 
Q8ZLM1;Q8Z1X6;Q5PK07;Q2NQP
4 
>sp|Q8ZLM1|RS13_SALTY 30S 
ribosomal protein S13 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=rpsM PE=3 
SV=3;>sp|Q8Z1X6|RS13_SALTI 
30S ribosomal protein S13 
OS=Salmonella typhi GN=rpsM 
PE=3 
SV=3;>sp|Q5PK07|RS13_SALP
A 30S ribosomal prot 
13.161 
Q8ZLG5;Q8Z235;Q83PV3;Q5PM0
6;Q57IT8;Q3YW93;Q32AV3;Q31VJ
1;Q0SZN2;A9MTV4;A9MMA0;A6T
F51;A4WFL5;Q8X6X6;Q8FCR7;Q1
R5J4;Q0TC27;P07762;B1IP32;A8A
5P2;A7ZSW5;A1AGW5;O66936;A5
EPZ7;A4Z005;Q3STC2;A8AQY3 
>sp|Q8ZLG5|GLGB_SALTY 1,4-
alpha-glucan branching enzyme 
GlgB OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=glgB PE=3 
SV=1;>sp|Q8Z235|GLGB_SALT
I 1,4-alpha-glucan branching 
enzyme GlgB OS=Salmonella 
typhi GN=glgB PE=3 
SV=1;>sp|Q83PV3|GLG 
84.274 
Q8ZLD7;Q8Z268;P0AED4;P0AED3
;P0AED2;P0AED1;P0AED0;Q8ZA4
9 
>sp|Q8ZLD7|USPA_SALTY 
Universal stress protein A 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=uspA PE=3 
SV=3;>sp|Q8Z268|USPA_SALT
I Universal stress protein A 
OS=Salmonella typhi GN=uspA 
PE=3 
SV=3;>sp|P0AED4|USPA_SHIS
O Universal stress 
16.08 
Q8ZL56;Q8Z2F0;Q5PBZ2;Q57IC9;
A9MVK6;Q329P2;P59176;A4W533
;Q8ZJN0;Q66GC2;Q1CD17;Q1C28
2;A7MID1;A7FCU8;A4TSC2;A1JH
Y1 
>sp|Q8ZL56|GPMI_SALTY 2,3-
bisphosphoglycerate-
independent phosphoglycerate 
mutase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=gpmI PE=3 
SV=1;>sp|Q8Z2F0|GPMI_SALTI 
2,3-bisphosphoglycerate-
independent phosphoglycerate 
mutase OS=Salmone 
56.254 
Q8ZL52;Q8Z2F4;Q5PC07;Q57IC5;
Q3YVY1;Q329N8;Q31V06;Q0SYE
5;P59409;C0Q1V0;B7LVH6;B5XTI
4;B5RGH0;B5R5E1;B5FLI6;B5EXC
3;B5BHZ1;B4TZV9;B4T9A1;B4SX
B9;B2U5D5;A9MVL0;A9MKQ8;A8A
RK6;A7MID0;A6TFL2;Q8XEJ1;Q8F
CA2;Q1R4X4;Q0TBJ0;P07913;C4Z
XK8;B7ULH2;B7NPC5;B7NES3;B7
>sp|Q8ZL52|TDH_SALTY L-
threonine 3-dehydrogenase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=tdh PE=3 
SV=1;>sp|Q8Z2F4|TDH_SALTI 
L-threonine 3-dehydrogenase 
OS=Salmonella typhi GN=tdh 
PE=3 
37.212 
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N1S0;B7MFI0;B7M4A3;B7L742;B6I
3J6;B5YWB7;B1X950;B1LK55;B1I
ZH4;A8A681;A7ZTH0;A1AHF3 
SV=1;>sp|Q5PC07|TDH_SALP
A L-threonine 3-dehyd 
Q8ZKW8;Q8Z9S5;Q6CYJ4;Q663Q
7;Q5PKX1;Q57HX8;Q3YVN7;Q329
S2;Q31UN3;Q1CCH4;Q1C094;Q0
SYU3;P0ABA9;C6DJH1;C5BF39;C
0Q2N3;B7LK78;B5XZM3;B5RFW2;
B5QUS5;B5FN34;B5EYZ7;B5BIN7;
B4TN32;B4TAX3;B4SYD2;B2TUP2
;B2K846;B1JRN1;A9R5U0;A9MXA
7;A9MJR8;A8G7M7;A8ACN7;A7M
MX0;A7FPE1;A6TG37;A4WGF4;A
4TSJ2;A1JTC7;B2VCA5;Q1R4K1;
Q0TAX6;P0ABA8;P0ABA7;P0ABA
6;C4ZZ11;B7UMJ8;B7NR35;B7NF
49;B7N2H2;B7MGF3;B7M589;B7L
880;B6I3X0;B5YXD7;B1X9W1;B1L
L60;B1IX05;A8A6J6;A7ZTU5;A1AH
R5;C4LDW1;Q8Z2Q5;Q7NA93;Q2
NQ87;A4STP4;A0KQX9;A8G1W6 
>sp|Q8ZKW8|ATPG_SALTY 
ATP synthase gamma chain 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=atpG PE=2 
SV=1;>sp|Q8Z9S5|ATPG_YER
PE ATP synthase gamma chain 
OS=Yersinia pestis GN=atpG 
PE=3 
SV=1;>sp|Q6CYJ4|ATPG_PEC
AS ATP synthase gamma ch 
31.555 
Q8ZKQ0;Q8Z2X9;Q7CG47;Q66EZ
3;Q5PJE3;Q57HD9;Q1CN19;Q1C1
34;B2K3F7;B1JLQ4;A9R0S6;A9MZ
G5;A7FMK1;A4TQL9;A1JJ51;Q0T4
L4;Q7N2D6;A6TEB4;A4WER0;Q8
XAZ1;P76143;B1XEA5;B1LF98 
>sp|Q8ZKQ0|LSRF_SALTY 3-
hydroxy-5-
phosphonooxypentane-2,4-
dione thiolase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=lsrF PE=2 
SV=1;>sp|Q8Z2X9|LSRF_SALT
I 3-hydroxy-5-
phosphonooxypentane-2,4-
dione thiolase OS=Salmonella 
typhi GN=lsrF  
31.742 
Q8ZKL8;Q8Z309;Q5PK75;P59310;
P57907;Q8X732;P59306;P11446 
>sp|Q8ZKL8|ARGC_SALTY N-
acetyl-gamma-glutamyl-
phosphate reductase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=argC PE=1 
SV=1;>sp|Q8Z309|ARGC_SALT
I N-acetyl-gamma-glutamyl-
phosphate reductase 
OS=Salmonella typhi GN=argC 
PE=3 SV=1;>sp| 
35.949 
Q8ZK29;Q6DA52;Q5PJD4;Q57GC
3;Q3YU89;Q328S1;Q0SXK0;C6DJ
N2;C0Q7D6;B7LMT2;B5Y2T8;B5R
9L5;B5R1K2;B5FSH0;B5F465;B5B
KS6;B4TTA0;B4TG58;B4T3M4;A9
N680;A9MET9;A8AMA5;A6THI2;A
4WF25;Q1R2Z4;Q0T9D1;P68768;
P68767;P68766;C4ZRD1;B7UQR7;
B7NUH4;B7NGJ2;B7MSZ3;B7MLR
5;B7M9L9;B7LCX0;B6I2H3;B5Z3L
7;B1XEN9;B1LRE5;B1ISB1;A8A81
6;A7ZVE0;A1AJG3;Q83P64;Q31T
K2;B2VL42;B2TYY4;Q8Z116;C5BB
>sp|Q8ZK29|AMPA_SALTY 
Probable cytosol 
aminopeptidase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=pepA PE=3 
SV=1;>sp|Q6DA52|AMPA_PEC
AS Probable cytosol 
aminopeptidase 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) G 
54.889 
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Y4;Q8ZBH3;Q66F09;Q1CM01;Q1C
3R8;B2K3E9;B1JLS9;A9R5F5;A8G
978;A7FML9;A4TQP6;A1JJ31;Q7M
Z27;C4LA51;Q5QY05;Q488M4;Q1
5PX4;B4F2N1;Q8DCE5;Q87LG8;Q
7MHG4;Q6LUW0;Q5E7T8;B6EMT
2;B5F9Q6;A7MSE5;Q2NR41;P0C6
E1;C3LR42;A5F5D8;A1SRZ1 
Q8ZJV8;Q8Z0U3;B5FTC5;B4TGZ9
;Q83P02;Q3YU12;Q327L5;Q31SV
8;Q0SX30;B7LNS1;B2TZR4;Q8XB
36;Q0T8T2;P0A6L1;P0A6L0;C4ZT
63;B7UR09;B7NW61;B7NH49;B7N
2V7;B7MNI8;B7LXU3;B7LEM7;B6I
6M8;B5Z4R3;B1XFJ1;B1LEI6;B1IS
38;A8A8B0;A7ZVS4;A1AJU8;Q8D
BT2;Q7MI38 
>sp|Q8ZJV8|DEOC_SALTY 
Deoxyribose-phosphate 
aldolase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=deoC PE=1 
SV=2;>sp|Q8Z0U3|DEOC_SAL
TI Deoxyribose-phosphate 
aldolase OS=Salmonella typhi 
GN=deoC PE=3 
SV=2;>sp|B5FTC5|DEOC_SAL
DC Deoxyrib 
27.684 
Q8ZJV7;Q8Z0U2;Q83P00;Q5PK20
;Q3YU09;Q31SV5;Q0SX27;B7LNS
4;B5F527;B5BAK0;B4TU44;B4TH0
2;B4T4H3;B2TZR7;A9MRA4;A7MI
G7;Q8FA51;Q0T8S9;P0ABP9;P0A
BP8;C4ZT66;B7UR12;B7NW64;B7
NH52;B7N2V8;B7MNJ1;B7LXU6;B
7LEN0;B6I6N1;B5Z4R6;B1XFJ4;B
1LEI9;B1IS35;A8A8B3;A7ZVS7;Q5
7G38;Q327L2;B5R2J9;B5FTC8;A9
N7E3;A8ALX7;B5Y274;A4W6A1;C
5BHJ5;Q7N930;B2VH53;B5R9V2;
Q8ZIQ2;Q66EV7;Q1CMY7;Q1C16
6;B2K3J1;B1JL34;A9R046;A7FMH
2;A4TQJ0;Q9CLE6;Q4QN30;Q0I1
K5;P44417;B0UVM2;A5UH23;A5U
9X5;Q6D989;C6DKM0;Q59482;B8
F672;A1JJA0 
>sp|Q8ZJV7|DEOD_SALTY 
Purine nucleoside 
phosphorylase DeoD-type 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=deoD PE=3 
SV=1;>sp|Q8Z0U2|DEOD_SAL
TI Purine nucleoside 
phosphorylase DeoD-type 
OS=Salmonella typhi GN=deoD 
PE=3 SV=1;>sp|Q83P 
25.978 
Q8ZJG9;Q664K7;Q1CCM6;Q1C2M
9;B2K5U8;B1JI04;A9R4C2;A7FNU
8;A4TGS8 
>sp|Q8ZJG9|PCKA_YERPE 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Yersinia pestis GN=pckA 
PE=3 
SV=1;>sp|Q664K7|PCKA_YER
PS Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Yersinia 
pseudotuberculosis serotype I 
(strain IP32953) GN=pckA PE=3 
SV=1;>sp|Q1CCM6|PCKA_YE 
59.348 
Q8ZIN2;Q66ET5;B2K3L5;B1JL09;
A9R021;A7FME9;A1JJD0 
>sp|Q8ZIN2|TAL_YERPE 
Transaldolase OS=Yersinia 
pestis GN=tal PE=3 
SV=1;>sp|Q66ET5|TAL_YERPS 
Transaldolase OS=Yersinia 
pseudotuberculosis serotype I 
(strain IP32953) GN=tal PE=3 
35.049 
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SV=1;>sp|B2K3L5|TAL_YERPB 
Transaldolase OS=Yersinia 
pseudotuberculosis serotype 
Q8ZH40;Q8ZRN1;Q8Z992 
>sp|Q8ZH40|METQ_YERPE D-
methionine-binding lipoprotein 
MetQ OS=Yersinia pestis 
GN=metQ PE=3 SV=1 
29.376 
Q8ZDX0;Q669Z5;Q1CIG8;B2K664;
B1JJ21;A9R0A4;A7FHG5;A4TIL5;
A1JML2 
>sp|Q8ZDX0|SYFA_YERPE 
Phenylalanine--tRNA ligase 
alpha subunit OS=Yersinia 
pestis GN=pheS PE=3 
SV=1;>sp|Q669Z5|SYFA_YERP
S Phenylalanine--tRNA ligase 
alpha subunit OS=Yersinia 
pseudotuberculosis serotype I 
(strain IP32953) GN=pheS 
PE=3 SV=1;>sp|Q1CIG8|SYFA_ 
37.139 
Q8ZBB3;A9R594 
>sp|Q8ZBB3|GREA_YERPE 
Transcription elongation factor 
GreA OS=Yersinia pestis 
GN=greA PE=3 
SV=1;>sp|A9R594|GREA_YER
PG Transcription elongation 
factor GreA OS=Yersinia pestis 
bv. Antiqua (strain Angola) 
GN=greA PE=3 SV=1 
17.778 
Q8Z9I1;Q83SP1;Q5PDG2;Q57TE7
;Q3Z5T7;Q32K21;Q326G2;P37412
;Q8X9Z9;Q8FL76;P30125;Q1RGC
4;Q65V05;Q4QLS3;P43860;Q6LV2
5;Q9KP82;Q8ZIG9;Q8DEE0;Q87S
S8;Q7MP78;Q6D0G7;Q66EM2;Q5
E857;Q2NVW4 
>sp|Q8Z9I1|LEU3_SALTI 3-
isopropylmalate dehydrogenase 
OS=Salmonella typhi GN=leuB 
PE=3 
SV=1;>sp|Q83SP1|LEU3_SHIF
L 3-isopropylmalate 
dehydrogenase OS=Shigella 
flexneri GN=leuB PE=3 
SV=3;>sp|Q5PDG2|LEU3_SAL
PA 3-isopropylmalate 
dehydrogenase OS=Salmonella 
par 
39.619 
Q8Z6I4;Q5PH85;Q57PU8;P15434;
Q8ZDX1;Q669Z6;Q2NT27;Q7N3Q
1;Q65TL3;P57859;P43820;P37984 
>sp|Q8Z6I4|SYFB_SALTI 
Phenylalanine--tRNA ligase beta 
subunit OS=Salmonella typhi 
GN=pheT PE=3 
SV=1;>sp|Q5PH85|SYFB_SALP
A Phenylalanine--tRNA ligase 
beta subunit OS=Salmonella 
paratyphi A (strain ATCC 9150 / 
SARB42) GN=pheT PE=3 
SV=1;>sp|Q57PU8|SYFB_SAL
CH  
87.326 
Q8Z6F6;P15111 
>sp|Q8Z6F6|DHE4_SALTI 
NADP-specific glutamate 
dehydrogenase OS=Salmonella 
typhi GN=gdhA PE=3 
SV=1;>sp|P15111|DHE4_SALT
Y NADP-specific glutamate 
dehydrogenase OS=Salmonella 
typhimurium (strain LT2 / 
48.557 
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SGSC1412 / ATCC 700720) 
GN=gdhA PE=3 SV=2 
Q8Z320;Q5PK93;Q57H69;P06173;
C0Q2R7;B5QYD8;B5FQJ9;B5F0W
7;B5BJQ3;B4TQJ5;B4TCS4;B4T0Y
9;A9N0J4;A9MHF1;A8AKT9;B5XY
F5;A6TGP0;B5RFK1;A7MQQ9;Q3
YUZ7;Q32AF9;Q31U10;Q0SY13;P
0A8V5;B7LUL5;B2TWH3;Q1R5V3;
Q0TA78;P0A8V4;P0A8V3;P0A8V2;
C5A0S7;B7UPE2;B7NRR5;B7NFS
7;B7MRB3;B7MIX3;B7M734;B7LA
80;B6I5J7;B5Z083;B1XBY9;B1LNT
9;B1IUR0;A8A786;A7ZUK1;A1AIF9
;Q2NWR6;A1JII0;C5BHE3;B4EYU
9;Q8ZAP5;Q66FQ2;Q1CN78;Q1C1
U1;B2K113;B1JJJ9;A9R0H8;A7FNI
3;A4TS29;A8G8E7;Q8D233;P5714
6;B8D8J6;B8D6V0;Q1LSX7;Q7VK
L7;Q7N9A4;Q65W41;P41184;A6V
KC5;Q4QN33;P43738;A5UH20;A5
U9X8;Q9CK91;Q0I5B7;B0URZ6;B0
BSF5;A3N325;B8F741;Q5QWA5;Q
058E5;A1T065;Q5NID2;Q2A1M7;Q
14JT5;Q0BKC5;B2SFD6;B0TX10;A
7NEC0;A4IW99;A0Q867 
>sp|Q8Z320|RPOB_SALTI 
DNA-directed RNA polymerase 
subunit beta OS=Salmonella 
typhi GN=rpoB PE=3 
SV=1;>sp|Q5PK93|RPOB_SAL
PA DNA-directed RNA 
polymerase subunit beta 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=rpoB PE=3 
SV=1;>sp|Q57H69|RPOB_SAL
C 
150.63 
Q8Z2Y6;Q8ZKP3;Q5PIS3;Q57HD1
;C0Q436;B5RF85;B5QXL5;B5FPT
4;B5F0R7;B5BJK3;B4TPU7;B4TC
M2;B4T0T2;A9MZH4;A9MI40;A8AL
00;A4WG72;B5XTD4;A6TFR2;Q7U
B84;Q32A92;Q31U64;B7LUS9;B2T
WC2;Q8FBC3;Q0TAD8;P0A6F4;P
0A6F3;C5A093;B7UNP6;B7NU81;
B7NFM3;B7N2R7;B7MI58;B7M6X7
;B7LA23;B5YZ64;B1XB92;B1LNM9
;B1IVF3;A8A731;A7ZUE0 
>sp|Q8Z2Y6|GLPK_SALTI 
Glycerol kinase OS=Salmonella 
typhi GN=glpK PE=3 
SV=3;>sp|Q8ZKP3|GLPK_SALT
Y Glycerol kinase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=glpK PE=3 
SV=3;>sp|Q5PIS3|GLPK_SALP
A Glycerol kinase 
OS=Salmonella paratyph 
55.922 
Q8Z233;Q5PM08;Q57IU0;P05415;
C0Q0L0;B5R395;B5F8Q2;B5BHI0;
B4TY87;B4T868;B4SVN3;A9MTV2
;A9MMA2;A7MGF4;Q3YW95;Q32A
V5;Q0SZN4;P0A6V4;B7LSE1;B5X
TQ9;B5FKF5;A4WFL3;Q1R5J6;Q0
TC29;P0A6V3;P0A6V2;P0A6V1;C4
ZVY0;B7UKY7;B7NMJ5;B7NE40;B
7N1M2;B7MDR5;B7M2J3;B7L4W0;
B6I2Z6;B5YUI6;B1X775;B1LI91;B1
IP34;A8A5P0;A7ZSW3;Q31VJ3;B2
U4G2;A6TF49 
>sp|Q8Z233|GLGC_SALTI 
Glucose-1-phosphate 
adenylyltransferase 
OS=Salmonella typhi GN=glgC 
PE=3 
SV=1;>sp|Q5PM08|GLGC_SAL
PA Glucose-1-phosphate 
adenylyltransferase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=glgC PE=3 
SV=1;>sp|Q57IU0|GLGC_SALC
H  
48.435 
Q8Z123;Q3YU98;Q328S8;Q31TJ4;
Q08016;Q8ZBG8;Q66F14;Q1CM0
6;A7FMM5;A4TQQ1;Q83IM2;Q0SX
J4;Q8XCB8;Q8FAD6;P04391;B7N
GI6;B7MLQ9;B7M9L3;B7LCW4;B1I
SV4;A8A810;A7ZVD3 
>sp|Q8Z123|OTC_SALTI 
Ornithine carbamoyltransferase 
OS=Salmonella typhi GN=argI 
PE=3 
SV=3;>sp|Q3YU98|OTC_SHISS 
Ornithine carbamoyltransferase 
OS=Shigella sonnei (strain 
36.713 
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Ss046) GN=argI PE=3 
SV=1;>sp|Q328S8|OTC_SHIDS 
Ornithine carbamoyltransferase 
OS=Shigell 
Q8XNH2 
>sp|Q8XNH2|PFKA1_CLOPE 
ATP-dependent 6-
phosphofructokinase 1 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=pfkA1 
PE=3 SV=1 
34.066 
Q8XKU1;Q0TQY8;Q0STD6;O5263
3 
>sp|Q8XKU1|TPIS_CLOPE 
Triosephosphate isomerase 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=tpiA 
PE=1 
SV=1;>sp|Q0TQY8|TPIS_CLOP
1 Triosephosphate isomerase 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 / 
NCTC 8237 /  
27.058 
Q8XKU0;Q0TQY7;Q0STD5 
>sp|Q8XKU0|PGK_CLOPE 
Phosphoglycerate kinase 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=pgk 
PE=3 
SV=1;>sp|Q0TQY7|PGK_CLOP
1 Phosphoglycerate kinase 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 / 
NCTC 8237 / Type A) 
42.679 
Q8XHR7;Q0TMN7;Q0SQD5;A0PX
T7 
>sp|Q8XHR7|RL7_CLOPE 50S 
ribosomal protein L7/L12 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=rplL 
PE=3 
SV=1;>sp|Q0TMN7|RL7_CLOP
1 50S ribosomal protein L7/L12 
OS=Clostridium perfringens 
(strain ATCC 13124 / DSM 756 / 
JCM 1290 / NCIMB 6125 / 
NCTC 823 
12.535 
Q8XGX4;Q7CPE2;Q57HX9;Q3YV
N6;Q329S1;Q31UN2;Q0SYU4;P0A
BB7;C0Q2N2;B7LK77;B5RFW3;B5
QUS4;B5FN33;B5EYZ6;B4TN31;B
4TAX2;B4SYD1;B2TUP3;A9MXA6;
A9MJR9;A8ACN6;Q1R4K2;Q0TAX
7;P0ABB6;P0ABB5;P0ABB4;C4ZZ
10;B7UMJ7;B7NR34;B7NF48;B7N
2H1;B7MGF2;B7M588;B7L882;B6I
3W9;B5YXD6;B1X9W0;B1LL59;B1I
X06;A8A6J5;A7ZTU4;A1AHR4;Q5
PKX2;B5BIN6;C6DJH2;Q6CYJ5;Q
2NQ86;C5BF40;B2VCA4;Q4QN64;
P43715;A5UGY9;A5UA11;Q7NA94
>sp|Q8XGX4|ATPB_SALTI ATP 
synthase subunit beta 
OS=Salmonella typhi GN=atpD 
PE=3 
SV=1;>sp|Q7CPE2|ATPB_SAL
TY ATP synthase subunit beta 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=atpD PE=3 
SV=1;>sp|Q57HX9|ATPB_SAL
CH ATP synthase subun 
50.283 
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;Q7CFM8;Q663Q8;Q1CCH5;Q1C0
95;B4F0E7;B2K847;B1JRN2;A9R5
T9;A7FPE0;A4TSJ3;A1JTC6;Q7VP
P0;Q0I5X3;B3H2P3;B0UWG5;A3N
2U4;A6W3S8;A8G7M8;A4STP3;A0
KQX8;Q9CKW1;B8F774;B0BRX2;
Q65Q07;A6VL57;Q3IK50;Q3J6N1;
Q5ZRA1;Q5X0P3;Q5WSG8;A5III3;
Q60CR4;Q0VKX4;Q48AW0;Q1QS
D0;B8GRB8;A1SBU0;Q07VU4;B8E
DV0;A9KX06;A6WUJ0;A4YCH8;A3
DAR4;A1RQB0;Q8E8C0;Q0HPG1;
Q0HD79;A0L2S8;B8CVU5;B1KQ3
4;B0TQF4;A8HAG3;A8G1W5;A3Q
JR0;Q2S6P1;B3PIS7;C4LDW0;Q1
2HQ1;Q89B39;B0U598;Q07232;Q7
WEM9;Q7W3B0;Q7VU44;Q2KU36;
A9HY42;Q21DK8;C5BKJ5;Q5NIK3;
Q2A1I2;Q14K06;Q0BK84;B2SEY1;
A7NEH4;A4IW24;A0Q8D9;Q83AF5
;A9NBD0;A9KBF7;A1U7H4;Q1LTV
4;B0TWS7;A8EV70;A7ZC37;Q1GX
N0;Q1CSD5;Q17Y78;Q5P4E2;B1X
SD4;A4SUT4;A1K1S2;P42470;Q8
XU76;Q46VY0;Q1LHL0;Q0K5M7;B
3R7L5;Q30QQ1;B9MBA3;A1W2T7;
Q9ZK81;P55988;B6JMX2;B5Z8D0;
Q4FQ37;Q1Q899;B9KES3 
Q8XGN7;Q7CQ50;Q5PN54;Q57M
29;Q3YZS3;Q32DQ2;Q31YH4;Q0T
2K0;P0AFD0;C0Q040;B7LM45;B5
RCF2;B5R308;B5FPG8;B5EZK8;B
5BCL9;B4TPK9;B4TBJ3;B4SYZ8;B
2TW68;A9N581;A9MJ98;C4LB32;
Q87ZQ8;Q7N2I8;Q4ZRJ2;Q4K9T5;
Q48H53;Q3KA62;Q2NSK0;C5B8I5;
C3JY82;B5XNV5;B4EZC9;A8GH15
;A8ADV2;A7MH23;A6TBX3;A4WC
R6;Q9I0K0;Q7CJ93;Q669A1;Q1CH
Q2;Q1C6B0;Q02ND0;B7VAR4;B2K
820;B1JGL4;A9R6L9;A6V4E8;A4T
M35;A1JLG4;Q1QST3;A7FGQ6;Q1
R9D0;Q0TFF9;P0AFC9;P0AFC8;P
0AFC7;C4ZUD0;B7UFU5;B7NNW6
;B7N5P9;B7MXW6;B7MG51;B7M5
W6;B7LBP8;B6I7N7;B5YXS7;B1X8
Z9;B1LLP0;B1IXQ5;A8A2F6;A7ZP
A1;A1ADD5 
>sp|Q8XGN7|NUOB_SALTI 
NADH-quinone oxidoreductase 
subunit B OS=Salmonella typhi 
GN=nuoB PE=3 
SV=1;>sp|Q7CQ50|NUOB_SAL
TY NADH-quinone 
oxidoreductase subunit B 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=nuoB PE=3 
SV=1;>sp|Q5PN54|NUOB_ 
25.089 
Q8XEY8;Q7CPZ4;Q5PFG9;B5XVJ
9;B5RD90;B5QUG9;B5BE99;B4TS
61;B4TE57;B4T2B9;A6TCM1;A4W
DH8 
>sp|Q8XEY8|GRPE_SALTI 
Protein GrpE OS=Salmonella 
typhi GN=grpE PE=3 
SV=1;>sp|Q7CPZ4|GRPE_SAL
TY Protein GrpE 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=grpE PE=3 
SV=1;>sp|Q5PFG9|GRPE_SAL
PA Protein GrpE 
21.841 
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OS=Salmonella paratyphi A 
(stra 
Q8XEV3;Q7CR87;Q5PDE6;Q57TG
8;Q3Z5V6;Q32K41;Q326I0;P0ABZ
9;Q1RGE4;P0ABZ8;P0ABZ7;P0AB
Z6 
>sp|Q8XEV3|SURA_SALTI 
Chaperone SurA 
OS=Salmonella typhi GN=surA 
PE=3 
SV=1;>sp|Q7CR87|SURA_SAL
TY Chaperone SurA 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=surA PE=3 
SV=1;>sp|Q5PDE6|SURA_SAL
PA Chaperone SurA 
OS=Salmonella paratyphi A 
47.25 
Q8XD64;Q46814 
>sp|Q8XD64|XDHD_ECO57 
Probable hypoxanthine oxidase 
XdhD OS=Escherichia coli 
O157:H7 GN=xdhD PE=3 
SV=1;>sp|Q46814|XDHD_ECO
LI Probable hypoxanthine 
oxidase XdhD OS=Escherichia 
coli (strain K12) GN=xdhD PE=3 
SV=1 
103.59 
Q8XCJ6;P0AC54;P0AC53 
>sp|Q8XCJ6|G6PD_ECO57 
Glucose-6-phosphate 1-
dehydrogenase OS=Escherichia 
coli O157:H7 GN=zwf PE=3 
SV=1;>sp|P0AC54|G6PD_ECO
L6 Glucose-6-phosphate 1-
dehydrogenase OS=Escherichia 
coli O6:H1 (strain CFT073 / 
ATCC 700928 / UPEC) GN=zwf 
PE=3 SV=1;>sp|P0AC53|G6PD 
55.732 
Q8XBT3;Q8FK07;P39177;Q83M07 
>sp|Q8XBT3|USPG_ECO57 
Universal stress protein G 
OS=Escherichia coli O157:H7 
GN=uspG PE=3 
SV=1;>sp|Q8FK07|USPG_ECO
L6 Universal stress protein G 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=uspG PE=3 
SV=2;>sp|P39177|USPG_ECOL
I Universal 
15.936 
Q8X9B6;P24182 
>sp|Q8X9B6|ACCC_ECO57 
Biotin carboxylase 
OS=Escherichia coli O157:H7 
GN=accC PE=3 
SV=1;>sp|P24182|ACCC_ECOL
I Biotin carboxylase 
OS=Escherichia coli (strain K12) 
GN=accC PE=1 SV=2 
49.336 
Q8X6C0;Q8FE91;Q46803 
>sp|Q8X6C0|YGEW_ECO57 
Putative carbamoyltransferase 
YgeW OS=Escherichia coli 
O157:H7 GN=ygeW PE=3 
SV=1;>sp|Q8FE91|YGEW_ECO
44.186 
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L6 Putative 
carbamoyltransferase YgeW 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=ygeW PE=3 
SV=1;>sp|Q46803|YGEW 
Q8UJ19 
>sp|Q8UJ19|SLYX_AGRFC 
Protein SlyX homolog 
OS=Agrobacterium fabrum 
(strain C58 / ATCC 33970) 
GN=slyX PE=3 SV=2 
8.1341 
Q8RLE0 
>sp|Q8RLE0|KITH_MYCGA 
Thymidine kinase 
OS=Mycoplasma gallisepticum 
(strain R(low / passage 15 / 
clone 2)) GN=tdk PE=3 SV=2 
25.259 
Q8R753;Q8KCQ2;Q88Z84 
>sp|Q8R753|KPRS_CALS4 
Ribose-phosphate 
pyrophosphokinase 
OS=Caldanaerobacter 
subterraneus subsp. 
tengcongensis (strain DSM 
15242 / JCM 11007 / NBRC 
100824 / MB4) GN=prs PE=3 
SV=1;>sp|Q8KCQ2|KPRS_CHL
TE Ribose-phosphate 
pyrophosphokinase 
OS=Chlorobium tepidu 
34.174 
Q8KAH0;P42473;B4SBU5;B3EH93
;A4SCQ7;A1BJ36;O50340;C5CGR
6;A9BHA7 
>sp|Q8KAH0|EFTU_CHLTE 
Elongation factor Tu 
OS=Chlorobium tepidum (strain 
ATCC 49652 / DSM 12025 / 
NBRC 103806 / TLS) GN=tuf 
PE=3 SV=1 
42.899 
Q8K9G0 
>sp|Q8K9G0|RS9_BUCAP 30S 
ribosomal protein S9 
OS=Buchnera aphidicola subsp. 
Schizaphis graminum (strain Sg) 
GN=rpsI PE=3 SV=1 
14.891 
Q8GBW6 
>sp|Q8GBW6|12S_PROFR 
Methylmalonyl-CoA 
carboxyltransferase 12S subunit 
OS=Propionibacterium 
freudenreichii subsp. shermanii 
PE=1 SV=3 
65.926 
Q8G863;B7GPT0;B3DPM0 
>sp|Q8G863|SYDND_BIFLO 
Aspartate--tRNA(Asp/Asn) 
ligase OS=Bifidobacterium 
longum (strain NCC 2705) 
GN=aspS PE=3 
SV=1;>sp|B7GPT0|SYDND_BIF
LS Aspartate--tRNA(Asp/Asn) 
ligase OS=Bifidobacterium 
longum subsp. infantis (strain 
ATCC 15697 / DSM 20088 / 
JCM 1222  
66.935 
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Q8G7W9 
>sp|Q8G7W9|SYG_BIFLO 
Glycine--tRNA ligase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=glyQS 
PE=3 SV=1 
55.908 
Q8G7I6;Q47IJ3;Q3IKH4;Q6A5X5 
>sp|Q8G7I6|G6PI_BIFLO 
Glucose-6-phosphate isomerase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=pgi PE=3 
SV=1 
62.997 
Q8G7C3;B7GU03;B3DTU0 
>sp|Q8G7C3|GPDA_BIFLO 
Glycerol-3-phosphate 
dehydrogenase [NAD(P)+] 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=gpsA 
PE=3 
SV=1;>sp|B7GU03|GPDA_BIFL
S Glycerol-3-phosphate 
dehydrogenase [NAD(P)+] 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 
34.616 
Q8G784;C6A9K7 
>sp|Q8G784|GLGE_BIFLO 
Alpha-1,4-glucan:maltose-1-
phosphate maltosyltransferase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=glgE 
PE=3 
SV=1;>sp|C6A9K7|GLGE_BIFL
B Alpha-1,4-glucan:maltose-1-
phosphate maltosyltransferase 
OS=Bifidobacterium animalis 
subsp. l 
82.904 
Q8G769;B7GTU7;B3DU31 
>sp|Q8G769|GATB_BIFLO 
Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=gatB 
PE=3 
SV=1;>sp|B7GTU7|GATB_BIFL
S Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Bifidobacterium longum 
subsp. 
55.057 
Q8G6Z9 
>sp|Q8G6Z9|PEPD_BIFLO 
Dipeptidase OS=Bifidobacterium 
longum (strain NCC 2705) 
GN=pepD PE=1 SV=1 
59.75 
Q8G6V1;B8DVE0;Q8G6V2 
>sp|Q8G6V1|ILVC2_BIFLO 
Ketol-acid reductoisomerase 
(NADP(+)) 2 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=ilvC2 
PE=3 SV=1 
38.551 
380 
 
 
Q8G6C2;B7GR13;B3DRX5 
>sp|Q8G6C2|SYT_BIFLO 
Threonine--tRNA ligase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=thrS 
PE=3 
SV=1;>sp|B7GR13|SYT_BIFLS 
Threonine--tRNA ligase 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12) GN 
76.834 
Q8G6B1;B3DRY6 
>sp|Q8G6B1|PUR9_BIFLO 
Bifunctional purine biosynthesis 
protein PurH 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=purH 
PE=3 
SV=1;>sp|B3DRY6|PUR9_BIFL
D Bifunctional purine 
biosynthesis protein PurH 
OS=Bifidobacterium longum 
(strain DJO10A) GN=purH PE=3 
SV= 
58.412 
Q8G5X7;Q2G6R7;Q47QN2;Q2J87
8 
>sp|Q8G5X7|PYRG_BIFLO 
CTP synthase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=pyrG 
PE=3 SV=1 
60.982 
Q8G5P4;C5CBZ4;Q6AD51;Q891G
7;Q5L3E1;B0S0S7;Q81VE0;Q73E
R7;B7JM61;B7IUT1;B7H4Q8;A9V
QG9;A7GKG1;Q9KF78;Q8NY69;Q
8CMQ8;Q6GJQ6;Q6GC81;Q65MU
0;Q5HRX1;Q5HIQ6;Q4L386;Q49U
U9;Q2YVL5;Q2G0Y6;Q2FJM5;P99
105;P64296;B9E8Y0;B9DLM7;A8Z
0R1;A8FAH5;A7Z235;A7WY93;A6
TYP2;A6QE71;A5IPX0;Q720X7;B1
YIZ1;Q81IS3;Q6HPC6;Q63GV4;Q5
WJI0;C3PBL1;C3L508;C1EUB4;A0
R8W7;Q5FMD6;Q74LF7;Q38ZE1;
Q03H14;B2G994;A5VLY3;Q92CU0
;Q8Y822;Q88Y74;Q1WRY8;A0AH
K7;Q839J8;Q8NSR1;Q8FRZ3;A4Q
BV0;O52831;Q82HM9;Q73U79;P9
WMS7;P9WMS6;P60499;P0A5A2;
C1AHL0;B2HDP0;A5U871;A1KP87
;Q9L0H2;Q4JTG0;P46810;B8ZUE2
;P29727 
>sp|Q8G5P4|GUAA_BIFLO 
GMP synthase [glutamine-
hydrolyzing] 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=guaA 
PE=3 
SV=1;>sp|C5CBZ4|GUAA_MIC
LC GMP synthase [glutamine-
hydrolyzing] OS=Micrococcus 
luteus (strain ATCC 4698 / DSM 
20030 / JCM 1464 / NBRC 3333 
/ 
57.865 
Q8G5P2 
>sp|Q8G5P2|KPRS_BIFLO 
Ribose-phosphate 
pyrophosphokinase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=prs 
PE=3 SV=2 
36.863 
Q8G5F3;B3DSY6;B7GTN9;A9WQ9
1;A6WCT0 
>sp|Q8G5F3|ARLY_BIFLO 
Argininosuccinate lyase 
53.391 
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OS=Bifidobacterium longum 
(strain NCC 2705) GN=argH 
PE=3 
SV=1;>sp|B3DSY6|ARLY_BIFL
D Argininosuccinate lyase 
OS=Bifidobacterium longum 
(strain DJO10A) GN=argH PE=3 
SV=1;>sp|B7GTN9|ARLY_BIFL
S Argininosuccinate ly 
Q8G568;B7GUC1;B3DT87 
>sp|Q8G568|LUXS_BIFLO S-
ribosylhomocysteine lyase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=luxS 
PE=3 
SV=2;>sp|B7GUC1|LUXS_BIFL
S S-ribosylhomocysteine lyase 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 118 
18.451 
Q8G533;B3DTC2;B7GUF2;B8DW
H9 
>sp|Q8G533|GLMM_BIFLO 
Phosphoglucosamine mutase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=glmM 
PE=3 
SV=1;>sp|B3DTC2|GLMM_BIFL
D Phosphoglucosamine mutase 
OS=Bifidobacterium longum 
(strain DJO10A) GN=glmM 
PE=3 
SV=1;>sp|B7GUF2|GLMM_BIFL
S Phosphoglucosami 
48.66 
Q8G500;B7GUI8;B3DTF8 
>sp|Q8G500|LEU3_BIFLO 3-
isopropylmalate dehydrogenase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=leuB 
PE=3 
SV=1;>sp|B7GUI8|LEU3_BIFLS 
3-isopropylmalate 
dehydrogenase 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/  
37.246 
Q8G484;A1A1I1 
>sp|Q8G484|PYRH_BIFLO 
Uridylate kinase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=pyrH 
PE=3 
SV=1;>sp|A1A1I1|PYRH_BIFAA 
Uridylate kinase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=pyrH PE=3 
SV=1 
26.619 
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Q8G3W7;B7GN83;B3DQG7;A1A0
B7 
>sp|Q8G3W7|SYS_BIFLO 
Serine--tRNA ligase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=serS 
PE=3 
SV=1;>sp|B7GN83|SYS_BIFLS 
Serine--tRNA ligase 
OS=Bifidobacterium longum 
subsp. infantis (strain ATCC 
15697 / DSM 20088 / JCM 1222 
/ NCTC 11817 / S12) GN=serS  
47.956 
Q8FMB0;Q6NF38;Q4JXT3;B1VHT
9;A4QHG2;Q9RHX5;Q8NM16;C3P
JK0 
>sp|Q8FMB0|PURA_COREF 
Adenylosuccinate synthetase 
OS=Corynebacterium efficiens 
(strain DSM 44549 / YS-314 / AJ 
12310 / JCM 11189 / NBRC 
100395) GN=purA PE=3 
SV=1;>sp|Q6NF38|PURA_COR
DI Adenylosuccinate synthetase 
OS=Corynebacterium 
diphtheriae (strain ATCC  
46.785 
Q8FAT5;P0A8N6;P0A8N5;Q8ZHK
5;Q8Z3X8;Q83JU6;Q6D945;Q666T
3;Q5PL30;Q57K76;Q32BV3;Q31W
F2;Q1CF16;Q1CB23;Q0T106;P283
54;C6D8Z6;C0PY12;B5RE01;B5Q
XG7;B5FUF3;B5F5G4;B5BFK5;B4
TUQ8;B4TGW0;B4T535;B2U0Q7;B
2K0N6;B1JPH6;A9R4M4;A9N3L6;
A9MRI4;A8GIP4;A8AP96;A7MR65;
A7FF39;A4WE42;A4TIC5;A1JPL4;
B2VF45;Q8XD57;P0A8N4;P0A8N3 
>sp|Q8FAT5|SYK2_ECOL6 
Lysine--tRNA ligase, heat 
inducible OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
700928 / UPEC) GN=lysU PE=3 
SV=3;>sp|P0A8N6|SYK2_ECO5
7 Lysine--tRNA ligase, heat 
inducible OS=Escherichia coli 
O157:H7 GN=lysU PE=3 
SV=2;>sp|P0A8N5|SY 
57.854 
Q8F746;Q72PA2 
>sp|Q8F746|SUCC_LEPIN 
Succinate--CoA ligase [ADP-
forming] subunit beta 
OS=Leptospira interrogans 
serogroup Icterohaemorrhagiae 
serovar Lai (strain 56601) 
GN=sucC PE=3 
SV=1;>sp|Q72PA2|SUCC_LEPI
C Succinate--CoA ligase [ADP-
forming] subunit beta 
OS=Leptospira 
41.89 
Q8ET56 
>sp|Q8ET56|GLGC_OCEIH 
Glucose-1-phosphate 
adenylyltransferase 
OS=Oceanobacillus iheyensis 
(strain DSM 14371 / CIP 107618 
/ JCM 11309 / KCTC 3954 / 
HTE831) GN=glgC PE=3 SV=1 
43.424 
Q8ELI2;Q97TN4;Q8RGH3;Q73QV
3;A6LXU8;Q8NUM5;Q8CMY5;Q6G
DJ7;Q6G670;Q5HL21;Q5HCU6;Q4
L9B6;Q2YWF3;Q2FV17;Q2FDQ4;
Q07159;P99117;P67472;A8Z3K5;A
7X6Y6;A6U4Y6;A6QK93;A5IW31 
>sp|Q8ELI2|ALF1_OCEIH 
Fructose-bisphosphate aldolase 
class 1 OS=Oceanobacillus 
iheyensis (strain DSM 14371 / 
CIP 107618 / JCM 11309 / 
KCTC 3954 / HTE831) GN=fda 
PE=3 
32.819 
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SV=1;>sp|Q97TN4|ALF1_CLOA
B Fructose-bisphosphate 
aldolase class 1 OS=Clostridium 
acetobuty 
Q8E7S7;Q3K3V5 
>sp|Q8E7S7|RS8_STRA3 30S 
ribosomal protein S8 
OS=Streptococcus agalactiae 
serotype III (strain NEM316) 
GN=rpsH PE=3 
SV=1;>sp|Q3K3V5|RS8_STRA1 
30S ribosomal protein S8 
OS=Streptococcus agalactiae 
serotype Ia (strain ATCC 27591 
/ A909 / CDC SS700) GN=rpsH 
PE 
14.785 
Q8DFM0;Q7MMR7;B7VII6;Q87RH
5 
>sp|Q8DFM0|HTPG_VIBVU 
Chaperone protein HtpG 
OS=Vibrio vulnificus (strain 
CMCP6) GN=htpG PE=3 
SV=1;>sp|Q7MMR7|HTPG_VIB
VY Chaperone protein HtpG 
OS=Vibrio vulnificus (strain 
YJ016) GN=htpG PE=3 
SV=2;>sp|B7VII6|HTPG_VIBTL 
Chaperone protein HtpG 
OS=Vibrio tas 
72.343 
Q8CS54;Q6GFY8;Q6G8K8;Q5HNI
5;Q5HF54;Q4L760;Q49YF2;Q2YT
H0;Q2FXK6;Q2FG18;P66564;P665
63;P66562;A8Z2N6;A7X3F0;A6U2I
6;A6QHQ3;A5ITP2;B9DN91 
>sp|Q8CS54|RS4_STAES 30S 
ribosomal protein S4 
OS=Staphylococcus epidermidis 
(strain ATCC 12228) GN=rpsD 
PE=3 
SV=1;>sp|Q6GFY8|RS4_STAA
R 30S ribosomal protein S4 
OS=Staphylococcus aureus 
(strain MRSA252) GN=rpsD 
PE=3 
SV=1;>sp|Q6G8K8|RS4_STAA
S 30S ribosomal p 
23.105 
Q8ABA9;Q64RE7;Q5LAZ8 
>sp|Q8ABA9|HISX_BACTN 
Histidinol dehydrogenase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=hisD PE=3 
SV=1;>sp|Q64RE7|HISX_BACF
R Histidinol dehydrogenase 
OS=Bacteroides fragilis (strain 
YCH46) GN=hisD PE=3 
46.246 
Q8AA39;Q64T65;Q5LC76 
>sp|Q8AA39|SYFB_BACTN 
Phenylalanine--tRNA ligase beta 
subunit OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pheT PE=3 
SV=1;>sp|Q64T65|SYFB_BACF
90.919 
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R Phenylalanine--tRNA ligase 
beta subunit OS=Bacteroides 
fragil 
Q8A7M7 
>sp|Q8A7M7|SSB_BACTN 
Single-stranded DNA-binding 
protein OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=ssb PE=3 SV=1 
17.762 
Q8A7B8 
>sp|Q8A7B8|FOLD_BACTN 
Bifunctional protein FolD 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=folD PE=3 SV=1 
31.645 
Q8A6N4;A6L1X1 
>sp|Q8A6N4|PURA_BACTN 
Adenylosuccinate synthetase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=purA PE=3 
SV=1;>sp|A6L1X1|PURA_BAC
V8 Adenylosuccinate synthetase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / D 
46.789 
Q8A602;A6L3D0 
>sp|Q8A602|AROC_BACTN 
Chorismate synthase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=aroC PE=3 
SV=1;>sp|A6L3D0|AROC_BAC
V8 Chorismate synthase 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
58 
39.115 
Q8A455;Q64NI3;Q5L883;Q2S1L8;
A6TWK7;Q7MUF7;A6L0E8;B2RI67
;Q11PQ4 
>sp|Q8A455|SYE_BACTN 
Glutamate--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=gltX PE=3 
SV=1;>sp|Q64NI3|SYE_BACFR 
Glutamate--tRNA ligase 
OS=Bacteroides fragilis (strain 
YCH46) GN=gltX PE=3 SV=1; 
57.733 
Q8A3M1;Q64MP7;Q5L7I8;A6KYR3
;A6LFP0;Q7MXK7;B2RHF5;A0M5Z
9 
>sp|Q8A3M1|SYM_BACTN 
Methionine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
77.646 
385 
 
 
GN=metG PE=3 
SV=1;>sp|Q64MP7|SYM_BACF
R Methionine--tRNA ligase 
OS=Bacteroides fragilis (strain 
YCH46) GN=metG PE=3 SV= 
Q8A1G3 
>sp|Q8A1G3|SUSG_BACTN 
Alpha-amylase SusG 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susG PE=1 SV=1 
77.958 
Q8A1G2 
>sp|Q8A1G2|SUSD_BACTN 
Starch-binding protein SusD 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susD PE=1 SV=1 
62.308 
Q8A1A7;Q64YZ5;Q5LHZ1;A6KXY5 
>sp|Q8A1A7|ARGC_BACTN N-
acetyl-gamma-glutamyl-
phosphate reductase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=argC PE=3 
SV=1;>sp|Q64YZ5|ARGC_BAC
FR N-acetyl-gamma-glutamyl-
phosphate reductase 
OS=Bacteroide 
35.838 
Q8A1A2 
>sp|Q8A1A2|RHAA_BACTN L-
rhamnose isomerase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=rhaA PE=3 SV=1 
47.481 
Q8A137 
>sp|Q8A137|FABH2_BACTN 3-
oxoacyl-[acyl-carrier-protein] 
synthase 3 protein 2 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=fabH2 PE=3 SV=1 
36.978 
Q8A135 
>sp|Q8A135|DER_BACTN 
GTPase Der OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=der PE=3 SV=1 
49.722 
Q8A0Z8;Q64P24;Q5L8W2 
>sp|Q8A0Z8|SYN_BACTN 
Asparagine--tRNA ligase 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
53.295 
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10582 / E50 / VPI-5482) 
GN=asnS PE=3 
SV=1;>sp|Q64P24|SYN_BACF
R Asparagine--tRNA ligase 
OS=Bacteroides fragilis (strain 
YCH46) GN=asnS PE=3 SV= 
Q89YZ7 
>sp|Q89YZ7|PEPT_BACTN 
Peptidase T OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=pepT PE=3 SV=1 
45.178 
Q89G50;Q3SQ46;Q1QJU8;Q07PJ
7;A4YZA6 
>sp|Q89G50|ILVC_BRADU 
Ketol-acid reductoisomerase 
(NADP(+)) OS=Bradyrhizobium 
diazoefficiens (strain JCM 10833 
/ IAM 13628 / NBRC 14792 / 
USDA 110) GN=ilvC PE=3 
SV=1;>sp|Q3SQ46|ILVC_NITW
N Ketol-acid reductoisomerase 
(NADP(+)) OS=Nitrobacter 
winogradskyi (s 
36.887 
Q89AK1 
>sp|Q89AK1|G3P_BUCBP 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Buchnera 
aphidicola subsp. Baizongia 
pistaciae (strain Bp) GN=gapA 
PE=3 SV=1 
36.805 
Q89A90;P63238;P63237 
>sp|Q89A90|CSPE_BUCBP 
Cold shock-like protein CspE 
OS=Buchnera aphidicola subsp. 
Baizongia pistaciae (strain Bp) 
GN=cspE PE=3 
SV=3;>sp|P63238|CSPE_BUCA
P Cold shock-like protein CspE 
OS=Buchnera aphidicola subsp. 
Schizaphis graminum (strain Sg) 
GN=cspE PE=3 
7.4272 
Q899D9 
>sp|Q899D9|SYM_CLOTE 
Methionine--tRNA ligase 
OS=Clostridium tetani (strain 
Massachusetts / E88) GN=metG 
PE=3 SV=1 
73.21 
Q899C3;A0Q3B0;Q8XHE4 
>sp|Q899C3|SYI_CLOTE 
Isoleucine--tRNA ligase 
OS=Clostridium tetani (strain 
Massachusetts / E88) GN=ileS 
PE=3 
SV=2;>sp|A0Q3B0|SYI_CLONN 
Isoleucine--tRNA ligase 
OS=Clostridium novyi (strain 
NT) GN=ileS PE=3 
SV=1;>sp|Q8XHE4|SYI_CLOPE 
Isoleucine--tRNA ligase O 
120.32 
Q896K3 
>sp|Q896K3|VATB1_CLOTE V-
type ATP synthase beta chain 1 
OS=Clostridium tetani (strain 
51.213 
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Massachusetts / E88) 
GN=atpB1 PE=3 SV=1 
Q88YX0;Q035U8;B3WA09;Q38V0
5;Q1WST2;Q03ST9;Q03E48;B2GA
C2;B2G5T1;A5VIA4 
>sp|Q88YX0|RL11_LACPL 50S 
ribosomal protein L11 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=rplK PE=3 
SV=1;>sp|Q035U8|RL11_LACP
3 50S ribosomal protein L11 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 /  
14.76 
Q88YD2;Q81MN9;Q819I5 
>sp|Q88YD2|PPK1_LACPL 
Polyphosphate kinase 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=ppk PE=3 
SV=1;>sp|Q81MN9|PPK1_BAC
AN Polyphosphate kinase 
OS=Bacillus anthracis GN=ppk 
PE=3 
SV=1;>sp|Q819I5|PPK1_BACC
R Polyphosphate kinase O 
82.226 
Q88XY0;Q1WS96;A5VLJ9;Q74L83
;Q046B9 
>sp|Q88XY0|RS3_LACPL 30S 
ribosomal protein S3 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=rpsC PE=3 
SV=1;>sp|Q1WS96|RS3_LACS
1 30S ribosomal protein S3 
OS=Lactobacillus salivarius 
(strain UCC118) GN=rpsC PE=3 
SV=1;>sp|A5VLJ9|RS3 
24.208 
Q88P53;Q936V7;P08308 
>sp|Q88P53|OTCC_PSEPK 
Ornithine carbamoyltransferase, 
catabolic OS=Pseudomonas 
putida (strain ATCC 47054 / 
DSM 6125 / NCIMB 11950 / 
KT2440) GN=arcB PE=3 
SV=3;>sp|Q936V7|OTCC_PSE
ME Ornithine 
carbamoyltransferase, catabolic 
OS=Pseudomonas mendocina 
GN=arcB P 
37.911 
Q83S79;P33086;P37736;P33117;O
24755;P0C6C8;A5F6G4;P45599;P
0A9B1;P0A9B0;P0A9A9 
>sp|Q83S79|FUR_SHIFL Ferric 
uptake regulation protein 
OS=Shigella flexneri GN=fur 
PE=3 
SV=1;>sp|P33086|FUR_YERPE 
Ferric uptake regulation protein 
OS=Yersinia pestis GN=fur 
PE=3 
SV=2;>sp|P37736|FUR_VIBA7 
Ferric uptake regulation protein 
OS=Vibrio anguillaru 
16.724 
Q83P33;Q3YUG6;Q328F6;Q31TA7
;Q0SXA5;B7LLV9;B2TY52;Q1R383
>sp|Q83P33|PURA_SHIFL 
Adenylosuccinate synthetase 
47.314 
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;Q0T9L6;P0A7D6;P0A7D5;P0A7D4
;C4ZR54;B7UQI6;B7NTN3;B7NGB
1;B7MSJ5;B7MKY1;B7M8T7;B7LC
36;B6I281;B5Z2I3;B1XDS8;B1LQJ
7;B1IT29;A8A7S2;A7ZV47;A1AJ82
;Q5PL58;Q57GL4;P65883;P65882;
C0Q6D4;B5R9C3;B5R0P3;B5FRN
3;B5F392;B5BKI5;B4TSF7;B4TFB1
;B4T2S2;A9N4Z1;O30549;A5WGF
9;Q9PG47;Q8PNB5;Q8PBR6;Q88
DD8;Q87B33;Q5H4F2;Q4URT6;Q3
BWF4;Q2P782;Q1I454;Q0VMF3;C
1DLQ8;B8GND3;B4SS80;B2SNJ3;
B2I7V8;B1JAI0;B0U498;B0RYD5;B
0KKZ0;A5W9S5;Q8EAG5;Q12RX5
;Q07XS1;B8CIP5;B1KIH9;B0TUV4;
A8H8L8;A3QI59;A1SA65;Q9KNX8;
Q8ZIV7;Q82V29;Q7MAX9;Q6LM35
;Q66FB0;Q606N8;Q5QW95;Q3SL5
7;Q2SBC8;Q1CEG0;Q1C105;Q15Z
E1;Q0AHF5;C4L9M5;C3LRR4;B4S
195;B4F271;B2K2K4;B1JMN3;A9Q
YM6;A9MFN5;A8AMM3;A7FMX4;A
6VYL0;A5F534;A4TRN4;A1JIS0;C
4K3C2;A1SZK6;Q8DCU4;Q7MH07
;Q5E2D3;P40607;Q6FCS7;Q31GN
4 
OS=Shigella flexneri GN=purA 
PE=3 
SV=1;>sp|Q3YUG6|PURA_SHI
SS Adenylosuccinate 
synthetase OS=Shigella sonnei 
(strain Ss046) GN=purA PE=3 
SV=1;>sp|Q328F6|PURA_SHID
S Adenylosuccinate synthetase 
OS=Shigella dys 
Q83MH2;Q3Z5Y4;Q32K71;Q326J7
;B7LVN2;B2U245;Q8XA49;Q8FLB
7;Q1RGH6;Q0TLW5;P00956;C4ZP
V2;B7UI71;B7NHD0;B7N7Q0;B7M
NN1;B7MAE6;B7M0C2;B7L4E8;B6
HZ21;B5YYB8;B1XBF1;B1LFV6;B1
IRE9;A7ZVX4;A7ZHB5;A1A774;A7
MIM3;B5Y235;A8ALT6;P13502;B4
F2T5 
>sp|Q83MH2|SYI_SHIFL 
Isoleucine--tRNA ligase 
OS=Shigella flexneri GN=ileS 
PE=3 
SV=1;>sp|Q3Z5Y4|SYI_SHISS 
Isoleucine--tRNA ligase 
OS=Shigella sonnei (strain 
Ss046) GN=ileS PE=3 
SV=1;>sp|Q32K71|SYI_SHIDS 
Isoleucine--tRNA ligase 
OS=Shigella dysenteriae seroty 
104.27 
Q83LX5;Q3Z4F0;Q32IT9;Q324Q2;
Q0T6Q2;B7LLH1;B5XZR2;B2TU77
;A8AJG0;A7MQS0;A6T6A3;Q8XBN
8;Q8FJY9;Q1RER9;Q0TK31;P078
13;C4ZWC9;B7UKT2;B7NM01;B7
N9P8;B7MRS9;B7MFR5;B7M5G9;
B7L9I6;B6I153;B5YQJ4;B1LL91;B1
IYG6;A7ZXR8;A7ZJ31;A1A8R7;B3
H1L1;Q87RQ0;Q9KTE6;Q6LN98;Q
5E6U8;B7VKF7;B6EIN2;B5FBK7;A
5F2X0;Q8ZQZ6;Q8Z8H5;Q6D7L6;
Q65VR5;Q5PM88;Q57RS7;Q2NU
U7;Q0I5C5;P57923;C6DBW8;C0P
W78;B5R7Z6;B5QVP9;B5FMP4;B5
EZ89;B5BCE6;B4TPX5;B4TB51;B4
SYK7;B2VBM4;B0URM9;A9MUK3;
A9MKC8;A6VMB8;Q7VM66;B0BPF
7;A3N0N2;A7MY86;A4W827 
>sp|Q83LX5|SYL_SHIFL 
Leucine--tRNA ligase 
OS=Shigella flexneri GN=leuS 
PE=3 
SV=2;>sp|Q3Z4F0|SYL_SHISS 
Leucine--tRNA ligase 
OS=Shigella sonnei (strain 
Ss046) GN=leuS PE=3 
SV=1;>sp|Q32IT9|SYL_SHIDS 
Leucine--tRNA ligase 
OS=Shigella dysenteriae 
serotype 1 (str 
97.25 
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Q83L36;Q3Z261;Q32FI6;Q321K5;
Q8XE32;P59664;P07395 
>sp|Q83L36|SYFB_SHIFL 
Phenylalanine--tRNA ligase beta 
subunit OS=Shigella flexneri 
GN=pheT PE=3 
SV=1;>sp|Q3Z261|SYFB_SHIS
S Phenylalanine--tRNA ligase 
beta subunit OS=Shigella 
sonnei (strain Ss046) GN=pheT 
PE=3 
SV=1;>sp|Q32FI6|SYFB_SHIDS 
Phenylalanine--tRNA 
87.41 
Q83IT3;Q3YV31;Q31U45;Q0SY48;
B2TWE0;Q8FBA9;Q7A978;Q1R3X
0;Q0TAB7;P13029;B1XBA8;B1LN
Q3;B1IVD5;A8A750;A7ZUG1;A1AI
C1;A4WG57 
>sp|Q83IT3|KATG_SHIFL 
Catalase-peroxidase 
OS=Shigella flexneri GN=katG 
PE=3 
SV=4;>sp|Q3YV31|KATG_SHIS
S Catalase-peroxidase 
OS=Shigella sonnei (strain 
Ss046) GN=katG PE=3 
SV=1;>sp|Q31U45|KATG_SHIB
S Catalase-peroxidase 
OS=Shigella boydii serotype 4 
(strain S 
80.088 
Q83IR9;Q3YUX8;Q32AH9;Q31TZ1
;Q0SXZ4;B7LUJ6;B2TWJ3;A9MHC
3;A8AKS0;A6TGR3;Q8X611;Q8FB
68;Q1R5X1;Q0TA59;P15639;C5A0
U7;B7UPG1;B7NRT9;B7NFU7;B7
MRD0;B7MIZ2;B7M7R5;B7LAV3;B
6I5L8;B5Z0A3;B1XC09;B1LPG6;B
1IUP1;A7ZUM3;A1AIH7;Q8Z335;Q
5PKA9;P26978;C0Q2T8;B5XYD2;
B5RFH8;B5QYG1;B5FQM1;B5F1I9
;B5BJS5;B4TQL6;B4TDF3;B4T108
;A9N0L8;A8A7A6;Q16CE0;Q7N95
4;Q6DAL2;Q2NWQ7;C6DHT5;B2V
G81;A8G8G3;A7MJ89;Q9KV80;C4
LA41;C3LQN2;A5F3U8 
>sp|Q83IR9|PUR9_SHIFL 
Bifunctional purine biosynthesis 
protein PurH OS=Shigella 
flexneri GN=purH PE=3 
SV=1;>sp|Q3YUX8|PUR9_SHIS
S Bifunctional purine 
biosynthesis protein PurH 
OS=Shigella sonnei (strain 
Ss046) GN=purH PE=3 
SV=1;>sp|Q32AH9|PUR9_SHID
S Bifunct 
57.358 
Q83BM9;Q3J7V7;B6J4H5;B6IZ25;
A9N8Z4;A9KBI0;A4XQK6;Q9HVT8
;Q02GV8;B8GL95;B7V023;A6VBJ8
;Q47JV4;A1U486;Q1GYD3 
>sp|Q83BM9|GATA_COXBU 
Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Coxiella burnetii (strain 
RSA 493 / Nine Mile phase I) 
GN=gatA PE=3 
SV=1;>sp|Q3J7V7|GATA_NITO
C Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Nitrosococcus oceani 
(strain ATCC 19707 / 
52.561 
Q839E0;Q035A8;B3WAJ3;Q38UT6 
>sp|Q839E0|RS11_ENTFA 30S 
ribosomal protein S11 
OS=Enterococcus faecalis 
(strain ATCC 700802 / V583) 
GN=rpsK PE=3 
SV=1;>sp|Q035A8|RS11_LACP
3 30S ribosomal protein S11 
OS=Lactobacillus paracasei 
13.713 
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(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL  
Q821B1;Q3YZZ8;Q31Z32;Q0T2R6
;B7LJV0;B2TV26;Q8XE46;Q8CVW
3;Q1R9K8;Q0TFN2;P23827;C4ZU
52;B7UFM3;B7NN20;B7N5H1;B7M
XP0;B7MFC2;B7M5Q0;B7LAN3;B6
I1A7;B5YX01;B1X8A5;B1LKV6;B1I
Y63;A8A271;A7ZP31 
>sp|Q821B1|ECOT_SHIFL 
Ecotin OS=Shigella flexneri 
GN=eco PE=3 
SV=2;>sp|Q3YZZ8|ECOT_SHIS
S Ecotin OS=Shigella sonnei 
(strain Ss046) GN=eco PE=3 
SV=1;>sp|Q31Z32|ECOT_SHIB
S Ecotin OS=Shigella boydii 
serotype 4 (strain Sb227) 
GN=eco PE=3 
SV=1;>sp|Q0T2R6|ECOT_SH 
18.226 
Q81VQ4;Q81J18;Q73F69;Q6HPN2
;Q63H64;A7GK47;A0R8K6 
>sp|Q81VQ4|RPOA_BACAN 
DNA-directed RNA polymerase 
subunit alpha OS=Bacillus 
anthracis GN=rpoA PE=3 
SV=1;>sp|Q81J18|RPOA_BAC
CR DNA-directed RNA 
polymerase subunit alpha 
OS=Bacillus cereus (strain 
ATCC 14579 / DSM 31 / JCM 
2152 / NBRC 15305 / NCIMB 
9373 / NR 
34.935 
Q81K90;Q816H3;Q45099;P32081 
>sp|Q81K90|CSPD_BACAN 
Cold shock-like protein CspD 
OS=Bacillus anthracis GN=cspD 
PE=3 
SV=1;>sp|Q816H3|CSPD_BAC
CR Cold shock-like protein 
CspD OS=Bacillus cereus 
(strain ATCC 14579 / DSM 31 / 
JCM 2152 / NBRC 15305 / 
NCIMB 9373 / NRRL B-3711) 
GN=cspD PE=3 SV 
7.2389 
Q7VR21 
>sp|Q7VR21|ACP_BLOFL Acyl 
carrier protein OS=Blochmannia 
floridanus GN=acpP PE=3 SV=1 
8.7006 
Q7VL82;A6VM31;Q6LN26;Q8ZH64
;Q8DBF9;Q7MIG2;Q6D8E1;Q667J
1;Q5PD61;Q57T37;Q3Z5I7;Q32JT
8;Q325W9;Q2NRK9;Q1CFE9;Q1C
AN2;Q0T838;P65934;P65933;P0A
7F2;A8GIE4;A8ALB8;A7MGT0;A7F
FH1;A6T4X3;A4W6R6;A4TL89;Q7
N8P5;Q9KPV4;Q87ME0;Q5E3E1;
Q12NY5;A7N1X5;A5F619;A4SQI0;
A0KHG5;Q5QXS2;Q485G8;Q15W
G1;A3QGA1;A1JP80;Q3IIX6;A1SY
W1;Q1RG18;Q0TLG2;P0A7F1;P0A
7F0;P0A7E9;A7ZWB7;A7ZHR1;A1
A7L5 
>sp|Q7VL82|PYRH_HAEDU 
Uridylate kinase 
OS=Haemophilus ducreyi (strain 
35000HP / ATCC 700724) 
GN=pyrH PE=3 
SV=1;>sp|A6VM31|PYRH_ACT
SZ Uridylate kinase 
OS=Actinobacillus 
succinogenes (strain ATCC 
55618 / 130Z) GN=pyrH PE=3 
SV=1;>sp|Q6LN26|PYRH_PHO
PR Uridylat 
25.783 
Q7VH96 
>sp|Q7VH96|EFTS_HELHP 
Elongation factor Ts 
OS=Helicobacter hepaticus 
39.669 
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(strain ATCC 51449 / 3B1) 
GN=tsf PE=3 SV=1 
Q7U581 
>sp|Q7U581|SYE_SYNPX 
Glutamate--tRNA ligase 
OS=Synechococcus sp. (strain 
WH8102) GN=gltX PE=3 SV=1 
53.328 
Q7TUA3 
>sp|Q7TUA3|FMT_PROMP 
Methionyl-tRNA 
formyltransferase 
OS=Prochlorococcus marinus 
subsp. pastoris (strain 
CCMP1986 / NIES-2087 / 
MED4) GN=fmt PE=3 SV=1 
37.566 
Q7NAV2 
>sp|Q7NAV2|RS7_MYCGA 30S 
ribosomal protein S7 
OS=Mycoplasma gallisepticum 
(strain R(low / passage 15 / 
clone 2)) GN=rpsG PE=3 SV=1 
17.682 
Q7NA97;Q8Z9S8;Q663R1 
>sp|Q7NA97|GLMS_PHOLL 
Glutamine--fructose-6-
phosphate aminotransferase 
[isomerizing] OS=Photorhabdus 
luminescens subsp. laumondii 
(strain DSM 15139 / CIP 105565 
/ TT01) GN=glmS PE=3 
SV=3;>sp|Q8Z9S8|GLMS_YER
PE Glutamine--fructose-6-
phosphate aminotransferas 
66.946 
Q7N8C9;A8AKE2;A1JJH3;Q0I3R5;
B0UTZ3 
>sp|Q7N8C9|TNAA_PHOLL 
Tryptophanase 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=tnaA PE=3 
SV=1;>sp|A8AKE2|TNAA_CITK
8 Tryptophanase 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=tnaA PE=3  
52.276 
Q7MYF7;P46172;Q8ZJA6;Q664S7;
Q1CCV0;B5XNA0;B2VK58;B2K5M
4;B1JIW7;A9R902;A8GKJ1;A7FNM
9;A6TEW6;A4TGZ8;A1JS29;Q6CZ
X6;Q5PIV8;Q57J38;Q3YWU5;Q32
B37;Q31VW2;Q0SZY8;P59184;P0
A7V7;P0A7V6;C6DG68;C5BGL9;C
0Q0B0;B7LRT0;B5RH21;B5R285;
B5FJK8;B5F7T9;B5BGY0;B4TXD6;
B4TKK9;B4SUT4;B2U2T2;A9MSZ2
;A9MN54;A8AQL0;A7MPI5;A4WFC
2;A4ST00;A0KF27;Q1R612;Q0TC
E7;P0A7V5;P0A7V4;P0A7V3;C4Z
UG9;B7UK38;B7NLN3;B7NDT5;B7
N198;B7MCS9;B7M1M8;B7L4K3;B
6I228;B5YTN5;B1LHC8;B1IPY5;A8
A5B9;A7ZSK3;A1AGK2 
>sp|Q7MYF7|RS3_PHOLL 30S 
ribosomal protein S3 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=rpsC PE=3 
SV=1;>sp|P46172|RS3_BUCAK 
30S ribosomal protein S3 
(Fragment) OS=Buchnera 
aphidicola subsp. Acyrthosiphon 
kondoi  
26.071 
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Q7MY53 
>sp|Q7MY53|SECB_PHOLL 
Protein-export protein SecB 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=secB PE=3 SV=1 
17.521 
Q7MWI7;B2RII9 
>sp|Q7MWI7|TPIS_PORGI 
Triosephosphate isomerase 
OS=Porphyromonas gingivalis 
(strain ATCC BAA-308 / W83) 
GN=tpiA PE=3 
SV=1;>sp|B2RII9|TPIS_PORG3 
Triosephosphate isomerase 
OS=Porphyromonas gingivalis 
(strain ATCC 33277 / DSM 
20709 / CIP 103683 / JCM 
12257 /  
26.819 
Q7MW43;B2RJ01 
>sp|Q7MW43|NAGB_PORGI 
Glucosamine-6-phosphate 
deaminase OS=Porphyromonas 
gingivalis (strain ATCC BAA-308 
/ W83) GN=nagB PE=3 
SV=1;>sp|B2RJ01|NAGB_POR
G3 Glucosamine-6-phosphate 
deaminase OS=Porphyromonas 
gingivalis (strain ATCC 33277 / 
DSM 20709 / CIP 10368 
29.281 
Q7MTM3;B2RLY2;A6LEI1 
>sp|Q7MTM3|RL14_PORGI 
50S ribosomal protein L14 
OS=Porphyromonas gingivalis 
(strain ATCC BAA-308 / W83) 
GN=rplN PE=3 
SV=1;>sp|B2RLY2|RL14_POR
G3 50S ribosomal protein L14 
OS=Porphyromonas gingivalis 
(strain ATCC 33277 / DSM 
20709 / CIP 103683 / JCM 
12257 /  
13.065 
Q7MB46;Q492P4;Q1LT61;B8F8M2 
>sp|Q7MB46|FABA_PHOLL 3-
hydroxydecanoyl-[acyl-carrier-
protein] dehydratase 
OS=Photorhabdus luminescens 
subsp. laumondii (strain DSM 
15139 / CIP 105565 / TT01) 
GN=fabA PE=3 
SV=1;>sp|Q492P4|FABA_BLOP
B 3-hydroxydecanoyl-[acyl-
carrier-protein] dehydratase 
OS=B 
18.999 
Q7MA35 
>sp|Q7MA35|DNAK_WOLSU 
Chaperone protein DnaK 
OS=Wolinella succinogenes 
(strain ATCC 29543 / DSM 1740 
/ LMG 7466 / NCTC 11488 / 
FDC 602W) GN=dnaK PE=3 
SV=1 
68.39 
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Q7CP78 
>sp|Q7CP78|RIDA_SALTY 2-
iminobutanoate/2-
iminopropanoate deaminase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ridA PE=1 SV=1 
13.575 
Q74LS5;Q046V3 
>sp|Q74LS5|DDL_LACJO D-
alanine--D-alanine ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ddl PE=3 
SV=1;>sp|Q046V3|DDL_LACG
A D-alanine--D-alanine ligase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 1 
40.39 
Q74L95;Q046D2 
>sp|Q74L95|RPOB_LACJO 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
johnsonii (strain CNCM I-12250 / 
La1 / NCC 533) GN=rpoB PE=3 
SV=1;>sp|Q046D2|RPOB_LAC
GA DNA-directed RNA 
polymerase subunit beta 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / D 
135.81 
Q74L58 
>sp|Q74L58|RL13_LACJO 50S 
ribosomal protein L13 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rplM PE=3 SV=1 
16.402 
Q74K17;Q042L3;P17674;Q88UU1;
Q9CER8;Q02XA3;A4W1V9;A4VVK
1;A2RMI4;Q9PJ21;Q8E5V0;Q8E07
4;Q5HX61;Q3K1J7;Q1JHN7;P9578
7;C0MH19;C0M718;B9KES1;B9DR
T4;B4U2D9;A8FJR0;A7H1H9;A2R
FC4;A1VXI8;Q9A0I9;Q8P1K6;Q81
JZ3;Q72XE6;Q6HAX7;Q6GEX0;Q6
G7K5;Q630U1;Q5XCY2;Q5HE95;
Q4L7Y6;Q48UD5;Q2YUJ9;Q2FWE
8;Q2FF22;Q1JMJ1;Q1JCL5;Q1J7G
1;P99111;P63676;P63675;P0DA03
;P0DA02;C4KYS5;C3P1F6;C3LFI1;
C1F0N0;B9IRT9;B7JGN2;B7IQW0;
B7HY67;B7HFK4;B5XKP9;B1YMR
6;B1HM54;A9VSA5;A8YY72;A7X4
U5;A6U3J0;A6QIU9;A5IUQ0;A4ITJ
1;A0RL97;Q8CNJ5;Q5HMB7;Q49Z
52;Q1WUC8;B9E8E8;Q927W2;Q8
Y4C0;Q71WP7;A0ALL5;Q9Z689;Q
814W0;A8EV72;A7ZC35;A7I175;A
7H019;A6Q4C2;B7GMF5;A9H9A4;
Q831A3;P26679;Q5KUJ1;P42005;
P09219;C5D992;Q9ZK79;Q1CSD3
;Q17Y80;P55987;B6JMX4;B5Z8D2
;B2UUP2;Q30QP9;Q03EL2;Q6MG
>sp|Q74K17|ATPA_LACJO ATP 
synthase subunit alpha 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=atpA PE=3 
SV=1;>sp|Q042L3|ATPA_LACG
A ATP synthase subunit alpha 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB  
55.137 
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M5;Q03A20;B3WDL6;Q38WK3;Q0
3QY6 
Q74JZ8;Q5FKW5 
>sp|Q74JZ8|SYV_LACJO 
Valine--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=valS PE=3 
SV=1;>sp|Q5FKW5|SYV_LACA
C Valine--tRNA ligase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=valS PE=3 
SV=1 
101.24 
Q74JX6 
>sp|Q74JX6|SYI_LACJO 
Isoleucine--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=ileS PE=3 SV=2 
105.96 
Q74JC1;Q5FJY2;Q1GA94;Q043I0 
>sp|Q74JC1|FTHS_LACJO 
Formate--tetrahydrofolate ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=fhs PE=3 
SV=1;>sp|Q5FJY2|FTHS1_LAC
AC Formate--tetrahydrofolate 
ligase 1 OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 
60.474 
Q73PN3 
>sp|Q73PN3|EFTU_TREDE 
Elongation factor Tu 
OS=Treponema denticola (strain 
ATCC 35405 / CIP 103919 / 
DSM 14222) GN=tuf PE=3 
SV=1 
43.788 
Q72HB8;P96077 
>sp|Q72HB8|RF1_THET2 
Peptide chain release factor 1 
OS=Thermus thermophilus 
(strain HB27 / ATCC BAA-163 / 
DSM 7039) GN=prfA PE=1 
SV=1;>sp|P96077|RF1_THET8 
Peptide chain release factor 1 
OS=Thermus thermophilus 
(strain HB8 / ATCC 27634 / 
DSM 579) GN=prfA PE 
40.092 
Q6N3N0;Q2IZ52;Q07K70;B3QGK4 
>sp|Q6N3N0|URE3_RHOPA 
Urease subunit gamma 
OS=Rhodopseudomonas 
palustris (strain ATCC BAA-98 / 
CGA009) GN=ureA PE=3 
SV=1;>sp|Q2IZ52|URE3_RHOP
2 Urease subunit gamma 
OS=Rhodopseudomonas 
palustris (strain HaA2) GN=ureA 
PE=3 
SV=1;>sp|Q07K70|URE3_RHO
P5 Urease s 
11.088 
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Q6DAN3 
>sp|Q6DAN3|RL1_PECAS 50S 
ribosomal protein L1 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=rplA PE=3 
SV=1 
24.781 
Q6D8D2 
>sp|Q6D8D2|FABZ_PECAS 3-
hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=fabZ PE=3 
SV=1 
17.105 
Q6D400;C6DF64;A7MES8;Q83LP3
;Q3Z3L5;Q32E24;Q31YU4;B2TUH
4;A8AIH6;Q8XEA7;Q8FJB7;Q1RD
V1;Q0TJE6;P23721;C4ZQ33;B7U
MZ3;B7NM68;B7NAQ6;B7MS22;B
7MHL6;B7M835;B7LD99;B6I8X9;B
5YT41;B1X847;B1LJV7;B1IW24;A7
ZYL0;A7ZJZ6;A1A9I4 
>sp|Q6D400|SERC_PECAS 
Phosphoserine 
aminotransferase 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=serC 
PE=3 
SV=1;>sp|C6DF64|SERC_PEC
CP Phosphoserine 
aminotransferase 
OS=Pectobacterium 
carotovorum subsp. 
carotovorum (strain PC1) 
GN=se 
40.276 
Q6D1I0;Q5PF80;Q57ST7;P0A278;
P0A277;C0Q6T6;B5Y1E0;B5R5R4;
B5R4S1;B5FJW9;B5EWK0;B5BDQ
2;B4TZ85;B4T7Q0;B4SVV9;A9MY
09;A9MNR9;A8AKQ0;A7MEN2;A6
T532;A4W6X0;Q2NVF2;C6DCY0;B
2VHN3;Q3Z599;Q32J21;Q325P8;Q
0T7Q9;P0A9M7;B7LNG2;B2U3S9;
Q7N7B4;Q8FKM7;Q1RFT3;Q0TL7
8;P0A9M6;P0A9M5;C4ZT95;B7UJ
C6;B7NK87;B7N8G9;B7MQ74;B7
MC88;B7M267;B7L3Z0;B6I018;B5
Z1I2;B1XDY1;B1LHT4;B1J0Z6;A7Z
WK1;A7ZHZ7;A1A7U9;C5B9M4;A8
GAD0;B4EUU7 
>sp|Q6D1I0|XGPT_PECAS 
Xanthine 
phosphoribosyltransferase 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=gpt PE=3 
SV=1;>sp|Q5PF80|XGPT_SALP
A Xanthine 
phosphoribosyltransferase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=gpt 
17.014 
Q6D1G2;Q48389;C6DCZ3;B5XZU
3;B2VIR2;A8GAA9;A8ANI1;A6T67
3;A4W7Z3 
>sp|Q6D1G2|MTNC_PECAS 
Enolase-phosphatase E1 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=mtnC 
PE=3 
SV=1;>sp|Q48389|MTNC_KLE
OX Enolase-phosphatase E1 
OS=Klebsiella oxytoca 
GN=mtnC PE=3 
SV=1;>sp|C6DCZ3|MTNC_PEC
CP Enolase-phosphatase E 
25.874 
Q6CZX7;C6DG67;C5BGL8;B5XNA
1;B2VK57;A8GKJ0;A6TEW5;A4WF
C1 
>sp|Q6CZX7|RL16_PECAS 50S 
ribosomal protein L16 
OS=Pectobacterium 
15.321 
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atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=rplP PE=3 
SV=1;>sp|C6DG67|RL16_PEC
CP 50S ribosomal protein L16 
OS=Pectobacterium 
carotovorum subsp. 
carotovorum (strain PC1) 
GN=rplP PE=3 SV 
Q6CZK2;C6DH77;B2T2Z5;Q141E6
;B2JCH8;Q2A4U5;Q0BN65;B2SFM
9;A7NAI4;A4IZK0;A0Q595 
>sp|Q6CZK2|GLGC_PECAS 
Glucose-1-phosphate 
adenylyltransferase 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN=glgC PE=3 
SV=1;>sp|C6DH77|GLGC_PEC
CP Glucose-1-phosphate 
adenylyltransferase 
OS=Pectobacterium 
carotovorum subsp. 
carotovorum  
47.812 
Q68XM0 
>sp|Q68XM0|DAPB_RICTY 4-
hydroxy-tetrahydrodipicolinate 
reductase OS=Rickettsia typhi 
(strain ATCC VR-144 / 
Wilmington) GN=dapB PE=3 
SV=1 
26.577 
Q65RV7;A6VML2;Q9CM20;Q3IKQ
2;Q12PB2;Q15RT6;Q47XA7 
>sp|Q65RV7|HTPG_MANSM 
Chaperone protein HtpG 
OS=Mannheimia 
succiniciproducens (strain 
MBEL55E) GN=htpG PE=3 
SV=1;>sp|A6VML2|HTPG_ACT
SZ Chaperone protein HtpG 
OS=Actinobacillus 
succinogenes (strain ATCC 
55618 / 130Z) GN=htpG PE=3 
SV=1;>sp|Q9CM20|HTPG_PAS
MU  
71.305 
Q65PY6 
>sp|Q65PY6|TRMA_MANSM 
tRNA/tmRNA (uracil-C(5))-
methyltransferase 
OS=Mannheimia 
succiniciproducens (strain 
MBEL55E) GN=trmA PE=3 
SV=1 
41.948 
Q64QR7;Q5LAD5;B6YR45;A6LIF5;
A6H0U4;A5FHR3;A0LZF7 
>sp|Q64QR7|PURA_BACFR 
Adenylosuccinate synthetase 
OS=Bacteroides fragilis (strain 
YCH46) GN=purA PE=3 
SV=1;>sp|Q5LAD5|PURA_BAC
FN Adenylosuccinate 
synthetase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=purA PE=3 SV=1 
46.799 
Q63WJ7;Q62HK4;Q3JV86;Q2T0I7 
>sp|Q63WJ7|EFG1_BURPS 
Elongation factor G 1 
77.807 
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OS=Burkholderia pseudomallei 
(strain K96243) GN=fusA1 PE=3 
SV=1;>sp|Q62HK4|EFG1_BUR
MA Elongation factor G 1 
OS=Burkholderia mallei (strain 
ATCC 23344) GN=fusA1 PE=3 
SV=1;>sp|Q3JV86|EFG1_BURP
1 Elongation factor G  
Q60A10 
>sp|Q60A10|RL11_METCA 50S 
ribosomal protein L11 
OS=Methylococcus capsulatus 
(strain ATCC 33009 / NCIMB 
11132 / Bath) GN=rplK PE=3 
SV=1 
15.016 
Q60151 
>sp|Q60151|GSHR_STRTR 
Glutathione reductase 
OS=Streptococcus thermophilus 
GN=gor PE=3 SV=1 
48.711 
Q5XAQ7 
>sp|Q5XAQ7|HPF_STRP6 
Ribosome hibernation promotion 
factor OS=Streptococcus 
pyogenes serotype M6 (strain 
ATCC BAA-946 / MGAS10394) 
GN=hpf PE=1 SV=1 
21.1 
Q5U924 
>sp|Q5U924|HADB_CLODI (R)-
2-hydroxyisocaproyl-CoA 
dehydratase alpha subunit 
OS=Clostridioides difficile 
GN=hadB PE=1 SV=1 
46.333 
Q5U923 
>sp|Q5U923|HADC_CLODI (R)-
2-hydroxyisocaproyl-CoA 
dehydratase beta subunit 
OS=Clostridioides difficile 
GN=hadC PE=1 SV=1 
42.365 
Q5QY51 
>sp|Q5QY51|IXTPA_IDILO 
dITP/XTP pyrophosphatase 
OS=Idiomarina loihiensis (strain 
ATCC BAA-735 / DSM 15497 / 
L2-TR) GN=IL1979 PE=3 SV=1 
21.889 
Q5QXT4;B2GAT4;A9BDM9;Q9PET
2;Q9HVI7;Q8PPE3;Q8PCN4;Q88Q
27;Q87WC1;Q87AS2;Q5ZXK6;Q5
X722;Q5WYH4;Q5NFJ3;Q5GW07;
Q4ZNH2;Q4UQT6;Q4K5R9;Q48D
U7;Q3K6J0;Q3BXI8;Q2NZ83;Q2A4
98;Q14GZ5;Q0BMN1;C1DEQ3;B4
SJB0;B2SNV6;B2SGE5;B2I8R0;B2
FNK2;B0U4K9;B0TYH3;B0RVE1;A
7NB66;A5IGI2;A4VI36;A4IXD7;A3
QC57;A1TYW8;A0Q7C5;Q3II23;Q2
S9R4;Q15WB3;Q0VMH4;B8CJM7;
B4RV95;B1KJJ9;B0TJY5;A8H1Q0;
A8FSQ9;Q83BT3;Q488N6;B6J8Q9
;B6IZ80;A9N8T8;A9KBN4;Q21NP8
;A1SUU0;C5BS91;Q6CZV5;Q2S4
G9 
>sp|Q5QXT4|GLYA_IDILO 
Serine 
hydroxymethyltransferase 
OS=Idiomarina loihiensis (strain 
ATCC BAA-735 / DSM 15497 / 
L2-TR) GN=glyA PE=3 
SV=1;>sp|B2GAT4|GLYA_LAC
F3 Serine 
hydroxymethyltransferase 
OS=Lactobacillus fermentum 
(strain NBRC 3956 / LMG 
18251) GN=gl 
45.536 
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Q5QWR2 
>sp|Q5QWR2|HTPG_IDILO 
Chaperone protein HtpG 
OS=Idiomarina loihiensis (strain 
ATCC BAA-735 / DSM 15497 / 
L2-TR) GN=htpG PE=3 SV=1 
72.889 
Q5PL63;P0A1D6;P0A1D5;B5R990;
B5R004;B5FRK1;B5F2K9;B5BKF3;
B4TSC5;B4TF79;A9MFS0;Q6D9J1
;Q2NW95;C6DKC6;B4EXE3;A8G8
S6;A7MMB9;Q9F4E6;P25749;O51
831;B8D8I1;B8D6T5;Q7MAZ6;P48
228;A1JIP2;Q9F4F4;Q9F4F2;Q9F4
F0;Q9F4E8;Q9F4E4;Q9ANS0;Q49
3W8;Q058F4;P59525;C5BDK4;B2
VL85 
>sp|Q5PL63|CH10_SALPA 10 
kDa chaperonin OS=Salmonella 
paratyphi A (strain ATCC 9150 / 
SARB42) GN=groS PE=3 
SV=1;>sp|P0A1D6|CH10_SALT
I 10 kDa chaperonin 
OS=Salmonella typhi GN=groS 
PE=3 
SV=1;>sp|P0A1D5|CH10_SALT
Y 10 kDa chaperonin 
OS=Salmonella typhimurium  
10.318 
Q5PKX3;Q57HY0;P0A1B8;P0A1B7
;C0Q2N1;B5XZM5;B5RFW4;B5QU
S3;B5EYZ5;B5BIN5;B4SYD0;A9MJ
S1;A8ACN5;A7MMW8;A6TG35;Q6
CYJ6;Q3YVN5;Q329S0;Q31UN1;Q
0SYU5;P0A6E8;B7LK76;B2TUP4;
A4WGF6;Q1R4K3;Q0TAX8;P5864
6;P0A6E7;P0A6E6;C4ZZ09;B7UMJ
6;B7NR33;B7NF47;B7N2H0;B7MG
F1;B7M587;B7L881;B6I3W8;B5YX
D5;B1X9V9;B1LL58;B1IX07;A8A6J
4;A7ZTU3 
>sp|Q5PKX3|ATPE_SALPA 
ATP synthase epsilon chain 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=atpC PE=3 
SV=1;>sp|Q57HY0|ATPE_SAL
CH ATP synthase epsilon chain 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=atpC PE=3 
SV=1;>sp|P0A1B8|ATPE_SALT
I ATP 
15.064 
Q5PK94;Q57H70;Q3YUZ8;P0A2A0
;P0A299;C0Q2R6;B5XYF6;B5RFK
2;B5QYD7;B5FQJ8;B5F0W6;B5BJ
Q2;B4TQJ4;B4TCS3;B4T0Y8;A9N
0J3;A8AKU0;A6TGN9;A4W5A6;A7
MQP6;A9MHF3;Q32AF8;Q31U11;
Q0SY14;P0A7K5;B7LUL6;B4EYV0
;B2VG95;B2TWH2;A8G8E6;Q6DA
N1;C6DHR4;B8F6N0;B3GYU7;B0B
SE8;A3N319;Q1R5V1;Q0TA79;P0
A7K4;P0A7K3;P0A7K2;C5A0S6;B7
UPE1;B7NRR4;B7NFS6;B7MRB2;
B7MIX2;B7M733;B7LA79;B6I5J6;B
5Z082;B1XBY8;B1LNT8;B1IUR1;A
8A785;A7ZUK0 
>sp|Q5PK94|RL7_SALPA 50S 
ribosomal protein L7/L12 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=rplL PE=3 
SV=3;>sp|Q57H70|RL7_SALCH 
50S ribosomal protein L7/L12 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=rplL PE=3 
SV=3;>sp|Q3YUZ8|RL7_SHISS 
50 
12.299 
Q5PK21;Q57G39;P63924;P63923;
C0Q7M5;B5R9V1;B5R2J8;B5F526;
B5BAJ9;B4TU43;B4TH01;B4T4H2;
A9N7E1;A9MRA5;B5FTC7;A4W6A
0;C6DKL9;A8G9H8;A1JJ99 
>sp|Q5PK21|DEOB_SALPA 
Phosphopentomutase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=deoB PE=3 
SV=1;>sp|Q57G39|DEOB_SAL
CH Phosphopentomutase 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=deoB PE=3 
SV=1;>sp|P63924|DEOB_SALT
I Phosphopentomutase  
44.303 
Q5PI26;Q57LQ8;Q3YZA9;Q32DB9
;Q31Y46;Q0T275;P63424;P63423;
P63422;Q1R8T7;Q0TF35;P76539;
>sp|Q5PI26|YPEA_SALPA 
Acetyltransferase YpeA 
OS=Salmonella paratyphi A 
16.284 
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P63421;P63420;A1ADU8;Q6D8U7;
Q2NS89 
(strain ATCC 9150 / SARB42) 
GN=ypeA PE=3 
SV=1;>sp|Q57LQ8|YPEA_SAL
CH Acetyltransferase YpeA 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=ypeA PE=3 
SV=2;>sp|Q3YZA9|YPEA_SHIS
S Acetyltrans 
Q5PGI6;Q57R38;Q3Z3M7;Q32E12
;Q323L0;Q0T8M9;P67564;P67563;
P0A8L4;C0PXT0;B7LN61;B5R8I1;
B5QYP4;B5FQ36;B5F146;B5BBR2
;B4TRS5;B4TD24;B4T128;B2TUI5;
A9N7X6;A8AII9;Q1RE21;Q0TJF7;
P0A8L3;P0A8L2;P0A8L1;C4ZQ19;
B7UMY4;B7NM82;B7NAP4;B7MR
V6;B7MHK5;B7M821;B7LD85;B6I8
W4;B5YT28;B1X833;B1LJX0;B1IW
N0;A7ZYJ7;A7ZJW2;A1A9D6;A9M
HZ1;Q7N6E7;C5BE90 
>sp|Q5PGI6|SYS_SALPA 
Serine--tRNA ligase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=serS PE=3 
SV=1;>sp|Q57R38|SYS_SALC
H Serine--tRNA ligase 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=serS PE=3 
SV=1;>sp|Q3Z3M7|SYS_SHISS 
Serine--tRNA ligase  
48.58 
Q5PFN4;Q57SB5;Q3Z4W6;Q32JJ
3;Q325G4;Q0T7E6;P0A6H0;P0A1
D8;P0A1D7;B5QTJ6;B5BD83;B4T
MC6;B4T9E3;B4SWU1;Q1RF98;Q
0TKK4;P0A6G9;P0A6G8;P0A6G7;
B1J011;A7ZX95;A7ZIJ5;A1A8A6 
>sp|Q5PFN4|CLPP_SALPA 
ATP-dependent Clp protease 
proteolytic subunit 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=clpP PE=3 
SV=1;>sp|Q57SB5|CLPP_SALC
H ATP-dependent Clp protease 
proteolytic subunit 
OS=Salmonella choleraesuis 
(strain SC-B67) GN= 
23.158 
Q5PFK8;Q57S76;P0A1V5;P0A1V4
;C0Q812;B5R612;B5QU77;B5FLJ7
;B5EXN0;B5BD44;B4TMG6;B4T9I1
;B4SWY1;A8AJW9 
>sp|Q5PFK8|KAD_SALPA 
Adenylate kinase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=adk PE=3 
SV=1;>sp|Q57S76|KAD_SALC
H Adenylate kinase 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=adk PE=3 
SV=1;>sp|P0A1V5|KAD_SALTI 
Adenylate kinase OS=Salmonel 
23.488 
Q5PF18;Q57KU7;Q3YYG7;Q32CN
2;Q31X61;Q0T1C2;P69918;P6991
7;P69916;C0PWL9;B7LW33;B5XV
B9;B5RDF1;B5QV75;B5FSX7;B5F
349;B5BEN4;B4TT03;B4TF10;B4T
397;B2U050;A9N0C0;A9MFZ2;A8A
NQ0;A7MJ32;A6TCV8;A4WDQ5;Q
1R805;Q0TEI4;P69915;P69914;P6
9913;C4ZYU1;B7UHB4;B7NSH6;B
7N6S6;B7MYZ3;B7MKG5;B7M9D3
;B7LEA7;B6I682;B5Z2A6;B1XCM4;
B1LQ13;B1IUY3;A8A3H3;A7ZQC4 
>sp|Q5PF18|CSRA_SALPA 
Carbon storage regulator 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=csrA PE=3 
SV=1;>sp|Q57KU7|CSRA_SAL
CH Carbon storage regulator 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=csrA PE=3 
SV=1;>sp|Q3YYG7|CSRA_SHI
SS Carbon  
6.8558 
Q5PEH4;Q57KH0;P64077;P64076;
C0PXD5;B5RDS5;B5QW40;B5F4N
9;B5BF02;B4TTY5;B4TFZ1;B4T48
>sp|Q5PEH4|ENO_SALPA 
Enolase OS=Salmonella 
paratyphi A (strain ATCC 9150 / 
45.598 
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3;A9N2F4;A9MF11;A7MQZ0;B5FT
U9;B4EUF7;Q9KPC5;C3LQZ0;A5F
5I3;C4LBR1;Q4QLX6;P43806;A5UI
73;A5UDD6 
SARB42) GN=eno PE=3 
SV=3;>sp|Q57KH0|ENO_SALC
H Enolase OS=Salmonella 
choleraesuis (strain SC-B67) 
GN=eno PE=3 
SV=1;>sp|P64077|ENO_SALTI 
Enolase OS=Salmonella typhi 
GN=eno PE=3 SV=2;> 
Q5NG17;Q2A3F9;Q14HG9;Q0BLX
1;B2SGI4;A7NC76;A4IXY7;A0Q6E
3 
>sp|Q5NG17|TTCA1_FRATT 
tRNA 2-thiocytidine biosynthesis 
protein TtcA 1 OS=Francisella 
tularensis subsp. tularensis 
(strain SCHU S4 / Schu 4) 
GN=ttcA1 PE=3 
SV=1;>sp|Q2A3F9|TTCA2_FRA
TH tRNA 2-thiocytidine 
biosynthesis protein TtcA 2 
OS=Francisella tularensis 
30.896 
Q5LMA7 
>sp|Q5LMA7|CLPS_RUEPO 
ATP-dependent Clp protease 
adapter protein ClpS 
OS=Ruegeria pomeroyi (strain 
ATCC 700808 / DSM 15171 / 
DSS-3) GN=clpS PE=3 SV=1 
13.118 
Q5LH68 
>sp|Q5LH68|MGP_BACFN 4-O-
beta-D-mannosyl-D-glucose 
phosphorylase OS=Bacteroides 
fragilis (strain ATCC 25285 / 
DSM 2151 / JCM 11019 / NCTC 
9343) GN=BF0772 PE=1 SV=1 
43.885 
Q5L301;A4IK95 
>sp|Q5L301|LUTB_GEOKA 
Lactate utilization protein B 
OS=Geobacillus kaustophilus 
(strain HTA426) GN=lutB PE=3 
SV=1;>sp|A4IK95|LUTB_GEOT
N Lactate utilization protein B 
OS=Geobacillus 
thermodenitrificans (strain 
NG80-2) GN=lutB PE=3 SV=1 
53.088 
Q5KX76 
>sp|Q5KX76|GCST_GEOKA 
Aminomethyltransferase 
OS=Geobacillus kaustophilus 
(strain HTA426) GN=gcvT PE=3 
SV=1 
39.762 
Q5FN09 
>sp|Q5FN09|RS6_LACAC 30S 
ribosomal protein S6 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsF PE=3 
SV=1 
11.336 
Q5FM97 
>sp|Q5FM97|RPOB_LACAC 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=rpoB PE=3 SV=1 
135.82 
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Q5FM87;Q38UR5;Q839G1;Q5WL
Q9;A9NED6;Q97SV2;Q97EI1;Q8E
7T5;Q8E2C8;Q8CWV5;Q71WE9;Q
5XED2;Q5M2B6;Q5LXR4;Q48VU6;
Q3K3W6;Q1WS93;Q1JP14;Q1JJ5
9;Q1JE55;Q1J911;Q04MN3;Q03Z
P2;Q03IF4;P60435;P60434;P6042
6;P60425;P0DE35;P0DE34;C1KZH
7;C1CP91;C1CIA0;C1CC09;C1CA
L5;C0MCB3;C0M6X2;B9DYB2;B9
DSV3;B8ZKG0;B5XJ39;B5E6F8;B4
U503;B2UYB3;B2TIH8;B2IS43;B1
MW11;B1I8K1;A8AZM2;A6LPR4;A
5N4Q0;A4VYP6;A4VSF7;A3CK66;
A2RC17;A0PXU9;A0ALW5;Q1GBL
5;Q04C12;Q034Y6;B3WAL4;Q88X
Y3;Q04G82;B2GDW6;B2G8X5;A9
KJJ1;A5VLK2;Q601L2;Q4AAE3;Q4
A8H4;Q03PW0;Q03EB9 
>sp|Q5FM87|RL2_LACAC 50S 
ribosomal protein L2 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplB PE=3 
SV=1 
30.34 
Q5FM80;A8YXL5 
>sp|Q5FM80|RL14_LACAC 50S 
ribosomal protein L14 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplN PE=3 
SV=1;>sp|A8YXL5|RL14_LACH
4 50S ribosomal protein L14 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rplN 
PE=3 SV=1 
13.161 
Q5FM78;Q74L78;Q046B3;A8YXL7 
>sp|Q5FM78|RL5_LACAC 50S 
ribosomal protein L5 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplE PE=3 
SV=1;>sp|Q74L78|RL5_LACJO 
50S ribosomal protein L5 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rplE PE= 
20.264 
Q5FM76;A8YXM0 
>sp|Q5FM76|RL6_LACAC 50S 
ribosomal protein L6 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplF PE=3 
SV=1;>sp|A8YXM0|RL6_LACH4 
50S ribosomal protein L6 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rplF 
PE=3 SV=1 
19.172 
Q5FM59;A8YTB1 
>sp|Q5FM59|RL13_LACAC 50S 
ribosomal protein L13 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplM PE=3 
SV=1;>sp|A8YTB1|RL13_LACH
4 50S ribosomal protein L13 
OS=Lactobacillus helveticus 
16.432 
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(strain DPC 4571) GN=rplM 
PE=3 SV=1 
Q5FLW6 
>sp|Q5FLW6|SYA_LACAC 
Alanine--tRNA ligase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=alaS PE=3 
SV=1 
98.286 
Q5FLL0;A8YTZ7;Q041K6;P61344 
>sp|Q5FLL0|GATB_LACAC 
Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=gatB PE=3 
SV=1;>sp|A8YTZ7|GATB_LAC
H4 Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Lac 
53.822 
Q5FL75;A8YUC4;Q74KA5;Q042C9
;Q03GZ8;Q88YL7;Q38YD2;Q1WS
W8;Q03SQ0;Q03AP4;B3WCM7;B2
G5Y8;A5VIG0;Q04ED0;Q1GB45;Q
04BJ2;Q81X26;Q815G7;Q72XS9;
Q6HB99;Q631G4;B7IPV1;B7HEI8;
A0RKX7;Q97PD6;Q927Y3;Q8DNT
8;Q5KV94;Q04J70;C1CSW3;C1C
M38;C1C8U0;B5E749;A4IST9;A0A
LJ4;Q9K6W8;Q9AET4;A8AVC1;Q9
9Y96;Q8NZK2;Q8DSF0;Q5XAA2;Q
48RM6;Q1JK98;Q1JF92;Q1JA48;Q
1J543;P0DF67;P0DF66;B5XI23;A3
CLD3;A2RCT1;Q65EC5;Q5WDF8;
A8FHW5;A7Z999;Q8E3M6;Q8DY0
7;Q3JZK2;P47994;C0MEB9;C0M6
83;B9EAE8;B9DVI5;B4U176;Q99V
M2;Q7A6R5;Q7A1G4;Q6GIN8;Q6
GB77;Q5HHR7;Q49VV2;Q2YSH6;
Q2FIN8;O06446;A7WZP8;A6QF62;
Q8CPZ2;Q5HQX6;A4W3N7;A4VX
E1;Q834A7;Q4L4H8;A4XJ42;Q5M
2S3;Q5LY68;Q03IX4;Q7VJC6;A6L
KK5;A0RNI3;Q30RR0;A9KS12;Q7
M919;Q5HUL7;Q0P9V7;A8FLZ7;A
7H409;A1VZT4;B9KFM5;A8F530;Q
9ZL57;Q1CT83;Q17XE2;O25475;B
6JM18;B5Z7E8;B2UT44;A7ZD16;A
7GYW4;A8EUE3;A7I1V8;Q6MR29;
Q3A245;Q8RCB4;Q1AVJ6;Q8YMS
8;Q3MB92;B2IUA9;Q55709;B8HSJ
5;B1X0K6;B7K818;B7K110;B1XL0
2;Q46IG8;B4U965;Q2JW99;Q2JJ0
9;A5URI4;B3ECJ8;B4S7J9;Q4A6S
2;P28366 
>sp|Q5FL75|SECA_LACAC 
Protein translocase subunit 
SecA OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=secA PE=3 
SV=1;>sp|A8YUC4|SECA_LAC
H4 Protein translocase subunit 
SecA OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=secA PE=3 
91.554 
Q5FL70;A8YUC9 
>sp|Q5FL70|GPDA_LACAC 
Glycerol-3-phosphate 
36.493 
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dehydrogenase [NAD(P)+] 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=gpsA PE=3 
SV=1;>sp|A8YUC9|GPDA_LAC
H4 Glycerol-3-phosphate 
dehydrogenase [NAD(P)+] 
OS=Lactobacillus helveticus 
(strai 
Q5FL04;Q97NG0;Q8VVB7;Q8DN7
4;Q5M1N9;Q04IA2;Q03ML5;B5E37
9;B2IMZ0;B1I9D8;A8AUL5;Q03EI3 
>sp|Q5FL04|G6PI_LACAC 
Glucose-6-phosphate isomerase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=pgi PE=3 
SV=1 
49.506 
Q5FKZ0;Q1GAX5;Q04BB3;Q74K2
5;Q042K5;A8YUJ1 
>sp|Q5FKZ0|RF1_LACAC 
Peptide chain release factor 1 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=prfA PE=3 
SV=1;>sp|Q1GAX5|RF1_LACD
A Peptide chain release factor 1 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
1184 
41.522 
Q5FKY2;A8YUJ9;Q1GAW7;Q04BA
5;B1MW87;Q03V27;Q04G22 
>sp|Q5FKY2|ATPA_LACAC 
ATP synthase subunit alpha 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=atpA PE=2 
SV=1;>sp|A8YUJ9|ATPA_LACH
4 ATP synthase subunit alpha 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=atpA 
PE=3 SV=1;>sp|Q1 
54.932 
Q5FKY0;A8YUK1;Q9A0I7;Q97PT6;
Q8P1K5;Q8E5U8;Q8E072;Q8DP4
4;Q831A5;Q5XCY0;Q5M5J1;Q5M1
04;Q48UD3;Q3K1J5;Q1JMI9;Q1JH
N5;Q1JCL3;Q1J7F9;Q04HT9;Q03L
X3;P95789;P43451;P0DA05;P0DA
04;C1CSC8;C1CLK6;C1CF93;C1C
899;C0MH17;C0M720;B9DRT6;B8
ZLA9;B5E670;B4U2E1;B2IQX0;B1I
CS9;A8AYG1;A4W1V7;A4VVJ9;A3
CM14;A2RFC2;Q74K15;Q042L5;B
5XKQ1;Q9CES0;Q02XA5;A2RMI2;
B9DME3;A6TK65;B0THN2;Q2RV1
8;P05038;Q6MS94;Q2ST34;A7IH3
1;A1UR49 
>sp|Q5FKY0|ATPB_LACAC 
ATP synthase subunit beta 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=atpD PE=2 
SV=1;>sp|A8YUK1|ATPB_LAC
H4 ATP synthase subunit beta 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=atpD 
PE=3 SV=1;>sp|Q9A0 
52.215 
Q5FKS2 
>sp|Q5FKS2|RS20_LACAC 30S 
ribosomal protein S20 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsT PE=3 
SV=1 
9.481 
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Q5FKR7 
>sp|Q5FKR7|TIG_LACAC 
Trigger factor OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=tig PE=3 SV=1 
49.305 
Q5FKK7 
>sp|Q5FKK7|LDH2_LACAC L-
lactate dehydrogenase 2 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=ldh2 PE=3 
SV=1 
33.349 
Q5FK48;Q049W0;A8YXQ1;Q88YI6
;Q5QHW1;B2GE54;B2G970;A5VL
V3 
>sp|Q5FK48|LUXS_LACAC S-
ribosylhomocysteine lyase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=luxS PE=3 
SV=1 
17.665 
Q5FJU0;A8YVM4;Q04A23;Q038U3
;B3WEK6;Q03F66;B2G6Z6;A5VJI1
;B2GBZ7;Q88VS3 
>sp|Q5FJU0|SYGB_LACAC 
Glycine--tRNA ligase beta 
subunit OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=glyS PE=3 
SV=1;>sp|A8YVM4|SYGB_LAC
H4 Glycine--tRNA ligase beta 
subunit OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=glyS PE 
78.622 
Q5FJT2;A8YVN2;Q74IY4;Q042X7;
Q831T1 
>sp|Q5FJT2|PDRP_LACAC 
Putative pyruvate, phosphate 
dikinase regulatory protein 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=LBA1206 
PE=3 
SV=1;>sp|A8YVN2|PDRP_LAC
H4 Putative pyruvate, phosphate 
dikinase regulatory protein 
OS=Lact 
31.258 
Q5FJK8;A8YVT1;Q1G9L7;Q049S3
;Q92AM1;Q81WJ6;Q819W6;Q732
N0;Q71YM9;Q6HEX5;Q636I6;O53
083;C3P5P1;C3L787;C1KW86;C1
EP64;B9IVC9;B8DDW6;B7JJS6;B7
IUJ9;B7HLH3;B7HDW3;B1HQI4;A9
VT78;A0RHL3;A0AJP5;Q833P5;Q3
8XQ6;Q038K1;B3WET9;A8MHC5;
B1YIM3;Q88WJ1;Q03RU8;Q03FW
2;B1MZW8 
>sp|Q5FJK8|RL19_LACAC 50S 
ribosomal protein L19 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rplS PE=3 
SV=1;>sp|A8YVT1|RL19_LACH
4 50S ribosomal protein L19 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rplS 
PE=3 SV=1;>sp|Q1G9 
13.057 
Q5FIW3 
>sp|Q5FIW3|SYT_LACAC 
Threonine--tRNA ligase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=thrS PE=3 
SV=1 
73.642 
Q5FIS5;A8YWH0 
>sp|Q5FIS5|TRMB_LACAC 
tRNA (guanine-N(7)-)-
25.359 
405 
 
 
methyltransferase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=trmB PE=3 
SV=1;>sp|A8YWH0|TRMB_LAC
H4 tRNA (guanine-N(7)-)-
methyltransferase 
OS=Lactobacillus helveticus 
(strain DPC 4571)  
Q5FIN5;A8YWU9;Q74HZ5;Q041F5
;Q6MUG5;Q6F2A0;Q2SR32;B8J4S
2;Q88XZ7;Q03EA5;Q316Z9;Q037
M7;B3W8V7;Q8NYY2;Q8CU95;Q6
GKT6;Q6GD81;Q5HK07;Q5HJY7;
Q4LAK8;Q2FKP7;P99178;P95689;
P61083;A8YYT2;A7WWP0;A6TXF
9;A6QD48;A5INQ0;Q1G8N2;Q048
F6 
>sp|Q5FIN5|SYS_LACAC 
Serine--tRNA ligase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=serS PE=3 
SV=1;>sp|A8YWU9|SYS_LACH
4 Serine--tRNA ligase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=serS 
PE=3 
SV=1;>sp|Q74HZ5|SYS_LACJO 
S 
49.616 
Q5FI54;Q1G8B5;Q047T2 
>sp|Q5FI54|MURE_LACAC 
UDP-N-acetylmuramyl-tripeptide 
synthetase OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=murE PE=3 SV=1 
57.633 
Q59800 
>sp|Q59800|G3P_KITAU 
Glyceraldehyde-3-phosphate 
dehydrogenase 
OS=Kitasatospora aureofaciens 
GN=gap PE=3 SV=1 
35.312 
Q59727 
>sp|Q59727|PHTD_COMTE 
4,5-dihydroxyphthalate 
decarboxylase OS=Comamonas 
testosteroni GN=phtD PE=4 
SV=1 
37.156 
Q59677 
>sp|Q59677|MUTB_PORGI 
Methylmalonyl-CoA mutase 
large subunit 
OS=Porphyromonas gingivalis 
(strain ATCC BAA-308 / W83) 
GN=mutB PE=3 SV=1 
78.702 
Q59643 
>sp|Q59643|HEM2_PSEAE 
Delta-aminolevulinic acid 
dehydratase OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=hemB 
PE=1 SV=1 
37.037 
Q59485;A8YVY9;Q9Z5K9;Q1G9E8
;Q049K4;P40334 
>sp|Q59485|PEPX_LACHE 
Xaa-Pro dipeptidyl-peptidase 
OS=Lactobacillus helveticus 
GN=pepX PE=1 
SV=1;>sp|A8YVY9|PEPX_LAC
H4 Xaa-Pro dipeptidyl-peptidase 
90.486 
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OS=Lactobacillus helveticus 
(strain DPC 4571) GN=pepX 
PE=3 SV=1 
Q59477;P45513 
>sp|Q59477|DHAT_KLEPN 1,3-
propanediol dehydrogenase 
OS=Klebsiella pneumoniae 
GN=dhaT PE=1 SV=1 
41.465 
Q59111 
>sp|Q59111|GCTA_ACIFV 
Glutaconate CoA-transferase 
subunit A OS=Acidaminococcus 
fermentans (strain ATCC 25085 
/ DSM 20731 / VR4) GN=gctA 
PE=1 SV=3 
35.721 
Q57K60;C0PY28;B5RE16;B5QXI2;
B5FUG8;B4TGX5;B4T550;A4WE5
7;Q5PJG4;P64223;P64222;B5F5I0;
B5BFM0;B4TV24;A9N3N3;A9MRH
0;A8APB4 
>sp|Q57K60|GCST_SALCH 
Aminomethyltransferase 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=gcvT PE=3 
SV=1;>sp|C0PY28|GCST_SAL
PC Aminomethyltransferase 
OS=Salmonella paratyphi C 
(strain RKS4594) GN=gcvT 
PE=3 
SV=1;>sp|B5RE16|GCST_SAL
G2 Aminomethyltransferase 
40.217 
Q56131;P40827;P39700;P0ADA4;
P0ADA3 
>sp|Q56131|NLPD_SALTI 
Murein hydrolase activator NlpD 
OS=Salmonella typhi GN=nlpD 
PE=3 
SV=2;>sp|P40827|NLPD_SALT
Y Murein hydrolase activator 
NlpD OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=nlpD PE=3 
SV=2;>sp|P39700|NLPD_SALD
U Murein 
39.182 
Q53560;P0A393;P0A392;P13154;P
54531 
>sp|Q53560|DHLE_BACLI 
Leucine dehydrogenase 
OS=Bacillus licheniformis 
GN=ldh PE=1 
SV=1;>sp|P0A393|DHLE_BACC
E Leucine dehydrogenase 
OS=Bacillus cereus GN=ldh 
PE=1 
SV=1;>sp|P0A392|DHLE_BACC
R Leucine dehydrogenase 
OS=Bacillus cereus (strain 
ATCC 14579 / DSM 3 
40.04 
Q51772;P94188;Q52109;P94702 
>sp|Q51772|MERA_PSEFL 
Mercuric reductase 
OS=Pseudomonas fluorescens 
GN=merA PE=3 
SV=1;>sp|P94188|MERA_ALCS
P Mercuric reductase 
OS=Alcaligenes sp. GN=merA 
PE=3 
SV=1;>sp|Q52109|MERA_ACIC
57.566 
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A Mercuric reductase 
OS=Acinetobacter calcoaceticus 
GN=merA PE=3 SV=1;>s 
Q51561;Q02T87;B7V637;A6UZI1;A
4XZ97;C1DKK5;A4VHM3;Q88QP2;
Q889X8;Q4ZMN7;Q4K526;Q48D2
9;Q3K5Y1;Q1IFX3;C3K2Y3;B1JDX
1;B0KK60;A5VXP0;A1TYJ0;A3M1
G3;Q6FF90;B7I360;B7H1J8;B2I1Z
1;B0VLZ6;B0VDI0;Q5ZYQ0;Q5X86
6;Q5WZL9;O86094;A5IHS1 
>sp|Q51561|RPOB_PSEAE 
DNA-directed RNA polymerase 
subunit beta OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=rpoB 
PE=3 
SV=2;>sp|Q02T87|RPOB_PSE
AB DNA-directed RNA 
polymerase subunit  
150.84 
Q4QJQ4;P44291;A5UBI8 
>sp|Q4QJQ4|ETCG_HAEI8 
Electron transport complex 
subunit G OS=Haemophilus 
influenzae (strain 86-028NP) 
GN=rnfG PE=3 
SV=1;>sp|P44291|ETCG_HAEI
N Electron transport complex 
subunit G OS=Haemophilus 
influenzae (strain ATCC 51907 / 
DSM 11121 / KW20 / Rd) 
GN=HI_ 
22.952 
Q49X88 
>sp|Q49X88|MUTS_STAS1 
DNA mismatch repair protein 
MutS OS=Staphylococcus 
saprophyticus subsp. 
saprophyticus (strain ATCC 
15305 / DSM 20229) GN=mutS 
PE=3 SV=1 
101.23 
Q49419 
>sp|Q49419|Y328_MYCGE 
Uncharacterized protein MG328 
OS=Mycoplasma genitalium 
(strain ATCC 33530 / G-37 / 
NCTC 10195) GN=MG328 
PE=4 SV=1 
88.406 
Q48558 
>sp|Q48558|PEPDA_LACHE 
Dipeptidase A OS=Lactobacillus 
helveticus GN=pepDA PE=1 
SV=1 
53.512 
Q48436;Q04520 
>sp|Q48436|BUDC_KLEPN 
Diacetyl reductase [(S)-acetoin 
forming] OS=Klebsiella 
pneumoniae GN=budC PE=1 
SV=2 
26.642 
Q47454 
>sp|Q47454|PCOC_ECOLX 
Copper resistance protein C 
OS=Escherichia coli GN=pcoC 
PE=1 SV=1 
13.256 
Q46289 
>sp|Q46289|KPYK_CLOPE 
Pyruvate kinase OS=Clostridium 
perfringens (strain 13 / Type A) 
GN=pykF PE=3 SV=2 
52.081 
Q46130 
>sp|Q46130|ABGA_CLOLO 6-
phospho-beta-glucosidase 
54.413 
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OS=Clostridium longisporum 
GN=abgA PE=3 SV=1 
Q3ZWQ1;Q3ZA07;A5FP73 
>sp|Q3ZWQ1|SYL_DEHMC 
Leucine--tRNA ligase 
OS=Dehalococcoides mccartyi 
(strain CBDB1) GN=leuS PE=3 
SV=1;>sp|Q3ZA07|SYL_DEHM
1 Leucine--tRNA ligase 
OS=Dehalococcoides mccartyi 
(strain ATCC BAA-2266 / KCTC 
15142 / 195) GN=leuS PE=3 
SV=1;>sp|A5FP73|SYL_DEHM
B Le 
92.973 
Q3Z8V4;Q3ZX01;A5FRK5 
>sp|Q3Z8V4|RPOB_DEHM1 
DNA-directed RNA polymerase 
subunit beta 
OS=Dehalococcoides mccartyi 
(strain ATCC BAA-2266 / KCTC 
15142 / 195) GN=rpoB PE=3 
SV=1;>sp|Q3ZX01|RPOB_DEH
MC DNA-directed RNA 
polymerase subunit beta 
OS=Dehalococcoides mccartyi 
(strain CBDB1) 
141.36 
Q3Z606;P0A872;P0A871;P0A870;
Q326L3;Q32KB0;K0BE10;Q8FLD1;
Q9S0X4;Q9KLW8;Q8D6H9;Q87GY
5;Q7MDD5;Q6LLF0;Q6D8W0;Q3Y
Z89;Q1H0R4;C3LVN8;B6ERE2;A7
N1Z7;A5F028;Q0I1U0;B0UV30;P0
A869;P0A868;P0A867;Q83QM8;A1
S414;C4K4G2 
>sp|Q3Z606|TAL1_SHISS 
Transaldolase 1 OS=Shigella 
sonnei (strain Ss046) GN=tal1 
PE=3 
SV=1;>sp|P0A872|TALB_SHIFL 
Transaldolase B OS=Shigella 
flexneri GN=talB PE=3 
SV=2;>sp|P0A871|TALB_ECO5
7 Transaldolase B 
OS=Escherichia coli O157:H7 
GN=talB PE=3 SV=2;>sp|P 
35.219 
Q3Z583;A7KGA5;A6TI29;A7ZWZ1;
A7ZI91;Q8X685;B7UJI9;B7N8Q1;B
5Z2P7;P00722;B1J0T5;Q8VNN2;Q
32JB6;B1LIM9;Q8FKG6;Q1RFJ2;Q
0TKT1;A1A831;A8AKB8;A9R0J8;A
1JTC4;Q7CIZ3;Q1CI76;Q1C6T8;A
4TLL5;Q669R9;B2K6E6;B1JI86;A7
FH78 
>sp|Q3Z583|BGAL_SHISS 
Beta-galactosidase OS=Shigella 
sonnei (strain Ss046) GN=lacZ 
PE=3 
SV=1;>sp|A7KGA5|BGAL2_KLE
PN Beta-galactosidase 
OS=Klebsiella pneumoniae 
GN=lacZ PE=3 
SV=1;>sp|A6TI29|BGAL2_KLEP
7 Beta-galactosidase 2 
OS=Klebsiella pneumoniae 
subsp. pn 
116.31 
Q3Z4Z4;Q32JG9;Q325I6;P61718;B
7LMH2;B5Y0X6;B2U4L8;A8AK39;
A6T5E8;Q0TKM6;P61717;P61715;
P61714;C4ZTH2;B7UJN8;B7NJ82;
B7N8W7;B7MQD0;B7MD73;B7M3
Q4;B7L649;B6HZL6;B5Z3R9;B1XF
03;B1LJG5;B1J034;A7ZX67;A7ZIG
8;A7MFG5;B4EU19;A8GAN7;A1JN
S3;Q5PFS8;Q57SE7;P66039;P660
38;C5BCH5;C0Q7U2;B5R6R8;B5Q
>sp|Q3Z4Z4|RISB_SHISS 6,7-
dimethyl-8-ribityllumazine 
synthase OS=Shigella sonnei 
(strain Ss046) GN=ribH PE=3 
SV=1;>sp|Q32JG9|RISB_SHID
S 6,7-dimethyl-8-ribityllumazine 
synthase OS=Shigella 
dysenteriae serotype 1 (strain 
Sd197) GN=ribH PE=3 
SV=1;>sp|Q325I6|R 
16.156 
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TG5;B5FKS2;B5EXF8;B5BDB5;B4
TM97;B4T8Q8;B4SWQ9;B2VHS9;
Q6D848;C6DB33 
Q3Z0G5;Q32EE9;Q323J2;P59401;
Q8X8T3;Q8FG52;P06988 
>sp|Q3Z0G5|HISX_SHISS 
Histidinol dehydrogenase 
OS=Shigella sonnei (strain 
Ss046) GN=hisD PE=3 
SV=1;>sp|Q32EE9|HISX_SHID
S Histidinol dehydrogenase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=hisD PE=3 
SV=1;>sp|Q323J2|HISX_SHIBS 
Histidinol dehydroge 
46.131 
Q3YY77;Q32CD6;Q31XL1;P0A6Q
2;B7LWP5;B2TZF4;Q1R7R4;Q0TE
80;P0A6Q1;P0A6Q0;P0A6P9;C4Z
ZT2;B7UHJ5;B7NV69;B7N715;B7
MZ75;B7MLA0;B7LXJ5;B7LEJ8;B6
I6H5;B5Z3E3;B1XDI9;B1LQB2;B1I
U62;A8A3R4;A7ZQM2;A1AEW7;Q
0T1P7;Q6D182;B2VFY8;C6DDJ5;
Q8ZBN2;Q1CLT2;Q1C3Y6;A9R1D
1;A4TPY1;A8G9W1;Q66ED8;B2K5
61;B1JK09;A7FLZ5;A1JJR4;Q8GE
63;Q6LMT1;A4SRC1;A0KGH3;Q8
DC62;Q87LQ0;Q7MHQ1;A6VR00;
Q7N835;B6EKL8;Q7VNM6;Q0I1Z1
;P57975;B0UV89;Q65VZ7;B3GY00
;B0BQ53;A3N1B9;B8F8L5;A4Y943
;A1RHF3;A6VUU9;Q0VQD6;Q15Q
R6;B4RVU5;Q8EBR0;Q0HXH0;Q0
HL72;A1S4D7;B8E8T1;A9KYH0;A6
WR28;A3D795;Q3IDM2;B8CJP6;Q
9JZ53;Q9JU46;Q886M3;Q5F8Z2;Q
4ZWQ8;Q48F79;Q21LC2;B4RMD8
;A9LZL4;A1KUB6;Q9HXZ5;Q88MF
9;Q4KHF6;Q3KH92;Q39T27;Q1I64
6;Q02RA7;B7V7V4;B7I918;B7H22
7;B3PJB3;B2I2A5;B1JB38;B0KSB9
;A6V1F3;A4XWS1;A3M5Y1;Q12PZ
4;B0VQI4;B0V677;A3QC77;A0KU8
2;Q47WR1;A1SSQ7;Q4FR74;A5W
G13;Q7VIH4;C6E471;B5EGF2;A5
GEW5;Q67SV9;Q5R143;C6BSL8;
B9M3M1;Q2SKX0;Q6FAT9;Q316Q
0;B3E2S8;B1KPT6;B0TK04;A8H1S
5;A8FSS8;Q1MS78;Q086B0;Q1Q9
K6 
>sp|Q3YY77|ENO_SHISS 
Enolase OS=Shigella sonnei 
(strain Ss046) GN=eno PE=3 
SV=1;>sp|Q32CD6|ENO_SHID
S Enolase OS=Shigella 
dysenteriae serotype 1 (strain 
Sd197) GN=eno PE=3 
SV=1;>sp|Q31XL1|ENO_SHIBS 
Enolase OS=Shigella boydii 
serotype 4 (strain Sb227) 
GN=eno 
45.698 
Q3YXD9;Q31WU2;Q0T0H6;P0A8G
5;B7LMX3;Q8XAI7;Q0TD14;P0A8
G4;P0A8G3;C4ZR08;B7UIZ9;B7NJ
V5;B7ND80;B7N095;B7MB25;B7L
ZZ6;B7LH20;B6I464;B5YRY4;B1X
G96;B1LFJ0;B1IRM5;A8A4Q0;A7Z
RX6;A1AG09;B5XTW7;B2U1U1;Q
6D9H0;C6DKE7;Q8ZIC6;Q665N8;
>sp|Q3YXD9|UXAC_SHISS 
Uronate isomerase OS=Shigella 
sonnei (strain Ss046) GN=uxaC 
PE=3 
SV=1;>sp|Q31WU2|UXAC_SHI
BS Uronate isomerase 
OS=Shigella boydii serotype 4 
(strain Sb227) GN=uxaC PE=3 
53.987 
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Q1CMK0;Q1C300;C5BH54;B2K3C
6;B1JL96;A9R1P0;A7FE06;A4THL
9;A1JR25;A8GJX5;Q65V59;Q4QPJ
6;B0URH4;A6VKM8;A5UFL7;Q8Z
M23;Q8Z3R7;Q8D556;Q87FH3;Q7
MBZ3;Q5PMP8;Q57JX8;C0PYB6;
B5RE96;B5QYB2;B5FV01;B5F623;
B5BFV0;B4TVB3;B4THM8;B4T5P8
;A9N4U7;A9MQL9;Q7N9X5 
SV=1;>sp|Q0T0H6|UXAC_SHIF
8 Uronate isomerase 
OS=Shigella flexneri  
Q3YX68;Q32BG2;Q31W50;Q0T0B
0;P59609;B7LR40;B2U204;Q8X9M
0;Q1R6G5;Q0TCT8;P0A6E5;P0A6
E4;C4ZSR2;B7UJ66;B7NKP0;B7N
DF7;B7N0V6;B7MB92;B7M079;B7
LHN6;B6I1P6;B5YS62;B1XGY3;B1
LFS3;B1IQV0;A8A4Y7;A7ZS69;A1
AG76;Q8Z3H5;B5QZW1;B5FI16;B
5F6U1;B4T702;B5XSX1;A8AQ63;A
6TEJ0;A9MP33;P0C1A0;Q65SH4;
Q4QJM0;Q392V6;Q0I4M1;P44315;
B2JP23;B0UW58;A9BM60;A6VN06
;A5UFF8;A5UBF3;Q8XWC1;Q7WK
W7;Q7W7H8;Q7VTJ9;Q6NCS7;Q2
1DC6;Q1BLH4;Q13D88;Q0B4C4;Q
07VN9;P59608;P59607;P57877;C1
F510;C1A3S5;B6JAT0;B4EM48;B3
Q9D3;B2UBA3;B1Z0E2;B1K5H3;A
9IQ90;A4JLD9;A4G3H1;A1VL71;A
0AYH4;Q62EQ4;Q3JWY8;Q2T1W2
;Q12D55;C5CUG9;A3NQI1;A3N4T
7;A3MNB7;A2SK99;A2S7V6;A1V7
X3;Q9JXC1;Q9JWM1;Q8ZLT0;Q5F
5G5;B4TWE1;B4TJ09;B4RQS8;A9
N735;A9M4B1;A6SW90;A3M3K6;A
1KWJ8;B9MBJ2;A4WEY6;A1W9F9
;A6W614;A4FDS0;A1SJJ3;Q06734 
>sp|Q3YX68|ASSY_SHISS 
Argininosuccinate synthase 
OS=Shigella sonnei (strain 
Ss046) GN=argG PE=3 
SV=1;>sp|Q32BG2|ASSY_SHID
S Argininosuccinate synthase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=argG PE=3 
SV=1;>sp|Q31W50|ASSY_SHIB
S Argininosuccinat 
49.928 
Q3YVX7;Q31V09;Q8XDE9;Q8FCA
6;Q0TBJ4;P37689;B1IZH8;A8A677
;A7ZTG6;A1AHE9 
>sp|Q3YVX7|GPMI_SHISS 2,3-
bisphosphoglycerate-
independent phosphoglycerate 
mutase OS=Shigella sonnei 
(strain Ss046) GN=gpmI PE=3 
SV=1;>sp|Q31V09|GPMI_SHIB
S 2,3-bisphosphoglycerate-
independent phosphoglycerate 
mutase OS=Shigella boydii 
serotype 4 (strain Sb 
56.109 
Q3YV62;Q32A80;Q31U74;P0A798;
C4LEQ5;B7LVC9;B5XZ40;B2TVQ8
;A6TGB8;Q8FBD0;Q0TAE8;P0A79
7;P0A796;C5A083;B7UNN6;B7NU
91;B7NFL3;B7N2Q7;B7MI48;B7M6
W7;B7LA13;B6I4Q8;B5YZ53;B1XB
82;B1LNL9;B1IVG3;A8A720;A7ZU
C9;Q9Z6C3;Q9KNP2;Q8K9N0;Q8
DCY1;Q87KX0;Q7MGW6;Q6CZ46;
Q5PIR6;Q57HF3;P65693;P65692;
P59563;P57391;C6DHK2;C5BC26;
>sp|Q3YV62|PFKA_SHISS 
ATP-dependent 6-
phosphofructokinase isozyme 1 
OS=Shigella sonnei (strain 
Ss046) GN=pfkA PE=3 
SV=1;>sp|Q32A80|PFKA_SHID
S ATP-dependent 6-
phosphofructokinase isozyme 1 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=pfkA PE=3 SV=1; 
34.842 
411 
 
 
C0Q414;B8D996;B8D7J8;B5RFA9;
B5QWZ5;B5FPR2;B5F0P6;B5BJI2;
B4TPS6;B4TCK0;B4T049;B2VF62;
A9MZE7;A9MI50;A8AL13;A7MQ83
;A4WG81;Q8ZJL6;Q66GA8;Q1CD
33;Q1C297;C4K7E1;B2JZA3;B1JQ
U4;A9R6A3;A7FCW1;A4TSA7;A1J
HZ3;B8D1K5 
Q3YV16;Q32AB5;Q31U28;Q0SY34
;P59619;B7LUN5;B5XZ16;B2TWF5
;A9MHH3;A8AKW2;A6TGE4;Q8ZK
L6;Q8Z311;Q5PK73;Q57H93;C0Q
476;B5RF45;B5QXQ5;B5FPX5;B5
F0U9;B5BJN4;B4TQH6;B4TCQ6;B
4T0X1;A9N0H0;Q8X730;Q8FB96;
Q1R3V1;Q0TAA0;P11447;C5A0Q9
;B7UNT6;B7NU40;B7NFR0;B7MR5
1;B7MI96;B7M714;B7LA60;B6I5H6
;B5Z062;B1XBC5;B1IVB8;A8A768;
A7ZUH8;A1AID8;A8GL81;A4WG51 
>sp|Q3YV16|ARLY_SHISS 
Argininosuccinate lyase 
OS=Shigella sonnei (strain 
Ss046) GN=argH PE=3 
SV=1;>sp|Q32AB5|ARLY_SHID
S Argininosuccinate lyase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=argH PE=3 
SV=1;>sp|Q31U28|ARLY_SHIB
S Argininosuccinate lyas 
50.23 
Q3YUW0;Q328X7;Q31TX1;B2TX5
0;Q8FB44;Q1R3R3;Q0TA36;P0A6
T2;P0A6T1;C5A0W2;B7UPI6;B7N
RZ0;B7MRF7;B7MJ15;B7M7T4;B7
LAX0;B6I5N7;B5Z0C4;B1XC24;B1
LPI9;B1IUM7;A8A7C4;A7ZUP3;A1
AIK3;B7LKZ8;Q83IN9;Q0SXP3;B7
NFW8;A7MPC2 
>sp|Q3YUW0|G6PI_SHISS 
Glucose-6-phosphate isomerase 
OS=Shigella sonnei (strain 
Ss046) GN=pgi PE=3 
SV=1;>sp|Q328X7|G6PI_SHIDS 
Glucose-6-phosphate isomerase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=pgi PE=3 
SV=1;>sp|Q31TX1|G6PI_SHIBS 
Glucose-6-ph 
61.529 
Q3YUE7;Q328J9;Q31TD1;Q0SX85
;P0A4D2;B7LLY2;B2TY73;Q1R360
;P0A4D1;P0A4D0;C4ZR77;B7UQK
9;B7NTQ6;B7NGD4;B7MST0;B7M
LK5;B7M9G2;B7LCQ6;B6I2A6;B5Z
2K6;B1XDV1;B1LQM0;B1IT06;A8A
7U6;A7ZV71;A1AJA5;P02358 
>sp|Q3YUE7|RS6_SHISS 30S 
ribosomal protein S6 
OS=Shigella sonnei (strain 
Ss046) GN=rpsF PE=3 
SV=1;>sp|Q328J9|RS6_SHIDS 
30S ribosomal protein S6 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=rpsF PE=3 
SV=1;>sp|Q31TD1|RS6_SHIBS 
30S ribosomal protein S 
15.187 
Q3SVL8;Q1QQV5;B6J9Z3;Q6NCH
9;Q2J2Q3;Q21BW8;Q13EG6;Q07V
E4;B3QAG7;Q89XZ3;A5ETA3;A4Y
KZ2 
>sp|Q3SVL8|RL28_NITWN 50S 
ribosomal protein L28 
OS=Nitrobacter winogradskyi 
(strain ATCC 25391 / DSM 
10237 / CIP 104748 / NCIMB 
11846 / Nb-255) GN=rpmB 
PE=3 
SV=1;>sp|Q1QQV5|RL28_NITH
X 50S ribosomal protein L28 
OS=Nitrobacter hamburgensis 
(strain DSM 10229  
10.855 
Q3IIX4 
>sp|Q3IIX4|RS2_PSEHT 30S 
ribosomal protein S2 
OS=Pseudoalteromonas 
26.843 
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haloplanktis (strain TAC 125) 
GN=rpsB PE=3 SV=1 
Q3A4A7 
>sp|Q3A4A7|IF2_PELCD 
Translation initiation factor IF-2 
OS=Pelobacter carbinolicus 
(strain DSM 2380 / NBRC 
103641 / GraBd1) GN=infB 
PE=3 SV=1 
102.91 
Q38WN0 
>sp|Q38WN0|GCH1_LACSS 
GTP cyclohydrolase 1 
OS=Lactobacillus sakei subsp. 
sakei (strain 23K) GN=folE 
PE=3 SV=1 
21.753 
Q38UM4 
>sp|Q38UM4|SYS_LACSS 
Serine--tRNA ligase 
OS=Lactobacillus sakei subsp. 
sakei (strain 23K) GN=serS 
PE=3 SV=1 
47.704 
Q32DE6;A8ADJ2;Q8XBN2;Q8FFC
9;Q1R8W9;Q0TF64;P04805;B6I6U
7;B5YZV2;B1X9R9;B1LMJ5;B1IX6
5;A8A2Q2;A7ZPK7;A1ADS2;Q6D2
06;Q3YZD6;B2TX02;Q83K84;Q5P
NE5;Q57LU0;Q0T2A3;P0A2K4;P0
A2K3;B5RCP1;B5R3U6;B5FQB0;B
5F0E6;B5BB76;B4TQE9;B4TCE7;
B4SZT6;A9N372;A9MIG3;A6TC43;
Q7N6Y2;B4EZQ7;P0C6Q1;A5F649 
>sp|Q32DE6|SYE_SHIDS 
Glutamate--tRNA ligase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=gltX PE=3 
SV=1;>sp|A8ADJ2|SYE_CITK8 
Glutamate--tRNA ligase 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=gltX PE=3 
SV=1;>sp|Q8XBN2|SY 
53.813 
Q327L3;Q31SV6;Q0SX28;P0A6K9;
B7LNS3;B2TZR6;Q1R260;Q0T8T0
;P0A6K8;P0A6K7;P0A6K6;C4ZT65
;B7UR11;B7NW63;B7NH51;B7MT
C9;B7MNJ0;B7LXU5;B7LEM9;B6I6
N0;B5Z4R5;B1XFJ3;B1LEI8;B1IS3
6;A8A8B2;A7ZVS6;A1AJV0;Q3YU
10;Q8DBT0;Q87M24;Q7MI40;A7M
UW4 
>sp|Q327L3|DEOB_SHIDS 
Phosphopentomutase 
OS=Shigella dysenteriae 
serotype 1 (strain Sd197) 
GN=deoB PE=3 
SV=1;>sp|Q31SV6|DEOB_SHIB
S Phosphopentomutase 
OS=Shigella boydii serotype 4 
(strain Sb227) GN=deoB PE=3 
SV=1;>sp|Q0SX28|DEOB_SHIF
8 Phosphopentomutase OS 
44.381 
Q31FN8 
>sp|Q31FN8|FLIE_THICR 
Flagellar hook-basal body 
complex protein FliE 
OS=Thiomicrospira crunogena 
(strain XCL-2) GN=fliE PE=3 
SV=1 
11.978 
Q2SDQ4 
>sp|Q2SDQ4|URED_HAHCH 
Urease accessory protein UreD 
OS=Hahella chejuensis (strain 
KCTC 2396) GN=ureD PE=3 
SV=2 
34.357 
Q2S235 
>sp|Q2S235|RL19_SALRD 50S 
ribosomal protein L19 
OS=Salinibacter ruber (strain 
DSM 13855 / M31) GN=rplS 
PE=3 SV=1 
13.087 
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Q2RKX4 
>sp|Q2RKX4|DNAK_MOOTA 
Chaperone protein DnaK 
OS=Moorella thermoacetica 
(strain ATCC 39073 / JCM 
9320) GN=dnaK PE=3 SV=1 
66.214 
Q2RH96 
>sp|Q2RH96|PCKA2_MOOTA 
Phosphoenolpyruvate 
carboxykinase (ATP) 2 
OS=Moorella thermoacetica 
(strain ATCC 39073 / JCM 
9320) GN=pckA2 PE=3 SV=1 
57.521 
Q2LVS9 
>sp|Q2LVS9|LON_SYNAS Lon 
protease OS=Syntrophus 
aciditrophicus (strain SB) 
GN=lon PE=3 SV=1 
88.438 
Q2JH49 
>sp|Q2JH49|DNAJ_SYNJB 
Chaperone protein DnaJ 
OS=Synechococcus sp. (strain 
JA-2-3Ba(2-13)) GN=dnaJ PE=3 
SV=1 
42.763 
Q2GCD7;Q5NPK5;A5VBZ8 
>sp|Q2GCD7|RPOB_NOVAD 
DNA-directed RNA polymerase 
subunit beta 
OS=Novosphingobium 
aromaticivorans (strain ATCC 
700278 / DSM 12444 / CIP 
105152 / NBRC 16084 / F199) 
GN=rpoB PE=3 
SV=1;>sp|Q5NPK5|RPOB_ZYM
MO DNA-directed RNA 
polymerase subunit beta 
OS=Zymomona 
154.13 
Q215W3 
>sp|Q215W3|GATB_RHOPB 
Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Rhodopseudomonas 
palustris (strain BisB18) 
GN=gatB PE=3 SV=1 
53.377 
Q1R185;Q21CF0;Q2G479 
>sp|Q1R185|KATG_CHRSD 
Catalase-peroxidase 
OS=Chromohalobacter 
salexigens (strain DSM 3043 / 
ATCC BAA-138 / NCIMB 13768) 
GN=katG PE=3 
SV=1;>sp|Q21CF0|KATG_RHO
PB Catalase-peroxidase 
OS=Rhodopseudomonas 
palustris (strain BisB18) 
GN=katG PE=3 
SV=1;>sp|Q2G479|K 
80.004 
Q1QEB6 
>sp|Q1QEB6|ACSA_PSYCK 
Acetyl-coenzyme A synthetase 
OS=Psychrobacter 
cryohalolentis (strain K5) 
GN=acsA PE=3 SV=1 
72.312 
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Q1IPQ9 
>sp|Q1IPQ9|CINAL_KORVE 
CinA-like protein OS=Koribacter 
versatilis (strain Ellin345) 
GN=Acid345_2140 PE=3 SV=1 
45.283 
Q1GBM5;Q04C22 
>sp|Q1GBM5|RPOB_LACDA 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
delbrueckii subsp. bulgaricus 
(strain ATCC 11842 / DSM 
20081 / JCM 1002 / NBRC 
13953 / NCIMB 11778) 
GN=rpoB PE=3 
SV=1;>sp|Q04C22|RPOB_LAC
DB DNA-directed RNA 
polymerase subunit  
135.84 
Q1GBM1;Q04C18 
>sp|Q1GBM1|RS7_LACDA 30S 
ribosomal protein S7 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=rpsG PE=3 
SV=1;>sp|Q04C18|RS7_LACDB 
30S ribosomal protein S7 
OS=Lactobacillus delbrueckii  
17.95 
Q1GBL2;Q04C09;Q5FM84;A8YXL
1;Q9CDW8;Q5M2B9;Q5LXR7;Q03I
F7;Q02W30;P59186;A2RNP9;Q03
4Y9 
>sp|Q1GBL2|RS3_LACDA 30S 
ribosomal protein S3 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=rpsC PE=3 
SV=1;>sp|Q04C09|RS3_LACDB 
30S ribosomal protein S3 
OS=Lactobacillus delbrueckii  
24.853 
Q1GAY0;Q8ENY8 
>sp|Q1GAY0|G6PI_LACDA 
Glucose-6-phosphate isomerase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=pgi PE=3 SV=1 
49.288 
Q1GAR4;Q04B51 
>sp|Q1GAR4|DEF_LACDA 
Peptide deformylase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=def PE=3 
SV=1;>sp|Q04B51|DEF_LACDB 
Peptide deformylase 
OS=Lactobacillus delbrueckii 
subsp. bulg 
20.62 
Q1G937;Q048Y3;B5YJN3;B1GYR7
;P23033;B2S1X8;A9WFA3;Q6MRI
1;A7NMS9;A5US83;B8FM86;Q1D2
S1;Q2IZ16;Q130Z3;Q4FPA5 
>sp|Q1G937|CH60_LACDA 60 
kDa chaperonin 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus (strain ATCC 
57.331 
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11842 / DSM 20081 / JCM 1002 
/ NBRC 13953 / NCIMB 11778) 
GN=groL PE=3 
SV=1;>sp|Q048Y3|CH60_LACD
B 60 kDa chaperonin 
OS=Lactobacillus delbrueckii 
subsp. bulga 
Q1BZE9;A0K4A1 
>sp|Q1BZE9|ZAPD_BURCA 
Cell division protein ZapD 
OS=Burkholderia cenocepacia 
(strain AU 1054) GN=zapD 
PE=3 
SV=1;>sp|A0K4A1|ZAPD_BUR
CH Cell division protein ZapD 
OS=Burkholderia cenocepacia 
(strain HI2424) GN=zapD PE=3 
SV=1 
28.934 
Q1BEM5;A3PTW3;A1UAA8 
>sp|Q1BEM5|ACKA_MYCSS 
Acetate kinase 
OS=Mycobacterium sp. (strain 
MCS) GN=ackA PE=3 
SV=1;>sp|A3PTW3|ACKA_MYC
SJ Acetate kinase 
OS=Mycobacterium sp. (strain 
JLS) GN=ackA PE=3 
SV=1;>sp|A1UAA8|ACKA_MYC
SK Acetate kinase 
OS=Mycobacterium sp. (strain 
KMS) GN=ackA 
42.76 
Q18C83 
>sp|Q18C83|ILVC_PEPD6 
Ketol-acid reductoisomerase 
(NADP(+)) OS=Peptoclostridium 
difficile (strain 630) GN=ilvC 
PE=3 SV=1 
36.877 
Q18B36;B1GZX0 
>sp|Q18B36|ACKA_PEPD6 
Acetate kinase 
OS=Peptoclostridium difficile 
(strain 630) GN=ackA PE=3 
SV=1 
43.32 
Q189R8 
>sp|Q189R8|FOLD_PEPD6 
Bifunctional protein FolD 
OS=Peptoclostridium difficile 
(strain 630) GN=folD PE=3 
SV=2 
30.913 
Q186R1 
>sp|Q186R1|THIG_PEPD6 
Thiazole synthase 
OS=Peptoclostridium difficile 
(strain 630) GN=thiG PE=3 
SV=1 
27.558 
Q186R0 
>sp|Q186R0|THIC_PEPD6 
Phosphomethylpyrimidine 
synthase OS=Peptoclostridium 
difficile (strain 630) GN=thiC 
PE=3 SV=1 
48.45 
Q184E4 
>sp|Q184E4|VATD_PEPD6 V-
type ATP synthase subunit D 
OS=Peptoclostridium difficile 
25.585 
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(strain 630) GN=atpD PE=3 
SV=1 
Q17ZY4;A8DEZ8 
>sp|Q17ZY4|PRAC_PEPD6 
Proline racemase 
OS=Peptoclostridium difficile 
(strain 630) GN=CD630_32370 
PE=3 
SV=1;>sp|A8DEZ8|PRAC_CLO
DI Proline racemase 
OS=Clostridioides difficile PE=1 
SV=1 
36.22 
Q165D5;Q1IE16;B0KUG0;A8F679;
Q51390 
>sp|Q165D5|GLPK_ROSDO 
Glycerol kinase 
OS=Roseobacter denitrificans 
(strain ATCC 33942 / OCh 114) 
GN=glpK PE=3 
SV=1;>sp|Q1IE16|GLPK_PSEE
4 Glycerol kinase 
OS=Pseudomonas entomophila 
(strain L48) GN=glpK PE=3 
SV=1;>sp|B0KUG0|GLPK_PSE
PG Glycerol kinase OS=Pseu 
53.685 
Q12MB3 
>sp|Q12MB3|PEPE_SHEDO 
Peptidase E OS=Shewanella 
denitrificans (strain OS217 / 
ATCC BAA-1090 / DSM 15013) 
GN=pepE PE=3 SV=1 
25.833 
Q11QQ3 
>sp|Q11QQ3|MDH_CYTH3 
Malate dehydrogenase 
OS=Cytophaga hutchinsonii 
(strain ATCC 33406 / NCIMB 
9469) GN=mdh PE=3 SV=1 
33.35 
Q10744;Q48543 
>sp|Q10744|PEPC_LACHE 
Aminopeptidase C 
OS=Lactobacillus helveticus 
GN=pepC PE=3 SV=1 
51.399 
Q10730 
>sp|Q10730|AMPN_LACHE 
Aminopeptidase N 
OS=Lactobacillus helveticus 
GN=pepN PE=3 SV=1 
95.836 
Q0VQE1 
>sp|Q0VQE1|ACCA_ALCBS 
Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit 
alpha OS=Alcanivorax 
borkumensis (strain ATCC 
700651 / DSM 11573 / NCIMB 
13689 / SK2) GN=accA PE=3 
SV=1 
35.718 
Q0I2M9;B0UTU8 
>sp|Q0I2M9|SYN_HAES1 
Asparagine--tRNA ligase 
OS=Haemophilus somnus 
(strain 129Pt) GN=asnS PE=3 
SV=1;>sp|B0UTU8|SYN_HISS2 
Asparagine--tRNA ligase 
OS=Histophilus somni (strain 
2336) GN=asnS PE=3 SV=1 
52.796 
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Q0HVI0 
>sp|Q0HVI0|CHEB2_SHESR 
Chemotaxis response regulator 
protein-glutamate 
methylesterase 2 
OS=Shewanella sp. (strain MR-
7) GN=cheB2 PE=3 SV=1 
37.905 
Q0BIM8 
>sp|Q0BIM8|TRPC_BURCM 
Indole-3-glycerol phosphate 
synthase OS=Burkholderia 
ambifaria (strain ATCC BAA-244 
/ AMMD) GN=trpC PE=3 SV=1 
28.551 
Q0AYS2 
>sp|Q0AYS2|SYH_SYNWW 
Histidine--tRNA ligase 
OS=Syntrophomonas wolfei 
subsp. wolfei (strain DSM 2245B 
/ Goettingen) GN=hisS PE=3 
SV=1 
48.266 
Q0AVM3 
>sp|Q0AVM3|THLA_SYNWW 
Acetyl-CoA acetyltransferase 
OS=Syntrophomonas wolfei 
subsp. wolfei (strain DSM 2245B 
/ Goettingen) GN=Swol_1934 
PE=1 SV=1 
41.282 
Q0AVM1;P52046 
>sp|Q0AVM1|CRCH_SYNWW 
Crotonyl-CoA hydratase 
OS=Syntrophomonas wolfei 
subsp. wolfei (strain DSM 2245B 
/ Goettingen) GN=Swol_1936 
PE=1 
SV=1;>sp|P52046|CRT_CLOAB 
Short-chain-enoyl-CoA 
hydratase OS=Clostridium 
acetobutylicum (strain ATCC 
824 / DSM 792 / JCM 1 
27.944 
Q08518;Q9KUW5;P0A699;P0A196
;P0A195;Q9JUS4;Q9JZP1;Q50968
;Q8X5U9;Q8FB02;P0A698;Q8DCJ
3;Q87LA0;Q7MHB5;Q7VLW2;P579
79;Q88QK7;Q9HWG0;Q8ZJ07;O51
777;Q9PAR9;Q87BK9;Q8PN26;Q8
PBH3;Q829X3;Q9Z507 
>sp|Q08518|UVRA_VITST 
UvrABC system protein A 
(Fragment) OS=Vitreoscilla 
stercoraria GN=uvrA PE=3 
SV=1;>sp|Q9KUW5|UVRA_VIB
CH UvrABC system protein A 
OS=Vibrio cholerae serotype O1 
(strain ATCC 39315 / El Tor 
Inaba N16961) GN=uvrA PE=3 
SV=1;>sp|P0A699|UVRA_ 
61.917 
Q06879 
>sp|Q06879|NIFJ_NOSS1 
Pyruvate-flavodoxin 
oxidoreductase OS=Nostoc sp. 
(strain PCC 7120 / SAG 25.82 / 
UTEX 2576) GN=nifJ PE=2 
SV=2 
132.17 
Q05619;B2UYH0;B2TIN4;B8DFV8;
Q45829;Q890U0;Q0TMV4;Q0SQK
0;P0C2D8 
>sp|Q05619|BUK_CLOB8 
Butyrate kinase OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=buk PE=3 
SV=1;>sp|B2UYH0|BUK_CLOB
A Probable butyrate kinase 
OS=Clostridium botulinum 
38.433 
418 
 
 
(strain Alaska E43 / Type E3) 
GN=buk PE=3 
SV=1;>sp|B2TIN4|BUK_CLOBB 
Pr 
Q05203;P80583;P02968 
>sp|Q05203|FLA_BACHD 
Flagellin OS=Bacillus 
halodurans (strain ATCC BAA-
125 / DSM 18197 / FERM 7344 / 
JCM 9153 / C-125) GN=hag 
PE=1 
SV=1;>sp|P80583|FLA_CLOTY 
Flagellin (Fragment) 
OS=Clostridium tyrobutyricum 
GN=fla PE=1 
SV=2;>sp|P02968|FLA_BACSU 
Flagellin O 
30.009 
Q05097 
>sp|Q05097|PA1L_PSEAE PA-I 
galactophilic lectin 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=lecA PE=1 
SV=2 
12.893 
Q04EV5 
>sp|Q04EV5|ARCA_OENOB 
Arginine deiminase 
OS=Oenococcus oeni (strain 
ATCC BAA-331 / PSU-1) 
GN=arcA PE=3 SV=1 
46.721 
Q043G9;Q74JA9;P54262;Q88Y40 
>sp|Q043G9|SYN_LACGA 
Asparagine--tRNA ligase 
OS=Lactobacillus gasseri (strain 
ATCC 33323 / DSM 20243 / 
JCM 1131 / NCIMB 11718 / 
AM63) GN=asnS PE=3 
SV=1;>sp|Q74JA9|SYN_LACJO 
Asparagine--tRNA ligase 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 
50.282 
Q03E93 
>sp|Q03E93|RNY2_PEDPA 
Ribonuclease Y 2 
OS=Pediococcus pentosaceus 
(strain ATCC 25745 / CCUG 
21536 / LMG 10740 / 183-1w) 
GN=rny2 PE=3 SV=1 
58.703 
Q03D47;B3W6R4 
>sp|Q03D47|RS6_LACP3 30S 
ribosomal protein S6 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=rpsF PE=3 
SV=1;>sp|B3W6R4|RS6_LACC
B 30S ribosomal protein S6 
OS=Lactobacillus casei (strain 
BL23) GN=rpsF PE=3  
11.572 
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Q03CR5;B3W7C1 
>sp|Q03CR5|DDL_LACP3 D-
alanine--D-alanine ligase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=ddl PE=3 
SV=1;>sp|B3W7C1|DDL_LACC
B D-alanine--D-alanine ligase 
OS=Lactobacillus casei (strain 
BL23) GN=ddl P 
39.02 
Q03AF5;B3WD20 
>sp|Q03AF5|Y1022_LACP3 
Probable transcriptional 
regulatory protein LSEI_1022 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=LSEI_1022 
PE=3 
SV=1;>sp|B3WD20|Y1186_LAC
CB Probable transcriptional 
regulatory p 
27.106 
Q03AC0;B3WD57 
>sp|Q03AC0|GATA_LACP3 
Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=gatA PE=3 
SV=1;>sp|B3WD57|GATA_LAC
CB Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Lac 
51.332 
Q03A25;B3WDL1;Q93CX7;Q38WJ
8 
>sp|Q03A25|UPP_LACP3 Uracil 
phosphoribosyltransferase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=upp PE=3 
SV=1;>sp|B3WDL1|UPP_LACC
B Uracil 
phosphoribosyltransferase 
OS=Lactobacillus casei (strain 
BL23 
22.808 
Q039P0;B3WE10 
>sp|Q039P0|Y1299_LACP3 
UPF0356 protein LSEI_1299 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=LSEI_1299 
PE=3 
SV=1;>sp|B3WE10|Y1530_LAC
CB UPF0356 protein 
LCABL_15300 
OS=Lactobacillus casei (strain 
BL23)  
8.2653 
Q038N3;B3WEQ7;P17820 
>sp|Q038N3|DNAK_LACP3 
Chaperone protein DnaK 
67.563 
420 
 
 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=dnaK PE=3 
SV=1;>sp|B3WEQ7|DNAK_LAC
CB Chaperone protein DnaK 
OS=Lactobacillus casei (strain 
BL23) GN=dnaK PE=3 SV 
Q038L5;B3WES5;Q38W67;A8YVR
6 
>sp|Q038L5|RRF_LACP3 
Ribosome-recycling factor 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=frr PE=3 
SV=1;>sp|B3WES5|RRF_LACC
B Ribosome-recycling factor 
OS=Lactobacillus casei (strain 
BL23) GN=frr PE=3  
20.593 
Q035V6;B3WA01 
>sp|Q035V6|RL7_LACP3 50S 
ribosomal protein L7/L12 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=rplL PE=3 
SV=1;>sp|B3WA01|RL7_LACC
B 50S ribosomal protein L7/L12 
OS=Lactobacillus casei (strain 
BL23) GN=rp 
12.518 
Q034Z7;B3WAK4 
>sp|Q034Z7|RS8_LACP3 30S 
ribosomal protein S8 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=rpsH PE=3 
SV=1;>sp|B3WAK4|RS8_LACC
B 30S ribosomal protein S8 
OS=Lactobacillus casei (strain 
BL23) GN=rpsH PE=3  
14.774 
Q03234;Q03A18;B3WDL8;Q04G20
;A7I177;Q7VJ21;A6QB59;P41168;
Q2GD08;A0LDA0;O67828;O50292;
Q2GKK8;Q5PAN2;A9H9A8;Q2RZV
3;Q1AVH9;Q5HB71;Q5FGY3;Q3Y
S09;Q2GGP9;Q6G1W9;Q6FYM3 
>sp|Q03234|ATPB_LACCA ATP 
synthase subunit beta 
OS=Lactobacillus casei 
GN=atpD PE=3 
SV=1;>sp|Q03A18|ATPB_LACP
3 ATP synthase subunit beta 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441) GN=atpD PE=3 
SV=1;>sp|B 
51.456 
Q02RC7;O82851;B7V7F8;A6V1D3;
C1DSU5 
>sp|Q02RC7|EFTS_PSEAB 
Elongation factor Ts 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=tsf 
PE=3 
SV=1;>sp|O82851|EFTS_PSEA
E Elongation factor Ts 
OS=Pseudomonas aeruginosa 
30.653 
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(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
10 
Q02PG5 
>sp|Q02PG5|GAP2_PSEAB 
Glyceraldehyde-3-phosphate 
dehydrogenase-like protein 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=gap2 
PE=1 SV=1 
50.082 
Q02NB5;Q9ZH99 
>sp|Q02NB5|IDH_PSEAB 
Isocitrate dehydrogenase 
[NADP] OS=Pseudomonas 
aeruginosa (strain UCBPP-
PA14) GN=icd PE=1 
SV=1;>sp|Q9ZH99|IDH_COXB
U Isocitrate dehydrogenase 
[NADP] OS=Coxiella burnetii 
(strain RSA 493 / Nine Mile 
phase I) GN=icd PE=1 SV=1 
45.577 
Q02KR1 
>sp|Q02KR1|PPSA_PSEAB 
Phosphoenolpyruvate synthase 
OS=Pseudomonas aeruginosa 
(strain UCBPP-PA14) GN=ppsA 
PE=1 SV=1 
85.816 
Q02K94 
>sp|Q02K94|FABB_PSEAB 3-
oxoacyl-[acyl-carrier-protein] 
synthase 1 OS=Pseudomonas 
aeruginosa (strain UCBPP-
PA14) GN=fabB PE=1 SV=1 
42.878 
Q02E40;P26276 
>sp|Q02E40|ALGC_PSEAB 
Phosphomannomutase/phospho
glucomutase OS=Pseudomonas 
aeruginosa (strain UCBPP-
PA14) GN=algC PE=1 
SV=2;>sp|P26276|ALGC_PSEA
E 
Phosphomannomutase/phospho
glucomutase OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 /  
50.295 
Q022G3 
>sp|Q022G3|OBG_SOLUE 
GTPase Obg OS=Solibacter 
usitatus (strain Ellin6076) 
GN=obg PE=3 SV=1 
36.446 
Q01770;A8ZYF3;P31101;Q97DP4;
Q898N5 
>sp|Q01770|HCP_DESDA 
Hydroxylamine reductase 
OS=Desulfovibrio desulfuricans 
(strain ATCC 27774 / DSM 
6949) GN=hcp PE=1 
SV=2;>sp|A8ZYF3|HCP_DESO
H Hydroxylamine reductase 
OS=Desulfococcus oleovorans 
(strain DSM 6200 / Hxd3) 
GN=hcp PE=3 
SV=1;>sp|P31101|HCP_DE 
58.659 
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Q01234 
>sp|Q01234|NFSB_ENTCL 
Oxygen-insensitive NAD(P)H 
nitroreductase OS=Enterobacter 
cloacae GN=nfsB PE=1 SV=1 
23.95 
Q00767;P40171;Q82DI5;A4J8H4 
>sp|Q00767|CH601_STRAL 60 
kDa chaperonin 1 
OS=Streptomyces albus G 
GN=groL1 PE=1 
SV=3;>sp|P40171|CH601_STR
CO 60 kDa chaperonin 1 
OS=Streptomyces coelicolor 
(strain ATCC BAA-471 / A3(2) / 
M145) GN=groL1 PE=3 
SV=3;>sp|Q82DI5|CH601_STR
AW 60 kDa chaperonin 1 O 
56.715 
P9WQH7;P9WQH6 
>sp|P9WQH7|PCC5_MYCTU 
Probable propionyl-CoA 
carboxylase beta chain 5 
OS=Mycobacterium tuberculosis 
(strain ATCC 25618 / H37Rv) 
GN=accD5 PE=1 
SV=1;>sp|P9WQH6|PCC5_MY
CTO Probable propionyl-CoA 
carboxylase beta chain 5 
OS=Mycobacterium tuberculosis 
(strain C 
59.354 
P9WGW5;P9WGW4;P59975 
>sp|P9WGW5|RTCB_MYCTU 
RNA-splicing ligase RtcB 
OS=Mycobacterium tuberculosis 
(strain ATCC 25618 / H37Rv) 
GN=rtcB PE=2 
SV=1;>sp|P9WGW4|RTCB_MY
CTO RNA-splicing ligase RtcB 
OS=Mycobacterium tuberculosis 
(strain CDC 1551 / Oshkosh) 
GN=rtcB PE=2 
SV=1;>sp|P59975 
45.527 
P94870;P94869 
>sp|P94870|PEPE_LACHE 
Aminopeptidase E 
OS=Lactobacillus helveticus 
GN=pepE PE=1 SV=1 
50.022 
P85098;Q83RN5;P11349 
>sp|P85098|NARH_BRASZ 
Respiratory nitrate reductase 
beta chain (Fragments) 
OS=Bradyrhizobium sp. 
GN=narH PE=1 
SV=1;>sp|Q83RN5|NARH_SHIF
L Respiratory nitrate reductase 1 
beta chain OS=Shigella flexneri 
GN=narH PE=3 
SV=1;>sp|P11349|NARH_ECOL
I Respiratory nit 
29.401 
P83513 
>sp|P83513|XY11A_PSEXY 
Bifunctional 
xylanase/deacetylase 
OS=Pseudobutyrivibrio 
65.922 
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xylanivorans GN=xyn11A PE=1 
SV=2 
P81284 
>sp|P81284|CH60_TANFO 60 
kDa chaperonin OS=Tannerella 
forsythia GN=groL PE=1 SV=3 
57.971 
P80019;Q88VY1 
>sp|P80019|PFKA_LACDE 
ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus delbrueckii 
subsp. bulgaricus GN=pfkA 
PE=1 
SV=2;>sp|Q88VY1|PFKA_LACP
L ATP-dependent 6-
phosphofructokinase 
OS=Lactobacillus plantarum 
(strain ATCC BAA-793 / NCIMB 
8826 / WCFS1) GN=pf 
34.008 
P76558;P43837 
>sp|P76558|MAO2_ECOLI 
NADP-dependent malic enzyme 
OS=Escherichia coli (strain K12) 
GN=maeB PE=1 SV=1 
82.416 
P76513 
>sp|P76513|YFDQ_ECOLI 
Uncharacterized protein YfdQ 
OS=Escherichia coli (strain K12) 
GN=yfdQ PE=4 SV=1 
30.442 
P76177 
>sp|P76177|YDGH_ECOLI 
Protein YdgH OS=Escherichia 
coli (strain K12) GN=ydgH PE=1 
SV=1 
33.903 
P76149 
>sp|P76149|SAD_ECOLI 
Succinate semialdehyde 
dehydrogenase [NAD(P)+] Sad 
OS=Escherichia coli (strain K12) 
GN=sad PE=1 SV=2 
49.717 
P76002 
>sp|P76002|PLIG_ECOLI 
Inhibitor of g-type lysozyme 
OS=Escherichia coli (strain K12) 
GN=pliG PE=1 SV=1 
14.906 
P73313;B7K241;B1WQR7;Q8DMM
5;Q18CG4;B1I1J5;B0TC63;A6LPR
8;Q250M5;B8I7Y6;B8G1X3;A3DJH
9;Q97EI5;C3KVP4;C1FMU4;B9MK
H4;B9DYB6;B1KSL8;B1IGE7;A8M
LE7;A7GJ67;A7FZ62;A5N4Q4;A5I
7J9;A4XLS3;A0PXV3 
>sp|P73313|RL16_SYNY3 50S 
ribosomal protein L16 
OS=Synechocystis sp. (strain 
PCC 6803 / Kazusa) GN=rplP 
PE=3 
SV=1;>sp|B7K241|RL16_CYAP
8 50S ribosomal protein L16 
OS=Cyanothece sp. (strain PCC 
8801) GN=rplP PE=3 
SV=1;>sp|B1WQR7|RL16_CYA
A5 50S ribosomal prot 
16.035 
P72173 
>sp|P72173|AAT_PSEAE 
Aspartate aminotransferase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=aspC PE=3 
SV=2 
43.319 
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P71296 
>sp|P71296|YAGM_ECOLI 
Uncharacterized protein YagM 
OS=Escherichia coli (strain K12) 
GN=yagM PE=4 SV=1 
32.678 
P69912;P69911;P69910;P69909;P
69908;Q83PR1;Q8FHG5;P58228 
>sp|P69912|DCEB_SHIFL 
Glutamate decarboxylase beta 
OS=Shigella flexneri GN=gadB 
PE=3 
SV=1;>sp|P69911|DCEB_ECO5
7 Glutamate decarboxylase beta 
OS=Escherichia coli O157:H7 
GN=gadB PE=3 
SV=1;>sp|P69910|DCEB_ECOL
I Glutamate decarboxylase beta 
OS=Escherichia col 
52.668 
P69800;P69799;P69798;P69797 
>sp|P69800|PTNAB_SHIFL 
PTS system mannose-specific 
EIIAB component OS=Shigella 
flexneri GN=manX PE=3 
SV=2;>sp|P69799|PTNAB_ECO
57 PTS system mannose-
specific EIIAB component 
OS=Escherichia coli O157:H7 
GN=manX PE=3 
SV=2;>sp|P69798|PTNAB_ECO
L6 PTS system man 
35.047 
P67271;P67270;P0AFP8;P0AFP7;
P0AFP6 
>sp|P67271|GCH1L_SALTI 
GTP cyclohydrolase 1 type 2 
homolog OS=Salmonella typhi 
GN=ybgI PE=3 
SV=1;>sp|P67270|GCH1L_SAL
TY GTP cyclohydrolase 1 type 2 
homolog OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=ybgI PE=3 
SV=1;>sp|P0AFP8|GCH1L_E 
26.945 
P67094;P67093 
>sp|P67094|USPG_SALTI 
Universal stress protein G 
OS=Salmonella typhi GN=uspG 
PE=3 
SV=1;>sp|P67093|USPG_SALT
Y Universal stress protein G 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=uspG PE=3 SV=1 
15.901 
P67092;P67091;P0A4P8;P9WFD5;
P9WFD4;Q0TI19;P37903;P0A4P7;
P0A4P6 
>sp|P67092|USPF_SALTI 
Universal stress protein F 
OS=Salmonella typhi GN=uspF 
PE=3 
SV=1;>sp|P67091|USPF_SALT
Y Universal stress protein F 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=uspF PE=1 
SV=1;>sp|P0A4P8|USPF_SHIF
L Universal stress 
15.714 
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P65809;P65808;P65807 
>sp|P65809|YGEY_ECO57 
Uncharacterized protein YgeY 
OS=Escherichia coli O157:H7 
GN=ygeY PE=3 
SV=1;>sp|P65808|YGEY_ECOL
6 Uncharacterized protein YgeY 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=ygeY PE=3 
SV=1;>sp|P65807|YGEY_ECOL
I Uncha 
44.803 
P65765;P65764;P45523 
>sp|P65765|FKBA_ECO57 
FKBP-type peptidyl-prolyl cis-
trans isomerase FkpA 
OS=Escherichia coli O157:H7 
GN=fkpA PE=3 
SV=1;>sp|P65764|FKBA_ECOL
6 FKBP-type peptidyl-prolyl cis-
trans isomerase FkpA 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) G 
28.912 
P65749;P65748;Q8FAG0;P0A7B0;
P0A7A9 
>sp|P65749|IPYR_SALTI 
Inorganic pyrophosphatase 
OS=Salmonella typhi GN=ppa 
PE=3 
SV=2;>sp|P65748|IPYR_SALTY 
Inorganic pyrophosphatase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ppa PE=3 
SV=2;>sp|Q8FAG0|IPYR_ECOL
6 Inorganic pyrophosph 
19.676 
P63412;P63411;P0A6A5;P0A6A4;
P0A6A3;A7MH28;A8GH24;Q9KT0
7;Q8ZDJ6;Q7N2I1;Q6D2Q6;Q668Z
0;Q1CHP3;Q1C6A1;B4EZD9;B2VI
P6;B2K830;B1JGK4;A9R6M9;A7F
GP4;A4TM44;Q8DAH8;Q87MZ4;Q
7MJM8;Q6LNF6;Q5E6L4;B1KJX4;
A8H356;A7MVE1;A3QFL1;Q8ED5
5;Q0HWE9;Q0HK48;A0KVG7;Q2N
SJ4;Q1LT88;Q080J4;C6DA54;A4Y
819;A1RIH0 
>sp|P63412|ACKA_SALTI 
Acetate kinase OS=Salmonella 
typhi GN=ackA PE=3 
SV=1;>sp|P63411|ACKA_SALT
Y Acetate kinase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ackA PE=1 
SV=1;>sp|P0A6A5|ACKA_ECO
57 Acetate kinase 
OS=Escherichia coli O157: 
43.257 
P61342;A4QDM0 
>sp|P61342|GATB_CORDI 
Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subunit B 
OS=Corynebacterium 
diphtheriae (strain ATCC 
700971 / NCTC 13129 / Biotype 
gravis) GN=gatB PE=3 
SV=1;>sp|A4QDM0|GATB_CO
RGB Aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase subu 
54.614 
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P58581;P58580;Q83Q91;P58582;P
58578;Q8FE30;P04425 
>sp|P58581|GSHB_SALTI 
Glutathione synthetase 
OS=Salmonella typhi GN=gshB 
PE=3 
SV=1;>sp|P58580|GSHB_SALT
Y Glutathione synthetase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=gshB PE=3 
SV=1;>sp|Q83Q91|GSHB_SHIF
L Glutathione synthetase O 
35.379 
P57958;P57927 
>sp|P57958|TKT2_PASMU 
Transketolase 2 OS=Pasteurella 
multocida (strain Pm70) 
GN=tktB PE=3 
SV=1;>sp|P57927|TKT1_PASM
U Transketolase 1 
OS=Pasteurella multocida 
(strain Pm70) GN=tktA PE=3 
SV=1 
73.354 
P57508;P0A3B4;Q8K9C8;P44910;
P32132;P0A3B3;P0A3B2;P0A3B1;
Q89AC9;O07631 
>sp|P57508|TYPA_BUCAI GTP-
binding protein TypA/BipA 
homolog OS=Buchnera 
aphidicola subsp. Acyrthosiphon 
pisum (strain APS) GN=typA 
PE=3 
SV=1;>sp|P0A3B4|TYPA_SHIF
L GTP-binding protein 
TypA/BipA OS=Shigella flexneri 
GN=typA PE=3 
SV=1;>sp|Q8K9C8|TYPA_BUC
AP GT 
68.506 
P54334 
>sp|P54334|XKDO_BACSU 
Phage-like element PBSX 
protein XkdO OS=Bacillus 
subtilis (strain 168) GN=xkdO 
PE=4 SV=2 
145.22 
P54298;A7MRY3 
>sp|P54298|LUXM_VIBHA Acyl-
homoserine-lactone synthase 
LuxM OS=Vibrio harveyi 
GN=luxM PE=1 
SV=2;>sp|A7MRY3|LUXM_VIB
CB Acyl-homoserine-lactone 
synthase LuxM OS=Vibrio 
campbellii (strain ATCC BAA-
1116 / BB120) GN=luxM PE=3 
SV=1 
46.371 
P54226;E3VWI2 
>sp|P54226|G3P1_STRAE 
Glyceraldehyde-3-phosphate 
dehydrogenase 1 
OS=Streptomyces arenae 
GN=gap1 PE=1 
SV=1;>sp|E3VWI2|G3P2_STRA
E Glyceraldehyde-3-phosphate 
dehydrogenase 2 
OS=Streptomyces arenae 
GN=gap2 PE=1 SV=1 
34.945 
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P53578 
>sp|P53578|FIXB_CLOSA 
Protein FixB OS=Clostridium 
saccharobutylicum GN=fixB 
PE=3 SV=1 
35.68 
P53381 
>sp|P53381|APBC_CLOPE 
Iron-sulfur cluster carrier protein 
OS=Clostridium perfringens 
(strain 13 / Type A) GN=mrp 
PE=3 SV=2 
30.835 
P52937;P52936 
>sp|P52937|SP0A_CLOBU 
Stage 0 sporulation protein A 
homolog (Fragment) 
OS=Clostridium butyricum 
GN=spo0A PE=3 
SV=1;>sp|P52936|SP0A_CLOB
8 Stage 0 sporulation protein A 
homolog OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=spo0A PE=3 
SV=2 
18.134 
P52662;Q8VWE6;P36771 
>sp|P52662|PECT_DICD3 HTH-
type transcriptional regulator 
PecT OS=Dickeya dadantii 
(strain 3937) GN=pecT PE=4 
SV=1;>sp|Q8VWE6|LRHA_ECO
57 Probable HTH-type 
transcriptional regulator LrhA 
OS=Escherichia coli O157:H7 
GN=lrhA PE=3 
SV=1;>sp|P36771|LRHA_ECOL
I Pro 
34.756 
P51591 
>sp|P51591|RUBY_CLOPE 
Rubrerythrin OS=Clostridium 
perfringens (strain 13 / Type A) 
GN=rbr PE=3 SV=2 
22.158 
P51181;P80885 
>sp|P51181|KPYK_BACLI 
Pyruvate kinase OS=Bacillus 
licheniformis GN=pyk PE=3 
SV=1;>sp|P80885|KPYK_BACS
U Pyruvate kinase OS=Bacillus 
subtilis (strain 168) GN=pyk 
PE=1 SV=2 
61.942 
P47234 
>sp|P47234|LACY_CITFR 
Lactose permease 
OS=Citrobacter freundii 
GN=lacY PE=3 SV=1 
46.537 
P45511 
>sp|P45511|GLDA_CITFR 
Glycerol dehydrogenase 
OS=Citrobacter freundii 
GN=dhaD PE=1 SV=1 
39.018 
P45361 
>sp|P45361|CRT_CLODI Short-
chain-enoyl-CoA hydratase 
(Fragment) OS=Clostridioides 
difficile GN=crt PE=3 SV=1 
16.581 
P44271 
>sp|P44271|Y1603_HAEIN 
UPF0111 protein HI_1603 
OS=Haemophilus influenzae 
26.482 
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(strain ATCC 51907 / DSM 
11121 / KW20 / Rd) 
GN=HI_1603 PE=1 SV=1 
P43099;P44317;P21169;P24169 
>sp|P43099|DCOR_LACS3 
Inducible ornithine 
decarboxylase 
OS=Lactobacillus sp. (strain 
30a) GN=odcI PE=1 SV=2 
82.687 
P42953 
>sp|P42953|TAGG_BACSU 
Teichoic acid translocation 
permease protein TagG 
OS=Bacillus subtilis (strain 168) 
GN=tagG PE=1 SV=1 
32.184 
P41576;P37754;P41583;P41577;P
41575 
>sp|P41576|6PGD_KLEPN 6-
phosphogluconate 
dehydrogenase, decarboxylating 
OS=Klebsiella pneumoniae 
GN=gnd PE=3 
SV=2;>sp|P37754|6PGD9_ECO
LX 6-phosphogluconate 
dehydrogenase, decarboxylating 
OS=Escherichia coli GN=gnd 
PE=3 SV=1 
51.327 
P40947;Q8K933;P57610;P28046 
>sp|P40947|SSB_PSEAE 
Single-stranded DNA-binding 
protein OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=ssb PE=1 
SV=3;>sp|Q8K933|SSB_BUCA
P Single-stranded DNA-binding 
protein OS=Buchn 
18.557 
P40720;Q8X4P8;P0AC34;P0AC33 
>sp|P40720|FUMA_SALTY 
Fumarate hydratase class I, 
aerobic OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=fumA PE=3 
SV=3;>sp|Q8X4P8|FUMA_ECO
57 Fumarate hydratase class I, 
aerobic OS=Escherichia coli 
O157:H7 GN=fumA PE=3 
SV=3;>sp|P0AC34|F 
63.824 
P39384 
>sp|P39384|YJIM_ECOLI 
Putative dehydratase subunit 
YjiM OS=Escherichia coli (strain 
K12) GN=yjiM PE=3 SV=2 
42.742 
P39364 
>sp|P39364|SGCQ_ECOLI 
Putative sgc region protein 
SgcQ OS=Escherichia coli 
(strain K12) GN=sgcQ PE=3 
SV=1 
29.354 
P39325 
>sp|P39325|YTFQ_ECOLI ABC 
transporter periplasmic-binding 
protein YtfQ OS=Escherichia 
34.344 
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coli (strain K12) GN=ytfQ PE=1 
SV=1 
P39265 
>sp|P39265|ALSB_ECOLI D-
allose-binding periplasmic 
protein OS=Escherichia coli 
(strain K12) GN=alsB PE=1 
SV=1 
32.91 
P37902 
>sp|P37902|GLTI_ECOLI 
Glutamate/aspartate import 
solute-binding protein 
OS=Escherichia coli (strain K12) 
GN=gltI PE=1 SV=2 
33.42 
P37798 
>sp|P37798|ACCC_PSEAE 
Biotin carboxylase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=accC PE=1 
SV=1 
48.887 
P37755 
>sp|P37755|RFBK9_ECOLX 
Phosphomannomutase 
OS=Escherichia coli GN=manB 
PE=3 SV=1 
50.423 
P37647;E0J5J4 
>sp|P37647|KDGK_ECOLI 2-
dehydro-3-deoxygluconokinase 
OS=Escherichia coli (strain K12) 
GN=kdgK PE=1 
SV=1;>sp|E0J5J4|KDGK_ECOL
W 2-dehydro-3-
deoxygluconokinase 
OS=Escherichia coli (strain 
ATCC 9637 / CCM 2024 / DSM 
1116 / NCIMB 8666 / NRRL B-
766 / W) GN=kdgK  
33.962 
P37450 
>sp|P37450|PDUC_SALTY 
Propanediol dehydratase large 
subunit OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=pduC PE=1 SV=3 
60.362 
P37424;P37425;P0ACJ4;P0ACJ3;
P0A2S0;P45265;P0ACJ2;P0ACJ1;
P0ACJ0 
>sp|P37424|LRP_KLEPN 
Leucine-responsive regulatory 
protein OS=Klebsiella 
pneumoniae GN=lrp PE=3 
SV=3;>sp|P37425|LRP_SERMA 
Leucine-responsive regulatory 
protein OS=Serratia 
marcescens GN=lrp PE=3 
SV=3;>sp|P0ACJ4|LRP_KLEAE 
Leucine-responsive regulatory 
prote 
18.873 
P37419;P0AB79;P0AB78;P0AB77 
>sp|P37419|KBL_SALTY 2-
amino-3-ketobutyrate coenzyme 
A ligase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
43.031 
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GN=kbl PE=3 
SV=2;>sp|P0AB79|KBL_SHIFL 
2-amino-3-ketobutyrate 
coenzyme A ligase OS=Shigella 
flexneri GN=kbl PE=3 
SV=1;>sp|P0AB78|KB 
P36938 
>sp|P36938|PGM_ECOLI 
Phosphoglucomutase 
OS=Escherichia coli (strain K12) 
GN=pgm PE=1 SV=1 
58.36 
P36683 
>sp|P36683|ACNB_ECOLI 
Aconitate hydratase B 
OS=Escherichia coli (strain K12) 
GN=acnB PE=1 SV=3 
93.497 
P35596 
>sp|P35596|GLPO_STRPN 
Alpha-glycerophosphate oxidase 
OS=Streptococcus pneumoniae 
serotype 4 (strain ATCC BAA-
334 / TIGR4) GN=glpO PE=3 
SV=2 
66.795 
P35482 
>sp|P35482|PPBL_PSEAE 
Alkaline phosphatase L 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=phoA2 PE=1 
SV=2 
37.885 
P30860 
>sp|P30860|ARTJ_ECOLI ABC 
transporter arginine-binding 
protein 1 OS=Escherichia coli 
(strain K12) GN=artJ PE=1 
SV=2 
26.829 
P30859 
>sp|P30859|ARTI_ECOLI 
Putative ABC transporter 
arginine-binding protein 2 
OS=Escherichia coli (strain K12) 
GN=artI PE=1 SV=3 
26.929 
P29847;P0A9D7;P0A9D6;P0A9D5;
P0A9D4 
>sp|P29847|CYSE_SALTY 
Serine acetyltransferase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=cysE PE=1 
SV=1;>sp|P0A9D7|CYSE_SHIF
L Serine acetyltransferase 
OS=Shigella flexneri GN=cysE 
PE=3 
SV=1;>sp|P0A9D6|CYSE_ECO
57 Serine acetyltransf 
29.29 
P28997 
>sp|P28997|DHE2_PEPAS 
NAD-specific glutamate 
dehydrogenase 
OS=Peptoniphilus 
asaccharolyticus PE=1 SV=1 
46.513 
P27735 
>sp|P27735|THRC_SERMA 
Threonine synthase 
47.093 
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OS=Serratia marcescens 
GN=thrC PE=3 SV=1 
P26975;P28581 
>sp|P26975|PHON_PROST 
Non-specific acid phosphatase 
OS=Providencia stuartii 
GN=phoN PE=3 
SV=1;>sp|P28581|PHOC_MOR
MO Major phosphate-
irrepressible acid phosphatase 
OS=Morganella morganii 
GN=phoC PE=1 SV=1 
27.043 
P26478;P03841 
>sp|P26478|MALM_SALTY 
Maltose operon periplasmic 
protein OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=malM PE=3 
SV=2;>sp|P03841|MALM_ECO
LI Maltose operon periplasmic 
protein OS=Escherichia coli 
(strain K12) GN=malM PE=3 
SV=1 
31.823 
P25762;P0A2F7;P0A2F6;Q8ZJ06;
Q87LA3;Q9KUW2;Q9RHF4;P0AG
E3;Q8DCJ0;Q8EA81;P28045;P280
44;P18022;P0AGE2;P0AGE1;P0A
GE0;P28043 
>sp|P25762|SSB_SERMA 
Single-stranded DNA-binding 
protein OS=Serratia 
marcescens GN=ssb PE=1 
SV=2;>sp|P0A2F7|SSB1_SALTI 
Single-stranded DNA-binding 
protein 1 OS=Salmonella typhi 
GN=ssb PE=3 
SV=2;>sp|P0A2F6|SSB1_SALT
Y Single-stranded DNA-binding 
protein 1 OS 
18.808 
P25253 
>sp|P25253|OMPX_ENTCL 
Outer membrane protein X 
OS=Enterobacter cloacae 
GN=ompX PE=1 SV=1 
18.653 
P23925 
>sp|P23925|DGAL_CITFR D-
galactose-binding periplasmic 
protein OS=Citrobacter freundii 
GN=mglB PE=3 SV=1 
35.816 
P23869 
>sp|P23869|PPIB_ECOLI 
Peptidyl-prolyl cis-trans 
isomerase B OS=Escherichia 
coli (strain K12) GN=ppiB PE=1 
SV=2 
18.153 
P23843 
>sp|P23843|OPPA_ECOLI 
Periplasmic oligopeptide-binding 
protein OS=Escherichia coli 
(strain K12) GN=oppA PE=1 
SV=2 
60.898 
P23538 
>sp|P23538|PPSA_ECOLI 
Phosphoenolpyruvate synthase 
OS=Escherichia coli (strain K12) 
GN=ppsA PE=1 SV=5 
87.434 
P21883;P11961 
>sp|P21883|ODP2_BACSU 
Dihydrolipoyllysine-residue 
47.538 
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acetyltransferase component of 
pyruvate dehydrogenase 
complex OS=Bacillus subtilis 
(strain 168) GN=pdhC PE=1 
SV=2;>sp|P11961|ODP2_GEO
SE Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate de 
P21631 
>sp|P21631|SUMT_PSEDE 
Uroporphyrinogen-III C-
methyltransferase 
OS=Pseudomonas denitrificans 
GN=cobA PE=1 SV=1 
29.252 
P21184;P72151 
>sp|P21184|FLICA_PSEAI A-
type flagellin OS=Pseudomonas 
aeruginosa GN=fliC PE=1 
SV=3;>sp|P72151|FLICB_PSEA
E B-type flagellin 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=fliC PE=1 SV 
40.066 
P19926 
>sp|P19926|AGP_ECOLI 
Glucose-1-phosphatase 
OS=Escherichia coli (strain K12) 
GN=agp PE=1 SV=1 
45.682 
P17838 
>sp|P17838|FMP1_PSEAI 
Fimbrial protein 
OS=Pseudomonas aeruginosa 
GN=pilA PE=1 SV=1 
16.175 
P15288 
>sp|P15288|PEPD_ECOLI 
Cytosol non-specific dipeptidase 
OS=Escherichia coli (strain K12) 
GN=pepD PE=1 SV=3 
52.915 
P14165 
>sp|P14165|CISY_PSEAE 
Citrate synthase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=gltA PE=1 
SV=2 
47.694 
P14062 
>sp|P14062|6PGD_SALTY 6-
phosphogluconate 
dehydrogenase, decarboxylating 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=gnd PE=3 SV=1 
51.395 
P13981;Q88P52;P41142 
>sp|P13981|ARCA_PSEAE 
Arginine deiminase 
OS=Pseudomonas aeruginosa 
(strain ATCC 15692 / DSM 
22644 / CIP 104116 / JCM 
14847 / LMG 12228 / 1C / PRS 
101 / PAO1) GN=arcA PE=1 
SV=2;>sp|Q88P52|ARCA_PSE
46.435 
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PK Arginine deiminase 
OS=Pseudomonas putida (strain 
ATCC 4705 
P11570 
>sp|P11570|HGDB_ACIFV (R)-
2-hydroxyglutaryl-CoA 
dehydratase subunit beta 
OS=Acidaminococcus 
fermentans (strain ATCC 25085 
/ DSM 20731 / VR4) GN=hgdB 
PE=1 SV=3 
42.028 
P0DOV9;P94428;P25526 
>sp|P0DOV9|SLAD_PSEPU 3-
sulfolactaldehyde 
dehydrogenase 
OS=Pseudomonas putida 
GN=PpSQ1_00395 PE=1 
SV=1;>sp|P94428|GABD_BACS
U Succinate-semialdehyde 
dehydrogenase [NADP(+)] 
OS=Bacillus subtilis (strain 168) 
GN=gabD PE=1 
SV=1;>sp|P25526|GABD_ECOL
I Succinate- 
52.148 
P0DM31;E6ER18 
>sp|P0DM31|ENO_ENTFA 
Enolase OS=Enterococcus 
faecalis (strain ATCC 700802 / 
V583) GN=eno PE=3 
SV=1;>sp|E6ER18|ENO_ENTF
T Enolase OS=Enterococcus 
faecalis (strain TX4000 / JH2-2) 
GN=eno PE=1 SV=1 
46.511 
P0CW93;E8ME30;B8DSV5 
>sp|P0CW93|LDH2_BIFLO L-
lactate dehydrogenase 2 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=ldh2 
PE=1 
SV=1;>sp|E8ME30|LDH2_BIFL
2 L-lactate dehydrogenase 2 
OS=Bifidobacterium longum 
subsp. longum (strain ATCC 
15707 / DSM 20219 / JCM 1217 
/ NCTC 11818 / E 
34.24 
P0AGK7;P0AGK6;P0AGK5;P0AGK
4 
>sp|P0AGK7|YHBY_SHIFL 
RNA-binding protein YhbY 
OS=Shigella flexneri GN=yhbY 
PE=4 
SV=1;>sp|P0AGK6|YHBY_ECO
57 RNA-binding protein YhbY 
OS=Escherichia coli O157:H7 
GN=yhbY PE=4 
SV=1;>sp|P0AGK5|YHBY_ECO
L6 RNA-binding protein YhbY 
OS=Escherichia coli O6:H1 (str 
10.784 
P0AGF1;P0AGF0;P0AGE9;Q1RH5
6;P53591 
>sp|P0AGF1|SUCD_ECO57 
Succinate--CoA ligase [ADP-
forming] subunit alpha 
OS=Escherichia coli O157:H7 
GN=sucD PE=3 
29.777 
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SV=2;>sp|P0AGF0|SUCD_ECO
L6 Succinate--CoA ligase [ADP-
forming] subunit alpha 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN= 
P0AG83;P0AG82 
>sp|P0AG83|PSTS_SHIFL 
Phosphate-binding protein PstS 
OS=Shigella flexneri GN=pstS 
PE=3 
SV=1;>sp|P0AG82|PSTS_ECO
LI Phosphate-binding protein 
PstS OS=Escherichia coli (strain 
K12) GN=pstS PE=1 SV=1 
37.023 
P0AG79;P02906;P0AG78 
>sp|P0AG79|SUBI_SHIFL 
Sulfate-binding protein 
OS=Shigella flexneri GN=sbp 
PE=3 
SV=1;>sp|P02906|SUBI_SALTY 
Sulfate-binding protein 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=sbp PE=1 
SV=3;>sp|P0AG78|SUBI_ECOL
I Sulfate-binding protein 
36.659 
P0AG70;P0AG69;P0AG68;P0AG6
7;P37985;P14128;P57395;Q44653 
>sp|P0AG70|RS1_SHIFL 30S 
ribosomal protein S1 
OS=Shigella flexneri GN=rpsA 
PE=3 
SV=1;>sp|P0AG69|RS1_ECO57 
30S ribosomal protein S1 
OS=Escherichia coli O157:H7 
GN=rpsA PE=3 
SV=1;>sp|P0AG68|RS1_ECOL6 
30S ribosomal protein S1 
OS=Escherichia coli O6:H1 
(strain 
61.157 
P0AFL0;P0AFK9;P0A2C8;P0A2C7 
>sp|P0AFL0|POTD_SHIFL 
Spermidine/putrescine-binding 
periplasmic protein OS=Shigella 
flexneri GN=potD PE=3 
SV=1;>sp|P0AFK9|POTD_ECO
LI Spermidine/putrescine-
binding periplasmic protein 
OS=Escherichia coli (strain K12) 
GN=potD PE=1 
SV=1;>sp|P0A2C8|POTD_SALT
I  
38.867 
P0AFJ0;P0AFI9 
>sp|P0AFJ0|PERM_ECO57 
Putative permease PerM 
OS=Escherichia coli O157:H7 
GN=perM PE=3 
SV=1;>sp|P0AFI9|PERM_ECOL
I Putative permease PerM 
OS=Escherichia coli (strain K12) 
GN=perM PE=3 SV=1 
39.194 
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P0AFH9;P0AFH8 
>sp|P0AFH9|OSMY_ECOL6 
Osmotically-inducible protein Y 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=osmY PE=3 
SV=1;>sp|P0AFH8|OSMY_ECO
LI Osmotically-inducible protein 
Y OS=Escherichia coli (strain 
K12) GN=osmY PE=1 SV=1 
21.073 
P0AFG9;P0AFG8;P57301;Q8K9T9
;P45119;Q89AR0;Q59097 
>sp|P0AFG9|ODP1_ECO57 
Pyruvate dehydrogenase E1 
component OS=Escherichia coli 
O157:H7 GN=aceE PE=1 
SV=2;>sp|P0AFG8|ODP1_ECO
LI Pyruvate dehydrogenase E1 
component OS=Escherichia coli 
(strain K12) GN=aceE PE=1 
SV=2 
99.667 
P0AF95;P0AF94;P0AF93 
>sp|P0AF95|RIDA_SHIFL 2-
iminobutanoate/2-
iminopropanoate deaminase 
OS=Shigella flexneri GN=yjgF 
PE=3 
SV=2;>sp|P0AF94|RIDA_ECOL
6 2-iminobutanoate/2-
iminopropanoate deaminase 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=yjgF PE=3 SV=2;>s 
13.611 
P0AEU2;P0AEU1;P0AEU0 
>sp|P0AEU2|HISJ_ECO57 
Histidine-binding periplasmic 
protein OS=Escherichia coli 
O157:H7 GN=hisJ PE=3 
SV=1;>sp|P0AEU1|HISJ_ECOL
6 Histidine-binding periplasmic 
protein OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
700928 / UPEC) GN=hisJ PE=3 
SV=1;>sp|P0AEU 
28.483 
P0AET4;P0AET3;P0AET2 
>sp|P0AET4|HDEB_SHIFL Acid 
stress chaperone HdeB 
OS=Shigella flexneri GN=hdeB 
PE=3 
SV=1;>sp|P0AET3|HDEB_ECO
L6 Acid stress chaperone HdeB 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=hdeB PE=3 
SV=1;>sp|P0AET2|HDEB_ECO
LI Acid stress chap 
12.043 
P0AES5;P37411;P0AES4 
>sp|P0AES5|GYRA_SHIFL 
DNA gyrase subunit A 
OS=Shigella flexneri GN=gyrA 
PE=1 
SV=1;>sp|P37411|GYRA_SALT
Y DNA gyrase subunit A 
OS=Salmonella typhimurium 
96.962 
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(strain LT2 / SGSC1412 / ATCC 
700720) GN=gyrA PE=1 
SV=3;>sp|P0AES4|GYRA_ECO
LI DNA gyrase subunit A 
OS=Esc 
P0AES3;P0AES2;Q6FFQ2;P42238 
>sp|P0AES3|GUDD_ECO57 
Glucarate dehydratase 
OS=Escherichia coli O157:H7 
GN=gudD PE=3 
SV=2;>sp|P0AES2|GUDD_ECO
LI Glucarate dehydratase 
OS=Escherichia coli (strain K12) 
GN=gudD PE=1 
SV=2;>sp|Q6FFQ2|GUDD_ACI
AD Glucarate dehydratase 
OS=Acinetobacter baylyi (st 
49.14 
P0AEQ5;P0AEQ4;P0AEQ3 
>sp|P0AEQ5|GLNH_ECO57 
Glutamine-binding periplasmic 
protein OS=Escherichia coli 
O157:H7 GN=glnH PE=3 
SV=1;>sp|P0AEQ4|GLNH_ECO
L6 Glutamine-binding 
periplasmic protein 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=glnH PE=3 
SV=1;>sp|P0AEQ 
27.19 
P0AEN0;P0AEM9 
>sp|P0AEN0|FLIY_ECOL6 L-
cystine-binding protein FliY 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=fliY PE=3 
SV=1;>sp|P0AEM9|FLIY_ECOL
I L-cystine-binding protein FliY 
OS=Escherichia coli (strain K12) 
GN=fliY PE=1 SV=1 
29.039 
P0AEE7;P0AEE6;P0AEE5 
>sp|P0AEE7|DGAL_SHIFL D-
galactose-binding periplasmic 
protein OS=Shigella flexneri 
GN=mglB PE=3 
SV=1;>sp|P0AEE6|DGAL_ECO
L6 D-galactose-binding 
periplasmic protein 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=mglB PE=3 
SV=1;>sp|P0AEE5|D 
35.712 
P0AE21;P0AE20;P0AE19;P0AE18;
Q8K9T1;P57324;P0A1X7;P0A1X6;
Q89AP3 
>sp|P0AE21|MAP1_SHIFL 
Methionine aminopeptidase 
OS=Shigella flexneri GN=map 
PE=3 
SV=1;>sp|P0AE20|MAP1_ECO
57 Methionine aminopeptidase 
OS=Escherichia coli O157:H7 
GN=map PE=3 
SV=1;>sp|P0AE19|MAP1_ECO
29.33 
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L6 Methionine aminopeptidase 
OS=Escherichia coli O6:H1 (st 
P0ADA6;P0ADA5 
>sp|P0ADA6|YAJG_ECOL6 
Uncharacterized lipoprotein 
YajG OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
700928 / UPEC) GN=yajG PE=3 
SV=1;>sp|P0ADA5|YAJG_ECO
LI Uncharacterized lipoprotein 
YajG OS=Escherichia coli 
(strain K12) GN=yajG PE=3 
SV=1 
20.95 
P0AD60;P0AD59 
>sp|P0AD60|IVY_ECO57 
Inhibitor of vertebrate lysozyme 
OS=Escherichia coli O157:H7 
GN=ivy PE=3 
SV=1;>sp|P0AD59|IVY_ECOLI 
Inhibitor of vertebrate lysozyme 
OS=Escherichia coli (strain K12) 
GN=ivy PE=1 SV=1 
16.872 
P0ACK1;P0A2T7;P0A2T6;P0ACK0
;P0ACJ9;P0ACJ8;O05689 
>sp|P0ACK1|CRP_SHIFL 
cAMP-activated global 
transcriptional regulator CRP 
OS=Shigella flexneri GN=crp 
PE=3 
SV=1;>sp|P0A2T7|CRP_KLEAE 
cAMP-activated global 
transcriptional regulator CRP 
OS=Klebsiella aerogenes 
GN=crp PE=1 
SV=1;>sp|P0A2T6|CRP_SALTY 
cAMP-activ 
23.64 
P0ACA6;P0ACA5;P0ACA4;P0ACA
3;Q9CNB0;P45207;P31784;Q7VLK
4 
>sp|P0ACA6|SSPA_SHIFL 
Stringent starvation protein A 
OS=Shigella flexneri GN=sspA 
PE=3 
SV=2;>sp|P0ACA5|SSPA_ECO
57 Stringent starvation protein A 
OS=Escherichia coli O157:H7 
GN=sspA PE=3 
SV=2;>sp|P0ACA4|SSPA_ECO
L6 Stringent starvation protein A 
OS=Escherich 
24.305 
P0AC87;P0AC86 
>sp|P0AC87|PHSG_SHIFL 
Glycogen phosphorylase 
OS=Shigella flexneri GN=glgP 
PE=3 
SV=1;>sp|P0AC86|PHSG_ECO
LI Glycogen phosphorylase 
OS=Escherichia coli (strain K12) 
GN=glgP PE=3 SV=1 
93.171 
P0AC50;P0AC49;P0AC48;P0AC47
;P20921 
>sp|P0AC50|FRDB_SHIFL 
Fumarate reductase iron-sulfur 
subunit OS=Shigella flexneri 
GN=frdB PE=3 
SV=2;>sp|P0AC49|FRDB_ECO
57 Fumarate reductase iron-
27.123 
438 
 
 
sulfur subunit OS=Escherichia 
coli O157:H7 GN=frdB PE=3 
SV=2;>sp|P0AC48|FRDB_ECO
L6 Fumarate reductase iron-sul 
P0ABS4;P0A1G6;P0A1G5;P0ABS
3;P0ABS2;P0ABS1;Q8K9U5 
>sp|P0ABS4|DKSA_SHIFL RNA 
polymerase-binding transcription 
factor DksA OS=Shigella 
flexneri GN=dksA PE=3 
SV=1;>sp|P0A1G6|DKSA_SALT
I RNA polymerase-binding 
transcription factor DksA 
OS=Salmonella typhi GN=dksA 
PE=3 
SV=1;>sp|P0A1G5|DKSA_SALT
Y RNA polymerase- 
17.528 
P0ABQ3;P0ABQ2 
>sp|P0ABQ3|GARR_ECOL6 2-
hydroxy-3-oxopropionate 
reductase OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
700928 / UPEC) GN=garR 
PE=3 
SV=1;>sp|P0ABQ2|GARR_ECO
LI 2-hydroxy-3-oxopropionate 
reductase OS=Escherichia coli 
(strain K12) GN=garR PE=1 
SV=1 
30.427 
P0ABD4;P0ABD3;O68926;O68935;
O50172 
>sp|P0ABD4|BFR_ECOL6 
Bacterioferritin OS=Escherichia 
coli O6:H1 (strain CFT073 / 
ATCC 700928 / UPEC) GN=bfr 
PE=3 
SV=1;>sp|P0ABD3|BFR_ECOLI 
Bacterioferritin OS=Escherichia 
coli (strain K12) GN=bfr PE=1 
SV=1;>sp|O68926|BFR_SALTY 
Bacterioferritin OS=Salmonell 
18.495 
P0AB73;P0AB72;P0AB71 
>sp|P0AB73|ALF_SHIFL 
Fructose-bisphosphate aldolase 
class 2 OS=Shigella flexneri 
GN=fbaA PE=3 
SV=2;>sp|P0AB72|ALF_ECO57 
Fructose-bisphosphate aldolase 
class 2 OS=Escherichia coli 
O157:H7 GN=fbaA PE=3 
SV=2;>sp|P0AB71|ALF_ECOLI 
Fructose-bisphosphate aldolase 
39.147 
P0A9Z0;P0A9Y9;P0A9Y8;P0A9Y7;
P0A9Y6;E0J500;Q83RI9;Q56922 
>sp|P0A9Z0|CSPC_SALTI Cold 
shock-like protein CspC 
OS=Salmonella typhi GN=cspC 
PE=3 
SV=2;>sp|P0A9Y9|CSPC_SALT
Y Cold shock-like protein CspC 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=cspC PE=3 
SV=2;>sp|P0A9Y8|CSPC_ECO
57 Cold shock-l 
7.4023 
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P0A9S6;P0A9S5;P50173 
>sp|P0A9S6|GLDA_ECOL6 
Glycerol dehydrogenase 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
UPEC) GN=gldA PE=3 
SV=1;>sp|P0A9S5|GLDA_ECO
LI Glycerol dehydrogenase 
OS=Escherichia coli (strain K12) 
GN=gldA PE=1 
SV=1;>sp|P50173|GLDA_PSEP
U Glycerol deh 
38.712 
P0A9R1;P0A1F9;P0A1F8;Q8FCR6
;P0A9R0;P0A9Q9 
>sp|P0A9R1|DHAS_SHIFL 
Aspartate-semialdehyde 
dehydrogenase OS=Shigella 
flexneri GN=asd PE=3 
SV=1;>sp|P0A1F9|DHAS_SALT
I Aspartate-semialdehyde 
dehydrogenase OS=Salmonella 
typhi GN=asd PE=3 
SV=1;>sp|P0A1F8|DHAS_SALT
Y Aspartate-semialdehyde 
dehydrogenase OS=S 
40.017 
P0A9Q4;P0A9Q3;P0A9Q2;P0A9Q
1 
>sp|P0A9Q4|ARCA_SHIFL 
Aerobic respiration control 
protein ArcA OS=Shigella 
flexneri GN=arcA PE=3 
SV=1;>sp|P0A9Q3|ARCA_ECO
57 Aerobic respiration control 
protein ArcA OS=Escherichia 
coli O157:H7 GN=arcA PE=3 
SV=1;>sp|P0A9Q2|ARCA_ECO
L6 Aerobic respiration con 
27.292 
P0A9P5;P0A9P4;Q9KSS4;P43788;
P80892;Q93HX6;P39916 
>sp|P0A9P5|TRXB_ECO57 
Thioredoxin reductase 
OS=Escherichia coli O157:H7 
GN=trxB PE=3 
SV=2;>sp|P0A9P4|TRXB_ECO
LI Thioredoxin reductase 
OS=Escherichia coli (strain K12) 
GN=trxB PE=1 
SV=2;>sp|Q9KSS4|TRXB_VIBC
H Thioredoxin reductase 
OS=Vibrio cholerae serotype 
34.623 
P0A9P3;P0A9P2;P0A9P1;P0A9P0;
Q9KPF6 
>sp|P0A9P3|DLDH_SHIFL 
Dihydrolipoyl dehydrogenase 
OS=Shigella flexneri GN=lpdA 
PE=3 
SV=2;>sp|P0A9P2|DLDH_ECO
57 Dihydrolipoyl dehydrogenase 
OS=Escherichia coli O157:H7 
GN=lpdA PE=3 
SV=2;>sp|P0A9P1|DLDH_ECO
L6 Dihydrolipoyl dehydrogenase 
OS=Escherichia coli O 
50.688 
P0A9M9;P0A9M8;Q7CJ96;Q820S1
;Q9RY77;Q1J2D0 
>sp|P0A9M9|PTA_SHIFL 
Phosphate acetyltransferase 
OS=Shigella flexneri GN=pta 
77.171 
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PE=3 
SV=2;>sp|P0A9M8|PTA_ECOLI 
Phosphate acetyltransferase 
OS=Escherichia coli (strain K12) 
GN=pta PE=1 SV=2 
P0A9L2;P0A9L1;P0A9L0;P0A9K9 
>sp|P0A9L2|SLYD_SHIFL 
FKBP-type peptidyl-prolyl cis-
trans isomerase SlyD 
OS=Shigella flexneri GN=slyD 
PE=3 
SV=1;>sp|P0A9L1|SLYD_ECO5
7 FKBP-type peptidyl-prolyl cis-
trans isomerase SlyD 
OS=Escherichia coli O157:H7 
GN=slyD PE=3 
SV=1;>sp|P0A9L0|SLYD_ECOL
6 FKB 
20.853 
P0A9K6;P0A9K5;P0A9K4;P0A9K3 
>sp|P0A9K6|PHOL_SHIFL 
PhoH-like protein OS=Shigella 
flexneri GN=ybeZ PE=3 
SV=2;>sp|P0A9K5|PHOL_ECO
57 PhoH-like protein 
OS=Escherichia coli O157:H7 
GN=ybeZ PE=3 
SV=2;>sp|P0A9K4|PHOL_ECO
L6 PhoH-like protein 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700 
39.038 
P0A9J7;P0A9J6 
>sp|P0A9J7|RBSK_ECO57 
Ribokinase OS=Escherichia coli 
O157:H7 GN=rbsK PE=3 
SV=1;>sp|P0A9J6|RBSK_ECOL
I Ribokinase OS=Escherichia 
coli (strain K12) GN=rbsK PE=1 
SV=1 
32.29 
P0A9C8;P0A9C7;P0A9C6;P0A9C5 
>sp|P0A9C8|GLN1B_SHIFL 
Glutamine synthetase 
OS=Shigella flexneri GN=glnA 
PE=3 
SV=2;>sp|P0A9C7|GLN1B_EC
O57 Glutamine synthetase 
OS=Escherichia coli O157:H7 
GN=glnA PE=3 
SV=2;>sp|P0A9C6|GLN1B_EC
OL6 Glutamine synthetase 
OS=Escherichia coli O6:H1 
(strain CFT07 
51.903 
P0A9A1;P0A9A0;P0A999;P0A998 
>sp|P0A9A1|FTNA_SHIFL 
Bacterial non-heme ferritin 
OS=Shigella flexneri GN=ftnA 
PE=3 
SV=1;>sp|P0A9A0|FTNA_ECO5
7 Bacterial non-heme ferritin 
OS=Escherichia coli O157:H7 
GN=ftnA PE=3 
SV=1;>sp|P0A999|FTNA_ECOL
19.424 
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6 Bacterial non-heme ferritin 
OS=Escherichia coli O 
P0A992;P0A991;O84217;Q9Z8Q7;
Q9PKH8 
>sp|P0A992|ALF1_ECOL6 
Fructose-bisphosphate aldolase 
class 1 OS=Escherichia coli 
O6:H1 (strain CFT073 / ATCC 
700928 / UPEC) GN=fbaB PE=3 
SV=2;>sp|P0A991|ALF1_ECOLI 
Fructose-bisphosphate aldolase 
class 1 OS=Escherichia coli 
(strain K12) GN=fbaB PE=1 
SV=2 
38.109 
P0A958;P0A957;P0A956;P0A955 
>sp|P0A958|ALKH_SHIFL 
KHG/KDPG aldolase 
OS=Shigella flexneri GN=eda 
PE=3 
SV=1;>sp|P0A957|ALKH_ECO5
7 KHG/KDPG aldolase 
OS=Escherichia coli O157:H7 
GN=eda PE=3 
SV=1;>sp|P0A956|ALKH_ECOL
6 KHG/KDPG aldolase 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 70092 
22.284 
P0A907;P0A1X1;P0A1X0;P0A906;
P0A905 
>sp|P0A907|SLYB_SHIFL Outer 
membrane lipoprotein SlyB 
OS=Shigella flexneri GN=slyB 
PE=3 
SV=1;>sp|P0A1X1|SLYB_SALTI 
Outer membrane lipoprotein 
SlyB OS=Salmonella typhi 
GN=slyB PE=3 
SV=1;>sp|P0A1X0|SLYB_SALT
Y Outer membrane lipoprotein 
SlyB OS=Salmonella typ 
15.601 
P0A904;P0A903 
>sp|P0A904|BAMC_SHIFL 
Outer membrane protein 
assembly factor BamC 
OS=Shigella flexneri GN=bamC 
PE=3 
SV=1;>sp|P0A903|BAMC_ECO
LI Outer membrane protein 
assembly factor BamC 
OS=Escherichia coli (strain K12) 
GN=bamC PE=1 SV=1 
36.842 
P0A866;P0A865;P0A864;P0A863;
P0A862 
>sp|P0A866|TPX_SHIDY Thiol 
peroxidase OS=Shigella 
dysenteriae GN=tpx PE=3 
SV=2;>sp|P0A865|TPX_SHIFL 
Thiol peroxidase OS=Shigella 
flexneri GN=tpx PE=3 
SV=2;>sp|P0A864|TPX_ECO57 
Thiol peroxidase 
OS=Escherichia coli O157:H7 
GN=tpx PE=3 
SV=2;>sp|P0A863|TPX_ECO 
17.835 
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P0A330;P0A329;P0A328 
>sp|P0A330|CCMK_SYNPW 
Carbon dioxide-concentrating 
mechanism protein CcmK 
OS=Synechococcus sp. (strain 
WH7803) GN=ccmK PE=3 
SV=1;>sp|P0A329|CCMK_SYN
PX Carbon dioxide-
concentrating mechanism 
protein CcmK 
OS=Synechococcus sp. (strain 
WH8102) GN=ccmK PE=3 SV= 
10.584 
P0A2D0;P0A2C9;P0AEK3;P0AEK2 
>sp|P0A2D0|FABG_SALTI 3-
oxoacyl-[acyl-carrier-protein] 
reductase FabG OS=Salmonella 
typhi GN=fabG PE=3 
SV=1;>sp|P0A2C9|FABG_SALT
Y 3-oxoacyl-[acyl-carrier-protein] 
reductase FabG OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=fabG PE=1 S 
25.545 
P0A284;P0A283;P69785;P69784;P
69783 
>sp|P0A284|PTGA_SALTI PTS 
system glucose-specific EIIA 
component OS=Salmonella 
typhi GN=crr PE=1 
SV=2;>sp|P0A283|PTGA_SALT
Y PTS system glucose-specific 
EIIA component OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=crr PE=1 SV=2;>sp|P697 
18.247 
P0A250;P0A249;P08839;P43922;Q
8KA50;Q9WXI6;Q89B04 
>sp|P0A250|PT1_SALTI 
Phosphoenolpyruvate-protein 
phosphotransferase 
OS=Salmonella typhi GN=ptsI 
PE=3 
SV=1;>sp|P0A249|PT1_SALTY 
Phosphoenolpyruvate-protein 
phosphotransferase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ptsI PE=1 SV=1; 
63.368 
P0A1Y9;P0A1Y8 
>sp|P0A1Y9|NUOE_SALTI 
NADH-quinone oxidoreductase 
subunit E OS=Salmonella typhi 
GN=nuoE PE=3 
SV=1;>sp|P0A1Y8|NUOE_SAL
TY NADH-quinone 
oxidoreductase subunit E 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=nuoE PE=3 SV=1 
18.602 
P0A1W7;P0A1W6;P04816 
>sp|P0A1W7|LIVK_SALTI 
Leucine-specific-binding protein 
OS=Salmonella typhi GN=livK 
PE=3 
SV=1;>sp|P0A1W6|LIVK_SALT
39.4 
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Y Leucine-specific-binding 
protein OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=livK PE=1 
SV=1;>sp|P04816|LIVK_ECOLI 
Leuc 
P0A1P7;P0A1P6 
>sp|P0A1P7|GLN1B_SALTI 
Glutamine synthetase 
OS=Salmonella typhi GN=glnA 
PE=1 
SV=2;>sp|P0A1P6|GLN1B_SAL
TY Glutamine synthetase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=glnA PE=1 SV=2 
51.785 
P0A1F7;P0A1F6;P12758;P43770 
>sp|P0A1F7|UDP_SALTI 
Uridine phosphorylase 
OS=Salmonella typhi GN=udp 
PE=3 
SV=2;>sp|P0A1F6|UDP_SALTY 
Uridine phosphorylase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=udp PE=1 
SV=2;>sp|P12758|UDP_ECOLI 
Uridine phosphorylase 
OS=Escher 
27.139 
P0A1A6;P0A1A5;P0AB82;P0AB81;
P0AB80 
>sp|P0A1A6|ILVE_SALTI 
Branched-chain-amino-acid 
aminotransferase 
OS=Salmonella typhi GN=ilvE 
PE=3 
SV=2;>sp|P0A1A5|ILVE_SALTY 
Branched-chain-amino-acid 
aminotransferase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=ilvE PE=1 
SV=2;>sp|P0 
34.052 
P09831 
>sp|P09831|GLTB_ECOLI 
Glutamate synthase [NADPH] 
large chain OS=Escherichia coli 
(strain K12) GN=gltB PE=1 
SV=3 
163.3 
P09394 
>sp|P09394|GLPQ_ECOLI 
Glycerophosphodiester 
phosphodiesterase, periplasmic 
OS=Escherichia coli (strain K12) 
GN=glpQ PE=1 SV=2 
40.843 
P09148;P22714;P31764 
>sp|P09148|GAL7_ECOLI 
Galactose-1-phosphate 
uridylyltransferase 
OS=Escherichia coli (strain K12) 
GN=galT PE=1 
SV=2;>sp|P22714|GAL7_SALT
Y Galactose-1-phosphate 
39.645 
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uridylyltransferase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=galT PE=3  
P08331 
>sp|P08331|CPDB_ECOLI 2,3-
cyclic-nucleotide 2-
phosphodiesterase/3-
nucleotidase OS=Escherichia 
coli (strain K12) GN=cpdB PE=1 
SV=2 
70.831 
P08200;P50214;P80046;P39126 
>sp|P08200|IDH_ECOLI 
Isocitrate dehydrogenase 
[NADP] OS=Escherichia coli 
(strain K12) GN=icd PE=1 SV=1 
45.756 
P07094 
>sp|P07094|PHSM_KLEPN 
Maltodextrin phosphorylase 
(Fragment) OS=Klebsiella 
pneumoniae GN=malP PE=3 
SV=1 
12.325 
P06999 
>sp|P06999|PFKB_ECOLI ATP-
dependent 6-
phosphofructokinase isozyme 2 
OS=Escherichia coli (strain K12) 
GN=pfkB PE=1 SV=2 
32.456 
P06960 
>sp|P06960|OTC2_ECOLI 
Ornithine carbamoyltransferase 
subunit F OS=Escherichia coli 
(strain K12) GN=argF PE=1 
SV=4 
36.827 
P06202 
>sp|P06202|OPPA_SALTY 
Periplasmic oligopeptide-binding 
protein OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=oppA PE=1 SV=2 
61.291 
P06175;P06179;P06178;P52615;P
06176;P06177;P52616;Q56826;P4
2272;P42273;Q06983;Q06982;Q06
981;Q06973;Q06972;Q06971;Q069
70;Q06969;O52959;Q06974;Q0696
8;Q08860;P04949 
>sp|P06175|FLIC_SALRU 
Flagellin OS=Salmonella 
rubislaw GN=fliC PE=3 
SV=2;>sp|P06179|FLIC_SALTY 
Flagellin OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=fliC PE=1 
SV=4;>sp|P06178|FLIC_SALPA 
Flagellin OS=Salmonella 
paratyphi A (strain ATC 
51.416 
P04825 
>sp|P04825|AMPN_ECOLI 
Aminopeptidase N 
OS=Escherichia coli (strain K12) 
GN=pepN PE=1 SV=2 
98.918 
P02910 
>sp|P02910|HISJ_SALTY 
Histidine-binding periplasmic 
protein OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=hisJ PE=1 SV=1 
28.379 
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P00934 
>sp|P00934|THRC_ECOLI 
Threonine synthase 
OS=Escherichia coli (strain K12) 
GN=thrC PE=1 SV=1 
47.113 
P00862 
>sp|P00862|DCHS_LACS3 
Histidine decarboxylase 
proenzyme OS=Lactobacillus 
sp. (strain 30a) GN=hdcA PE=1 
SV=2 
34.233 
P00805 
>sp|P00805|ASPG2_ECOLI L-
asparaginase 2 OS=Escherichia 
coli (strain K12) GN=ansB PE=1 
SV=2 
36.85 
P00509;Q56114;P58661 
>sp|P00509|AAT_ECOLI 
Aspartate aminotransferase 
OS=Escherichia coli (strain K12) 
GN=aspC PE=1 
SV=1;>sp|Q56114|AAT_SALTI 
Aspartate aminotransferase 
OS=Salmonella typhi GN=aspC 
PE=3 
SV=2;>sp|P58661|AAT_SALTY 
Aspartate aminotransferase 
OS=Salmonella typhimuri 
43.573 
P00490 
>sp|P00490|PHSM_ECOLI 
Maltodextrin phosphorylase 
OS=Escherichia coli (strain K12) 
GN=malP PE=1 SV=7 
90.521 
P00370;P14657 
>sp|P00370|DHE4_ECOLI 
NADP-specific glutamate 
dehydrogenase OS=Escherichia 
coli (strain K12) GN=gdhA PE=1 
SV=1 
48.581 
P00282;B3EWN9 
>sp|P00282|AZUR_PSEAE 
Azurin OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=azu 
PE=1 
SV=2;>sp|B3EWN9|AZUR_PSE
AI Azurin OS=Pseudomonas 
aeruginosa PE=1 SV=1 
16.008 
O69395;P74841;Q47066;P28585;E
1ANH6 
>sp|O69395|BLT2_ECOLX 
Beta-lactamase Toho-2 
OS=Escherichia coli GN=bla 
PE=3 SV=1 
30.745 
O68883;P0ABH8;P0ABH7;P20901;
P51031;P20902 
>sp|O68883|CISY_SALTY 
Citrate synthase OS=Salmonella 
typhimurium (strain LT2 / 
SGSC1412 / ATCC 700720) 
GN=gltA PE=3 
SV=1;>sp|P0ABH8|CISY_ECOL
6 Citrate synthase 
OS=Escherichia coli O6:H1 
(strain CFT073 / ATCC 700928 / 
48.106 
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UPEC) GN=gltA PE=3 
SV=1;>sp|P0ABH7|CISY 
O67820;P9WKI7;P9WKI6;P65168 
>sp|O67820|IMDH_AQUAE 
Inosine-5-monophosphate 
dehydrogenase OS=Aquifex 
aeolicus (strain VF5) GN=guaB 
PE=3 
SV=1;>sp|P9WKI7|IMDH_MYC
TU Inosine-5-monophosphate 
dehydrogenase 
OS=Mycobacterium tuberculosis 
(strain ATCC 25618 / H37Rv) 
GN=guaB PE=1 SV=1;>sp|P9W 
53.4 
O53079 
>sp|O53079|CILA_LEUMC 
Citrate lyase alpha chain 
OS=Leuconostoc 
mesenteroides subsp. cremoris 
GN=citF PE=3 SV=1 
55.067 
O52836 
>sp|O52836|TETW_BUTFI 
Tetracycline resistance protein 
TetW OS=Butyrivibrio 
fibrisolvens GN=tetW PE=3 
SV=1 
71.294 
O52762 
>sp|O52762|CATA_PSEAE 
Catalase OS=Pseudomonas 
aeruginosa (strain ATCC 15692 
/ DSM 22644 / CIP 104116 / 
JCM 14847 / LMG 12228 / 1C / 
PRS 101 / PAO1) GN=katA 
PE=1 SV=1 
55.588 
O52402 
>sp|O52402|ALF_EDWI9 
Fructose-bisphosphate aldolase 
OS=Edwardsiella ictaluri (strain 
93-146) GN=fba PE=3 SV=2 
39.154 
O08444 
>sp|O08444|UDP_KLEAE 
Uridine phosphorylase 
OS=Klebsiella aerogenes 
GN=udp PE=3 SV=1 
27.034 
O05508 
>sp|O05508|GMUD_BACSU 6-
phospho-beta-glucosidase 
GmuD OS=Bacillus subtilis 
(strain 168) GN=gmuD PE=1 
SV=1 
54.333 
J7T0S1 
>sp|J7T0S1|CSXB_CLOS1 
Exosporium protein B 
OS=Clostridium sporogenes 
(strain ATCC 15579) GN=csxB 
PE=1 SV=1 
16.609 
G8JZT0 
>sp|G8JZT0|SUSE_BACTN 
Outer membrane protein SusE 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susE PE=1 SV=1 
42.754 
G8JZS6 
>sp|G8JZS6|SUSF_BACTN 
Outer membrane protein SusF 
52.124 
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OS=Bacteroides 
thetaiotaomicron (strain ATCC 
29148 / DSM 2079 / NCTC 
10582 / E50 / VPI-5482) 
GN=susF PE=1 SV=1 
C7NB67;Q97LM4;P54716 
>sp|C7NB67|PAGL_LEPBD 6-
phospho-alpha-glucosidase 
OS=Leptotrichia buccalis (strain 
ATCC 14201 / DSM 1135 / JCM 
12969 / NCTC 10249 / C-1013-
b) GN=pagL PE=1 
SV=1;>sp|Q97LM4|MALH_CLO
AB Maltose-6-phosphate 
glucosidase MalH 
OS=Clostridium acetobutylicum 
(strai 
49.678 
C5D4X9 
>sp|C5D4X9|MTNN_GEOSW 5-
methylthioadenosine/S-
adenosylhomocysteine 
nucleosidase OS=Geobacillus 
sp. (strain WCH70) GN=mtnN 
PE=3 SV=1 
25.072 
C5CFU0 
>sp|C5CFU0|COAX_KOSOT 
Type III pantothenate kinase 
OS=Kosmotoga olearia (strain 
TBF 19.5.1) GN=coaX PE=3 
SV=1 
28.542 
C5CC02 
>sp|C5CC02|CH10_MICLC 10 
kDa chaperonin 
OS=Micrococcus luteus (strain 
ATCC 4698 / DSM 20030 / JCM 
1464 / NBRC 3333 / NCIMB 
9278 / NCTC 2665 / VKM Ac-
2230) GN=groS PE=3 SV=1 
10.346 
C5BF98 
>sp|C5BF98|MDH_EDWI9 
Malate dehydrogenase 
OS=Edwardsiella ictaluri (strain 
93-146) GN=mdh PE=3 SV=1 
32.348 
C5B846;B5XQC6;Q480A9;Q5QYN
4;B4RSL8;Q88K27;Q1IC15;B0KKR
8;A5W5E1;Q8ZPS9;Q8ZDW5;Q8Z
6I2;Q6D4G8;Q669Z0;Q5PH96;Q57
PV3;Q3Z267;Q32FI0;Q321L0;Q2N
T31;Q1CIG3;Q1C728;Q0T4S9;P0A
8M5;C6DFY6;C4LFH3;C0Q647;B7
LQ71;B5RAX3;B5QVW8;B5FJA8;B
5F7G2;B5BA42;B4TUF0;B4TGH1;
B4T4M8;B3PL16;B2VEM1;B2U397
;B2K668;B1JJ17;A9R0A8;A9N243;
A8GDQ5;A7FHG1;A4W9M3;A4TIL
1;A1S6G4;A1JMJ9;Q7N3P6;Q3JC
02;A6VYI1;Q8XE27;Q1RB76;Q0TH
B0;P0A8M4;P0A8M3;C4ZYI1;B7U
SA2;B7NT58;B7N556;B7MVJ7;B7
MAS9;B7M1C7;B7L6J2;B6IBD7;B5
YQ07;B1XGI1;B1LE12;B1IPK9;A8
A0R2;A7ZMI6;A1ABQ2 
>sp|C5B846|SYT_EDWI9 
Threonine--tRNA ligase 
OS=Edwardsiella ictaluri (strain 
93-146) GN=thrS PE=3 
SV=1;>sp|B5XQC6|SYT_KLEP3 
Threonine--tRNA ligase 
OS=Klebsiella pneumoniae 
(strain 342) GN=thrS PE=3 
SV=1;>sp|Q480A9|SYT_COLP3 
Threonine--tRNA ligase 
OS=Colwel 
73.938 
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C4Z4Y1 
>sp|C4Z4Y1|DAPAT_EUBE2 
LL-diaminopimelate 
aminotransferase 
OS=Eubacterium eligens (strain 
ATCC 27750 / VPI C15-48) 
GN=dapL PE=3 SV=1 
44.387 
C4XPE9;B8J2T3 
>sp|C4XPE9|KAD_DESMR 
Adenylate kinase 
OS=Desulfovibrio magneticus 
(strain ATCC 700980 / DSM 
13731 / RS-1) GN=adk PE=3 
SV=1;>sp|B8J2T3|KAD_DESDA 
Adenylate kinase 
OS=Desulfovibrio desulfuricans 
(strain ATCC 27774 / DSM 
6949) GN=adk PE=3 SV=1 
24.648 
C4L8U2 
>sp|C4L8U2|KAD_TOLAT 
Adenylate kinase 
OS=Tolumonas auensis (strain 
DSM 9187 / TA4) GN=adk PE=3 
SV=1 
23.46 
C4K799;Q9KP03;Q8ZJ93;Q8EK51;
Q8DE59;Q87SZ4;Q7MPG9;Q6LV9
7;Q6CZY9;Q664U0;Q5PK03;Q5E8
95;Q57J51;Q3YWV8;Q32B50;Q31
VX5;Q2NQP1;Q21M39;Q1CCW3;
Q1C2W6;Q12SU0;Q0T001;Q0I086
;Q0HNR8;Q089N5;P66075;P66074
;P66073;P46185;C6DG55;C5BGK6
;C4L7U9;C3LRN9;C0PZW4;B8EBI
6;B8CNF2;B7VLD8;B7LRR7;B6EP
U4;B5XNB2;B5RH34;B5R1F8;B5F
JJ5;B5FGD5;B5F7S6;B5BGW7;B4
TXC3;B4TJZ0;B4SUS1;B2VK77;B2
U2R9;B2K518;B1KMW4;B1JIY0;B0
TLZ3;A9R913;A9MSX9;A9MN68;A
9KWC1;A8GYZ5;A8GKH8;A8G1D0
;A8AQJ5;A7MWH7;A7FNL5;A6WH
U7;A6TEV3;A5F561;A4YBW4;A4T
H10;A3Q9A1;A3DA53;A1T0C3;A1
S237;A1RED3;A1JS08;A0KRP3;A4
SSY7;A0KF40;Q1R630;Q0TCG0;P
66072;P66071;P02413;C4ZUF6;B7
UK25;B7NLM0;B7NDS2;B7N185;B
7MCR6;B7M106;B7LI02;B6I215;B5
YTM2;B1X6F3;B1LHB5;B1IPZ8;A8
A5A6;A7ZSJ0;A1AGJ1 
>sp|C4K799|RL15_HAMD5 50S 
ribosomal protein L15 
OS=Hamiltonella defensa 
subsp. Acyrthosiphon pisum 
(strain 5AT) GN=rplO PE=3 
SV=1;>sp|Q9KP03|RL15_VIBC
H 50S ribosomal protein L15 
OS=Vibrio cholerae serotype O1 
(strain ATCC 39315 / El Tor 
Inaba N16961) GN=rp 
15.328 
C4K4K1 
>sp|C4K4K1|ENO_HAMD5 
Enolase OS=Hamiltonella 
defensa subsp. Acyrthosiphon 
pisum (strain 5AT) GN=eno 
PE=3 SV=1 
46.564 
C4K4F1 
>sp|C4K4F1|RPOB_HAMD5 
DNA-directed RNA polymerase 
subunit beta OS=Hamiltonella 
defensa subsp. Acyrthosiphon 
150.44 
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pisum (strain 5AT) GN=rpoB 
PE=3 SV=1 
C3PF03 
>sp|C3PF03|PUR9_CORA7 
Bifunctional purine biosynthesis 
protein PurH 
OS=Corynebacterium 
aurimucosum (strain ATCC 
700975 / DSM 44827 / CN-1) 
GN=purH PE=3 SV=1 
54.833 
C3L179;C1FTE9;B1KXQ3;B1IJJ6;
A7GGI0;A7FWM4;A5I524 
>sp|C3L179|OTC_CLOB6 
Ornithine carbamoyltransferase 
OS=Clostridium botulinum 
(strain 657 / Type Ba4) 
GN=arcB PE=3 
SV=1;>sp|C1FTE9|OTC_CLOB
J Ornithine 
carbamoyltransferase 
OS=Clostridium botulinum 
(strain Kyoto / Type A2) 
GN=arcB PE=3 
SV=1;>sp|B1KXQ3|OTC_CL 
37.248 
C1F111 
>sp|C1F111|RECR_ACIC5 
Recombination protein RecR 
OS=Acidobacterium capsulatum 
(strain ATCC 51196 / DSM 
11244 / JCM 7670 / NBRC 
15755 / NCIMB 13165 / 161) 
GN=recR PE=3 SV=1 
21.824 
C0ZZ48 
>sp|C0ZZ48|RUVB_RHOE4 
Holliday junction ATP-
dependent DNA helicase RuvB 
OS=Rhodococcus erythropolis 
(strain PR4 / NBRC 100887) 
GN=ruvB PE=3 SV=1 
38.812 
C0ZDI3 
>sp|C0ZDI3|PEPT_BREBN 
Peptidase T OS=Brevibacillus 
brevis (strain 47 / JCM 6285 / 
NBRC 100599) GN=pepT PE=3 
SV=1 
45.43 
C0QWA9 
>sp|C0QWA9|UXAC_BRAHW 
Uronate isomerase 
OS=Brachyspira hyodysenteriae 
(strain ATCC 49526 / WA1) 
GN=uxaC PE=3 SV=1 
54.435 
C0QJ86 
>sp|C0QJ86|DNLJ_DESAH 
DNA ligase 
OS=Desulfobacterium 
autotrophicum (strain ATCC 
43914 / DSM 3382 / HRM2) 
GN=ligA PE=3 SV=1 
75.283 
B9M7V0 
>sp|B9M7V0|CBID_GEODF 
Cobalt-precorrin-5B C(1)-
methyltransferase 
OS=Geobacter daltonii (strain 
DSM 22248 / JCM 15807 / FRC-
32) GN=cbiD PE=3 SV=1 
38.09 
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B9L698 
>sp|B9L698|CH60_NAUPA 60 
kDa chaperonin OS=Nautilia 
profundicola (strain ATCC BAA-
1463 / DSM 18972 / AmH) 
GN=groL PE=3 SV=1 
57.85 
B9JH59 
>sp|B9JH59|RSMH_AGRRK 
Ribosomal RNA small subunit 
methyltransferase H 
OS=Agrobacterium radiobacter 
(strain K84 / ATCC BAA-868) 
GN=rsmH PE=3 SV=1 
35.957 
B9J8C6 
>sp|B9J8C6|FMT_AGRRK 
Methionyl-tRNA 
formyltransferase 
OS=Agrobacterium radiobacter 
(strain K84 / ATCC BAA-868) 
GN=fmt PE=3 SV=1 
33.657 
B9E972 
>sp|B9E972|OLHYD_MACCJ 
Oleate hydratase 
OS=Macrococcus caseolyticus 
(strain JCSC5402) 
GN=MCCL_0076 PE=1 SV=1 
67.309 
B8J123 
>sp|B8J123|CH60_DESDA 60 
kDa chaperonin 
OS=Desulfovibrio desulfuricans 
(strain ATCC 27774 / DSM 
6949) GN=groL PE=3 SV=1 
58.418 
B8HMR7 
>sp|B8HMR7|RS8_CYAP4 30S 
ribosomal protein S8 
OS=Cyanothece sp. (strain PCC 
7425 / ATCC 29141) GN=rpsH 
PE=3 SV=1 
14.699 
B8DWI2 
>sp|B8DWI2|DAPA_BIFA0 4-
hydroxy-tetrahydrodipicolinate 
synthase OS=Bifidobacterium 
animalis subsp. lactis (strain 
AD011) GN=dapA PE=3 SV=1 
32.204 
B8DUT6;Q9AEM9 
>sp|B8DUT6|PHK_BIFA0 
Probable phosphoketolase 
OS=Bifidobacterium animalis 
subsp. lactis (strain AD011) 
GN=BLA_1483 PE=3 
SV=1;>sp|Q9AEM9|XFP_BIFAS 
Xylulose-5-phosphate/fructose-
6-phosphate phosphoketolase 
OS=Bifidobacterium animalis 
subsp. lactis (strain DS 
92.501 
B8DUF4 
>sp|B8DUF4|SYT_BIFA0 
Threonine--tRNA ligase 
OS=Bifidobacterium animalis 
subsp. lactis (strain AD011) 
GN=thrS PE=3 SV=1 
78.614 
B7VQ85;Q5E0Z0;B6ER09;B5ET10
;Q8DBM6;Q87M72;Q7MI93;A7N1R
1;Q8XHD3;Q0TMA0;Q0SQ01;Q7M
YB6;Q9KLJ9;C3LW10;A5EZR2;A1
SZE1 
>sp|B7VQ85|GLPK_VIBTL 
Glycerol kinase OS=Vibrio 
tasmaniensis (strain LGP32) 
GN=glpK PE=3 
SV=1;>sp|Q5E0Z0|GLPK_VIBF
55.869 
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1 Glycerol kinase OS=Vibrio 
fischeri (strain ATCC 700601 / 
ES114) GN=glpK PE=3 
SV=1;>sp|B6ER09|GLPK_ALIS
L Glycerol kinase OS=Aliivibrio 
salmon 
B7LKL8 
>sp|B7LKL8|TOLB_ESCF3 
ProteintolB OS=Escherichia 
fergusonii (strain ATCC 35469 / 
DSM 13698 / CDC 0568-73) 
GN=tolB PE=3 SV=1 
46.251 
B5YFZ0 
>sp|B5YFZ0|GLYA_THEYD 
Serine 
hydroxymethyltransferase 
OS=Thermodesulfovibrio 
yellowstonii (strain ATCC 51303 
/ DSM 11347 / YP87) GN=glyA 
PE=3 SV=1 
45.672 
B5Y369;A6TH52;Q93FU7;A4W5N7
;P43734;Q3YUJ8;Q328C5;Q31T77
;Q0SXD7;P95801;P0A6G2;B7LLS4
;B2TY17;Q1R3B7;Q0T9P9;P0A6G
1;P0A6G0;P0A6F9;C5A1D4;B7UP
W2;B7NTK1;B7NG80;B7MSG3;B7
MKU7;B7M8Q3;B7LC01;B6I614;B5
Z2F1;B1XDP6;B1LQG3;B1ITQ6;A8
A7N8;A7ZV11;Q8CWL1;Q7M7I6;Q
5E8E7;Q59686;Q4QN06;Q0I285;B
5FFX9;B0USK5;A5UH47;A5U9V3;
A3QA45;Q59176 
>sp|B5Y369|CH10_KLEP3 10 
kDa chaperonin OS=Klebsiella 
pneumoniae (strain 342) 
GN=groS PE=3 
SV=1;>sp|A6TH52|CH10_KLEP
7 10 kDa chaperonin 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=groS PE=3 
SV=1;>sp|Q93FU7|CH10_KLEA
E 10 k 
10.36 
B5Y277;A7MGB0 
>sp|B5Y277|DEOC_KLEP3 
Deoxyribose-phosphate 
aldolase OS=Klebsiella 
pneumoniae (strain 342) 
GN=deoC PE=3 
SV=1;>sp|A7MGB0|DEOC_CR
OS8 Deoxyribose-phosphate 
aldolase OS=Cronobacter 
sakazakii (strain ATCC BAA-
894) GN=deoC PE=3 SV=1 
27.712 
B5Y1Y1;A6T4K0;Q7UDT4;Q5PDF
2;Q57TF9;Q3Z5U9;Q32K31;Q326
H3;Q0T8D5;P58539;P06189;B7LV
T3;B5RGD3;B5R1T9;B5F783;B5BL
43;B4TWU8;B4TJ59;B4SU23;B2U
268;A9MYN8;A8ALP0;Q8FL89;Q1
RGD7;Q0TLS8;P58538;P08202;C4
ZPY5;B7UIA8;B7NHG8;B7N7T6;B
7MNR9;B7MAI5;B7M0F7;B7L4I3;B
6HZ42;B5YZ98;B1LFZ6;B1IRB6;A
7ZW12;A7ZHF3;A1A7A9;B5FI45;A
9MQF1;A4W6G6 
>sp|B5Y1Y1|ARAA_KLEP3 L-
arabinose isomerase 
OS=Klebsiella pneumoniae 
(strain 342) GN=araA PE=3 
SV=1;>sp|A6T4K0|ARAA_KLEP
7 L-arabinose isomerase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=araA PE=3 
SV=1;>sp|Q7UDT4|ARAA_SH 
55.868 
B5Y1P5 
>sp|B5Y1P5|PANB_KLEP3 3-
methyl-2-oxobutanoate 
hydroxymethyltransferase 
OS=Klebsiella pneumoniae 
28.043 
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(strain 342) GN=panB PE=3 
SV=1 
B5Y1K5;A6T4W8;Q3Z5J2;Q32JU3;
Q0T843;P0A9D9;B7LWA5;Q8X8Y7
;Q8FL11;Q1RG24;Q0TLG7;P0A9D
8;C4ZRQ8;B7UIL1;B7NIC7;B7N83
3;B7MBE7;B7M1A5;B6HZE0;B5Z0
E4;B1XD35;B1LGW7;B1IQH5;A7Z
WB2;A7ZHQ6;A1A7L0;A8GIE9;Q3
25X4 
>sp|B5Y1K5|DAPD_KLEP3 
2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-
succinyltransferase 
OS=Klebsiella pneumoniae 
(strain 342) GN=dapD PE=3 
SV=1;>sp|A6T4W8|DAPD_KLE
P7 2,3,4,5-tetrahydropyridine-
2,6-dicarboxylate N-
succinyltransferase 
OS=Klebsiella pneumoni 
29.832 
B5Y1J9;Q57T36;Q3Z5I6;Q32JT7;Q
325W8;Q0T837;P66739;P66738;P
0A808;C0Q6J5;B7LWB1;B5RHF7;
B5R3I5;B5FJ19;B5F8T3;B4TYD2;B
4TK47;B4SV01;B2U315;A9N0S0;A
9MPI9;Q1RG17;Q0TLG1;P0A807;
P0A806;P0A805;C4ZRR4;B7UIL7;
B7NID4;B7N839;B7MP32;B7MBF3
;B7M1X4;B7LGN3;B6HZE6;B5Z0F
1;B1XD41;B1LGX4;B1IQG9;A7ZW
B8;A7ZHR2;Q5PD60;B5BAM9;B2V
E11;A8GIE3;Q9KPV5;Q8GRF5;Q8
3BV4;Q7N8P4;Q7MIG3;Q6LN27;Q
6D8E0;Q65R74;Q60BA7;Q5E3E2;
Q4QM92;Q2NRL0;Q0I379;P57984;
P44307;C6DAI6;C5BHB9;C3LQ29;
B8F3D4;B6J8M4;B6IZA9;B6EK54;
B5F9X3;B4F2D0;B3GXB4;B0UUI5;
B0BUC8;A9N8Q7;A9KBR6;A7MXZ
7;A6VM32;A5UHW0;A5F618;A4SQ
H9;A3MZT6;A0KHG6 
>sp|B5Y1J9|RRF_KLEP3 
Ribosome-recycling factor 
OS=Klebsiella pneumoniae 
(strain 342) GN=frr PE=3 
SV=1;>sp|Q57T36|RRF_SALCH 
Ribosome-recycling factor 
OS=Salmonella choleraesuis 
(strain SC-B67) GN=frr PE=3 
SV=1;>sp|Q3Z5I6|RRF_SHISS 
Ribosome-recycling factor  
20.63 
B5Y1F4;A6T518;Q5PF73;Q57SU4;
Q3Z5B4;Q32JN6;Q325S4;P63227;
P63223;P63222;B7LW94;B5R5Q7;
B5R470;B5FJW2;B5EWJ3;B5BDQ
9;B4TYM6;B4T7P3;B4SVV2;B4EU
T1;B2U3R4;A9MY16;A4W6W5;Q7
N7F7;A8GAB6;A7MI45;A1JP02;Q0
TL93;P63226;P63225;P63224;C4Z
RV8;B7NKV9;B7N8A8;B7MQ59;B7
MC74;B7M252;B7LHF3;B6HZW0;B
5Z0M1;B1XD84;B1LHM8;B1IPP6;A
7ZWI6;A7ZHY1 
>sp|B5Y1F4|GMHA_KLEP3 
Phosphoheptose isomerase 
OS=Klebsiella pneumoniae 
(strain 342) GN=gmhA PE=3 
SV=1;>sp|A6T518|GMHA_KLE
P7 Phosphoheptose isomerase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=gmhA PE=3 
SV=1;>sp|Q5PF73|G 
20.9 
B5Y0U3;A8AK17;A6T5H9;A4W7A7
;Q5PFN3;Q57SB6;P66933;P66932
;C0Q7X2;B5R6U8;B5QTJ5;B5FKV
2;B5EXI7;B5BD84;B4TMC5;B4T9E
2;B4SWU0;A9MWX9;A7MFI9;Q3Z
4W7;Q325G5;Q0T7E7;P0A852;B2
U4P1;Q1RFA0;B7MD95;A1A8A5;Q
8FKA7;Q0TKK5;P0A851;P0A850;C
4ZTJ3;B7UJQ9;B7NJ58;B7N8Z0;B
7MQF2;B7M3S9;B7L673;B6HZP3;
B5Z3U4;B1XFM4;B1LJJ3;B1J012;
>sp|B5Y0U3|TIG_KLEP3 
Trigger factor OS=Klebsiella 
pneumoniae (strain 342) GN=tig 
PE=3 
SV=1;>sp|A8AK17|TIG_CITK8 
Trigger factor OS=Citrobacter 
koseri (strain ATCC BAA-895 / 
CDC 4225-83 / SGSC4696) 
GN=tig PE=3 
SV=1;>sp|A6T5H9|TIG_KLEP7 
Trigger factor OS=Kleb 
48.056 
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A7ZX94;A7ZIJ4;Q32JJ2;B7LME3;A
9MM24;A8GAQ8;Q7N0L2;B2VHT7
;Q8ZC64;Q66DT5;Q1CL66;Q1C4K
7;B2K6V6;B1JHS2;A9QZQ4;A7FL
C5;A4TPE4;B8F6T9;Q6D828;C6D
B54;B4EU52;A1JNN4 
B5XZM4 
>sp|B5XZM4|ATPB_KLEP3 
ATP synthase subunit beta 
OS=Klebsiella pneumoniae 
(strain 342) GN=atpD PE=3 
SV=1 
50.238 
B5XZD1;A6T6F6;Q5PCM7;Q57RL
3;P66870;P66869;C0PWE7;B5R68
9;B5QWG8;B5FNF9;B5EZG1;B5B
C72;B4TQ53;B4TBD7;B4SZE2;A9
MTQ2;A9MJL9;A7MQX5;A4W879;
Q3Z476;Q32IK3;Q324I4;Q0T6W6;
P0A839;B2TUB2;P0A838;P0A837;
P0A836;C4ZWK2;B7NMS9;B7N9W
6;B7LAD4;B6I7Z9;B5YQR7;B1X6Q
8;B1LLG1;B1IY02;A7ZXY8;A7ZJA8
;B7M5P1;B4ESR1;Q8ZH00;Q66DA
0;Q2NUM2;Q1CFM0;Q1CAG1;B2K
8F1;B1JG57;A9R2F2;A8GB83;A7F
KR4;A4TNT8;A1JRB6;Q5X7K6;Q5
WZ04;A5IH21;Q9JZP4;Q9JUT0;Q8
8FB2;Q883Z4;Q7N6V5;Q6F8L4;Q6
D7G2;Q5F878;Q4ZUW7;Q4KFY6;
Q4FVH9;Q48K68;Q3KFU6;Q2SD3
5;Q21IW6;Q1I7L3;Q02K73;P53593
;C6DCD6;C3K6N0;B7UVD3;B7I6T
2;B7GXK7;B4RL77;B2HXG0;B1JA
V3;B0VSL0;B0VEF2;B0KNW8;A9M
4F8;A6V7K5;A5W114;A4XV90;A3
M887;A1KTM6;C5BL83;A5WC33 
>sp|B5XZD1|SUCC_KLEP3 
Succinate--CoA ligase [ADP-
forming] subunit beta 
OS=Klebsiella pneumoniae 
(strain 342) GN=sucC PE=3 
SV=1;>sp|A6T6F6|SUCC_KLEP
7 Succinate--CoA ligase [ADP-
forming] subunit beta 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 70 
41.502 
B5XZC1 
>sp|B5XZC1|TOLB_KLEP3 
ProteintolB OS=Klebsiella 
pneumoniae (strain 342) 
GN=tolB PE=3 SV=1 
45.795 
B5XZ39;A6TGB9;A7ML69;A4WG6
9;Q5PIS0;Q57HC8;P67652;P6765
1;C5BB79;C0Q439;B5RF82;B5QX
L8;B5FPT8;B5F0S0;B5BJK6;B4TP
V0;B4TCM6;B4T0T6;A9MI36;A8AK
Z4 
>sp|B5XZ39|RRAA_KLEP3 
Regulator of ribonuclease 
activity A OS=Klebsiella 
pneumoniae (strain 342) 
GN=rraA PE=3 
SV=1;>sp|A6TGB9|RRAA_KLE
P7 Regulator of ribonuclease 
activity A OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) GN=rra 
17.385 
B5XZ19;A4WG54 
>sp|B5XZ19|ARGE_KLEP3 
Acetylornithine deacetylase 
OS=Klebsiella pneumoniae 
(strain 342) GN=argE PE=3 
SV=1;>sp|A4WG54|ARGE_ENT
38 Acetylornithine deacetylase 
42.352 
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OS=Enterobacter sp. (strain 
638) GN=argE PE=3 SV=1 
B5XZ01;A6TGF8;Q8FBR5;B7UMM
8;B3GZT6;B0BS03;A3MYG9;B0U
W18;Q4QMF8;P44851;A5UHP2;A5
UDY7;Q9KVW0;Q8DDG1;Q87KB6;
Q7MGI8;C3LPA1;A5F497;A4WG37
;B4F1U3;Q8Z377;Q7MYJ5;Q5PK0
0;Q57HU7;Q2NQA6;P40810;C6DH
H1;C0Q2U8;B5RFT3;B5QVG2;B5F
N65;B5EZ28;B5BIR7;B4TNS1;B4T
B04;B4SZ17;A9MXE2;A8GL60;A0
KS32 
>sp|B5XZ01|ILVD_KLEP3 
Dihydroxy-acid dehydratase 
OS=Klebsiella pneumoniae 
(strain 342) GN=ilvD PE=3 
SV=1;>sp|A6TGF8|ILVD_KLEP
7 Dihydroxy-acid dehydratase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=ilvD PE=3 SV=1;>sp|Q8FB 
65.691 
B5XYL1;A6TGI8 
>sp|B5XYL1|HEM3_KLEP3 
Porphobilinogen deaminase 
OS=Klebsiella pneumoniae 
(strain 342) GN=hemC PE=3 
SV=1;>sp|A6TGI8|HEM3_KLEP
7 Porphobilinogen deaminase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=hemC PE=3 SV=1 
33.725 
B5XY99;A6T6Z0;A4W8R7 
>sp|B5XY99|SYS_KLEP3 
Serine--tRNA ligase 
OS=Klebsiella pneumoniae 
(strain 342) GN=serS PE=3 
SV=1;>sp|A6T6Z0|SYS_KLEP7 
Serine--tRNA ligase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=serS PE=3 SV=1 
48.645 
B5XXK6 
>sp|B5XXK6|OPGG_KLEP3 
Glucans biosynthesis protein G 
OS=Klebsiella pneumoniae 
(strain 342) GN=mdoG PE=3 
SV=1 
57.821 
B5XWV7;A6T9S2 
>sp|B5XWV7|RIHA_KLEP3 
Pyrimidine-specific 
ribonucleoside hydrolase RihA 
OS=Klebsiella pneumoniae 
(strain 342) GN=rihA PE=3 
SV=1;>sp|A6T9S2|RIHA_KLEP
7 Pyrimidine-specific 
ribonucleoside hydrolase RihA 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC  
34.003 
B5XW55;A6TAN5;Q8ZEX4;Q6D54
7;Q66AX1;Q5PNK8;Q57NN9;Q3Z0
T2;Q32GZ2;Q31ZQ8;Q1CJJ7;Q1C
850;Q0T5I0;P65216;P65215;P0A7
16;C5B817;C0Q363;B7LSH5;B5R6
I4;B5R3K3;B5FU23;B5F4I0;B5BI79
;B4TXT8;B4TKA0;B4SUF8;B4EVS
0;B2TZW3;B2K2Z4;B1JM81;A9QZ
>sp|B5XW55|KDSA_KLEP3 2-
dehydro-3-
deoxyphosphooctonate aldolase 
OS=Klebsiella pneumoniae 
(strain 342) GN=kdsA PE=3 
SV=1;>sp|A6TAN5|KDSA_KLE
P7 2-dehydro-3-
deoxyphosphooctonate aldolase 
30.824 
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04;A9MW08;A9MPA5;A8GDA7;A8
AG06;A7FIF7;A4TJN3;Q8XDE7;Q8
FHZ8;Q1RCM3;P0A715;C4ZTQ6;B
7UQA3;B7NUY1;B7N426;B7MTZ9;
B7MKB7;B7LXX2;B7LGX6;B6I9T0;
B5YXN3;B1XAQ6;B1LH85;B1ITN8;
A7ZZF1;A7ZKY9;A1AAE2;B2VEI7;
A7MKA7;A4WBC2;A1JRS8;Q7N58
3;Q65TB4;Q2NRS7;Q0I3B9;P5785
3;B8F521;B3GZI6;B0UUE2;B0BU6
9;A6VP95;O68662;P61653 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 785 
B5XVC4;Q8ZBU3;Q6D1T5;Q66E6
3;Q1CLK4;Q1C416;C6DCQ4;B2K5
Y4;B1JJ95;A9R0V3;A9MFZ6;A8AN
P5;A7FLR2;A4TQ57;A1JK16 
>sp|B5XVC4|LUXS_KLEP3 S-
ribosylhomocysteine lyase 
OS=Klebsiella pneumoniae 
(strain 342) GN=luxS PE=3 
SV=1 
19.454 
B5XUD5;A6TDR5;Q8Z3X0;A4WE5
5;A7MR85 
>sp|B5XUD5|GCSP_KLEP3 
Glycine dehydrogenase 
(decarboxylating) OS=Klebsiella 
pneumoniae (strain 342) 
GN=gcvP PE=3 
SV=1;>sp|A6TDR5|GCSP_KLE
P7 Glycine dehydrogenase 
(decarboxylating) OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578)  
104.61 
B5XTS2;A6TF37;A4WFK2;Q9EXI9;
Q8ZLI7;Q8ZJI0;Q664J6;Q5PLY6;Q
57IW3;Q3YWL1;Q32AM7;Q31VL8;
Q1CCL5;Q1C2L8;Q0SZQ1;P63023
;C0Q0I7;B7LSB7;B5R7K3;B5R371;
B5FKD2;B5F8M8;B5BHG9;B4TY7
1;B4TKT8;B4SVL5;B2U3M4;B2K5
V9;B1JHZ3;A9R4D2;A9MTT1;A9M
MB3;A8GKT7;A8AQW7;A7FNW0;A
4TGR7;A1JSF6;Q1R5M0;Q0TC53;
P63022;P63021;P63020;C4ZVW3;
B7UKB9;B7NMH9;B7NE19;B7N14
7;B7MDP0;B7M1X0;B7L4U4;B6I2X
8;B5YTW5;B1X760;B1LHL4;B1IP5
1;A8A5M2;A7ZSU3;A1AGT8 
>sp|B5XTS2|NFUA_KLEP3 
Fe/S biogenesis protein NfuA 
OS=Klebsiella pneumoniae 
(strain 342) GN=nfuA PE=3 
SV=1;>sp|A6TF37|NFUA_KLEP
7 Fe/S biogenesis protein NfuA 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=nfuA PE=3 SV=1;>sp| 
21.004 
B5XTJ1;A6TFK4;B2VL52;Q8XGG5
;Q7CPH8;Q5PBZ5;Q57ID2;C0Q1U
3;B7LTL6;B5RGH7;B5R5D4;B5FL
H9;B5EXB6;B5BHY4;B4TZV2;B4T
994;B4SXB2;A9MVK3;A9MKR5;A8
ARJ6;A4W536;Q8KRM2;C6DIA3;A
8GLB9;A1JHY4;B4F139;Q8ZJM7;
Q6DAT1;Q66GB9;Q1CD20;Q1C28
5;B2JYQ0;B1JQV6;A9R690;A7FC
V1;A4TSB9 
>sp|B5XTJ1|SECB_KLEP3 
Protein-export protein SecB 
OS=Klebsiella pneumoniae 
(strain 342) GN=secB PE=3 
SV=1;>sp|A6TFK4|SECB_KLEP
7 Protein-export protein SecB 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=secB PE=3 SV=1 
17.19 
B5XSX9;A6TEI3;Q8ZLT3;Q8Z3I0;
Q83JG0;Q5PL97;Q57JI3;Q3YX77;
Q32BG9;Q31W43;Q0T0B7;C0PZ5
0;B7LR33;B5REN2;B5QZV4;B5BG
J1;B2U211;A9N728;A9MP39;Q8X9
>sp|B5XSX9|PNP_KLEP3 
Polyribonucleotide 
nucleotidyltransferase 
OS=Klebsiella pneumoniae 
(strain 342) GN=pnp PE=3 
76.859 
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M3;Q8FD87;Q1R6H4;Q0TCU5;P05
055;C4ZSQ5;B7UJ59;B7NKN3;B7
NDF0;B7N0U9;B7MB85;B7M072;B
7LH99;B6I1N9;B5YS54;B1XGX6;B
1LFR6;B1IQV7;A8A4Y0;A7ZS61;A
1AG69;A8AQ53;A4WEX9;Q66F56;
B2K2Q9;Q1CM51;Q1C3L8;Q0WBF
9;B1JLX6;A9R5A9;A7FMR8;A4TQ
U4;O34275;A1JIX3;C5BFC1;A7MI
N6;Q6D9A1;C6DKK7;Q4QNV7;P4
4584;B8F492;A5UG34;A5UAQ6;Q
0I2T0;B0UTJ5;Q9CLU1;B3GXC1;B
0BUD5;A3MZU3;Q65VB0;A6VR10;
Q9KU76;C3LSQ2;A5F913 
SV=1;>sp|A6TEI3|PNP_KLEP7 
Polyribonucleotide 
nucleotidyltransferase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
B5XSQ7;A6TEQ3;A7MNR3 
>sp|B5XSQ7|MDH_KLEP3 
Malate dehydrogenase 
OS=Klebsiella pneumoniae 
(strain 342) GN=mdh PE=3 
SV=1;>sp|A6TEQ3|MDH_KLEP
7 Malate dehydrogenase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=mdh PE=3 
SV=1;>sp|A7MNR3|MDH_CRO
S8 Mal 
32.398 
B5XR74;A6T8U4 
>sp|B5XR74|Y2871_KLEP3 
UPF0482 protein KPK_2871 
OS=Klebsiella pneumoniae 
(strain 342) GN=KPK_2871 
PE=3 
SV=1;>sp|A6T8U4|Y1554_KLE
P7 UPF0482 protein 
KPN78578_15540 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=KPN78578_15540  
12.916 
B5XQU5;A6T900;A4WAF9 
>sp|B5XQU5|UXAB_KLEP3 
Altronate oxidoreductase 
OS=Klebsiella pneumoniae 
(strain 342) GN=uxaB PE=3 
SV=1;>sp|A6T900|UXAB_KLEP
7 Altronate oxidoreductase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=uxaB PE=3 
SV=1;>sp|A4WAF9|U 
54.392 
B5XQ02;A6TB33;Q7N550;C4K4U6 
>sp|B5XQ02|Y1906_KLEP3 
Probable transcriptional 
regulatory protein KPK_1906 
OS=Klebsiella pneumoniae 
(strain 342) GN=KPK_1906 
PE=3 
SV=1;>sp|A6TB33|Y2343_KLE
P7 Probable transcriptional 
26.317 
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regulatory protein 
KPN78578_23430 
OS=Klebsiella pneumoniae 
subsp. pneumo 
B5XPZ4;A6TB41 
>sp|B5XPZ4|CUTC_KLEP3 
Copper homeostasis protein 
CutC OS=Klebsiella 
pneumoniae (strain 342) 
GN=cutC PE=3 
SV=1;>sp|A6TB41|CUTC_KLEP
7 Copper homeostasis protein 
CutC OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) GN=cutC 
PE=3 SV= 
26.458 
B5XPE6;A6TBC4;A4WC70;Q83KJ
6;Q3Z0G4;Q32EF0;Q323J1;Q0T3A
6;B7LUF2;B2TYF9;Q8Z5J9;Q5PD
P4;Q57MS2;P10369;C0Q1K1;B5R
BR3;B5QZL3;B5FM42;B5EX40;B5
BFB9;B4TMR6;B4T9N5;B4SX42;A
9MSC2;A9ML15;A8AEK3;A7MJP4;
Q9S5G6;Q8FG51;Q1RA52;Q0TG6
6;P06986;C4ZSB0;B7UT58;B7NQ
G9;B7NC61;B7MWU0;B7MDH5;B7
M400;B7L9P8;B6I848;B5YU77;B1
X6V8;B1LP20;B1IZ53;A8A1P5;A7Z
NJ3;A1ACN3 
>sp|B5XPE6|HIS8_KLEP3 
Histidinol-phosphate 
aminotransferase OS=Klebsiella 
pneumoniae (strain 342) 
GN=hisC PE=3 
SV=1;>sp|A6TBC4|HIS8_KLEP
7 Histidinol-phosphate 
aminotransferase OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) GN=h 
38.632 
B5XNV6;A6TBX2;Q57M30;P0A1Y7
;P0A1Y6;B5RCF1;B5R307;B5FPG
7;B4TBJ2;Q5PN53;C0Q041;B5EZ
K7;B5BCM0;B4TPK8;B4SYZ7;A9N
582;A9MJ99;Q9I0J9;Q88FH5;Q1I7
Z8;Q02ND1;B1J6N2;B0KMY0;A6V
4E7;A5W190;A4XV04;A4WCR5;Q0
T2K1;Q6D2R9;B2VIV5;Q83QS6;Q
3YZS4;Q32DQ3;Q31YH5;B7LM46;
B2TW67;A8ADV3;Q0TFG0;P33599
;Q8XCW9;Q8FFJ7;Q1R9D1;B7UF
U4;B7NNW5;B7N5P8;B7MXG5;B7
MG50;B7M5W5;B7LAU8;B6I7N6;B
5YXS6;B1X8Z8;B1LLN9;B1IXQ6;A
8A2F5;A7ZPA0;A1ADD4 
>sp|B5XNV6|NUOCD_KLEP3 
NADH-quinone oxidoreductase 
subunit C/D OS=Klebsiella 
pneumoniae (strain 342) 
GN=nuoC PE=3 
SV=1;>sp|A6TBX2|NUOCD_KL
EP7 NADH-quinone 
oxidoreductase subunit C/D 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578 
69.099 
B5XNU6;A8ADU4 
>sp|B5XNU6|Y1463_KLEP3 
UPF0304 protein KPK_1463 
OS=Klebsiella pneumoniae 
(strain 342) GN=KPK_1463 
PE=3 SV=1 
19.397 
B5XNK4;A6TCE4 
>sp|B5XNK4|PEPB_KLEP3 
Peptidase B OS=Klebsiella 
pneumoniae (strain 342) 
GN=pepB PE=3 
SV=1;>sp|A6TCE4|PEPB_KLEP
7 Peptidase B OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
46.217 
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700721 / MGH 78578) 
GN=pepB PE=3 SV=1 
B5XNB4;A6TEV1 
>sp|B5XNB4|RS13_KLEP3 30S 
ribosomal protein S13 
OS=Klebsiella pneumoniae 
(strain 342) GN=rpsM PE=3 
SV=1;>sp|A6TEV1|RS13_KLEP
7 30S ribosomal protein S13 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=rpsM PE=3 SV=1 
13.21 
B5RRF3;B5RLS4 
>sp|B5RRF3|RL13_BORRA 
50S ribosomal protein L13 
OS=Borrelia recurrentis (strain 
A1) GN=rplM PE=3 
SV=1;>sp|B5RLS4|RL13_BORD
L 50S ribosomal protein L13 
OS=Borrelia duttonii (strain Ly) 
GN=rplM PE=3 SV=1 
17.303 
B5FAF9;Q5E326;B1GYL7 
>sp|B5FAF9|ENO_VIBFM 
Enolase OS=Vibrio fischeri 
(strain MJ11) GN=eno PE=3 
SV=1;>sp|Q5E326|ENO_VIBF1 
Enolase OS=Vibrio fischeri 
(strain ATCC 700601 / ES114) 
GN=eno PE=3 SV=1 
45.514 
B3WF72;Q037X5 
>sp|B3WF72|Y1944_LACCB 
UPF0342 protein LCABL_19440 
OS=Lactobacillus casei (strain 
BL23) GN=LCABL_19440 PE=3 
SV=1;>sp|Q037X5|Y1724_LAC
P3 UPF0342 protein LSEI_1724 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
NRRL B-441 
13.22 
B3WBT3;Q033M9 
>sp|B3WBT3|MTLD_LACCB 
Mannitol-1-phosphate 5-
dehydrogenase 
OS=Lactobacillus casei (strain 
BL23) GN=mtlD PE=3 
SV=1;>sp|Q033M9|MTLD_LAC
P3 Mannitol-1-phosphate 5-
dehydrogenase 
OS=Lactobacillus paracasei 
(strain ATCC 334 / BCRC 17002 
/ CIP 107868 / KCTC 3260 / 
42.453 
B3WAJ7 
>sp|B3WAJ7|KAD_LACCB 
Adenylate kinase 
OS=Lactobacillus casei (strain 
BL23) GN=adk PE=3 SV=1 
23.667 
B3QY22 
>sp|B3QY22|EFTU_CHLT3 
Elongation factor Tu 
OS=Chloroherpeton thalassium 
(strain ATCC 35110 / GB-78) 
GN=tuf PE=3 SV=1 
42.99 
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B2VGN7;A8G911;P41121;B4F2C3;
Q2NW19;Q7MYZ0 
>sp|B2VGN7|PNP_ERWT9 
Polyribonucleotide 
nucleotidyltransferase 
OS=Erwinia tasmaniensis (strain 
DSM 17950 / CIP 109463 / 
Et1/99) GN=pnp PE=3 
SV=1;>sp|A8G911|PNP_SERP5 
Polyribonucleotide 
nucleotidyltransferase 
OS=Serratia proteamaculans 
(strain 568) GN=pnp P 
76.715 
B2V307;B2TL32;A6LVY2 
>sp|B2V307|Y1879_CLOBA 
UPF0210 protein CLH_1879 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=CLH_1879 PE=3 
SV=1;>sp|B2TL32|Y1718_CLO
BB UPF0210 protein 
CLL_A1718 OS=Clostridium 
botulinum (strain Eklund 17B / 
Type B) GN=CLL_A1718 PE=3 
SV=1;>sp|A 
47.435 
B2V1S6;B2TRE4;A6M3K0 
>sp|B2V1S6|PURA_CLOBA 
Adenylosuccinate synthetase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=purA PE=3 
SV=1;>sp|B2TRE4|PURA_CLO
BB Adenylosuccinate 
synthetase OS=Clostridium 
botulinum (strain Eklund 17B / 
Type B) GN=purA PE=3 
SV=1;>sp|A6M3K0| 
47.393 
B2V049;B2TR28 
>sp|B2V049|GLGA_CLOBA 
Glycogen synthase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=glgA PE=3 
SV=1;>sp|B2TR28|GLGA_CLO
BB Glycogen synthase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=glgA PE=3 SV=1 
55.86 
B2UZL5;B2TK15 
>sp|B2UZL5|SECA_CLOBA 
Protein translocase subunit 
SecA OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=secA PE=3 
SV=1;>sp|B2TK15|SECA_CLO
BB Protein translocase subunit 
SecA OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=secA PE=3 SV=1 
94.707 
B2UZK0;B2TK00;Q9Z687;C3KYJ3;
C1FQP5;B1KSS8;B1IE34;A7G9Q9
;A7FQH9;A5HY52;Q180W5;A5N3H
7;Q4A604;Q8XID4;Q0TNC4;Q0SQ
>sp|B2UZK0|ATPB_CLOBA 
ATP synthase subunit beta 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
50.327 
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Z5;P33253;Q9PR15;B5ZAW1;B1AI
B8;Q8KAC9;Q3B6W8;Q3AP13;P35
110;B4SAN6;B3EJK9;B3EDQ7;A4
SC45;A1BCJ2;B3QUP6;Q601Z5;Q
4AAV7;Q4A8V9;P42465;A5EBX1 
GN=atpD PE=3 
SV=1;>sp|B2TK00|ATPB_CLOB
B ATP synthase subunit beta 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=atpD PE=3 
SV=1;>sp|Q9Z687|ATPB 
B2UZJ8;B2TJZ8;A6LQH4;Q8XID2;
Q0TNC2;Q0SQZ3 
>sp|B2UZJ8|ATPA_CLOBA 
ATP synthase subunit alpha 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=atpA PE=3 
SV=1;>sp|B2TJZ8|ATPA_CLOB
B ATP synthase subunit alpha 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=atpA PE=3 
SV=1;>sp|A6LQH4|AT 
55.429 
B2UYW3;B2TIT5 
>sp|B2UYW3|SYT_CLOBA 
Threonine--tRNA ligase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=thrS PE=3 
SV=1;>sp|B2TIT5|SYT_CLOBB 
Threonine--tRNA ligase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=thrS PE=3 SV=1 
73.795 
B2UYT8;B2TIR4;B0JRP2;B2J2U6 
>sp|B2UYT8|ILVC_CLOBA 
Ketol-acid reductoisomerase 
(NADP(+)) OS=Clostridium 
botulinum (strain Alaska E43 / 
Type E3) GN=ilvC PE=3 
SV=1;>sp|B2TIR4|ILVC_CLOBB 
Ketol-acid reductoisomerase 
(NADP(+)) OS=Clostridium 
botulinum (strain Eklund 17B / 
Type B) GN=ilvC P 
37.036 
B2UXS0;B2TI01 
>sp|B2UXS0|SYN_CLOBA 
Asparagine--tRNA ligase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=asnS PE=3 
SV=1;>sp|B2TI01|SYN_CLOBB 
Asparagine--tRNA ligase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=asnS PE=3 SV=1 
53.34 
B2UXF7;B2TPG6 
>sp|B2UXF7|CBID_CLOBA 
Cobalt-precorrin-5B C(1)-
methyltransferase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=cbiD PE=3 
SV=1;>sp|B2TPG6|CBID_CLOB
B Cobalt-precorrin-5B C(1)-
methyltransferase 
41.825 
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OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
B2UW93;B2TNG3;A6TVR2 
>sp|B2UW93|PYRB_CLOBA 
Aspartate carbamoyltransferase 
OS=Clostridium botulinum 
(strain Alaska E43 / Type E3) 
GN=pyrB PE=3 
SV=1;>sp|B2TNG3|PYRB_CLO
BB Aspartate 
carbamoyltransferase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=pyrB PE=3 SV=1;>sp|A 
35.169 
B2TS78;A6LUD2;C3KTL7;C1FL32;
B2V5B7;B1L0V4;B1IMX1;A7GI22;
A7FYA5;A5I6N5 
>sp|B2TS78|DAPH_CLOBB 
2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-
acetyltransferase 
OS=Clostridium botulinum 
(strain Eklund 17B / Type B) 
GN=dapH PE=3 
SV=1;>sp|A6LUD2|DAPH_CLO
B8 2,3,4,5-tetrahydropyridine-
2,6-dicarboxylate N-
acetyltransferase OS=Clostri 
25.085 
B2ICU4 
>sp|B2ICU4|CH60_BEII9 60 
kDa chaperonin OS=Beijerinckia 
indica subsp. indica (strain 
ATCC 9039 / DSM 1715 / NCIB 
8712) GN=groL PE=3 SV=1 
57.711 
B2GIL1 
>sp|B2GIL1|EFG_KOCRD 
Elongation factor G OS=Kocuria 
rhizophila (strain ATCC 9341 / 
DSM 348 / NBRC 103217 / 
DC2201) GN=fusA PE=3 SV=1 
77.514 
B2GDD5 
>sp|B2GDD5|Y1331_LACF3 
UPF0342 protein LAF_1331 
OS=Lactobacillus fermentum 
(strain NBRC 3956 / LMG 
18251) GN=LAF_1331 PE=3 
SV=1 
13.72 
B2FNJ0 
>sp|B2FNJ0|SMF1_STRMK 
Major fimbrial subunit SMF-1 
OS=Stenotrophomonas 
maltophilia (strain K279a) 
GN=smf-1 PE=1 SV=1 
17.205 
B2AIJ5 
>sp|B2AIJ5|HOA_CUPTR 4-
hydroxy-2-oxovalerate aldolase 
OS=Cupriavidus taiwanensis 
(strain DSM 17343 / BCRC 
17206 / CIP 107171 / LMG 
19424 / R1) GN=mhpE PE=3 
SV=1 
36.628 
B2A4D6 
>sp|B2A4D6|EFG_NATTJ 
Elongation factor G 
OS=Natranaerobius 
thermophilus (strain ATCC BAA-
77.425 
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1301 / DSM 18059 / JW/NM-
WN-LF) GN=fusA PE=3 SV=1 
B1MVW3;Q03ZK4 
>sp|B1MVW3|ENO_LEUCK 
Enolase OS=Leuconostoc 
citreum (strain KM20) GN=eno 
PE=3 
SV=1;>sp|Q03ZK4|ENO_LEUM
M Enolase OS=Leuconostoc 
mesenteroides subsp. 
mesenteroides (strain ATCC 
8293 / NCDO 523) GN=eno 
PE=3 SV=1 
47.495 
B1KTJ5 
>sp|B1KTJ5|PGK_CLOBM 
Phosphoglycerate kinase 
OS=Clostridium botulinum 
(strain Loch Maree / Type A3) 
GN=pgk PE=3 SV=1 
43.27 
B1KF50 
>sp|B1KF50|IHFB_SHEWM 
Integration host factor subunit 
beta OS=Shewanella woodyi 
(strain ATCC 51908 / MS32) 
GN=ihfB PE=3 SV=1 
10.703 
B0TJY6 
>sp|B0TJY6|NRDR_SHEHH 
Transcriptional repressor NrdR 
OS=Shewanella halifaxensis 
(strain HAW-EB4) GN=nrdR 
PE=3 SV=1 
17.062 
B0SYX8;Q1QMI9 
>sp|B0SYX8|ENO_CAUSK 
Enolase OS=Caulobacter sp. 
(strain K31) GN=eno PE=3 
SV=1;>sp|Q1QMI9|ENO_NITHX 
Enolase OS=Nitrobacter 
hamburgensis (strain DSM 
10229 / NCIMB 13809 / X14) 
GN=eno PE=3 SV=1 
44.949 
B0S1E5 
>sp|B0S1E5|IF2_FINM2 
Translation initiation factor IF-2 
OS=Finegoldia magna (strain 
ATCC 29328) GN=infB PE=3 
SV=1 
85.138 
A9MKA9;Q3Z4C2;Q324M6;Q0T6S
6;P59688;B7LKT5;B2TU53;Q8FJX
7;Q1REP9;Q0TK13;P0A760;P0A75
9;C4ZWF4;B7UKV0;B7NMM9;B7N
9S4;B7MPI3;B7MFT4;B7M5J6;B7L
9L4;B6HYN6;B5YQM0;B1X6L1;B1
LLC0;B1IY50;A7ZXT7;A7ZJ60;A1A
8T7;Q8ZDE1;Q66DC7;Q1CKN7;Q
1C537;B2K8A2;B1JG88;A9R7S4;A
7MQT6;A7FKU3;A4TNY0;Q32IQ2;
Q9CMF4;Q65QE8 
>sp|A9MKA9|NAGB_SALAR 
Glucosamine-6-phosphate 
deaminase OS=Salmonella 
arizonae (strain ATCC BAA-731 
/ CDC346-86 / RSK2980) 
GN=nagB PE=3 
SV=1;>sp|Q3Z4C2|NAGB_SHIS
S Glucosamine-6-phosphate 
deaminase OS=Shigella sonnei 
(strain Ss046) GN=nagB PE=3 
SV=1;>sp|Q32 
29.669 
A9KKU0;Q92BN8;Q71ZJ7;P0DJM2
;G2K046;C1KVC0;B8DE38;A0AIS4 
>sp|A9KKU0|DNAK_LACP7 
Chaperone protein DnaK 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=dnaK PE=3 
66.126 
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SV=1;>sp|Q92BN8|DNAK_LISI
N Chaperone protein DnaK 
OS=Listeria innocua serovar 6a 
(strain ATCC BAA-680 / CLIP 
11262) GN=dn 
A9KJI0 
>sp|A9KJI0|RS8_LACP7 30S 
ribosomal protein S8 
OS=Lachnoclostridium 
phytofermentans (strain ATCC 
700394 / DSM 18823 / ISDg) 
GN=rpsH PE=3 SV=1 
14.498 
A8YXL4;Q5FM81;Q1GBK9;Q04C0
6 
>sp|A8YXL4|RS17_LACH4 30S 
ribosomal protein S17 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rpsQ 
PE=3 
SV=1;>sp|Q5FM81|RS17_LACA
C 30S ribosomal protein S17 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsQ PE=3 
SV=1 
10.562 
A8YXK8;Q74L86;Q046C2 
>sp|A8YXK8|RL2_LACH4 50S 
ribosomal protein L2 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rplB 
PE=3 
SV=1;>sp|Q74L86|RL2_LACJO 
50S ribosomal protein L2 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1 / 
NCC 533) GN=rplB PE=3 
SV=1;>sp|Q046C2|RL2_LA 
30.297 
A8YXJ8;Q661M9;Q59191;Q0SNB8
;B7J1W1;B5RRJ7;B5RLU9;B2S09
2;A1QZH7;Q9CEN6;Q02X59;A2R
ML9;Q9Z9A0;Q822J1;Q5L5I3;Q3K
M47;Q255E6;P56869;P0CE09;B0B
BU6;B0B7N1 
>sp|A8YXJ8|RPOB_LACH4 
DNA-directed RNA polymerase 
subunit beta OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=rpoB PE=3 SV=1 
135.7 
A8YXJ3;Q5FMA2 
>sp|A8YXJ3|HSLO_LACH4 33 
kDa chaperonin 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=hslO 
PE=3 
SV=1;>sp|Q5FMA2|HSLO_LAC
AC 33 kDa chaperonin 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=hslO PE=3 
SV=1 
32.09 
A8YWE1;Q037Z6;B3WF49 
>sp|A8YWE1|SYT_LACH4 
Threonine--tRNA ligase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=thrS 
PE=3 SV=1 
73.46 
A8YVR8;Q5FJM4;Q044C9;P61334
;Q8DS12 
>sp|A8YVR8|EFTS_LACH4 
Elongation factor Ts 
37.706 
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OS=Lactobacillus helveticus 
(strain DPC 4571) GN=tsf PE=3 
SV=1;>sp|Q5FJM4|EFTS_LACA
C Elongation factor Ts 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=tsf PE=3 
SV=1;>sp|Q044C9|EFTS_LACG 
A8YVR3 
>sp|A8YVR3|SYP_LACH4 
Proline--tRNA ligase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=proS 
PE=3 SV=1 
63.228 
A8YVQ7;Q5FJN6;Q74IS8;Q044B7 
>sp|A8YVQ7|IF2_LACH4 
Translation initiation factor IF-2 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=infB 
PE=3 
SV=1;>sp|Q5FJN6|IF2_LACAC 
Translation initiation factor IF-2 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=infB PE 
97.278 
A8YVJ7 
>sp|A8YVJ7|SYN_LACH4 
Asparagine--tRNA ligase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=asnS 
PE=3 SV=1 
50.26 
A8YUS4;Q5M5B0;Q5M0S4;Q03LN
0;Q74JU4;Q042T7;C4LJV6;Q83MI
6;Q83G50;Q9L7X5;Q8YHC7;Q8G0
I5;Q6G3Z2;Q6G177;Q6AFZ6;Q2Y
PX2;C0RJ80;B2S5W0;B0CGR0;A9
M5C1;A9ISA8;A6X117;A1USA8;Q9
2QQ2;Q8UFY5;Q2K9U6;Q1MIM6;
C3MA45;B9JVD6;B5ZY09;B3PVY5
;A6U7U8;B8HA33;A1SME0;A9WU
W1;A5VQN3;A0LSV2;A0JXL2;B5R
PV8;B5RMG2;Q6NFU7;C3PI25;Q8
91J8;C5CAX2;Q7UKU7 
>sp|A8YUS4|CLPX_LACH4 
ATP-dependent Clp protease 
ATP-binding subunit ClpX 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=clpX 
PE=3 
SV=1;>sp|Q5M5B0|CLPX_STR
T2 ATP-dependent Clp protease 
ATP-binding subunit ClpX 
OS=Streptococcus thermophilus 
(strain ATCC B 
47.074 
A8YUS3 
>sp|A8YUS3|TIG_LACH4 
Trigger factor OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=tig PE=3 SV=1 
50.48 
A8YUR0 
>sp|A8YUR0|DEF_LACH4 
Peptide deformylase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=def PE=3 
SV=1 
20.66 
A8YUL2;Q5FKX2 
>sp|A8YUL2|RS4_LACH4 30S 
ribosomal protein S4 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rpsD 
PE=3 
SV=1;>sp|Q5FKX2|RS4_LACA
C 30S ribosomal protein S4 
OS=Lactobacillus acidophilus 
23.386 
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(strain ATCC 700396 / NCK56 / 
N2 / NCFM) GN=rpsD PE=3 
SV=1 
A8YUI5 
>sp|A8YUI5|G6PI_LACH4 
Glucose-6-phosphate isomerase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=pgi PE=3 
SV=1 
49.633 
A8YUH0 
>sp|A8YUH0|Y777_LACH4 
Probable transcriptional 
regulatory protein lhv_0777 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=lhv_0777 
PE=3 SV=1 
26.604 
A8YUF8;Q5FL35;Q1GB12;Q04BF6 
>sp|A8YUF8|GLMM_LACH4 
Phosphoglucosamine mutase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=glmM 
PE=3 
SV=1;>sp|Q5FL35|GLMM_LAC
AC Phosphoglucosamine 
mutase OS=Lactobacillus 
acidophilus (strain ATCC 
700396 / NCK56 / N2 / NCFM) 
GN=glmM PE=3 
SV=1;>sp|Q1GB 
48.903 
A8YUD9;Q74K84;Q5FL55;Q042E8
;Q1GB31;Q04BH7 
>sp|A8YUD9|CLPP_LACH4 
ATP-dependent Clp protease 
proteolytic subunit 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=clpP 
PE=3 
SV=1;>sp|Q74K84|CLPP_LACJ
O ATP-dependent Clp protease 
proteolytic subunit 
OS=Lactobacillus johnsonii 
(strain CNCM I-12250 / La1  
21.312 
A8YUD6;Q1GB34;Q04BI0;Q5FL58;
Q74K87;Q042E5 
>sp|A8YUD6|Y732_LACH4 
Nucleotide-binding protein 
lhv_0732 OS=Lactobacillus 
helveticus (strain DPC 4571) 
GN=lhv_0732 PE=3 
SV=1;>sp|Q1GB34|Y621_LACD
A Nucleotide-binding protein 
Ldb0621 OS=Lactobacillus 
delbrueckii subsp. bulgaricus 
(strain ATCC 11842 / DSM 2 
33.264 
A8YUC7;Q5FL72;Q042D2;P61324 
>sp|A8YUC7|HPRK_LACH4 
HPr kinase/phosphorylase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=hprK 
PE=3 
SV=1;>sp|Q5FL72|HPRK_LACA
C HPr kinase/phosphorylase 
OS=Lactobacillus acidophilus 
(strain ATCC 700396 / NCK56 / 
35.956 
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N2 / NCFM) GN=hprK PE=3 
SV=1 
A8YTZ6;Q5FLL1 
>sp|A8YTZ6|GATA_LACH4 
Glutamyl-tRNA(Gln) 
amidotransferase subunit A 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=gatA 
PE=3 SV=1 
51.787 
A8YTK7 
>sp|A8YTK7|ASNA_LACH4 
Aspartate--ammonia ligase 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=asnA 
PE=3 SV=1 
38.899 
A8YTE3 
>sp|A8YTE3|RL1_LACH4 50S 
ribosomal protein L1 
OS=Lactobacillus helveticus 
(strain DPC 4571) GN=rplA 
PE=3 SV=1 
24.775 
A8LJA8 
>sp|A8LJA8|CLPP_DINSH ATP-
dependent Clp protease 
proteolytic subunit 
OS=Dinoroseobacter shibae 
(strain DSM 16493 / NCIMB 
14021 / DFL 12) GN=clpP PE=3 
SV=1 
23.177 
A8GKU8 
>sp|A8GKU8|GLGC_SERP5 
Glucose-1-phosphate 
adenylyltransferase OS=Serratia 
proteamaculans (strain 568) 
GN=glgC PE=3 SV=1 
47.779 
A8GAV0;A8AJX2;Q8ZC96;Q66DQ
0;Q1CL31;Q1C4P5;B2K6Z3;B1JH
N4;A9R0Q3;A7FL90;A4TPA8;A1JN
B8 
>sp|A8GAV0|Y1136_SERP5 
Nucleoid-associated protein 
Spro_1136 OS=Serratia 
proteamaculans (strain 568) 
GN=Spro_1136 PE=3 
SV=1;>sp|A8AJX2|Y2678_CITK
8 Nucleoid-associated protein 
CKO_02678 OS=Citrobacter 
koseri (strain ATCC BAA-895 / 
CDC 4225-83 / SGSC4696) GN 
11.998 
A8G8E4 
>sp|A8G8E4|RL1_SERP5 50S 
ribosomal protein L1 
OS=Serratia proteamaculans 
(strain 568) GN=rplA PE=3 
SV=1 
24.719 
A8FIE5 
>sp|A8FIE5|PYRG_BACP2 CTP 
synthase OS=Bacillus pumilus 
(strain SAFR-032) GN=pyrG 
PE=3 SV=1 
59.67 
A8FBJ4 
>sp|A8FBJ4|Y927_BACP2 
UPF0754 membrane protein 
BPUM_0927 OS=Bacillus 
pumilus (strain SAFR-032) 
GN=BPUM_0927 PE=3 SV=1 
42.873 
A8AQV7;Q8Z216;Q5PLX8;C0Q0H
5;B5R360;B5FJS1;B5F8L6;B5BHF
8;B4TY59;B4TKS6;B4SVK3;A9MT
>sp|A8AQV7|PCKA_CITK8 
Phosphoenolpyruvate 
carboxykinase (ATP) 
59.671 
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72;P41033;A9MMC5;B5R7L4;Q57I
X4 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=pckA PE=3 
SV=1;>sp|Q8Z216|PCKA_SALT
I Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Salmonella typhi GN=pckA 
PE=3 SV=1;>sp|Q5P 
A8APB1;C6D8X1;Q8ZM76;Q83QA
2;Q3YXW7;Q32BW5;Q31WG4;Q0
T0Z5;C0PY26;B7LPB7;B5RE14;B5
QXI0;B5FUG6;B5F5H7;B4TGX3;B
4T548;B2U0S0;A9N3N1;Q8XD33;
Q8FE67;Q1R7C8;Q0TDU9;P33195
;C5A0H5;B7UHV1;B7NHW4;B7N7
E6;B7MZ55;B7MM89;B7LYG7;B7L
F89;B6I736;B5YQ95;B1XEJ0;B1LD
A3;B1IT99;A8A444;A7ZR12;A1AF9
2;Q6D974;A9MRH2;Q7N199;Q8ZH
I8;Q666R7;Q1CEZ9;Q1CB42;B2K0
Q3;B1JNS8;A9R4K8;A8GIR9;A7FF
21;A4TIA7;A1JPN3 
>sp|A8APB1|GCSP_CITK8 
Glycine dehydrogenase 
(decarboxylating) 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=gcvP PE=3 
SV=1;>sp|C6D8X1|GCSP_PEC
CP Glycine dehydrogenase 
(decarboxylating) 
OS=Pectobacterium 
carotovorum subsp. carotovo 
104.55 
A8AMJ4;Q8ZK80;Q8Z163;Q5PJ55;
Q57GI8;C0Q6G1;B5R9F1;B5R0S1
;B5FSA4;B5F3C0;B5BKL2;B4TT36
;B4TFD8;B4T3F4;A9N521;A9MF07
;Q3YUE4;Q31TD4;Q0SX83;P0A7R
4;B7LLY5;B2TY76;Q1R357;Q0T9J
0;P0A7R3;P0A7R2;P0A7R1;C4ZR
80;B7UQL2;B7NTQ8;B7NGD7;B7
MT77;B7MLK8;B7M9G5;B7LCR4;B
6I2A9;B5Z2K8;B1XDV3;B1LR79;B
1IT03;A8A7U9;A7ZV74;A1AJA7;Q
328J6;Q8ZB84;Q66F99;Q1CEH3;
Q1CBW7;B2K2L6;B1JMM1;A9QYL
3;A7FMW2;A4TRM3;A1JIT1 
>sp|A8AMJ4|RL9_CITK8 50S 
ribosomal protein L9 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=rplI PE=3 
SV=1;>sp|Q8ZK80|RL9_SALTY 
50S ribosomal protein L9 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=rplI PE=3  
15.77 
A8ALC4;A4W6R1;Q8ZRP4;Q5PD5
7;B5FJ13;B5BL93;A9N0R2;A9MPJ
6;B4TK41;Q8Z9A8;Q57T42;C0Q5S
6;B5RHF1;B5R3H8;B4SUZ5;B5F8
S7;B4TXR8;P41397;P56220;B2U3
08;B8GPS1;Q8ZH69;Q667I6;Q1CF
E3;Q1CAN9;B2JZ37;B1JQF7;A9R
398;A7FFG6;A4TL95;A1JP86;A7M
GS1;Q2NRK4;B4F2D6;C1DD37;Q
82S90;Q5NYT9;Q2Y7X5;Q0AJF8;
A1K717;Q7N8Q0;Q3SJI4;C5BHB3;
B2VE16;Q9CMZ2;Q7VNC4;Q1LNH
0;P41396;B1Y6E5;A6SZR2;A4G4R
0;A3N3F7;Q6D8E6;Q4QL69;Q470
C6;Q0KA05;P45284;B3R2C8;A6V
P50;A5UCM7 
>sp|A8ALC4|DAPD_CITK8 
2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-
succinyltransferase 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=dapD PE=3 
SV=1;>sp|A4W6R1|DAPD_ENT
38 2,3,4,5-tetrahydropyridine-
2,6-dicarboxylate N-succinyltra 
29.864 
A8AFH5;Q7UAE6;Q3Z2M4;Q32H9
5;Q322D4;Q0T3U0;B7LPH8;B2TX
L2;Q8ZNV2;Q5PMZ6;Q57N96;C0Q
2E8;B5R8D6;B5R1V2;B5FSN0;B5
F3I9;B5BH54;B4TYS4;B4T7Z9;B4
>sp|A8AFH5|SYD_CITK8 
Aspartate--tRNA ligase 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=aspS PE=3 
65.661 
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SVF1;A9MUB9;A9MND2;Q8XCI7;
Q8FGQ9;Q1RAR8;Q0TGW6;P218
89;C4ZQF0;B7USP3;B7NS52;B7N
BL7;B7MVZ7;B7MBS5;B7M2F7;B7
L7R9;B6IBU5;B5YR11;B1XHD4;B1
LD05;B1J0M2;A8A166;A7ZMZ0;A1
AC27;A4WBM3;Q8Z5W1;B5XQ00;
A6TB35;A4SPN5;Q5QYV2;Q8EEE
9;Q5E6A2;Q0HUY7;Q0HIZ5;Q081
N5;B6EGJ1;B5FCP9;A0KWL5;Q3II
N7;B8EA71;B7VMI0;A9L3I1;A6WN
Q6;A4Y6S5;A3QEP7;A3D477;A1R
JQ6;A7MEB6;Q12N06;B8CNX7;A8
GFJ2;B1KHG7;A8FUW6;B2VJ90;Q
2NTJ3;Q6LT53;A8H549;C6DFE7;B
0TSA3;Q6D497 
SV=1;>sp|Q7UAE6|SYD_SHIFL 
Aspartate--tRNA ligase 
OS=Shigella flexneri GN=aspS 
PE=3 
SV=2;>sp|Q3Z2M4|SYD_SHISS 
Aspartate--tRNA ligas 
A8ACS4;B5XYZ8;Q7UB34;Q3YVJ
0;Q329V3;Q31UL0;B7LU79;B2TU1
7;A9MJN4;Q8FBR2;Q1R4G3;Q0T
AU6;P58256;P05793;C4ZZ44;B7U
MN1;B7NTG7;B7NF81;B7N269;B7
MGI6;B7M5C2;B7L8B5;B6I4B1;B5
YY23;B1X9Z0;B1LLU9;B1IWC4;A8
A6N0;A7ZTX6;A1AHU6;P05989;A6
TGG1;A4WG34;A7MQH1;B4F1U6;
A8GL54;Q8ZAC2;Q7MYK9;Q6CZD
1;Q66G37;Q1CNM0;Q1CBS1;C6D
HG3;B2VG69;B2JZH8;B1JQ26;A9
R8G1;A7FD32;A4TRD9;A1JI57;A4
STE2;A0KEM1;Q9KVI4;Q6LVZ5;C
4L8N9;C3LQ01;A5F449;A5FFY3;C
5BBA8;B4S1X4;Q9CLF1;Q4QMN4;
Q2NQA9;P44822;A5UHH1;A5UE3
4;B8F6G2;B0BTD3;A3N3E9;B7VG
L9 
>sp|A8ACS4|ILVC_CITK8 Ketol-
acid reductoisomerase 
(NADP(+)) OS=Citrobacter 
koseri (strain ATCC BAA-895 / 
CDC 4225-83 / SGSC4696) 
GN=ilvC PE=3 
SV=1;>sp|B5XYZ8|ILVC_KLEP
3 Ketol-acid reductoisomerase 
(NADP(+)) OS=Klebsiella 
pneumoniae (strain 342) 
GN=ilvC PE= 
53.974 
A8ACN8 
>sp|A8ACN8|ATPA_CITK8 ATP 
synthase subunit alpha 
OS=Citrobacter koseri (strain 
ATCC BAA-895 / CDC 4225-83 / 
SGSC4696) GN=atpA PE=3 
SV=1 
55.278 
A7MGY5;A4WDC0;B5XNI6;A9MHI
3;A6TCG5;Q9KTG1;Q8ZCR1;Q8E
BN8;Q7N216;Q6D246;Q667X1;Q5
PII3;Q57LF7;Q481S6;Q47WY2;Q3
YZ04;Q32D21;Q31XT6;Q2NS25;Q
1CKB8;Q1C5G0;Q0T1W9;Q0HXJ6
;Q0HL93;P0A827;P0A2E2;P0A2E1
;C5BEV2;C4LAE6;C0PYJ5;B5F1D
2;B5BAV4;B4TRY8;B4TDC8;B4T1
D1;B4EZV5;B2VI25;B2TXW4;B2K9
S8;B1JRX7;A9R8C1;A9N1W0;A8G
HZ4;A8AD38;A7FFW1;A4TMW4;A
1S4B5;A1JKP3;A0KU60;Q8XA55;
Q1R8I4;Q0TET8;P0A826;P0A825;
C4ZXC6;B7UGZ1;B7NRK2;B7N6D
8;B7MYI0;B7MIN5;B7M8A7;B7LDE
>sp|A7MGY5|GLYA_CROS8 
Serine 
hydroxymethyltransferase 
OS=Cronobacter sakazakii 
(strain ATCC BAA-894) 
GN=glyA PE=3 
SV=2;>sp|A4WDC0|GLYA_ENT
38 Serine 
hydroxymethyltransferase 
OS=Enterobacter sp. (strain 
638) GN=glyA PE=3 
SV=1;>sp|B5XNI6|GLYA_KLEP
3 Serine hyd 
45.497 
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3;B6I5C4;B5Z123;B1XB26;B1LNK7
;B1IVS6;A8A359;A7ZPZ4;A1AE82 
A7MGT1 
>sp|A7MGT1|EFTS_CROS8 
Elongation factor Ts 
OS=Cronobacter sakazakii 
(strain ATCC BAA-894) GN=tsf 
PE=3 SV=1 
30.56 
A7I3Z5 
>sp|A7I3Z5|PPK1_CAMHC 
Polyphosphate kinase 
OS=Campylobacter hominis 
(strain ATCC BAA-381 / LMG 
19568 / NCTC 13146 / CH001A) 
GN=ppk PE=3 SV=1 
80.339 
A7HZ35;A9KN01 
>sp|A7HZ35|GPMA_PARL1 2,3-
bisphosphoglycerate-dependent 
phosphoglycerate mutase 
OS=Parvibaculum 
lavamentivorans (strain DS-1 / 
DSM 13023 / NCIMB 13966) 
GN=gpmA PE=3 
SV=1;>sp|A9KN01|GPMA_LAC
P7 2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Lac 
23.686 
A6VXD0;Q88NJ4;Q1I6E5;B1JD74;
B0KTJ6;A5VZU3;Q1QWG2;Q7NR
P0;A1KAJ9;C5BPP4;A5WE50;Q9K
0U5;Q9JT23;B4RPA1;A9M257;A1
KVG2;C1DB91;Q4FSF4;Q1QBI9 
>sp|A6VXD0|SYDND_MARMS 
Aspartate--tRNA(Asp/Asn) 
ligase OS=Marinomonas sp. 
(strain MWYL1) GN=aspS PE=3 
SV=1;>sp|Q88NJ4|SYDND_PS
EPK Aspartate--tRNA(Asp/Asn) 
ligase OS=Pseudomonas putida 
(strain ATCC 47054 / DSM 6125 
/ NCIMB 11950 / KT2440) 
GN=aspS PE=3 SV=1; 
65.837 
A6UDW1 
>sp|A6UDW1|RLMH_SINMW 
Ribosomal RNA large subunit 
methyltransferase H 
OS=Sinorhizobium medicae 
(strain WSM419) GN=rlmH 
PE=3 SV=1 
17.441 
A6TDS5;Q8RLY6;B5XUC4;Q5PJH
1;Q57K52;Q3YXV7;Q32BX5;Q31W
H4;Q0T0Y5;P66693;P66692;P0A7
Z3;C0PY37;B5RE24;B5QXJ0;B5B
FM8;B2U0T0;A9N3P6;A9MRG2;P0
A7Z2;P0A7Z1;P0A7Z0;C5A0I5;B7
UHW1;B7NHX4;B7N7F6;B7MZL0;
B7MM99;B7LYT1;B7LFH2;B6I746;
B5YQA8;B1XEJ9;B1LDB5;B1IT89;
A8A454;A7ZR23;A1AFA2;B7LPC8;
A1JPP4;Q0TDT9;Q8PH49;Q5H3U
0;Q3BPQ4;Q2P6P9;B4SI18;B2SL
M6;B2FT30;Q8ZHH8;Q666Q7;Q60
BV9;Q3SGD3;B7VK98;B4F0Q0;B2
K0R4;Q82TX6;Q7N189;Q6D093;Q
2YBX7;C6DF34;A0KTU4;B2VF17;
>sp|A6TDS5|RPIA_KLEP7 
Ribose-5-phosphate isomerase 
A OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=rpiA PE=3 
SV=1;>sp|Q8RLY6|RPIA_ENTC
L Ribose-5-phosphate 
isomerase A OS=Enterobacter 
cloacae GN=rpiA PE=3 
SV=1;>sp|B5XUC4|RPI 
22.735 
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C5BMC8;Q7WH03;Q7W9Q5;Q7V
WC1;Q21F87 
A6TD53;B5XV19 
>sp|A6TD53|ENO_KLEP7 
Enolase OS=Klebsiella 
pneumoniae subsp. 
pneumoniae (strain ATCC 
700721 / MGH 78578) GN=eno 
PE=3 
SV=1;>sp|B5XV19|ENO_KLEP3 
Enolase OS=Klebsiella 
pneumoniae (strain 342) 
GN=eno PE=3 SV=1 
45.549 
A6TCV9;Q8ZMK6;Q8Z4D5;Q5PF1
7;Q57KU6;A9N0C1;Q1C420;Q0I42
6;B0UTE1;Q8ZBT8;Q6D1T0;Q66E
68;Q2NVL2;Q1CLK9;B2K5X9;B1JJ
A0;A9R0V7;A8GA09;A7MJ41;A7FL
R7;A4TQ52;A1JK09;Q9ZJY5;Q1C
S22;Q17ZF3;P56452;B2UV04;Q30
PA9;A6Q576;A8EWI6;Q5ZUJ9;Q5
X4B7;Q5WVQ2;A5ICV6;Q2YD40;Q
82TF8;Q0VNK2;Q0AHX2;A1WXK5
;Q31F91;Q83CQ6;Q5QUV7;Q15R
G5;A9NCN7;A9KG28;A5CVU0;A1
AXE0;Q60BS6;Q3ILF3;A6SVH6;A4
G2S9;Q47AU8;Q3SLA9;A6W1F1;A
1WIG8;Q5P7Q3;Q3JCK8;Q2KY72;
A9IK31;A5EW88;Q9JYG6;Q9JTG4
;Q9I553;Q88EI8;Q885J0;Q7WHL6;
Q7W6N4;Q7VXE1;Q7VLK0;Q63TF
9;Q62KZ3;Q5F7C4;Q4ZQI4;Q4QM
86;Q4K843;Q48G25;Q474F4;Q3K8
92;Q3JT87;Q39HB7;Q2SV73;Q1L
Q59;Q1I6Z8;Q1H3U9;Q1BX19;Q13
W97;Q0K823;Q0BG79;Q02I63;P57
933;P43815;B3H177;B2SZN0;B2J
K72;B1YNJ6;B1K026;B1JCG9;B0K
R43;B0BNS8;A9M198;A9C0B9;A9
AC16;A6VKD6;A6VA71;A5W0D9;A
5UHW6;A5UDR0;A4XWE2;A4VJB
3;A4SS99;A4JDM9;A3NUB0;A3N8
K7;A3N018;A3MJ36;A2S3D4;A1W
7D0;A1VQK2;A1V3F2;A1KV20;A0
KPG1;A0K6N4;Q65VQ5;Q21L68;A
2SI90;Q7N7A5;Q487H5;Q2SBT9;Q
221G2;A8ZY67;A1TZ92;Q7NXM2;
Q56273;Q1RKG2;B0BVK9;A8GU1
6;Q92G00;Q4UJT5;Q129G8;A8GQ
73;A8F323;A8F078;Q6AQ16;Q8Y1
93;A1K991;Q7VHV4;A1TRL4 
>sp|A6TCV9|SYA_KLEP7 
Alanine--tRNA ligase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=alaS PE=3 
SV=1;>sp|Q8ZMK6|SYA_SALT
Y Alanine--tRNA ligase 
OS=Salmonella typhimurium 
(strain LT2 / SGSC1412 / ATCC 
700720) GN=alaS PE=3 S 
95.63 
A6T726;Q5PGF0;Q57QZ8;Q56112
;P58696;Q3Z3J0;Q32E51;Q31YR7;
Q0T6B1;P0A8M2;Q1RDS7;Q0TJC
3;P58694;P0A8M1;P0A8M0;B1IW0
1;A7ZYN3;A7ZK21;A4W8U9;Q2NU
85;A8GCJ5;Q7N622;A3QE68;A6V
NV7;Q3IGU4;Q15UN9;Q6D453;Q6
>sp|A6T726|SYN_KLEP7 
Asparagine--tRNA ligase 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=asnS PE=3 
SV=1;>sp|Q5PGF0|SYN_SALP
52.495 
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6CG7;Q1CGI7;Q1CA47;P58697;A7
FJU5;A4TMZ6;A1JMN8;A0KXL6;Q
9CN06;P43829;A5UF16;A5UCB9;
Q65TR1;B8F3Y5;B3H198;A3N039;
Q73P19;Q662R1;Q0SP63;O51128;
Q8EEZ1;Q8DAF0;Q7MJS0;Q0HUL
3;Q0HIB6;A4Y6E4;A1S684;A1RK5
2;B0TUU1;A8H467;A1SW33;Q6LP
Q6;Q481G3;Q081Q0;A8FVU8;A0K
IC3;Q1LT63;Q7VLL7;B0BNV4;Q7V
R09;Q492P3;O83618;B2S3J9 
A Asparagine--tRNA ligase 
OS=Salmonella paratyphi A 
(strain ATCC 9150 / SARB42) 
GN=asnS PE=3 SV=1; 
A6T5N6;P58482;A8GAV2;Q66DP8
;Q5PFK7;Q57S77;Q1CL28;Q1C4P
8;P58480;P58479;A9MW88;A8AJX
0;A7MJW4;A4TPA5;A1JNB3;Q2NV
58;Q7N0P4;A4W7F7;B3GXX7;B0B
PS7;A3N0Z5;Q4QP81;Q0I2A3;P54
649;P44516;B0USJ0;A5UFQ9;A5U
B42;Q6D7Z6;Q1H2K2;B8F5X3;Q7
NYF6;Q1LTX6;Q3SJW8;Q9I3C5;Q
88FB9;Q6LTE2;Q60AK3;Q142T5;A
6V7J7;A4XV81;A4SLY0;Q2YA09;Q
82TV8;Q0AHI5;A0KL53 
>sp|A6T5N6|HTPG_KLEP7 
Chaperone protein HtpG 
OS=Klebsiella pneumoniae 
subsp. pneumoniae (strain 
ATCC 700721 / MGH 78578) 
GN=htpG PE=3 SV=1 
71.106 
A6QGY4;Q99U54;Q931R6;A7X2C
3;Q2FYJ6;Q8NWQ6;Q2FH04;A8Z4
14;Q5HFY8;A6U1Q5;A5ISW6 
>sp|A6QGY4|EBHA_STAAE 
Extracellular matrix-binding 
protein EbhA 
OS=Staphylococcus aureus 
(strain Newman) GN=ebhA 
PE=4 
SV=1;>sp|Q99U54|EBHA_STA
AN Extracellular matrix-binding 
protein EbhA 
OS=Staphylococcus aureus 
(strain N315) GN=ebhA PE=4 
SV=1;>sp|Q931R6|E 
378.16 
A6QD02 
>sp|A6QD02|ILVD_SULNB 
Dihydroxy-acid dehydratase 
OS=Sulfurovum sp. (strain 
NBC37-1) GN=ilvD PE=3 SV=1 
60.582 
A6M334 
>sp|A6M334|GLGA_CLOB8 
Glycogen synthase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=glgA PE=3 SV=1 
55.552 
A6LSF9 
>sp|A6LSF9|Y1107_CLOB8 
UPF0473 protein Cbei_1107 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=Cbei_1107 PE=3 
SV=1 
10.827 
A6LRN4 
>sp|A6LRN4|DNAK_CLOB8 
Chaperone protein DnaK 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=dnaK PE=3 SV=1 
65.341 
A6LQH6 
>sp|A6LQH6|ATPB_CLOB8 
ATP synthase subunit beta 
50.232 
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OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=atpD PE=3 SV=1 
A6LQ99 
>sp|A6LQ99|G6PI_CLOB8 
Glucose-6-phosphate isomerase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=pgi PE=3 SV=1 
49.803 
A6LPT2 
>sp|A6LPT2|KAD_CLOB8 
Adenylate kinase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=adk PE=3 SV=1 
23.905 
A6LPS5 
>sp|A6LPS5|RS8_CLOB8 30S 
ribosomal protein S8 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=rpsH PE=3 SV=1 
14.651 
A6LPQ3 
>sp|A6LPQ3|RL7_CLOB8 50S 
ribosomal protein L7/L12 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=rplL PE=3 SV=1 
12.542 
A6LPP1 
>sp|A6LPP1|SYC_CLOB8 
Cysteine--tRNA ligase 
OS=Clostridium beijerinckii 
(strain ATCC 51743 / NCIMB 
8052) GN=cysS PE=3 SV=1 
54.167 
A6LPJ0 
>sp|A6LPJ0|SP5G_CLOB8 
Putative septation protein 
SpoVG OS=Clostridium 
beijerinckii (strain ATCC 51743 / 
NCIMB 8052) GN=spoVG PE=3 
SV=1 
10.176 
A6L9B7 
>sp|A6L9B7|SERC_PARD8 
Phosphoserine 
aminotransferase 
OS=Parabacteroides distasonis 
(strain ATCC 8503 / DSM 20701 
/ CIP 104284 / JCM 5825 / 
NCTC 11152) GN=serC PE=3 
SV=1 
39.505 
A6L4M4;Q8A9U7;Q64UA4;Q5LD8
2 
>sp|A6L4M4|ATPA_BACV8 
ATP synthase subunit alpha 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
5826 / NBRC 14291 / NCTC 
11154) GN=atpA PE=3 
SV=1;>sp|Q8A9U7|ATPA_BAC
TN ATP synthase subunit alpha 
OS=Bacteroides 
thetaiotaomicron (strain ATCC 
2914 
57.714 
A6L0V2 
>sp|A6L0V2|EFTS_BACV8 
Elongation factor Ts 
OS=Bacteroides vulgatus (strain 
ATCC 8482 / DSM 1447 / JCM 
35.502 
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5826 / NBRC 14291 / NCTC 
11154) GN=tsf PE=3 SV=1 
A6L012 
>sp|A6L012|SPEA_BACV8 
Biosynthetic arginine 
decarboxylase OS=Bacteroides 
vulgatus (strain ATCC 8482 / 
DSM 1447 / JCM 5826 / NBRC 
14291 / NCTC 11154) GN=speA 
PE=3 SV=1 
71.487 
A5WGL0;Q6FDS6 
>sp|A5WGL0|EFG_PSYWF 
Elongation factor G 
OS=Psychrobacter sp. (strain 
PRwf-1) GN=fusA PE=3 
SV=1;>sp|Q6FDS6|EFG_ACIAD 
Elongation factor G 
OS=Acinetobacter baylyi (strain 
ATCC 33305 / BD413 / ADP1) 
GN=fusA PE=3 SV=1 
79.387 
A5EX82 
>sp|A5EX82|RL3_DICNV 50S 
ribosomal protein L3 
OS=Dichelobacter nodosus 
(strain VCS1703A) GN=rplC 
PE=3 SV=1 
22.963 
A5D2Z8 
>sp|A5D2Z8|NADK_PELTS 
NAD kinase OS=Pelotomaculum 
thermopropionicum (strain DSM 
13744 / JCM 10971 / SI) 
GN=nadK PE=3 SV=1 
32.264 
A5D0W6 
>sp|A5D0W6|MUTS2_PELTS 
Endonuclease MutS2 
OS=Pelotomaculum 
thermopropionicum (strain DSM 
13744 / JCM 10971 / SI) 
GN=mutS2 PE=3 SV=1 
86.174 
A4XJ60 
>sp|A4XJ60|RS9_CALS8 30S 
ribosomal protein S9 
OS=Caldicellulosiruptor 
saccharolyticus (strain ATCC 
43494 / DSM 8903 / Tp8T 6331) 
GN=rpsI PE=3 SV=2 
14.606 
A4WFJ1 
>sp|A4WFJ1|PCKA_ENT38 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Enterobacter sp. (strain 
638) GN=pckA PE=3 SV=1 
59.474 
A4WE78;Q8K9E5;B4RWC7;B8F4B
2;Q8EIB4;Q6D081;Q65UT4;Q3IDQ
1;Q15QK1;Q0HRM1;Q0HM65;C6D
FI3;B7VKB3;B3H1W3;B0BQ17;A8
FRL1;A6VMK8;A4Y3R7;A3QAX5;A
3N186;A1S9A6;A1RN71;A0L0K9;Q
8ZHG7;Q8DCA3;Q87LK6;Q7MHK6
;Q6LMM8;Q666P5;Q5PJJ2;Q5E7R
2;Q57K26;Q4QLC5;Q3YXS9;Q32C
11;Q31WK4;Q1CEX6;Q1CB69;Q0
T0V0;Q0I559;P66765;P66764;P57
897;P43762;P0A820;C5BAV4;B7L
>sp|A4WE78|METK_ENT38 S-
adenosylmethionine synthase 
OS=Enterobacter sp. (strain 
638) GN=metK PE=3 
SV=1;>sp|Q8K9E5|METK_BUC
AP S-adenosylmethionine 
synthase OS=Buchnera 
aphidicola subsp. Schizaphis 
graminum (strain Sg) GN=metK 
PE=3 
SV=1;>sp|B4RWC7|METK_ALT
MD 
41.909 
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PQ9;B6EMV8;B5XUA8;B5RE50;B5
QY66;B5FUK0;B5F9T2;B5F5L4;B5
BFP7;B4TV58;B4THH4;B4T5J6;B4
F1A5;B2VF06;B2U0W2;B2K0S7;B
1JNQ2;B0UWT3;A9R314;A9MRD1
;A8GIX9;A8APG1;A7MTQ7;A7MJQ
6;A7FEZ7;A6TDV1;A5UIU0;A5UCT
6;A4TI83;A1JPS4;Q9KUP3;Q8D2N
8;Q2NRD1;C4K3W7;C3LRY9;A5F9
H4;Q7VNG7;Q7NZF9;P61946;C6E
2L2;C6C1U5;C4XPZ6;C1DCT7;B8
DSC3;A5GA66;A0LF65;Q7N119;Q
729A3;Q311V1;A1VBJ1;Q0TDR0;P
0A819;P0A818;P0A817;C5A0L1;B
7UHY9;B7NI05;B7N7J5;B7LYX2;B
7LFK4;B6I780;B5YQD9;B1XFA4;B
1LDF1;B1IT65;A8A481;A7ZR64 
A4WDW7;Q2NVN7 
>sp|A4WDW7|ENO_ENT38 
Enolase OS=Enterobacter sp. 
(strain 638) GN=eno PE=3 
SV=1;>sp|Q2NVN7|ENO_SOD
GM Enolase OS=Sodalis 
glossinidius (strain morsitans) 
GN=eno PE=3 SV=1 
45.467 
A4WDQ6 
>sp|A4WDQ6|SYA_ENT38 
Alanine--tRNA ligase 
OS=Enterobacter sp. (strain 
638) GN=alaS PE=3 SV=1 
95.942 
A4WD70;C5BHQ5;B5XNQ4;A8AD
93;A6TCB0;Q7N3F8;Q5PNJ7;Q57
LL1;Q0T222;P0A8F3;P0A2M6;P0A
2M5;C0PYQ8;B7LKE4;B5RCX0;B5
R560;B5FQJ0;B5F173;B5BB06;B4
TR74;B4TD73;B4T0M7;B2TXS3;A
9N2Y1;A9MHP1;Q0TEZ0;P0A8F2;
P0A8F1;P0A8F0;C4ZX73;B7UGN6
;B7NQN7;B7N680;B7MYC5;B7MH
X9;B7M7K2;B7LCN8;B6I570;B5Z0
35;B1XAX3;B1LNE8;B1IWG2;A8A
2Z0;A7ZPU1;A1ADZ1;Q9KPY7;Q6
LN74;Q6D7S0;Q2NS69;C6DBR1;C
3LPM9;A5F642;P43857;A6VQ76;A
5UF76;A5UBP1 
>sp|A4WD70|UPP_ENT38 
Uracil 
phosphoribosyltransferase 
OS=Enterobacter sp. (strain 
638) GN=upp PE=3 
SV=1;>sp|C5BHQ5|UPP_EDWI
9 Uracil 
phosphoribosyltransferase 
OS=Edwardsiella ictaluri (strain 
93-146) GN=upp PE=3 
SV=1;>sp|B5XNQ4|UPP_KLEP
3 Uracil phosphoribos 
22.549 
A4WBM1;B2VJ92 
>sp|A4WBM1|Y2432_ENT38 
Probable transcriptional 
regulatory protein Ent638_2432 
OS=Enterobacter sp. (strain 
638) GN=Ent638_2432 PE=3 
SV=1;>sp|B2VJ92|Y1487_ERW
T9 Probable transcriptional 
regulatory protein ETA_14870 
OS=Erwinia tasmaniensis (strain 
DSM 17950  
26.173 
A4W787;Q8ZC41;Q66DV8;Q1CL9
2;Q1C4I4;B2K6T3;B1JIE2;A9R2J8;
A7FLE8;A4TPG7 
>sp|A4W787|RISB_ENT38 6,7-
dimethyl-8-ribityllumazine 
synthase OS=Enterobacter sp. 
(strain 638) GN=ribH PE=3 
16.097 
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SV=1;>sp|Q8ZC41|RISB_YERP
E 6,7-dimethyl-8-ribityllumazine 
synthase OS=Yersinia pestis 
GN=ribH PE=3 
SV=1;>sp|Q66DV8|RISB_YERP
S 6,7-dimethyl-8-ribityl 
A4W6R5 
>sp|A4W6R5|EFTS_ENT38 
Elongation factor Ts 
OS=Enterobacter sp. (strain 
638) GN=tsf PE=3 SV=1 
30.371 
A4W5T2 
>sp|A4W5T2|RL9_ENT38 50S 
ribosomal protein L9 
OS=Enterobacter sp. (strain 
638) GN=rplI PE=3 SV=1 
15.66 
A4W5F0 
>sp|A4W5F0|LAMB_ENT38 
Maltoporin OS=Enterobacter sp. 
(strain 638) GN=lamB PE=3 
SV=1 
49.236 
A4W5A7;C6DHR5;Q6DAN0;Q3ILP
9 
>sp|A4W5A7|RPOB_ENT38 
DNA-directed RNA polymerase 
subunit beta OS=Enterobacter 
sp. (strain 638) GN=rpoB PE=3 
SV=1;>sp|C6DHR5|RPOB_PEC
CP DNA-directed RNA 
polymerase subunit beta 
OS=Pectobacterium 
carotovorum subsp. 
carotovorum (strain PC1) 
GN=rpoB PE=3 SV=1 
150.47 
A4VMP0 
>sp|A4VMP0|FLIE_PSEU5 
Flagellar hook-basal body 
complex protein FliE 
OS=Pseudomonas stutzeri 
(strain A1501) GN=fliE PE=3 
SV=1 
12.002 
A4VFW9 
>sp|A4VFW9|FDHE_PSEU5 
Protein FdhE homolog 
OS=Pseudomonas stutzeri 
(strain A1501) GN=fdhE PE=3 
SV=1 
33.325 
A4SIZ9 
>sp|A4SIZ9|RL9_AERS4 50S 
ribosomal protein L9 
OS=Aeromonas salmonicida 
(strain A449) GN=rplI PE=3 
SV=1 
15.329 
A4J592;C4K7W8 
>sp|A4J592|KAD_DESRM 
Adenylate kinase 
OS=Desulfotomaculum 
reducens (strain MI-1) GN=adk 
PE=3 
SV=1;>sp|C4K7W8|KAD_HAMD
5 Adenylate kinase 
OS=Hamiltonella defensa 
subsp. Acyrthosiphon pisum 
(strain 5AT) GN=adk PE=3 
SV=1 
23.245 
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A2RIX0 
>sp|A2RIX0|HPF_LACLM 
Ribosome hibernation promotion 
factor OS=Lactococcus lactis 
subsp. cremoris (strain 
MG1363) GN=hpf PE=1 SV=1 
21.314 
A2BQ46 
>sp|A2BQ46|DNAA_PROMS 
Chromosomal replication 
initiator protein DnaA 
OS=Prochlorococcus marinus 
(strain AS9601) GN=dnaA PE=3 
SV=1 
52.144 
A1SGG5;A6W6U1;C5C046 
>sp|A1SGG5|SYM_NOCSJ 
Methionine--tRNA ligase 
OS=Nocardioides sp. (strain 
ATCC BAA-499 / JS614) 
GN=metG PE=3 
SV=1;>sp|A6W6U1|SYM_KINR
D Methionine--tRNA ligase 
OS=Kineococcus radiotolerans 
(strain ATCC BAA-149 / DSM 
14245 / SRS30216) GN=metG 
PE=3 SV=1;>sp|C5 
66.251 
A1S1X0 
>sp|A1S1X0|PCKA_SHEAM 
Phosphoenolpyruvate 
carboxykinase (ATP) 
OS=Shewanella amazonensis 
(strain ATCC BAA-1098 / SB2B) 
GN=pckA PE=3 SV=1 
55.974 
A1JRT1;Q7N6S0;B2VBS6;Q9CKU
9;Q4QME2;Q0I4D8;P44865;B8F5J
4;B3H1G9;B0US27;B0BPB3;A5UH
R1;A5UDW8;A3N0J2;P53531;B8Z
T86;Q8NTA5;A4QB41;Q9PC88;Q8
7CZ1;Q73SU2;Q6ADH3;P9WIC9;P
9WIC8;P0A5R7;C1AKG7;B2I4U0;B
0U2F2;A5TZL7;A1KFW3;A0QLK3;
Q727C0;A1VAI9;B2HQV4;A0PVZ3 
>sp|A1JRT1|GPMA_YERE8 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase OS=Yersinia 
enterocolitica serotype O:8 / 
biotype 1B (strain NCTC 13174 / 
8081) GN=gpmA PE=3 
SV=1;>sp|Q7N6S0|GPMA_PHO
LL 2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutas 
28.344 
A1JI23;Q6DAR0;C6DI80;B5XZ17;B
5FPX4;B5F0U8;B5BJN3;B4TQH5;
B4TCQ5;B4T0X0;B2TWF4;A9N0G
9;A8GL83;A4WG52;Q8ZA87;Q66G
71;Q5PK74;Q57H94;Q3YV17;Q32
AB6;Q31U29;Q1CNQ4;Q1CBV5;Q
0SY35;P63558;P63557;P59302;C0
Q475;B5RF46;B5QXQ4;B2JZE3;B
1JQ60;A9R515;A8AKW3;A7ML88;
A7FD00;A6TGE3;A4TRH4;B7MI95;
B7M713;B7LA54;B6I5H5;B5Z061;B
1XBC4;B1IVB9;A8A767;A7ZUH7;Q
1R3V2;Q0TAA1;P59298;P0A6C9;P
0A6C8;C5A0Q8;A1AID7 
>sp|A1JI23|ARGB_YERE8 
Acetylglutamate kinase 
OS=Yersinia enterocolitica 
serotype O:8 / biotype 1B (strain 
NCTC 13174 / 8081) GN=argB 
PE=3 
SV=1;>sp|Q6DAR0|ARGB_PEC
AS Acetylglutamate kinase 
OS=Pectobacterium 
atrosepticum (strain SCRI 1043 / 
ATCC BAA-672) GN= 
26.373 
A1A3N3;P59076;B7GP85;B8DT48 
>sp|A1A3N3|SYM_BIFAA 
Methionine--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
68.693 
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15703 / DSM 20083 / NCTC 
11814 / E194a) GN=metG PE=3 
SV=1 
A1A3C7;Q8G7B1;B7GTZ1;B3DTV
2;C5C1U6;B8DWS4;A4XAW4;Q73
X57;A0QCX6;Q72E02;B8DRD0;A1
VFJ3;B2GLY8;Q83HY2;Q83G89;Q
6NHT1;Q6AG60;B0RED6;A5CQ58;
B8HAZ1;A0JY66;Q4JUJ8;B1VFY5;
Q8FQ22;C3PFR3;Q79VG7;Q0SGP
7;C1AW01;C1A1Y0;A4QDH1;P9W
PU7;P9WPU6;P63674;C1AMV2;B2
HQK4;A5U207;A1KI96;A0PUK2;A6
W7G7;P45825;B8ZR40;Q05FY3;Q
8RGE0;Q180W8;Q5M5J3;Q5M106
;Q3A944;Q03LX5;Q9K6H3;Q24MN
9;P50000;C6E9F3;C5CIV6;C4XI08;
B9LZ86;B8FZ36;B5YI22;B5EFI9;B
4U989;B3EA03;B0THN4;B0JWV1;
A9KK94;A5G9D6;A1ALL5;Q8DLP3
;Q74GY2;Q3Z8Z4;Q39Q54;Q0537
2;O66907;C0Z778;B7KKR4;Q2LQZ
7;Q0AUD1;C3KYJ1;C1FQP3;B9DX
63;B2V6N6;B1KSS6;B1IE32;B0SL
C6;B0SDA3;A7G9Q7;A7FQH7;A6
QB61;A5N3H9;A5HY50;Q7V5S7;Q
31RF1;Q112Z6;P08449;B8HPK1;B
0BZL2;A8MJW1;A8G6V1;A6TK63;
A3PET9;A2BT25;A0RR28;Q8RC17
;Q67TB9;Q2JSW1;Q2JIG0;Q2RFX
7;B7IG42;A6LJR3;B9JTR4;Q98EV
6;Q92LK6;Q8YJ37;Q8UC74;Q8FY
R3;Q89X72;Q5NQZ1;Q57B86;Q2Y
LI5;Q2VZN0;Q2N8Z5;Q2K3G8;Q2
G5N7;Q1MAZ0;Q1GQS7;Q11DD7;
C3M9S3;C0RF52;B8IN03;B8EQP9
;B7KUA4;B5ZSN9;B3PQ70;B2S7M
5;B1ZEE9;B0UE41;A9WWS4;A9W
2R3;A9M839;A7IH29;A7HT50;A6W
XW9;A6UDM3;A5VSE3;A5V3X3;A
5E948;A4YKD8;Q9A2V7;Q92G86;
Q6NDD0;Q4UK16;Q3SVJ4;Q2J3I2
;Q21CY5;Q1QQS5;Q13DP4;Q0AK
V8;Q07UZ3;C4K229;B8H5I2;B4RD
45;B1LVH1;B0T338;B0BVB8;A8HS
15;A8GTS8;A8F2U2;A5FZ52;Q6G
1W7;Q6FYM1;Q4FP36;Q0C0Z8;Q
0BQE6;A9IYX0;A1UR47;A1B8N8;
Q68VU6;Q5P4E4;Q5LNN9;Q1IIG6;
Q162S7;O50288;B3CSS9;B2KEX0
;A8GY42;A8GPZ6;A5CD07;A1K1S
0;Q82XQ0;Q7WEM7;Q7W3A8;Q7
VU46;Q7NCS3;Q63PH8;Q62FR7;
Q60CR6;Q5NIK5;Q46VX8;Q3SF64
;Q3JXV6;Q39KX8;Q2YCA5;Q2STE
7;Q2KU34;Q2A1I0;Q21DK6;Q1GE
U6;Q1BRA8;Q14K08;Q0K5M5;Q0
BK82;Q0BJL7;Q0AJB2;Q0A4M6;C
>sp|A1A3C7|ATPA_BIFAA ATP 
synthase subunit alpha 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=atpA PE=3 
SV=1;>sp|Q8G7B1|ATPA_BIFL
O ATP synthase subunit alpha 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=atpA 
PE= 
58.683 
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5BKJ7;B8GRC0;B4EEY7;B2SEX9;
B1YQL2;B1JSV5;B0TWS5;A9HY4
0;A9AJG2;A7NEH6;A5EXJ7;A5CVI
8;A4JA33;A4IW22;A3P0Z2;A3NF4
2;A3MQJ7;A2S6K0;A1WZT3;A1V8
T3;A1AXU4;A0Q8E1;A0K2Y1;Q7P
097;Q2S6N9;Q0VKX2;P41167;C1
D5G4;B7JB86;B5ER44;A6W3T0;A
9AVV2;B8G6G8;A9WGS6;B1W0A
5;Q6MS92;Q6F204;Q2ST36;A6H2
D7;A5FL34;Q8KAW8;Q3AUA7;Q11
YP1;B4SGC7;B3EL39;B3EHU6;A7
NIR1;A1BJF5;A5UQN5;Q9K4D5;Q
82J82;P50001;B3EU98;C1F3N8;B
3QWX7;A1WF56;B8CZ12;Q6A8C5
;Q5Z0Y3;A9WNC6;A1R7V5;Q47M
80;A1SHI9;B1MLW0;A4FN29;A8M
2J5;Q2J6N1;Q0RDB2;A8L3W3;A0
LSL4;A9GHR6;Q9PR12;B1AIC1 
A1A3B6;B8DWR0 
>sp|A1A3B6|SYR_BIFAA 
Arginine--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=argS PE=3 
SV=1 
64.876 
A1A399 
>sp|A1A399|BGAL_BIFAA Beta-
galactosidase BgaB 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=bgaB PE=1 
SV=2 
78.024 
A1A2Z2 
>sp|A1A2Z2|GLMM_BIFAA 
Phosphoglucosamine mutase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=glmM PE=3 
SV=1 
48.354 
A1A2L6 
>sp|A1A2L6|MURI_BIFAA 
Glutamate racemase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=murI PE=3 
SV=1 
28.338 
A1A2H2 
>sp|A1A2H2|HIS4_BIFAA 1-(5-
phosphoribosyl)-5-[(5-
phosphoribosylamino)methylide
neamino] imidazole-4-
carboxamide isomerase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=hisA PE=3 
SV=1 
25.734 
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A1A2F1 
>sp|A1A2F1|MURD_BIFAA 
UDP-N-acetylmuramoylalanine--
D-glutamate ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=murD PE=3 
SV=1 
51.021 
A1A2E9 
>sp|A1A2E9|MURG_BIFAA 
UDP-N-acetylglucosamine--N-
acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol 
N-acetylglucosamine 
transferase OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=murG PE=3 
SV=1 
41.546 
A1A2E8 
>sp|A1A2E8|MURC_BIFAA 
UDP-N-acetylmuramate--L-
alanine ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=murC PE=3 
SV=1 
55.602 
A1A1V0;Q2GLH3;Q73WG1;P5995
3;A0QC23;Q5PBM8;B9KHP8;Q5Y
Q76;B1VFM5;B7GTL3;Q4JU69;P9
WGI9;P9WGI8 
>sp|A1A1V0|GLYA_BIFAA 
Serine 
hydroxymethyltransferase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=glyA PE=3 
SV=1;>sp|Q2GLH3|GLYA_ANA
PZ Serine 
hydroxymethyltransferase 
OS=Anaplasma 
phagocytophilum (strain HZ) 
GN=g 
46.576 
A1A1U9;C1DMQ0;Q8G5H9;B7GTL
2 
>sp|A1A1U9|PROA_BIFAA 
Gamma-glutamyl phosphate 
reductase OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=proA PE=3 
SV=1 
45.48 
A1A1R2 
>sp|A1A1R2|SYL_BIFAA 
Leucine--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=leuS PE=3 
SV=1 
110.94 
A1A1N3 
>sp|A1A1N3|PGK_BIFAA 
Phosphoglycerate kinase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
42.09 
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15703 / DSM 20083 / NCTC 
11814 / E194a) GN=pgk PE=3 
SV=1 
A1A1I0 
>sp|A1A1I0|EFTS_BIFAA 
Elongation factor Ts 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=tsf PE=3 
SV=1 
30.628 
A1A1G3 
>sp|A1A1G3|PYRE_BIFAA 
Orotate 
phosphoribosyltransferase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=pyrE PE=3 
SV=1 
24.908 
A1A1F7;Q8G655;B7GRV4;B3DS61 
>sp|A1A1F7|PYRB_BIFAA 
Aspartate carbamoyltransferase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=pyrB PE=3 
SV=2;>sp|Q8G655|PYRB_BIFL
O Aspartate 
carbamoyltransferase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN= 
35.385 
A1A1B4;B8DUN4 
>sp|A1A1B4|GLGC_BIFAA 
Glucose-1-phosphate 
adenylyltransferase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=glgC PE=3 
SV=1 
45.609 
A1A1A2 
>sp|A1A1A2|AROC_BIFAA 
Chorismate synthase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=aroC PE=3 
SV=1 
42.456 
A1A198 
>sp|A1A198|SYA_BIFAA 
Alanine--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=alaS PE=3 
SV=1 
97.575 
A1A171 
>sp|A1A171|FOLD_BIFAA 
Bifunctional protein FolD 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
31.278 
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11814 / E194a) GN=folD PE=3 
SV=1 
A1A0T7;Q8G3H2;B7GUP9 
>sp|A1A0T7|ILVD_BIFAA 
Dihydroxy-acid dehydratase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=ilvD PE=3 
SV=1 
66.449 
A1A0T4;B8DTW3;Q8G815;B3DQ3
2 
>sp|A1A0T4|CARB_BIFAA 
Carbamoyl-phosphate synthase 
large chain OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=carB PE=3 
SV=1;>sp|B8DTW3|CARB_BIF
A0 Carbamoyl-phosphate 
synthase large chain 
OS=Bifidobacterium animalis 
123.2 
A1A0T0;B8DTV6;Q8G5B6;B3DT30
;A6W5T4;P09952;C3PKP1 
>sp|A1A0T0|EFG_BIFAA 
Elongation factor G 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=fusA PE=3 
SV=1 
78.465 
A1A0K4;Q8G3N0;B8DTM3;Q5YSB
9 
>sp|A1A0K4|SYP_BIFAA 
Proline--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=proS PE=3 
SV=1 
67.087 
A1A0A9;Q8G3X9;B7GN96;B3DQF
7 
>sp|A1A0A9|RPIA_BIFAA 
Ribose-5-phosphate isomerase 
A OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=rpiA PE=3 
SV=1 
25.266 
A1A0A2;Q8G3Y5;B3DQF0;B7GNA
3 
>sp|A1A0A2|IF2_BIFAA 
Translation initiation factor IF-2 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=infB PE=3 
SV=1;>sp|Q8G3Y5|IF2_BIFLO 
Translation initiation factor IF-2 
OS=Bifidobacterium longum 
(strain NCC 270 
99.002 
A1A095;Q8G3Z3;B8HCX4;A9WSR
1;A0JZ49;A6W5W5;Q82QR5;C5C0
G1;Q9X4V6;P60313;P60312;B1W3
Y0;Q9X798;Q73S43;P9WGZ1;P9
WGZ0;P66702;A5U8D3;A1KPE3;A
0QKU5;A0PMB7;Q1BD08;A3PVL8;
>sp|A1A095|RPOA_BIFAA 
DNA-directed RNA polymerase 
subunit alpha 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=rpoA PE=3 
36.232 
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A1UBY5;A1T520;A0QSL8;Q5Z1K9
;Q0S3E7;A4FPJ2 
SV=2;>sp|Q8G3Z3|RPOA_BIFL
O DNA-directed RNA 
polymerase subunit alpha 
OS=Bifidobacterium longum 
A1A008;B7GNH2;Q8G447;B3DPX
0;B8DVV8 
>sp|A1A008|PNP_BIFAA 
Polyribonucleotide 
nucleotidyltransferase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=pnp PE=3 
SV=1;>sp|B7GNH2|PNP_BIFLS 
Polyribonucleotide 
nucleotidyltransferase 
OS=Bifidobacterium longum su 
99.739 
A0ZZT4;B7GU04;B3DTT9;Q8G7C
4 
>sp|A0ZZT4|DDL_BIFAA D-
alanine--D-alanine ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=ddl PE=3 
SV=1 
40.528 
A0ZZS4;Q8G709;B3DU87;Q83HJ1
;Q83GP4;Q5YRX6;Q6AEQ1;Q0S2
G8;A1SM03;O86528;A6W7Q5;O33
120;A4FMP6;Q82JR3;B1VZ06;A0J
XY5;B2GFK2;B0RIP8;A5CPZ8;A1
R7K6 
>sp|A0ZZS4|SYE_BIFAA 
Glutamate--tRNA ligase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=gltX PE=3 
SV=1;>sp|Q8G709|SYE_BIFLO 
Glutamate--tRNA ligase 
OS=Bifidobacterium longum 
(strain NCC 2705) GN=gltX 
PE=3 SV=1;>sp 
56.634 
A0ZZG5;B7GT29 
>sp|A0ZZG5|PURA_BIFAA 
Adenylosuccinate synthetase 
OS=Bifidobacterium 
adolescentis (strain ATCC 
15703 / DSM 20083 / NCTC 
11814 / E194a) GN=purA PE=3 
SV=1 
46.637 
A0RN28 
>sp|A0RN28|ISPDF_CAMFF 
Bifunctional enzyme IspD/IspF 
OS=Campylobacter fetus subsp. 
fetus (strain 82-40) GN=ispDF 
PE=3 SV=1 
41.387 
A0QYY6;P9WH43;P9WH42;P4683
6 
>sp|A0QYY6|RS1_MYCS2 30S 
ribosomal protein S1 
OS=Mycobacterium smegmatis 
(strain ATCC 700084 / 
mc(2)155) GN=rpsA PE=1 
SV=1;>sp|P9WH43|RS1_MYCT
U 30S ribosomal protein S1 
OS=Mycobacterium tuberculosis 
(strain ATCC 25618 / H37Rv) 
GN=rpsA PE=1 
SV=1;>sp|P9WH42| 
53.315 
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A0Q087 
>sp|A0Q087|EFP_CLONN 
Elongation factor P 
OS=Clostridium novyi (strain 
NT) GN=efp PE=3 SV=1 
20.784 
A0L9N3 
>sp|A0L9N3|SECA3_MAGMM 
Protein translocase subunit 
SecA 3 OS=Magnetococcus 
marinus (strain ATCC BAA-1437 
/ JCM 17883 / MC-1) GN=secA3 
PE=3 SV=1 
73.775 
